<SEC-DOCUMENT>0001558370-17-001962.txt : 20170321
<SEC-HEADER>0001558370-17-001962.hdr.sgml : 20170321
<ACCEPTANCE-DATETIME>20170320214955
ACCESSION NUMBER:		0001558370-17-001962
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170321
DATE AS OF CHANGE:		20170320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gemphire Therapeutics Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		17702853

	BUSINESS ADDRESS:	
		STREET 1:		17199 N. LAUREL PARK DRIVE
		STREET 2:		SUITE 401
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
		BUSINESS PHONE:		248-980-6538

	MAIL ADDRESS:	
		STREET 1:		17199 N. LAUREL PARK DRIVE
		STREET 2:		SUITE 401
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>gemp-20161231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/20/2017 8:19:14 PM-->
<html>
	<head>
		<title>
			gemp_Current_Folio_10K
		</title>
	</head>
	<body><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a>&nbsp;</font>

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p style="margin:0pt;border-top:3pt double #000000 ;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;color:#000000;font-size:12pt;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;color:#000000;font-size:12pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Washington, DC 20549</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;color:#000000;font-size:12pt;">Form 10-K</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">(Mark One)</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">&#x2612;</font></p>
				</td>
				<td valign="bottom" style="width:92.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:92.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">For the fiscal year ended December 31, 2016</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">OR</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">&#x2610;</font></p>
				</td>
				<td valign="bottom" style="width:92.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:07.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:92.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">For the transition period from&nbsp;</font><font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;to&nbsp;</font><font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Commission file number 001-37809</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman Bold;font-weight:bold;color:#000000;font-size:12pt;">Gemphire Therapeutics&nbsp;Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">(Exact name of Registrant as specified in its charter)</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:49.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Delaware</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:48.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
						<font style="display:inline;font-weight:bold;font-size:6.5pt;">47&#8209;2389984</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">(State or other jurisdiction of incorporation or organization)</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:48.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">(IRS Employer Identification No.)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
						<font style="display:inline;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
						<font style="display:inline;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:48.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
						<font style="display:inline;font-size:6pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">17199 N. Laurel Park Drive, Suite 401, Livonia, MI</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:48.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">48152</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">(Address of principal executive offices)</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:48.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">(Zip Code)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-weight:bold;font-size:6.5pt;">(248)&nbsp;681&#8209;9815</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">(Registrant&#x2019;s telephone number, including area code)</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Securities&nbsp;registered&nbsp;pursuant&nbsp;to&nbsp;Section&nbsp;12(b)&nbsp;of&nbsp;the&nbsp;Securities&nbsp;Exchange&nbsp;Act&nbsp;of</font><font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font><font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">1934:</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:49.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;text-decoration:underline;">Title of Each Class</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:48.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;text-decoration:underline;">Name of Exchange on Which Registered</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Common stock, $0.001 par value</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:48.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">The NASDAQ Stock Market LLC</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">Securities&nbsp;registered&nbsp;pursuant&nbsp;to&nbsp;Section&nbsp;12(g)&nbsp;of&nbsp;the&nbsp;Act:&nbsp;None</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </font><font style="display:inline;font-family:Segoe UI Symbol;color:#000000;font-size:6pt;">&#x2610;</font><font style="display:inline;color:#000000;font-size:6pt;">Yes </font><font style="display:inline;font-family:Segoe UI Symbol;color:#000000;font-size:6pt;">&#x2611;</font><font style="display:inline;color:#000000;font-size:6pt;">No</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act</font><font style="display:inline;color:#000000;font-size:6pt;">.&nbsp; </font><font style="display:inline;font-family:Segoe UI Symbol;color:#000000;font-size:6pt;">&#x2610;</font><font style="display:inline;color:#000000;font-size:6pt;">Yes&nbsp;</font><font style="display:inline;font-family:Segoe UI Symbol;color:#000000;font-size:6pt;">&#x2611;</font><font style="display:inline;color:#000000;font-size:6pt;">No</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:9pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes&nbsp;&#x2612;&nbsp;&nbsp;&nbsp;No&nbsp;&#x2610;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:9pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes&nbsp; &#x2612;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#x2610;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&#xA7; 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant&#x2019;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp; Yes&nbsp;&nbsp;&#x2612; &nbsp;No&nbsp;&nbsp;&#x2610;</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:9pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer&#x201D; and &#x201C;smaller reporting company&#x201D; in Rule 12b-2 of the Exchange Act. (Check one):</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">Large accelerated filer&nbsp;&nbsp;&#x2610;</font></p>
				</td>
				<td valign="bottom" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">Accelerated filer&nbsp;&nbsp;&#x2610;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
						<font style="display:inline;color:#000000;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
						<font style="display:inline;font-size:6pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">Non-accelerated filer&nbsp;&nbsp;&#x2612;</font></p>
				</td>
				<td valign="bottom" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">Smaller reporting company&nbsp;&nbsp;&#x2610;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">(Do not check if a smaller reporting company)</font></p>
				</td>
				<td valign="bottom" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Securities Exchange Act of 1934). Yes&nbsp;&nbsp;&#x2610; &nbsp;No&nbsp;&nbsp;&#x2612;</font>
		</p>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:9pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">The registrant was not a public company as of June 30, 2016, the last day of the registrant&#x2019;s most recently completed second quarter.&nbsp;&nbsp;The aggregate market value of the registrant&#x2019;s common stock held by non-affiliates of the registrant as of August 5, 2016, the initial trading date on the NASDAQ Global Market was $30.3 million based on the closing price of the registrant&#x2019;s common stock of $9.20, as reported by Nasdaq on that date. Shares of the registrant&#x2019;s common stock held by executive officers, directors and holders of 10% or more of the registrant&#x2019;s common stock have been excluded from this calculation because such persons may be deemed affiliates of the registrant; such exclusions do not reflect a determination that such persons are affiliates of the registrant for any other purpose. </font>
		</p>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">The number of outstanding shares of the registrant&#x2019;s common stock, $0.001 par value, as of March 3, 2017 was&nbsp;9,272,582.&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:8pt;">D</font><font style="display:inline;font-weight:bold;font-size:8pt;">OCUMENTS INCORPORATED BY REFERENCE</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;color:#000000;font-size:8pt;">Parts of the Proxy Statement for the Registrant&#x2019;s 2017 Annual Meeting of Stockholders to be filed subsequently are incorporated by reference into Part III of this Annual Report on Form 10-K.</font>
		</p>
		<p style="margin:0pt;border-bottom:3pt double #000000 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:4.41176470588235%;margin-right:4.41176470588235%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">Gemphire Therapeutics Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">FORM 10-K</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<a name="TOC"></a><font style="display:inline;font-weight:bold;color:#000000;">INDEX</font>
		</p>
		<p style="margin:0pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;line-height:100%;margin-bottom:0pt;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PARTI_33046"><font style="display:inline;font-weight:bold;">PART I</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1BUSINESS_589988"><font style="display:inline;">Item 1</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1BUSINESS_589988"><font style="display:inline;">Business</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1ARISKFACTORS_84111"><font style="display:inline;">Item 1A</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1ARISKFACTORS_84111"><font style="display:inline;">Risk Factors</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_130840"><font style="display:inline;">Item 1B</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM1BUNRESOLVEDSTAFFCOMMENTS_130840"><font style="display:inline;">Unresolved Staff Comments</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM2PROPERTIES_644950"><font style="display:inline;">Item 2</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM2PROPERTIES_644950"><font style="display:inline;">Properties</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM3LEGALPROCEEDINGS_754217"><font style="display:inline;">Item 3</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM3LEGALPROCEEDINGS_754217"><font style="display:inline;">Legal Proceedings</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM4MINESAFETYDISCLOSURES_848551"><font style="display:inline;">Item 4</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM4MINESAFETYDISCLOSURES_848551"><font style="display:inline;">Mine Safety Data</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PARTII_387386"><font style="display:inline;font-weight:bold;">PART II</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><font style="display:inline;">Item 5</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"><font style="display:inline;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM6SELECTEDFINANCIALDATA_394630"><font style="display:inline;">Item 6</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM6SELECTEDFINANCIALDATA_394630"><font style="display:inline;">Selected Financial Data</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>89&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><font style="display:inline;">Item 7</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"><font style="display:inline;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>90&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><font style="display:inline;">Item 7A</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"><font style="display:inline;">Quantitative and Qualitative Disclosures About Market Risk</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>104&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><font style="display:inline;">Item 8</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"><font style="display:inline;">Financial Statements and Supplementary Data</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>105&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><font style="display:inline;">Item 9</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"><font style="display:inline;">Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9ACONTROLSANDPROCEDURES_927934"><font style="display:inline;">Item 9A</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9ACONTROLSANDPROCEDURES_927934"><font style="display:inline;">Controls and Procedures</a></font><font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9BOTHERINFORMATION_848698"><font style="display:inline;">Item 9B</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM9BOTHERINFORMATION_848698"><font style="display:inline;">Other Information</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PARTIII_373562"><font style="display:inline;font-weight:bold;">PART III</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><font style="display:inline;">Item 10</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"><font style="display:inline;background-color: #FFFFFF;">Directors, Executive Officers and Corporate Governance</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM11EXECUTIVECOMPENSATION_915549"><font style="display:inline;">Item 11</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM11EXECUTIVECOMPENSATION_915549"><font style="display:inline;background-color: #FFFFFF;">Executive Compensation</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><font style="display:inline;">Item 12</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"><font style="display:inline;background-color: #FFFFFF;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder&nbsp;Matters</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><font style="display:inline;">Item 13</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"><font style="display:inline;background-color: #FFFFFF;">Certain Relationships and Related Transactions and Director Independence</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"><font style="display:inline;">Item 14</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"><font style="display:inline;background-color: #FFFFFF;">Principal Accountant Fees and Services</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#PARTIV_999314"><font style="display:inline;font-weight:bold;">PART IV</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM15EXHIBITSandFINANCIALSTATEMENTSCHED"><font style="display:inline;">Item 15</font><font style="display:inline;font-family:Symbol;">&#xF03A;</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ITEM15EXHIBITSandFINANCIALSTATEMENTSCHED"><font style="display:inline;background-color: #FFFFFF;">Exhibits and Financial Statement Schedules</a></font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:09.56%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:84.42%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:06.02%;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:93.98%;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#SIGNATURES_603331"><font style="display:inline;font-weight:bold;">SIGNATURES</a></font><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.02%;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Unless the context requires otherwise, references in this Annual Report on Form 10-K (this &#x201C;Report&#x201D;) to "we," "us," "the Company" and "our" refer to Gemphire Therapeutics&nbsp;Inc. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">This Report, including under the headings &#x201C;Business,&#x201D; "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains forward-looking statements. We may, in some cases, use words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Report include, but are not limited to, statements about:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our anticipated timing of regulatory submissions; commencement and completion of preclinical studies and clinical trials, meetings with the FDA and other regulatory authorities; and product approvals for gemcabene or any other product candidates we may pursue in the future; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the outcome of our ongoing preclinical toxicology studies related to our partial clinical hold with respect to clinical trials of longer than six months in duration; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the outcome of our Phase&nbsp;2 and Phase&nbsp;3 clinical trials of gemcabene and our ability to replicate positive results from a completed clinical trial in a future clinical trial; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our expected clinical trial designs and regulatory pathways; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our expectation that the FDA will not require us to complete a cardiovascular outcomes trial prior to approval; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our expectations for the attributes of gemcabene or any other product candidate we may pursue in the future, including pharmaceutical properties, efficacy, safety, dosing regimens and cost, as compared to other lipid-lowering therapies; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our ability to design an efficient development plan; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our expectation that our existing capital resources will be sufficient to enable us to complete our planned late stage clinical trials and complete certain preclinical studies; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our plans to advance the late-stage clinical development of gemcabene across multiple target indications, pursue oral combination opportunities for gemcabene, maximize the global commercial value of gemcabene and leverage the expertise and experience of our management team to evaluate future in-license acquisition opportunities; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our estimates regarding industry trends and market potential for gemcabene; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">if approved, our ability to maintain regulatory approval of gemcabene and respond and adhere to regulatory requirements; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our ability to identify, in-license or acquire, develop and, if approved, successfully commercialize best-in-class products, including gemcabene or any other product candidates we may pursue in the future; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our ability to enhance brand awareness among key thought leaders and physicians; </font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">3</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">if approved, the rate and degree of market acceptance of gemcabene or any other product candidates we may pursue in the future; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">if approved, our ability to compete with other companies that are, or may be, developing or selling products that may compete with gemcabene; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">reimbursement policies, including any future changes to such policies or related government legislation and our ability to sell gemcabene, if approved; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">regulatory and legal developments in the United States and in foreign countries; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 10pt;">
				<font style="margin:0pt 0pt 10pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 10pt;">
			<font style="display:inline;">our ability to obtain and maintain intellectual property protection for gemcabene or any other product candidates we may pursue in the future and not infringe upon the intellectual property of others; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our ability to fund our working capital requirements; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for, or ability to, obtain additional financing; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the ability of any third parties with whom we collaborate for the development and commercialization of gemcabene to successfully perform their assigned functions; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our ability to retain and recruit key scientific and management personnel; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our financial performance; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:90pt;"><p style="width:90pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;line-height:115%;border-top:1pt none #D9D9D9;font-size:10pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:115%;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act. </font></p></td></tr></table></div>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">These forward-looking statements reflect our management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Report and are subject to risks and uncertainties. We discuss many of these risks in greater detail under "Risk Factors." Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Given these uncertainties, you should not place undue reliance on these forward-looking statements. </font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. </font>
		</p>
		<p style="margin:5pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">4</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">PART I<a name="PARTI_33046"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM 1.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 51pt 0pt 0pt;"></font>BUSINESS<a name="ITEM1BUSINESS_589988"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Overview </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Gemphire is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate, gemcabene, as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. We are developing our product candidate gemcabene (CI&#8209;1027), a novel, once&#8209;daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL&#8209;C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. Gemcabene&#x2019;s mechanism of action is designed to enhance the clearance of very low&#8209;density lipoproteins (VLDLs) in the plasma and inhibit the production of fatty acids and cholesterol in the liver. Gemcabene is liver&#8209;directed and inhibits apolipoprotein C&#8209;III (apoC&#8209;III) protein in the liver and may inhibit acetyl&#8209;CoA carboxylase (ACC) and HMG-CoA Synthase in the liver. Gemcabene has been tested as monotherapy and in combination with all doses of statins and other drugs in 895&nbsp;subjects, which we define as healthy volunteers and patients, across 18 Phase&nbsp;1 and Phase&nbsp;2 clinical trials and has demonstrated promising evidence of efficacy, safety and tolerability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Cardiovascular disease is a major health concern, causing more deaths globally than any other disease. Dyslipidemia leads to cardiovascular disease and is generally an important predictor of cardiovascular events including heart attack and stroke. Dyslipidemia is generally characterized by an elevation of low&#8209;density lipoprotein cholesterol (LDL&#8209;C), or bad cholesterol, triglycerides, or fat in the blood, or both. It represents one of the largest therapeutic areas with annual worldwide drug sales of approximately $22&nbsp;billion in 2013. We estimate more than 40% of Americans have elevated LDL&#8209;C or triglycerides, or both. Statins, such as atorvastatin or rosuvastatin, are standard of care for LDL&#8209;C lowering, while fibrates, prescription fish oils and niacin are standard of care for triglyceride lowering. Although these drugs are highly prescribed and capable of reducing LDL&#8209;C and triglyceride levels, many patients are unable to effectively manage their dyslipidemia with currently approved therapies and are in need of additional treatment options. For example, approximately 40% of patients on statins are unable to meet their LDL&#8209;C lowering goal, and doubling a statin dose has shown to incrementally lower LDL&#8209;C levels by a nominal percentage (approximately 6% based on historical evidence), while increasing safety and tolerability concerns. An even higher percentage of patients with severe hypertriglyceridemia do not achieve triglyceride levels low enough to reduce the risk of developing co&#8209;morbidities such as pancreatitis.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Non-alcoholic steatohepatitis (NASH) is part of a group of conditions called nonalcoholic fatty liver disease (NAFLD) that affects one out of four people in the United States. In the United States NASH affects up to approximately 2&#8209;5% of the population, or between six to eight&nbsp;million people. The presentation of NASH resembles alcoholic liver disease but occurs in people who drink little or no alcohol. The major feature of NASH is excess fat content in the liver, along with inflammation and liver damage. It can lead to liver cirrhosis, fibrosis, hepatocellular carcinoma, liver failure, liver&#8209;related death and liver transplantation. NASH can also lead to an increased risk of cardiovascular disease, which is a leading cause of death in this patient population. Prevalence of NASH has increased due to the growing number of obese and diabetic patients. It is more common in women than in men and currently there are no FDA approved therapies for treating NASH.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe gemcabene possesses a differentiated product profile compared to other therapies in the market and in clinical development. Key attributes of our product candidate include the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;">Cost&#8209;effective, once&#8209;daily, oral therapy.&nbsp; </font><font style="display:inline;color:#000000;">Gemcabene is a small molecule formulated as a tablet and is cost effective to manufacture. As a once&#8209;daily, oral therapy, gemcabene, if approved, would be more convenient than other non&#8209;statin therapies, many of which require frequent injections or multiple daily doses. We expect to take a value&#8209;based approach to pricing across all the target indications.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;">Promising safety and tolerability.&nbsp; </font><font style="display:inline;color:#000000;">Gemcabene was observed to be well tolerated in 895&nbsp;subjects across 18 Phase&nbsp;1 and Phase&nbsp;2 trials both as monotherapy and in combination with statins. No subjects died and no subjects experienced a serious adverse event (SAE) that was considered to be related to gemcabene. Adverse events (AEs) reported were generally mild to moderate in intensity. Gemcabene did not appear to increase the reporting of myalgia (muscle pain) when added to statin therapy and no treatment related events of myalgia were reported in any gemcabene monotherapy arm in the dyslipidemia trials.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">5</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;">First-in-class mechanism.&nbsp; </font><font style="display:inline;color:#000000;">Gemcabene&#x2019;s pleotropic mechanism of action hits multiple established targets that lower LDL-C, TG, and hsCRP in plasma. Gemcabene has been observed to reduce production of cholesterol and triglyceride pathways inside the liver. This gemcabene effect may be due to inhibition of acetyl CoA carboxylase (ACC) and HMG-CoA Synthase in the liver. Gemcabene has also been shown to enhance clearance of VLDL in the plasma. This is likely due to gemcabene&#x2019;s effect on reduction of apoC-III gene expression and reduction of plasma apoC-III levels, which may facilitate the uptake of VLDL remnants via hepatic remnant receptors. Gemcabene&#x2019;s effects on hsCRP may be due to its effect on reduction of IL-6 expression, as well as its direct effects on inhibiting transcription factors </font><font style="display:inline;font-family:Times;">C/EBP-&#x3B2; and NF-kB interaction with the CRP gene.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;">Significant lipid&#8209;lowering of LDL&#8209;C, high&#8209;sensitivity C&#8209;reactive protein (hsCRP) and triglycerides.&nbsp; </font><font style="display:inline;color:#000000;">In Phase&nbsp;2 trials, patients with hypercholesterolemia treated with gemcabene as monotherapy were observed to have significantly lowered LDL&#8209;C by approximately 30% from baseline and significantly lowered hsCRP by approximately 40% from baseline. In addition, patients with hypertriglyceridemia (&#x2265;200&nbsp;mg/dL) were observed to have significantly lowered triglycerides by approximately 40%, and based on post&#8209;hoc analysis, gemcabene was observed to lower triglycerides by up to 60% in patients with severe triglyceride levels (&#x2265;500&nbsp;mg/dL). Our product candidate&#x2019;s ability to meaningfully lower levels of multiple key lipids attributable to cardiovascular disease may expand its use across multiple indications within the dyslipidemia and NASH Market.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;">Additive effect in combination with statins.&nbsp; </font><font style="display:inline;color:#000000;">In a Phase&nbsp;2 trial in patients with uncontrolled hypercholesterolemia while on stable statin therapy (Trial 2017-018), gemcabene was observed to significantly lower LDL&#8209;C by an additional 25% to 31% from baseline. This data indicates that gemcabene may better treat a large population of patients who are unable to reach their lipid goal with statins and other currently prescribed therapies, including those medications commonly used for diabetes and NASH patients.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;">No drug&#8209;drug interactions when combined with high&#8209;intensity statin doses.&nbsp; </font><font style="display:inline;color:#000000;">In two Phase&nbsp;1 trials, gemcabene was tested in combination with high&#8209;intensity statin doses, 80&nbsp;mg simvastatin and 80&nbsp;mg atorvastatin. No clinically relevant drug&#8209;drug interactions were observed. In addition, gemcabene has been formulated as a fixed&#8209;dose combination tablet with various atorvastatin doses, which may offer additional convenience and compliance to patients.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are pursuing gemcabene in the following indications (representing approximately 20&nbsp;million addressable at-risk patients in the United States) as a treatment for: (1) dyslipidemia in patients on maximally tolerated statin therapy, unable to reach their lipid&#8209;lowering goal, and (2) in patients diagnosed with NASH as monotherapy or in combination with other approved treatments.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">homozygous familial hypercholesterolemia (HoFH), a rare genetic lipid disorder which results in elevated LDL&#8209;C usually due to mutations in both alleles, a pair of genes on a chromosome, responsible for a specific trait of the LDL&#8209;receptor gene. There are approximately 300-2,000 patients in the US and 6,000 to 45,000 patients worldwide;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">heterozygous familial hypercholesterolemia (HeFH), a more prevalent genetic lipid condition which results in elevated LDL&#8209;C usually due to a mutation in one allele of the LDL&#8209;receptor gene. The US population is estimated at .5M - 1.5M and an additional 15 - 30M worldwide;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">atherosclerotic cardiovascular disease (ASCVD), patients with hypercholesterolemia, or patients with elevated LDL-C who have had or are at risk for a cardiovascular event, such as heart attack, stroke, and/or revascularization. This is an estimated 10M patients in the US of which approximately half have mixed dyslipidemia. Worldwide estimates of ASCVD patients range from 100 - 120M;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">severe hypertriglyceridemia (SHTG), in which patients with elevated triglycerides are at an increased risk of developing co-morbidities such as pancreatitis. There are 3 - 3.5M patients in the US and another estimated 60 - 75M worldwide; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">6</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD), are severe diseases of the liver caused by inflammation and a buildup of fat in the organ, which can lead to liver cirrhosis, fibrosis, hepatocellular carcinoma, liver failure, liver related death and liver transplantation. There is an estimated 80M patients with NAFLD and 6 to 8M patients with NASH in the US.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We initially began pursuing HoFH given that gemcabene has received orphan drug designation for this indication. We believe we can design an efficient development plan to provide a new treatment alternative for these patients. Furthermore, we believe that gemcabene&#x2019;s potential ability to treat patients in the most severe segment of the dyslipidemia market, HoFH, can further enhance brand awareness among key thought leaders and physicians. We are in parallel developing gemcabene for HeFH, ASCVD, SHTG and NASH given gemcabene&#x2019;s: (1)&nbsp;promising clinical data and mechanism in these indications; (2)&nbsp;cost&#8209;effective manufacturing process; (3)&nbsp;convenient oral dosing; (4)&nbsp;viability as safe adjunctive combination therapy; and (5)&nbsp;large commercial potential. By the end of 2017, we expect to report top-line data from all three dyslipidemia trials (COBALT-1, ROYAL-1 and INDIGO-1). We expect to initiate our clinical trial in NASH (AZURE-1) in 2017, with top-line data available in the second half of 2018.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Gemcabene Pipeline Indications</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k001.jpg" style="width: 6.625in; height: 3.489583in" alt="Picture 15"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Upon completion of one or more of our trials, we intend to request one or more End of Phase&nbsp;2 (EOP2) meetings with the U.S. Food and Drug Administration (FDA) to reach an agreement on the design of Phase&nbsp;3 registration trials and long&#8209;term safety exposure for our target indications. We intend to pursue similar discussions with Canadian and European health authorities. Other markets will be considered as appropriate.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe it is unlikely the FDA will require us to initiate a cardiovascular outcomes trial for our target dyslipidemia indications. The FDA has not required the initiation or completion of cardiovascular outcomes trials for recent approvals of certain dyslipidemia therapies, including non&#8209;statin therapies targeting LDL&#8209;C for the treatment of HoFH, HeFH and ASCVD and triglyceride lowering for treatment of SHTG. Cardiovascular outcomes trials require evaluation of cardiovascular clinical conditions in large patient populations over a long period of time and are both costly and time&#8209;consuming. However, for commercial and competitive reasons, such as the potential to broaden the label claims, we intend to review with the FDA a design for a cardiovascular outcomes trial enriched with diabetic and obese (&#x201C;diabesity&#x201D;) patients which we may initiate before an NDA submission and complete post&#8209;approval.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our company was co&#8209;founded by Dr.&nbsp;Charles Bisgaier, who was responsible for licensing exclusive worldwide rights to gemcabene from Pfizer in April 2011. Prior to co&#8209;founding the original Esperion Therapeutics, Inc. (Esperion) in 1998, which was acquired by Pfizer in 2004, Dr.&nbsp;Bisgaier worked at Parke&#8209;Davis, a division of Warner-Lambert Company from 1990 to 1998, and was instrumental in the discovery and development of gemcabene, as well as the development of Lipitor and Lopid. Many of our employees and consultants have been involved in the historical development of </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">7</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">gemcabene and other innovative dyslipidemia product candidates in development, including ETC&#8209;216, a synthetic high&#8209;density lipoprotein mimetic based on ApoAI&#8209;Milano (developed by the original Esperion, Pfizer, and currently The Medicines Company), ACP&#8209;501 (developed by AlphaCore Pharma, later acquired by AstraZeneca) and ETC&#8209;1002 (developed by the original Esperion, Pfizer and the current Esperion). We have organized a medical and scientific advisory board including Drs.&nbsp;John Kastelein, Evan Stein, Robert Hegele, Dirk Blom, Harold Bays, Peter Toth, Jay Horton, David Cohen, Rohit Loomba, Brian Krause, Gerald Watts, Todd Leff, and Kevin Williams, who combined have been involved in numerous dyslipidemia, cardiovascular and NASH clinical trials (e.g., statins from their earliest trials, fibrates, ezetimibe, cholesteryl ester transfer protein (CETP) inhibitors, extended release niacin, antisense oligonucleotides (mipomersen), monoclonal antibodies including PCSK9 inhibitors and multiple development stage NASH drugs) and published numerous research papers. The management team, led by our CEO Mina Sooch, collectively has significant experience in operating and financing biopharmaceutical companies and discovering, developing and commercializing treatments in the cardiovascular and orphan markets.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Our Strategy</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our goal is to become a leading cardiometabolic biopharmaceutical company that develops and commercializes best&#8209;in&#8209;class therapies for lipid disorders including dyslipidemia and NASH</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The core elements of our strategy to achieve our goal are the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Advance the late&#8209;stage clinical development of gemcabene across multiple target indications.&nbsp; </font><font style="display:inline;color:#000000;">We are focused on a broad spectrum of indications for dyslipidemia patients ranging from the orphan indication HoFH to more prevalent conditions, such as HeFH, ASCVD and SHTG. The data from our 18 Phase&nbsp;1 and Phase&nbsp;2 trials and multiple preclinical studies have provided us with a comprehensive set of information and key insights into gemcabene&#x2019;s mechanism of action, lipid&#8209;lowering effects and safety profile. Furthermore, recent approvals of cardiovascular therapies in gemcabene&#x2019;s target indications, such as biologic PCSK9 inhibitors for HoFH, HeFH and ASCVD and prescription fish oils for SHTG have provided us with a better understanding of current FDA views on approval of new dyslipidemia drugs. As a result, we believe that we have identified indications for gemcabene with favorable, precedent regulatory pathways and the highest likelihood of commercial success compared to other potential indications for gemcabene. By the end of 2017, we should read out our three late stage clinical dyslipidemia trials for gemcabene: an 8&nbsp;patient open label trial for HoFH, a 104&nbsp;patient trial for hypercholesterolemia on high&#8209;intensity statin therapy including HeFH and ASCVD patients, and a 90 patient trial for SHTG. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Expand the breadth of indications beyond dyslipidemia for gemcabene.&nbsp; </font><font style="display:inline;color:#000000;">We are pursuing the utility of gemcabene in NASH and/or NAFLD given its mechanism of action that decreases the production of the apoC&#8209;III protein and may inhibit ACC, which has been observed to result in the lowering of triglycerides in the plasma and inhibiting de novo lipogenesis, and may reduce liver fat. We have completed pre-clinical testing for gemcabene in an established NASH preclinical model (STAM&#x2122;) designed by SMC Laboratories of Japan. We expect to initiate our NASH trial (AZURE 1) in the second half of 2017.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Pursue oral combination opportunities for gemcabene.&nbsp; </font><font style="display:inline;color:#000000;">Oral combination therapy is the current paradigm for the treatment of dyslipidemia (and expected for treatment of NASH), as patients typically require multiple drugs to address their dyslipidemia as well as other co&#8209;morbidities such as diabesity. Based on existing data demonstrating additive effects on LDL&#8209;C and triglyceride lowering as well as no drug&#8209;drug interactions with statins, we believe that gemcabene has the potential to be developed as a fixed&#8209;dose combination with low to high dose statins, which, if approved, may enhance adoption in the market and patient compliance. As part of our development strategy, we plan to formulate and manufacture gemcabene in fixed&#8209;dose combination with statins and other lipid&#8209;lowering agents.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Continue to build out our patent portfolio for gemcabene.&nbsp; </font><font style="display:inline;color:#000000;">We believe our patents and patent applications provide us with a significant competitive advantage. As of February 20, 2017, we had 49 issued patents and 24 pending patent applications for gemcabene in the United States and internationally directed to formulations, compositions, methods of use and methods of manufacturing. We intend to aggressively prosecute and defend our patent portfolio and pursue new patents in order to ensure the long term commercial success of gemcabene.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">8</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Maximize the global commercial value of gemcabene.&nbsp; </font><font style="display:inline;color:#000000;">We have retained all commercial and manufacturing rights to gemcabene. We intend to evaluate our strategic alternatives to collaborate with global biopharmaceutical companies for the development and commercialization of gemcabene. We believe we could independently commercialize gemcabene for the treatment of patients with HoFH in the United States with a targeted sales force and would seek commercial partners outside of the United States. We may co-promote the SHTG indication with a partner with our internal sales force and distributor(s). For larger indications, such as HeFH, ASCVD, and NASH we would assess partnership opportunities for Phase&nbsp;3 development and the worldwide commercialization of gemcabene.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Leverage the expertise and experience of our management team to evaluate future in&#8209;licensing and acquisition opportunities.&nbsp; </font><font style="display:inline;color:#000000;">Across our leadership team, we have discovered and/or developed Lipitor, Lopid, ETC&#8209;1002, ETC&#8209;216, ACP&#8209;501, CER&#8209;209, CER&#8209;001 and PNT&#8209;2258, and commercialized many lipid regulating and orphan drugs including Crestor, Myalept and Lynparza. Our team is well&#8209;qualified to identify and in&#8209;license or acquire clinical&#8209;stage cardio&#8209;metabolic assets, and we intend to evaluate these opportunities to diversify our pipeline and generate long&#8209;term growth.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Overview of Dyslipidemia Market</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">According to the World Health Organization, cardiovascular disease is the number one cause of death in the world, responsible for 17.5&nbsp;million, or approximately one in three, deaths in 2012. Cardiovascular disease is influenced by both environment and genetics. Environmental factors include diet, smoking, excess weight and sedentary lifestyle. Genetic defects can cause certain types of cardiovascular disease, such as familial hypercholesterolemia, a condition in which mutations on a gene are responsible for the elevated LDL&#8209;C levels in patients. Cardiovascular burden in the US is expanding at an alarming rate. The prevalence of CVD was in 41.5% in 2015, due to the rising effects of obesity and the earlier onset of type 2 diabetes. It is estimated that 45% of the US population will have at least one cardiovascular condition by 2035. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Dyslipidemia is characterized by an elevation of LDL&#8209;C, triglycerides or both. Dyslipidemia leads to cardiovascular disease and is generally an important predictor of cardiovascular events, including heart attack and stroke,. It is estimated that 71&nbsp;million American adults, or approximately 33%, have high LDL&#8209;C levels, which is a major risk factor for cardiovascular disease. We estimate from 2013 data that over 33&nbsp;million patients are prescribed statins, of which a little more than half, or 19&nbsp;million, are secondary prevention patients.</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">1</font><font style="display:inline;"> Of these 19&nbsp;million secondary prevention patients, approximately 10&nbsp;million are ASCVD&nbsp;patients who are not at their LDL-C goal. Furthermore, it is estimated that over 30% of American adults have elevated triglycerides above 150&nbsp;mg/dL, and high levels of triglycerides are even evident in patients with normal cholesterol levels. If untreated, elevated triglycerides levels may lead to more serious illnesses, such as atherosclerosis (plaque build&#8209;up in the arteries) and severely elevated triglyceride levels may lead to pancreatitis (inflammation of the pancreas). The dyslipidemia market has achieved approximately $22&nbsp;billion in worldwide drug sales in 2013 and remains one of the largest therapeutic markets.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">9</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Global Dyslipidemia Market</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">2013 Worldwide Drug Sales of $22&nbsp;Billion</font><font style="display:inline;font-weight:bold;font-size:5pt;top:-4pt;position:relative;line-height:100%">1</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k002.jpg" style="width: 6.59375in; height: 4.270833in" alt="Picture 14"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">1<font style="display:inline;font-size:8pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 30.6pt 0pt 0pt;"></font></font><font style="display:inline;font-size:8pt;">&#xA9;&nbsp;2015 DR/Decision Resources, LLC. All rights reserved. Reproduction, distribution, transmission or publication is prohibited. Reprinted with permission. DR/Decision Resources, LLC (&#x201C;DR&#x201D;) makes no representation or warranty as to the accuracy or completeness of the data (&#x201C;DR Material&#x201D;) set forth herein and shall have, and accept, no liability of any kind, whether in contract, tort (including negligence) or otherwise, to any third party arising from or related to use of the DR Material by Gemphire Therapeutics Inc. Any use which Gemphire Therapeutics&nbsp;Inc. or a third party makes of the DR Material, or any reliance on it, or decisions to be made based on it, are the sole responsibilities of Gemphire Therapeutics Inc. and such third party. In no way shall any data appearing in the DR Material amount to any form of prediction of future events or circumstances and no such reliance may be inferred or implied.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Recent Developments in the Dyslipidemia Market</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In 2015 there were key advisory panel meetings and regulatory approvals for non&#8209;statin LDL&#8209;C lowering drugs. Specifically, Biologics License Applications (BLAs) for two PCSK9 inhibitors were considered by the FDA and have subsequently been approved in the United States and Europe. We believe these approvals signal the FDA&#x2019;s continued view that LDL&#8209;C lowering is an acceptable surrogate endpoint for traditional drug approval in certain lipid indications and that cardiovascular outcomes trials would not be required for such approvals. The FDA however noted that one should accept very little risk from a novel LDL&#8209;C&#8209;lowering drug when approving for a broad population only based on its effects on LDL&#8209;C. The approved PCSK9 products are described below. Their FDA&#8209;approved labels indicate that their effects on cardiovascular morbidity and mortality have not yet been determined.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 7pt;">
				<font style="margin:0pt 0pt 7pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 7pt;">
			<font style="display:inline;color:#000000;">On August&nbsp;27, 2015, Repatha&#xAE;, developed by Amgen&nbsp;Inc. (Amgen), was approved in the United States for use along with diet and maximally tolerated statin therapy in adults with HoFH, HeFH and ASCVD, who need additional lowering of LDL&#8209;C.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 7pt;">
				<font style="margin:0pt 0pt 7pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 7pt;">
			<font style="display:inline;color:#000000;">On July&nbsp;24, 2015, Praluent&#xAE;, developed by Regeneron Pharmaceuticals, Inc. (Regeneron) and Sanofi&#8209;Aventis U.S., LLC (Sanofi), was approved in the United States for use as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH and ASCVD, who require additional lowering of LDL&#8209;C.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">10</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 7pt;">
				<font style="margin:0pt 0pt 7pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 7pt;">
			<font style="display:inline;color:#000000;">On July&nbsp;21, 2015 and September&nbsp;28, 2015, the European Commission approved Repatha and Praluent respectively, each with a broader label compared to that in the United States. The approved indications in Europe included the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia as: (1)&nbsp;combination therapy with maximally tolerated dose of statin or statin and other lipid&#8209;lowering drugs; or (2)&nbsp;monotherapy or combination therapy with other lipid&#8209;lowering drugs in patients who are statin&#8209;intolerant, or for whom statin is contraindicated. Repatha is also approved for the treatment of HoFH in adults and adolescents aged 12&nbsp;years and over in combination with other lipid&#8209;lowering drugs.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="background-color: #FFFFFF;vertical-align:baseline;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;background-color:#FFFFFF;vertical-align:baseline;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="background-color: #FFFFFF;vertical-align:baseline;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:10pt;">On November 1, 2016 Pfizer announced the discontinuation of the global clinical development program for bococizumab, its investigational Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) inhibitor. The totality of clinical information now available for bococizumab, taken together with the evolving treatment and market landscape for lipid-lowering agents, led Pfizer to discontinue the development program, including the two ongoing SPIRE-1 and SPIRE-2 cardiovascular outcome studies.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="background-color: #FFFFFF;vertical-align:baseline;border-top:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;background-color:#FFFFFF;vertical-align:baseline;border-top:1pt none #D9D9D9;color:#000000;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="background-color: #FFFFFF;vertical-align:baseline;border-top:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:10pt;">On February 2, 2017 Amgen</font><font style="display:inline;color:#0000FF;font-size:10pt;text-decoration:underline;">&nbsp;</font><font style="display:inline;font-size:10pt;">announced that the FOURIER trial evaluating whether Repatha (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident ASCVD met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke).&nbsp;No new safety issues were observed.</font></p></td></tr></table></div>
		<p style="margin:12pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">At the close of 2016, the sales of PCSK9 inhibitors Repatha and Praluent have been limited post&#8209;launch as a result of access being limited by pricing and payors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Regulatory Precedents for Approval in Dyslipidemia Indications </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Historical data suggest a linear relationship between LDL&#8209;C and cardiovascular disease, showing that lower LDL&#8209;C levels reduces the risk of mortality and other cardiovascular events (for example, every 39&nbsp;mg/dL LDL&#8209;C lowering results in 24% cardiovascular risk reduction). The chart below by Cholesterol Treatment Trialists&#x2019; (CTT) Collaboration provides the foundation for this &#x2018;LDL&#8209;C hypothesis&#x2019;.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">11</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;">Lowering LDL&#8209;C Decreases Cardiovascular Risk</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Elevated LDL&#8209;C lowering is the #1 Modifiable Risk Factor</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k003.jpg" style="width: 6.447917in; height: 4.84375in" alt="Picture 13"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-size:8pt;">Sources: CTT Cholesterol Treatment Trialist&#x2019;s Collaboration and Study Papers for each Trial</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-size:8pt;">CV = Cardiovascular; MACE=Major Adverse Cardiovascular Events</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-size:8pt;">*<font style="display:inline;font-size:8pt;;font-size: 8pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 30.6pt 0pt 0pt;"></font>A&#8209;Z p=.14 and IDEAL p=.07</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-size:8pt;">Key For LDL&#8209;C Lowering Drug with Successful Trial Results:&nbsp; </font><font style="display:inline;font-weight:bold;font-size:8pt;">Gemfibrozil: </font><font style="display:inline;font-size:8pt;">HHS; </font><font style="display:inline;font-weight:bold;font-size:8pt;">Atorvastatin: </font><font style="display:inline;font-size:8pt;">IDEAL, TNT, PROVE&#8209;IT, ASCOT&#8209;LLA, SPARCL; </font><font style="display:inline;font-weight:bold;font-size:8pt;">Pravastatin: </font><font style="display:inline;font-size:8pt;">ALLHAT, CARE, PROSPER, LIPID, WOSCOPS; </font><font style="display:inline;font-weight:bold;font-size:8pt;">Simvastatin: </font><font style="display:inline;font-size:8pt;">A&#8209;Z, HPS, 4S; </font><font style="display:inline;font-weight:bold;font-size:8pt;">Lovastatin: </font><font style="display:inline;font-size:8pt;">AFCAPS; </font><font style="display:inline;font-weight:bold;font-size:8pt;">Rosuvastatin: </font><font style="display:inline;font-size:8pt;">JUPITER; </font><font style="display:inline;font-weight:bold;font-size:8pt;">Ezetimibe: </font><font style="display:inline;font-size:8pt;">IMPROVE&#8209;IT.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For nearly three decades (1987 to 2015), the FDA has accepted LDL&#8209;C lowering as a surrogate endpoint for reducing cardiovascular risk for </font><font style="display:inline;font-style:italic;">traditional</font><font style="display:inline;"> approval on over 15 lipid&#8209;lowering drugs without requirements to initiate or complete a cardiovascular outcomes trial. Traditional approval may be based on surrogate endpoints such as LDL&#8209;C and blood pressure that are </font><font style="display:inline;font-style:italic;">known</font><font style="display:inline;"> to predict clinical benefit, in contrast to accelerated approval based on surrogate endpoints that are only </font><font style="display:inline;font-style:italic;">reasonably likely</font><font style="display:inline;"> to predict clinical benefit and require confirmatory evidence of actual benefit after approval. With traditional approval based on LDL&#8209;C reduction, the FDA does not have a regulatory mechanism to require any further efficacy trials and does not require sponsors to conduct a post&#8209;approval cardiovascular outcomes trial. Sponsors who have chosen to conduct cardiovascular outcomes trials before or after traditional approval, which is encouraged by the FDA, have voluntarily done so to seek additional claims.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In approving drugs, the FDA considers the magnitude of effect in relation to the safety profile. Not only has the use of LDL&#8209;C as a surrogate marker to predict the risk of cardiovascular events been accepted by the FDA but the importance </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">12</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">of LDL&#8209;C lowering has also been recognized by clinical organizations such as American College of Cardiology, American Heart Association (AHA), National Cholesterol Education Program Adult Treatment Panel&nbsp;III (NCEP ATP&#8209;III), American Association of Clinical Endocrinologists, and National Lipid Association.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">These approvals have occurred over the last decade, as have studies showing that certain LDL&#8209;C lowering statin and non&#8209;statin drugs did not in fact provide cardiovascular benefits (e.g., Niacin in AIM&#8209;HIGH trial) and/or show unexpected safety concerns (e.g., ezetimibe in ENHANCE with cancer). In addition, a class of drugs known as cholesteryl ester transfer protein inhibitors (CETPi) with a different mechanism (which increases high&#8209;density lipoprotein cholesterol (HDL&#8209;C) while sometimes lowering LDL&#8209;C), has 3 drugs that failed to demonstrate efficacy in Phase&nbsp;3 cardiovascular outcome trials. The first CETPi drug, Pfizer&#x2019;s torcetrapib, lowered LDL&#8209;C but showed increased cardiovascular event rates in patients due to off&#8209;target effects in ILLUMINATE, which we believe established a higher FDA standard for cardiovascular outcomes trials for the CETPi class.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In patient populations such as HoFH and SHTG, we believe the FDA recognizes that an outcomes trial would be difficult and as a result has established precedent drug approvals over time based on surrogate endpoints (LDL&#8209;C for cardiovascular risk and triglycerides for pancreatitis risk, respectively). Recent examples include Juxtapid (2012), Kynamro (2013) and Repatha (2015) for HoFH and Vascepa (2012) for SHTG.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the broader populations HeFH and ASCVD, the FDA recently approved PCSK9 inhibitors based on LDL&#8209;C as the surrogate endpoint and did not require the completion of cardiovascular outcomes trial in these high&#8209;risk dyslipidemia patients. The FDA approved Praluent and Repatha based on LDL&#8209;C reduction as an adjunct to maximally tolerated statin therapy (and diet), but did not approve these drugs for monotherapy or primary patients, noting that such approval may be premature in the absence of cardiovascular outcomes data.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Collectively, recent approvals of new cardiovascular drugs, results from clinical trials of non&#8209;statin product candidates, and our recent regulatory guidance that we received from the FDA regarding our development plans have provided us with some assurance that LDL&#8209;C lowering product candidates in development, such as gemcabene, will not be required to conduct cardiovascular outcomes trials in the United States and Europe prior to approval for our target indications planned in combination with statins assuming a favorable benefit/risk profile.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">hsCRP Biomarker of Interest</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Inflammation plays a significant role in the propagation of atherosclerosis and susceptibility to cardiovascular events. Of the wide array of inflammatory biomarkers that have been studied, hsCRP (or CRP) has received the most attention for its use in risk reclassification of cardiovascular disease. Recently, at the 2015 European Society for Cardiology meeting, Merck presented a post&#8209;hoc analysis of the IMPROVE&#8209;IT trial which confirmed the importance of lowering both LDL&#8209;C and hsCRP levels to below 70&nbsp;mg/dL and 2&nbsp;mg/L, respectively, with a 27% relative risk reduction in cardiovascular events occurring in patients that were able to attain these target levels compared to those patients who achieved neither of these target levels. These findings support the potential for novel non&#8209;statin therapies that can demonstrate clinical efficacy in both LDL&#8209;C and hsCRP reduction. Gemcabene&#x2019;s ability to substantially lower hsCRP in conjunction with LDL&#8209;C may offer further benefit to the cardiovascular health of patients.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Overview of NASH Market</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">NASH is an advanced form of NAFLD in which a buildup of excess triglycerides in the liver (steatosis), usually in the&nbsp;context of metabolic dysregulation, results in liver damage (hepatocyte ballooning) and increased inflammation. This condition can lead to hepatic fibrosis and cirrhosis and eventually hepatocellular carcinoma (HCC) in some patients. NASH is now one of the most common causes for liver transplantation. There are currently no approved medications for treating NASH in any market across the globe. Disease management chiefly involves lifestyle modification, some off-label medication use, and monitoring for disease progression. Off-label medications typically include antioxidant, antidiabetic, and lipid modifying agents. Despite the potentially serious liver complications, the natural progression of NASH is relatively slow, and CV disease is the leading cause of death among NASH patients, partly as a result of the disease and partly due to the common comorbidities in patients with NASH, including type 2 diabetes and obesity. NASH is now the second most common cause for liver transplantation in the U.S. and it is anticipated to become the&nbsp;leading cause&nbsp;by 2020.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">13</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Regulatory Trends for Approval in NASH</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As the NASH competitive landscape matures, the clinical and regulatory pathways are evolving. In February of 2017, the FDA approved a significant amendment to Intercept Pharmaceuticals, Inc.&#x2019;s obeticholic acid (OCA) protocol signaling potential standards for future NASH trials: (1) only one primary endpoint is required for success &#x2013; either improvement in fibrosis or NASH resolution &#x2013; but not both; and (2) the FDA agreed upon an objective definition of NASH resolution.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Our Target Indications</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe that oral, once&#8209;daily gemcabene as an add&#8209;on to statin and other existing therapies is differentiated by the ability to lower multiple risk factors (LDL&#8209;C, hsCRP and triglycerides) and, if approved, presents a significant opportunity across multiple indications in dyslipidemia and NASH. These indications span from HoFH to more prevalent conditions, such as HeFH, ASCVD, SHTG and NASH, in which therapies are required to reduce elevated levels of LDL&#8209;C, triglycerides, inflammation or any combination thereof. Our target indications are summarized below with a total of approximately 14&nbsp;million addressable dyslipidemia patients in the United States who could be treated with gemcabene, and another six million patients with NASH in the U.S.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Patient Related Large Markets for Dyslipidemia and NASH</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;"><img src="gemp20161231x10k004.jpg" style="width: 6.364583in; height: 4.135417in" alt="Picture 12"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Homozygous Familial Hypercholesterolemia (HoFH)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">HoFH is a rare genetic disease that is usually caused by mutation in both alleles of the LDL receptor gene responsible for removing LDL from the blood. As a result of having defective or deficient LDL receptor function, HoFH patients exhibit severely high LDL-C levels, are at very high risk of experiencing premature cardiovascular events, such as a heart attack or stroke, and develop premature and progressive atherosclerosis. LDL&#8209;C levels in HoFH patients are often in the range of 500&nbsp;mg/dL to 1,000&nbsp;mg/dL, compared to a normal target range of 70&nbsp;mg/dL to 100&nbsp;mg/dL. Unless treated, most patients with HoFH do not survive adulthood beyond 30&nbsp;years of age. There are approximately 300 to 2,000 HoFH </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">14</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">patients in the United States and 6,000 to 45,000&nbsp;patients in the rest of the world based on an estimated prevalence rate of one in 160,000 to one in one million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Current available treatments for HoFH generally include a combination of dietary intervention, statins, ezetimibe and other approved LDL&#8209;C lowering therapies, including lipoprotein apheresis. However, even when combination therapies are utilized, many patients still have high LDL&#8209;C levels and are still at high risk of cardiovascular disease. The FDA has approved two non&#8209;statin therapies for HoFH, Juxtapid, marketed by Aegerion Pharmaceuticals, Inc. (Aegerion), and Kynamro, marketed by Sanofi. Although these drugs have demonstrated efficacy, they have significant safety and tolerability concerns, including boxed warnings for liver toxicity on the product labels. Recently, the FDA has also approved Amgen&#x2019;s PCSK9 inhibitor, Repatha, for HoFH patients, but this therapy has limitations due to its mechanism of action reliant on functional LDL&#8209;receptors. In clinical trials, Repatha has shown substantially less LDL&#8209;C lowering from baseline in patients with HoFH compared to LDL-C lowering in patients with other hypercholesterolemia indications.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On February&nbsp;6, 2014, gemcabene received orphan drug designation by the FDA for treatment of HoFH. We believe that pursuing the HoFH indication may enable gemcabene to reach the market sooner than for other indications due to: (1)&nbsp;approval pathway based on a single, small Phase&nbsp;3 trial; (2)&nbsp;no requirement for cardiovascular outcomes trials; and (3)&nbsp;potential for priority review by the FDA in light of the unmet medical need in this orphan population. Furthermore, we believe that gemcabene&#x2019;s potential to treat patients in the most severe segment of the dyslipidemia market on top of statins and other lipid&#8209;lowering therapies (including ezetimibe and Repatha) will enhance brand awareness among key thought leaders and physicians.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Heterozygous Familial Hypercholesterolemia (HeFH)</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The HeFH patient population is generally comprised of individuals who have one defective gene that leads to elevated LDL-C levels between 190 mg/dL and 500 mg/dL. These patients are prone to premature cardiovascular events. The incidence of patients with HeFH is estimated to be one in 200 and one in 500, and, accordingly, we estimate there are approximately 0.5 to 1.5 million patients with HeFH in the United States and 15 to 30 million in the rest of the world.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Current approved treatments for HeFH include statins, ezetimibe, bile acid sequestrants and the recently approved injectable PCSK9 inhibitors. Despite the availability of various treatments, many patients are still unable to achieve recommended LDL-C levels. In addition, patients, physicians and payors may prefer more convenient, cost-effective, oral drugs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe obtaining approval for the HeFH indication will enable gemcabene to reach a large market of patients with the inability to attain their LDL&#8209;C goal using current therapies (including high&#8209;intensity statins, ezetimibe and PCSK9 inhibitors). An approval in HeFH would allow gemcabene to be introduced into another indication for very high LDL&#8209;C levels and enable physicians globally to have another oral, once&#8209;daily, cost&#8209;effective, well&#8209;tolerated with high intensity statins option in treating this complex patient population, while also lowering LDL&#8209;C, hsCRP, and triglycerides.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Atherosclerotic Cardiovascular Disease (ASCVD)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">ASCVD represents patients who have experienced or are at risk of a cardiovascular event and are unable to meet their LDL-C lowering goal of less than 70 mg/dL with maximally tolerated statin therapy. This population also includes many patients who, in addition to not being able to meet their LDL-C lowering goal, have elevated triglyceride levels greater than 150 mg/dL and less than 500 mg/dL, categorized as mixed dyslipidemia. We estimate that approximately 10 million patients in the United States and 200 million patients in the rest of the world have a need for additional therapies to effectively and safely bring them closer to their LDL-C and triglyceride lowering goals.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Currently approved treatments for both primary hypercholesterolemia and ASCVD include statins, ezetimibe, bile acid sequestrants, niacin, fibrates and recently approved PCSK9 inhibitors. While these drugs have demonstrated efficacy in lipid-lowering in this population, they do not sufficiently address the patients with mixed dyslipidemia who need to lower both LDL-C and triglycerides.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe that there is a meaningful number of underserved ASCVD patients who are: (1)&nbsp;unable to reach LDL&#8209;C and triglyceride goals on maximally tolerated statin therapy; (2)&nbsp;require LDL&#8209;C reduction beyond the 6% reduction observed when statin dose is doubled; or (3)&nbsp;unable to tolerate higher doses of statins. If gemcabene is approved for this </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">15</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">indication, it may potentially offer patients, especially diabesity patients, a preferred well&#8209;tolerated combination therapy with a statin and/or ezetimibe that is convenient, oral, once&#8209;daily, cost effective, and effective in achieving LDL&#8209;C, hsCRP and triglyceride goals.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Severe Hypertriglyceridemia (SHTG)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Elevated triglycerides are often caused by an inherited disorder or exacerbated by uncontrolled diabetes mellitus, obesity, hypothyroidism and sedentary habits. A recent scientific statement on &#x201C;Triglycerides and Cardiovascular Disease&#x201D; issued by the American Heart Association based on a review of the pivotal role of triglycerides in lipid metabolism, reaffirmed that triglycerides are not directly atherogenic, but represent an important biomarker of cardiovascular disease. Patients with severe triglycerides greater than 500&nbsp;mg/dL, or SHTG, have increased risk of developing pancreatitis, a painful and potentially life&#8209;threatening inflammation of the pancreas. Based on a 1.1% prevalence rate in the United States, as published by the American Heart Association, we estimate there are approximately 3.5&nbsp;million patients with SHTG in the United States and 75&nbsp;million patients in the rest of the world.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Current available treatments for SHTG consist of dietary modifications to lower the intake of fatty foods and the use of fibrates, prescription fish oils and niacin. These treatments are often inadequate in lowering triglyceride levels below 500&nbsp;mg/dL, the level at which patients are at an increased risk for developing pancreatitis. Due to the severely elevated triglyceride levels in this patient population, reducing triglyceride levels below 500&nbsp;mg/dL may require reductions in triglyceride levels of 40% or more. Current therapies, even in combination, are often insufficient in achieving such a result. In addition, many of the existing treatments do not combine well with statins for treating SHTG.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe that pursuing SHTG may enable gemcabene to reach a large population of patients with triglyceride levels above 500&nbsp;mg/dL and offer a convenient, oral, once&#8209;daily dosing with no food effects that may have the potential to result in better efficacy than standard of care, while being well&#8209;tolerated with statins.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Non-alcoholic Steatohepatitis (NASH)</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">NASH is a severe disease of the liver caused by inflammation and a buildup of fat in the organ. In the United States, NASH affects up to approximately 2-5% of the population roughly at 6 million NASH patients. An additional 10-30% of Americans have fat in their liver, but no inflammation or liver damage, a condition called NAFLD or &#x201C;fatty liver.&#x201D; The underlying cause of NASH is unclear, but it most often occurs in persons who are middle-aged and overweight or obese.&nbsp;&nbsp;Many patients with NASH have elevated serum lipids, diabetes or pre-diabetes. Progression of NAFLD/NASH can lead to liver cirrhosis, fibrosis, hepatocellular carcinoma, liver failure and liver-related death. Liver transplantation is currently the only treatment for advanced cirrhosis with liver failure. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">At this time, there are no approved treatments by the FDA for NAFLD/NASH. Based on the current understanding of pathophysiological mechanisms associated with NASH, several compounds are in clinical development, although none have been approved to date. The Clinical Trials website lists many trials for NASH. These compounds target the regulation of dyslipidemia (e.g. acetyl CoA carboxylase inhibitors, bile acid/fatty acid conjugates), inflammation (e.g. combined CCR2/CCRCR5 inhibitor) and/or fibrosis (e.g. 6-ethylchenodeoxycholic acid). </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Gemcabene may be effective in treating patients for NASH given its mechanism of action around inflammation and triglycerides, especially for diabesity patients. Gemcabene will likely be used as an oral combination with statins and other to be approved NASH drugs with complementary mechanisms. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Our Product Candidate&nbsp;&#x2014; Gemcabene</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our product candidate, gemcabene, is a novel, once&#8209;daily, oral therapy designed to target known lipid metabolic pathways to lower levels of LDL&#8209;C, hsCRP and triglycerides. Gemcabene shares many of the attributes of statin therapy, including broad therapeutic applications, convenient route of administration and cost&#8209;effective manufacturing process, but does not appear to increase the reporting of myalgia when added to statin therapy. Gemcabene has also shown additive LDL-C lowering in combination with stable low, moderate or high&#8209;intensity statin therapy. We also plan to develop a fixed&#8209;dose combination product of gemcabene with atorvastatin to enhance market adoption and maximize the likelihood of commercial success.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">16</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are developing multiple indications for gemcabene, ranging from HoFH, an orphan indication, to more prevalent conditions, such as HeFH, ASCVD, SHTG and NASH. By the end of 2017, we should read out all three late stage dyslipidemia clinical trials for gemcabene: an 8&nbsp;patient trial for HoFH (COBALT-1), a 104&nbsp;patient trial for hypercholesterolemia on high&#8209;intensity statin therapy including HeFH and ASCVD patients (ROYAL-1), and a 90&nbsp;patient trial for SHTG (INDIGO-1). In addition, we expect to launch our NASH clinical trial (AZURE-1) in the second half of 2017.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We licensed global rights to gemcabene from Pfizer in April 2011. We will continue to leverage the extensive preclinical, clinical, manufacturing and formulation work previously conducted to further advance the development of gemcabene.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Mechanism of Action</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Gemcabene has a mechanism of action that involves: (1)&nbsp;enhancing the clearance of VLDL; and (2)&nbsp;blocking the overall production of hepatic triglyceride and cholesterol synthesis. Based on prior clinical trials, the combined effect for these mechanisms has been observed to result in a reduction of plasma VLDL&#8209;C, LDL&#8209;C, triglycerides and hsCRP, as well as elevation of HDL&#8209;C. Gemcabene mainly distributes to the liver where it has its effect as the active molecule.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(1)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 27pt 0pt 0pt;"></font>ApoC&#8209;III protein is known to be causal in cardiovascular disease. Gemcabene enhances VLDL clearance by decreasing apoC-III messenger RNA (mRNA) expression, thereby reducing apoC&#8209;III protein production and plasma levels. ApoC&#8209;III is a small protein (~9 kDa) that inhibits hepatic uptake of triglyceride&#8209;rich particles such as VLDL. VLDL lipoproteins are catabolized to VLDL remnants in plasma. The VLDL remnants are either cleared from the plasma via remnant receptors or are further catabolized to LDL. The reduction in apoC-III exposes apolipoprotein E (apoE), a 35 kDa protein that is also present on the VLDL lipoproteins and VLDL remnants. ApoE is essential for the normal catabolism of triglyceride&#8209;rich particles. This favors the enhanced clearance of the VLDL remnants via ApoE remnant receptors and reduces the formation of LDL particles, while also breaking down triglycerides by lipoprotein lipase to deliver more fatty acids to muscle and adipose tissue. We have observed in preclinical studies that gemcabene significantly clears VLDL in the plasma with corresponding reductions in the liver apoC&#8209;III mRNA levels and apoC&#8209;III plasma protein levels in rats. In a hypertriglyceridemic human clinical trial, gemcabene was shown to significantly decrease both apoC&#8209;III and triglycerides.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:auto;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:105%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Reduction of Plasma ApoC&#8209;III and TG </font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Reduction of Plasma ApoC&#8209;III and TG<br />in Humans</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:auto;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 10.1pt;line-height:105%;text-indent: -10.1pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;"><img src="gemp20161231x10k005.jpg" style="width: 2.541667in; height: 3.354167in" alt="Picture 18"></font></p>
				</td>
				<td valign="bottom" style="width:auto;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;"><img src="gemp20161231x10k006.jpg" style="width: 3.197917in; height: 3.364583in" alt="Picture 17"></font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">17</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:12pt 0pt 12pt 72pt;text-indent: -36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(2)<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 27pt 0pt 0pt;"></font></font><font style="display:inline;font-family:Times;">Gemcabene reduces de novo lipogenesis through both hepatic cholesterol and TG synthesis, which lowers TG-rich lipoproteins (e.g., VLDLs) and their metabolic product (LDL) in the plasma. Gemcabene has been shown to inhibit radiolabeled acetate incorporation into TG and cholesterol in primary rat hepatocytes in culture and in the liver of mice, supporting gemcabene&#x2019;s mechanism of action by inhibition of the synthesis of both fatty acids and cholesterol. </font><font style="display:inline;">Gemcabene may act as an inhibitor of ACC targeting the rate&#8209;limiting enzyme in fatty acid synthesis, subsequently leading to a decreased hepatic triglyceride production. Gemcabene, also appears to inhibit HMGCoA synthase, an early step in the cholesterol synthesis pathway.</font>
		</p>
		<p style="margin:12pt 0pt 12pt 72pt;text-indent: -36pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Gemcabene Inhibits </font><font style="display:inline;font-weight:bold;font-style:italic;">de novo</font><font style="display:inline;font-weight:bold;"> Synthesis of Both Cholesterol and Triglycerides</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k007.jpg" style="width: 4.229167in; height: 2.885417in" alt="Picture 16"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-size:8pt;">Source: Research Report 76100065 (2013)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The diagram below depicts the novel mechanisms of gemcabene. We will continue to undertake preclinical studies to further clarify gemcabene&#x2019;s involvement in various metabolic pathways.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">18</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Gemcabene Novel Mechanism of Action</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k008.jpg" style="width: 6.729167in; height: 4.6875in" alt="Picture 10"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, we believe gemcabene may result in the reduction of inflammation, inflammatory markers and triglycerides (as a result of reduced apoC&#8209;III production) in the plasma of a patient in an inflammatory state. C&#8209;reactive Protein (CRP) is an inflammatory marker protein. CRP levels increase in response to inflammatory states and are associated with medical conditions such as atherosclerosis and other cardiovascular diseases, arthritis, hypertension, obesity, insulin resistance, and fatty liver disease. CRP expression is regulated by proteins in the nucleus of cells known as nuclear hormone receptors (NHRs). In inflammatory states, cytokines, such as interleukin&#8209;6 (IL&#8209;6) and interleukin (IL1&#8209;&#x3B2;), activate NHRs, such as C/EPB&#8209;&#x3B2;, C/EPB&#8209;&#x3B4; and nuclear factor kappa B (NF&#8209;&#x3BA;B), and lead them to bind to the CRP promoter and increase CRP mRNA production. Based on preclinical studies, gemcabene may inhibit the interaction of these NHRs on the CRP promoter and therefore reduce CRP mRNA production. Gemcabene has also been shown in preclinical studies to inhibit tissue necrosis factor&#8209;&#x3B1; (TNF&#8209;&#x3B1;) induced expression of the inflammatory cytokine IL&#8209;6 in human coronary artery endothelial cells and in a human hepatoma cell line. Overall, gemcabene may not only decrease the expression of CRP, but may also decrease the expression of the inflammatory cytokine IL&#8209;6 resulting in a reduction of inflammation. Gemcabene has been shown to reduce the level of CRP in human clinical trials, to decrease inflammation in a mouse model of arthritis, a mouse model of NASH, and to decrease pain in a rat model of thermal hyperalgesia.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The apoC&#8209;III promoter also contains a NF&#8209;&#x3BA;B binding site, and as such, the apoC&#8209;III gene may be upregulated under a chronic inflammatory state. Gemcabene&#x2019;s ability to reduce apoC&#8209;III&nbsp;mRNA levels may result from gemcabene inhibiting NF&#8209;&#x3BA;B interaction with its binding site on the apoC&#8209;III promoter. We are further exploring this common transcription factor NF&#8209;&#x3BA;B as a binding site for gemcabene to reduce hsCRP and apoC&#8209;III. In contrast, Gemcabene has not been shown to directly or strongly bind to PPARs. See &#x201C;Additional Studies and Trials.&#x201D;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">19</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Clinical Experience</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Gemcabene has been assessed in 18 Phase&nbsp;1 and Phase&nbsp;2 clinical trials. One Phase&nbsp;1 trial was not completed when the program was previously discontinued. Across all trials, 1,289 adult subjects have participated, including healthy volunteers and patients with various underlying conditions (see summary table below). Of the subjects, 895 have been exposed to at least one dose of gemcabene.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe that gemcabene&#x2019;s efficacy across the clinical and non-clinical trials support our development plan focused on HoFH, HeFH, ASCVD, SHTG and NASH patients. In Phase 2 studies, patients treated with gemcabene were observed to have significantly lowered LDL&#8209;C, hsCRP and triglycerides with results from the trials summarized below:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">In a four week, double&#8209;blind, multiple dose, Phase&nbsp;1 trial in 50 healthy subjects (Trial 1027&#8209;003), gemcabene monotherapy doses (450&nbsp;mg, 600&nbsp;mg and 900&nbsp;mg) significantly lowered LDL&#8209;C from baseline by approximately 30%.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">In an eight week, double&#8209;blind, placebo&#8209;controlled, Phase&nbsp;2 trial in 66 patients with elevated LDL&#8209;C on background stable statin therapy (Trial 1027&#8209;018), both gemcabene doses (300&nbsp;mg and 900&nbsp;mg) in combination with statins significantly lowered LDL&#8209;C from baseline by approximately 25% to 31%. Additionally, gemcabene demonstrated reductions in hsCRP of up to 54%.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">In an eight week, double&#8209;blind, placebo&#8209;controlled, Phase&nbsp;2 trial in 277 patients with hypercholesterolemia (Trial A4141001), gemcabene monotherapy doses (300&nbsp;mg, 600&nbsp;mg and 900&nbsp;mg) significantly lowered LDL&#8209;C, with the 600&nbsp;mg and 900&nbsp;mg doses lowering LDL&#8209;C by approximately 30%. Gemcabene monotherapy doses (600&nbsp;mg and 900&nbsp;mg) also significantly lowered hsCRP by approximately 40%.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">In a 12&#8209;week, double&#8209;blind, placebo&#8209;controlled, Phase&nbsp;2 trial (Trial 1027&#8209;004), 94 of the 161 patients had elevated triglycerides (&#x2265; 200&nbsp;mg/dL). For those patients, gemcabene lowered triglycerides in all dose arms, with the 300&nbsp;mg dose lowering triglycerides by 40%. A post&#8209;hoc analysis of nine patients with severe triglyceride levels (&#x2265;500&nbsp;mg/dL) treated with 150&nbsp;mg and 300&nbsp;mg suggest gemcabene has the potential to lower triglycerides by as much as 60%.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Gemcabene was observed to be well tolerated at single doses up to 1,500&nbsp;mg and multiple doses up to 900&nbsp;mg/day. This includes 837&nbsp;subjects who received multiple doses of up to 900&nbsp;mg for up to 12&nbsp;weeks. Safety of the subjects in these trials was evaluated by AE monitoring, clinical laboratory assessments, electrocardiograms (ECGs), physical examinations, and vital sign assessments. Across all trials, 10 healthy volunteers or patients reported a treatment&#8209;emergent SAE, none of which were considered by the clinician to be related to gemcabene. No deaths occurred in any of the trials. AEs reported were generally mild to moderate in intensity with the most common events being headache, weakness, nausea, dizziness, upset stomach, infection and abnormal bowel movements. Gemcabene, when compared with placebo, was not associated with an increased incidence of myalgia or liver enzyme elevations, whether as monotherapy or in combination with statin therapy. Elevated levels of liver enzymes, specifically alanine transaminase (ALT) and/or aspartate aminotransferase (AST), were observed in a few patients (0.23% of gemcabene patients compared to 0.26% of placebo patients had ALT or AST levels more than three times the upper limit of normal (ULN)) returning to baseline after cessation of treatment. Small mean increases in serum creatinine and blood urea nitrogen (BUN) have been observed in some trials. The increase was reversible with all creatinine values returning to baseline within approximately two&nbsp;weeks of cessation of gemcabene. No clinically meaningful changes were observed in physical examinations or vital signs, including blood pressure.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, gemcabene demonstrated promising clinical pharmacology attributes across 10 completed Phase&nbsp;1 trials in healthy subjects, such as once&#8209;daily dosing, no meaningful drug&#8209;drug interactions with high&#8209;intensity statins and no observed food effect. Gemcabene can be taken with or without food. Gemcabene was observed to: (1) be rapidly absorbed following oral administration with time of maximum concentration within two hours and (2)&nbsp;reach maximum plasma concentration (Cmax) and area under the curve over 24&nbsp;hours (AUC 0&#8209;24) that were dose proportional following both single&#8209; and multiple&#8209;dose administration. Steady state concentrations were achieved within six days of repeated dose administration. Average half&#8209;life ranged from 32 to 41&nbsp;hours. Gemcabene&#x2019;s primary route of elimination was renal. In addition, no significant drug&#8209;drug interactions were observed with digoxin, a cardiovascular drug for the treatment of atrial fibrillation, atorvastatin and simvastatin, both agents used as background therapy in patients with HoFH, HeFH and ASCVD. Patients with SHTG and NASH often have statin therapy prescribed as well. There were no observed clinically </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">20</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">relevant effects on QTc, a measure of cardiac rhythm, and no observed clinically relevant effect on blood pressure. Renal clearance was slightly decreased and was associated with a slight increase in serum creatinine. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Based on the results of these trials, we believe gemcabene has the potential to have a differentiated profile as an oral once&#8209;daily, well tolerated adjunct therapy with promising evidence of efficacy in lowering of LDL&#8209;C, hsCRP and triglycerides in patients with dyslipidemia and NASH.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Gemcabene Phase&nbsp;2 Completed Clinical Trials</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Gemcabene has been evaluated in seven Phase&nbsp;2 trials across a diverse patient population. These trials explored safety, tolerability and efficacy and multiple doses of gemcabene as monotherapy and in combination with low&#8209;, moderate&#8209; and high&#8209;intensity statins. The table below summarizes our completed Phase&nbsp;2 clinical trials.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Summary of Phase&nbsp;2 Completed Clinical Trials with Gemcabene </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt solid #000000 ;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 2pt;">
			<font style="display:inline;font-size:2pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:08.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:30.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:08.44%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Trial<br />Number</font></p>
				</td>
				<td valign="bottom" style="width:16.04%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Patient / Indication</font></p>
				</td>
				<td valign="bottom" style="width:30.38%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Trial Objectives</font></p>
				</td>
				<td valign="bottom" style="width:14.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Doses</font></p>
				</td>
				<td valign="bottom" style="width:11.76%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;"># Patients</font></p>
				</td>
				<td valign="bottom" style="width:07.74%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Duration</font></p>
				</td>
				<td valign="bottom" style="width:11.34%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Key Lipid and<br />Other Endpoints</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:08.44%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;text-decoration:underline;">1027-004</font></p>
				</td>
				<td valign="top" style="width:16.04%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Low HDL&#8209;C and normal or elevated TG (including SHTG)</font></p>
				</td>
				<td valign="top" style="width:30.38%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Double&#8209;blind, placebo&#8209;controlled, randomized trial to determine the efficacy and safety of gemcabene in subjects with low HDL&#8209;C and either normal or elevated triglycerides</font></p>
				</td>
				<td valign="top" style="width:14.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">150, 300, 600, 900&nbsp;mg</font></p>
				</td>
				<td valign="top" style="width:11.76%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM=129</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">placebo=32</font></p>
				</td>
				<td valign="top" style="width:07.74%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">12&nbsp;weeks</font></p>
				</td>
				<td valign="top" style="width:11.34%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">HDL&#8209;C, TG, LDL&#8209;C, hsCRP, apoB, Total cholesterol</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:08.44%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">1027&#8209;012</font></p>
				</td>
				<td valign="top" style="width:16.04%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Hypertension</font></p>
				</td>
				<td valign="top" style="width:30.38%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Double&#8209;blind, placebo&#8209;controlled, randomized trial to determine the effect of gemcabene compared to quinapril</font></p>
				</td>
				<td valign="top" style="width:14.30%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">900&nbsp;mg</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">(with quinapril 20&nbsp;mg)</font></p>
				</td>
				<td valign="top" style="width:11.76%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM=43</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">quinapril=18</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">placebo=41</font></p>
				</td>
				<td valign="top" style="width:07.74%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">12&nbsp;weeks</font></p>
				</td>
				<td valign="top" style="width:11.34%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Systolic&nbsp;BP, Diastolic&nbsp;BP</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:08.44%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">1027&#8209;014</font></p>
				</td>
				<td valign="top" style="width:16.04%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Healthy Obese Non&#8209;diabetic</font></p>
				</td>
				<td valign="top" style="width:30.38%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Double&#8209;blind, placebo&#8209;controlled, randomized trial to determine the effect of gemcabene on insulin sensitivity</font></p>
				</td>
				<td valign="top" style="width:14.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">900&nbsp;mg</font></p>
				</td>
				<td valign="top" style="width:11.76%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM=26</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">placebo=27</font></p>
				</td>
				<td valign="top" style="width:07.74%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">4&nbsp;weeks</font></p>
				</td>
				<td valign="top" style="width:11.34%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Insulin sensitivity</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:08.44%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">1027&#8209;015</font></p>
				</td>
				<td valign="top" style="width:16.04%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Hypertension</font></p>
				</td>
				<td valign="top" style="width:30.38%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Double&#8209;blind, placebo&#8209;controlled, randomized trial to determine the effect of gemcabene on blood pressure</font></p>
				</td>
				<td valign="top" style="width:14.30%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">900&nbsp;mg</font></p>
				</td>
				<td valign="top" style="width:11.76%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM=23</font></p>
				</td>
				<td valign="top" style="width:07.74%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">4&nbsp;weeks</font></p>
				</td>
				<td valign="top" style="width:11.34%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Systolic&nbsp;BP, Diastolic&nbsp;BP</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:08.44%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;text-decoration:underline;">1027-018</font></p>
				</td>
				<td valign="top" style="width:16.04%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Hypercholesterolemia (not at goal on stable statin)</font></p>
				</td>
				<td valign="top" style="width:30.38%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Double&#8209;blind, placebo&#8209;controlled, randomized trial to determine the efficacy and safety of gemcabene on stable statin therapy</font></p>
				</td>
				<td valign="top" style="width:14.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">300, 900&nbsp;mg</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">(with various low, moderate and high intensity statins)</font></p>
				</td>
				<td valign="top" style="width:11.76%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM=42</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">placebo=24</font></p>
				</td>
				<td valign="top" style="width:07.74%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">8&nbsp;weeks</font></p>
				</td>
				<td valign="top" style="width:11.34%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">LDL&#8209;C, hsCRP, apoB, TG, HDL&#8209;C, VLDL, Total cholesterol</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:08.44%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;text-decoration:underline;">A4141001</font></p>
				</td>
				<td valign="top" style="width:16.04%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Hypercholesterolemia</font><font style="display:inline;font-weight:bold;font-size:8pt;text-decoration:underline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:30.38%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Double&#8209;blind, placebo&#8209;controlled, randomized trial to determine the efficacy and safety of gemcabene as monotherapy or in combination with atorvastatin (after statin washout)</font></p>
				</td>
				<td valign="top" style="width:14.30%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">300, 600, 900&nbsp;mg</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">(with 10, 40, 80&nbsp;mg atorvastatin)</font></p>
				</td>
				<td valign="top" style="width:11.76%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM=208</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">atorvastatin=52</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">placebo=17</font></p>
				</td>
				<td valign="top" style="width:07.74%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">8&nbsp;weeks</font></p>
				</td>
				<td valign="top" style="width:11.34%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">LDL&#8209;C, hsCRP, apoB, TG, HDL&#8209;C, Total cholesterol</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:08.44%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">A4141004</font></p>
				</td>
				<td valign="top" style="width:16.04%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Osteoarthritis</font></p>
				</td>
				<td valign="top" style="width:30.38%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Double blind, placebo controlled, randomized trial to determine the efficacy and safety of gemcabene in patients with osteoarthritis of the knee</font></p>
				</td>
				<td valign="top" style="width:14.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">150, 450, 900&nbsp;mg</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">(with rofecoxib 25&nbsp;mg)</font></p>
				</td>
				<td valign="top" style="width:11.76%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM=242</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">rofecoxib=79</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">placebo=83</font></p>
				</td>
				<td valign="top" style="width:07.74%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">4&nbsp;weeks</font></p>
				</td>
				<td valign="top" style="width:11.34%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Pain assessment, CGIC, PGIC, SODA</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">SODA=Sequential occupational dexterity assessment, PGIC=Patients global impression of change, CGIC=Clinical global impression of change, GEM=gemcabene; TG=triglycerides.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">21</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Gemcabene Phase&nbsp;2 Trial in Patients with Hypercholesterolemia on Stable Statin Therapy (Trial 1027&#8209;018)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">This Phase&nbsp;2 double&#8209;blind, placebo&#8209;controlled, randomized trial in patients with hypercholesterolemia was designed to assess the efficacy and safety of gemcabene when added to stable statin therapy. A majority of the patients were on moderate&#8209; to high&#8209;intensity statin therapy for at least three months (high &#x2248;20%, mod &#x2248;60% and low &#x2248;20%). Gemcabene was administered at 300&nbsp;mg and 900&nbsp;mg once&#8209;daily for eight weeks. The primary endpoint was median percent change from baseline in LDL&#8209;C. Other endpoints included median percent change from baseline in hsCRP, apoB, total cholesterol, VLDL&#8209;C and triglycerides at Week&nbsp;8. A total of 66&nbsp;patients were randomized and 61 patients were evaluated for efficacy. Baseline LDL&#8209;C levels were similar across the treatment arms at approximately 150&nbsp;mg/dL.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Efficacy:</font><font style="display:inline;"> &nbsp;As presented in the figure below, patients treated with gemcabene were observed to have significantly lowered LDL&#8209;C from baseline at 300&nbsp;mg and 900&nbsp;mg by 25% (p=0.005) and 31% (p&lt;0.001), respectively. Patients treated with gemcabene were also observed to have significantly lowered hsCRP, apoB and total cholesterol. At 900&nbsp;mg, patients treated with gemcabene demonstrated significantly lowered hsCRP by 54% (p&lt;0.001). At 300&nbsp;mg and 900&nbsp;mg, patients treated with gemcabene demonstrated significantly lowered apoB by 20% (p=0.033) and 24% (p=0.003), respectively. At 300&nbsp;mg and 900&nbsp;mg, patients treated with gemcabene demonstrated significantly lowered total cholesterol by 18% (p=0.008) and 22% (p&lt;0.001), respectively. It was further observed that all four (4) patients treated with 900&nbsp;mg gemcabene on high&#8209;intensity statins have a mean LDL&#8209;C reduction of 24%. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe these results support the continued development of gemcabene for the treatment HoFH, HeFH and ASCVD indications on maximally tolerated statins. Classification of statin dose intensity is defined in the 2013 ACC guidelines.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Median Percent Change from Baseline at Week&nbsp;8 in Patients with Hypercholesterolemia</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">on Background Stable Statin Therapy</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k009.jpg" style="width: 6.875in; height: 3.625in" alt="Picture 9"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">22</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">LDL&#8209;C Median Percent Change from Baseline at Week&nbsp;8 in Patients with Hypercholesterolemia</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">on Background Stable Statin Therapy</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt solid #000000 ;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 2pt;">
			<font style="display:inline;font-size:2pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:50.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:17.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:50.90%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.12%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Placebo&nbsp;+&nbsp;Statin</font></p>
				</td>
				<td valign="bottom" style="width:17.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">GEM 300&nbsp;mg&nbsp;+&nbsp;Statin</font></p>
				</td>
				<td valign="bottom" style="width:18.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">GEM 900&nbsp;mg&nbsp;+&nbsp;Statin</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.90%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">n</font></p>
				</td>
				<td valign="bottom" style="width:13.12%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>22&nbsp;
				</td>
				<td valign="bottom" style="width:17.68%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18&nbsp;
				</td>
				<td valign="bottom" style="width:18.30%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.90%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Median Baseline LDL&#8209;C</font></p>
				</td>
				<td valign="bottom" style="width:13.12%;background-color: #DCDDDE;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153.3&nbsp;
				</td>
				<td valign="bottom" style="width:17.68%;background-color: #DCDDDE;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>143.5&nbsp;
				</td>
				<td valign="bottom" style="width:18.30%;background-color: #DCDDDE;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>142.5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.90%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Median Week&nbsp;8 LDL&#8209;C</font></p>
				</td>
				<td valign="bottom" style="width:13.12%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>137&nbsp;
				</td>
				<td valign="bottom" style="width:17.68%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101.5&nbsp;
				</td>
				<td valign="bottom" style="width:18.30%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.90%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Median % Change</font></p>
				</td>
				<td valign="bottom" style="width:13.12%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2212;7.9%</font></p>
				</td>
				<td valign="bottom" style="width:17.68%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2212;24.8%</font></p>
				</td>
				<td valign="bottom" style="width:18.30%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2212;31.0%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.90%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">p&#8209;Value vs. Placebo</font></p>
				</td>
				<td valign="bottom" style="width:13.12%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">N/A</font></p>
				</td>
				<td valign="bottom" style="width:17.68%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.005&nbsp;
				</td>
				<td valign="bottom" style="width:18.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&lt;0.001</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:12pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">*N/A = not applicable</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Safety:</font><font style="display:inline;"> &nbsp;Gemcabene was observed to be well tolerated. Patients taking either 300&nbsp;mg or 900&nbsp;mg of gemcabene were observed to have a safety profile similar to that of placebo (300&nbsp;mg: 20%; 900&nbsp;mg: 23%; placebo: 29%). One patient experienced an SAE in the gemcabene 900&nbsp;mg treatment arm, which was not considered related to treatment. Three patients (placebo: 2, gemcabene 300&nbsp;mg: 1)&nbsp;withdrew from the trial due to an AE, all of which were considered possibly related to treatment. AEs reported were generally mild to moderate in intensity. The most frequent AE in the placebo arm was infection (13%). The most frequent AEs in the gemcabene treatment arms were headache (10%) and infection (10%). There were no meaningful changes in liver enzymes ALT and AST. One patient in the 300&nbsp;mg gemcabene treatment arm had a single laboratory assessment with a rise in creatine kinase of 5 &#xD7; upper limit of normal (ULN). No clinically meaningful changes in physical examinations or vital signs from baseline to the end of the trial were observed for any patient.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Gemcabene Phase&nbsp;2 Trial in Patients with Hypercholesterolemia (Trial A4141001)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">This Phase&nbsp;2 double&#8209;blind, placebo&#8209;controlled, randomized trial was designed to assess the efficacy and safety of gemcabene administered as monotherapy, atorvastatin monotherapy or gemcabene initiated simultaneously in combination with atorvastatin in the treatment of patients with hypercholesterolemia. When applicable, patients were washed out of statins and other lipid&#8209;lowering therapies. Gemcabene was administered as monotherapy once&#8209;daily at 300&nbsp;mg, 600&nbsp;mg or 900&nbsp;mg or in combination with atorvastatin once&#8209;daily at 10&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg. The primary endpoint was percent change in LDL&#8209;C from baseline at Week&nbsp;8. Secondary endpoints included percent change in hsCRP, apoB, HDL&#8209;C and triglycerides from baseline at Week&nbsp;8. A total of 277&nbsp;patients were randomized and 255 patients with at least one post baseline assessment were included in the efficacy analysis. Baseline LDL&#8209;C levels for the evaluable patients after washout were similar across treatment arms at approximately 175&nbsp;mg/dL.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Efficacy:</font><font style="display:inline;"> &nbsp;As presented in the figure below, patients treated with gemcabene were observed to have significantly lowered LDL&#8209;C by 17% (p=0.0013), 26% (p=0.0001) and 29% (p=0.0001) as monotherapy at 300 mg, 600&nbsp;mg and 900&nbsp;mg, respectively. The LDL&#8209;C lowering effect was seen within two weeks and was stable for the duration of the eight week trial. It is important to note that the patients included in this trial were statin responsive (able to reach goal near or below 100&nbsp;mg/dL) at 10&nbsp;mg, 40&nbsp;mg and 80&nbsp;mg atorvastatin monotherapy. While the trial demonstrated gemcabene provided additional dose dependent LDL&#8209;C lowering (statistically significant at 600&nbsp;mg and 900&nbsp;mg when compared to atorvastatin alone), the gemcabene treatment effect was less pronounced due to the patients already being at or below LDL&#8209;C goal of 100&nbsp;mg/dL on atorvastatin monotherapy. Patients treated with gemcabene were observed to have lowered hsCRP by 26% (p=0.1612), 42% (p=0.0070) and 35% (p=0.0018) as monotherapy at 300&nbsp;mg, 600&nbsp;mg and 900&nbsp;mg, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Patients treated with gemcabene in combination with atorvastatin aggregated over the dose range were observed to have mean LDL&#8209;C lowering of 50% (p=0.0852), 52% (p=0.0045) and 54% (p=0.0006) at 300&nbsp;mg, 600&nbsp;mg and 900&nbsp;mg, respectively. Patients treated with gemcabene in combination with atorvastatin aggregated over the dose range were observed to have median hsCRP lowering of 47% (p=0.0237), 54% (p=0.0017) and 60% (p=0.0001) at 300&nbsp;mg, 600&nbsp;mg and 900&nbsp;mg, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe these results support the continued development of gemcabene for the treatment HoFH, HeFH and ASCVD indications including mixed dyslipidemia.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">23</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;">LDL&#8209;C Mean Percent Change from Baseline in Patients with Hypercholesterolemia</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(with wash&#8209;out of statins)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k010.jpg" style="width: 6.958333in; height: 4.5in" alt="Picture 8"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Safety:</font><font style="display:inline;"> &nbsp;Gemcabene was observed to be well tolerated. Patients taking any dose of gemcabene (300 mg, 600 mg or 900 mg) were observed to have a safety profile similar to that of atorvastatin monotherapy. A similar percentage of patients experienced an associated AE between placebo (18%), atorvastatin monotherapy arms (14%) compared to gemcabene monotherapy (18%) and gemcabene plus atorvastatin treatment arms (17%). Three patients in the gemcabene plus atorvastatin arm experienced a SAE, none of which were considered related to treatment. 16 patients (placebo: 1, atorvastatin monotherapy: 2, gemcabene monotherapy: 6, gemcabene plus atorvastatin: 7)&nbsp;withdrew from the trial due to AEs, nine (atorvastatin monotherapy: 2, gemcabene monotherapy: 4, gemcabene plus atorvastatin: 3)&nbsp;of which were considered possibly related to treatment. AEs reported were generally mild to moderate in intensity. 14&nbsp;patients (placebo: 1, atorvastatin monotherapy: 2, gemcabene monotherapy: 1, gemcabene plus atorvastatin: 10)&nbsp;reported an AE considered severe in intensity, one (gemcabene plus atorvastatin: 1)&nbsp;of which was considered possibly related to treatment. The most frequently occurring AEs across all treatment arms were infection (8%), pain (6%) and headache (6%). Small mean increases in serum creatinine and BUN were observed in the gemcabene monotherapy arms. One patient treated with 600 mg gemcabene plus atorvastatin had a clinically significant ALT elevation (&gt;3 &#xD7; ULN on two separate occasions) that returned to near normal levels while treatment continued. No other patient had a pre&#8209;specified clinically significant lab abnormality in ALT, AST, creatinine kinase or serum creatinine. No clinically meaningful changes in physical examinations or vital signs from baseline to the end of the trial were observed for any patient. The AEs experienced by more than 10% of patients in any treatment group are summarized below.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">24</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;font-weight:bold;">Adverse Events by Body System Occurring With &#x2265; 10% of Patients in</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Any Treatment Group for Study A4141001</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt solid #000000 ;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 2pt;">
			<font style="display:inline;font-size:2pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.04%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:16.08%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Atorvastatin Mono</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:21.54%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Gemcabene 300 mg&nbsp;+<br />Atorvastatin</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:22.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Gemcabene 600 mg&nbsp;+<br />Atorvastatin</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:22.58%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Gemcabene 900 mg&nbsp;+<br />Atorvastatin</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">AE Category</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Pbo<br />N=17</font></p>
				</td>
				<td valign="bottom" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">10 mg<br />N=17</font></p>
				</td>
				<td valign="bottom" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">40 mg<br />N=18</font></p>
				</td>
				<td valign="bottom" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">80 mg<br />N=17</font></p>
				</td>
				<td valign="bottom" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Mono<br />N=16</font></p>
				</td>
				<td valign="bottom" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">10 mg<br />N=17</font></p>
				</td>
				<td valign="bottom" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">40 mg<br />N=18</font></p>
				</td>
				<td valign="bottom" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">80 mg<br />N=18</font></p>
				</td>
				<td valign="bottom" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Mono<br />N=18</font></p>
				</td>
				<td valign="bottom" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">10 mg<br />N=18</font></p>
				</td>
				<td valign="bottom" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">40 mg<br />N=16</font></p>
				</td>
				<td valign="bottom" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">80 mg<br />N=18</font></p>
				</td>
				<td valign="bottom" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Mono<br />N=17</font></p>
				</td>
				<td valign="bottom" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">10 mg<br />N=18</font></p>
				</td>
				<td valign="bottom" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">40 mg<br />N=16</font></p>
				</td>
				<td valign="bottom" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">80 mg<br />N=18</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="18" valign="top" style="width:99.98%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">All Adverse Events</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Body as a whole</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">5 (29)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">4 (24)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">5 (28)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">4 (24)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">5 (31)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (18)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">5 (28)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">4 (22)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">7 (39)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">7 (39)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">4 (25)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">4 (22)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">4 (24)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">5 (28)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">8 (50)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 3.3pt 0pt 0pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">10 (56)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Asthenia</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Back Pain</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Headache</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (17)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Infection</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (18)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">3 (19)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">3 (17)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (17)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Pain</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (12)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (17)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Digestion</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (12)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (12)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">5 (28)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (18)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">3 (31)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (18)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">4 (22)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (17)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">4 (22)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">5 (28)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (19)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">4 (22)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">4 (24)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (17)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (17)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Constipation</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (17)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (12)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Diarrhea</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (18)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">2 (13)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Dyspepsia</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Flatulence</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">2 (13)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Nausea</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">2 (13)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">3 (18)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Musculoskeletal</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (12)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (17)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (12)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (17)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (19)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">3 (17)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Arthralgia</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (12)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (13)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:11.14%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">Myalgia</font></p>
				</td>
				<td valign="top" style="width:05.94%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.32%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.46%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.20%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.66%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.36%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.62%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">2 (11)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:06.06%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.48%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">1 (6)</font></p>
				</td>
				<td valign="top" style="width:05.72%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
				<td valign="top" style="width:05.68%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">0 (0)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6.5pt;">AE&nbsp;= adverse event; Mono&nbsp;= monotherapy; Pbo&nbsp;= placebo.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 6pt;">
			<font style="display:inline;font-size:6.5pt;">Source: Report A4141001, Table&nbsp;40 (Cowmeadow et al., 2003)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Gemcabene Phase&nbsp;2 Trial in Patients with Elevated Triglycerides (Trial 1027&#8209;004)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">This Phase&nbsp;2 double&#8209;blind, placebo&#8209;controlled, randomized trial was designed to assess the efficacy and safety of gemcabene in patients with low HDL&#8209;C and either normal or elevated triglycerides. Gemcabene was administered at 150, 300, 600 and 900 mg once&#8209;daily for 12&nbsp;weeks. The objectives of this trial were to evaluate percentage change from baseline in HDL&#8209;C, LDL&#8209;C, triglycerides and other lipids and apolipoprotein variables at Week 12. A total of 161 patients were randomized. At baseline, 67 patients were normotriglyceridemic (&lt;200 mg/dL) and 94 patients were hypertriglyceridemic (&#x2265;200 mg/dL). Baseline triglycerides were approximately 370 mg/dL across the treatment arms with hypertriglyceridemia with the exception of the 600 mg treatment arm (580 mg/dL). A total of 155 patients (89 hypertriglyceridemic patients) had a post randomization assessment to be evaluated for efficacy. Baseline LDL&#8209;C levels for the evaluable patients, regardless of the triglyceride stratum, were similar across the treatment arms at approximately 110 mg/dL.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Efficacy:</font><font style="display:inline;"> &nbsp;As presented in the figure below, patients with triglyceride levels greater than 200 mg/dL (hypertriglyceridemic patients), treated with gemcabene at 150 mg and 300 mg were observed to have lowered triglycerides by 27% (p=0.002) and 39% (p&lt;0.001), respectively compared to baseline. Although patients treated with gemcabene at 600 mg and 900 mg were observed to have lower triglycerides, the lowering effect was not significant when compared to placebo. Therefore, the anticipated dose for treatment of patients with elevated triglyceride levels is 150 mg or 300 mg. Notably, patients treated with gemcabene were observed to have significantly lowered LDL&#8209;C by 19% (p&lt;0.001) and 20% (p&lt;0.001) at 600 mg and 900 mg, respectively, compared to baseline.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A post&#8209;hoc analysis of the nine patients with severe triglyceride levels (&#x2265;500 mg/dL; baseline means of two weeks prior and time zero was approximately 600 mg/dL) treated with 150 mg and 300 mg suggest gemcabene has the potential to lower triglycerides by as much as 60%.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe these results support the continued development of gemcabene for the treatment SHTG and ASCVD patients with mixed dyslipidemia.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">25</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Triglyceride Median Percent Change from Baseline at Week 12 in Patients with High to Severe Hypertriglyceridemia</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k011.jpg" style="width: 7in; height: 3.4375in" alt="Picture 7"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Safety:</font><font style="display:inline;"> &nbsp;Gemcabene was observed to be well tolerated. Patients taking any dose of gemcabene (150 mg, 300 mg, 600 mg or 900 mg) were observed to have a safety profile similar to that of placebo. Fewer patients experienced an associated AE in the placebo arm (9%) compared to gemcabene treatment arms (17%). Three patients (placebo: 1, gemcabene: 2)&nbsp;experienced SAEs, none of which were considered related to treatment. Six patients (placebo: 2, gemcabene: 4)&nbsp;withdrew from the trial due to AEs, four (placebo: 1, gemcabene: 3)&nbsp;of which were considered possibly related to treatment. AEs reported were generally mild to moderate in intensity. Two patients (placebo: 1, gemcabene: 1)&nbsp;reported an AE considered severe in intensity. The most frequent AEs in the placebo arm were infection (16%), accidental injury (6%), back pain (6%), dyspepsia (6%), headache (6%) and sinusitis (6%). The most frequently observed AEs in the gemcabene arms were infection (12%), headache (7%) and asthenia (5%). Two patients had ALT values that met the definition of a clinically important laboratory abnormality (placebo: 1, 600 mg gemcabene: 1). One patient had elevated BUN values considered clinically significant (600 mg gemcabene: 1). All of these laboratory abnormalities were considered mild to moderate. No clinically meaningful changes in physical examinations or vital signs from baseline to the end of the trial were observed for any patient.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Gemcabene Phase&nbsp;1 Clinical Trials</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Gemcabene has been evaluated in ten completed Phase&nbsp;1 trials in healthy volunteers. These trials explored safety, tolerability, pharmacokinetics, pharmacodynamics and dose response as monotherapy and in combination with high&#8209;intensity statin doses and other drugs. The table below summarizes our completed Phase&nbsp;1 trials. Select trials are described in more detail below.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">26</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Summary of Phase&nbsp;1 Clinical Trials of Gemcabene in Healthy Volunteers</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:10.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:44.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:18.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.00%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Trial Number</font></p>
				</td>
				<td valign="bottom" style="width:05.88%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-size:7pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:44.12%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Trial Objectives</font></p>
				</td>
				<td valign="bottom" style="width:18.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Doses</font></p>
				</td>
				<td valign="bottom" style="width:11.44%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;"># Volunteers</font></p>
				</td>
				<td valign="bottom" style="width:10.26%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 1pt;border-bottom:1pt solid #000000 ;line-height:105%;text-align:center;font-family:Times New Roman,Times,serif;font-size: 7pt;">
						<font style="display:inline;font-weight:bold;font-size:7pt;">Duration</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.88%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">1027&#8209;001</font></p>
				</td>
				<td valign="top" style="width:44.12%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Single&#8209;dose trial to evaluate safety, tolerability and pharmacokinetics (PK) of gemcabene</font></p>
				</td>
				<td valign="top" style="width:18.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">25, 100, 300, 600, 1,050, 1,500&nbsp;mg</font></p>
				</td>
				<td valign="top" style="width:11.44%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM&nbsp;= 12</font></p>
				</td>
				<td valign="top" style="width:10.26%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Single Dose</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.88%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">1027&#8209;002</font></p>
				</td>
				<td valign="top" style="width:44.12%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Single&#8209;dose trial to evaluate the effect of food on the PK of gemcabene</font></p>
				</td>
				<td valign="top" style="width:18.30%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">450&nbsp;mg</font></p>
				</td>
				<td valign="top" style="width:11.44%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM&nbsp;= 12</font></p>
				</td>
				<td valign="top" style="width:10.26%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Single Dose</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.88%;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;text-decoration:underline;">1027-003</font></p>
				</td>
				<td valign="top" style="width:44.12%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Double blind, placebo controlled, randomized trial to evaluate the PK and pharmacodynamics (PD) at multiple doses of gemcabene</font></p>
				</td>
				<td valign="top" style="width:18.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">50, 150, 450, 750/600, 900&nbsp;mg</font></p>
				</td>
				<td valign="top" style="width:11.44%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM&nbsp;= 40</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">placebo&nbsp;= 10</font></p>
				</td>
				<td valign="top" style="width:10.26%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">4 Weeks</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.88%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;text-decoration:underline;">1027-008</font></p>
				</td>
				<td valign="top" style="width:44.12%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Trial to determine the potential drug&#8209;drug interactions of simvastatin with gemcabene</font></p>
				</td>
				<td valign="top" style="width:18.30%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">900&nbsp;mg</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">(with 80&nbsp;mg simvastatin)</font></p>
				</td>
				<td valign="top" style="width:11.44%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM&nbsp;= 20</font></p>
				</td>
				<td valign="top" style="width:10.26%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">15 Days</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.88%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">1027&#8209;009</font></p>
				</td>
				<td valign="top" style="width:44.12%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Trial to evaluate the bioequivalence between a capsule and tablet formulation of gemcabene</font></p>
				</td>
				<td valign="top" style="width:18.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">300&nbsp;mg</font></p>
				</td>
				<td valign="top" style="width:11.44%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM&nbsp;= 16</font></p>
				</td>
				<td valign="top" style="width:10.26%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Single Dose</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.88%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">1027&#8209;010</font></p>
				</td>
				<td valign="top" style="width:44.12%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Trial to evaluate the mass balance and metabolism of gemcabene</font></p>
				</td>
				<td valign="top" style="width:18.30%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">600&nbsp;mg</font></p>
				</td>
				<td valign="top" style="width:11.44%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM&nbsp;= 6</font></p>
				</td>
				<td valign="top" style="width:10.26%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Single Dose</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.88%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">1027&#8209;011</font></p>
				</td>
				<td valign="top" style="width:44.12%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Trial to determine the potential drug&#8209;drug interactions of digoxin with gemcabene</font></p>
				</td>
				<td valign="top" style="width:18.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">900&nbsp;mg</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">(with 0.25&nbsp;mg digoxin)</font></p>
				</td>
				<td valign="top" style="width:11.44%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM&nbsp;= 12</font></p>
				</td>
				<td valign="top" style="width:10.26%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">10 Days</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.88%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;text-decoration:underline;">A4141002</font></p>
				</td>
				<td valign="top" style="width:44.12%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Trial to determine the potential drug&#8209;drug interactions of atorvastatin with gemcabene</font></p>
				</td>
				<td valign="top" style="width:18.30%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">300, 900&nbsp;mg</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">(with 80&nbsp;mg atorvastatin)</font></p>
				</td>
				<td valign="top" style="width:11.44%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM&nbsp;= 20</font></p>
				</td>
				<td valign="top" style="width:10.26%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">22 Days</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.88%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">A4141003</font></p>
				</td>
				<td valign="top" style="width:44.12%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Trial to evaluate the effect of gemcabene on QT interval</font></p>
				</td>
				<td valign="top" style="width:18.30%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">900&nbsp;mg</font></p>
				</td>
				<td valign="top" style="width:11.44%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM&nbsp;= 20</font></p>
				</td>
				<td valign="top" style="width:10.26%;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">8 Days</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:15.88%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt 10pt;line-height:105%;text-indent: -10pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">A4141005</font></p>
				</td>
				<td valign="top" style="width:44.12%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Trial to evaluate the effect of gemcabene on the glomerular filtration rate</font></p>
				</td>
				<td valign="top" style="width:18.30%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">900&nbsp;mg</font></p>
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">(with 3,235&nbsp;mg lohexol)</font></p>
				</td>
				<td valign="top" style="width:11.44%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">GEM&nbsp;= 12</font></p>
				</td>
				<td valign="top" style="width:10.26%;background-color: #DCDDDE;padding:0pt 4.3pt;">
					<p style="margin:0pt 0pt 4pt;line-height:105%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">10 Days</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 12pt 36pt;text-indent: -36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Note:<font style="display:inline;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 21pt 0pt 0pt;"></font>One trial (A4141006; 23&nbsp;volunteers) was stopped prior to completion as a result of discontinuation of the program. The trial was designed to evaluate multiple fixed&#8209;dose combinations of gemcabene with atorvastatin.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Gemcabene Phase&nbsp;1 Drug&#8209;Drug Interaction Trials to Assess PK on Statins (Trials 1027&#8209;008 and A4141002)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Two open&#8209;label, multiple&#8209;dose, Phase&nbsp;1 trials were conducted to assess PK of gemcabene in combination with high&#8209;intensity statins. In Trial&nbsp;1027&#8209;008, 900&nbsp;mg of gemcabene was co&#8209;administered with 80&nbsp;mg simvastatin in 20 healthy volunteers. In Trial A4141002, 300&nbsp;mg and 900&nbsp;mg of gemcabene were co&#8209;administered with 80&nbsp;mg atorvastatin in 20 healthy volunteers. In both trials, treatment with gemcabene in combination with statins was observed to be well tolerated by volunteers. Furthermore, as presented in the figures below, the PK profiles with and without 900&nbsp;mg gemcabene were observed to be similar, suggesting no clinically relevant drug&#8209;drug interactions with either 80&nbsp;mg simvastatin or 80&nbsp;mg&nbsp;atorvastatin. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">PK Profiles of High&#8209;Intensity Statins Co&#8209;administered with Gemcabene</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k012.jpg" style="width: 7in; height: 2.3125in" alt="Picture 6"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">27</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Gemcabene Preclinical Studies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As part of a comprehensive nonclinical toxicology program, over 30 exploratory and definitive single and repeated&#8209;dose toxicity studies with gemcabene were conducted in mice, rats, dogs and monkeys. There are very few outstanding nonclinical studies needed for registration such as two&#8209;year carcinogenicity studies in rodents and juvenile toxicology. Gemcabene was well tolerated in these completed studies, including a 26&#8209;week repeat dose study in rats and monkeys and 52&#8209;week repeat dose study in monkeys. The completed studies support conducting clinical trials up to six months.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In multiple preclinical efficacy studies, gemcabene was observed to have lowering effects on plasma LDL&#8209;C, triglycerides and anti&#8209;inflammatory markers in diet&#8209;induced and genetic preclinical models of dyslipidemia.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">In Vivo Proof of Principle Study for HoFH</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In LDL&#8209;receptor deficient mice, gemcabene at 60&nbsp;mg/kg/day was observed to reduce LDL&#8209;C up to 55% as monotherapy and 72% in combination with statins. This dose in mice is equivalent to approximately a 450&nbsp;mg gemcabene tablet per day in humans. This LDL&#8209;receptor deficient animal model has been reported in literature to be fairly predictive of HoFH therapies in practice. For example, statin lowering of approximately 20% in LDL&#8209;receptor deficient&#8209;mice model correlates well to the approximately 15% to 20% LDL&#8209;C lowering observed in HoFH patients, and Juxtapid lowering of approximately 50% to 80% in LDL&#8209;receptor deficient&#8209;rabbits model correlates well to the approximately 40% to 50% in HoFH patients.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Gemcabene Preclinical HoFH Mice Model</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k013.jpg" style="width: 4.052083in; height: 2.75in" alt="Picture 5"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:105.83%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">28</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">In Vivo Proof of Principle for Hepatic Triglyceride Reduction </font>
		</p>
		<p style="margin:12pt 0pt 6pt;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">Gemcabene was studied in a chow-fed Sprague-Dawley rat model to explore the effects on fat content in the liver. The results of gemcabene 10 and 30 mg/kg/day doses in this rat model were similar to gemfibrozil. Gemcabene treatment significantly reduced hepatic triglycerides by 74% in chow-fed Sprague-Dawley rats.</font>
		</p>
		<p style="margin:12pt 0pt 6pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Hepatic Lipids in Male Sprague-Dawley Rats Treated with Gemfibrozil or Gemcabene</font>
		</p>
		<p style="margin:12pt 0pt 6pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"><img src="gemp20161231x10k014.jpg" style="width: 5.090278in; height: 3.604167in" alt="Picture 19"></font>
		</p>
		<p style="margin:12pt 0pt 6pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">In Vivo Proof of Concept for NASH (STAM Murine Model of NASH and Hepatocellular Carcinoma)</font><font style="display:inline;font-family:Times;">&nbsp;</font>
		</p>
		<p style="margin:12pt 0pt 6pt;border-top:1pt none #D9D9D9 ;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times;font-size:10pt;">NASH was induced in 40 male mice by a single subcutaneous injection of 200 &#xB5;g streptozotocin solution 2 days after birth and feeding with a high fat diet. Histological analyses of the liver were the key endpoints for the determination of an effect of gemcabene in this preclinical model of NASH.</font><font style="display:inline;font-size:10pt;"> NASH is defined by the presence and pattern of specific histological abnormalities on liver biopsy. The NAFLD Activity Score (NAS) is a composite score that was developed as a tool to measure changes in NAFLD during therapeutic trials. NAS is a composite score comprised of three components that includes scores for steatosis, lobular inflammation and hepatocyte ballooning. NAS was defined as the unweighted sum of the scores for steatosis, lobular inflammation and hepatocyte ballooning. Steatosis grade is quantified as the percentage of hepatocytes that contain fat droplets. The fibrosis stage of the liver is evaluated separately from NAS by histological evaluation of the intensity of sirius red staining of collagen in the pericentral region of liver lobules. NAS scores of 0-2 are not considered diagnostic for NASH, NAS scores of 3-4 are considered either not diagnostic, borderline or positive for NASH, while NAS scores of 5-8 are largely considered diagnostic for NASH. A treatment effect for NASH is based on differences in both NAS and fibrosis levels.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">29</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The gemcabene 30 and 300 mg/kg groups and telmisartan group (included as a positive control) showed significant reduction in NAS compared with the Vehicle in NASH group. Since gemcabene reduced steatosis and ballooning scores, the data suggested that gemcabene improved NASH pathology by inhibiting hepatocyte damage and ballooning cell formation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">STAM Model NAFLD Activity Score (NAS)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k015.jpg" style="width: 2.625in; height: 3.260417in" alt="Picture 3"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Sirius red-stained liver sections were evaluated to determine liver fibrosis. Liver sections from the Vehicle in NASH group showed increased collagen deposition in the pericentral region of liver lobule compared with the Vehicle in Normal group. All gemcabene groups showed significant decreases in fibrosis area compared with the Vehicle in NASH group.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">STAM Model Fibrosis (Sirius Red-Positive Area)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 13pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:13.5pt;"><img src="gemp20161231x10k016.jpg" style="width: 2.833333in; height: 3.28125in" alt="Picture 2"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">30</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Additionally, hepatic gene expression and plasma markers indicative of inflammation (e.g., CRP and CCR2/CCR5), and lipid modulation (e.g., ApoC-III and ACC1) were significantly reduced as were other markers. Gemcabene demonstrated proof of concept on NAS score and fibrosis, supporting further development in the clinic.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Gemcabene Clinical Development Plan</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In June and September 2015, Gemphire received FDA feedback from its Type&nbsp;C meetings related to the development of gemcabene for the treatment of patients with HoFH. The FDA indicated that historically LDL&#8209;C has been accepted as a surrogate endpoint for cardiovascular risk reduction for lipid&#8209;altering drugs to support traditional approval, including patients with HoFH. The FDA reiterated weighing the magnitude of LDL&#8209;C reduction in light of the drug&#x2019;s safety profile (e.g., benefit/risk) when using a surrogate endpoint such as LDL&#8209;C. Our investigational new drug application (IND) was submitted to the FDA in December 2015 and is in effect. We have also received approvals to initiate studies in the dyslipidemic indications in Canada and Israel.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have initiated three late stage clinical trials in 2016, and plan to initiate a late stage trial in NASH in 2017. Upon completion of one or more of these clinical trials, we intend to request one or more EOP2 meetings with the FDA and other foreign regulatory authorities to discuss the design and scope of the Phase&nbsp;3 registration trials and long&#8209;term safety exposure needed for registration. We would expect to launch multiple Phase&nbsp;3 registration trials no later than 2018 for our targeted indications. The development programs for our targeted indications are described below. The in&#8209;vitro drug transport studies have been completed in accordance with FDA guidelines, and we expect to conduct a few additional clinical pharmacology Phase&nbsp;1 trials to support registration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">HoFH: COBALT Program</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The clinical development program HoFH patients is expected to include one Phase&nbsp;2 (GEM-201, COBALT-1) and one Phase&nbsp;3 (GEM&#8209;202, COBALT&#8209;2) registration trial. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">COBALT-1 is an open-label, dose-escalation study in subjects with HoFH. Up to 8 subjects with genetically diagnosed or meeting clinical criteria are given once daily gemcabene and sequentially titrated every four weeks. Gemcabene doses are 300 mg, 600 mg and 900 mg. Patients are on a background of maximized tolerated stable statin therapy, with or without ezetimibe and with or with evolocumab. The primary endpoint will be LDL&#8209;C lowering from baseline at 4, 8, and 12&nbsp;weeks, the acceptable surrogate endpoint for approval. Other endpoints will include hsCRP, apoB, non-HDL&#8209;C, triglycerides, VLDL and total cholesterol. Safety of these patients will be assessed by AE monitoring, clinical laboratory assessments, ECGs, physical examinations and vital sign assessments. An interim analysis on the first two genetically diagnosed HoFH patients was performed in January 2017. The mean percent reduction in LDL-C for these two subjects was 28%. As of March 2017, six patients have been enrolled in COBALT-1 with two additional patients being evaluated for enrollment for a total of 6 to 8 patients, which we believe will be sufficient to support advancement into Phase 3. Top-line results at the 600 mg target commercial dose are expected by end of June 2017. </font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Phase&nbsp;3 registration trial (COBALT&#8209;2) is estimated to enroll 30 to 60&nbsp;patients, and will be conducted globally with the potential for patients to continue in an open&#8209;label safety extension. It is anticipated that a single Phase&nbsp;3 registration trial is expected to be sufficient to support registration.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Hypercholesterolemia HeFH/ASCVD: ROYAL Program</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The clinical development program for adult patients with hypercholesterolemia (including but not limited to HeFH and ASCVD) with elevated LDL&#8209;C levels while on maximally tolerated high&#8209;intensity statin therapy is expected to include one Phase&nbsp;2 trial (GEM&#8209;301, ROYAL-1) followed by Phase&nbsp;3 registration trials. Current precedent for this high-risk population of patients is that reductions in LDL-C is an acceptable surrogate for registration.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">ROYAL-1 is a 12 week, multicenter, double-blind, placebo-controlled, randomized trial in patients with HeFH and/or ASCVD on stable moderate or high intensity statin therapy with or without ezetimibe. The study will include 104 subjects in two arms, gemcabene 600 mg or placebo. The primary endpoint will be LDL&#8209;C lowering from baseline at 12&nbsp;weeks. Other endpoints will include hsCRP, apoB, non HDL&#8209;C, triglycerides, VLDL and total cholesterol. Safety of these patients will be assessed by AE monitoring, clinical laboratory assessments, ECGs, physical examinations and vital sign assessments. Enrollment initiated in November 2016 and completed in February 2017 with 105 patients, earlier than originally expected, and we expect top-line results will now be available in the third quarter of 2017.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">31</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">After our Phase&nbsp;2 trial and after EOP2 discussions with the FDA meeting and other regulatory agencies, we believe we will be able to better define the Phase&nbsp;3 registration trials and long&#8209;term safety exposure needed for registration.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">SHTG: INDIGO Program</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The clinical development program for adult patients with SHTG with elevated triglyceride levels is expected to include one Phase&nbsp;2 trial (GEM&#8209;401, INDIGO-1) designed to meet anticipated registration standards, followed by a single Phase&nbsp;3 registration trial. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">INDIGO-1 is a 12 week, multicenter, double-blind, placebo-controlled, randomized trial in patients with severe hypertriglyceridemia (SHTG) (TG&#x2265;500mg/dL) with or without statin therapy. The study will enroll 90 subjects into one of three arms, gemcabene 300 mg, gemcabene 600 mg and placebo. The primary endpoint will be TG lowering from baseline after 12&nbsp;weeks. Other endpoints will include LDL&#8209;C, hsCRP, apoB, non HDL&#8209;C, VLDL and total cholesterol. Safety of these patients will be assessed by AE monitoring, clinical laboratory assessments, ECGs, physical examinations and vital sign assessments. We announced that pre-screening activities initiated in December 2016 and top-line results are expected in the fourth quarter of 2017.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">After completion of the Phase&nbsp;2 trial and after EOP2 discussions with the FDA and other regulatory agencies, we believe we will be able to better define the Phase&nbsp;3 registration trials and long&#8209;term safety exposure needed for registration.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">NASH: AZURE Program</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We plan to submit an IND to initiate a Phase 2 clinical program in NASH patients. The trial design will be finalized after review with regulatory authorities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">AZURE-1 (GEM-501) is expected to be a 16 week, multicenter, double-blind, placebo-controlled, randomized study in patients with NASH. Adult patients with MRI-PDFF detected hepatic steatosis (liver fat content) &gt;10% and either biopsy proven NASH with no more than moderate fibrosis, or a magnetic resonance elastography threshold suggestive of NASH with moderate fibrosis will be eligible for enrollment. We expect to enroll 81 subjects in the Phase 2 trial with 27 subjects randomized to one of three arms: gemcabene 300 mg, gemcabene 600 mg, or placebo. The primary endpoint will be the change in fat content from baseline as detected by MRI-PDFF. We expect to initiate this POC study in the second half of 2017, and we anticipate top-line results in the second half of 2018.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">After completion of the Phase 2 trial and after EOP2 discussions with the FDA and other regulatory agencies, we believe we will be able to better define the Phase 3 registration trials and long term safety exposure needed for registration. </font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Additional Studies and Trials</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Studies in Response to Partial Clinical Hold for Compounds in PPAR Class</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Peroxisome proliferation&#8209;activated receptor (PPAR) agonists are drugs which bind and turn on the many PPARs in the nucleus. PPARs comprises three subtypes, PPAR&#x3B1;, PPAR&#x3B3; and PPAR&#x3B2; (also referred to as PPAR&#x3B4;). When the PPARs are activated by natural or pharmaceutical molecules those molecules can regulate (turn&#8209;off or turn&#8209;on) the transcription (making the messenger RNA) of genes that regulate the storage and mobilization of lipids (fats), glucose metabolism, and inflammatory responses. PPAR&#8209;&#x3B1; and PPAR&#x3B3; are the molecular targets of a number of marketed drugs to treat metabolic syndrome including lowering triglycerides and cholesterol such as fibrate drugs and to treat diabetes mellitus and insulin resistance such as thiazolidinedione drugs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Beginning in 2004, the FDA began issuing partial clinical holds to all sponsors of PPARs or agents deemed to have PPAR&#8209;like properties from preclinical studies. The FDA takes the position that preclinical data suggest PPAR agonists are carcinogenic in rodents. In 2004, the FDA determined that gemcabene was a PPAR agonist and issued a partial clinical hold. Our current IND is subject to the same partial clinical hold. The partial clinical hold permits clinical trials of up to six months for gemcabene and also requires us to conduct two&#8209;year rat and mouse carcinogenicity studies before conducting clinical trials of longer than six months. Our two&#8209;year rat and mouse carcinogenicity studies are underway and scheduled for completion by the end of 2017 and draft reports will be issued shortly thereafter.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe the apparent weak PPAR&#x3B1; effects observed in rodents (for example, peroxisome proliferation and elevation of liver weight) are likely rodent&#8209;specific phenomena, and, based on scientific publications reviewing nonclinical and clinical experience, share little apparent relevance for human risk assessment. In a recently completed PPAR agonist receptor binding assays we observed essentially no gemcabene binding to the mouse, rat, or human PPAR&#x3B1;, PPAR&#x3B2;, or PPAR&#x3B3; receptors, whereas reference agents for each of the receptors showed the expected binding, including the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">32</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">marketed PPAR&#x3B1; agents, such as fibrates, including gemfibrozil. We believe the PPAR&#x3B1; responses in the rat are secondary and perhaps related to the mobilization or formation of a naturally occurring molecule that binds to PPAR&#x3B1; in response to gemcabene administration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Cardiovascular Outcomes Trials</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe it is well accepted that every 1.6&nbsp;mg/dL lowering of LDL&#8209;C through the cholesterol synthesis pathway results in a 1% lowering of cardiovascular disease risk. The FDA has not required any approved therapy targeting LDL&#8209;C lowering, including non&#8209;statin therapies, to initiate or complete a cardiovascular outcomes trial in connection with its approval of HoFH, HeFH and ASCVD therapies. Based on recent drug approvals, we believe it is unlikely that the FDA will require us to initiate or complete a cardiovascular outcomes trial for any of the targeted indications, although we would plan to initiate a cardiovascular outcomes trial, for illustration in high&#8209;risk ASCVD patients with mixed dyslipidemia, prior to NDA filing to pursue broader label indications related to cardiovascular disease risk reduction. Notwithstanding our current expectations, the FDA could require us to initiate or complete a cardiovascular outcomes trial as a condition to filing or approving an NDA for gemcabene.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Future In&#8209;licensing and Acquisition Opportunities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our scientific team is well&#8209;qualified to identify, in&#8209;license or acquire, and develop additional product candidates to diversify our pipeline and generate long&#8209;term growth. We continually evaluate and prioritize interesting product candidates based on scientific merit, regulatory pathways, and commercial differentiation. Our focus is on cardiometabolic product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Sales and Marketing</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Given our current stage of development, we have not yet established a commercial organization or distribution capabilities, nor have we entered into any partnership or co&#8209;promotion arrangements with an established pharmaceutical company. To develop the appropriate commercial infrastructure to launch gemcabene in the United States, if approved, for the narrower indications of HoFH, we may build out a specialty sales force to reach a concentrated number of approximately 50 lipid centers and 500&nbsp;lipidologists across the country. This would require additional financial and managerial resources. We may co-promote the SHTG indication with a partner or use a contract sales force along with our internal sales force and distributor(s). We may engage in partnering discussions with third parties from time to time. As we further develop and seek approval as well as launch commercial sales of gemcabene outside of the United States or for broader patient populations in the United States, including patients with HeFH, ASCVD and NASH, we may establish partnerships with one or more pharmaceutical company collaborators, depending on, among other things, the applicable indications, the related costs and our available resources.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">33</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Chemistry, Manufacturing and Controls (CMC)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Gemcabene is a small molecule drug candidate that can be synthesized as a single polymorph crystalline monocalcium salt, using readily available raw materials and based on conventional chemical processes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely on contract manufacturers to produce both the drug substance and drug product amounts required for our preclinical studies and clinical trials under current good manufacturing practices (cGMP), a quality system regulating CMC activities. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since 2015 to date, research and development performed for both drug substance and drug product resulted in a manufacturing process utilized for the production of clinical supply for on-going clinical trials. More specifically, drug substance and drug product process and analytical development have been completed in compliance with the FDA guidelines for Phase 2 clinical trials, and on-going activities are directed to process and method validations for compliance with Phase 3 clinical trials. In addition, our drug product manufacturer has sufficient analytical and process development data to support the manufacture of tablets of various strengths. On-going stability studies for both the drug substance and drug product currently support more than two years of shelf life, sufficient for this stage of development. CMC activities are also oriented towards the initiation of the production of the registration stability lots and validations to support NDA filing and regulatory approvals necessary for the commercial stage.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our contract manufacturers are currently producing, and will produce in the future, our bulk drug substance and drug product for use in our preclinical studies and clinical trials on a purchase order basis, and do not have any long term arrangements. We intend to identify and qualify our current manufacturers as well as alternative manufacturers to provide bulk drug substance and drug product prior to the NDA submission to the FDA to ensure the regulatory support necessary for multiple manufacturing sites in order to supply sufficient commercial quantities at the drug launch and forward. We plan to continue to rely upon contract manufacturers and, potentially, collaboration partners to manufacture commercial quantities of our drug substances and drug product candidates, if approved for marketing by the applicable regulatory authorities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Pfizer License Agreement </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2011, we entered into a license agreement with Pfizer (the Pfizer Agreement) for a worldwide exclusive license to certain patent rights to make, use, sell, offer for sale and import the clinical product candidate gemcabene. In exchange for this license, we agreed to issue shares of our common stock to Pfizer representing 15% of our fully diluted capital at the close of the first arms&#8209;length series&nbsp;A financing, which occurred on March&nbsp;31, 2015.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We agreed to make milestone payments totaling up to $37&nbsp;million upon the achievement of certain milestones, including the first regulatory submission in any country, regulatory approval in each of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of gemcabene or any product containing gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have also agreed to pay Pfizer tiered royalties on a country&#8209;by&#8209;country basis based upon the annual amount of net sales as specified in the Pfizer Agreement until expiration of the last valid claim of the licensed patent rights, including any patent term extensions or supplemental protection certificates. The royalty rates range from the high single digits to the low teens depending on the level of net sales. Under the Pfizer Agreement we are obligated to use commercially reasonable efforts to develop and commercialize gemcabene.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Pfizer Agreement will expire upon expiration of the last royalty term. Either party may terminate the Pfizer Agreement for the other party&#x2019;s uncured material breach and specified bankruptcy events. Pfizer may terminate the Pfizer Agreement if we or any of our sublicensees challenge the validity, enforceability or ownership of the licensed patents. Additionally, Pfizer may revoke the license if we are unable to adequately commercialize gemcabene by April 2021.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Intellectual Property</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our patent estate includes patents and/or patent applications to forms of gemcabene, methods of using gemcabene, and methods of manufacturing gemcabene. The patent estate includes patents licensed from Pfizer and additional patents and </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">34</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">applications that have been filed subsequent to obtaining the license that are entirely owned by Gemphire. Charles Bisgaier, a co-founder of Gemphire, is an inventor on nine of the pending eleven patent families. As of February 20, 2017, Gemphire&#x2019;s patent estate, including patents we own or license from third parties, on a worldwide basis, included four issued U.S. patents, eight pending U.S. patent applications, 45 issued patents in foreign jurisdictions including Canada, France, Germany, Great Britain, Ireland, Italy, Mexico and Spain and 16 pending patent applications in foreign jurisdictions including Australia, Canada, China, Europe, Hong Kong, Japan and Mexico. Of our worldwide patents and pending applications, all relate to our product candidate gemcabene.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">U.S. Patent number&nbsp;6,861,555, which was in&#8209;licensed from Pfizer, includes claims directed to the calcium salt crystal form of gemcabene that is used in our clinical formulations and will constitute the commercial product as well as other crystalline forms of gemcabene. This patent is expected to expire in 2021; however, we may select this patent for patent term extension from the U.S. Patent and Trademark Office (USPTO) if such an extension is available. Given the expected length of the regulatory review, the expiry date of this patent may be extended to 2023, or possibly 2024. Assuming market approval of gemcabene in 2019, data exclusivity would provide exclusivity for gemcabene out to about 2024. Furthermore, and importantly in our case, the FDA orphan designation for HoFH may provide us seven years of market exclusivity for gemcabene in the United States for HoFH. This market exclusivity would provide protection for gemcabene for treating HoFH out to about 2026. Related foreign patents, which have issued in jurisdictions including Canada, Denmark, Finland, France, Germany, Great Britain, Ireland, Italy, the Netherlands, Sweden, Spain, Japan, Mexico and New Zealand, are expected to expire in 2021, absent any adjustments or extensions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">U.S. Patent Number&nbsp;8,557,835, which was also in&#8209;licensed from Pfizer, includes claims directed to pharmaceutical compositions comprised of combinations of gemcabene with statins and methods of using a combination of gemcabene and a statin for treating several conditions including hyperlipidemia. This patent is expected to expire in 2021, absent any extension. Related foreign patents, which have issued in jurisdictions including France, Germany, Great Britain, Ireland, Italy, Spain, Mexico, and Singapore are expected to expire in 2018, absent any adjustments or extensions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">U.S. Patent No.&nbsp;8,846,761, which is owned by Gemphire, includes claims directed to methods of reducing risk of pancreatitis for patients with TG&#x2265; 500&nbsp;mg/dL with gemcabene treatment. This patent is expected to expire in 2032, absent any extension. Foreign patents have issued in Australia, Mexico and Europe. The European patent was validated into 21 European countries. Foreign counterpart patent applications are pending in Australia, Canada, China, Europe, Hong Kong, Mexico and Japan, and any patents issuing from such applications are expected to expire in 2031, absent any adjustments or extensions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">U.S. patent application number&nbsp;14/370,722, which we own, is directed to methods of decreasing a patient&#x2019;s risk for developing coronary heart disease or preventing, delaying or reducing the severity of a secondary cardiovascular event by administering gemcabene with a statin. Related patent applications are pending in foreign jurisdictions including Australia, Canada, China, Europe, Japan and Mexico. Any patent that may issue in this family, absent any patent term adjustment or extension, is expected to expire in 2033.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In 2015-2017, we filed, two non&#8209;provisional patent applications on methods of large scale manufacturing for making dicarboxyalkyl ethers (US Application&nbsp;Number&nbsp;14/942,765 and corresponding PCT application Number&nbsp;PCT/US2015/060917), any patent issuing from this patent family is expected to expire in 2035. In addition, we filed U.S. provisional patent applications of which 62/300,393, 62/314,597, 62/411,997 and 62/412,017, are pending, and two PCT applications one for methods of treating mixed dyslipidemia using gemcabene in combination with statins and treatment of NASH using gemcabene as a monotherapy (PCT/US2016/060837), and the other relating to fixed dose combinations and modified release formulations of gemcabene and statins (PCT/US2016/060849). Two U.S. Patent Applications were filed as continuations of PCT/US2016/060837. U.S. Patent Application Number 15/416,911, is directed to methods of treating NASH by administering gemcabene as a monotherapy and U.S. Patent Application Number 15/424,620, is directed methods for treating Mixed Dyslipidemia by administering gemcabene and a statin.&nbsp;&nbsp;Any patent that may issue in either of these two families, absent any patent term adjustment or extension, is expected to expire in 2037.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As background, the patent term is typically 20&nbsp;years from the date of filing a non&#8209;provisional application. In the United States, a patent&#x2019;s term may be lengthened several ways. First, patent term adjustment (PTA) compensates a patentee for administrative delays by the USPTO in granting a patent. Second, in certain instances, a patent term extension (PTE) can be granted to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, as provided under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch&#8209;Waxman Act. This </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">35</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">restoration period cannot be longer than five years for approval of a drug compound, and the total patent term, including the restoration period, must not exceed 14&nbsp;years following FDA approval. Only one patent applicable to an approved drug is eligible for the PTE and the application for the extension must be submitted prior to the expiration of the patent and within 60&nbsp;days from market approval. Independent of patent protection, in the United States, the Hatch&#8209;Waxman Act provides a five&#8209;year period of non&#8209;patent data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity (NCE). Under this provision, gemcabene may be eligible for up to five years of data and market exclusivity under the Hatch&#8209;Waxman Act, because it is considered a NCE because the FDA has not previously approved any other drug containing the active ingredient of gemcabene. In Europe, under the Data Exclusivity Directive, pharmaceutical companies may receive up to 11&nbsp;years to market their product without risk of competition. In Japan, under the Pharmaceuticals Act of Japan, the market authorization holder, based on the length of a required study period reexamination, may have up to 10&nbsp;years before a generic can enter the market.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Competition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our industry is highly competitive and subject to rapid and significant innovation and change. The market for lipid regulating therapies is especially large and competitive. Our potential competitors include large pharmaceutical and biopharmaceutical companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. Gemcabene, if approved, will face intense competition. Key competitive factors affecting its commercial success will include efficacy, safety, tolerability, reliability, convenience of dosing, price and reimbursement. Although there are currently no approved therapies for NASH, the market for NASH is continuing to evolve with many drug candidates in late stage development.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Statins are the most commonly used therapy to lower LDL&#8209;C in the dyslipidemia market. They are used by patients with HoFH as well as HeFH and ASCVD. Branded statins include AstraZeneca&#x2019;s Crestor (rosuvastatin), Merck&#x2019;s Zocor (simvastatin) and Pfizer&#x2019;s Lipitor (atorvastatin) among others. Generic statins are marketed by several companies including Apotex Inc., Mylan&nbsp;N.V. (Mylan), Dr.&nbsp;Reddy&#x2019;s Laboratories Ltd. and Lupin Pharmaceuticals, Inc. (Lupin) among others.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Non&#8209;statin based therapies are also used to lower LDL&#8209;C in dyslipidemia patients. Merck&#x2019;s Zetia (ezetimibe) is a common non&#8209;statin therapy that is often combined with statins for HoFH, HeFH and ASCVD patients. Merck&#x2019;s Vytorin and Liptruzet are fixed&#8209;dose combination therapies that combine ezetimibe with statins. Non&#8209;statin therapies are combined with statins to improve LDL&#8209;C lowering or to offer other efficacy benefits, including Daiichi Sankyo Inc.&#x2019;s (Daiichi Sankyo) Welchol, a bile acid sequestrant and niacin. Non&#8209;statin therapies are also used to treat HoFH. These therapies include Aegerion&#x2019;s Juxtapid, a once&#8209;daily oral microsomal triglyceride transfer protein (MTP) inhibitor and Ionis and Genzyme Corporation&#x2019;s, a Sanofi Company (Genzyme), Kynamro, a once&#8209;weekly injectable apoB antisense therapy. These agents have boxed warnings associated with liver toxicity and significant tolerability issues on their labels. Amgen&#x2019;s Repatha, an injectable PCSK9 inhibitor, was recently approved for HoFH, HeFH and ASCVD, and Sanofi&#x2019;s and Regeneron&#x2019;s PCSK9 inhibitor, Praluent, was recently approved for HeFH and ASCVD.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There are multiple product candidates in late stage development for HoFH, HeFH and ASCVD. CymaBay Therapeutic&#x2019;s (CymaBay) MBX&#8209;8025 (Phase&nbsp;2), Regeneron&#x2019;s RGEN&#8209;1500 (Phase&nbsp;2), and Madrigal&#x2019;s MGL-3196 (Phase 2) are in development for the treatment of HoFH. For hypercholesterolemia, including HeFH and ASCVD, drugs in development include oral CETPi, Merck&#x2019;s anacetrapib (Phase&nbsp;3), Eli Lilly and Company&#x2019;s evacetrapib (recently discontinued Phase&nbsp;3), and Amgen/Dezima&#x2019;s TA&#8209;8995 (Phase&nbsp;2), current Esperion&#x2019;s oral product, ETC&#8209;1002 (completed Phase&nbsp;2), The Medicines Company/Alnylam Pharmaceuticals, Inc.&#x2019;s (Alnylam) injectable PCSK9 inhibitor, ALN&#8209;PCSsc (completed Phase&nbsp;2), Eli Lilly&#x2019;s injectable PCSK9 inhibitor, LY3015014 (Phase&nbsp;2), and Pfizer&#x2019;s injectable PCSK9 inhibitor bococizumab (recently discontinued Phase 3).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The market for LDL lowering therapy is both large and competitive, and the diagram below depicts the opportunity for gemcabene in 2</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">nd</font><font style="display:inline;"> line oral therapy, especially with discontinuation of competing oral CETPi and injectable PCSK9 inhibitor.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">36</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Competitive LDL&#8209;C Lowering Landscape</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"><img src="gemp20161231x10k017.jpg" style="width: 7in; height: 4.645833in" alt="Picture 1"></font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Fibrates, niacin and prescription fish oil are common therapies used to lower triglycerides in patients with severe hypertriglyceridemia. Examples of branded fibrates include AbbVie&nbsp;Inc.&#x2019;s (AbbVie) Tricor and Trilipix, and an example of a branded niacin includes AbbVie&#x2019;s Niaspan, an extended&#8209;release niacin. In addition, AbbVie markets combination therapies, such as Advicor (niacin extended release and lovastatin) and Simcor (niacin extended release and simvastatin). Prescribed generic versions of fibrates, such as gemfibrozil, are manufactured by many companies including Impax Laboratories, Inc. (Impax), Teva Pharmaceutical Industries Ltd. (Teva), Mylan and Lupin among others. Generic versions of niacins are manufactured by many companies including Teva, Lupin and Zydus Pharmaceuticals (USA), Inc., among others. Commonly used prescription fish oils include GlaxoSmithKline plc&#x2019;s (GlaxoSmithKline) Lovaza, AstraZeneca&#x2019;s Epanova and Amarin&#x2019;s Vascepa. Drugs that are in development for SHTG include Ionis&#x2019; volanesorsen (Phase&nbsp;2).</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Currently there are currently no approved therapies for NASH and older medications are written off label to treat the disease. There are currently more than thirty assets in various stages of development for NASH. Several drug candidates are in late stage development and may be approved for the NASH indication as soon as 2019/2020: OCALIVA (Obeticholic Acid) (FXR Agonist) being developed by Intercept Pharmaceuticals, Inc., Elafibranor (PPAR Agonist) being developed by Genfit SA, Selonsertib (formerly GS-4997) (ASK-1 Inhibitor) being developed by Gilead Sciences, Inc., GS-0976 (ACC Inhibitor) being developed by Gilead Sciences, Inc., Cenicriviroc (CVC) (CCR2/CCR5 Inhibitor) being developed by Tobira Therapeutics, Inc. (a wholly-owned subsidiary of Allergan plc), Emricasan (Caspase Inhibitor) being developed by Conatus Pharmaceuticals Inc., Aramchol (Synthetic Fatty Acid/Bile Acid Conjugate) being developed by Galmed, GR-MD-02 (Galectin-3 Inhibitor) being developed by Galectin Therapeutics, and MGL-3196 (THR Agonist) being developed by Madrigal.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Government Regulation</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Government authorities at the federal, state and local level in the United States and in other countries extensively regulate, among other things, the research, development, testing, manufacture (including any manufacturing changes), </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">37</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post&#8209;approval monitoring and reporting, import and export of pharmaceutical products, such as those we are developing.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">United States&nbsp;&#x2014; FDA Regulation</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">FDA Approval Process</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act (FDC Act) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post&#8209;approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions by the FDA, including FDA refusal to approve pending NDAs, partial or full clinical holds, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pharmaceutical product development for a new product or certain changes to an approved product in the United States typically involves preclinical laboratory and animal tests, the submission of an investigational new drug application (IND) to the FDA, which must become effective before clinical trials may commence, and adequate and well&#8209;controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of the FDA&#x2019;s pre&#8209;market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Preclinical studies include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical studies must comply with federal regulations and requirements, including good laboratory practices, or GLP. The results of preclinical studies are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, available clinical data, and a proposed clinical trial protocol. Long term preclinical studies, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">An IND automatically becomes effective 30&nbsp;days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (1)&nbsp;in compliance with federal regulations; (2)&nbsp;in compliance with good clinical practice (GCP), an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (3)&nbsp;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions if it believes that the clinical trial is either not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The clinical trial protocol and informed consent information for patients in clinical trials must also be submitted to an IRB, for approval. An IRB must operate in compliance with FDA regulations. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#x2019;s requirements or may impose other conditions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">Phase&nbsp;1 trials: The drug is initially introduced into healthy volunteers or patients, with the target disease or condition. The drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence of effectiveness.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">38</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">Phase&nbsp;2 trials: The drug is administered to a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance, optimum dosage and to identify common adverse effects and safety risks.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">Phase&nbsp;3 trials: If the drug demonstrates evidence of effectiveness and an acceptable safety profile in Phase&nbsp;2 trials, Phase&nbsp;3 trials, including registration trials, are undertaken to obtain additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit&#8209;risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases, the FDA requires two adequate and well&#8209;controlled Phase&nbsp;3 registration trials to demonstrate the efficacy of the drug. A single Phase&nbsp;3 registration trial with other confirmatory evidence may be sufficient in rare instances where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and, more frequently, if SAEs occur. Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3 trials may not be completed successfully within any specified period, or at all.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">After completion of the required clinical trials, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the United States. The NDA must include, among other things, the results of all preclinical studies, clinical trials and other testing, a compilation of data relating to the product&#x2019;s pharmacology, chemistry, manufacture and controls, and the proposed product labeling. The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, currently exceeding $2,374,000 for fiscal year 2016, and the manufacturer and/or applicant under an approved NDA are also subject to annual product and establishment user fees, currently exceeding $114,000 per product and $585,000 per establishment. These fees are typically increased annually.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA has 60&nbsp;days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#x2019;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in&#8209;depth review. The FDA has agreed to certain performance goals in the review of new drug applications. Most such applications for standard review drug products are reviewed within ten to twelve months; most applications for priority review drugs are reviewed in six to eight months. Priority review can be applied to drugs that the FDA determines offer major advances in treatment, diagnosis, or prevention of diseases or provide a treatment where no adequate therapy exists. For biologics, priority review is further limited only for drugs intended to treat a serious or life&#8209;threatening disease relative to the currently approved products. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late&#8209;submitted information, or information intended to clarify information already provided in the submission.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee&nbsp;&#x2014; typically a panel that includes clinicians and other experts&nbsp;&#x2014; for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless it is compliant with cGMP, is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#x2019;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. Even if the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, or require that post&#8209;approval studies, </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">39</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">including Phase&nbsp;4 clinical trials, be conducted to further assess a drug&#x2019;s safety after approval. As a condition of NDA approval, the FDA may also require a risk evaluation and mitigation strategy (REMS) to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use. Elements to assure safe use can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post&#8209;approval testing and surveillance to monitor the drug&#x2019;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Fast Track Designation and Accelerated Approval</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life&#8209;threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the fast track program, the sponsor of a new product candidate may request that the FDA designate the product candidate for a specific indication as a fast track drug concurrent with, or after, the filing of the IND for the product candidate. The FDA must determine if the product candidate qualifies for fast track designation within 60&nbsp;days of receipt of the sponsor&#x2019;s request.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the fast track program and the FDA&#x2019;s accelerated approval regulations, the FDA may approve a drug for a serious or life&#8209;threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A product candidate approved on this basis is subject to rigorous post&#8209;marketing compliance requirements, including the completion of Phase&nbsp;4 or post&#8209;approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post&#8209;approval studies, or confirm a clinical benefit during post&#8209;marketing studies, will allow FDA to withdraw the drug from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by FDA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition to other benefits such as the ability to use surrogate endpoints and engage in more frequent interactions with the FDA, the FDA may initiate review of sections of a fast track drug&#x2019;s NDA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA&#x2019;s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Breakthrough Therapy Designation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA is also required to expedite the development and review of the application for approval of drugs that are intended to treat a serious or life&#8209;threatening disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Under the breakthrough therapy program, the sponsor of a new product candidate may request that the FDA designate the product candidate for a specific indication as a breakthrough therapy concurrent with, or after, the filing of the IND for the product candidate. The FDA must determine if the product candidate qualifies for breakthrough therapy designation within 60&nbsp;days of receipt of the sponsor&#x2019;s request. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">40</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">a breakthrough therapy. Even if a product qualifies for this program, the FDA may later decide that the product no longer meets the conditions for qualification.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Orphan Drugs</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition&nbsp;&#x2014; generally a disease or condition that affects fewer than 200,000&nbsp;individuals in the U.S. Orphan Drug Designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven&#8209;year exclusive marketing period in the United States for that product, for that indication. During the seven&#8209;year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application user fee.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Pediatric Information</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the Pediatric Research Equity Act (PREA), NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers for submission of data, as well as deferrals for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric studies are complete or that additional safety or effectiveness data needs to be collected before the pediatric studies begin. Unless otherwise required by regulation, PREA does not apply to any drug for an indication for which orphan designation has been granted.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Best Pharmaceuticals for Children Act (BPCA) provides NDA holders a six&#8209;month extension of any exclusivity&nbsp;&#x2014; patent or non&#8209;patent&nbsp;&#x2014; for a drug if certain conditions are met. Conditions for exclusivity include the FDA&#x2019;s determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Special Protocol Assessment</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A company may reach an agreement with the FDA under the Special Protocol Assessment (SPA) process as to the required design and size of clinical trials intended to form the primary basis of an efficacy claim. Under the FDC Act and FDA guidance implementing the statutory requirement, an SPA is generally binding upon the FDA except in limited circumstances, such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy after the clinical trial begins, public health concerns emerge that were unrecognized at the time of the protocol assessment, the sponsor and FDA agree to the change in writing, or if the clinical trial sponsor fails to follow the protocol that was agreed upon with the FDA.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Disclosure of Clinical Trial Information</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Sponsors of clinical trials of FDA&#8209;regulated products, including drugs, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, clinical trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly&#8209;available information to gain knowledge regarding the progress of development programs.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Post&#8209;Approval Requirements</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Once an NDA is approved, a product will be subject to certain post&#8209;approval requirements. For instance, the FDA closely regulates the post&#8209;approval marketing and promotion of drugs, including standards and regulations for </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">41</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">direct&#8209;to&#8209;consumer advertising, off&#8209;label promotion, industry&#8209;sponsored scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">AE reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post&#8209;marketing testing, known as Phase&nbsp;4 testing, REMS and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality&#8209;control, drug manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality&#8209;control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">The Hatch&#8209;Waxman Amendments</font>
		</p>
		<p style="margin:0pt 0pt 10pt 54pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Orange Book Listing</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#x2019;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application (ANDA). An ANDA provides for marketing of a drug product that has the same active ingredient in the same strength, route of administration and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical studies or clinical trials to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#x201C;generic equivalents&#x201D; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#x2019;s Orange Book. Specifically, the applicant must certify that: (1)&nbsp;the required patent information has not been filed; (2)&nbsp;the listed patent has expired; (3)&nbsp;the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (4)&nbsp;the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section&nbsp;viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method&#8209;of&#8209;use rather than certify to a listed method&#8209;of&#8209;use patent. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A certification that the new product will not infringe the already approved product&#x2019;s listed patents, or that such patents are invalid, is called a Paragraph&nbsp;IV certification. If the ANDA applicant has provided a Paragraph&nbsp;IV certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&nbsp;IV certification. The filing of a patent infringement lawsuit within 45&nbsp;days of the receipt of a Paragraph&nbsp;IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&nbsp;months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The ANDA application also will not be approved until any applicable non&#8209;patent exclusivity listed in the Orange Book for the referenced product has expired.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Exclusivity</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Upon NDA approval of a drug containing a NCE, which is a drug substance that contains an active moiety that has not been approved by the FDA in any other NDA, that moiety will receive five years of marketing exclusivity during which the FDA cannot approve any ANDA seeking approval of a generic version of that moiety. Certain changes to a drug, </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">42</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">such as the addition of a new indication to the package insert, may receive a three&#8209;year period of exclusivity during which the FDA cannot approve an ANDA for a generic drug that includes the change.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If no Paragraph&nbsp;IV certification is made, an ANDA may not be filed until expiry of the NCE exclusivity period, however, if a Paragraph&nbsp;IV certification is filed, the ANDA may be submitted one year before the NCE exclusivity period expires. If there is no listed patent in the Orange Book, there may not be a Paragraph&nbsp;IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 54pt;text-indent: -18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Patent Term Extension</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">After NDA approval, owners of relevant drug patents may apply for up to a five year patent extension. The allowable patent term extension is calculated as half of the drug&#x2019;s testing phase&nbsp;&#x2014; the time between IND application and NDA submission&nbsp;&#x2014; and all of the review phase&nbsp;&#x2014; the time between NDA submission and approval up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The extension may not extend the patent beyond 14&nbsp;years from market approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post&#8209;approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Prescription Drug Marketing Act</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As part of the sales and marketing process, pharmaceutical companies frequently provide samples of approved drugs to physicians. The Prescription Drug Marketing Act (PDMA) imposes requirements and limitations upon the provision of drug samples to physicians, as well as prohibits states from licensing distributors of prescription drugs unless the state licensing program meets certain federal guidelines that include minimum standards for storage, handling and record keeping. In addition, the PDMA sets forth civil and criminal penalties for violations.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">United States&nbsp;&#x2014; Anti&#8209;Kickback, False Claims Laws and Other Healthcare Laws </font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain general business and marketing practices in the pharmaceutical industry in recent years. These laws include anti&#8209;kickback statutes, false claims statutes and other statutes pertaining to health care fraud and abuse.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The federal Anti&#8209;Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. The Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act (PPACA) amended the intent element of the federal Anti&#8209;Kickback Statute so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to be in violation. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Violations of the Anti&#8209;Kickback Statute are punishable by penalties including imprisonment, criminal fines, civil monetary penalties, damages, disgorgement and exclusion from participation in federal healthcare programs.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Federal false claims laws, including the civil False Claims Act, prohibit any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs where the federal government reimburses, such as Medicaid, as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply Schedule. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">43</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off&#8209;label promotion, may also violate false claims laws. Additionally, PPACA amended the federal Anti&#8209;Kickback Statute such that a violation of that statute can serve as a basis for liability under the federal civil False Claims Act. The majority of states also have statutes or regulations similar to the federal Anti&#8209;Kickback Statute and False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Other federal statutes pertaining to healthcare fraud and abuse include the Civil Monetary Penalties Statute, which prohibits the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offerer/payor knows or should know is likely to influence the beneficiary to order a receive a reimbursable item or service from a particular supplier, and the healthcare fraud provisions of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which prohibits knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations, or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items, or services.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For example, several pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices undertaken by pharmaceutical companies, including off&#8209;label promotion, may violate false claims laws.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to PPACA, the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS) has issued a final rule that requires manufacturers of certain prescription drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, with specific exceptions, to collect and report information on payments or transfers of value to physicians and teaching hospitals, as well as investment interests held by physicians and their immediate family members. The first reports were due in 2014 and must be submitted on an annual basis. The reported data were posted by CMS in searchable form on a public website on September&nbsp;30, 2014, and will be posted on an annual basis. Failure to submit required information may result in civil monetary penalties.</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, several states now require prescription drug companies to report expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual physicians in these states. Other states prohibit various other marketing&#8209;related activities. Still other states require the posting of information relating to clinical studies and their outcomes. In addition, California, Connecticut, Nevada and Massachusetts require pharmaceutical companies to implement compliance programs and/or marketing codes. Several additional states are considering similar proposals. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws may face civil penalties.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Other federal and state requirements include the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (the HITECH Act) and its implementing regulations, which imposes obligations, including mandatory contractual terms, on certain people and entities with respect to safeguarding the privacy, security and transmission of individually identifiable health information; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">United States Healthcare Reform</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Current and future legislative proposals to further reform healthcare or reduce healthcare costs may result in lower reimbursement for our products. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could significantly reduce our revenues from the sale of our products.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For example, in March 2010, PPACA was signed into law. PPACA has begun to, and will likely continue to, substantially change healthcare financing and delivery by both governmental and private insurers, and significantly impact the pharmaceutical industry. The PPACA, among other things: established an annual, nondeductible fee on any </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">44</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">entity that manufactures or imports certain specified branded prescription drugs and biologic agents; revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; implemented a new Medicare Part&nbsp;D coverage gap discount program; expanded the entities eligible for discounts under the Public Health Services pharmaceutical pricing program; created a new Patient Centered Outcomes Research Institute; and provided incentives to programs that increase the federal government&#x2019;s comparative effectiveness research.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2&nbsp;trillion for the years 2012 through 2021, triggering the legislation&#x2019;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2025 unless additional Congressional action is taken. Additionally, in January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">With the election of President Donald J. Trump in November and his inauguration in January 2017, we expect that additional state and federal healthcare reform measures will be adopted in the future, including the possible repeal and replacement of PPACA and related legislation, regulations and programs.&nbsp;&nbsp;Any new state and federal healthcare reform measures could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressure. We are unsure of the ways in which PPACA will continue to be challenged, repealed, amended or replaced in the months and years to come.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Review and Approval of Drug Products in the European Union</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of drug products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to the European Clinical Trials Directive, a system for the approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of a European Union member state in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial after a competent ethics committee has issued a favorable opinion. Clinical trial application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by the European Clinical Trials Directive and corresponding national laws of the member states and further detailed in applicable guidance documents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To obtain marketing approval of a drug under European Union regulatory systems, an applicant must submit a marketing authorization application (MAA) either under a centralized or decentralized procedure.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. The centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">45</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Under the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the European Medicines Agency (EMA) is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post&#8209;authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210&nbsp;days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given within 150&nbsp;days.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The decentralized procedure is available to applicants who wish to market a product in various European Union member states where such product has not received marketing approval in any European Union member states before. The decentralized procedure provides for approval by one or more other, or concerned, member states of an assessment of an application performed by one member state designated by the applicant, known as the reference member state. Under this procedure, an applicant submits an application based on identical dossiers and related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference member state and concerned member states. The reference member state prepares a draft assessment report and drafts of the related materials within 210&nbsp;days after receipt of a valid application. Within 90&nbsp;days of receiving the reference member state&#x2019;s assessment report and related materials, each concerned member state must decide whether to approve the assessment report and related materials.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If a member state cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the European Commission, whose decision is binding on all member states.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Data and Market Exclusivity in the European Union</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the European Union, NCEs qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#x2019;s data to assess a generic (abbreviated) application for eight years, after which generic marketing authorization can be submitted, and the innovator&#x2019;s data may be referenced, but not approved for two years. The overall ten&#8209;year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization (MA) holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a NCE and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the drug if such company can complete a full MAA with a complete database of pharmaceutical test, preclinical studies and clinical trials and obtain marketing approval of its product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Data and Market Exclusivity in Japan</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Japan has no established system for data exclusivity or marketing exclusivity. However, the Pharmaceuticals Act of Japan (PAA) provides for a re&#8209;examination system after drug approval. This system imposes an obligation on the MA holder to continue to collect clinical data after market approval during a study period. The MA holder must apply for reexamination to the Minster of Health Labor and Welfare within three months of the expiration of the study period. During the study and reexamination period no generic drug may be approved, effectively providing a form of market exclusivity. The study period is determined by the drug category. The study period for an orphan drug is 10&nbsp;years from MA, the study period for an NCE is eight&nbsp;years from MA, and for an improvement (new indication, formulation, etc.) the study period is four to six&nbsp;years from MA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Patent Term Extension in Japan</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The term of a patent that covers the approved drug may be extended for the shorter of five years, or the period during which the patent could not be worked (exploited) due to obtaining regulatory approval. This period is calculated from the later of the patent registration date (grant date) or the clinical trial start date to the regulatory approval date.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">46</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Foreign Regulation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Pharmaceutical Coverage, Pricing and Reimbursement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory approval. Sales of any of our product candidates, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third&#8209;party payors, including government health programs such as Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug product once coverage is approved. Third&#8209;party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the approved drugs for a particular indication.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In order to secure coverage and adequate reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost&#8209;effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Our product candidates may not be considered medically necessary or cost&#8209;effective. A payor&#x2019;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#x2019;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage or adequate reimbursement for the drug product. Third&#8209;party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third&#8209;party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost&#8209;effectiveness of medical products and services, in addition to their safety and efficacy. If these third&#8209;party payors do not consider our products to be cost&#8209;effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government&#8209;paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as the product candidates that we are developing and could adversely affect our net revenue and results.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost&#8209;effectiveness of a particular product candidate to currently available therapies. For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross&#8209;border imports from low&#8209;priced markets exert competitive pressure that may reduce pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for drug products will allow favorable reimbursement and pricing arrangements for any of our products.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">47</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third&#8209;party payors fail to provide coverage and adequate reimbursement. In addition, the emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on drug pricing. Coverage policies, third&#8209;party reimbursement rates and drug pricing regulation may change at any time. In particular, the PPACA contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&nbsp;D beneficiaries and annual fees based on pharmaceutical companies&#x2019; share of sales to federal health care programs. Even if favorable coverage status and adequate reimbursement level status are obtained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Employees</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of February 20, 2017, we had sixteen employees, all of whom are full&#8209;time, four of whom hold Ph.D. or M.D. degrees, nine of whom were engaged in research and development activities and seven of whom were engaged in business development, finance, information systems, facilities, human resources or administrative support. None of our employees is represented by a labor union or subject to a collective bargaining agreement. We consider our relationship with our employees to be good.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Corporate Information </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We were formed in Michigan as Michigan Life Therapeutics, LLC (MLT) in November 2008. In October 2014, we incorporated a new entity under the name Gemphire Therapeutics Inc. in Delaware. MLT then merged with and into Gemphire, with Gemphire as the surviving entity. The purpose of the merger was to change the jurisdiction of our incorporation from Michigan to Delaware and to convert from a limited liability company to a corporation. Our principal executive offices are located at 17199 N. Laurel Park Dr., Suite 401, Livonia, MI 48152, and our telephone number is (734) 245-1700. Our corporate website address is www.gemphire.com. Information contained on or accessible through our website is not a part of this Report, and the inclusion of our website address in this Report is an inactive textual reference only.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 1A.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 48pt 0pt 0pt;"></font>RISK FACTORS<a name="ITEM1ARISKFACTORS_84111"></a></font>
		</p>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Our business, prospects, financial condition or results of operations could be materially adversely affected by any of the risks and uncertainties set forth below, as well as in any amendments or updates reflected in subsequent filings with the Securities and Exchange Commission (SEC). In assessing these risks, you should also refer to other information contained in this Report, including our financial statements and related notes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to the Development of Gemcabene or any Future Product Candidate</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We currently depend entirely on the success of gemcabene, our only product candidate. We may never receive marketing approval for, or successfully commercialize, gemcabene for any indication.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We currently have only one product candidate, gemcabene, in clinical development, and our business depends on its successful clinical development, regulatory approval and commercialization. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of a drug product are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, where regulations differ from country to country. We are not permitted to market gemcabene in the United States until we receive approval of a new drug application (NDA) from the FDA or in any foreign countries until we receive the requisite approval from such countries. We have not submitted an NDA to the FDA or comparable applications to other regulatory authorities or received marketing approval for gemcabene. Before obtaining regulatory approval for the commercial sale of gemcabene for a particular indication, we must demonstrate through preclinical testing and clinical trials that gemcabene is safe and effective for use in that target indication. This process can take many years and may be followed by post&#8209;marketing studies and surveillance, which will require the expenditure of substantial resources beyond our current cash and cash equivalents. Of the large number of drugs in development in the United States, only a small percentage of drugs successfully complete the FDA regulatory approval process and are commercialized. Accordingly, even if we are able to complete development of gemcabene, we cannot assure you that gemcabene will be approved or commercialized.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">48</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Obtaining approval of an NDA is an extensive, lengthy, expensive and uncertain process, and the FDA may delay, limit or deny approval of gemcabene for many reasons, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the data collected from preclinical studies and clinical trials of gemcabene may not be sufficient to support the submission of an NDA;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">we may not be able to demonstrate to the satisfaction of the FDA that gemcabene is safe and effective for any indication;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the results of clinical trials may not meet the level of statistical significance or clinical significance required by the FDA for approval;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the FDA may disagree with the number, design, size, conduct or implementation of our clinical trials;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the FDA may not find the data from preclinical studies and clinical trials sufficient to demonstrate that gemcabene&#x2019;s clinical and other benefits outweigh its safety risks;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the FDA may not accept data generated at our clinical trial sites;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the FDA may require development of a risk evaluation and mitigation strategy (REMS) as a condition of approval;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the FDA may identify deficiencies in the manufacturing processes or facilities of third party manufacturers with which we enter into agreements for clinical and commercial supplies; or</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the FDA may change its approval policies or adopt new regulations.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non&#8209;U.S. regulatory authorities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The results from the prior preclinical studies and clinical trials for gemcabene discussed elsewhere in this report may not necessarily be predictive of the results of future preclinical studies or clinical trials. Even if we are able to complete our planned clinical trials of gemcabene according to our current development timeline, the results from our prior clinical trials of gemcabene may not be replicated in these future trials. Many companies in the pharmaceutical and biotechnology industries (including those with greater resources and experience than us) have suffered significant setbacks in late&#8209;stage clinical trials after achieving positive results in early stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in clinical trials, including previously unreported AEs. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless have failed to obtain FDA approval. If we fail to produce positive results in our clinical trials of gemcabene, the development timeline and regulatory approval and commercialization prospects for gemcabene and our business and financial prospects, would be adversely affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Further, gemcabene may not be approved even if it achieves its primary endpoint in Phase&nbsp;3 registration trials. The FDA or non&#8209;U.S. regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal clinical trial that has the potential to result in approval by the FDA or another regulatory authority. Furthermore, any of these regulatory </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">49</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">authorities may also approve our product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post&#8209;marketing clinical trials.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We commenced three Phase 2b clinical trials in 2016 and plan to initiate a fourth Phase 2 clinical trial in 2017. If successful, we plan to eventually seek regulatory approvals of gemcabene initially in the United States, Canada and Europe, and we may seek approvals in other geographies. Before obtaining regulatory approvals for the commercial sale of any product candidate for any target indication, we must demonstrate with substantial evidence gathered in preclinical studies and adequate and well&#8209;controlled clinical studies, and, with respect to approval in the United States, to the satisfaction of the FDA, that the product candidate is safe and effective for use for that target indication. We cannot assure you that the FDA or non&#8209;U.S. regulatory authorities would consider our planned clinical trials to be sufficient to serve as the basis for approval of gemcabene for any indication. The FDA and non&#8209;U.S. regulatory authorities retain broad discretion in evaluating the results of our clinical trials and in determining whether the results demonstrate that gemcabene is safe and effective. If we are required to conduct clinical trials of gemcabene in addition to those we have planned prior to approval, such as a cardiovascular outcomes trial, we will need substantial additional funds, and we cannot assure you that the results of any such outcomes trial or other clinical trials will be sufficient for approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If clinical trials of gemcabene or any future product candidate fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Before obtaining marketing approval from regulatory authorities for the sale of gemcabene, we must complete preclinical development (including, but not limited to, two&#8209;year rat and mouse carcinogenicity studies), and supportive pharmacology studies and Phase&nbsp;2 and Phase&nbsp;3 clinical trials to demonstrate the safety and efficacy in humans. Preclinical development and extensive clinical trials will also be required before obtaining marketing approval from regulatory authorities for any other product candidate we may pursue in the future. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of development.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We, or our future collaborators, may experience numerous unforeseen events during, or as a result of, clinical trials that could result in increased development costs, delay, limit or prevent our ability to receive marketing approval or commercialize gemcabene or any other product candidate we may pursue in the future, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">regulators or institutional review boards (IRBs) may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">government or regulatory delays and changes in regulatory requirements, policy and guidelines may require us to perform additional clinical trials or use substantial additional resources to obtain regulatory approval;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the number of patients required for clinical trials may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our third&#8209;party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our patients or medical investigators may be unwilling to follow our clinical trial protocols;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">we might have to suspend or terminate clinical trials for various reasons, including a finding that the participants are being exposed to unacceptable health risks;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">50</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the cost of clinical trials may be greater than we anticipate;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the supply or quality of any product candidate or other materials necessary to conduct clinical trials may be insufficient or inadequate; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the product candidate may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs to suspend or terminate the trials.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We or our future collaborators may not be able to initiate or continue clinical trials for gemcabene or any future product candidate if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or analogous regulatory authorities outside the United States. Orphan indications, in particular, have small populations, and it may be difficult for us to locate and enroll sufficient patients in trials for orphan&#8209;designated indications. Patient enrollment can be affected by many factors, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">severity of the disease under investigation;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 0pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">availability and efficacy of medications already approved for the disease under investigation;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">eligibility criteria for the trial in question;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">competition for eligible patients with other companies conducting clinical trials for product candidates seeking to treat the same indication or patient population;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">our payments for conducting clinical trials;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">perceived risks and benefits of the product candidate under study;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">efforts to facilitate timely enrollment in clinical trials;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">patient referral practices of physicians;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">the ability to monitor patients adequately during and after treatment; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">proximity and availability of clinical trial sites for prospective patients.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Three of our Phase 2b clinical trials of gemcabene commenced in 2016 and we expect a fourth Phase 2 trial of gemcabene will commence in 2017 and may take up to 12&nbsp;months to enroll; however, we cannot assure you that our timing and enrollment assumptions are correct given the above factors. Our inability to enroll a sufficient number of patients for our clinical trials or retain sufficient enrollment through the completion of our trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and cause our stock price to decline.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We or others could discover that gemcabene or any product candidate we may pursue in the future lacks sufficient efficacy, or that it causes undesirable side effects that were not previously identified, which could delay or prevent regulatory approval or commercialization.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Because gemcabene has been tested in relatively small patient populations and for limited durations to date, it is possible that our clinical trials have or will indicate an apparent positive effect of gemcabene that is greater than the actual positive effect, if any, or that additional and unforeseen side effects may be observed as its development progresses. The discovery that gemcabene lacks sufficient efficacy, or that it causes undesirable side effects (including side effects not previously identified in our completed clinical trials), could cause us or regulatory authorities to interrupt, delay or discontinue clinical trials and could result in the denial of regulatory approval by the FDA or other non&#8209;U.S. regulatory </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">51</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">authorities for any or all targeted indications. The most common events reported to date have been headache, weakness, nausea, dizziness, upset stomach, infection, abnormal bowel movements, myalgia and abnormal kidney function tests.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The discovery that gemcabene or any future product candidate lacks sufficient efficacy or that it causes undesirable side effects that were not previously identified could prevent us from commercializing such product candidate and generating revenues from its sale. In addition, if we receive marketing approval for gemcabene and we or others later discover that it is less effective, or identify undesirable side effects caused by gemcabene:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">regulatory authorities may withdraw their approval of the product;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">we may be required to recall the product, change the way this product is administered, conduct additional clinical trials or change the labeling or distribution of the product (including REMS);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the product;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">we could be sued and held liable for harm caused to patients;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the product may be rendered less competitive and sales may decrease; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">our reputation may suffer generally both among clinicians and patients.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Any one or a combination of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase the costs and expenses of commercializing the product, which in turn could delay or prevent us from generating significant, or any, revenues from the sale of the product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we fail to receive regulatory approval for any of our planned indications for gemcabene or fail to develop additional product candidates, our commercial opportunity will be limited.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have initially focused on the development of gemcabene for our target indications in cardiovascular diseases and recently expanded our program to include a clinical trial to support an indication for gemcabene in NASH and/or nonalcoholic fatty liver disease (NAFLD). However, we cannot assure you that we will be able to obtain regulatory approval of gemcabene for any indication, or successfully commercialize gemcabene, if approved. If we do not receive regulatory approval for, or successfully commercialize, gemcabene for one or more of our targeted or other indications, our commercial opportunity will be limited.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We may pursue clinical development of additional product candidates, including product candidates that we acquire or in&#8209;license. Acquiring, in&#8209;licensing, developing, obtaining regulatory approval for and commercializing additional product candidates will require substantial additional funding and are prone to the risks of failure inherent in drug product development. We cannot assure you that we will be able to successfully advance any additional product candidates through the development process.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even if we obtain FDA approval to market additional product candidates, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity will be limited.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Changes in regulatory requirements or FDA guidance, or unanticipated events during our clinical trials, may result in changes to clinical trial protocols or additional clinical trial requirements, such as the initiation or completion of a cardiovascular outcomes trial, which could result in increased costs to us and could delay our development timeline.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Changes in regulatory requirements or FDA guidance, or unanticipated events during our clinical trials, may force us to amend clinical trial protocols or the FDA may impose additional clinical trial requirements. Amendments to our clinical trial protocols would require resubmission to the FDA and IRBs for review and approval, and may adversely impact the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">52</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">cost, timing or successful completion of a clinical trial. If we experience delays completing, or if we terminate, any of our Phase&nbsp;2 or Phase&nbsp;3 trials, or if we are required to conduct additional clinical trials, such as a cardiovascular outcomes trial prior to approval, the commercial prospects for gemcabene may be harmed and our ability to generate product revenue will be delayed. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For cardiovascular disease related indications, if the FDA requires us to conduct a cardiovascular outcomes trial sooner than planned, we may not be able to identify and enroll the requisite number of patients in that trial. Even if we are successful in enrolling patients in a cardiovascular outcomes trial, we may not ultimately be able to demonstrate that lowering LDL&#8209;C levels using gemcabene provides patients with an incremental lowering of cardiovascular disease risks, and our failure to do so may delay or prejudice our ability to obtain FDA approval for gemcabene. Although the validity of lipid&#8209;lowering effects (including LDL&#8209;C reduction) as a surrogate endpoint for cardiovascular benefit continues to be debated in the medical community, given historical precedent and recent FDA guidance, our current development timeline for gemcabene does not contemplate the completion of a cardiovascular outcomes trial prior to approval. Such trial would be costly and time&#8209;consuming and, regardless of the outcome, would adversely affect our development timeline and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For nonalcoholic steatohepatitis (NASH) related indications, the current guidance for approval for a therapy for NASH is based on changes in hepatic biopsy histological scoring and fibrosis staging.&nbsp;&nbsp;Although it is not expected to change over the near term, we cannot predict if the FDA and other global health authorities may change to an endpoint that is more clinically based. If such an endpoint is required, such trial(s) would be costly and time&#8209;consuming and, regardless of the outcome, would adversely affect our development timeline and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We have not generated any revenue and may never be profitable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our development stage product candidate, gemcabene, and we do not currently have any other products or product candidates. We do not know when, or if, we will generate any revenue. We do not expect to generate significant revenue unless or until we obtain marketing approval of, and commercialize, gemcabene. Our ability to generate revenue depends on a number of factors, including our ability to:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">successfully complete preclinical carcinogenicity studies to remove the partial clinical hold to allow us to complete longer term registration trials for marketing approval of gemcabene;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">obtain favorable results from and complete the clinical development of gemcabene for our planned indications, including successful completion of our Phase&nbsp;2 and Phase&nbsp;3 trials for these indications;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">submit an application to regulatory authorities for gemcabene and receive marketing approval in the United States and foreign countries;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">contract for the manufacture of commercial quantities of gemcabene, if approved, at acceptable cost levels;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">establish sales and marketing capabilities to effectively market and sell gemcabene, if approved, in the United States and the European Union, alone or with a pharmaceutical partner; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">achieve market acceptance of gemcabene in the medical community and with third&#8209;party payors.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even if gemcabene is approved for commercial sale in one or all of the initial indications that we are pursuing, it may not gain market acceptance or achieve commercial success. In addition, we anticipate incurring significant costs associated with commercializing gemcabene. Moreover, some of the indications we are targeting are small enough to be eligible for orphan drug designation, and our potential patient market is relatively smaller than other drugs, and therefore the price of gemcabene may need to be higher than other drugs. We may not achieve profitability soon after generating product revenue, if ever, and may be unable to continue operations without continued funding.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">53</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We depend on intellectual property licensed from Pfizer for gemcabene, and the termination of this license would harm our business. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pfizer has granted us a worldwide exclusive license to make, use, sell, offer for sale and import the clinical product candidate gemcabene, along with certain intellectual property for the purposes of development and commercialization of gemcabene. We or Pfizer may terminate this license in the event of a material breach that remains uncured for 30&nbsp;days from the date that the breaching party is provided with notice of such breach, provided that if such breach is capable of being cured, the cure period may be extended up to an additional 60&nbsp;days, or immediately upon certain insolvency events relating to the other party. Pfizer may immediately terminate this license in the event that we, or any of our affiliates, consent, challenge, support or assist any third party to contest or challenge Pfizer&#x2019;s ownership of or rights in, or the validity, enforceability or scope of, any of the patents licensed under this license. Furthermore, upon termination of the license agreement for cause by Pfizer, we must grant Pfizer a non-exclusive license to use any intellectual property rights arising from the development or commercialization of gemcabene. Additionally, Pfizer may revoke the license if we are unable to adequately commercialize gemcabene by April 2021. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Disputes may arise between us and Pfizer regarding intellectual property subject to this license agreement, including with respect to:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the scope of rights granted under the license agreement and other interpretation&#8209;related issues;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">whether and the extent to which our technology and processes infringe on intellectual property of Pfizer that is not subject to the licensing agreement;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the amount and timing of milestone and royalty payments;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the rights of Pfizer under the license agreement;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">our right to sublicense patent and other rights to third parties under collaborative development relationships; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the ownership of inventions and know&#8209;how resulting from the joint creation or use of intellectual property by Pfizer and us and our partners.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Any disputes with Pfizer may prevent or impair our ability to maintain our current licensing arrangement. We depend on the intellectual property and the historical preclinical and clinical data package licensed from Pfizer to develop and commercialize gemcabene. Termination of our license agreement could result in the loss of significant rights and would harm our ability to further develop and commercialize gemcabene. In addition, Pfizer has a non&#8209;exclusive, sub licensable, royalty&#8209;free right and license for non&#8209;commercial research or development purposes to intellectual property rights relating to gemcabene that are developed by us after the effective date of the license with Pfizer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">The development of gemcabene or pursuit of any future product candidate for broad patient populations will be more costly and commercial pricing for any approved indication would likely be lower.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are initially pursuing development of gemcabene for the treatment of patients with HoFH, HeFH, ASCVD and SHTG. We also plan to pursue development of gemcabene for the treatment of NASH and/or NAFLD. Expanding our development and commercialization of gemcabene or any future product candidate in these or other broader patient populations would be more costly and take longer to complete and would be subject to development and commercialization risks that may not be applicable to HoFH orphan indication.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Specifically, this may involve clinical trials with larger numbers of patients possibly taking the drug for longer periods of time. In addition, we believe that the FDA and, in some cases, the European Medicines Agency (EMA) may require a clinical outcomes trial demonstrating a reduction in cardiovascular events either prior to or after the submission of an application for marketing approval for the broader LDL&#8209;C indications. Clinical outcomes trials are particularly expensive and time consuming to conduct because of the larger number of patients required to establish that the drug being tested has the desired effect. It may also be more difficult for us to demonstrate the desired outcomes in these trials than to achieve validated surrogate endpoints. In addition, in considering approval of gemcabene for broader patient populations </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">54</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">with less severely elevated lipid levels, the FDA and other regulatory authorities may place greater emphasis on the side effect and risk profile of the drug in comparison to the drug&#x2019;s efficacy and potential clinical benefit than in smaller, more severely afflicted patient populations. These factors may make it more difficult for us to achieve marketing approvals of gemcabene for these broader patient populations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Moreover, if we pursue and are able to successfully develop and obtain marketing approval of gemcabene and any future product candidate in broader patient populations, we likely will not be able to obtain the same pricing level that we expect to obtain for orphan indications. The pricing of some drugs intended for orphan populations is often related to the size of the patient population, with smaller patient populations often justifying higher prices. If the pricing is lower in broader patient populations, we may not be able to maintain higher pricing in the population of more severely afflicted patients. This would lead to a decrease in revenue from sales to more severely afflicted patients and could make it more difficult for us to achieve or maintain profitability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We do not have drug research or discovery capabilities and will need to acquire or license product candidates from third parties to expand our product candidate pipeline.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We currently have no drug research or discovery capabilities. Accordingly, if we are to expand our product candidate pipeline beyond gemcabene, we will need to acquire or license product candidates from third parties. We will face significant competition in seeking to acquire or license promising product candidates. Many of our competitors for such promising product candidates may have significantly greater financial resources and more extensive experience in preclinical testing and clinical trials, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products, and thus, may be a more attractive option to a potential licensor than us. If we are unable to acquire or license additional promising product candidates, we will not be able to expand our product candidate pipeline.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we are able to acquire or license other product candidates, such license agreements will likely impose various obligations upon us, and our licensors may have the right to terminate the license thereunder in the event of a material breach or, in some cases, at will. A termination of future licenses could result in our loss of the right to use the licensed intellectual property, which could adversely affect our ability to develop and commercialize a future product candidate, if approved, as well as harm our competitive business position and our business prospects.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Because we have limited financial and managerial resources, we are currently focusing only on development programs that we identify for specific indications for gemcabene. As a result, we may forego or delay pursuit of opportunities for other indications, or with other potential product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs for specific indications or future product candidates may not yield any commercially viable product. If we do not accurately evaluate the commercial potential or target market for gemcabene, we may not gain approval or achieve market acceptance of that candidate, and our business and financial results will be harmed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We have incurred only losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since inception, we have incurred only operating losses. Our net losses were $14.6 million, $9.0 million and $0.3 million for the years ended December 31, 2016, 2015 and 2014, respectively. As of December 31, 2016, we had an accumulated deficit of $27.1&nbsp;million. We have financed our operations primarily through the issuance of common stock in our initial public offering (IPO), a private placement of our preferred stock and the issuance of convertible debt securities. We have devoted substantially all of our financial resources and efforts on research and development, including clinical development of gemcabene. We expect that it will be a number of years, if ever, before we have a product candidate ready for commercialization. We expect to continue to incur significant expenses and increased operating losses for the foreseeable future.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">55</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To become and remain profitable, we must develop and eventually commercialize a product with market potential. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials, obtaining regulatory approval for a product candidate, manufacturing, marketing and selling any drug for which we may obtain regulatory approval and satisfying any post&#8209;marketing requirements. We are in the early stages of most of these activities. We may never succeed in these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Although we believe that cash on hand will be sufficient to fund our operations into at least late 2018, we will need to raise additional capital to continue to fund the further development of gemcabene and our operations. Our future capital requirements may be substantial and will depend on many factors including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the scope, size, rate of progress, results and costs of researching and developing gemcabene and initiating and completing our preclinical studies and clinical trials;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the cost, timing and outcome of our efforts to obtain marketing approval for gemcabene in the United States and other countries, including to fund the preparation and filing of an NDA with the FDA for gemcabene and to satisfy related FDA requirements and regulatory requirements in other countries;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the number and characteristics of any additional product candidates we develop or acquire, if any;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">our ability to establish and maintain collaborations on favorable terms, if at all;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the timing and amount of milestone and royalty payments;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the amount of revenue, if any, from commercial sales, should any product candidate receive marketing approval;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the costs associated with commercializing gemcabene or any future product candidates, if we receive marketing approval, including the cost and timing of developing sales and marketing capabilities or entering into strategic collaborations to market and sell gemcabene or any future product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the cost of manufacturing gemcabene or any future product candidates and any product we successfully commercialize; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the costs associated with general corporate activities, such as the cost of filing, prosecuting and enforcing patent claims and making regulatory filings.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Changing circumstances may cause us to consume capital significantly faster than we currently anticipate. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development, regulatory approval and commercialization of gemcabene and any future product candidates. Additional financing may not be available when we need it or may not be available on terms that are favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. If adequate funds are unavailable to us on a timely basis, or at all, we may not be able to continue the development of gemcabene or any future product candidate, or commercialize gemcabene or any future product candidate, if approved, unless we find a strategic partner.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">56</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Raising additional capital may cause dilution to our stockholders and restrict our operations or require us to relinquish rights to our technologies or product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity and debt financings as well as potential strategic collaborations and licensing arrangements. We do not have any committed external source of funds.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing or preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we raise funds through strategic collaborations or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. This may reduce the value of our common stock.</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In the past, we issued options to acquire common stock at prices significantly below the initial public offering price. Pursuant to our A&amp;R 2015 Plan, our management is authorized to grant stock options to our employees, directors and consultants. The aggregate number of shares of our common stock remaining available for issuance under the A&amp;R 2015 Plan is 2 355,200 shares at December 31, 2016. The number of shares of our common stock reserved for issuance under the A&amp;R 2015 Plan will automatically increase on January&nbsp;1 of each year, continuing through and including January&nbsp;1, 2026, to an amount equal to 20% of the fully&#8209;diluted shares as of December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. </font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">In September 2016 our board of directors approved the Inducement Plan. We initially reserved 300,000 shares of common stock to be used exclusively for grants of awards to individuals who were not previously our employees or directors, as an inducement material to the individual&#x2019;s entry into employment with us within the meaning of Rule&nbsp;5635(c)(4)&nbsp;of the NASDAQ Listing Rules. The Inducement Plan was approved by our board of directors without stockholder approval pursuant to Rule&nbsp;5635(c)(4), and the terms and conditions of the Inducement Plan are substantially similar to our stockholder-approved A&amp;R 2015 Plan.&nbsp;&nbsp;At December 31, 2016, 102,000 shares remained available for issuance under the Inducement Plan.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:10pt;">To the extent these outstanding options are ultimately exercised or the number of shares available for future grant under our equity incentive plans each year are increased, investors will sustain further dilution. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to Government Regulation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Gemcabene is subject to a partial clinical hold with respect to clinical trials of longer than six months in duration until ongoing preclinical toxicology studies are complete, which may lead to a significant delay in the commencement of long term clinical trials by us or the failure of gemcabene to obtain marketing approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In 2004, the FDA determined that gemcabene was a potential peroxisome proliferator&#8209;activated receptor (PPAR) agonist. As a result, the FDA imposed a partial clinical hold, which restricts us from conducting clinical trials for gemcabene beyond six months in duration, and requires us to conduct two&#8209;year rat and mouse carcinogenicity studies before conducting trials of longer than six months. The FDA has issued these notices to all sponsors of product candidates with PPAR properties based on preclinical studies. We plan to complete our two&#8209;year rat and mouse carcinogenicity studies by the end of 2017, with draft reports issued soon after. Clinical trials may be delayed due to these clinical restrictions and additional oversight by the FDA. For example, if the results of the two&#8209;year rat and mouse carcinogenicity studies do not address FDA concerns related to the partial clinical hold, our Phase&nbsp;3 long term safety exposure registration trials of longer than six&nbsp;months could be delayed. Also, the findings in the carcinogenicity studies could impact the NDA review, and, if approved, labeling and use of gemcabene.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">57</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Even if we receive marketing approval for gemcabene or any product candidate we may pursue in the future in the United States, we may never receive regulatory approval to market such product candidate outside of the United States.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition to the United States, we intend to seek regulatory approval to market gemcabene in Canada and Europe and potentially other markets. If we pursue additional product candidates in the future, we may seek regulatory approval of such product candidates outside the United States. In order to market any product outside of the United States, however, we must establish and comply with the numerous and varying safety, efficacy and other regulatory requirements of these other countries. Approval procedures vary among countries and can involve additional product candidate testing and additional administrative review periods. The time required to obtain approvals in other countries might differ from that required to obtain FDA approval. The marketing approval processes in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. In particular, in many countries outside of the United States, products must receive pricing and reimbursement approval before the product can be commercialized. Obtaining this approval can result in substantial delays in bringing products to market in such countries. Marketing approval in one country does not ensure marketing approval in another, but a failure or delay in obtaining marketing approval in one country may have a negative effect on the regulatory process in others. Failure to obtain marketing approval in other countries or any delay or other setback in obtaining such approval would impair our ability to market gemcabene or any future product candidate in such foreign markets. Any such impairment would reduce the size of our potential market, which could have an adverse impact on our business, results of operations and prospects.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Even if we obtain marketing approval for gemcabene or any product candidate we may pursue in the future, such product candidate could be subject to post&#8209;marketing restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or experience unanticipated problems with a product candidate following approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Any product candidate for which we, or our future collaborators, obtain marketing approval in the future, as well as the manufacturing processes, post&#8209;approval studies and measures, labeling, advertising and promotional activities for such drug, among other things, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post&#8209;marketing information and reports, registration and listing requirements, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may be marketed or to the conditions of approval, including the requirement to implement a REMS, which could include requirements for a restricted distribution system.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA may also impose requirements for costly post&#8209;marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product candidate. The FDA and other agencies, including the Department of Justice, closely regulate and monitor the post&#8209;approval marketing and promotion of drugs to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#x2019; communications regarding off&#8209;label use and if we, or our future collaborators, do not market a product candidate for which we, or they, receive marketing approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for off&#8209;label promotion. Violation of the Federal Food, Drug, and Cosmetic Act (FDC Act) and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, later discovery of previously unknown AEs or other problems with our product candidate or its manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">litigation involving patients taking our drug;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">restrictions on such drugs, manufacturers or manufacturing processes;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">restrictions on the labeling or marketing of a drug;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">restrictions on drug distribution or use;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">58</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">requirements to conduct post&#8209;marketing studies or clinical trials;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">warning letters or untitled letters;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">withdrawal of the drugs from the market;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">refusal to approve pending applications or supplements to approved applications that we submit;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">product recall or public notification or medical product safety alerts to healthcare professionals;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">fines, restitution or disgorgement of profits or revenues;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">suspension or withdrawal of marketing approvals;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">damage to relationships with any potential collaborators;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">unfavorable press coverage and damage to our reputation;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">refusal to permit the import or export of drugs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">product seizure; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">injunctions or the imposition of civil or criminal penalties.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We may seek to avail ourselves of mechanisms to expedite the development or approval of gemcabene or any other product candidate we may pursue in the future, such as fast track designation, but such mechanisms may not actually lead to a faster development or regulatory review or approval process.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We may seek fast track designation, priority review, or accelerated approval for gemcabene or any other product candidate we may pursue in the future. For example, if a drug is intended for the treatment of a serious or life&#8209;threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation. However, the FDA has broad discretion with regard to these mechanisms, and even if we believe a particular product candidate is eligible for any such mechanism, we cannot assure you that the FDA would decide to grant it. Even if we do obtain fast track or priority review designation or pursue an accelerated approval pathway, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw a particular designation if it believes that the designation is no longer supported by data from our clinical development program.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">A breakthrough therapy designation by the FDA for a product candidate may not lead to a faster development or regulatory review or approval process, and it may not increase the likelihood that a product candidate will receive marketing approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Depending on the results of our clinical trials, we may seek a breakthrough therapy designation for gemcabene or any other product candidate we may pursue in the future. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life&#8209;threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. For drugs that are designated as breakthrough therapies, interaction and communication between the FDA and the sponsor can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. We cannot be sure that our evaluation of a product candidate as qualifying for breakthrough therapy designation will meet the FDA&#x2019;s requirements. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more product candidate </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">59</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">qualifies as a breakthrough therapy, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Recently&#8209;enacted and future legislation may increase the difficulty and cost for us and our future collaborators to obtain marketing approval of our product candidate and affect its pricing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of a product candidate, restrict or regulate post&#8209;approval activities and affect our ability, or the ability of our future collaborators, to profitably sell any drug for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and cause downward pressure on the price that we, or our future collaborators, may receive for any approved drug.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For example, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the PPACA). This is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, improve healthcare quality, enhance remedies against fraud and abuse, add new transparency requirements for certain components of the health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the PPACA of importance to gemcabene and any future product candidates are:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">extension of a manufacturer&#x2019;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">a Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must agree to offer 50% point&#8209;of&#8209;sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#x2019;s outpatient drugs to be covered under Medicare Part&nbsp;D;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">a new Patient&#8209;Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There have been judicial and Congressional challenges and amendments to certain aspects of the PPACA, and we expect there will be additional challenges and amendments to, and attempts to repeal, the PPACA in the future. In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. These new laws have resulted in additional reductions in Medicare and other healthcare funding and otherwise may affect the prices we may obtain for any product candidate for which marketing approval is obtained. Any reduction in reimbursement from Medicare or other government&#8209;funded programs may result in a similar reduction in payments from private payors. Moreover, </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">60</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Legislative and regulatory proposals have been made to expand post&#8209;approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of a product candidate, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#x2019;s approval process may significantly delay or prevent marketing approval, as well as subject us and our future collaborators to more stringent drug labeling and post&#8209;marketing testing and other requirements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Governments outside of the United States tend to impose strict price controls, which may adversely affect our revenues from the sales of a drug, if any.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we, or our future collaborators, may be required to conduct a clinical trial that compares the cost&#8209;effectiveness of our drug to other available therapies. If reimbursement of our drug is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our relationships with healthcare providers and third&#8209;party payors will be subject to applicable fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings, among other penalties and consequences.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Healthcare providers and third&#8209;party payors will play a primary role in the recommendation and prescription of any product candidate for which we obtain marketing approval. Our current and future arrangements with third&#8209;party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidate for which we obtain marketing approval. Restrictions and obligations under applicable federal and state healthcare laws and regulations include the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the federal Anti&#8209;Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the federal false claims and civil monetary penalties laws, including the civil False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain people and entities with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the federal Physician Payments Sunshine Act under the PPACA requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services within the U.S. Department of Health and Human Services information </font></p></td></tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">61</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top"><p style="margin:0pt 0pt 12pt 54pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;;"><font style="display:inline;color:#000000;">related to physician payments and other transfers of value and physician ownership and investment interests; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">analogous state and foreign laws and regulations, such as state anti&#8209;kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non&#8209;governmental third&#8209;party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Certain state and foreign laws also govern the privacy and security of health information in ways that differ from each other and often are not preempted by HIPAA, thus complicating compliance efforts.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Defending against any such actions can be costly, time&#8209;consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti&#8209;corruption laws, and anti&#8209;money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations which can harm our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#x2019;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#xA7;&nbsp;201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti&#8209;bribery and anti&#8209;money laundering laws in the countries in which we conduct activities. Anti&#8209;corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government&#8209;affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Our violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our employees may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in insider trading, which could significantly harm our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA and applicable non&#8209;U.S. regulators, provide accurate information to the FDA and applicable non&#8209;U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">62</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">intended to prevent fraud, misconduct, kickbacks, self&#8209;dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including trading on, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs such as Medicare and Medicaid, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off&#8209;label uses. If we are found to have improperly promoted off&#8209;label uses, we may become subject to significant liability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as gemcabene, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#x2019;s approved labeling. If we receive marketing approval for gemcabene or any future product candidate for a certain indication, physicians may nevertheless prescribe gemcabene or such future product candidate to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off&#8209;label uses, we may become subject to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off&#8209;label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of gemcabene or any future product candidate, if approved, we could become subject to significant liability, which would adversely affect our business and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to the Commercialization of Gemcabene or Any Future Product Candidate</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The development and commercialization of new drug products is highly competitive. We expect to face competition with respect to gemcabene, if approved, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities and other research institutions and government agencies worldwide. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The lipid&#8209;lowering therapies market is highly competitive and dynamic and dominated by the sale of statin treatments including the cheaper generic versions of statins. Our success will depend, in part, on our ability to obtain a share of the market for our planned indications. Other pharmaceutical companies may develop lipid&#8209;lowering therapies for the same indications that compete with gemcabene, if approved, that do not infringe the claims of our patents, pending patent applications or other proprietary rights which could adversely affect our business and results of operations.&nbsp;&nbsp;Lipid&#8209;lowering therapies currently on the market that would compete with gemcabene, if approved, include the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">statins, such as Crestor marketed by AstraZeneca, Livalo marketed by Kowa Pharmaceuticals America,&nbsp;Inc. (Kowa), Zocor marketed by Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc. (Merck), Lipitor marketed by Pfizer, and their generic versions;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">cholesterol absorption inhibitors, such as Zetia, marketed by Merck;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">apoB antisense Kynamro marketed by Genzyme Corporation, a Sanofi company, and MTTP inhibitor Juxtapid marketed by Aegerion Pharmaceuticals,&nbsp;Inc.;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">combination therapies, such as Vytorin and Liptruzet, both marketed by Merck;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">63</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">other lipid&#8209;lowering monotherapies, including: fibrates, such as TriCor and Trilipix, both marketed by AbbVie Inc. (AbbVie), and Lipofen marketed by Kowa; niacin, such as Niaspan marketed by AbbVie; bile acid sequestrants, such as Welchol, marketed by Daiichi Sankyo&nbsp;Inc.; combination therapies, such as Advicor and Simcor, both of which are marketed by AbbVie; and their generic version of these drugs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">prescription fish oils, such as Lovaza marketed by GlaxoSmithKline, Epanova marketed by AstraZeneca and Vascepa marketed by Amarin Corporation&nbsp;plc; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">PCSK9 inhibitors, such as Praluent, developed by Sanofi&#8209;Aventis U.S. LLC, and Regeneron Pharmaceuticals, Inc. and Repatha marketed by Amgen&nbsp;Inc.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">Several other pharmaceutical companies have other lipid&#8209;lowering therapies in development that may be approved for marketing in the United States or outside of the United States. Based on publicly available information, we believe the current therapies in development that would compete with gemcabene include:</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">for HoFH, RGEN&#8209;1500 being developed by Regeneron Pharmaceuticals,&nbsp;Inc. MGL-3196 developed by Madrigal Pharmaceuticals (Madrigal) for HoFH, and ALN&#8209;PCSsc being developed by The Medicines Company and Alnylam Pharmaceuticals,&nbsp;Inc.;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">for HeFH and ASCVD, drugs include: oral cholesteryl ester transfer protein inhibitors, such as anacetrapib being developed by Merck and TA&#8209;8995 being developed by Amgen/Dezima; ATP citrate lyase inhibitor, ETC&#8209;1002 developed by current Esperion; PCSK9&nbsp;inhibitors, such as </font><font style="display:inline;">ALN&#8209;PCSsc being developed by The Medicines Company and Alnylam Pharmaceuticals,&nbsp;Inc., and MGL-3196 developed by Madrigal (HeFH only); </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;">for SHTG, ISIS&#8209;APOCIII-LRX being developed by Ionis Pharmaceuticals, Inc. (formerly Isis Pharmaceuticals, Inc.); and&nbsp; </font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 90pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">This means that there is significant competition for investigational sites and patients to enroll in clinical studies.&nbsp;&nbsp;Additionally, since some drug candidates may be further along in development, approval of such drug candidates could lead to the FDA and other global health authorities to request and/or require changes to ongoing or future clinical trial designs that could impact timelines and cost.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The biomarkers and pathogenesis of NASH are less understood than the dyslipidemia market and for that reason there are many mechanisms of action under investigation to better understand how to effectively treat the disease. Currently accepted diagnosis of the NASH is confirmed through liver biopsy which is invasive, time consuming and costly. Future growth and evolution of the NASH market may rely on development of less invasive technologies to increase diagnoses rates to broaden the drug treated patient population. Several companies have late stage assets (Phase 3 or outcomes studies) well under way with projected market approval dates in NASH as soon as 2019/2020.&nbsp;&nbsp;For NASH, the market is currently evolving with no approved therapies for the indication across the globe.&nbsp;&nbsp;Current thought leader opinions are pointing to a multiple mechanistic approach to effectively treat NASH.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Several pharmaceutical companies have NASH therapies in development that may be approved for marketing in the United States or outside of the United States. Based on publicly available information, we believe the current therapies in development that would compete with gemcabene in NASH include but are not limited to:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;">OCALIVA (Obeticholic Acid) (FXR Agonist) being developed by Intercept Pharmaceuticals, Inc.; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;">Elafibranor (PPAR Agonist) being developed by Genfit SA; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;">Selonsertib (formerly GS-4997) (ASK1 Inhibitor) being developed by Gilead Sciences, Inc.; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;">GS-0976 (ACC Inhibitor) being developed by Gilead Sciences, Inc.; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;">Cenicriviroc (CVC) (CCR2/CCR5 Inhibitor) being developed by Tobira Therapeutics, Inc. (a wholly-owned subsidiary of Allergan plc); </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;">Emricasan (Caspase Inhibitor) being developed by Conatus Pharmaceuticals Inc. </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;">Aramchol (Synthetic Fatty Acid/Bile Acid Conjugate) being developed by Galmed;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;">GR-MD-02 (Galectin-3 Inhibitor) being developed by Galectin Therapeutics; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Courier New;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> o</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;">MGL-3196 (THR Agonist) being developed by Madrigal.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">64</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:10pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non&#8209;competitive. Our competitors may also render our technologies obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Many of our competitors have significantly greater name recognition, financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials and entering into strategic transactions, as well as in acquiring technologies complementary to, or necessary for, our programs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We lack experience commercializing products, which may have an adverse effect on our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If gemcabene or any product candidate we may pursue in the future receives marketing approval, we will need to transition from a company with a development focus to a company capable of supporting commercial activities, and we may not be successful in making that transition. We have never filed an NDA, and have not yet demonstrated an ability to obtain marketing approval for, or to commercialize, any product candidate. As a result, our clinical development and regulatory approval process, and our ability to successfully commercialize any approved products, may involve more inherent risk, take longer, and cost more than it would if we were a company with experience obtaining marketing approval for and commercializing a product candidate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market gemcabene, if approved, or any other product candidate we may pursue, we may not be successful in commercializing such product candidate if and when approved.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We do not have a global sales or marketing infrastructure and have no capabilities in place at the present time for the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource part or all of these functions to other third parties.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Factors that may inhibit our efforts to commercialize gemcabene or any future product candidate on our own include:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe our product candidate;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">unforeseen costs and expenses associated with creating an independent sales and marketing organization; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">65</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">inability to obtain sufficient coverage and reimbursement from third&#8209;party payors and governmental agencies.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenues or the profitability of these product revenues to us are likely to be lower than if we were to market and sell a product that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market any product candidate or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market a drug effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing gemcabene or any future product candidate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Even if gemcabene or any future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even if gemcabene or any future product candidate receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. If such product candidate does not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of a product candidate, if approved for commercial sale, will depend on a number of factors, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">efficacy and potential advantages compared to alternative treatments;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the ability to offer our product for sale at competitive prices;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">any restrictions on the use of our product together with other medications;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">interactions of our product with other medicines patients are taking;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">inability of certain types of patients to take our product;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">demonstrated ability to treat patients and, if required by any applicable regulatory authority in connection with the approval for target indications, to provide patients with incremental cardiovascular disease benefits, as compared with other available therapies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the relative convenience and ease of administration of gemcabene, including as compared with other treatments available for approved indications;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the prevalence and severity of any adverse side effects;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">limitations or warnings contained in the labeling approved by the FDA;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">availability of alternative treatments already approved or expected to be commercially launched in the near future;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the effectiveness of our sales and marketing strategies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">our ability to increase awareness through marketing efforts;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">guidelines and recommendations of organizations involved in research, treatment and prevention of various diseases that may advocate for alternative therapies;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">66</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">our ability to obtain sufficient third&#8209;party coverage and adequate reimbursement;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the willingness of patients to pay out&#8209;of&#8209;pocket in the absence of third&#8209;party coverage; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">physicians or patients may be reluctant to switch from existing therapies even if potentially more effective, safe or convenient.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If the FDA or a comparable foreign regulatory authority approves generic versions of gemcabene or any future product candidates that receive marketing approval, or such authorities do not grant our product candidates appropriate periods of data exclusivity before approving generic versions of our products, the sales of our products could be adversely affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Once an NDA is approved, the product covered thereby becomes a &#x201C;reference listed drug&#x201D; in the FDA&#x2019;s publication, &#x201C;Approved Drug Products with Therapeutic Equivalence Evaluations.&#x201D; Manufacturers may seek approval of generic versions of reference listed drugs through submission of abbreviated new drug applications (ANDAs) in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical studies. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug may be typically lost to the generic product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The FDA may not approve an ANDA for a generic product until any applicable period of non&#8209;patent exclusivity for the reference listed drug has expired. The FDC Act provides a period of five years of non&#8209;patent exclusivity for a new drug containing a new chemical entity (NCE). Specifically, in cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification that a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference listed drug. It is unclear whether the FDA will treat the active ingredients in our product candidates as NCEs and, therefore, afford them five years of NCE data exclusivity if they are approved. If any product we develop does not receive five years of NCE exclusivity, it may nonetheless be eligible for three years of exclusivity, which means that the FDA may approve generic versions of such product three years after its date of approval. Manufacturers may seek to launch these generic products following the expiration of the applicable marketing exclusivity period, even if we still have patent protection for our product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Competition that gemcabene or any future product candidates may face from generic versions of our products could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in any such product candidate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Even if we are able to commercialize gemcabene or any future product candidate, the profitability of such product candidate will likely depend in significant part on third&#8209;party reimbursement practices, which, if unfavorable, would harm our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our ability to commercialize a drug successfully will depend in part on the extent to which coverage and adequate reimbursement will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third&#8209;party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and third&#8209;party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third&#8209;party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if coverage is available, whether the level of reimbursement will be adequate. Assuming we obtain coverage for gemcabene, if approved, by a third&#8209;party payor, the resulting reimbursement payment rates may not be adequate or may require co&#8209;payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third&#8209;party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely to use a product candidate, if approved, unless coverage is provided and reimbursement is </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">67</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which a product candidate is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for a new product, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the product and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost medicines and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the United States. Third&#8209;party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. However, no uniform policy requirement for coverage and reimbursement for drug products exists among third&#8209;party payors in the United States. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time&#8209;consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our inability to promptly obtain coverage and profitable payment rates from both government&#8209;funded and private payors for any approved products that we develop could have an adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We face an inherent risk of product liability exposure related to the testing of our product candidate in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise coming into contact with gemcabene or any future product candidate during product testing, manufacturing, marketing or sale. For example, we may be sued on allegations that a product candidate caused injury or that the product is otherwise unsuitable. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, including as a result of interactions with alcohol or other drugs, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against claims that our product candidate caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">decreased demand for any product candidate that we are developing;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">injury to our reputation and significant negative media attention;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">withdrawal of clinical trial participants;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">increased FDA warnings on product labels;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">significant costs to defend the related litigation;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">substantial monetary awards to trial participants or patients;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">distraction of management&#x2019;s attention from our primary business;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">loss of revenue; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">68</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the inability to commercialize any product candidate that we may develop.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Any product liability or clinical trial insurance coverage that we do obtain may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand clinical trials and if we successfully commercialize gemcabene or any other product candidate we may pursue in the future. Insurance coverage is increasingly expensive, and we may not be able to obtain product liability insurance on commercially reasonable terms or in an amount adequate to satisfy any liability that may arise.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we or our third&#8209;party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials, by ourselves and our third&#8209;party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States and abroad governing laboratory procedures and the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#x2019; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. Compliance with applicable environmental, health and safety laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Federal legislation and actions by state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could adversely affect our operating results.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We may face competition for gemcabene, if approved, from cheaper lipid&#8209;lowering therapies sourced from foreign countries that have placed price controls on pharmaceutical products. The Medicare Modernization Act contains provisions that may change U.S. importation laws and expand pharmacists&#x2019; and wholesalers&#x2019; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. These changes to U.S. importation laws will not take effect unless and until the Secretary of Health and Human Services certifies that the changes will pose no additional risk to the public&#x2019;s health and safety and will result in a significant reduction in the cost of products to consumers. The Secretary of Health and Human Services has so far declined to approve a reimportation plan. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any product we may develop and adversely affect our future revenues and prospects for profitability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to our Dependence on Third Parties</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We will be unable to directly control all aspects of our clinical trials due to our reliance on clinical research organizations (CROs) and other third parties that assist us in conducting clinical trials.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We will rely on CROs to conduct part or all of our preclinical studies and clinical trials for any product candidate, including our Phase&nbsp;2 and Phase&nbsp;3 trials for gemcabene. As a result, we will have limited control over the conduct, timing and completion of these clinical trials and the management of data developed through the clinical trials. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">have staffing difficulties;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">69</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">fail to comply with contractual obligations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">experience regulatory compliance issues;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">undergo changes in priorities or become financially distressed; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">form relationships with other entities, some of which may be our competitors.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">These factors may adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Moreover, the FDA and other global health authorities require us to comply with standards, commonly referred to as good clinical practices, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Problems with the timeliness or quality of the work of any CRO may lead us to seek to terminate our relationship with any such CRO and use an alternative service provider. Making this change may be costly and may delay our clinical trials, and contractual restrictions may make such a change difficult or impossible to effect. If we must replace any CRO that is conducting our clinical trials, our clinical trials may have to be suspended until we find another CRO that offers comparable services. The time that it takes us to find alternative organizations may cause a delay in the commercialization of gemcabene or may cause us to incur significant expenses to replicate data that may be lost. Although we do not believe that any CRO on which we may rely will offer services that are not available elsewhere, it may be difficult to find a replacement organization that can conduct our clinical trials in an acceptable manner and at an acceptable cost. Any delay in or inability to complete our clinical trials could significantly compromise our ability to secure regulatory approval of gemcabene and preclude our ability to commercialize gemcabene, thereby limiting or preventing our ability to generate revenue from its sales.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We rely completely on third parties to supply and manufacture our preclinical and clinical drug supplies for gemcabene, and we intend to rely on third parties to produce commercial supplies of gemcabene and preclinical, clinical and commercial supplies of any future product candidate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We do not currently have, nor do we plan to acquire, the infrastructure or capability to internally manufacture our clinical drug supply of gemcabene, or any future product candidates, for use in the conduct of our preclinical studies and clinical trials, and we lack the internal resources and the capability to manufacture any product candidates on a clinical or commercial scale. The process of manufacturing drug products is complex, highly regulated and subject to several risks. For example, the facilities used by our contract manufacturers to manufacture the active pharmaceutical ingredient (or drug substance) and final drug product for gemcabene, or any future product candidates, must be inspected by the FDA and other comparable foreign regulatory agencies in connection with our submission of an NDA or relevant foreign regulatory submission to the applicable regulatory agency. In addition, the manufacturing of drug substance or product is susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, or vendor or operator error. Moreover, the manufacturing facilities in which gemcabene or any future product candidates are made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures or other factors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We do not control the manufacturing process of, and are completely dependent on, our contract manufacturers to comply with current good manufacturing practices (cGMP) for manufacture of both active drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or applicable foreign regulatory agencies, we will not be able to secure and/or maintain regulatory approval for our products. In addition, we have no direct control over our contract manufacturers&#x2019; ability to maintain adequate quality control, quality assurance and qualified personnel. Failure to satisfy the regulatory requirements for the production of those materials and products may affect the regulatory clearance of our contract manufacturers&#x2019; facilities generally. If the FDA or a comparable foreign regulatory agency does not approve these facilities for the manufacture of gemcabene or any future product candidates, or if it withdraws its approval in the future, we may need to find alternative manufacturing facilities, which would adversely impact our ability to develop, obtain regulatory approval for or market gemcabene or such future product candidates. Furthermore, all of our contract </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">70</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">manufacturers are engaged with other companies to supply and/or manufacture materials or products for such companies, which exposes our manufacturers to regulatory and sourcing risks for the production of such materials and products. To the extent practicable, we attempt to identify more than one supplier, but some raw materials are available only from a single source or only one supplier has been identified, even in instances where multiple sources exist.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have relied upon third&#8209;party manufacturers for the manufacture of our product candidate for preclinical and clinical testing purposes and intend to continue to do so in the future, including for commercial purposes. If our third party manufacturers are unable to supply drug substance and/or drug product on a commercial basis, we may not be able to successfully produce and market gemcabene, if approved, or could be delayed in doing so. For instance, we rely on one supplier for the drug substance for gemcabene. The manufacturer of the drug substance for gemcabene will need to manufacture batches of the drug substance that will serve as the validation batches that will be reviewed by the FDA in connection with its review of the NDA for gemcabene and as the supply of gemcabene, if approved and successfully launched commercially. If there is any delay or problem with the manufacture of these batches of drug substance or if there is a delay in producing finished product from these batches, the approval of gemcabene may be delayed or any potential launch of gemcabene may be adversely affected. We will rely on comparison of product specifications (identity, strength, quality, potency) to demonstrate equivalence of the current drug substance and/or drug product to the drug substance and/or drug product used in previously completed preclinical and clinical testing. If we are unable to demonstrate such equivalence, we may be required to conduct additional preclinical and/or clinical testing of our product candidate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">These and other problems with any manufacturer may lead us to seek to terminate our relationship with any such manufacturer and use an alternative manufacturer. Making this change may be costly, time consuming and difficult to effectuate, and may delay our research and development activities. If we must replace any manufacturer, our research and development activities may have to be suspended until we find another manufacturer that offers comparable services. The time that it takes us to find alternative organizations may cause a delay in the development and commercialization of gemcabene or any future product candidate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to gemcabene and any future product candidates that we may develop. Any of these relationships may require us to incur non&#8209;recurring and other charges, increase our near and long&#8209;term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. Our likely collaborators include large and mid&#8209;size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. If we enter into any such arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of gemcabene or any future product candidate. Our ability to generate revenues from these arrangements will depend on our collaborators&#x2019; abilities to successfully perform the functions assigned to them in these arrangements. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Collaborations involving gemcabene or any future product candidate pose the following risks to us:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">collaborators may not perform their obligations as expected;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">collaborators may not pursue development and commercialization or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#x2019;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">71</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidate if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">a collaborator with marketing and distribution rights to one or more product candidates may not commit sufficient resources to the marketing and distribution of any such product candidate;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidate or that result in costly litigation or arbitration that diverts management attention and resources;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change of control;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">collaborators may learn about our discoveries and use this knowledge to compete with us in the future;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the results of collaborators&#x2019; preclinical or clinical studies could harm or impair other development programs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">there may be conflicts between different collaborators that could negatively affect those collaborations and potentially others;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">collaboration agreements may not lead to development or commercialization of our product candidate in the most efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">collaborators may be unable to obtain the necessary marketing approvals.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If future collaboration partners fail to develop or effectively commercialize gemcabene or any future product candidate for any of these reasons, such product candidate may not be approved for sale and our sales of such product candidate, if approved, may be limited, which would have an adverse effect on our operating results and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we are not able to establish new collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We face significant competition in attracting collaborators. Whether we reach a definitive agreement for collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of a number of factors related to the associated product candidate. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">72</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Much of the potential revenue from future collaborations may consist of contingent payments, such as payments for achieving regulatory milestones or royalties payable on sales of our product candidate, if approved. The milestone and royalty revenue that we may receive under these collaborations will depend upon our collaborators&#x2019; ability to successfully develop, introduce, market and sell new our product candidate, if approved. In addition, collaborators may decide to enter into arrangements with third parties to commercialize products developed under collaborations related to our product candidate, which could reduce the milestone and royalty revenue received, if any.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time&#8209;consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidate or bring it to market and generate product revenue.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to our Intellectual Property</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we are unable to adequately protect our proprietary technology or maintain issued patents sufficient to protect gemcabene or any future product candidate, others could compete against us more directly, which would have an adverse impact on our business, results of operations, financial condition and prospects.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our commercial success will depend in part on our success obtaining and maintaining issued patents and other intellectual property rights in the United States and elsewhere and protecting our proprietary technology. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability.&nbsp;&nbsp;We licensed patents relating to our current product candidate, gemcabene, from Pfizer. Pursuant to the license agreement, we are responsible for filing, prosecuting and maintaining the patent rights in Pfizer&#x2019;s name at our own cost and expense. In connection with this obligation, we are granted the first right to control the enforcement of the license patents against any third&#8209;party infringement actions. Risks related to our Pfizer license are discussed elsewhere in this &#x201C;Risk Factors&#x201D; section under &#x201C;</font><font style="display:inline;font-style:italic;">We depend on intellectual property licensed from Pfizer for gemcabene, and the termination of this license would harm our business.</font><font style="display:inline;">&#x201D; The termination of this license could result in the loss of significant rights, which would harm our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of February 20, 2017, our patent estate, including patents we own or license from third parties, on a worldwide basis, included four issued U.S. patents, eight pending U.S. patent applications, 45 issued patents in foreign jurisdictions including Canada, France, Germany, Great Britain, Ireland, Italy, Mexico and Spain and 16 pending patent applications in foreign jurisdictions including Australia, Canada, China, Europe, Hong Kong, Japan and Mexico. Our worldwide patents and pending applications all relate to our product candidate, gemcabene. Our patents claiming the gemcabene composition of matter generically, which were in&#8209;licensed from Pfizer, have all expired; however, our clinical formulation comprises a specific calcium salt crystal form of gemcabene, which form is claimed in U.S. Patent Number&nbsp;6,861,555. This patent, which was in&#8209;licensed from Pfizer, is expected to expire in 2021, absent any patent term extension. Our current patent estate includes eight patent families that have claims directed to methods of treatment using gemcabene. These patent families include, for example, U.S. Patent Number 8,557,835, licensed from Pfizer that has claims directed to using a statin&#8209;gemcabene combination for treating hyperlipidemia, angina pectoris and atherosclerosis. U.S. Patent Number 8,557,835 is expected to expire in 2021, absent any patent term extension, and corresponding foreign patents are expected to expire in 2018, absent any adjustment or extension. Additionally, U.S. </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">73</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">Patent Number&nbsp;8,846,761 and U.S. Patent Application Number&nbsp;14/370,722, are owned by us. U.S. Patent Number&nbsp;8,846,761 is directed to methods of decreasing a subject&#x2019;s risk for developing pancreatitis by administering gemcabene and is expected to expire in 2032, absent any patent term extension. Any foreign patent in this family that may issue is expected to expire in 2031, absent any patent term extension. U.S. Patent Application Number&nbsp;14/370,722, is directed to methods of decreasing a patient&#x2019;s risk for developing coronary heart disease or preventing, delaying or reducing the severity of a secondary cardiovascular event by administering gemcabene with a statin. Related patent applications are pending in foreign jurisdictions including Australia, Canada, China, Europe, Japan and Mexico. Any patent that may issue in this family, absent any patent term adjustment or extension, is expected to expire in 2033.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In 2015-2017, we filed two non&#8209;provisional patent applications on methods of large scale manufacturing for making dicarboxyalkyl ethers (US Application&nbsp;Number&nbsp;14/942,765 and corresponding PCT application Number&nbsp;PCT/US2015/060917), any patent issuing from this patent family is expected to expire in 2035. In addition, we filed U.S. provisional patent applications of which 62/300,393, 62/314,597, 62/411,997 and 62/412,017, are pending, and two PCT applications one for methods of treating mixed dyslipidemia using gemcabene in combination with statins and treatment of NASH using gemcabene as a monotherapy (PCT/US2016/060837), and the other relating to fixed dose combinations and modified release formulations of gemcabene and statins (PCT/US2016/060849). Two U.S. Patent Applications were filed as continuations of PCT/US2016/060837.&nbsp;&nbsp;U.S. Patent Application Number 15/416,911, is directed to methods of treating NASH by administering gemcabene as a monotherapy and U.S. Patent Application Number 15/424,620, is directed methods for treating Mixed Dyslipidemia by administering gemcabene and a statin.&nbsp;&nbsp;Any patent that may issue in either of these two families, absent any patent term adjustment or extension, is expected to expire in 2037.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The patent prosecution process is expensive and time&#8209;consuming, and we and our current or future licensors, licensees or collaboration partners may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our licensors will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Our and our licensors&#x2019; patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover the technology.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We cannot assure you that any of our patents have, or that any of our pending patent applications will mature into issued patents that will include, claims with a scope sufficient to protect gemcabene or any future product candidate. Others have developed technologies that may be related or competitive to our approach, and may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or formulations or by claiming subject matter that could dominate our patent position. The patent positions of biotechnology and pharmaceutical companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity and enforceability of any patent claims that we may obtain cannot be predicted with certainty. Patents, if issued, may be challenged, deemed unenforceable, invalidated, or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, </font><font style="display:inline;font-style:italic;">ex parte</font><font style="display:inline;"> reexamination, or </font><font style="display:inline;font-style:italic;">inter partes</font><font style="display:inline;"> review proceedings, supplemental examination and challenges in district court. Patents may be subjected to opposition, post&#8209;grant review, or comparable proceedings lodged in various national and regional patent offices. These proceedings could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, re&#8209;examination, opposition, post&#8209;grant review, </font><font style="display:inline;font-style:italic;">inter partes</font><font style="display:inline;"> review, supplemental examination or revocation proceedings may be costly. Thus, any patents that we may own or exclusively license may not provide any protection against competitors. Furthermore, an adverse decision in an interference proceeding can result in a third&#8209;party receiving the patent right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize gemcabene.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Furthermore, the issuance of a patent, while presumed valid, is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products. Competitors may also be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs or methods. We may not be able to prevent the unauthorized disclosure or use of any technical knowledge or trade secrets by consultants, vendors, former employees and current employees. The laws of some foreign countries do not protect our proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these countries. If these developments were to occur, they could have a material adverse effect on our sales.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">74</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our ability to enforce our patent rights depends on our ability to detect infringement. It is difficult to detect infringers who do not advertise the components that are used in their products. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#x2019;s or potential competitor&#x2019;s product. Any litigation to enforce or defend our patent rights, if any, even if we were to prevail, could be costly and time&#8209;consuming and would divert the attention of our management and key personnel from our business operations. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded if we were to prevail may not be commercially meaningful.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable, or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If, in any proceeding, a court invalidated or found unenforceable our patents covering gemcabene or any future product candidate, our financial position and results of operations would be adversely impacted. In addition, if a court found that valid, enforceable patents held by third parties covered gemcabene or any future product candidate, our financial position and results of operations would also be adversely impacted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect gemcabene;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">any of our pending patent applications will result in issued patents;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">we will be able to successfully commercialize gemcabene or any future product candidate, if approved, before our relevant patents expire;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">we were the first to make the inventions covered by each of our patents and pending patent applications;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">we were the first to file patent applications for these inventions;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">others will not develop similar or alternative technologies that do not infringe our patents;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">any of our patents will be valid and enforceable;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">we will develop additional proprietary technologies or product candidates that are separately patentable; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">that our commercial activities or products will not infringe upon the patents of others.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Patents have a limited lifespan. The natural expiration of a patent is generally 20&nbsp;years after its effective filing date. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the extensive period of time between patent filing and regulatory approval for a product candidate, the time during which we can market a product candidate under patent protection is limited, and our patent may expire before we obtain such approval. Without patent protection for gemcabene or any future product candidates, we may be open to competition from generic versions of our product candidates, which may affect the profitability of our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we do not obtain protection under the Hatch&#8209;Waxman Act and similar foreign legislation by extending the patent terms and obtaining data exclusivity for our product candidate, our business may be materially harmed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Depending upon the timing, duration of regulatory review, and date of FDA marketing approval of gemcabene or any future product candidate, if any, one of our U.S. patents may be eligible for patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch&#8209;Waxman Act. The Hatch&#8209;Waxman Act provides for a patent restoration term of up to five years as compensation for the time the product is under FDA regulatory review (patent term extension). The duration of patent term extension is calculated based on the time spent in the regulatory review process. Our basic U.S. composition of matter patent for gemcabene has expired. We plan to seek </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">75</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">patent term extension for one of our patents related to gemcabene. However, we may not be granted an extension because of, for example, failing to apply within the applicable deadline, expiration of relevant patents prior to obtaining approval, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our revenue could be reduced, possibly materially.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, we believe that gemcabene is a NCE in the United States and may be eligible for data exclusivity under the Hatch&#8209;Waxman Act. A single&#8209;ingredient drug can be classified as a NCE if the FDA has not previously approved any other new drug containing the same active ingredient. Under sections&nbsp;505(c)(3)(E)(ii) and 505(j)(5)(F)(ii) of the FDC Act, as amended, a NCE that is granted marketing approval may, even in the absence of patent protections, be eligible for five years of data exclusivity in the United States following marketing approval. During the data exclusivity period, if granted, the FDA is precluded from approving 505(b)(2) applications or abbreviated new drug applications submitted by another company that references the FDA&#x2019;s findings of safety and efficacy for the approved NDA. In the European Union, NCEs qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from reviewing a generic application for eight years, after which generic marketing authorization can be approved but the generic drug may not be marketed during the two&#8209;year marketing exclusivity period. However, gemcabene may not be considered to be a NCE for these purposes or be entitled to the period of data exclusivity. If we are not able to gain or exploit the period of data exclusivity, we may face significant competitive threats to our commercialization of gemcabene from other manufacturers, including the manufacturers of generic alternatives. Further, even if our compound is considered to be a NCE and we are able to gain the prescribed period of data exclusivity, another company nevertheless could gain marketing approval for the same compound if they independently generate preclinical and clinical data and get market approval through the NDA process without benefit of our data.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we fail to maintain orphan drug exclusivity for gemcabene for HoFH, we will have to rely on data and marketing exclusivity for HoFH that is not based on an orphan drug designation, if any, and on our intellectual property rights.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As part of our business strategy, in the United States we have obtained orphan drug designation for gemcabene for the treatment of HoFH. We may submit an application to the FDA for other orphan drug designations for gemcabene such as for the treatment of TG greater than approximately 750 mg/dL (F) or Familial Partial Lipodystrophy under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, defined, in part, as a patient population of fewer than 200,000 in the United States.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the United States, the company that first obtains FDA approval for a designated orphan drug for the specified rare disease or condition receives orphan drug marketing exclusivity for that drug for a period of seven years. This orphan drug exclusivity prevents the FDA from approving another application, including a full NDA, to market the same drug for the same orphan indication, except in very limited circumstances. For purposes of small molecule drugs, the FDA defines &#x201C;same drug&#x201D; as a drug that contains the same active pharmaceutical ingredient (API) and is intended for the same use as the drug in question. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The EMA grants orphan drug designation to promote the development of products that may offer therapeutic benefits for life&#8209;threatening or chronically debilitating conditions affecting not more than five in 10,000 people in the European Union. Orphan drug designation from the EMA provides ten years of marketing exclusivity following drug approval, subject to reduction to six years if the designation criteria are no longer met.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even if we are able to obtain and maintain orphan drug exclusivity for gemcabene for HoFH, the designation may not effectively protect it from competition for HoFH because different drugs can be approved for the same condition. Moreover, even with an orphan drug designation, the FDA can subsequently approve a different formulation of the same API for the same condition if the FDA concludes that the later formulation of the API is safer, more effective or makes a major contribution to patient care.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect gemcabene and any product candidate we may pursue in the future.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">76</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In 2011, the United States enacted wide&#8209;ranging patent reform legislation with the America Invents Act (AIA).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">An important change introduced by the AIA is that, as of March&nbsp;16, 2013, the United States transitioned to a &#x201C;first&#8209;to&#8209;file&#x201D; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files&nbsp;a patent application in the U.S. Patent and Trademark Office (USPTO) after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file&nbsp;a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March&nbsp;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. The AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years, such as </font><font style="display:inline;font-style:italic;">Association for Molecular Pathology v. Myriad Genetics,&nbsp;Inc. (Myriad&nbsp;I)</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;font-style:italic;">Mayo Collaborative Services v. Prometheus Laboratories,&nbsp;Inc.</font><font style="display:inline;"> and </font><font style="display:inline;font-style:italic;">Alice Corporation Pty.&nbsp;Ltd. v. CLS Bank International</font><font style="display:inline;">, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We may not be able to protect or practice our intellectual property rights throughout the world.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In jurisdictions where we have not obtained patent protection, competitors may use our intellectual property to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the U.S. Competitor products may compete with gemcabene, if approved, or any future product candidate in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to pharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we, or our licensors, encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we, or any of our licensors, are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">77</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Competitors may infringe our patents and other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, or may refuse to stop the other party from using the technology on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Litigation proceedings may fail and, even if successful, may result in substantial costs and distraction of our management and other employees. We may not be able to prevent, alone or with our collaborators, misappropriation of our proprietary rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have an adverse effect on the success of our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell gemcabene and any other product candidate we may pursue in the future and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. We may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our medicines and technology, including interference or derivation proceedings, post&#8209;grant reviews, inter partes reviews, or other procedures before the USPTO or other similar procedures in foreign jurisdictions. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we are found to infringe a third party&#x2019;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our medicines and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non&#8209;exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. We could be forced, including by court order, to cease developing and commercializing the infringing technology or medicine. In addition, we could be found liable for substantial monetary damages, potentially including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed. A finding of infringement could prevent us from commercializing a product candidate or force us to cease some of our business operations, which could harm our business. Alternatively, we may need to redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The cost to us of any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial and may result in substantial costs and distraction of our management and other employees. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of their former employers.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our employees and consultants have been previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we are not aware of any claims currently pending against </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">78</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">us, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information or intellectual property of the former employers of our employees. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product could hamper or prevent our ability to commercialize gemcabene, which would adversely affect our commercial development efforts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of any product we may pursue could be significantly diminished.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We may rely upon trade secrets, know&#8209;how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers, contract manufacturers, vendors and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, we cannot guarantee that we have executed these agreements with each party that may have or have had access to trade secrets.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Moreover, because we acquired certain rights to gemcabene from Pfizer, we must rely on Pfizer&#x2019;s practices, and those of its predecessors, with regard to parties that may have had access to trade secrets related thereto. Any party with whom they or we have executed such an agreement may breach that agreement and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time&#8209;consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they disclose such trade secrets, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third&#8209;party, our competitive position would be harmed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We have filed U.S. applications for certain of our trademarks, but we have not yet obtained registration of any of our trademarks.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have filed U.S. applications for three trademarks, &#x201C;Gemphire&#x201D;, the Gemphire logo and &#x201C;Advancing a class on top of statins&#x201D;, but we have not yet obtained registration of any of our trademarks in the United States or other countries. If we do not secure and maintain registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would, which could affect our business. We have also not yet registered trademarks for any product candidate in any jurisdiction. When we file trademark applications for a product candidate, those applications may not be allowed for registration, and registered trademarks may not be obtained, maintained or enforced. During trademark registration proceedings in the United States and foreign jurisdictions, we may receive rejections. We are given an opportunity to respond to those rejections, but we may not be able to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, any proprietary name we propose to use with gemcabene or any future product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed drug names, including an evaluation of potential for confusion with other drug names. If the FDA objects to any proposed proprietary drug name for any product candidate, we may be required to expend significant additional resources in an effort to identify a suitable substitute proprietary drug name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If we register any of our trademarks, our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to infringe on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">79</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment or other provisions during the patent application process. In addition, periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which would have an adverse effect on our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to Employee Matters and Managing Growth</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We are dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are highly dependent on our management, scientific and medical personnel, including Dr.&nbsp;Charles L. Bisgaier, our co&#8209;founder, Chairman of our board of directors and Chief Scientific Officer, and Mina Sooch, our President, Chief Executive Officer and director. We have entered into employment agreements with our executive officers, but any employee may terminate his or her employment with us. The loss of the services of either Dr.&nbsp;Bisgaier or Ms.&nbsp;Sooch, any of our executive officers, other key employees or consultants and other scientific and medical advisors in the foreseeable future, might impede the achievement of our research, development and commercialization objectives. We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Recruiting and retaining qualified scientific personnel and business and commercial personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific personnel from universities and research institutions. Failure to succeed in clinical trials may also make it more challenging to recruit and retain qualified scientific personnel.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We will need to develop and expand our company, and we may encounter difficulties in managing this development and expansion, which could disrupt our operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2016, we had twelve full&#8209;time employees, and we expect to increase our number of employees and the scope of our operations as we further the clinical development of gemcabene and continue to operate as a public company. To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away from its day&#8209;to&#8209;day activities and devote a substantial amount of time to managing these development activities. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, and give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of gemcabene. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize gemcabene or any future product candidate, if approved, and compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">A variety of risks associated with operating internationally for us and our collaborators could adversely affect our business.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">80</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition to our U.S. operations, we may pursue international operations in the future and would face risks associated with such global operations, including possible unfavorable regulatory, pricing and reimbursement, legal, political, tax and labor conditions, which could harm our business. We plan to conduct clinical trials outside of the United States. We are subject to numerous risks associated with international business activities, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">compliance with differing or unexpected regulatory requirements for gemcabene or any other product candidate;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">different medical practices and customs affecting acceptance of gemcabene, if approved, or any other approved product in the marketplace;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">language barriers;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the interpretation of contractual provisions governed by foreign law in the event of a contract dispute;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">difficulties in staffing and managing foreign operations, and an inability to control commercial or other activities where we are relying on third parties;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">workforce uncertainty in countries where labor unrest is more common than in the United States;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">potential liability under the Foreign Corrupt Practice Act of 1977 or comparable foreign regulations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">production shortages resulting from any events affecting raw material supply or manufacturing capability abroad;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">foreign government taxes, regulations and permit requirements;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">U.S. and foreign government tariffs, trade restrictions, price and exchange controls and other regulatory requirements;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">economic weakness, including inflation, natural disasters, war, events of terrorism or political instability in particular foreign countries;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">fluctuations in currency exchange rates, which could result in increased operating expenses and reduced revenues;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">compliance with tax, employment, immigration and labor laws, regulations and restrictions for employees living or traveling abroad;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">changes in diplomatic and trade relationships; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">challenges in enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our business and operations would suffer in the event of system failures or unplanned events.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Despite the implementation of security measures, our internal computer systems and those of our current and future contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we are not aware of any such material system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">81</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Furthermore, any unplanned event, such as flood, fire, explosion, tornadoes, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize the facilities, may have an adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Risks Related to our Common Stock </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses of our common stock. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The trading price of our common stock O is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#x201C;Risk Factors&#x201D; section and elsewhere in this report, these factors include:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">adverse results or delays in preclinical studies, clinical trials, regulatory decisions or the development status of gemcabene or any product candidates we may pursue in the future;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">decisions to initiate a clinical trial, not initiate a clinical trial, or terminate an existing clinical trial;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">adverse regulatory decisions, including failure to receive regulatory approval for gemcabene;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">changes in applicable laws, rules or regulations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">disputes with Pfizer regarding our licensed rights to gemcabene;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">adverse developments concerning our manufacturers, suppliers, collaborators and other third parties;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">our failure to commercialize gemcabene or any product candidates we may pursue in the future;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the success of competitive drugs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">additions or departures of key scientific or management personnel;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">unanticipated safety concerns related to the use of gemcabene or any product candidates we may pursue in the future;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">our announcements or our competitor&#x2019;s announcements regarding new products, enhancements, significant contracts, acquisitions or strategic partnerships and investments;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">changes in the structure of healthcare payment systems;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the size and growth of our target markets;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">our failure, or companies perceived to be similar to us, to meet external expectations or management guidance;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">publication of research reports about us or our industry, recommendations, earning results or estimates or withdrawal of research coverage by securities analysts;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">changes in the market valuations of similar companies;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">82</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">changes in general economic, political and market conditions in any of the regions in which we conduct our business;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">changes in our capital structure or dividend policy, future issuances of securities, sales of large blocks of common stock by our stockholders or our incurrence of additional debt;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">trading volume of our common stock;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">changes in accounting practices and ineffectiveness of our internal controls;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">disputes, litigation or developments relating to proprietary rights;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">timing of milestones and royalty payments; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">other events or factors, many of which are beyond our control.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, the stock market in general, NASDAQ, and the stock of biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#x2019;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#x2019;s attention and resources, which would harm our business, operating results or financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">establish a classified board of directors such that not all members of the board are elected at one time;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">allow the authorized number of our directors to be changed only by resolution of our board of directors;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">limit the manner in which stockholders can remove directors from the board;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">prohibit stockholders from calling special meetings;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">authorize our board of directors to issue preferred stock without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock, and which could be used to institute a shareholder rights plan, or so&#8209;called &#x201C;poison pill,&#x201D; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">83</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">require the approval of the holders of at least two&#8209;thirds of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We do not know whether an active, liquid and orderly trading market will develop for our common stock or what the market price of our common stock will be and as a result it may be difficult for you to sell your shares of our common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Prior to the IPO there has been no public market for shares of our common stock. Although our common stock has been approved for listing on NASDAQ, an active trading market for our shares may never develop or be sustained. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our executive officers, directors, principal stockholders and their affiliates exercise significant control over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2016, our officers, directors, five percent or greater stockholders and their respective affiliates had beneficial ownership, in the aggregate, of approximately 63.7% of our outstanding common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">These stockholders, if they act together, will be able to influence our management and affairs and control the outcome of matters submitted to our stockholders for approval, including the election of directors, amendments of our organizational documents, and any merger, consolidation, sale of all or substantially all of our assets or other major corporate transaction. These stockholders acquired their shares of common stock for substantially less than the current trading price of our common stock, and these stockholders may have interests, with respect to their common stock, that are different from yours. In addition, this concentration of ownership might adversely affect the market price of our common stock, have the effect of delaying, deferring or preventing a change of control of our company, or discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We are an &#x201C;emerging growth company,&#x201D; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are an &#x201C;emerging growth company,&#x201D; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not &#x201C;emerging growth companies,&#x201D; including exemption from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes&#8209;Oxley Act of 2002 (Sarbanes&#8209;Oxley Act), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non&#8209;binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">84</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of the closing of the IPO, (b)&nbsp;in which we have total annual gross revenue of at least $1&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non&#8209;affiliates exceeds $700&nbsp;million as of the prior June&nbsp;30th, and (2)&nbsp;the date on which we have issued more than $1&nbsp;billion in non&#8209;convertible debt during the prior three&#8209;year period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#x201C;smaller reporting company,&#x201D; which would allow us to take advantage of many of the same exemptions from disclosure requirements including exemption from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes&#8209;Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As a public company, and particularly after we are no longer an &#x201C;emerging growth company,&#x201D; we will incur significant legal, accounting and other expenses that we did not incur as a private company. For example, we will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes&#8209;Oxley Act and rules subsequently implemented by the SEC and NASDAQ have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time&#8209;consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Further, there are significant corporate governance and executive compensation related provisions in the Dodd&#8209;Frank Wall Street Reform and Consumer Protection Act that require the SEC to adopt additional rules and regulations in these areas such as &#x201C;say on pay&#x201D; and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of the IPO. We intend to take advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are subject to Section&nbsp;404 of the Sarbanes&#8209;Oxley Act and the related rules of the SEC that generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Beginning with the second annual report that we will be required to file with the SEC, Section&nbsp;404 of the Sarbanes&#8209;Oxley Act requires an annual management assessment of the effectiveness of our internal control over financial reporting. However, for so long as we remain an &#x201C;emerging growth company&#x201D; as defined in the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes&#8209;Oxley Act. Once we are no longer an &#x201C;emerging growth company&#x201D; or, if before such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To date, we have never conducted a review of our internal control for the purpose of providing the reports required by these rules. To achieve compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, hire additional finance and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">85</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. During the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. Furthermore, if we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In addition, as a public company we will be required to timely file accurate quarterly and annual reports with the SEC under the Exchange Act. In order to report our results of operations and financial statements on an accurate and timely basis, we will depend on CROs to provide timely and accurate notice of their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from NASDAQ or other adverse consequences that would materially harm our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have never declared or paid any cash dividend on our capital stock and do not currently intend to do so in the foreseeable future. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business. Therefore, the success of an investment in shares of our common stock will depend upon any future appreciation in their value. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which you purchased them.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">A significant portion of our total outstanding shares are restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. As of December 31, 2016, we had 9,270,255&nbsp;shares of common stock outstanding. This included 2,121,435&nbsp;shares that we sold in the IPO that, may be resold in the public market immediately without restriction. The remaining 7,148,820 shares, as well as any shares purchased by our affiliates in the IPO, are currently or will be restricted as a result of securities laws</font><font style="display:inline;color:#000000;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Moreover, holders of an aggregate of approximately 1,436,161&nbsp;shares of our common stock will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">An aggregate of 355,200 shares reserved under the A&amp;R 2015 Plan, 102,000 shares reserved under the Inducement Plan and 150,000&nbsp;shares reserved under our employee stock purchase plan remained available for issuance as of December 31, 2016. If a large number of these shares are sold in the public market, the sales could reduce the trading price of our common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our issuance of the common stock in connection with the IPO may have resulted in an &#x201C;ownership change&#x201D; at the time of issuance, or has increased the risk that we could experience an ownership change in the future. Any ownership change would significantly limit our ability to utilize our net operating loss carryforwards and certain other tax attributes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2016, we had approximately $6.2&nbsp;million in U.S. federal and state net operating loss carryforwards, which will begin to expire in 2034 for federal and 2026 for state, that we can use in certain circumstances to offset any future taxable income and thus reduce any federal income tax liability. We also had net tax credit carryforwards of $0.7 million and $24,000 available to reduce future tax liabilities, if any, for U.S. federal and state purposes, respectively. Our ability to utilize these net operating losses and tax credit carryforwards to offset future taxable income may be significantly limited if we have experienced or if we experience in the future an &#x201C;ownership change,&#x201D; as defined in Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code. In general, an ownership change will occur if there is a cumulative change in our ownership by &#x201C;5&#8209;percent shareholders&#x201D; (as defined in the Code) that exceeds 50 </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">86</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">percentage points over a rolling three&#8209;year period. A corporation that experiences an ownership change will generally be subject to an annual limitation on the corporation&#x2019;s subsequent use of net operating loss carryovers that arose from pre&#8209;ownership change periods and use of losses that are subsequently recognized with respect to assets that had a built&#8209;in&#8209;loss on the date of the ownership change. The amount of the annual limitation generally equals the value of the corporation immediately before the ownership change multiplied by the long&#8209;term tax&#8209;exempt interest rate (subject to certain adjustments). To the extent that the limitation in a post&#8209;ownership&#8209;change year is not fully utilized, the amount of the limitation for the succeeding year will be increased.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We do not expect to have experienced an ownership change as a result of our issuance of common stock in connection with the IPO. Nevertheless, the rules regarding the determination of whether an ownership change exists are complicated and are subject to differing interpretations, and it is possible that such issuances might be treated as having resulted in an ownership change. We have not completed a study to assess whether an ownership change for purposes of Section&nbsp;382 has occurred, or whether there have been multiple ownership changes since our inception, due to the significant costs and complexities associated with such study. Even if there was no ownership change as a result of such issuance, the issuance of stock pursuant to the IPO will be taken into account in determining the cumulative change in our ownership for Section&nbsp;382 purposes. As a result, the IPO has materially increased the risk that we could experience an ownership change in the future. If we experience an ownership change, we may not be able to fully utilize our net operating losses, resulting in additional income taxes and a reduction in our stockholders&#x2019; equity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Our amended and restated bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our amended and restated bylaws provide that, subject to limited exceptions, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, as amended, our amended and restated certificate of incorporation or our amended and restated bylaws, any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws or any other action asserting a claim against us that is governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This choice of forum provision may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. We cannot assure you that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">87</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM 1B.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 48pt 0pt 0pt;"></font>UNRESOLVED STAFF COMMENTS<a name="ITEM1BUNRESOLVEDSTAFFCOMMENTS_130840"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Not applicable</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM 2.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 51pt 0pt 0pt;"></font></font><font style="display:inline;"></font><font style="display:inline;font-weight:bold;">PROPERTIES<a name="ITEM2PROPERTIES_644950"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We lease an approximately 5,300 square foot facility in Livonia, Michigan that is primarily used for our headquarters and our research and development activities under a 3 year non&#8209;cancellable facility lease that commenced in August&nbsp;2016. We also lease approximately 1,450 square feet for limited use of office space relating to research and development in our previous Northville, Michigan headquarters location under a cancelable lease agreement that became effective in August 2016 and expires in September 2017. We believe that these facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM 3.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 51pt 0pt 0pt;"></font>LEGAL PROCEEDINGS<a name="ITEM3LEGALPROCEEDINGS_754217"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 4.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 51pt 0pt 0pt;"></font>MINE SAFETY DISCLOSURES<a name="ITEM4MINESAFETYDISCLOSURES_848551"></a></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Not applicable.</font>
		</p>
		<p style="margin:12pt 0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">PART II<a name="PARTII_387386"></a>&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 5.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 51pt 0pt 0pt;"></font>MARKET FOR REGISTRANT&#x2019;S COMMON EQUITY, RELATED STOCKHOLDER<a name="ITEM5MARKETFORREGISTRANTSCOMMONEQUITYREL"></a> MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Price Range of Common Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Our common stock has been listed on the NASDAQ Global Market</font><font style="display:inline;color:#000000;"> under the symbol &#x201C;GEMP&#x201D;</font><font style="display:inline;color:#000000;font-size:10pt;"> since August 5, 2016. Our common stock priced at $10.00 per share in our initial public offering on August 4, 2016</font><font style="display:inline;color:#000000;">. &nbsp;</font><font style="display:inline;color:#000000;font-size:10pt;">Prior to that date, there was no public trading market for our common stock. The following table sets forth for the periods indicated the high and low sale prices per share of our common stock as reported on the NASDAQ Global Market:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The following table sets forth the high and low intra-day sales prices of our common stock for the periods indicated.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:19.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">High</font></p>
				</td>
				<td valign="bottom" style="width:03.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:19.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Low</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Third quarter (from August 5, 2016)</font></p>
				</td>
				<td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13.98
				</td>
				<td valign="bottom" style="width:03.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.50
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Fourth quarter</font></p>
				</td>
				<td valign="bottom" style="width:02.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11.95
				</td>
				<td valign="bottom" style="width:03.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.25
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;">Stockholders</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">On March 3, 2017, we had 9,272,582 shares of common stock outstanding and 114 holders of record of our common stock. A substantially greater number of holders are beneficial owners whose shares are held of record by banks, brokers and other nominees. The transfer agent and registrar for our common stock is Computershare, Inc. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;">Dividend Policy</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">We have never declared or paid any dividends on our common stock, and we do not currently intend to pay any dividends on our common stock for the foreseeable future. Any future determination to pay dividends on our common stock will be, subject to applicable law, at the discretion of our Board of Directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, and contractual restrictions in loan or other agreements.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">88</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;">Recent Sales of Unregistered Equity Securities </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 10 2017, we entered into a securities purchase agreement for a private placement with a select group of accredited investors whereby, on March 15, 2017 we issued and sold 1,324,256 units at a price of $9.47 per unit for gross proceeds of approximately $12.5 million. Each unit consists of one share of our common stock and a warrant to purchase 0.75 shares of common stock. The warrants have an exercise price of $10.40 per share and are exercisable for a period of five years from the date of issuance. The private placement included 56,678 units sold to 3 board members, for aggregate proceeds totaling approximately $0.5 million and 52,798 units sold to 1 investor who is related to 1 board member, for proceeds totaling approximately $0.5 million. Piper Jaffray &amp; Co. acted as sole lead placement agent and Laidlaw &amp; Company (UK) Ltd. and LifeSci Capital LLC acted as co-placement agents in connection with the private placement and will receive fees of approximately $1.0 million in the aggregate.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The securities were issued and sold in the private placement only to accredited investors&nbsp;in reliance on the exemption from registration provided by Section&nbsp;4(a)(2)&nbsp;of the Securities Act of 1933, as amended (the &#x201C;Securities Act&#x201D;), and Rule&nbsp;506 of Regulation D promulgated thereunder,</font><font style="display:inline;font-weight:bold;text-decoration:underline;">&nbsp;</font><font style="display:inline;">have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. We have agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the private placement and issuable upon exercise of the warrant issued in the private placement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;background-color: #FFFFFF;">Use of Proceeds from Registered Securities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On August 4, 2016, our Registration Statement on Form S-1 (File No 333-210815) relating to our IPO was declared effective by the Securities and Exchange Commission (SEC). The Registration Statement registered an aggregate of 3,450,000 shares of our common stock, including 450,000 shares of common stock registered to cover in full over-allotments by the underwriters.&nbsp;&nbsp;On August 10, 2016, we closed our IPO whereby 3,000,000 shares of our common stock were sold at a public offering price of $10.00 per share. On September 8, 2016, we closed the sale of 27,755 shares of our common stock at the public offering price of $10.00 per share, representing a partial exercise of the underwriters&#x2019; over-allotment option, following which, the IPO terminated.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The managing underwriters of the IPO were Jefferies LLC and RBC Capital Markets, LLC. We paid to the underwriters of the initial public offering underwriting discounts and commissions totaling approximately $2.1 million. In addition, we incurred expenses of approximately $2.1 million which, when added to the underwriting discounts and commissions, amounted to total expenses of approximately $4.2 million. Thus, the net offering proceeds, after deducting underwriting discounts and commissions and offering expenses, were approximately $26.1 million. &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b) on August 8, 2016.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Securities Authorized for Issuance under Equity Compensation Plans</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The information called for by this item is incorporated by reference to our Proxy Statement for the 2017 Annual Meeting of Stockholders. See Part III, Item&nbsp;12 &#x201C;Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 6.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 51pt 0pt 0pt;"></font></font><font style="display:inline;color:#000000;"></font><font style="display:inline;font-weight:bold;color:#000000;">SELECTED FINANCIAL DATA<a name="ITEM6SELECTEDFINANCIALDATA_394630"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">We have derived the following selected statement of operations data for the years ended December&nbsp;31, 2016, 2015 and 2014 and the selected balance sheet data as of December&nbsp;31, 2016 and 2015 from our audited financial statements included elsewhere in this report. The selected balance sheet information as of December&nbsp;31, 2014 is derived from our audited financial statements which are not included in this report.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">Our historical results are not necessarily indicative of the results that may be expected in the future. You should read the selected financial data below in conjunction with &#x201C;Part II, Item&nbsp;7. &#x201C;Management&#x2019;s Discussion and Analysis of Financial </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">89</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;color:#000000;background-color: #FFFFFF;">Condition and Results of Operations&#x201D; and our financial statements and the related notes included in Part II, Item 8 &#x201C;</font><font style="display:inline;">Financial Statements and Supplementary Data</font><font style="display:inline;color:#000000;background-color: #FFFFFF;">&#x201D; in this Report.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Statements of Operations Data:</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:41.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:41.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,956
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,177
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>214
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,740
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,991
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Acquired in&#x2013;process research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>908
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,696
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,076
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>266
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,696)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,076)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(266)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Interest income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(762)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss on convertible note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(198)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other (expense) income</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss before income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision (benefit) for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other comprehensive loss, net of tax</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustment to redemption value on Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(366)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,968)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium upon substantial modification of convertible notes with certain stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,047)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss attributable to common stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,952)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,044)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss per share:</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.57)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.54)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.21)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Number of shares used in per share calculations:</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,809,396
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,875,053
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,521,703
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Balance Sheet Information:</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:41.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:41.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Cash and cash equivalents </font></p>
				</td>
				<td valign="top" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="top" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,033
				</td>
				<td valign="top" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="top" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,620
				</td>
				<td valign="top" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="top" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>317&nbsp;
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total assets </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,754
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,490
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>330
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes (including premium conversion derivative) </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,769
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>810
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total liabilities </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,122
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,917
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>861
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Series&nbsp;A convertible preferred stock </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,953
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accumulated deficit</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,059)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,392)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(584)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total stockholders&#x2019; equity (deficit) </font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,632
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,380)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(531)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 7<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 54pt 0pt 0pt;"></font>MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND<a name="ITEM7MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a> RESULTS OF OPERATIONS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;">The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and notes included in Part II, Item 8 &#x201C;Financial Statements and Supplementary Data&#x201D; of this Report.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Overview</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are a clinical&#8209;stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease and nonalcoholic fatty liver disease (NAFLD/NASH). Dyslipidemia is generally characterized by an elevation of </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">90</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">LDL&#8209;C, or bad cholesterol, triglycerides, or fat in the blood, as well as inflammation, especially in diabesity patients. We are developing our product candidate gemcabene, a novel, once&#8209;daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL&#8209;C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. Gemcabene&#x2019;s mechanism of action is designed to enhance the clearance of VLDLs in the plasma and inhibit the production of fatty acids and cholesterol in the liver. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in 895 subjects, which we define as healthy volunteers and patients, across 18 Phase&nbsp;1 and Phase&nbsp;2 clinical trials and has demonstrated promising evidence of efficacy, safety and tolerability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We are pursuing gemcabene in the following indications as a treatment in addition to maximally tolerated statin therapy for patients who are unable to reach their lipid&#8209;lowering goals: HoFH, HeFH, ASCVD, SHTG and NASH. We believe we can design an efficient development plan to provide a new treatment alternative for HoFH patients while demonstrating gemcabene&#x2019;s potential ability to treat patients in the most severe segment of the dyslipidemia market can further enhance brand awareness among key thought leaders and physicians. We are developing in parallel gemcabene for HeFH, ASCVD, SHTG and NASH given gemcabene&#x2019;s: (1)&nbsp;promising clinical data and mechanism in these indications; (2)&nbsp;cost&#8209;effective manufacturing process; (3)&nbsp;convenient oral dosing; (4)&nbsp;viability as adjunct combination therapy; and (5)&nbsp;large commercial potential. During 2016, we initiated three late stage clinical trials for gemcabene in HoFH, hypercholesterolemia, including HeFH and ASCVD patients on maximally tolerated statins, and SHTG. By the end of 2017, we expect to report top-line data from all three dyslipidemia trials (COBALT-1, ROYAL-1 and INDIGO-1). We plan to initiate a fourth Phase 2 clinical trial in 2017 to study gemcabene in NASH. Upon completion of one or more of these clinical trials, we intend to request an End of Phase&nbsp;2 (EOP2) meeting with the FDA to reach an agreement on the design of Phase&nbsp;3 registration trials and long term safety exposure for our target indications. We intend to pursue similar discussions with Canadian and European health authorities.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our Company was co&#8209;founded in November 2008 as a limited liability company under the name Michigan Life Therapeutics,&nbsp;LLC (MLT) by former Pfizer employees, including Dr.&nbsp;Charles Bisgaier, who were responsible for licensing exclusive worldwide rights to gemcabene from Pfizer in April 2011. In October 2014, we incorporated a new entity under the name Gemphire Therapeutics&nbsp;Inc. in Delaware. In November 2014, we entered into a merger agreement with Gemphire whereby MLT was merged with and into Gemphire, with Gemphire as the surviving entity and all outstanding units of membership interest in MLT were exchanged for shares of common stock of Gemphire. The purpose of the merger was to change the jurisdiction of our incorporation from Michigan to Delaware and to convert from a limited liability company to a corporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">In April 2016, our board of directors approved an amendment to our certificate of incorporation to effect a 1-for-3.119 reverse stock split (the Reverse Stock Split) for all common and Series A preferred stock. The Reverse Stock Split became effective on April 27, 2016 upon the filing of the amendment to the certificate of incorporation. The authorized shares and par value of the common stock and Series A preferred stock were not adjusted as a result of the Reverse Stock Split. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">On August 4, 2016, our Registration Statement on Form S-1 (File No 333-210815) relating to our initial public offering (&#x201C;IPO&#x201D;) of our common stock was declared effective by the SEC. Pursuant to such Registration Statement, on August 10, 2016, we closed our IPO whereby 3,000,000 shares of our common stock were sold at a public offering price of $10.00 per share. On September 8, 2016, we closed the sale of 27,755 shares of our common stock at the public offering price of $10.00 per share, representing a partial exercise of the underwriters&#x2019; over-allotment option, following which, the IPO terminated. We received net proceeds of approximately $26.1 million after deducting underwriting discounts and commissions of $2.1 million and other offering expenses of $2.1 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To date, our primary activities have been conducting research and development activities, planning clinical trials, performing business and financial planning, recruiting personnel and raising capital. We do not have any products approved for sale and have not generated any revenue. We do not expect to generate revenue until, and unless, the FDA or other regulatory authorities approve gemcabene and we successfully commercialize gemcabene. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity and debt financings as well as collaborations, strategic alliances and licensing arrangements. Through December 31, 2016, we have funded our operations primarily through the issuance of common stock in our IPO, totaling $30.3 million in gross proceeds, and the issuance of preferred stock and convertible notes, totaling $14.8&nbsp;million in gross proceeds. Our net losses were $14.6 million, $9.0 million and $0.3 million during the years ended December 31, 2016, </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">91</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">2015 and 2014, respectively. As of December 31, 2016, we had an accumulated deficit of $27.1&nbsp;million. We anticipate that our expenses will increase substantially as we:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">continue clinical trials for gemcabene and for any other product candidate in our future pipeline;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">contract to manufacture our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">establish on our own or with partners, a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">maintain, expand and protect our intellectual property portfolio;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">hire additional staff, including clinical, scientific, operational and financial personnel, to execute our business plan;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">add operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">to enable us to operate as a public company.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our net losses may fluctuate significantly from quarter&#8209;to&#8209;quarter and year&#8209;to&#8209;year, depending on the timing of our preclinical studies, clinical trials and our expenditures on other research and development activities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Recent Developments</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 10 2017, we entered into a securities purchase agreement for a private placement with a select group of accredited investors whereby, on March 15, 2017 we issued and sold 1,324,256 units at a price of $9.47 per unit for gross proceeds of approximately $12.5 million. Each unit consists of one share of our common stock and a warrant to purchase 0.75 shares of common stock. The warrants have an exercise price of $10.40 per share and are exercisable for a period of five years from the date of issuance. The private placement included 56,678 units sold to 3 board members, for aggregate proceeds totaling approximately $0.5 million and 52,798 units sold to 1 investor who is related to 1 board member, for proceeds totaling approximately $0.5 million. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The securities were issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. We have agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the private placement and issuable upon exercise of the warrant issued in the private placement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Financial Operations Overview</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Revenue</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To date, we have not generated any revenue. We do not expect to generate revenue unless or until we obtain regulatory approval of and commercialize gemcabene. If we fail to complete the development of gemcabene, or any other product candidate we may pursue in the future, in a timely manner, or fail to obtain regulatory approval, our ability to generate future revenue would be compromised.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Operating Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our operating expenses are classified into three categories: general and administrative, research and development and acquired in&#8209;process research and development.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">92</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">General and Administrative</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">General and administrative expenses consist primarily of personnel&#8209;related costs, including salaries and share&#8209;based compensation costs, for personnel in functions not directly associated with research and administrative activities. Other significant costs include legal fees relating to intellectual property and corporate matters and professional fees for accounting and other services. We anticipate that our general and administrative expenses will continue to be higher than comparable periods in the future to support our continued research and development activities, potential commercialization of gemcabene, if approved, and any future product candidates we may develop and the increased costs of operating as a public company. These increases will include increased costs related to the hiring of additional personnel and fees for legal and professional services, significantly increased share-based compensation costs related to stock options issued in conjunction with our IPO and anticipated future option grants in conjunction with personnel additions, as well as other public&#8209;company related costs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">To date, our research and development expenses have related primarily to the clinical stage development of gemcabene. Research and development expenses consist of costs incurred in performing research and development activities, including compensation for research and development employees, costs associated with preclinical studies and trials, regulatory activities, manufacturing activities to support clinical activities, license fees, nonlegal patent costs, fees paid to external service providers that conduct certain research and development, clinical costs and an allocation of overhead expenses. Research and development costs are expensed as incurred and costs incurred by third parties are expensed as the contracted work is performed. We accrue for costs incurred as the services are being provided by monitoring the status of the study or project, and the invoices received from our external service providers. We adjust our accrual as actual costs become known. Research and development activities are central to our business model.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We expect that gemcabene will have higher development costs during its later stages of clinical development, as compared to costs incurred during its earlier stages of development, primarily due to the increased size and duration of the later&#8209;stage clinical trials, so we expect our research and development expenses to significantly increase in the future as we continue to conduct preclinical studies and clinical trials for gemcabene and potentially develop other product candidates. However, it is difficult to determine with certainty the duration, costs and timing to complete our current or future preclinical programs and clinical trials of gemcabene. The duration, costs and timing of clinical trials and development of gemcabene will depend on a variety of factors that include, but are not limited to, the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">per patient trial costs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the number of patients that participate in the trials;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the number of sites included in the trials;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the countries in which the trials are conducted;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the length of time required to enroll eligible patients;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the number of doses that patients receive;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the drop&#8209;out or discontinuation rates of patients;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">potential additional safety monitoring or other studies requested by regulatory agencies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the duration of patient follow&#8209;up;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the phase of development of the product candidate;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">arrangements with contract research organizations and other service providers; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the efficacy and safety profile of the product candidates.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">93</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Acquired In&#8209;Process Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We include costs to acquire or in&#8209;license product candidates in acquired in&#8209;process research and development expenses. When we acquire the right to develop and commercialize a new product candidate, any up&#8209;front payments, or any future milestone payments that relate to the acquisition or licensing of such a right are immediately expensed as acquired in&#8209;process research and development in the period in which they are incurred. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &#x201C;business&#x201D; as defined under generally accepted accounting principles in the United States (GAAP), or provided that the product candidate has not achieved regulatory approval for marketing and, and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Interest Income (Expense)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Interest income (expense) consists of activity related to convertible notes issued by us, activity associated with the underlying premium conversion derivative related to such notes, and interest earnings from cash and cash equivalents. The notes we issued had an annual interest rate of 8%. The interest on the Interim Notes compounded on an annual basis while the interest on the Convertible Notes compounded daily. The principal and accrued and unpaid interest on the Convertible Notes converted into shares of the Company&#x2019;s Series&nbsp;A preferred stock upon the closing of the Series A preferred stock financing on March 31, 2015, which shares of Series A preferred stock, and accrued dividends thereon, converted into common stock immediately prior to the closing of the IPO. The principal and accrued and unpaid interest on the Interim Notes converted into shares of common stock immediately prior to the closing of the IPO.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We expect to earn interest income in future periods from the investment of cash and cash equivalents and a significant decrease in interest income (expense) given the conversion of the principal and accrued and unpaid interest on both the Convertible Notes and Interim Notes in August 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 9pt;background-color: #FFFFFF;text-indent: -9pt;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Loss on convertible note extinguishment</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">Loss on convertible note extinguishment consists of losses stemming from a convertible note amendment accounted for as note extinguishment. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Other (Expense) Income</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Other (expense) income relates to foreign currency exchange gains and losses. Foreign currency exchange gains and losses relate to transactions and monetary asset and liability balances denominated in currencies other than the U.S. dollar. Foreign currency gains and losses may continue to fluctuate in the future due to changes in foreign currency exchange rates.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">94</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Results of Operations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Comparison of Years Ended December 31, 2016 and 2015</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes our operating results for the periods indicated:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:35.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For&nbsp;the Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:35.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Change</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:35.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,956
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,177
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,779
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,740
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,991
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,749
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Acquired in&#x2013;process research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>908
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(908)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,696
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,076
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,620
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,696)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,076)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,620)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Interest income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(762)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>876
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss on convertible note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(198)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>198
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other (expense) income</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss before income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,557)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision (benefit) for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,557)
				</td>
				<td valign="bottom" style="width:00.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">General and Administrative</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">General and administrative expenses for the year ended December 31, 2016 were $6.0&nbsp;million compared to $3.2&nbsp;million for the year ended December 31, 2015. The $2.8&nbsp;million increase was primarily attributable to an increase in staffing and professional services associated largely with supporting our clinical trials and becoming a public company in 2016. General and administrative expenses included $1.2 million and $0.3 million in share&#8209;based compensation expense during the year ended December 31, 2016 and 2015, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development expenses for the year ended December 31, 2016 were $8.7 million compared to $4.0&nbsp;million for the year ended December 31, 2015. The $4.7&nbsp;million increase was primarily attributable to increased staffing and fees paid to external service providers for clinical trial development, regulatory consulting, preclinical studies and manufacturing activities to support clinical advancement of gemcabene. Research and development expenses included $0.6 million in share&#8209;based compensation expense during the year ended December 31, 2016. There was no share&#8209;based compensation expense during the year ended December 31, 2015.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Acquired In&#8209;process Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">No acquired in&#8209;process research and development expenses were incurred during the year ended December 31, 2016. Acquired in&#8209;process research and development expenses during the year ended December 31, 2015 were $0.9&nbsp;million which was the result of an equity milestone payment under our license agreement with Pfizer. We issued 675,250 shares of common stock to Pfizer and immediately expensed the equity milestone payment in the first quarter of 2015 as acquired in&#8209;process research and development expenses at the fair value equivalent of the shares issued in the amount of $0.9&nbsp;million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Interest Income (Expense)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Interest income (expense) for the year ended December 31, 2016 was $0.1 million compared to $(0.8)&nbsp;million for the year ended December 31, 2015. The $0.9&nbsp;million increase in net interest income, primarily non-cash, was largely due to the amortization of the note premium associated with the July 2015 Interim Notes, fair value adjustments of the derivative liability associated with the Interim Notes, and interest earnings of $23,000 from IPO cash proceeds. Interest income was offset in part by non-cash interest expense associated with the conversion of the April 2016 Interim Notes </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">95</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">along with the amortization of the underlying beneficial conversion feature. The unpaid principal and accrued interest on the Convertible Notes converted into shares of Series&nbsp;A preferred stock on March 31, 2015 and no Convertible Notes were outstanding following such date. The principal and accrued and unpaid interest on the Interim Notes converted to common stock immediately prior to the closing of the IPO, and as a result, no Interim Notes were outstanding as of December 31, 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Loss on convertible note extinguishment</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Non&#8209;cash loss on convertible note extinguishment for the years ended December&nbsp;31, 2016 and 2015 was zero and $0.2&nbsp;million, respectively. The convertible notes issued in July 2015 were amended in December 2015. The amendment added a new contingent conversion feature, serving to extend the maturity date by five months and revise certain conversion premiums. As a result of the modifications made to such convertible notes, we accounted for the amendment as a note extinguishment which gave rise to the $0.2&nbsp;million non&#8209;cash loss in 2015. During the year ended 2016, there were no modifications to convertible notes that required note extinguishment accounting treatment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Provision for Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Provision for income taxes consists of federal and state income taxes in the United States, as well as deferred income taxes and changes in related valuation allowance reflecting the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Currently, there is no provision for income taxes, as we have incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets as of December 31, 2016 and December&nbsp;31, 2015.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Comparison of the Years Ended December 31, 2015 and 2014</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes our operating results for the periods indicated:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:32.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For&nbsp;the Year Ended </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:33.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Change</font></p>
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:33.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,177
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>214
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,963
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,991
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,939
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Acquired in&#x2013;process research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>908
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>908
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 25.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,076
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>266
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,810
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,076)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(266)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,810)
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Interest expense</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(762)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(707)
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss on convertible note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(198)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(198)
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other income</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss before income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,709)
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision (benefit) for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,709)
				</td>
				<td valign="bottom" style="width:00.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">General and Administrative</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">General and administrative expenses for the year ended December&nbsp;31, 2015 were $3.2&nbsp;million compared to $0.2&nbsp;million for the year ended December&nbsp;31, 2014. The $3.0&nbsp;million increase was primarily attributable to an increase in staffing and professional services. General and administrative expenses included $0.3 million and $53,000 in share&#8209;based compensation expense in the years ended December&nbsp;31, 2015 and 2014, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development expenses for the year ended December&nbsp;31, 2015 were $4.0&nbsp;million compared to $52,000 for the year ended December&nbsp;31, 2014. The $3.9&nbsp;million increase was primarily attributable to preclinical studies and manufacturing activities to support clinical advancement of gemcabene and fees paid to external service providers for clinical trial development and regulatory consulting.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">96</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Acquired In&#8209;process Research and Development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Acquired in&#8209;process research and development expenses for the year ended December&nbsp;31, 2015 were $0.9&nbsp;million. There were no acquired in&#8209;process research and development expenses during the year ended December 31, 2014. The increase was attributable to an equity milestone payment under our license agreement with Pfizer. We issued 675,250 shares of common stock to Pfizer and immediately expensed the equity milestone payment in the first quarter of 2015 as acquired in&#8209;process research and development expenses at the fair value equivalent of the shares issued in the amount of $0.9&nbsp;million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Interest Expense</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Non&#8209;cash interest expense for the year ended December&nbsp;31, 2015 was $0.8&nbsp;million compared to $55,000 for the year ended December&nbsp;31, 2014. The $0.7&nbsp;million increase was primarily due to the issuance of convertible notes in the first, third and fourth quarters of 2015. Cash interest paid during the years ended December&nbsp;31, 2015 and 2014 was $2,000 and zero, respectively. The convertible notes issued through the first quarter of 2015 were converted to Series&nbsp;A preferred shares on March&nbsp;31, 2015. The convertible notes issued in July and December 2015 were outstanding at December&nbsp;31, 2015.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Loss on convertible note extinguishment</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Non&#8209;cash loss on convertible note extinguishment for the years ended December&nbsp;31, 2015 and 2014 was $0.2 million and zero, respectively. The convertible notes issued in July 2015 were amended in December 2015. The amendment added a new contingent conversion feature, serving to extend the maturity date by five months and revise certain conversion premiums. As a result of the modifications made to such convertible notes, we accounted for the amendment as a note extinguishment which gave rise to the $0.2&nbsp;million non&#8209;cash loss in 2015.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Provision for Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Provision for income taxes consists of federal and state income taxes in the United States, as well as deferred income taxes and changes in related valuation allowance reflecting the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Currently, there is no provision for income taxes, as we have incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets as of December 31, 2015 and December&nbsp;31, 2014.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Liquidity and Capital Resources</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Capital Resources</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2016, our principal sources of liquidity consisted of cash and cash equivalents of approximately $24.0 million. Our cash and cash equivalents are invested in cash deposits and money market accounts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have not generated any revenue, and we anticipate that we will continue to incur losses for the foreseeable future.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We anticipate that our expenses will increase substantially as we:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">continue clinical trials for gemcabene and for any other product candidate in our future pipeline;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">contract to manufacture our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">establish on our own or with partners, a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">maintain, expand and protect our intellectual property portfolio;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">97</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">hire additional staff, including clinical, scientific, operational and financial personnel, to execute our business plan;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">add operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">to enable us to operate as a public company.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Historical Capital Resources</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">On August 4, 2016, our Registration Statement on Form S-1 (File No 333-210815) relating to our IPO of our common stock was declared effective by the SEC. Pursuant to such Registration Statement, on August 10, 2016, we closed our IPO whereby 3,000,000 shares of our common stock were sold at a public offering price of $10.00 per share. On September 8, 2016, we closed the sale of 27,755 shares of our common stock at the public offering price of $10.00 per share, representing a partial exercise of the underwriters&#x2019; over-allotment option, following which, the IPO terminated. We received net proceeds of approximately $26.1 million after deducting underwriting discounts and commissions of $2.1 million and other offering expenses of $2.1 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our primary source of cash prior to the IPO was proceeds from the issuance of preferred stock and from the issuance of convertible notes and promissory notes described below. The proceeds from the issuances of preferred stock and from the issuances of the convertible and promissory notes have been used to fund our operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">From March 2009 through October 2014, we issued promissory notes for aggregate net proceeds of $0.3&nbsp;million. The promissory notes compounded at an 8% rate per annum basis and were exchanged for the convertible notes described below on November&nbsp;1, 2014. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">From November 2014 through February 2015, we issued convertible notes for aggregate net proceeds of $2.4&nbsp;million (the &#x201C;Convertible Notes&#x201D;). The Convertible Notes converted into shares of the Company&#x2019;s Series&nbsp;A preferred stock upon close of the Series A preferred stock financing on March 31, 2015. The conversion equaled 125% of the unpaid principal plus unpaid accrued interest on the Convertible Notes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In March 2015, we issued Series A convertible preferred stock for aggregate net proceeds of approximately $1.5&nbsp;million. On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In July and December 2015, we entered into convertible note financings in which we issued 8% convertible notes in an aggregate principal amount of $5.5&nbsp;million to various investors. In February&nbsp;and April 2016, we issued additional 8% convertible notes in an aggregate principal amount of $5.2 million to various investors (collectively with the July and December 2015 notes, the &#x201C;Interim Notes&#x201D;). The principal and accrued and unpaid interest on the Interim Notes converted into shares of common stock immediately prior to the closing of the IPO.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes our cash flows for the periods indicated:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.14%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:65.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:31.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For&nbsp;the&nbsp;Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:31.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:31.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net cash used in operating activities</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,043)
				</td>
				<td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,433)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(195)
				</td>
				<td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net cash provided by (used in) investing activities</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net cash provided by financing activities</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,456
				</td>
				<td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,736
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>509
				</td>
				<td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net increase in cash</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,413
				</td>
				<td valign="bottom" style="width:00.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,303
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>314
				</td>
				<td valign="bottom" style="width:00.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Cash Flow from Operating Activities</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For the year ended December 31, 2016, cash used in operating activities of $11.0&nbsp;million was attributable to a net loss of $14.6&nbsp;million which included $1.6 million in non&#8209;cash expenses and a net change of $1.9 million in our net operating assets and liabilities. The non&#8209;cash (income) expenses consisted of $1.7 million of share&#8209;based compensation offset by </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">98</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">net non&#8209;cash interest income of $(0.1) million related to both the Interim Notes and the premium conversion derivative. The net change in operating assets and liabilities was primarily attributable to increases in our accounts payable and accrued liabilities associated with our increased operating expenses and a net decrease in our deferred offering costs following the completion of our IPO.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For the year ended December&nbsp;31, 2015, cash used in operating activities of $5.4&nbsp;million was attributable to a net loss of $9.0&nbsp;million, partially offset by $2.2&nbsp;million in non&#8209;cash expenses and a net change of $1.4&nbsp;million in our net operating assets and liabilities. The non&#8209;cash expenses consist of $0.3&nbsp;million of share&#8209;based compensation, non&#8209;cash interest of $0.8&nbsp;million related to both the convertible notes and to the premium conversion derivative, $0.9&nbsp;million related to a non&#8209;cash purchase of acquired in&#8209;process research and development pursuant to the issuance of common stock and $0.2&nbsp;million related to a non&#8209;cash loss on extinguishment of convertible notes. The change in operating assets and liabilities was attributable to increases in accounts payable and accrued liabilities associated with our increased operating expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For the year ended December 31, 2014, cash used in operating activities of $0.2&nbsp;million was attributable to a net loss of $0.3&nbsp;million, partially offset by $108,000 in non&#8209;cash expenses and a net change of $17,000 in our net operating assets and liabilities. The non&#8209;cash expenses consisted of $53,000 of share&#8209;based compensation and non&#8209;cash interest of $55,000 related to both the convertible notes and to the premium conversion derivative. The change in operating assets and liabilities was primarily attributable to increases in accrued liabilities associated with our increased operating expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Cash Flow from Investing Activities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There were no sources or uses of funds from investing activities for all periods presented.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Cash Flow from Financing Activities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net cash provided by financing activities during the year ended December 31, 2016 was $31.5 million consisting of $26.3 million in IPO proceeds, net of discounts, commissions and other offering costs of $4.0 million paid through December 31, 2016, and $5.2&nbsp;million in proceeds from the issuance of Interim Notes in February 2016 and April 2016. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net cash provided by financing activities was $8.7&nbsp;million during the year ended December&nbsp;31, 2015. Net cash provided by financing activities during the year ended December&nbsp;31, 2015 consisted of $1.5&nbsp;million in proceeds from the issuance of Series&nbsp;A preferred stock and $7.4&nbsp;million in proceeds from the issuance of Convertible Notes and Interim Notes, offset by financing costs of $0.2&nbsp;million associated with the proposed initial public offering.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Net cash provided by financing activities during the year ended December&nbsp;31, 2014 was $0.5&nbsp;million, consisting of $0.4&nbsp;million in proceeds from the issuance of Convertible Notes and $0.1&nbsp;million in proceeds received from the issuance of promissory notes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Liquidity and Capital Resource Requirements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have no current source of revenue to sustain our present activities, and we do not expect to generate revenue until, and unless, the FDA or other regulatory authorities approve gemcabene and we successfully commercialize gemcabene. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity and debt financings as well as collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or through collaborations, strategic alliances or licensing arrangements when needed, we may be required to delay, limit, reduce or terminate our product development, future commercialization efforts, or grant rights to develop and market gemcabene that we would otherwise prefer to develop and market ourselves.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">99</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We believe the $24.0 million cash on hand at December 31, 2016, together with the net proceeds from the private completed on March 15, 2017 will be sufficient to fund our operations through completion of all three of the dyslipidemia Phase2b studies in 2017 as well as completion of the AZURE-1 study in the second half of 2018. The development of gemcabene is subject to numerous uncertainties, and we have based these estimates on assumptions that may prove to be substantially different than we currently anticipate and could use our cash resources sooner than we expect. Additionally, the process of advancing early&#8209;stage product candidates and testing product candidates in clinical trials is costly, and the timing of progress in these clinical trials is uncertain. Our ability to successfully transition to profitability will be dependent upon achieving a level of product sales adequate to support our cost structure. We cannot assure that we will ever be profitable or generate positive cash flow from operating activities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Furthermore, we will need to raise additional capital to continue to fund the further development of gemcabene and other potential product candidates, our operations, and commercialization of gemcabene and other potential product candidates, if approved.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Contractual Obligations and Commitments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes our contractual obligations as of December 31, 2016, which represent material expected or contractually committed future obligations.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:47.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:43.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Payments&nbsp;Due&nbsp;by&nbsp;Period</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Less&nbsp;than&nbsp;1&nbsp;year</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">1&#x2013;3&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">3&#x2013;5&nbsp;Years</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">More&nbsp;than&nbsp;5&nbsp;years</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:05.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="14" valign="bottom" style="width:50.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Facility lease</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>159
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>260
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:47.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:01.64%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>159
				</td>
				<td valign="bottom" style="width:01.64%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>260
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In May 2016, we entered into a 3 year non-cancellable facility lease commencing August 1, 2016 and made an initial payment of approximately $91,000, $75,000 of which is treated as prepaid rent. The initial term of the agreement is three years with an initial monthly base rent of approximately $8,400. Additionally, in the course of our normal operations, we have entered into cancellable purchase commitments with our suppliers for various key research and clinical services and raw materials. The purchase commitments covered by these arrangements are subject to change based on our research and development efforts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2011, we entered into a license agreement with Pfizer (the Pfizer Agreement) for a worldwide exclusive license to certain patent rights to make, use, sell, offer for sale and import the clinical product candidate gemcabene. In exchange for this license, we agreed to issue shares of our common stock to Pfizer representing 15% of our fully diluted capital at the close of our first arms&#8209;length Series&nbsp;A financing, which occurred in March 2015.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We agreed to make milestone payments totaling up to $37&nbsp;million upon the achievement of certain milestones, including the first regulatory submission in any country, regulatory approval in each of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of gemcabene or any product containing gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We have also agreed to pay Pfizer tiered royalties on a country&#8209;by&#8209;country basis based upon the annual amount of net sales as specified in the Pfizer Agreement until expiration of the last valid claim of the licensed patent rights, including any patent term extensions or supplemental protection certificates. The royalty rates range from the high single digits to the low teens depending on the level of net sales. Under the Pfizer Agreement we are obligated to use commercially reasonable efforts to develop and commercialize gemcabene.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Pfizer Agreement will expire upon expiration of the last royalty term. Either party may terminate the Pfizer Agreement for the other party&#x2019;s uncured material breach and specified bankruptcy events. Pfizer may terminate the Pfizer Agreement if we or any of our sublicensees challenge the validity, enforceability or ownership of the licensed patents. Upon termination of the license agreement for cause by Pfizer, we must grant Pfizer a non-exclusive license to use any intellectual property rights arising from the development or commercialization of gemcabene. Additionally, Pfizer may revoke the license if we are unable to adequately commercialize gemcabene by April 2021.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">100</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pfizer has a non&#8209;exclusive, sub licensable, royalty&#8209;free right and license for non&#8209;commercial research or development purposes to intellectual property rights relating to gemcabene that are developed by us after the effective date of the license with Pfizer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2016, no obligations were recorded related to the Pfizer Agreement due to the inability to reasonably estimate the timing and outcomes of the gemcabene trials as well as the timing and amounts of future sales of gemcabene, if any.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Critical Accounting Policies and Estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our financial statements are prepared in accordance with GAAP. These accounting principles require us to make estimates and judgments that can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenue and expense during the periods presented. We believe that the estimates and judgments upon which we rely are reasonably based upon information available to us at the time that we make these estimates and judgments. To the extent that there are material differences between these estimates and actual results, our financial results will be affected. The accounting policies that reflect our more significant estimates and judgments and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results are described below.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following is not intended to be a comprehensive list of all of our accounting policies or estimates. Our accounting policies are more fully described in Note&nbsp;2&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Summary of Significant Accounting Policies</font><font style="display:inline;">, &nbsp;</font><font style="display:inline;color:#000000;">included in &#x201C;Item 8 &#x2014; Financial Statements and Supplementary Data&#x201D; in this report.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We utilize the liability method of accounting for income taxes as required by Accounting Standards Codification (ASC) 740, </font><font style="display:inline;font-style:italic;">Income Taxes</font><font style="display:inline;">. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is no provision for income taxes, as we have incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. MLT was treated as a partnership for federal and state income tax purposes. Accordingly, no provision was made for income taxes for periods prior to October&nbsp;30, 2014, since the net losses incurred up to that time (subject to certain limitations) was passed through to the income tax returns of its members. Upon incorporation on October&nbsp;30, 2014 we became taxable as a corporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Since incorporation, we have filed U.S. federal and Michigan state income tax returns. Our deferred tax assets were primarily comprised of federal and state tax net operating loss carryforwards, acquired intangibles and tax credit carryforwards and were recorded using enacted tax rates expected to be in effect in the years in which these temporary differences are expected to be utilized. As of December&nbsp;31, 2016, the tax effect of our federal and state net operating loss carryforwards was approximately $2.1 million and $0.2 million, respectively, and our federal and state research and development credit carryforwards were $0.7 million and $24,000, respectively. As of December&nbsp;31, 2015, the tax effect of our federal and state net operating loss carryforwards was approximately $2.4&nbsp;million and $0.3&nbsp;million, respectively, and our federal research and development credit carryforward was $95,000. We did not have any state research and development credit carryforwards in 2015. The federal net operating loss and tax credit carryforwards will begin to expire in 2034 if not utilized. The state net operating loss carryforwards will begin to expire in 2026 if not utilized.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Utilization of the net operating loss and tax credit carryforwards may be subject to an annual limitation due to historical or future ownership percentage change rules provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of certain net operating loss and tax credit carryforwards before their utilization. However, due to uncertainties surrounding our ability to generate future taxable income to realize these tax assets, a full valuation allowance has been established to offset our deferred tax assets.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Convertible Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We initially record preferred stock that may be redeemed at the option of the holder, or based on the occurrence of events outside our control, in mezzanine equity at the value of the proceeds received. Subsequently, if it is probable that the preferred stock will become redeemable, we recognize changes in the redemption value immediately as they occur </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">101</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. If it is not probable that the preferred stock will become redeemable, we do not adjust the carrying value. In the absence of retained earnings these charges are recorded against additional paid&#8209;in&#8209;capital, if any, and then to accumulated deficit. Since the conversion of the Series A preferred stock into shares of common stock in August 2016 upon the closing of the IPO, there was no convertible preferred stock issued.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Share&#8209;Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our share&#8209;based compensation for share&#8209;based awards is accounted for in accordance with authoritative guidance and is estimated at the grant date based on the fair value of the award and recognized as expense ratably over the requisite vesting period of the award. Determining the appropriate fair value of share&#8209;based awards requires judgment. We calculate the fair value of each award to employees on the date of grant based on the fair value of our common stock. See &#x201C;&#x2014;&nbsp;Common Stock Valuation&#x201D; below.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We calculate the fair value of each stock option award to employees on the date of grant under the Black&#8209;Scholes option&#8209;pricing model using certain assumptions related to the fair value of our common stock, the option&#x2019;s expected term, our expected stock price volatility, risk free interest rates and our expected dividend rate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For options to purchase common stock issued to non&#8209;employees, including consultants, we record share&#8209;based compensation based on the fair value of the options. We calculate the fair value of each share&#8209;based award to non&#8209;employees on each measurement date based on the fair value of our common stock. The fair value of options granted to non&#8209;employees is remeasured as the options vest and is recognized in the statements of operations during the period the related services are rendered.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The fair value of each stock option grant was determined using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment and estimation by management.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-style:italic;">Fair Value of Common Stock.&nbsp; </font><font style="display:inline;color:#000000;">As discussed below in &#x201C;&#x2014;&nbsp;Common Stock Valuation,&#x201D; because there was no public market for our common stock prior to our IPO, our board of directors has determined the fair value of the common stock by considering a number of objective and subjective factors, including based on contemporaneous valuations of our common stock performed by an unrelated valuation specialist. Currently, the fair value of our common stock is based on the quoted market price.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-style:italic;">Expected Term.&nbsp; </font><font style="display:inline;color:#000000;">The expected term represents the period that share&#8209;based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time&#8209;to&#8209;vesting and the contractual life of the share&#8209;based awards. The expected term for options issued to nonemployees is the contractual term.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-style:italic;">Expected Volatility.&nbsp; </font><font style="display:inline;color:#000000;">Since we do not have a trading history of our common stock, the expected volatility was derived from the historical stock volatilities of comparable peer public companies within our industry that we consider to be comparable to our business over a period equivalent to the expected term of the share&#8209;based awards.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-style:italic;">Risk&#8209;Free Interest Rate.&nbsp; </font><font style="display:inline;color:#000000;">The risk&#8209;free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero&#8209;coupon U.S. Treasury notes with maturities approximately equal to the share&#8209;based awards&#x2019; expected term.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-style:italic;">Expected Dividend Rate.&nbsp; </font><font style="display:inline;color:#000000;">The expected dividend is zero as we have not paid and do not anticipate paying any dividends on our common stock for the foreseeable future.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">102</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The estimated grant&#8209;date fair value of our share&#8209;based awards was calculated using Black&#8209;Scholes option&#8209;pricing model, based on the following assumptions for the following periods presented:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year&nbsp;&nbsp;Ended </font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="3" valign="middle" style="width:17.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="middle" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:17.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected stock price volatility </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71.4
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71.0
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected life of options (years)</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.0
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.5
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected dividend yield </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Risk free interest rate </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.7
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">If any of the assumptions used in the Black&#8209;Scholes option&#8209;pricing model change significantly, share&#8209;based compensation for future awards may differ materially compared with the awards granted previously.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For 2016, 2015 and 2014, share&#8209;based compensation was $1.7 million, $0.3 million and $53,000, respectively. As of December 31, we had unrecognized share&#8209;based compensation expense totaling $11.2&nbsp;million.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Common Stock Valuation</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During periods when there was an absence of a public trading market for our common stock prior to the IPO, on each grant date, we developed an estimate of the fair value of our common stock in order to determine an exercise price for each share&#8209;based award. We determined the fair value of our common stock using methodologies, approaches and assumptions consistent with the </font><font style="display:inline;font-style:italic;">American Institute of Certified Public Accountants Practice Aid, Valuation of Privately&#8209;Held&#8209;Company Equity Securities Issued as Compensation</font><font style="display:inline;">. Our board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of our common stock, including having contemporaneous and retrospective valuations of our common stock performed by an unrelated valuation specialist, valuations of comparable securities transactions, sales of our convertible preferred stock to unrelated third parties, the rights, preferences and privileges of our common stock versus our preferred stock, our operating and financial performance, our stage of development, current business conditions, our projections, business developments, the lack of liquidity of our capital stock and general and industry specific economic outlook.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For our common stock valuations performed from November&nbsp;1, 2014 up until the issuance of our Series&nbsp;A convertible preferred stock (the Series&nbsp;A preferred stock) in March 2015, the fair value of our common stock was estimated entirely using a hybrid of two market approaches, specifically a proposed Series&nbsp;A preferred stock </font><font style="display:inline;font-style:italic;">Securities Transaction&nbsp;&#x2014; Backsolve</font><font style="display:inline;"> method and the Series&nbsp;A preferred stock post&#8209;money value. This later approach considers the implied equity value based on a common equivalent capitalization table associated with an IPO exit.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Once the Series&nbsp;A preferred stock round was consummated in March 2015, common stock valuations began to rely on the indications of value realized in the transaction through June&nbsp;30, 2015. The fair value of our common stock was estimated using a hybrid of two market approaches, specifically the realized Series&nbsp;A preferred stock </font><font style="display:inline;font-style:italic;">Recent Securities Transaction&nbsp;&#x2014; Backsolve</font><font style="display:inline;"> method and the Series&nbsp;A preferred stock post&#8209;money value. This later approach considers our implied equity value based on a common equivalent capitalization table associated with an IPO exit.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the third quarter of 2015, the fair value of our common stock was estimated using a hybrid of two market approaches, specifically the value of a potential Series&nbsp;B convertible preferred stock financing utilizing a </font><font style="display:inline;font-style:italic;">Proposed Securities Transaction&nbsp;&#x2014; Backsolve</font><font style="display:inline;"> method and the value of a potential Series&nbsp;B financing post&#8209;money as a common stock equivalent for an IPO exit. Lastly, the completed Series&nbsp;A preferred stock </font><font style="display:inline;font-style:italic;">Recent Securities Transaction&nbsp;&#x2014; Backsolve</font><font style="display:inline;"> method was considered in the event that a Series&nbsp;B convertible preferred stock financing or an IPO could not be achieved.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Beginning in the fourth quarter of 2015 and up until the closing of the IPO, the fair value of our common stock was estimated using a hybrid of two market approaches, specifically the value of a potential Series&nbsp;B convertible preferred stock financing utilizing a </font><font style="display:inline;font-style:italic;">Proposed Securities Transaction&nbsp;&#x2014; Backsolve</font><font style="display:inline;"> method and a pre&#8209;money IPO value for an IPO exit. Lastly, the completed Series&nbsp;A preferred stock </font><font style="display:inline;font-style:italic;">Recent Securities Transaction&nbsp;&#x2014; Backsolve</font><font style="display:inline;"> method was considered in the event that a Series&nbsp;B convertible preferred stock financing or an IPO could not be achieved.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">103</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We considered the various methods for allocating the enterprise value across our classes and series of capital stock to determine the fair value of our common stock at each valuation date. The methods we used consisted of the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-style:italic;">Option pricing method (OPM).&nbsp; </font><font style="display:inline;color:#000000;">Under the option pricing method, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt; display: inline;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-style:italic;">Probability&#8209;weighted expected return method (PWERM).&nbsp; </font><font style="display:inline;color:#000000;">The PWERM is a scenario&#8209;based analysis that estimates the value per share based on the probability&#8209;weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Our per share common stock value was estimated by allocating the equity value using a hybrid combination of OPM and PWERM. We used either PWERM or a combination of the OPM and the PWERM as described above to allocate the equity value to each element of our capital structure, including our common stock. For both approaches, we applied a discount to the valuations due to the lack of marketability of the ordinary shares. We calculated the discount for lack of marketability using a Finnerty model and applied it as appropriate to each allocation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The dates of our valuations did not always coincide with the dates of our option grants. In such instances, management&#x2019;s estimates were based on the most recent valuation of shares of our common stock. For grants occurring between valuation dates, for financial reporting purposes, we considered the preceding valuations and our assessment of additional objective and subjective factors we believed were relevant as of the grant date to determine the fair value of our common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Related Party Transactions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">See Note 14 &#x2014;&nbsp;</font><font style="display:inline;font-style:italic;color:#000000;">&#x201C;Related Party Transactions&#x201D;</font><font style="display:inline;color:#000000;">&nbsp;and Note 4&nbsp;&#x2014; &nbsp;&#x201C;</font><font style="display:inline;font-style:italic;color:#000000;">Debt</font><font style="display:inline;color:#000000;">&#x201D; &nbsp;included in &#x201C;Item 8 &#x2014; Financial Statements and Supplementary Data&#x201D; in this Report</font><font style="display:inline;font-style:italic;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;">regarding the impact of certain related party transactions with respect to facility rent and financing activity related to the issuance of our various note instruments and convertible Series A preferred stock prior to the close of the IPO.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Off&#8209;Balance Sheet Arrangements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements as defined under the rules and regulations of the SEC. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">See Note 2 &#x2014;&nbsp;</font><font style="display:inline;font-style:italic;color:#000000;">&#x201C;Summary of Significant Accounting Policies&#x201D;</font><font style="display:inline;color:#000000;">&nbsp;included in &#x201C;Item 8 &#x2014; Financial Statements and Supplementary Data&#x201D; in this Report</font><font style="display:inline;font-style:italic;color:#000000;">&nbsp;</font><font style="display:inline;color:#000000;">regarding the impact of certain recent accounting pronouncements on our financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 7A.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 48pt 0pt 0pt;"></font>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK<a name="ITEM7AQUANTITATIVEANDQUALITATIVEDISCLOSU"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The market risk inherent in our financial instruments and in our financial position is the potential loss arising from adverse changes in interest rates. As of December 31, 2016, we had cash and cash equivalents of $24.0 million. We generally hold our excess cash in interest&#8209;bearing money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short&#8209;term maturities of our cash equivalents and the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">104</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 0pt 72pt;text-indent: -72pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">ITEM 8.<font style="display:inline;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 51pt 0pt 0pt;"></font>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA<a name="ITEM8FINANCIALSTATEMENTSANDSUPPLEMENTARY"></a></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;background-color: #FFFFFF;">INDEX TO FINANCIAL STATEMENTS</font><font style="display:inline;font-weight:bold;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:454.50pt;height:6.85pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ReportofIndependentRegisteredPublicAccou"><font style="display:inline;">Report of Independent Registered Public Accounting Firm</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.65pt;height:6.85pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.15pt;height:6.85pt;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:454.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#BalanceSheets_736952"><font style="display:inline;">Balance Sheets</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.15pt;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:454.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#ComprehensiveLoss_782761"><font style="display:inline;">Statements of Comprehensive Loss</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.15pt;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:454.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#EquityDeficit_89715"><font style="display:inline;">Statements of Changes in Convertible Preferred Stock and Stockholders' and Members' Equity (Deficit)</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.15pt;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>109&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:454.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#StatementsofCashFlows_804215"><font style="display:inline;">Statements of Cash Flows</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.15pt;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>110&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:454.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<a href="#NotestoFinancialStatements_550260"><font style="display:inline;">Notes to Financial Statements</a>&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:22.15pt;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>111&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">105</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Report of Independent Registered Public Accounting Firm<a name="ReportofIndependentRegisteredPublicAccou"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The Board of Directors and Shareholders<br />Gemphire Therapeutics&nbsp;Inc.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">We have audited the accompanying balance sheets of Gemphire Therapeutics&nbsp;Inc. (formerly known as Michigan Life Therapeutics,&nbsp;LLC) (the Company) as of December&nbsp;31, 2016 and 2015, and the related statements of comprehensive loss, changes in convertible preferred stock and stockholders' and members' equity (deficit) and cash flows for each of the three years in the period ended December&nbsp;31, 2016. Our audits also included the financial statement schedule included in Item 15(a)(2). These financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company's internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Gemphire Therapeutics&nbsp;Inc. (formerly known as Michigan Life Therapeutics,&nbsp;LLC) at December&nbsp;31, 2016 and 2015, and the results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31, 2016, in conformity with U.S. generally accepted accounting principles. Also in our opinion, the related financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly in all material respects the information set forth therein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">/s/ Ernst&nbsp;&amp; Young&nbsp;LLP<br />Detroit, Michigan<br />March&nbsp;20, 2017</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:107.92%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">106</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics&nbsp;Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Balance Sheets<a name="BalanceSheets_736952"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(in thousands, except share amounts and par value)</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Assets</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Current assets:</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,033
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,620
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Prepaid expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>713
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>23
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total current assets</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,746
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,643
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred offering costs</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>847
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deposits</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total assets</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,754
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,490
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Liabilities, convertible preferred stock and stockholders&#x2019; equity (deficit)</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Current liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accounts payable</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,008
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>531
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,113
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,617
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes to related parties</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,795
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,629
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium conversion derivative</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,121
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,917
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;Other liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,122
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,917
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Commitments and contingencies (Note&nbsp;5)</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Series&nbsp;A convertible preferred stock, $0.001 par value; no shares authorized as of December 31, 2016 and 2,325,581 shares authorized as of December&nbsp;31, 2015, no shares</font><font style="display:inline;color:#FF0000;">&nbsp;</font><font style="display:inline;">issued or outstanding as of December 31, 2016 and 745,637 shares</font><font style="display:inline;color:#FF0000;">&nbsp;</font><font style="display:inline;">issued and </font><font style="display:inline;color:#000000;">outstanding</font><font style="display:inline;color:#FF0000;">&nbsp;</font><font style="display:inline;">as of December&nbsp;31, 2015, aggregate liquidation preference as of December 31, 2016 and 2015 of zero and $7,953, respectively.</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,953
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stockholders&#x2019; equity (deficit):</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2016 and no shares authorized as of December&nbsp;31, 2015, no shares issued or outstanding as of December 31, 2016 and 2015.</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Common stock, $0.001 par value; 100,000,000 and 17,674,419 shares authorized as of&nbsp;December 31, 2016 and 2015, respectively, 9,270,255 and 3,758,488 shares issued and outstanding at December 31, 2016 and 2015, respectively.</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Additional paid&#x2013;in capital</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47,674
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accumulated deficit</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,059)
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,392)
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total stockholders&#x2019; equity (deficit)</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,632
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,380)
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total liabilities, convertible preferred stock and stockholders&#x2019; equity (deficit)</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,754
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,490
				</td>
				<td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">See accompanying notes.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">107</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"> Gemphire Therapeutics&nbsp;Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Statements of Comprehensive Loss<a name="ComprehensiveLoss_782761"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(in thousands, except share and per share amounts)</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.40%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:36.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:36.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,956
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,177
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>214
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,740
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,991
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Acquired in&#x2013;process research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>908
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14,696
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,076
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>266
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,696)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,076)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(266)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Interest income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(762)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss on convertible note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(198)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other (expense) income</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss before income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision (benefit) for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other comprehensive loss, net of tax</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustment to redemption value on Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(366)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,968)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium upon substantial modification of convertible notes with certain stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,047)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss attributable to common stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,952)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,044)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss per share:</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted (Note&nbsp;10)</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.57)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.54)
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.21)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Number of shares used in per share calculations:</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,809,396
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,875,053
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,521,703
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">See accompanying notes.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">108</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics&nbsp;Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Statements of Changes in Convertible Preferred Stock and Stockholders&#x2019; and Members&#x2019; Equity (Deficit)<a name="EquityDeficit_89715"></a></font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(in thousands, except share amounts)</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.28%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:17.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Series&nbsp;A&nbsp;Convertible</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Additional</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:17.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Preferred&nbsp;Stock</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Members'</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="4" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Common&nbsp;Stock</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Paid&#x2013;In</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Accumulated</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Equity</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Deficit</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:05.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Amount</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Capital</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Deficit</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(Deficit)</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Balance at January 1, 2014</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(264)
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(264)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net loss prior to merger</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(124)
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(124)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Effect of merger</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>388
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,987,817
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(388)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Restriction of initial common stock issuances</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(556,589)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Issuance of restricted stock awards</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,605,008
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Share&#x2013;based compensation&nbsp;&#x2014; employee</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net loss post-merger</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(196)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(196)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Balance at December&nbsp;31,&nbsp;2014</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,036,236
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(584)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(531)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Issuance of convertible Series A preferred stock, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>745,637
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,985
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Redemption value adjustment&nbsp;&#x2014; Series&nbsp;A preferred&nbsp;stock</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,968
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,130)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,838)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,968)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Issuance of common stock</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>677,685
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>908
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>911
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Convertible note extinguishment loss</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(106)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(941)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,047)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Issuance of restricted stock awards</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,567
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Share&#x2013;based compensation&nbsp;&#x2014; employee</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>131
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Share&#x2013;based compensation&nbsp;&#x2014; non&#x2013;employee</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>153
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Balance at December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>745,637
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,953
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,758,488
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,392)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12,380)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Redemption value adjustment&nbsp;&#x2014; Series&nbsp;A preferred&nbsp;stock</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>366
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(285)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(81)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(366)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Conversion of Series A preferred stock to common stock</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(745,637)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(8,319)
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>827,205
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,318
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,319
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Separation of convertible note beneficial conversion feature upon contingency resolution</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>372
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>372
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Conversion of convertible notes to common stock</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,656,807
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,444
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,445
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Issuance of common stock from offering</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,027,755
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,275
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,278
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Issuance costs of offering</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,168)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,168)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Share&#x2013;based compensation&nbsp;&#x2014; employee</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,498
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,498
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Share&#x2013;based compensation&nbsp;&#x2014; non&#x2013;employee</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>220
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:23.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Balance at December&nbsp;31,&nbsp;2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.20%;border-top:1pt none #D9D9D9 ;border-left:1pt solid #000000 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,270,255
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:04.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47,674
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(27,059)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,632
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">See accompanying notes.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">109</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics&nbsp;Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Statements of Cash Flows<a name="StatementsofCashFlows_804215"></a></font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(in thousands)</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:33.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For&nbsp;the&nbsp;Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:33.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">Operating activities</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Share-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,718
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>284
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Non-cash interest on promissory notes to related parties</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Non-cash interest on convertible notes to related parties</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>145
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Non-cash interest on convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>256
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Non-cash discount amortization on convertible notes to related parties</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(17)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>62
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Non-cash discount amortization on convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(276)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>261
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Revaluation of premium conversion derivative</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(850)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>297
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Non-cash loss on extinguishment of convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>198
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Non-cash interest upon conversion of convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>649
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Non-cash acquisition of in&#x2013;process research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>908
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Change in assets and liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 25.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Prepaid expenses and other assets</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(55)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 25.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Accounts payable</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,477
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>444
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 25.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Accrued and other liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>496
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,012
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>21
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net cash used in operating activities</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11,043)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,433)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(195)
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">Investing activities</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net cash provided by (used in) investing activities</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;">Financing activities</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Proceeds from issuance of convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,651
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,560
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>390
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Proceeds from issuance of convertible notes to related parties</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,500
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,856
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Issuance costs related to convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Proceeds from issuance of promissory notes to related parties</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Proceeds from issuance of Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,522
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Proceeds from issuance of common stock</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Proceeds from offering</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30,278
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Offering costs</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,963)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(205)
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net cash provided by financing activities</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31,456
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,736
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>509
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Net increase in cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,413
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,303
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>314
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Cash and cash equivalents at beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,620
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>317
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Cash and cash equivalents at end of period</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>24,033
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,620
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>317
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-style:italic;font-size:9pt;">Supplemental disclosure of cash flow information:</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Cash paid for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Cash paid for interest</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-style:italic;font-size:9pt;">Supplemental non-cash financing transactions:</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Conversion of Series A preferred stock to common stock</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8,319
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Conversion of convertible notes common stock</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11,445
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Conversion of convertible notes to Series&nbsp;A preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,778
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Exercise of premium conversion derivative</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>685
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Redemption value change of Series&nbsp;A preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>366
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,968
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Issuance of common stock for acquisition of in&#x2013;process research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>908
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Bifurcation of premium conversion derivative related to convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>505
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>842
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Convertible note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,426
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Premium conversion derivative reduction upon convertible note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>182
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Conversion of related party promissory notes to convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>359
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Separation of beneficial conversion feature associated with convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>372
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Offering costs in other assets paid in prior year</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>205
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:63.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">Offering costs in accounts payable and accrued liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:9pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>642
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">See accompanying notes.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">110</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a>&nbsp;</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics&nbsp;Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">(Formerly Known as Michigan Life Therapeutics,&nbsp;LLC)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Notes to Financial Statements <a name="NotestoFinancialStatements_550260"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">1. The Company and Basis of Presentation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On November&nbsp;10, 2008, Michigan Life Therapeutics,&nbsp;LLC (MLT) was organized as a limited liability company (LLC) in Michigan. On October&nbsp;30, 2014, Gemphire Therapeutics&nbsp;Inc. (Gemphire) was incorporated as a C corporation in the state of Delaware. On November&nbsp;1, 2014, MLT entered into a merger agreement with Gemphire whereby MLT was merged with and into Gemphire with Gemphire as the surviving entity; all outstanding membership interests of MLT were exchanged for shares of Gemphire&#x2019;s common stock. The purpose of the merger was to change the jurisdiction of MLT from Michigan to Delaware and to convert from an&nbsp;LLC to a corporation. All financial results presented prior to November 1, 2014 are from the operations of MLT. MLT and Gemphire are collectively referred to as the &#x201C;Company&#x201D; in the accompanying notes to the financial statements. The Company&#x2019;s headquarters are located in Livonia, Michigan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is a clinical&#8209;stage biopharmaceutical entity focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease and NAFLD/NASH (nonalcoholic fatty liver disease). The Company&#x2019;s primary activities have been conducting research and development activities, planning clinical trials, performing business and financial planning, recruiting personnel and raising capital. The Company is subject to certain risks, which include the need to research, develop, and clinically test potentially therapeutic products, initially one product candidate gemcabene (also known as CI&#8209;1027); obtain regulatory approval for its products and commercialize them around the world; expand its management scientific staff; finance its operations; and, find collaboration partners to further advance development and commercial efforts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">Initial Public Offering and Capital Requirements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">On August 4, 2016, the Company&#x2019;s Registration Statement on Form S-1 (File No 333-210815) relating to its IPO of its common stock was declared effective by the Securities and Exchange Commission (SEC). Pursuant to such Registration Statement, on August 10, 2016, the Company closed its IPO whereby 3,000,000 shares of its common stock were issued and sold at a public offering price of $10.00 per share. On September 8, 2016, the Company closed the sale of 27,755 shares of its common stock at the public offering price of $10.00 per share, representing a partial exercise of the underwriters&#x2019; over-allotment option, following which, the IPO terminated. The Company received net proceeds of approximately $26.1 million after deducting underwriting discounts and commissions of $2.1 million and other offering expenses of $2.1 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Immediately prior to the IPO, the Company amended and restated its certificate of incorporation and bylaws to, among other things, change its authorized capital stock to consist of (i) 100,000,000 shares of common stock and (ii) 10,000,000 shares of undesignated preferred stock.</font><font style="display:inline;color:#000000;background-color: #FFFFFF;"> Both the common stock and the preferred stock have a par value of $0.001 per share.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has sustained operating losses since inception and expects such losses to continue over the next several years. Management plans to continue financing the operations with equity issuances. The Company&#x2019;s management believes the cash and cash equivalents on hand are adequate to fund the Company&#x2019;s operations for at least the next 12 months. If adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate part or all of its research and development programs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Basis of Presentation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">Certain prior period balances have been reclassified to conform to the current period presentation. Specifically, the Company reclassified all current deferred tax liabilities as long term in the amount of $10,000 on its December 31, 2015 balance sheet in conformity with the adoption of</font><font style="display:inline;"> Accounting Standards Update (ASU) 2015&#8209;17, </font><font style="display:inline;font-style:italic;">Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</font><font style="display:inline;"> (ASU 2015&#8209;17).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;background-color: #FFFFFF;">Reverse Stock Split</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">In April 2016, the board of directors approved an amendment to the Company&#x2019;s certificate of incorporation to effect a 1-for-3.119 reverse stock split (the Reverse Stock Split) for all common and Series A preferred stock. The Reverse Stock </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">111</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;color:#000000;background-color: #FFFFFF;">Split became effective on April 27, 2016 upon the filing of the amendment to the certificate of incorporation. The authorized shares and par value of the common stock and Series A preferred stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common and Series A preferred stock, options for common stock and per share amounts contained in the financial statements were retroactively adjusted to reflect the Reverse Stock Split for all periods presented.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">2. Summary of Significant Accounting Policies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Use of Estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company considers all highly liquid investments with an original maturity of 90&nbsp;days or less at the time of deposit to be cash equivalents. The Company invests excess cash in readily available checking and savings accounts and highly liquid investments in money market accounts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s financial instruments include principally cash and cash equivalents, other current assets, accounts payable, accrued liabilities and debt. The carrying amounts for these financial instruments reported in the balance sheets approximate their fair values. See Note&nbsp;11&nbsp;&#x2014; Fair Value Measurements, for further discussion of fair value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">General and Administrative Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">General and administrative expenses consist primarily of personnel&#8209;related costs, including salaries and share&#8209;based compensation costs, for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Research and Development Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development expenses consist of costs incurred in performing research and development activities, including compensation for research and development employees, costs associated with preclinical studies and trials, regulatory activities, manufacturing activities to support clinical activities, license fees, non&#8209;legal patent costs, fees paid to external service providers that conduct certain research and development, clinical costs and an allocation of overhead expenses. Research and development costs are expensed as incurred.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Acquired In&#8209;Process Research and Development Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company includes costs to acquire or in&#8209;license product candidates in acquired in&#8209;process research and development expenses. The Company has acquired the right to develop and commercialize its product candidate gemcabene. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &#x201C;business&#x201D; as defined under GAAP or provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">112</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company utilizes the liability method of accounting for income taxes as required by Accounting Standards Codification (ASC) 740, </font><font style="display:inline;font-style:italic;">Income Taxes</font><font style="display:inline;">. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is no provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. MLT was treated as a partnership for federal and state income tax purposes. Accordingly, no provision was made for income taxes for periods prior to November&nbsp;1, 2014, since the Company&#x2019;s net loss (subject to certain limitations) was passed through to the income tax returns of its members. Upon incorporation on October&nbsp;30, 2014, the Company became taxed as a corporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Share&#8209;Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company accounts for share&#8209;based compensation in accordance with the provisions of ASC 718, </font><font style="display:inline;font-style:italic;">Compensation&nbsp;&#x2014; Stock Compensation</font><font style="display:inline;"> (ASC 718). Accordingly, compensation costs related to equity instruments granted are recognized at the grant&#8209;date fair value. Additionally, as a result of the early adoption of </font><font style="display:inline;color:#000000;">ASU 2016-09, </font><font style="display:inline;font-style:italic;color:#000000;">Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;">, the Company has made an accounting policy election to record forfeitures when they occur. Share&#8209;based compensation arrangements to non&#8209;employees are accounted for in accordance with the applicable provisions of ASC 718 and ASC 505, </font><font style="display:inline;font-style:italic;">Equity</font><font style="display:inline;">, using a fair value approach. The compensation costs of these arrangements are subject to re&#8209;measurement as the equity instruments vest and are recognized as expense over the related service period (typically the vesting period of the awards).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Common Stock Valuation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Due to the absence of an active market for the Company&#x2019;s common stock prior to the close of the IPO, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#x2019; Technical Practice Aid, </font><font style="display:inline;font-style:italic;">Valuation of Privately&#8209;Held Company Equity Securities Issued as Compensation</font><font style="display:inline;">, to estimate the fair value of its common stock. The valuation methodology included estimates and assumptions that required the Company&#x2019;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biopharmaceutical industry sector, and the likelihood of achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Convertible Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 31, 2015, the Company issued 745,637 shares of Series&nbsp;A convertible preferred stock (the Series&nbsp;A preferred stock). On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock. The Series&nbsp;A preferred stock prior to conversion was classified outside of permanent equity, in mezzanine equity, on the Company&#x2019;s balance sheet. The Company initially records preferred stock that may be redeemed at the option of the holder, or based on the occurrence of events outside of the Company&#x2019;s control, at the value of the proceeds received. Subsequently, if it is probable that the preferred stock will become redeemable, the Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying amount of the instrument to equal the redemption value at the end of each reporting period. If it is not probable that the preferred stock will become redeemable, the Company does not adjust the carrying value. In the absence of retained earnings, these charges are recorded against additional paid&#8209;in&#8209;capital, if any, and then to accumulated deficit See Note&nbsp;7&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Convertible Series&nbsp;A Preferred Stock</font><font style="display:inline;"> for further discussion. As a result of their conversion to common stock on August 10, 2016 as described above, no shares of Series A preferred stock were outstanding as of December 31, 2016.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">113</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Segment Information</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#x2019;s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer. The Company&#x2019;s Chief Executive Officer views the Company&#x2019;s operations and manages its business in one operating segment, which is the business of development and commercialization of therapeutics for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease and NAFLD/NASH. Accordingly, the Company has a single reporting segment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Jumpstart Our Business Startups Act Accounting Election</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As an emerging growth company under the Jumpstart Our Business Startups Act (JOBS Act), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has irrevocably elected not to avail itself of this exemption and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In May 2014, the FASB issued ASU 2014&#8209;09, </font><font style="display:inline;font-style:italic;">Revenue from Contracts with Customers&nbsp;&#x2014; Topic 606</font><font style="display:inline;">, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In 2015, the FASB agreed to allow companies to delay the implementation of this standard for one year effective for annual reporting periods beginning after December&nbsp;15, 2017, including interim periods within that reporting period. Early application is permitted only for periods beginning after December&nbsp;15, 2016. The Company plans to adopt this standard on January&nbsp;1, 2018 and to select the modified retrospective transition method. The Company plans to modify its accounting policies to reflect the requirements of this standard however, the planned adoption will not affect the Company&#x2019;s financial statements and related disclosures for these periods or future periods until the Company generates revenues.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In August 2014, the FASB issued Accounting Standards Update No.&nbsp;2014&#8209;15, </font><font style="display:inline;font-style:italic;">Presentation of Financial Statements&nbsp;&#x2014; Going Concern (Subtopic 205&#8209;40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern</font><font style="display:inline;"> (ASU 2014&#8209;15), which requires management to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events that, considered in the aggregate, raise substantial doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable) and provide related disclosures. ASU 2014&#8209;15 is effective for the annual period ending after December&nbsp;15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company elected to adopt this standard early as of December 31, 2015 and did not have a material impact on the Company&#x2019;s financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In November 2015, the Financial Accounting Standards Board (FASB) issued ASU 2015&#8209;17, </font><font style="display:inline;font-style:italic;">Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</font><font style="display:inline;"> (ASU 2015&#8209;17). The new guidance simplifies the presentation of deferred income taxes by requiring that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015&#8209;17 applies to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax&#8209;paying component of an entity be offset and presented as a single amount is not affected by this ASU. For public entities, ASU 2015&#8209;17 is effective for financial statements issued for annual periods beginning after December&nbsp;15, 2016 with earlier application permitted. The new guidance may be applied either prospectively or retrospectively to all periods presented. The Company </font><font style="display:inline;color:#000000;">adopted this standard effective April 1, 2016 on a retrospective basis for each period presented. </font><font style="display:inline;">The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In January 2016, the FASB issued ASU No.&nbsp;2016&#8209;01, </font><font style="display:inline;font-style:italic;">Financial Instruments&nbsp;&#x2014; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.</font><font style="display:inline;"> The guidance affects the accounting for equity investments, financial </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">114</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in the first quarter of fiscal 2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently evaluating the impact of the new guidance on its financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Leases (Topic </font><font style="display:inline;color:#000000;font-size:10pt;">842). The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The Company is currently evaluating the new guidance to determine the impact it may have on its financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">In March 2016, the FASB issued ASU 2016-09, </font><font style="display:inline;font-style:italic;color:#000000;">Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;color:#000000;">. This ASU simplifies the accounting for share-based payment award transactions including: income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December&nbsp;15, 2016, including interim periods within those fiscal years. Early adoption is permitted. </font><font style="display:inline;">The Company </font><font style="display:inline;color:#000000;">adopted this standard effective July 1, 2016 on a retrospective basis for each period presented. </font><font style="display:inline;">The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">In November 2016, the FASB issued ASU No.&nbsp;2016-18, </font><font style="display:inline;font-style:italic;color:#000000;background-color: #FFFFFF;">Statement of Cash Flows (Topic 230): Restricted Cash</font><font style="display:inline;color:#000000;background-color: #FFFFFF;">. The objective of this ASU is to eliminate the diversity in practice related to the classification of </font><font style="display:inline;">restricted cash or restricted cash equivalents in the statement of cash flows. </font><font style="display:inline;color:#000000;background-color: #FFFFFF;">For public business entities, this ASU is effective for annual and interim reporting periods beginning after December&nbsp;15, 2017, with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&#x2019;s financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">3. Accrued Liabilities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Accrued liabilities consist of the following (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued offering costs</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>575
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Legal costs</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>234
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued compensation costs</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>706
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,259
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>759
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other general and administrative expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,113
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,617
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">115</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">4. Debt</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Promissory Notes to Related Parties</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company issued promissory notes to related parties (the Promissory Notes) at a compound interest rate of 8% per annum for an aggregate principal amount of $0.3&nbsp;million on various dates from March 2009 through October 2014 with maturity dates through October&nbsp;31, 2014. The Promissory Notes along with accrued interest were exchanged for convertible notes (the Convertible Notes) on November&nbsp;1, 2014, in the amount of $0.4&nbsp;million inclusive of accrued interest.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Convertible Notes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company completed a series of convertible note financings with certain investors beginning on November 1, 2014 and ending on February&nbsp;18, 2015 (the Convertible Notes), whereby a total of $2.7&nbsp;million was loaned to the Company, of which $2.0&nbsp;million was loaned in 2015. Interest for the Convertible Notes compounded on a daily basis at a rate of 8&nbsp;percent per annum. The Convertible Notes converted into shares of the Company&#x2019;s Series&nbsp;A preferred stock upon close of the Series A preferred stock financing on March 31, 2015. The conversion equaled 125% of the unpaid principal plus unpaid accrued interest on the Convertible Notes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">At the time of their issuance, the Convertible Notes contained a conversion premium with regard to the conversion into the Series&nbsp;A preferred stock. The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Convertible Notes. The discount was amortized to interest expense over the term of the Convertible Notes using the straight&#8209;line method. The embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium conversion derivative associated with the Convertible Notes to interest expense that amounted to $0.4&nbsp;million and $18,000 for the years ended December 31, 2015 and 2014, respectively. As a result of their conversion into shares of Series A preferred stock on March 31, 2015 as described above, there were no Convertible Notes outstanding during 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Interim Notes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On July&nbsp;31, 2015, the Company entered into a convertible interim note financing (collectively with the notes issued in December 2015, February 2016 and April 2016, the Interim Notes), pursuant to which certain investors agreed to loan the Company approximately $2.8&nbsp;million. On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Interim Notes, together with accrued interest thereon, converted into 1,656,807 shares of common stock. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Interim Notes accrued interest at a rate of 8% per annum, compounded annually, and would automatically convert into shares issued to investors in the Company&#x2019;s next equity financing round that results in gross proceeds of at least $5.0&nbsp;million (a Qualified Financing). The conversion would be equal to unpaid principal at 115% plus any unpaid accrued interest. The investors would be paid out principal at 200% if a change of control occurred before the next financing round. In the event that a Qualified Financing, change of control, or an IPO did not occur before July&nbsp;31, 2016, the parties would then negotiate a price for conversion into a new round of stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In December 2015, the Company amended the Interim Notes and certain investors agreed to loan the Company an additional $2.7&nbsp;million for a revised financing total of $5.5&nbsp;million. The Interim Notes continued to accrue interest at an 8% rate per annum compounded annually, but were amended to automatically convert into shares of the same class of the Company&#x2019;s next convertible preferred stock financing round (the Preferred Stock Financing). The conversion into shares issued in the Preferred Stock Financing would be equal to unpaid principal at 115% plus unpaid accrued interest. In the event that either a change of control occurs or the Company completes a public transaction which results in the Company&#x2019;s stockholders holding securities listed on a national securities exchange, including an IPO, before the Preferred Stock Financing, the Interim Notes, as amended, would automatically convert into shares of the Company&#x2019;s common stock at a conversion price of $6.70585 per share (which represents the original issue price of the Series&nbsp;A preferred stock) based on 100% of outstanding principal and unpaid accrued interest. Lastly, if a Preferred Stock </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">116</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">Financing, change of control, or public transaction did not occur before December&nbsp;31, 2016, the parties agreed to then negotiate a conversion price into a new round of stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February 2016, certain investors agreed to loan the Company an additional $0.2&nbsp;million for a revised financing total of $5.6&nbsp;million. The Interim Notes continued to accrue interest at an 8% rate per annum compounded annually, but were amended to automatically convert into shares of the same class of the Company&#x2019;s next Preferred Stock Financing. The conversion into shares issued in the Preferred Stock Financing would be equal to unpaid principal at 115% plus unpaid accrued interest. In the event that either a change of control occurs or the Company completes a public transaction which results in the Company&#x2019;s stockholders holding securities listed on a national securities exchange, including an IPO, before the Preferred Stock Financing, the Interim Notes, as amended, would automatically convert into shares of the Company&#x2019;s common stock at a conversion price of $6.70585 per share (which represents the original issue price of the Series&nbsp;A preferred stock as adjusted for the Reverse Stock Split (as defined below)) based on 100% of outstanding principal and unpaid accrued interest. Lastly, if a Preferred Stock Financing, change of control, or public transaction did not occur before December&nbsp;31, 2016, the parties agreed to then negotiate a conversion price into a new round of stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2016, the Company amended the Interim Notes and certain investors agreed to loan the Company an additional $5.0&nbsp;million for a revised financing total, including Interim Notes previously issued, of $10.6&nbsp;million. The Interim Notes continued to accrue interest at an 8% rate per annum compounded annually, but were amended so that 125% of the unpaid principal and accrued interest, would automatically convert into shares of the same class of the Company&#x2019;s next convertible preferred stock financing round of at least $5.0&nbsp;million (the Qualified Financing). In the event that either a change of control occurs or the Company completes a public transaction which results in the Company&#x2019;s stockholders holding securities listed on a national securities exchange, including an IPO, before the Qualified Financing, 100% of outstanding principal and unpaid accrued interest on the Interim Notes, as amended, would automatically convert into shares of the Company&#x2019;s common stock at a conversion price of $6.70585 per share, as adjusted for the Reverse Stock Split. Lastly, if a Qualified Financing, change of control, or public transaction did not occur, the Interim Notes would become payable on demand anytime after December&nbsp;31, 2016. The Company incurred issuance costs related to the April 2016 financing in the amount of $10,000. The Interim Notes were discounted for the issuance costs, and the discount was amortized to interest expense over their remaining term using the straight&#8209;line method.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Interim Notes, together with accrued interest thereon, converted into 1,656,807 shares of common stock. At the time of their issuance, the Interim Notes contained a conversion premium with regard to the conversion into shares at the time of the next Qualified Financing. The Company determined that the redemption feature under the Interim Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Interim Notes. The discount was amortized to interest expense over the term of the Interim Notes using the straight&#8209;line method. The embedded derivative was accounted for separately on a fair market value basis. The fair value of the derivative associated with the Interim Notes was $0.3 million at December 31, 2015 and was included as premium conversion derivative on the accompanying balance sheets. As a result of the conversion of the Interim Notes, together with accrued interest thereon, into common stock immediately prior to the closing of the IPO, there was no premium conversion derivative outstanding as of December 31, 2016. The Company recorded the fair value changes of the premium conversion derivative associated with the Interim Notes to interest income (expense) that amounted to $0.2 million, $(0.1) million and zero for the years ended December 31, 2016, 2015 and 2014, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As a result of their conversion to common stock on August 10, 2016 as described above, there were no Interim Notes outstanding as of December 31, 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">5. Commitments and Contingencies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Pfizer License Agreement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2011, the Company and Pfizer&nbsp;Inc. (Pfizer) entered into an exclusive license agreement (the Pfizer Agreement) for the clinical product candidate gemcabene. In exchange for this worldwide exclusive right and license to certain patent rights to make, use, sell, offer for sale and import the clinical product gemcabene, the Company agreed to certain milestone and royalty payments on future sales (See Note&nbsp;6&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">License Agreement)</font><font style="display:inline;">. As of December 31, 2016, there was </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">117</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">sufficient uncertainty with regard to both the outcome of the clinical trials and the ability to obtain sufficient funding to support any of the cash milestone payments under the license agreement, and as such, no liabilities were recorded related to the license agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Series&nbsp;A Preferred Stock Dividends</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Holders of the Series&nbsp;A preferred stock were entitled to cumulative accruing dividends at a simple rate of 8% per year on the original issue price of the preferred stock of $6.70585 per share, as adjusted for the Reverse Stock Split. The dividends effectively accrued daily on each share of preferred stock. The dividends were payable upon the earliest to occur of (1)&nbsp;the date determined by the Board, (2)&nbsp;the liquidation of the Company (including a deemed liquidation event) or (3)&nbsp;the conversion or redemption of at least a majority of the outstanding shares of Series&nbsp;A preferred stock. If the board reasonably believed that the Company was not legally able to pay the dividends in cash at the payment date, or if elected by the majority of the Series&nbsp;A preferred stockholders or if issued in connection with an IPO, the dividends were to be paid in shares of common stock at the conversion price for the Series&nbsp;A preferred stock in effect at that time, which was the original issue price of the Series&nbsp;A preferred stock as adjusted from time to time for any stock dividends, combinations, splits or recapitalizations. Since the dividends were payable upon a contingent event, the Company did not record them in the accompanying financial statements as of December 31, 2015; however, cumulative unpaid dividends for the Series&nbsp;A preferred stock totaled $0.3&nbsp;million as of December&nbsp;31, 2015. On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock, and as such, there were no cumulative unpaid dividends for the Series A preferred stock as of December 31, 2016. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Other Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Both cancellable and non-cancellable facility agreements were in place that provided for fixed monthly rent for the years ended December 31, 2016, 2015 and 2014. The total rent expense was $58,000, &nbsp;$23,000 and $6,000 for the years ended December 31, 2016, 2015 and 2014, respectively. In May 2016, the Company entered into a new lease agreement for its headquarters location, commencing in August 2016. The initial term of the agreement is 3 years with an initial monthly base rent of approximately $8,400. In conjunction with entering into the new lease agreement, the Company cancelled its original Northville, Michigan lease agreement, as amended, effective August 31, 2016 and renegotiated a new cancellable lease agreement for limited use of office space in the Northville location that expires in September 2017.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Future minimum lease payments under fixed non-cancellable operating leases that expire on various dates through August 2019 consist of the following (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>58
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;Total</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>260
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">6. License Agreement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2011, the Company entered into the Pfizer Agreement for a worldwide exclusive license to certain patent rights to make, use, sell, offer for sale and import the clinical product candidate gemcabene. In exchange for this license, the Company agreed to issue shares of its common stock to Pfizer representing 15% of the Company&#x2019;s fully diluted capital at the close of its first arms&#8209;length Series&nbsp;A financing, which occurred on March 31, 2015.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company agreed to make milestone payments totaling up to $37&nbsp;million upon the achievement of certain milestones, including the first regulatory submission in any country, regulatory approval in each of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">118</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">aggregate sales levels of gemcabene or any product containing gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company also agreed to pay Pfizer tiered royalties on a country&#8209;by&#8209;country basis based upon the annual amount of net sales, as specified in the Pfizer Agreement until expiration of the last valid claim of the licensed patent rights including any patent term extensions or supplemental protection certificates. Under the Pfizer Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize gemcabene.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 31, 2015, upon the closing of the Series&nbsp;A preferred stock financing, the Company issued 675,250 shares of its common stock, at a fair market value of $0.9&nbsp;million, to Pfizer in connection with the first equity payment, pursuant to which Pfizer became the owner of more than 5% of the Company&#x2019;s capital stock. The transaction was recorded as acquired in&#8209;process research and development expenses based on the fair market value of the common shares issued since no processes or activities that would constitute a &#x201C;business&#x201D; were acquired and none of the rights and underlying assets acquired had alternative future uses or reached a stage of technological feasibility. None of the other milestone or royalty payments were triggered as of December 31, 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Pfizer Agreement will expire upon expiration of the last royalty term. Either party may terminate the Pfizer Agreement for the other party&#x2019;s uncured material breach or upon specified bankruptcy events. Pfizer may terminate the Pfizer Agreement if the Company or any of its sublicenses challenge the validity, enforceability or ownership of the licensed patents. Upon termination of the license agreement for cause by Pfizer, we must grant Pfizer a non-exclusive license to use any intellectual property rights arising from the development or commercialization of gemcabene. Additionally, Pfizer may revoke the license if the Company is unable to adequately commercialize gemcabene by April 2021.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pfizer has a non&#8209;exclusive, sub licensable, royalty&#8209;free right and license for non&#8209;commercial research or development purposes to intellectual property rights relating to gemcabene that are developed by us after the effective date of the license with Pfizer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">7. Convertible Series&nbsp;A Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 31, 2015, the Company issued 745,637 shares of Series&nbsp;A preferred stock at a per share price of $6.70585, as adjusted for the Reverse Stock Split, or $5.0&nbsp;million in the aggregate, consisting of $1.5&nbsp;million in cash and $3.5&nbsp;million representing 125% of the principal and accrued and unpaid interest on the Convertible Notes, all of which converted into shares of Series&nbsp;A preferred stock. On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Prior to their conversion into shares of common stock, the Series&nbsp;A preferred stock had the following rights and preferences:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Dividend Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Dividends effectively accrued on a daily basis at a simple rate of 8% per annum on the sum of the original per share issue price. Dividends were effectively deemed declared daily and were payable upon the occurrence of certain events. In addition, the holders of the Series&nbsp;A preferred stock had rights to participate in common stock dividends, entitling holders of Series&nbsp;A preferred stock to a dividend payable at the same time as the dividend paid on common stock based on the number of shares of common stock each share of Series&nbsp;A preferred stock would convert into if such shares had converted on the record date. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There were no dividends deemed payable and accrued as of December 31, 2016 due to the conversion of the Series A preferred stock, together with accrued dividends thereon, on August 10, 2016 immediately prior to the closing of the IPO. There were no dividends deemed payable and accrued as of December 31, 2015, but unpaid dividends were $0.3&nbsp;million as of December&nbsp;31, 2015. See Note&nbsp;5&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Commitments and Contingencies</font><font style="display:inline;">.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">119</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Voting Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Each share of Series&nbsp;A preferred stock was entitled to vote together with the common stock on all actions to be taken by the stockholders of the Company, based on the number of shares of common stock into which each share of Series&nbsp;A preferred stock could be converted. A separate vote of a majority of the outstanding shares of Series&nbsp;A preferred stock was required to (1)&nbsp;issue or authorize any class or series of equity securities or equivalents, (2)&nbsp;effect any transaction that results in a change in control, (3)&nbsp;change the principal business of the Company, enter new lines of business, or exit the current line of business, (4)&nbsp;issue of convertible debt above a certain threshold, or (5)&nbsp;materially sell, transfer, license, pledge or encumber technology or intellectual property. A management stock option plan approved by the board of directors, however, was not subject to a separate vote of the Series&nbsp;A preferred stockholders, but any subsequent increases to the authorized option pool were subject to approval by the Series&nbsp;A preferred stock holders via a separate vote.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Liquidation Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the event of any liquidation, dissolution, or winding&#8209;up of the Company, whether voluntary or involuntary, merger, consolidation or transaction in which over 50% of the Company&#x2019;s voting power was transferred, or a sale, lease, transfer, exclusive license or disposition of all or substantially all of the assets of the Company, the Series&nbsp;A preferred stock holders were entitled to the assets of the Company legally available for distribution before any distribution or payment was made to the holders of common stock. The distribution amount would have been equal the original issue price of the Series&nbsp;A preferred stock (as adjusted for any stock dividends, combinations, splits or other recapitalizations since issuance), plus any accrued or declared but unpaid dividends thereon. After payment of the full liquidation preference to the Series&nbsp;A preferred stock holders, the remaining assets legally available for distribution would have been distributed to the holders of common stock and holders of the Series&nbsp;A preferred stock pro rata based on the number of shares of common stock each share of Series&nbsp;A preferred stock would convert into if such shares had converted immediately prior to such liquidation, dissolution, or winding&#8209;up.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Conversion Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Shares of Series&nbsp;A preferred stock, at the option of the holder, could have been converted at any time into shares of common stock. The conversion rate would have been obtained by dividing the Series&nbsp;A preferred stock original issue price of $6.70585 per share, as adjusted for the Reverse Stock Split, by the conversion price per share in effect at the time of conversion. The Series&nbsp;A conversion price was initially equal to the original issue price, but could be adjusted on a broad&#8209;based weighted average basis in connection with certain dilutive events. The Series&nbsp;A holder was also entitled to receive additional shares of common stock for any unpaid Series&nbsp;A dividends (whether or not declared).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Shares of Series&nbsp;A preferred stock would have automatically converted into common stock based upon the then&#8209;effective Series&nbsp;A conversion price upon the affirmative vote or consent of the holders of at least a majority of the outstanding shares of the Series&nbsp;A preferred stock, or at the closing of a firmly underwritten public offering. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The conversion price for the Series&nbsp;A preferred stock was $6.70585 per share (as adjusted for the Reverse Stock Split) at the time of the conversion of the Series A preferred stock, together with accrued dividends thereon, immediately prior to the closing of the IPO on August 10, 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Redemption Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The holders of at least 80% of the outstanding shares of Series&nbsp;A preferred stock could have required the Company to redeem all outstanding shares of Series&nbsp;A preferred stock at any time on or after December&nbsp;31, 2020 at a redemption price equal to the greater of 150% of the liquidation preference of the Series&nbsp;A preferred stock or the fair market value per share plus any unpaid declared dividends. The liquidation preference of the Series&nbsp;A preferred stock was defined as an amount per share equal to $6.70585, as adjusted from time to time for any stock dividends, combinations, splits or recapitalizations, plus any accrued or declared but unpaid dividends thereon.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">120</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The redemption value for redeemable preferred stock could have at times been based on fair market value. The assumptions used in calculating the estimated fair market value at each reporting period represented the Company&#x2019;s best estimate, however, inherent uncertainties were involved. As a result, if factors or assumptions changed, the estimated fair value could have been materially different. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company recognized changes in the redemption value immediately as they occurred and adjusted the carrying amount of the instrument to equal the redemption value at the end of each reporting period since it was probable that the instruments would have become redeemable. In the absence of retained earnings, these charges were recorded against additional paid&#8209;in&#8209;capital, if any, and then to accumulated deficit.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company evaluated the Series&nbsp;A preferred stock and determined that it was considered an equity host under ASC 815</font><font style="display:inline;font-weight:bold;">, &nbsp;</font><font style="display:inline;font-style:italic;">Derivatives and Hedging.</font><font style="display:inline;"> In making this determination, the Company&#x2019;s analysis followed the whole instrument approach that compared an individual feature against the entire Series&nbsp;A preferred stock instrument that included that feature. The Company&#x2019;s analysis was based on a consideration of the economic characteristics and risks of the Series&nbsp;A preferred stock. More specifically, the Company evaluated all of the stated and implied substantive terms and features of the Series&nbsp;A preferred stock, including: (1)&nbsp;redemption features and their underlying exercisability, (2)&nbsp;existence of any protective covenants, (3)&nbsp;nature of dividends rights, (4)&nbsp;nature of voting rights, and (5)&nbsp;the existence and nature of any conversion rights. As a result of the above, the Company concluded that the Series&nbsp;A preferred stock represented an equity host, and as such, the redemption and/or conversion features of the Series&nbsp;A preferred stock were considered to be clearly and closely related to the associated Series&nbsp;A preferred stock host instrument. Accordingly, the redemption and/or conversion features of the Series&nbsp;A preferred stock were not considered an embedded derivative that required bifurcation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">8. Stockholders&#x2019; and Members&#x2019; Equity (Deficit)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The membership interests of MLT were converted to 1,431,228 shares of the Company&#x2019;s common stock on November&nbsp;1, 2014. The MLT members&#x2019; deficit was transferred to stockholders&#x2019; deficit on the accompanying balance sheets upon conversion to a C Corporation at that time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Common Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company had </font><font style="display:inline;color:#000000;">9,270,255</font><font style="display:inline;"> and 3,758,488 shares of its common stock issued and outstanding as of December 31, 2016 and December&nbsp;31, 2015, respectively. Voting, dividend and liquidation rights of the holders of the common stock are subject to the Company&#x2019;s articles of incorporation, corporate bylaws and underlying shareholder agreements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Dividend Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Common stock holders are entitled to receive dividends at the sole discretion of the board of directors of the Company. There have been no dividends declared on common stock as of December 31, 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Voting Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The holders of common stock are entitled to one vote for each share of common stock along with all other classes and series of stock of the Company on all actions to be taken by the stockholders of the Company, including actions that would amend the certificate of incorporation of the Company to increase the number of authorized shares of the common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Liquidation Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the event of any liquidation, dissolution, or winding&#8209;up of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution post preferential distributions made to holders of the Company&#x2019;s preferred stock.&nbsp;&nbsp;There was no preferred stock outstanding as of December 31, 2016. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">121</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Deferred Offering Costs</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">IPO offering costs of $4.2 million, consisting of </font><font style="display:inline;color:#000000;">underwriting discounts and commissions,</font><font style="display:inline;"> legal, accounting and other direct fees and costs, were initially capitalized and subsequently offset against the Company&#x2019;s IPO proceeds upon the close of the offering in August 2016. There were no deferred offering costs capitalized as of December 31, 2016. As of December 31, 2015, offering costs of $0.8 million were capitalized.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">9. Share&#8209;Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Share-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying statements of comprehensive loss (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="middle" style="width:50.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended </font></p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="middle" style="width:50.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,166
				</td>
				<td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="middle" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>284
				</td>
				<td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="middle" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>552
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total share-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,718
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>284
				</td>
				<td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53
				</td>
				<td valign="bottom" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Restricted Stock Awards</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the year ended December 31, 2016, the Company did not grant any restricted stock awards (RSAs). During the years ended December 31, 2015 and 2014, the Company granted an aggregate of 44,657 and 1,605,008 RSAs, respectively, to certain of its employees, members of its board of directors and consultants subject to a 2014 Shareholders Agreement (the Agreement). The RSAs are subject to various vesting schedules and generally vest ratably over a six to twenty four month period coinciding with their respective service periods. During the years ended December 31, 2016, 2015 and 2014, no RSAs were forfeited.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">A summary of RSA grant activity is as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:8pt;">Weighted-Average</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:8pt;">Fair Value (per share)</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2013 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,605,008
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(610,395)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>994,613
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,567
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.21
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(691,087)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>348,093
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(344,084)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2016 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,009
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.21
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There were no RSAs granted during the year ended December 31, 2016. The grant&#8209;date fair value of the RSAs issued during the years ended December 31, 2015 and 2014 was $9,000 and $140,000 respectively. Grant date fair market value in prior years was based on traditional valuation techniques and methods in determining the fair value of the Company&#x2019;s equity as a private company including market, income, and cost valuation approaches. A number of objective and subjective factors were considered including contemporaneous and retrospective valuations of its common stock performed by an unrelated valuation specialist, sales of the Company&#x2019;s convertible preferred stock to unrelated third parties, valuations of comparable peer public companies, the lack of liquidity of the Company&#x2019;s capital stock and general </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">122</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">and industry&#8209;specific economic outlook. The fair value of the Company&#x2019;s common stock was determined by the Company&#x2019;s board of directors prior to the IPO.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Stock Options</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2015, the Company adopted a 2015 Equity Incentive Plan (the 2015 Plan) under which 320,615 shares of the Company&#x2019;s common stock were reserved for issuance to employees, directors and consultants. The 2015 Plan permits the grant of incentive and non&#8209;statutory stock options, appreciation rights, restricted stock, restricted stock units, performance stock and cash awards, and other stock&#8209;based awards. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;">Amendment and Restatement of 2015 Equity Incentive Plan</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2016 the Company&#x2019;s board of directors approved the Company&#x2019;s amended and restated 2015 Plan (the A&amp;R 2015 Plan). The A&amp;R 2015 Plan became effective immediately upon the execution and delivery of the underwriting agreement related to the IPO. The A&amp;R 2015 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and other forms of equity awards, as well as performance cash awards. The Company initially reserved 2,400,000 shares of common stock for issuance under the A&amp;R 2015 Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the years ended December 31, 2016 and 2015, the Company granted an aggregate of 1,825,700 and 305,278, respectively, of stock options under the A&amp;R 2015 Plan or the 2015 Plan to its officers, directors, employees and consultants, generally vesting over a three or four-year period. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;">Inducement Plan</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In September 2016 the Company&#x2019;s board of directors approved the Company&#x2019;s Inducement Plan (the Inducement Plan). The Company initially reserved 300,000 shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual&#x2019;s entry into employment with the Company within the meaning of Rule&nbsp;5635(c)(4)&nbsp;of the NASDAQ Listing Rules. The Plan was approved by the Company&#x2019;s board of directors without stockholder approval pursuant to Rule&nbsp;5635(c)(4), and the terms and conditions of the Plan are substantially similar to the Company&#x2019;s stockholder-approved A&amp;R 2015 Plan. During the year ended December 31, 2016, 198,000 stock options to newly-hired officers and employees were granted under the Inducement Plan, generally vesting over a four-year period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">123</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">The following table summarizes the Company&#x2019;s stock option plan activity for the year ended December&nbsp;31, 2016 and 2015 as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Weighted&#x2011;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Remaining</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Aggregate</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Contractual</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Intrinsic</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Term (years)</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Value(1)</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>305,278
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.42
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,436)
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.34
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Forfeited/Cancelled </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding at December&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>302,842
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.43
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.60
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,031,000
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,023,700
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.07
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Forfeited/Cancelled </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(83,742)
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.12
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding at December 31, 2016 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,242,800
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.07
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.48
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,759,000)
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested and exercisable at December&nbsp;31, 2016 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373,158
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.86
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.06
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>740,000
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested and expected to vest at December 31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,242,800
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.07
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.48
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,759,000)
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 23.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<sup style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (1)</sup>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of December 31, 2016 and 2015 of $7.84 and $5.83 per share, respectively.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The weighted average fair value per share of options granted during the years ended December&nbsp;31, 2016 and 2015 was $6.37 and $1.50, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures the fair value of stock options with service&#8209;based and performance&#8209;based vesting criteria to employees, consultants and directors on the date of grant using the Black&#8209;Scholes option pricing model. The fair value of equity instruments issued to non&#8209;employees is re&#8209;measured as the award vests. The Company does not have history to support a calculation of volatility and expected term. As such, the Company has used a weighted&#8209;average volatility considering the volatilities of several guideline companies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For purposes of identifying similar entities, the Company considered characteristics such as industry, length of trading history, and stage of life cycle. The assumed dividend yield was based on the Company&#x2019;s expectation of not paying dividends in the foreseeable future. The average expected life of the options was determined based on the mid&#8209;point between the vesting date and the end of the contractual term according to the &#x201C;simplified method&#x201D; as described in Staff Accounting Bulletin 110. The risk&#8209;free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to the expected life assumed at the date of grant. As a result of the early adoption of </font><font style="display:inline;color:#000000;">ASU 2016-09, </font><font style="display:inline;font-style:italic;color:#000000;">Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;">, the Company has made an accounting policy election to record forfeitures when they occur. </font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">124</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The weighted&#8209;average assumptions used in the Black&#8209;Scholes option&#8209;pricing model are as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year&nbsp;&nbsp;Ended </font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="3" valign="middle" style="width:17.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="middle" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-family:Calibri;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:17.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected stock price volatility </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71.4
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71.0
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected life of options (years)</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.0
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.5
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected dividend yield </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Risk free interest rate </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.7
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the years ended December 31, 2016 and 2015, 276,248 and 104,907 stock options vested, respectively. The weighted average fair value per share of options vesting during the years ended December 31, 2016 and 2015 was $4.59 and $1.05, respectively. During the year ended December 31, 2016, 83,742 stock options were forfeited. During the years ended December 31, 2015 and 2014, no stock options were forfeited. As of December 31, 2016, 457,200 shares were available for future issuance under the A&amp;R 2015 and Inducement Plans.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Unrecognized share&#8209;based compensation cost for the RSAs and stock options issued under the Company&#x2019;s 2014 Shareholders Agreement, A&amp;R 2015 Plan and Inducement Plan was $11.2&nbsp;million as of December 31, 2016. Approximately $11.2 million of the unrecognized compensation cost was related to the stock options and under $1,000 related to the RSAs. The non&#8209;employee portion of the unrecognized compensation cost was estimated utilizing the Company&#x2019;s fair market value for its common stock as of December 31, 2016. The unrecognized share&#8209;based expense is expected to be recognized over a weighted average period of 3.2 years for the stock options and 0.1&nbsp;years for the RSAs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;">Adoption of 2016 Employee Stock Purchase Plan</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2016 the Company&#x2019;s board of directors approved the 2016 Employee Stock Purchase Plan (the ESPP) in order to enable eligible employees to purchase shares of the Company&#x2019;s common stock at a discount following the effective date of the IPO. The Company&#x2019;s stockholders also approved the ESPP in April, 2016 and the ESPP became effective immediately upon the execution and delivery of the underwriting agreement related to the IPO. The Company initially reserved 150,000 shares of common stock for issuance under the ESPP. As of December 31, 2016, no shares were purchased under the ESPP. &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">10. Net Loss Per Common Share</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic earnings or loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The holders of the Series&nbsp;A preferred stock had rights to participate in common stock dividends, entitling the holders of Series&nbsp;A preferred stock to a dividend payable at the same time and rate per share as the dividend paid on common stock based the number of shares of common stock each share of Series&nbsp;A preferred stock would have converted into if such shares had converted on the record date. The Series&nbsp;A preferred stock, however, did not have a contractual obligation to share in the losses of the Company, and as such, no losses were allocated to the Series&nbsp;A preferred stock for the purposes of the basic loss per share calculation while they were outstanding. Prior to the Company&#x2019;s incorporation, no common shares were outstanding when the Company operated as MLT.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#x2019;s RSAs, stock options, shares of Series&nbsp;A preferred stock, Convertible Notes and Interim Notes are considered common stock equivalents while outstanding for this purpose. Diluted earnings is computed utilizing the treasury method for the RSAs and stock options, and in the case of the Series&nbsp;A preferred stock, either the two&#8209;class method or the if&#8209;converted method, whichever was more dilutive. Diluted earnings with respect to the Convertible Notes and Interim Notes utilized the if&#8209;converted method, but was not applicable during the years ended December 31, 2016, 2015 and 2014 as no conditions required for conversion had </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">125</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;">occurred during these periods while the instruments were outstanding. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti&#8209;dilutive given the net loss reported for the years ended December 31, 2016, 2015 and 2014. The following table sets forth the computation of basic and diluted loss per share as of December 31, 2016, 2015 and 2014 (in thousands, except share and per share amounts):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:36.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Numerator:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustment to redemption value on Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(366)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,968)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium upon substantial modification of convertible notes with certain stockholders</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,047)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss attributed to common stock holders</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,952)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,044)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Denominator:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted weighted average common shares outstanding</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,809,396
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,875,053
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,521,703
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted net loss per share</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.57)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.54)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.21)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti&#8209;dilutive:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:29.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Restricted stock awards</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,009
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>348,093
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>994,613
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock options</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,242,800
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>302,842
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Series&nbsp;A</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>745,637
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>828,751
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">11. Fair Value Measurements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company follows accounting guidance that emphasizes that fair value is a market&#8209;based measurement, not an entity specific measurement. Fair value is defined as &#x201C;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#x201D; Fair value measurements are defined on a three level hierarchy:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Level&nbsp;1 inputs:</font><font style="display:inline;"> &nbsp;Unadjusted quoted prices for identical assets or liabilities in active markets;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Level&nbsp;2 inputs:</font><font style="display:inline;"> &nbsp;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, weather directly or indirectly, for substantially the full term of the asset or liability;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Level&nbsp;3 inputs:</font><font style="display:inline;"> &nbsp;Unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2016 and 2015, the fair values of cash and cash equivalents, other assets, accounts payable and accrued liabilities approximated their carrying values because of the short&#8209;term nature of these assets or liabilities. The estimated fair value of the Company&#x2019;s Interim Notes was based on amortized cost which was deemed to approximate fair value. The derivative liability associated with the conversion premium on the Interim Notes was based on cash flow models discounted at current implied market rates evidenced in recent arms&#8209;length transactions representing expected returns by market participants for similar instruments which were based on Level&nbsp;3 inputs. There were no transfers between fair value hierarchy levels during the years ended December 31, 2016 and 2015.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">126</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The fair value of financial instruments measured on a recurring basis is as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:39.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As of December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Description</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Level&nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium conversion derivative</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total liabilities at Fair Value</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table provides a roll&#8209;forward of the Company&#x2019;s premium conversion derivative liabilities measured at fair value on a recurring basis using unobservable level&nbsp;3 inputs (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 92.80%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For&nbsp;the Year Ended December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Balance as of beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Issuance of underlying convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>505
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>842
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Change in fair value of premium conversion derivative</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(850)
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>297
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Reversal of premium conversion derivative associated with note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(182)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Redemption of underlying convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(685)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Balance as of end of period</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There were no financial instruments measured on a recurring basis as of December 31, 2016 and on a non&#8209;recurring basis for any of the periods presented.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">12. Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The effective tax rate for the years ended December&nbsp;31, 2016, 2015 and 2014 was zero percent. MLT was treated as a partnership for federal and state income tax purposes. Accordingly, no provision was made for income taxes for periods prior to the merger, since the Company&#x2019;s net loss (subject to certain limitations) was passed through to the income tax returns of its members. Upon the incorporation of Gemphire on October&nbsp;30, 2014, the Company became taxed as a corporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying statements of comprehensive loss is as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="8" valign="bottom" style="width:40.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For the Year Ended December 31, </font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="middle" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="middle" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Income tax (benefit) provision at federal statutory rate </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34.0)
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34.0)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34.0)
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Valuation allowance </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40.2
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38.2
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36.8
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">State income tax, net of federal benefit </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.7)
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.0)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.0)
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.1
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.6
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research credits</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.0)
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.4
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.8)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Effective tax rate </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">127</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Significant components of the Company&#x2019;s deferred tax assets and liabilities are summarized in the tables below as of (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:36.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended December 31, </font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:17.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="middle" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:16.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Federal and state operating loss carryforwards </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,289
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,723
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development costs deferral election</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,254
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Acquired intangibles </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>351
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accruals</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>460
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Charitable contributions </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>633
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development credit carryforwards </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>768
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,320
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,668
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Valuation allowance </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,320)
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,657)
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total deferred tax assets, net of valuation allowance </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Restricted stock awards </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11)
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total deferred tax liabilities </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11)
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net deferred tax assets </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-size:8pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016 and 2015, the Company had gross deferred tax assets of approximately $9.3 million and $3.7&nbsp;million, respectively. Realization of the deferred assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre&#8209;tax losses since its inception. The Company has not yet generated revenues and faces significant challenges to becoming profitable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance of $9.3 million and $3.7&nbsp;million as of December&nbsp;31, 2016 and 2015, respectively. U.S. net deferred tax assets will continue to require a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016 and 2015, the tax effect of the Company&#x2019;s federal net operating loss carryforwards was approximately $2.1 million and $2.4&nbsp;million, respectively. The Company had federal research credit carryforwards as of December&nbsp;31, 2016 and 2015 of approximately $0.7 million and $95,000, respectively. The federal net operating loss and tax credit carryforwards will begin to expire in 2034 if not utilized. As of December&nbsp;31, 2016 and 2015, the Company had state net operating loss carryforwards with a tax effect of approximately $0.2 million and $0.3&nbsp;million, respectively. The Company had state research credit carryforwards of $24,000 as of December&nbsp;31, 2016 and no state research credit carryforwards as of December 31, 2015. The state net operating loss carryforwards will begin to expire in 2026, if not utilized, and the state research credit carryforwards will begin to expire in 2023 if not utilized.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more &#x201C;5-percent shareholders&#x201D; increase their ownership, in the aggregate, by more than 50&nbsp;percentage points over a 36&#8209;month time period testing period, or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of December&nbsp;31, 2016 and 2015, and as such, no interest or penalties were recorded to income tax expense.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s corporate returns are subject to examination for the 2014 and 2015 tax years for federal and subject to examination for the 2015 tax year in various state jurisdictions. Prior to this period, the Company filed partnership returns, resulting in its income being passed through to its members.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">13. </font><font style="display:inline;font-weight:bold;color:#000000;">Supplementary Data &#x2014; Quarterly Financial Data (unaudited)</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The following table presents certain unaudited quarterly financial information for each of the eight fiscal quarters in the period ended December 31, 2016. This quarterly information has been prepared on the same basis as the audited </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">128</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 6pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;color:#000000;font-size:10pt;">financial statements and includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the information for the periods presented. The results for these quarterly periods are not necessarily indicative of the operating results for a full year or any future period.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September 30,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June 30,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March 31,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016 (B)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands, except per share amounts)</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,389
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,466
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,051
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,050
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,839
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,936
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>789
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,176
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,228
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,402
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,840
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,226
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,228)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,402)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,840)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,226)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Interest income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(475)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>449
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss before income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision (benefit) for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other comprehensive loss, net of tax</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustment to redemption value on Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(67)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(150)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(149)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss attributable to common stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,945)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,541)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,252)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss per share:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted (A)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.78)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.56)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.42)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.65)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September 30,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June 30,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March 31,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands, except per share amounts)</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Calibri;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,047
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>997
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>658
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>475
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,464
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,369
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>952
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>206
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Acquired in&#x2013;process research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>908
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,511
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,366
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,610
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,589
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,511)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,366)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,610)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,589)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Interest income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>137
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(209)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(690)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss on convertible note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(198)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss before income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision (benefit) for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other comprehensive loss, net of tax</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustment to redemption value on Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(150)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(152)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(149)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,517)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium upon substantial modification of convertible notes with certain stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,047)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss attributable to common stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,767)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,721)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,760)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,796)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss per share:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted (A)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.14)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.87)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.60)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.27)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-family:Times New Roman Bold;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 23.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<sup style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (A)</sup>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Net loss per share for the year does not equal the sum of the four historical quarters loss per share due to changes in weighted-average shares outstanding.</font><font style="display:inline;">&nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">129</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 23.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<sup style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (B)</sup>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Activity for the quarterly period ending December 31, 2016 reflects activity post IPO depicting a ramp-up of research and development expenses given the additional IPO proceeds and an increase in general and administrative expenses attributed to becoming a public company.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">14. Related Party Transactions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company rented an office in Northville, Michigan from an&nbsp;LLC owned by two officers under short&#8209;term agreements during the years ended December 31, 2016, 2015 and 2014. The original facility lease, as amended, was cancelled and replaced with a cancellable lease agreement in August 2016 for limited use of office space in the same Northville location. The new lease agreement became effective in August 2016 and expires in September 2017. Rent expense under the related party agreements was $21,000, $23,000 and $6,000 during the years ended December 31, 2016, 2015 and 2014, respectively. A prepaid rent balance related to the short&#8209;term agreements amounted to zero and $3,000 as of December&nbsp;31, 2016 and 2015, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the first quarter of 2015, the Company issued $2.0&nbsp;million of additional Convertible Notes (the 2015 Notes) as part of the Convertible Notes described in Note&nbsp;4&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Debt</font><font style="display:inline;">. The 2015 Notes included four notes in the aggregate of $0.3&nbsp;million issued to investors who were related to one board member and three officers of the Company. On March 31, 2015, all of the Convertible Notes (including the 2015 Notes) were converted into 516,421 shares of Series&nbsp;A preferred stock. The conversion included a total of 68,649 shares of Series&nbsp;A preferred stock issued to two officers of the Company, and 63,967 shares of Series&nbsp;A preferred stock issued to investors related to one board member and three officers of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the third quarter of 2015, the Company issued $2.8&nbsp;million of Interim Notes as described in Note&nbsp;4&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Debt</font><font style="display:inline;">. Such Interim Notes included five notes issued to two officers and three board members (or entities they control) in the amount of $0.5&nbsp;million. In addition, such Interim Notes included four notes to investors who were related to three of the Company&#x2019;s officers and to one of the Company&#x2019;s key employees in the amount of $0.3&nbsp;million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In December 2015, the Company issued an additional $2.7&nbsp;million of Interim Notes, as described in Note&nbsp;4&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Debt,</font><font style="display:inline;"> which included six notes issued to two officers and four board members in the amount of $0.6&nbsp;million. The December 2015 Interim Note issuances also included five notes to investors who were related to three of the Company&#x2019;s officers in the amount of $0.2&nbsp;million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February 2016, the Company issued an additional $0.2 million of Interim Notes, as described in Note&nbsp;4&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Debt,</font><font style="display:inline;"> which included two notes issued to two board members (or entities they control) in the amount of $81,000. The February 2016 Interim Note issuances also included a $20,000 note to an investor who is related to an officer of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2016, the Company issued an additional $5.0 million of Interim Notes, as described in Note&nbsp;4&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Debt,</font><font style="display:inline;"> which included two notes to investors who were related to two of the Company&#x2019;s officers in the aggregate amount of $0.2&nbsp;million. The April 2016 Interim Notes issuances also included three notes to investors who were related to three of the Company&#x2019;s directors in the aggregate amount of $2.3 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The IPO included 154,450 shares sold to 5 officers and 3 board members, totaling $1.5 million. In addition, 500,000 shares were sold to 1 investor who is related to 1 of the Company&#x2019;s directors, totaling $5.0 million, and 47,000 shares totaling $0.5 million were sold to 14 investors who are related to 5 officers of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">15. </font><font style="display:inline;font-weight:bold;">Subsequent Events</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 10 2017, the Company entered into a securities purchase agreement for a private placement with a select group of accredited investors whereby, on March 15, 2017 the Company issued and sold 1,324,256 units at a price of $9.47 per unit for gross proceeds of approximately $12.5 million. Each unit consists of one share of the Company&#x2019;s common stock and a warrant to purchase 0.75 shares of common stock. The warrants have an exercise price of $10.40 per share and are exercisable for a period of five years from the date of issuance. The private placement included 56,678 units sold to 3 board members, for aggregate proceeds totaling approximately $0.5 million and 52,798 units sold to 1 investor who is related to 1 board member, for proceeds totaling approximately $0.5 million.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">130</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Gemphire Therapeutics Inc.<br />(Formerly Known as Michigan Life Therapeutics, LLC)<br />Notes to Financial Statements - continued</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The securities were issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company have agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the private placement and issuable upon exercise of the warrant issued in the private placement.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">131</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 9.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND<a name="ITEM9CHANGESINANDDISAGREEMENTSWITHACCOUN"></a> FINANCIAL DISCLOSRE</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">None</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 9A.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>CONTROLS AND PROCEDURES<a name="ITEM9ACONTROLSANDPROCEDURES_927934"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;">Evaluation of Disclosure Controls and Procedures</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">We maintain disclosure controls and procedures that are designed to ensure that information we are required to disclose in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">We designed and evaluate our disclosure controls and procedures recognizing that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance and not absolute assurance of achieving the desired control objectives. </font><font style="display:inline;">Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:normal;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:inherit;color:#000000;">Under the supervision of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15(d)- 15(e) promulgated under the Securities Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;) as of December 31, 2016. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Management&#x2019;s Annual Report on Internal Control Over Financial Reporting</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">This annual report does not include a report of management&#x2019;s assessment regarding internal control over financial reporting or an attestation report of our registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;">Changes in Internal Control Over Financial Reporting</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the quarter ended&nbsp;December 31, 2016, that have materially affected, or are reasonably likely to materially affect, the Company&#x2019;s internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 9B.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>OTHER INFORMATION <a name="ITEM9BOTHERINFORMATION_848698"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">None</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">PART II<a name="PARTIII_373562"></a>I</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 10.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE<a name="ITEM10DIRECTORSEXECUTIVEOFFICERSANDCORPO"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The information required by this Item is included in and incorporated by reference from the Company&#x2019;s Definitive Proxy Statement (the &#x201C;Proxy Statement&#x201D;) for our 2017 Annual Meeting of Stockholders, which will be filed by the Company with the SEC within 120 days of the end of the fiscal year covered by this Report.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">132</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 11.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>EXECUTIVE COMPENSATION<a name="ITEM11EXECUTIVECOMPENSATION_915549"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The information required by this Item is included in and incorporated by reference from the Proxy Statement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 12.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 48pt 0pt 0pt;"></font>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT<a name="ITEM12SECURITYOWNERSHIPOFCERTAINBENEFICI"></a> AND RELATED STOCKHOLDER MATTERS</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The information required by this Item is included in and incorporated by reference from the Proxy Statement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 13. <font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 45pt 0pt 0pt;"></font>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR<a name="ITEM13CERTAINRELATIONSHIPSANDRELATEDTRAN"></a> INDEPENDENCE</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The information required by this Item is included in and incorporated by reference from the Proxy Statement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 14. <font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 45pt 0pt 0pt;"></font>PRINCIPAL ACCOUNTANT FEES AND SERVICES<a name="ITEM14PRINCIPALACCOUNTANTFEESANDSERVICES"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">The information required by this Item is included in and incorporated by reference from the Proxy Statement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">PART I<a name="PARTIV_999314"></a>V</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -72pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">ITEM 15.<font style="display:inline;font-weight:bold;color:#000000;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 48pt 0pt 0pt;"></font>EXHIBITS and FINANCIAL STATEMENT SCHEDULES<a name="ITEM15EXHIBITSandFINANCIALSTATEMENTSCHED"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">(a) The following documents are filed as part of this report:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;"> &nbsp; 1. Financial Statements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;"> &nbsp;&nbsp;&nbsp; See Index to Financial Statements at Item&nbsp;8 herein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;border-top:1pt none #D9D9D9 ;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;"> &nbsp; 2. Financial Statement Schedules</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="16" valign="bottom" style="width:99.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">SCHEDULE II</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="16" valign="bottom" style="width:99.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">VALUATION AND QUALIFYING ACCOUNTS</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="14" valign="bottom" style="width:68.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Beginning </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:34.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Additions</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Ending </font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Balance of</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:18.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Charged to </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Charged to</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Balance of</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Description</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Period</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:18.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Costs and Expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Paid in Capital</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Releases</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Period</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="16" valign="bottom" style="width:99.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For the Year Ended December 31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Valuation allowance for deferred taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For the Year Ended December 31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Valuation allowance for deferred taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,447
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,657
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For the Year Ended December 31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Valuation allowance for deferred taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,657
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,937
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(274)
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,320
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">No other financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes thereto.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">133</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;"> &nbsp; 3. Exhibits:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">EXHIBIT<br />NUMBER</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">DESCRIPTION OF DOCUMENT</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">3.1</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Third Amended and Restated Certificate of Incorporation of Gemphire Therapeutics Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K, File No. 001-37809, filed on August 10, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">3.2</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Amended and Restated Bylaws of Gemphire Therapeutics Inc. (incorporated by reference to Exhibit 3.2 to the Registrant&#x2019;s Current Report on Form 8-K, File No. 001-37809, filed on August 10, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">4.1</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant&#x2019;s Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">4.2</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Investor Rights Agreement, dated as of March 31, 2015, by and among the Registrant and the Investors listed therein as amended by First Amendment to Investor Rights Agreement, dated as of April 14, 2016 (incorporated by reference to Exhibit 4.2 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.1*</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.2*</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Amended and Restated 2015 Equity Incentive Plan (incorporated by reference to Exhibit&nbsp;10.3 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.3*</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of 2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit&nbsp;10.4 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June 13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.4*</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Employment Agreement by and between the Registrant and Mina Sooch (incorporated by reference to Exhibit&nbsp;10.5 to the Registrant's Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.5*</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Employment Agreement by and between the Registrant and Jeffrey&nbsp;S. Mathiesen (incorporated by reference to Exhibit&nbsp;10.6 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.6*</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Employment Agreement by and between the Registrant and Charles&nbsp;L. Bisgaier (incorporated by reference to Exhibit&nbsp;10.7 to the Registrant's Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.7*</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Executive Officer Employment Agreement (incorporated by reference to Exhibit&nbsp;10.8 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.8+</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">License Agreement, dated April 16, 2011, by and between the Registrant and Pfizer Inc. (incorporated by reference to Exhibit 10.9 to the Registrant&#x2019;s Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.9</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Office Space Sublease Agreement, dated as of January 1, 2015, by and between the Registrant and Michigan Life Ventures, LLC, as amended on May 6, 2015, August 31, 2015, September 25, 2015, October 23, 2015, December 16, 2015 and March 4, 2016 (incorporated by reference to Exhibit 10.10 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.10</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Lease Agreement, dated as of May 18, 2016 and commencing on August 1, 2016, by and between the&nbsp;&nbsp;&nbsp;Registrant and North Laurel Project, LLC (incorporated by reference to Exhibit&nbsp;10.11 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016). </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.11</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Note Purchase Agreement dated July 31, 2015 as amended on December 10, 2015, March 27, 2016 and April 14, 2016 (incorporated by reference to Exhibit 10.12 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.12</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Joinder Agreement to Note Purchase Agreement (incorporated by reference to Exhibit 10.13 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">134</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.13</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Fourth Amendment to Note Purchase Agreement and Convertible Promissory Notes dated April 26, 2016 (incorporated by reference to Exhibit 10.14 to the Registrant&#x2019;s Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.14*</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit&nbsp;10.15 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June 13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.15*</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Gemphire Therapeutics Inc. Inducement Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K, File No. 001-37809, filed on October 3, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.16*</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Gemphire Therapeutics Inc. Inducement Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Current Report on Form 8-K, File No. 001-37809, filed on October 3, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">23.1</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Consent of Ernst &amp;Young LLP.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">31.1</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of The Sarbanes Oxley Act of 2002</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">31.2</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of The Sarbanes Oxley Act of 2002</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">32.1</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.INS</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Instance Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.SCH</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Schema Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.CAL</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Calculation Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.DEF</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Definition Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.LAB</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Label Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.PRE</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Presentation Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">*</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Indicates management contract or compensatory plan.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.66%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">+</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.26%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Registrant has omitted and filed separately with the SEC portions of the exhibit pursuant to a confidential treatment request under Rule 406 promulgated under the Securities Act.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">135</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">SIGNATURES<a name="SIGNATURES_603331"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:50.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:44.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.58%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Date: March&nbsp;20, 2017</font></p>
				</td>
				<td colspan="2" valign="top" style="width:49.42%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">GEMPHIRE THERAPEUTICS&nbsp;INC.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.58%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.58%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:44.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.58%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.58%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">By:</font></p>
				</td>
				<td valign="top" style="width:44.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/S/ MINA SOOCH</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.58%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.58%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:44.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Mina Sooch</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.58%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:04.58%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:44.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-style:italic;">President and Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:33.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:33.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">SIGNATURE</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">TITLE</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">DATE</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ </font><font style="display:inline;text-transform:uppercase;">Mina Sooch</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">President and Chief Executive Officer </font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 20,&nbsp;2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Mina Sooch</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">(Principal&nbsp;Executive&nbsp;Officer)</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ </font><font style="display:inline;text-transform:uppercase;">Jeffrey S. Mathiesen</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Chief Financial Officer (Principal Financial and </font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 20, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Jeffrey S. Mathiesen</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accounting Officer)</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ </font><font style="display:inline;text-transform:uppercase;">Charles&nbsp;l. bisgaier, P</font><font style="display:inline;">h</font><font style="display:inline;text-transform:uppercase;">.D.</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;background-color: #FFFFFF;">Chief Scientific Officer and Chairman of the </font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 20, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Charles&nbsp;L. Bisgaier, Ph.D.</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;background-color: #FFFFFF;">Board of Directors</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">/s/ STEVE GULLANS, Ph.D.</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Member of the Board of Directors</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 20, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Steve Gullans, Ph.D.</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">/s/ P.&nbsp;KENT HAWRYLUK</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Member of the Board of Directors</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 20, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">P.&nbsp;Kent Hawryluk</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">/s/ KENNETH KOUSKY</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Member of the Board of Directors</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 20, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Kenneth Kousky</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">/s/ PEDRO LICHTINGER</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Member of the Board of Directors</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 20, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Pedro Lichtinger</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">/s/ ANDREW SASSINE</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Member of the Board of Directors</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">March 20, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:33.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;text-indent: -10pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">Andrew Sassine</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:42.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:20.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">136</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">EXHIBIT INDEX</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:26.10pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">EXHIBIT<br />NUMBER</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:26.10pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:26.10pt;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">DESCRIPTION OF DOCUMENT</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">3.1</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Third Amended and Restated Certificate of Incorporation of Gemphire Therapeutics Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K, File No. 001-37809, filed on August 10, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">3.2</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Amended and Restated Bylaws of Gemphire Therapeutics Inc. (incorporated by reference to Exhibit 3.2 to the Registrant&#x2019;s Current Report on Form 8-K, File No. 001-37809, filed on August 10, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">4.1</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant&#x2019;s Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">4.2</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Investor Rights Agreement, dated as of March 31, 2015, by and among the Registrant and the Investors listed therein as amended by First Amendment to Investor Rights Agreement, dated as of April 14, 2016 (incorporated by reference to Exhibit 4.2 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.1*</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.2*</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Amended and Restated 2015 Equity Incentive Plan (incorporated by reference to Exhibit&nbsp;10.3 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.3*</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of 2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit&nbsp;10.4 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June 13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.4*</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Employment Agreement by and between the Registrant and Mina Sooch (incorporated by reference to Exhibit&nbsp;10.5 to the Registrant's Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.5*</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Employment Agreement by and between the Registrant and Jeffrey&nbsp;S. Mathiesen (incorporated by reference to Exhibit&nbsp;10.6 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.6*</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Employment Agreement by and between the Registrant and Charles&nbsp;L. Bisgaier (incorporated by reference to Exhibit&nbsp;10.7 to the Registrant's Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.7*</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Executive Officer Employment Agreement (incorporated by reference to Exhibit&nbsp;10.8 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.8+</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">License Agreement, dated April 16, 2011, by and between the Registrant and Pfizer Inc. (incorporated by reference to Exhibit 10.9 to the Registrant&#x2019;s Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.9</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Office Space Sublease Agreement, dated as of January 1, 2015, by and between the Registrant and Michigan Life Ventures, LLC, as amended on May 6, 2015, August 31, 2015, September 25, 2015, October 23, 2015, December 16, 2015 and March 4, 2016 (incorporated by reference to Exhibit 10.10 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.10</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Lease Agreement, dated as of May 18, 2016 and commencing on August 1, 2016, by and between the&nbsp;&nbsp;&nbsp;Registrant and North Laurel Project, LLC (incorporated by reference to Exhibit&nbsp;10.11 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016). </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.11</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Note Purchase Agreement dated July 31, 2015 as amended on December 10, 2015, March 27, 2016 and April 14, 2016 (incorporated by reference to Exhibit 10.12 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.12</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Joinder Agreement to Note Purchase Agreement (incorporated by reference to Exhibit 10.13 to the Registrant&#x2019;s Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on April 18, 2016).</font></p>
				</td>
			</tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">137</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;color:#0563C1;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<a href="#Toc"><font style="display:inline;color:#0563C1;">Table of Contents</a></font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">Gemphire Therapeutics Inc.</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">(Formerly Known as Michigan Life Therapeutics, LLC)</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">Form 10-Q</font>

		</p>

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.13</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Fourth Amendment to Note Purchase Agreement and Convertible Promissory Notes dated April 26, 2016 (incorporated by reference to Exhibit 10.14 to the Registrant&#x2019;s Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June&nbsp;13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.14*</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit&nbsp;10.15 to the Registrant's Amendment No.&nbsp;1 to the Registration Statement on Form&nbsp;S-1, File No.&nbsp;333-210815, filed on June 13, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.15*</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Gemphire Therapeutics Inc. Inducement Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K, File No. 001-37809, filed on October 3, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">10.16*</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Form of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the Gemphire Therapeutics Inc. Inducement Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Current Report on Form 8-K, File No. 001-37809, filed on October 3, 2016).</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">23.1 </font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Consent of Ernst &amp; Young LLP</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">31.1</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of The Sarbanes Oxley Act of 2002</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">31.2</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a) or 15d-14(a), as Adopted Pursuant to Section 302 of The Sarbanes Oxley Act of 2002</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">32.1</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.INS</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Instance Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.SCH</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Schema Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.CAL</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Calculation Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.DEF</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Definition Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.LAB</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Label Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">101.PRE</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">XBRL Taxonomy Extension Presentation Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">*</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Indicates management contract or compensatory plan.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">+</font></p>
				</td>
				<td valign="top" style="width:02.06%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.38%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Registrant has omitted and filed separately with the SEC portions of the exhibit pursuant to a confidential treatment request under Rule 406 promulgated under the Securities Act.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-indent: -36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;">138</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>gemp-20161231ex231b352d6.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/20/2017 8:20:01 PM-->
<html>
	<head>
		<title>
			gemp_Ex_231
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;background-color: #FFFFFF;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Exhibit&nbsp;23.1</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Gemphire Therapeutics Inc.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Livonia, Michigan</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#222222;background-color: #FFFFFF;">We consent to the incorporation by reference in the Registration Statements </font><font style="display:inline;background-color: #FFFFFF;">(Form S-8 Nos.&nbsp;333-213946 and 333-213014)&nbsp;</font><font style="display:inline;color:#222222;background-color: #FFFFFF;">of Gemphire Therapeutics Inc. of our report dated March 20, 2017, with respect to the financial statements&nbsp;and schedule&nbsp;of Gemphire Therapeutics Inc. included in the Annual Report on Form 10-K for the year ended December 31, 2016.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">/s/ ERNST &amp; YOUNG LLP</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Detroit, Michigan</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">March 20, 2017</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>gemp-20161231ex3110a4a14.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/20/2017 8:20:05 PM-->
<html>
	<head>
		<title>
			gemp_Ex_311
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Exhibit 31.1</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a), AS ADOPTED PURSUANT TO</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">I, Mina Sooch, certify that:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">1. I have reviewed this annual report on Form 10-K of Gemphire Therapeutics Inc. for the period ended December 31, 2016;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">4. The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(b) [Intentionally Omitted];</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">5. The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s Board of Directors (or persons performing the equivalent functions):</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;line-height:100%;margin-bottom:0pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:49.60%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Date: March 20, 2017</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:47.22%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ MINA SOOCH</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.60%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.84%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Name:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.40%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Mina Sooch</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.60%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.84%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Title:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">President and Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:49.60%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:03.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.84%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:41.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">(Principal Executive Officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>gemp-20161231ex312866184.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/20/2017 8:20:08 PM-->
<html>
	<head>
		<title>
			gemp_Ex_312
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Exhibit 31.2</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">PURSUANT TO EXCHANGE ACT RULE 13a-14(a) OR 15d-14(a), AS ADOPTED PURSUANT TO</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">SECTION 302 OF THE SARBANES OXLEY ACT OF 2002</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">I, Jeffrey S. Mathiesen, certify that:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">1. I have reviewed this annual report on Form 10-K of Gemphire Therapeutics Inc. for the period ended December 31, 2016;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">4. The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(b) [Intentionally Omitted];</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(c) Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(d) Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">5. The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s Board of Directors (or persons performing the equivalent functions):</font>
		</p>
		<p style="margin:0pt;text-indent:18pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;line-height:100%;margin-bottom:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:49.60%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Date: March 20, 2017</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.58%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="width:47.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ JEFFREY S. MATHIESEN</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.60%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.58%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Name:</font></p>
				</td>
				<td valign="top" style="width:42.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Jeffrey S. Mathiesen</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.60%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.58%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:05.76%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Title:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:42.04%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Chief Financial Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:49.60%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.58%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:05.76%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:42.04%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">(Principal Financial Officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>gemp-20161231ex3211a9a7b.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--HTML document created with Merrill Bridge  6.4.50.0-->
<!--Created on: 3/20/2017 8:20:12 PM-->
<html>
	<head>
		<title>
			gemp_Ex_321
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Exhibit 32.1</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER,</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;font-size:10pt;">SARBANES-OXLEY ACT OF 2002*</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to the requirement set forth in Rule 13a-14(b) or Rule 15d-14(b) of the Securities and Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;), and Section 1350 of Chapter 63 of Title 18 of the United States Code, Mina Sooch, President and Chief Executive Officer of Gemphire Therapeutics Inc. (the &#x201C;Company&#x201D;), and Jeffrey&nbsp;S. Mathiesen, Chief Financial Officer of the Company, each hereby certify that, to the best of their knowledge:</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:1.45pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">1. The Company&#x2019;s Annual Report on Form 10-K for the period ended December 31, 2016, to which this Certification is attached as Exhibit 32.1 (the &#x201C;Annual Report&#x201D;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:1.45pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Annual Report and results of operations of the Company for the period covered by the Annual Report.</font>
		</p>
		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;line-height:100%;margin-bottom:0pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:49.88%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ MINA SOOCH</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.02%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:48.08%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">/s/ JEFFREY S. MATHIESEN</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.88%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">President and Chief Executive Officer</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.02%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.08%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Chief Financial Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:49.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:02.02%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:48.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:49.88%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Dated: March 20, 2017</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:02.02%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:48.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Dated: March 20, &nbsp;2017</font></p>
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:25%;height:1pt;color:#000;background-color:#000;" align="left"></hr></div>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Symbol;">&#xF02A;</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This certification accompanies the report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Gemphire Therapeutics Inc. under the Securities Act of 1933, as amended, or the Exchange Act made before or after the date of the report, irrespective of any general incorporation language contained in such filing.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 36pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gemp20161231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k001.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   =AU$2
M  0    !   =AP       8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,
M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_  !$(!/0): ,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M .O_ .$LLQ_RPN/R7_'V-'_"5V8_Y87'7'1?\?K7(?7\?\_G_G-'^3_G\_\
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M[8/^?\_Y]@#K_P#A+++_ )X7'Y+_ (_YY]*/^$KLS_RPN.N.B_X_2N1[Y/\
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M )Y]*/\ A*[,_P#+"XZXZ+_C]*Y'OD_Y_P _Y]D_S_G_ #_]8 Z__A++,_\
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MQ^(7_'_/-<@/;O\ Y'\Q^OM1UZ?A_G\1_G% '7_\)79Y_P!1<=?1?\?<4?\
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M++C]Q<<^H7_&C_A++/\ YX7'XA?\?\\UR ]O\^G]/S^M'T_#_/Y?YS0!U_\
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M_M ?H/\ '_.:SNOX_P"?Z_I[T =?_P )79Y_U%QU]%_Q]C1_PEEG_P \+C\
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M^QKD.OX_Y_K^GO1U_'_/]?T]Z .O_P"$LL_^>%Q^ 7_'_/%'_"667/[BXX]
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M_GA<?@%_Q_SQ1_PEEES^XN./0+_C7(#G'OT_3_']/>CK^/\ G^OZ>] '7_\
M"5V>?]1<=?1?\?8T?\)99_\ /"X_ +_C_GBN0Z_C_G^OZ>] YQ[]/T_Q_3WH
M Z__ (2RRY_<7''H%_QH_P"$KL\_ZBXZ^B_X^QKD.OX_Y_K^GO1U_'_/]?T]
MZ .O_P"$LL_^>%Q^ 7_'_/%'_"667/[BXX] O^-<@.<>_3]/\?T]Z.OX_P"?
MZ_I[T =?_P )79Y_U%QU]%_Q]C1_PEEG_P \+C\ O^/^>*Y#K^/^?Z_I[T#G
M'OT_3_']/>@#K_\ A+++G]Q<<>@7_&C_ (2NSS_J+CKZ+_C[&N0Z_C_G^OZ>
M]'7\?\_U_3WH Z__ (2RS_YX7'X!?\?\\4?\)99<_N+CCT"_XUR YQ[]/T_Q
M_3WHZ_C_ )_K^GO0!U__  E=GG_47'7T7_'V-'_"66?_ #PN/P"_X_YXKD.O
MX_Y_K^GO0.<>_3]/\?T]Z .O_P"$LLN?W%QQZ!?\:/\ A*[//^HN.OHO^/L:
MY#K^/^?Z_I[T=?Q_S_7]/>@#K_\ A++/_GA<?@%_Q_SQ1_PEEES^XN./0+_C
M7(#G'OT_3_']/>CK^/\ G^OZ>] '7_\ "5V>?]1<=?1?\?8T?\)99_\ /"X_
M +_C_GBN0Z_C_G^OZ>] YQ[]/T_Q_3WH Z__ (2RRY_<7''H%_QH_P"$KL\_
MZBXZ^B_X^QKD.OX_Y_K^GO1U_'_/]?T]Z .O_P"$LL_^>%Q^ 7_'_/%.C\46
M<DJQB&?+,%!P/\:XX<X]^GZ?X_I[U-:<W<'NZ_S'^/\ G- 'H]%%% &%XK_Y
M!<7_ %W!_1JX_I^'^?Z?Y[=AXK_Y!<7_ %V'_H+5Q_U_S_GG_/0 .GX?Y_I_
MGL=/P_S_ $_SV/K_ )_SS_GH?7_/^>?\]  Z?A_G^G^>QT_#_/\ 3_/8^O\
MG_//^>A]?\_YY_ST #I^'^?Z?Y['3\/\_P!/\]CZ_P"?\\_YZ'U_S_GG_/0
M.GX?Y_I_GL=/P_S_ $_SV/K_ )_SS_GH?7_/^>?\]  Z?A_G^G^>QT_#_/\
M3_/8^O\ G_//^>A]?\_YY_ST #I^'^?Z?Y['3\/\_P!/\]CZ_P"?\\_YZ'U_
MS_GG_/0 .GX?Y_I_GL=/P_S_ $_SV/K_ )_SS_GH?7_/^>?\]  Z?A_G^G^>
MQT_#_/\ 3_/8^O\ G_//^>A]?\_YY_ST #I^'^?Z?Y['3\/\_P!/\]CZ_P"?
M\\_YZ'U_S_GG_/0 .GX?Y_I_GL=/P_S_ $_SV/K_ )_SS_GH?7_/^>?\]  Z
M?A_G^G^>QT_#_/\ 3_/8^O\ G_//^>A]?\_YY_ST #I^'^?Z?Y['3\/\_P!/
M\]CZ_P"?\\_YZ'U_S_GG_/0 .GX?Y_I_GL=/P_S_ $_SV/K_ )_SS_GH?7_/
M^>?\]  Z?A_G^G^>QT_#_/\ 3_/8^O\ G_//^>A]?\_YY_ST #I^'^?Z?Y['
M3\/\_P!/\]CZ_P"?\\_YZ'U_S_GG_/0 .GX?Y_I_GL=/P_S_ $_SV/K_ )_S
MS_GH?7_/^>?\]  Z?A_G^G^>QT_#_/\ 3_/8^O\ G_//^>A]?\_YY_ST #I^
M'^?Z?Y['3\/\_P!/\]CZ_P"?\\_YZ'U_S_GG_/0 .GX?Y_I_GL=/P_S_ $_S
MV/K_ )_SS_GH?7_/^>?\]  Z?A_G^G^>QT_#_/\ 3_/8^O\ G_//^>A]?\_Y
MY_ST #I^'^?Z?Y['3\/\_P!/\]CZ_P"?\\_YZ'U_S_GG_/0 .GX?Y_I_GL=/
MP_S_ $_SV/K_ )_SS_GH?7_/^>?\]  Z?A_G^G^>QT_#_/\ 3_/8^O\ G_//
M^>A]?\_YY_ST #I^'^?Z?Y['3\/\_P!/\]CZ_P"?\\_YZ'U_S_GG_/0 .GX?
MY_I_GL=/P_S_ $_SV/K_ )_SS_GH?7_/^>?\]  Z?A_G^G^>QT_#_/\ 3_/8
M^O\ G_//^>A]?\_YY_ST #I^'^?Z?Y['3\/\_P!/\]CZ_P"?\\_YZ'U_S_GG
M_/0 .GX?Y_I_GL=/P_S_ $_SV/K_ )_SS_GH?7_/^>?\]  Z?A_G^G^>QT_#
M_/\ 3_/8^O\ G_//^>A]?\_YY_ST #I^'^?Z?Y['3\/\_P!/\]CZ_P"?\\_Y
MZ'U_S_GG_/0 .GX?Y_I_GL=/P_S_ $_SV/K_ )_SS_GH?7_/^>?\]  Z?A_G
M^G^>QT_#_/\ 3_/8^O\ G_//^>A]?\_YY_ST #I^'^?Z?Y['3\/\_P!/\]CZ
M_P"?\\_YZ'U_S_GG_/0 .GX?Y_I_GL=/P_S_ $_SV/K_ )_SS_GH?7_/^>?\
M]  Z?A_G^G^>QT_#_/\ 3_/8^O\ G_//^>A]?\_YY_ST #I^'^?Z?Y[*.H_S
MZ?X?Y[)]?\_YY_ST7O\ Y_SW_G0!O^+/^/V#_KG_ %/^?\Y'/_Y_S_G_ .MT
M'BS_ (_8/^N?]3_G_.1S_P#G_/\ G_ZP ?Y_S_G_ .L?Y_S_ )_^L?Y_S_G_
M .L?Y_S_ )_^L '^?\_Y_P#K'^?\_P"?_K'^?\_Y_P#K'^?\_P"?_K !_G_/
M^?\ ZQ_G_/\ G_ZQ_G_/^?\ ZQ_G_/\ G_ZP ?Y_S_G_ .L?Y_S_ )_^L?Y_
MS_G_ .L?Y_S_ )_^L '^?\_Y_P#K'^?\_P"?_K'^?\_Y_P#K'^?\_P"?_K !
M_G_/^?\ ZQ_G_/\ G_ZQ_G_/^?\ ZQ_G_/\ G_ZP ?Y_S_G_ .L?Y_S_ )_^
ML?Y_S_G_ .L?Y_S_ )_^L '^?\_Y_P#K'^?\_P"?_K'^?\_Y_P#K'^?\_P"?
M_K !_G_/^?\ ZQ_G_/\ G_ZQ_G_/^?\ ZQ_G_/\ G_ZP ?Y_S_G_ .L?Y_S_
M )_^L?Y_S_G_ .L?Y_S_ )_^L '^?\_Y_#L>A\4?>LAT/EG@=NG_ -;\A7/?
MY_S_ )_#L>A\4?>LA_TS/'Y?Y_SP <]UZ?I_GW'Y#\#]/Z?Y_I^1^O\ G_/Y
M_D?Y_P _Y_\ K !^G]/\_P!/R/T_I_G^GY'^?\_Y_P#K'^?\_P"?_K !^G]/
M\_T_(_3^G^?Z?D?Y_P _Y_\ K'^?\_Y_^L 'Z?T_S_3\C]/Z?Y_I^1_G_/\
MG_ZQ_G_/^?\ ZP ?I_3_ #_3\C]/Z?Y_I^1_G_/^?_K'^?\ /^?_ *P ?I_3
M_/\ 3\C]/Z?Y_I^1_G_/^?\ ZQ_G_/\ G_ZP ?I_3_/]/R/T_I_G^GY'^?\
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M\_Y_S_\ 7/\ /^?\_P#US_/^?\_UH_S_ )_S_6@ _P _Y_S_ /7/\_Y_S_\
M7/\ /^?\_P!:/\_Y_P _UH /\_Y_S_\ 7/\ /^?\_P#US_/^?\_UH_S_ )_S
M_6@ _P _Y_S_ /7/\_Y_S_\ 7/\ /^?\_P!:/\_Y_P _UH /\_Y_S_\ 7/\
M/^?\_P#US_/^?\_UH_S_ )_S_6@ _P _Y_S_ /7/\_Y_S_\ 7/\ /^?\_P!:
M/\_Y_P _UH /\_Y_S_\ 7/\ /^?\_P#US_/^?\_UH_S_ )_S_6@ _P _Y_S_
M /7/\_Y_S_\ 7/\ /^?\_P!:/\_Y_P _UH /\_Y_S_\ 7/\ /^?\_P#US_/^
M?\_UH_S_ )_S_6@ _P _Y_S_ /7Z'7?^03I?&?W8_DM<_P!_\_Y_S]:Z#7?^
M03I?_7,?R6@#GAVSS_7I_P#7_/ZT?7\?\_G^?UH_S_G_ #_2C_/^?\__ %@
M^OX_Y_/\_K1]?Q_S^?Y_6C_/^?\ /_UC_/\ G_/_ -8 /K^/^?S_ #^M'U_'
M_/Y_G]:/\_Y_S_\ 6/\ /^?\_P#U@ ^OX_Y_/\_K1]?Q_P _G^?UH_S_ )_S
M_P#6/\_Y_P __6 #Z_C_ )_/\_K1]?Q_S^?Y_6C_ #_G_/\ ]8_S_G_/_P!8
M /K^/^?S_/ZT?7\?\_G^?UH_S_G_ #_]8_S_ )_S_P#6 #Z_C_G\_P _K1]?
MQ_S^?Y_6C_/^?\__ %C_ #_G_/\ ]8 /K^/^?S_/ZT?7\?\ /Y_G]:/\_P"?
M\_\ UC_/^?\ /_U@ ^OX_P"?S_/ZT?7\?\_G^?UH_P _Y_S_ /6/\_Y_S_\
M6 #Z_C_G\_S^M'U_'_/Y_G]:/\_Y_P __67]/\_Y_+\@!/K^/^?S_/ZT?7\?
M\_G^?UI1VS^/Z?\ U_UI!VS[9S^'_P!?]: .@UC/_"/:9Z[1GC_9K _S_G_/
M\ZW]8S_PCVE^NP9X_P!FN?\ \^O^?\^M !_G_/\ G_ZY_G_/^?\ ZZ]_\G_/
M^?Q3_/\ G_/_ -< /\_Y_P __7/\_P"?\_\ US_/^?\ /_US_/\ G_/_ -<
M/\_Y_P __7/\_P"?\_\ US_/^?\ /_US_/\ G_/_ -< /\_Y_P __7/\_P"?
M\_\ US_/^?\ /_US_/\ G_/_ -< /\_Y_P __7/\_P"?\_\ US_/^?\ /_US
M_/\ G_/_ -< /\_Y_P __7/\_P"?\_\ US_/^?\ /_US_/\ G_/_ -< /\_Y
M_P __7/\_P"?\_\ US_/^?\ /_US_/\ G_/_ -< /\_Y_P __7/\_P"?\_\
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M1_G_ #_G_P"N?Y_S_G_ZX #MCV_I_P#6H';'M_3_ .M1_G_/^?\ ZY_G_/\
MG_ZX #MCV_I_]:@=L>W]/_K4?Y_S_G_ZY_G_ #_G_P"N  [8]OZ?_6H';'M_
M3_ZU'^?\_P"?_KG^?\_Y_P#K@ .V/;^G_P!:@=L>W]/_ *U'^?\ /^?_ *Y_
MG_/^?_K@ .V/;^G_ -:@=L>W]/\ ZU'^?\_Y_P#KG^?\_P"?_K@ .V/;^G_U
MJ!VQ[?T_^M1_G_/^?_KG^?\ /^?_ *X #MCV_I_]:@=L>W]/_K4?Y_S_ )_^
MN?Y_S_G_ .N  [8]OZ?_ %J!VQ[?T_\ K4?Y_P _Y_\ KG^?\_Y_^N  [8]O
MZ?\ UJ!VQ[?T_P#K4?Y_S_G_ .N?Y_S_ )_^N  [8]OZ?_6H';'M_3_ZU'^?
M\_Y_^N?Y_P _Y_\ K@ .V/;^G_UJ!VQ[?T_^M1_G_/\ G_ZY_G_/^?\ ZX #
MMCV_I_\ 6H';'M_3_P"M1_G_ #_G_P"N?Y_S_G_ZX #MCV_I_P#6H';'M_3_
M .M1_G_/^?\ ZY_G_/\ G_ZX #MCV_I_]:@=L>W]/_K4?Y_S_G_ZY_G_ #_G
M_P"N  [8]OZ?_6H';'M_3_ZU'^?\_P"?_KG^?\_Y_P#K@ .V/;^G_P!:@=L>
MW]/_ *U'^?\ /^?_ *Y_G_/^?_K@ .V/;^G_ -:@=L>W]/\ ZU'^?\_Y_P#K
MG^?\_P"?_K@ .V/;^G_UJ!VQ[?T_^M1_G_/^?_KG^?\ /^?_ *X #MCV_I_]
M:@=L>W]/_K4?Y_S_ )_^N?Y_S_G_ .N  [8]OZ?_ %J!VQ[?T_\ K4?Y_P _
MY_\ KG^?\_Y_^N  [8]OZ?\ UJ!VQ[?T_P#K4?Y_S_G_ .N?Y_S_ )_^N  [
M8]OZ?_6H';'M_3_ZU'^?\_Y_^N?Y_P _Y_\ K@ .V/;^G_UJ!VQ[?T_^M1_G
M_/\ G_ZY_G_/^?\ ZX #MCV_I_\ 6H';'M_3_P"M1_G_ #_G_P"N?Y_S_G_Z
MX #MCV_I_P#6H';'M_3_ .M1_G_/^?\ ZY_G_/\ G_ZX #MCV_I_]:@=L>W]
M/_K4?Y_S_G_ZY_G_ #_G_P"N  [8]OZ?_6H';'M_3_ZU'^?\_P"?_KG^?\_Y
M_P#K@ .V/;^G_P!:@=L>W]/_ *U'^?\ /^?_ *Y_G_/^?_K@ .V/;^G_ -:@
M=L>W]/\ ZU'^?\_Y_P#KG^?\_P"?_K@ .V/;^G_UJ!VQ[?T_^M1_G_/^?_KG
M^?\ /^?_ *X #MCV_I_]:@=L>W]/_K4?Y_S_ )_^N?Y_S_G_ .N  [8]OZ?_
M %J!VQ[?T_\ K4?Y_P _Y_\ KG^?\_Y_^N  [8]OZ?\ UJ!VQ[?T_P#K4?Y_
MS_G_ .N?Y_S_ )_^N  [8]OZ?_6H';'M_3_ZU'^?\_Y_^N?Y_P _Y_\ K@ .
MV/;^G_UJ!VQ[?T_^M1_G_/\ G_ZY_G_/^?\ ZX #MCV_I_\ 6H';'M_3_P"M
M1_G_ #_G_P"N?Y_S_G_ZX #MCV_I_P#6H';'M_3_ .M1_G_/^?\ ZY_G_/\
MG_ZX #MCV_I_]:@=L>W]/_K4?Y_S_G_ZY_G_ #_G_P"N  [8]OZ?_6J:T_X^
MX.?XUZCW7_ZU0_YY_P _Y_G-:_\ 'Y!_UT7M[C_Z_P"M 'H]%%% &%XK_P"0
M7%_UW'\FKC^G^?\ /I^GUKL/%?\ R"XO^NX_DU<?T_#_ #_3]/K0 ?Y_S_G_
M .L?Y_S_ )_^L?T_S_G_ #@_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\
MG_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]
M8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/
M^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_
M -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\
M_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\
M/_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_
MS_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?
M\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC
M_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_
M #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\
MUC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\
MG_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]
M8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/
M^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_
M -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\
M_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\
M/_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_
MS_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?
M\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC
M_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_
M #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\
MUC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\
MG_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]
M8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/
M^?\ /_UC_/\ G_/_ -9>^,?YX_Q'^<4 '?&/\\?XC_.*0=N_3K^'^/ZG\0=N
M_3K^'^/ZG\0=N_3K^'^/ZG\0#H/%G_'[!_US_J?\_P"<CG_\_P"?\_\ UN@\
M6?\ '[!_US_J?\_YR.?_ ,_Y_P __6 #_/\ G_/_ -8_S_G_ #_]8_S_ )_S
M_P#6/\_Y_P __6 #_/\ G_/_ -8_S_G_ #_]8_S_ )_S_P#6/\_Y_P __6 #
M_/\ G_/_ -8_S_G_ #_]8_S_ )_S_P#6/\_Y_P __6 #_/\ G_/_ -8_S_G_
M #_]8_S_ )_S_P#6/\_Y_P __6 #_/\ G_/_ -8_S_G_ #_]8_S_ )_S_P#6
M/\_Y_P __6 #_/\ G_/_ -8_S_G_ #_]8_S_ )_S_P#6/\_Y_P __6 #_/\
MG_/_ -8_S_G_ #_]8_S_ )_S_P#6/\_Y_P __6 #_/\ G_/_ -8_S_G_ #_]
M8_S_ )_S_P#6/\_Y_P __6 #_/\ G_/_ -8_S_G_ #_]8_S_ )_S_P#6/\_Y
M_P __6 #_/\ G_/_ -8_S_G_ #_]8_S_ )_S_P#6/\_Y_P __6 #_/\ G_/X
M=CT/BC[UD/\ IF>/R_S_ )XY[_/^?\_AV/0^*/O60_Z9GC\O\_YX .>_7_/^
M?S]^#_\ 7_G]/\]#]?\ /^?S]^#]?\_Y_/\ ( /\_P"?\_\ UC_/^?\ /_UC
M_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_
M #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\
MUC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\
MG_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]
M8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/
M^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 7OZ?Y_S_GHG48/&>OM_G)_*C_/^?\
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M_K'^?\_Y_P#K'^?\_P"?_K !_G_/^?\ ZQ_G_/\ G_ZQ_G_/^?\ ZQ_G_/\
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M?Z?I^8 ?7_/^>?\ /0^O^?\ //\ GH=/;'^?Z?I^9^G^?\_E[<@"]\?Y[_\
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M_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\
MUS_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_
M )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P _
M_7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/
M^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S
M_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\
M_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\
M/_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7
M/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?
M\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP
M _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y
M_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\
MUS_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_
M )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P _
M_7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/
M^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S
M_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\
M_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\
M/_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7
M/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?
M\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP
M _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y
M_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\
MUS_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_
M )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P _
M_7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/
M^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S
M_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\
M_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\
M/_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7
M/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?
M\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP
M _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y
M_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\
MUS_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_
M )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\\_Y_S_
M #/\\_Y_S_-0>0>G^?\ ]?Z_6@ !Y!Z?Y_\ U_K]:EM/^/N#V=>OU'^'Z'\(
M1V[=.OX?X?H?PFM/^/N#V=>OU'^'Z'\ #T>BBB@#"\5_\@N+_KL/_06KC_\
M/^?\_P#UNP\5_P#(+B_Z[#_T%JX__/\ G_/_ -8 /\_Y_P __6/\_P"?\_\
MUC_/^?\ /_UC_/\ G_/_ -8 /\_Y_P __6/\_P"?\_\ UC_/^?\ /_UC_/\
MG_/_ -8 /\_Y_P __6/\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8 /\_Y_P _
M_6/\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8 /\_Y_P __6/\_P"?\_\ UC_/
M^?\ /_UC_/\ G_/_ -8 /\_Y_P __6/\_P"?\_\ UC_/^?\ /_UC_/\ G_/_
M -8 /\_Y_P __6/\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8 /\_Y_P __6/\
M_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8 /\_Y_P __6/\_P"?\_\ UC_/^?\
M/_UC_/\ G_/_ -8 /\_Y_P __6/\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8
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M_P __6/\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8 /\_Y_P __6/\_P"?\_\
MUC_/^?\ /_UC_/\ G_/_ -8 /\_Y_P __6/\_P"?\_\ UC_/^?\ /_UC_/\
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MYQGOC^G^)_.M*/0=3=0RVK =MS*#V[$^P_ST@N=.O+'!G@9!Q@Y!';N/H/\
M/0 J#G&>^/Z?XG\Z!SC/?']/\3^='3IV_P _T'^3P=.G;_/]!_D\ '0>(O\
MCRTO_KF>/P7_ #_G%8'?(_S_ )_S[]!XCQ]ETL#_ )YG!_[XKGAV_#^G^?PH
M ?%%)-(L<2,[GHJ#)/\ G'^>\XTV^X_T*Y_[]-[>W^>/>KWAG_D,)_US;^0_
MS^%:^LZW<Z;?+#%'$R% QW@YZGW]J .3DBDA?9)&R,/X6&#_ )Z?YZ:%AHES
MJ%L9X9(54'&'8@]CZ?Y_ETMTL.L:$960*2A=">2C#_.*@\,G_B3O_P!=&[^P
MH X[MG_/^?\ /T/\_P"?\_\ UM"'1=1GB65+5MI&06(![>IS5.6&2"5HY4*.
MO52/\^W^>@!'_G_/^?\ ZQ_G_/\ G_ZU^'1=1N(Q)';,5/()(7/TR1_G]&W.
MDWUG'YDUNRH.K @@?ET_S^ !2_S_ )_S_P#6/\_Y_P __6DA@EN)!'#&SOZ*
M/\_Y_2^= U11G[*>/1U/]?\ /\@#,_S_ )_S_P#6/\_Y_P __6<JLS!54EB<
M  <_YZ?YZ:"Z!J;*&%J<$9&74'\L_P"?Y &;_G_/^?\ ZQ_G_/\ G_ZTDT$M
MO*8Y8V1UZAAC_/;_ #TC_P _Y_S_ /6 'QQ23/LBC=V]%4D_Y_S]))+.ZA3?
M+;31H/XFC('^?\_34M->73].C@MK9?.YWN_0]?3K^E=#H^HG5+-GEC565MK
M9VG\Z .(MX&N;B.!" SL%!/0?Y_S[6=1TN?3#&)GC8R9QL)/3'L/4?YZ6O(2
MW\5+%$ $6=< =NAQ_GT^F-3Q+:SWEQ9Q01-(V') Z#E>M ')_P"?\_Y_^L?Y
M_P _Y_\ K7KG2;^TB\V>W94'4@@X^N#Q_G\*/^?\_P"?_K !_G_/^?\ ZW0Z
M]QI&EG_IG_[*#_2N>_S_ )_S_P#6Z'7?^03I?KY8_DM '/=/P_S_ $_7VHZ?
MA_G^GZ^U'^?\_I_GH?Y_S_G_ .L +T_#O_GZ9_R*L)87CJ&2TG92,@B,X/\
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M\_\ UC_/^?\ /_UG.CQ.4=2K*<$$8(_S_GVO0Z)J,\2R1VK;3TRP7]"1_G]
M#/\ \_Y_S_\ 6/\ /^?\_P#UI[JSN+*01W$9C8C(Y']/I_GM+:Z9>WB[K>!G
M4?Q9 'X$X_S^@!3_ ,_Y_P __6/\_P"?\_\ UKEUI=[9('GMV5?[P(('XCI_
MG\*?^?\ /^?_ *P O? _S_G_ #[6%T^]90RVEP5(R"(CS^G^?Y3:5>0V-X9I
M8?-PN$ QUXP>?Y_2MFQ\2SW.H1PO!&(I&"C;G<,__K'ZT <RRLC%6!##J,?Y
M_P X]L-_SQ_G_/'MCJ?%D$?D03@ 2;RI]2,?_6_6N7Z'_(_S_GWH .G^?\_Y
M/O2=.G;_ #_0?Y/!_G_/Y#_(X7_/^?\ /8>E '0:QQX>TP?[(_\ 0:Y[_/\
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M?\__ %S_ #_G_/\ ]<_S_G_/_P!< /\ /^?\_P#US_/^?\__ %S_ #_G_/\
M]<_S_G_/_P!< /\ /^?\_P#US_/^?\__ %S_ #_G_/\ ]<_S_G_/_P!< /\
M/^?\_P#US_/^?\__ %S_ #_G_/\ ]<_S_G_/_P!< /\ /^?\_P#US_/^?\__
M %S_ #_G_/\ ]<_S_G_/_P!< /\ /^?\_P#US_/^?\__ %S_ #_G_/\ ]<_S
M_G_/_P!< /\ /^?\_P#US_/^?\__ %S_ #_G_/\ ]<_S_G_/_P!< /\ /^?\
M_P#US_/^?\__ %S_ #_G_/\ ]<_S_G_/_P!< /\ /^?\_P#US_/^?\__ %S_
M #_G_/\ ]<_S_G_/_P!< /\ /^?\_P#US_/^?\__ %S_ #_G_/\ ]<_S_G_/
M_P!< /\ /^?\_P#UW*K.P5068] !G/\ G_/NWW_$_P"?\_X['ART^T:HKL/E
MA&\_7D#]>?PH SY+&[B1GDM9T1>K-&0!_G_/O!_G_/\ G_Z_H/F0Z@EW:Y^X
M?+;\NO\ GTK@)8VBE>-P R$@_AG_ .O_ )Z@#/\ /^?\_P#US_/^?\__ %[K
M:5>K;+<& ^4^-I# YSTXSGO_ )[R?V%J?E^9]D;;C.-PS^6<_P"?S ,[_/\
MG_/_ -<_S_G_ #_]>Y8V,]W=B..'>4.9%) XS@]3]?\ .:Z76]'$]HBV-G$)
M ^6V!4.,'Z>M '+6EC<WSLEM%YA49/( 'XG_ #U]\LN+>6UG:&=-LB]1G/\
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M )_^N?Y_S_G_ .NY5+L%499C@ =3_G_/OH'0]36/S#:/MQG 89_+.<]?\YH
M6;0[F'3Q>M)"8RH; 8[L'\/?_/?,_P _Y_S_ /7[2_R/"N">?)0$$8]*XO\
MS_G_ #_]< DB@FN&*PQ/(P&2$4MQ^'^?ZNFM+F!=TUO+&I[NA _7_/\ 7<\)
M_P#'W<G_ &!_/_\ 56[=HNHV5W;  NIVC/\ >&"/Z4 <#WP?\_Y_S[S16ES.
MF^&WED7.,HA(_P _Y^L01F81JOS'@#_/U'ZUW]NJ6$5I9@?,P(_(9)_/^= '
M!/!,DHB>)UD)P$92#S[?Y_QL76EWMG$);B'8C' .X'G\"?\ /ZZ7B5F36HF4
M_,L:D?FW_P!?]*-:N-7:S5+Z".*(N.4/4X/N?<]/\* *D6AW4VG_ &U7B\O:
M6P6.<#/MC_/YYO\ G_/^?_K]E8?\BKC_ *9/QCW/^?\ &N/CC>5PD:EW;H ,
MD_Y_S[@#/\_Y_P __7/\_P"?\_\ U]/^P-4*Y^RGD9Y=?\?\_P \^2-XI&CD
M1D=3@JPY'^?Z_F ,_P _Y_S_ /7/\_Y_S_\ 7OP:-J%S$)(K9BAZ%B%S^9_S
M_-&TB^2Y2W:W(ED!*@L.?7G./\_F 4?\_P"?\_\ US_/^?\ /_U^TNM(1]%$
M<5G"+KRU&0J@Y[\_G7)7-I/9S>3/&4D(SC(.<_3/^?U (/\ /^?\_P#US_/^
M?\__ %]&/0]2F0.MJV#_ 'F"G\B?\_SKW5C=61 N(63/0GD'\?\ /^(!6_S_
M )_S_P#7/\_Y_P __7MVNFW=[&TEO%O13ACN _F?\_SD@T;4+F(216S%#T+$
M+G\S_G^8!0_S_G_/_P!<_P _Y_S_ /7EGMYK:4Q3QLCCL?\ /^?YOM;*YO6*
MV\328ZD=!]3T_P G\0"O_G_/^?\ ZY_G_/\ G_Z]^?1M0MXS)+;,%'4@AL?D
M3_G]:<<;RN$C4N[= !DG_/\ GW &?Y_S_G_ZY_G_ #_G_P"OI_V!JA7/V4\C
M/+K_ (_Y_GGO&\<C(ZE64X8'L?\ .?\ /4 9_G_/^?\ ZY_G_/\ G_ZY_G_/
M^?\ ZY_G_/\ G_ZX ?Y_S_G_ .N?Y_S_ )_^N?Y_S_G_ .N?Y_S_ )_^N '^
M?\_Y_P#KG^?\_P"?_KG^?\_Y_P#KG^?\_P"?_K@!_G_/^?\ ZY_G_/\ G_ZY
M_G_/^?\ ZY_G_/\ G_ZX ?Y_S_G_ .N?Y_S_ )_^N?Y_S_G_ .N?Y_S_ )_^
MN '^?\_Y_P#KG^?\_P"?_KG^?\_Y_P#KG^?\_P"?_K@!_G_/^?\ ZY_G_/\
MG_ZY_G_/^?\ ZY_G_/\ G_ZX ?Y_S_G_ .N?Y_S_ )_^N?Y_S_G_ .N?Y_S_
M )_^N '^?\_Y_P#KG^?\_P"?_KG^?\_Y_P#KG^?\_P"?_K@!_G_/^?\ ZY_G
M_/\ G_ZY_G_/^?\ ZY_G_/\ G_ZX ?Y_S_G_ .N?Y_S_ )_^N?Y_S_G_ .N?
MY_S_ )_^N '^?\_Y_P#KG^?\_P"?_KG^?\_Y_P#KG^?\_P"?_K@!_G_/^?\
MZY_G_/\ G_ZY_G_/^?\ ZZ]3_G_/^?S #OD?Y_S_ )]T^G^?\\?YZJ.W^?3_
M #^(I!V_#I^'^?Q'IP 'T_S_ )X_SUFM>;R' _Y:+_/_ #^GMF$=OPZ?A_G\
M1Z<36G_'U#W^=?YC_/Y>G !Z/1110!A>*_\ D%Q?]=A_Z"U<?_G_ #_G_P"M
MV'BO_D%Q?]=A_P"@M7'_ .?\_P"?_K !_G_/^?\ ZQ_G_/\ G_ZQ_G_/^?\
MZQ_G_/\ G_ZP ?Y_S_G_ .L?Y_S_ )_^L?Y_S_G_ .L?Y_S_ )_^L '^?\_Y
M_P#K'^?\_P"?_K'^?\_Y_P#K'^?\_P"?_K !_G_/^?\ ZQ_G_/\ G_ZQ_G_/
M^?\ ZQ_G_/\ G_ZP ?Y_S_G_ .L?Y_S_ )_^L?Y_S_G_ .L?Y_S_ )_^L '^
M?\_Y_P#K'^?\_P"?_K'^?\_Y_P#K'^?\_P"?_K !_G_/^?\ ZQ_G_/\ G_ZQ
M_G_/^?\ ZQ_G_/\ G_ZP ?Y_S_G_ .L?Y_S_ )_^L?Y_S_G_ .L?Y_S_ )_^
ML '^?\_Y_P#K'^?\_P"?_K'^?\_Y_P#K'^?\_P"?_K !_G_/^?\ ZQ_G_/\
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M #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\
MUC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\
MG_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]
M8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/
M^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_
M -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\
M_P"?\_\ UC_/^?\ /_UC_/\ G_/_ -8_S_G_ #_]8 /\_P"?\_\ UC_/^?\
M/_UC_/\ G_/_ -9>^!_G_/\ GV -_P 6?\?L'_7/I^)_S^-<_P#K_7_/]?SZ
M#Q9_Q^P?]<_ZFN?_ ,_Y_P _UH /U_K_ )_K^;T_UB]^?S_S_7\V?Y_S_G^M
M.7[XSZ_Y_P __7H [S4]._M*R6W$OEX;=NVY[$=./6J]O%8^'[5S)/EVY8G[
MS>P'X_K47BC_ )!2Y'_+0?R/^?PKCNGM_G_/^>@!TF@W#7FNW-PPP70G'7 R
M./Y?Y-2:WKEU:WWV>V*H$ W-@-DG%5/"O_(2D_ZY'^8_S_G%0>(O^0W-ZX7^
M0_\ K?YZ@&]J["[\-&9U 9D5P/<X_P :Q]%EU4V\D-C'&$+;C*XZ'Z__ %JU
MKS_D4AVS"G]*7P^XET/RX7"2KN!..58]"1_GI0!9L(M5CF;[=<0RQD<;!@@_
MD*Q[OR+?Q<CRX6,[22>F2",_G_.M/3;&]M;AY;V^,H;*JF]B/U]O:LO5;,W_
M (E6W$GEEXQ\V,] 3_GZT ;&IQZJ65]/F0*!\T949)^I_P#K5ST8N-4\00QW
M\81U&&4+C@#/]:U]-TK4K"Y4?;$:U'5.3D?3''X&H-5OX+?Q!:."I,0VRD<X
MR?YC/ZT :E_%J+[$L)8(4 ^8L.?PX(Q226\\^C2PWYB>4QD%DS@\<'MS46I6
M5S?K'/8WS1<=!(P5AZ\'^E9D^DZE!832W&J2$(A)02,P;VR2* .;ZG_/^?\
M/YI_G_/^?_KG^?\ /^?ZU;L-/EU*=H8616"EB7/^?7_/- '3>&>-'?\ ZZ-_
M(5R,G^L;ZG_/^?\ ]?<Z/82Z?8-!*R%BY;*$XZ#Z5R^I:+<Z?$;B5XF1GQA2
M2>Y[C_/\P#+_ ,_Y_P __7/\_P"?\_\ USZ_Y_SS_GJ?7_/^>?\ /4 /\_Y_
MS_\ 7Z'Q1]ZRY_Y9GD_A_G\/RY[Z_P"?\\_YZ]#XH^]9<_\ +,_T_P __JX
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MMZ_XU0T74;<:M>1*P6.>3=$<\$^@^O\ 3%37ND:G)<N]KJ+K&QR$:5QM]N*
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M\_S^M '0:N<^'=+YZJOY[?\ /^>:Y_Z?Y_SQ_GIT.L?\B]IF?[HSG_=KGO\
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M_"NVU%1JF@>8G4H)5 ]1SBN([8_S_G_/U #_ #Q_G_/'MD_SQ_G_ #Q[9/\
M/^?\_P#US_/^?\__ %P _P \?Y_SQ[9/T_S_ /6/Y"E_S_G_ #_.D_S_ )_S
M_.@ /?/OG'X__7_2M#1?^0U;9Z[_ .A_^O\ I6?_ )Y_S_GGZ5H:)_R&;7C/
MS_T/^?SH 77?^0U=#_:'\A_G_/.=_G_/^?\ Z^CKO_(:N?\ >'\A_G_/.=_G
M_/\ G_ZX ?Y_S_G_ .N?Y_S_ )_^N?Y_S_G_ .N?Y_S_ )_^N '^?\_Y_P#K
MG^?\_P"?_KG^?\_Y_P#KG^?\_P"?_K@!_G_/^?\ ZY_G_/\ G_ZY_G_/^?\
MZY_G_/\ G_ZX ?Y_S_G_ .N?Y_S_ )_^N?Y_S_G_ .N?Y_S_ )_^N '^?\_Y
M_P#KG^?\_P"?_KG^?\_Y_P#KG^?\_P"?_K@!_G_/^?\ ZY_G_/\ G_ZY_G_/
M^?\ ZY_G_/\ G_ZX ?Y_S_G_ .N?Y_S_ )_^N?Y_S_G_ .N?Y_S_ )_^N '^
M?\_Y_P#KG^?\_P"?_KG^?\_Y_P#KG^?\_P"?_K@!_G_/^?\ ZY_G_/\ G_ZY
M_G_/^?\ ZY_G_/\ G_ZX ?Y_S_G_ .N?Y_S_ )_^N?Y_S_G_ .N?Y_S_ )_^
MN '^?\_Y_P#KG^?\_P"?_KG^?\_Y_P#KG^?\_P"?_K@!_G_/^?\ ZY_G_/\
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MU-4="UBZOKV2*=E92NY<+C;_ )SWJ>?CPD<_\\!_2LCPM_R%7_ZYG^?^?UH
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M"7Q+_P AJ+_KFO\ ,_Y_SQH^+/\ D&P_]=?_ &5JSO$O_(:B_P"N:_S/^?\
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MDL.WY5R20?J1QWKF-<EBFU>=X2"O +*<Y('/^?84 9_?!_S_ )_S[I_G_/\
MG_ZZ_E^'^?\ /XXI/\_Y_P __7 #_/\ G_/_ -<_S_G_ #_]<_S_ )_S_P#7
M/\_Y_P __7 #_/\ G_/_ -<_S_G_ #_]<_S_ )_S_P#7/\_Y_P __7 #_/\
MG_/_ -<_S_G_ #_]<_S_ )_S_P#7/\_Y_P __7 #_/\ G_/_ -<_S_G_ #_]
M<_S_ )_S_P#7/\_Y_P __7 #_/\ G_/_ -<_S_G_ #_]<_S_ )_S_P#7/\_Y
M_P __7 #_/\ G_/_ -<_S_G_ #_]<_S_ )_S_P#7/\_Y_P __7 #_/\ G_/_
M -<_S_G_ #_]<_S_ )_S_P#7/\_Y_P __7 #_/\ G_/_ -<_S_G_ #_]<_S_
M )_S_P#7/\_Y_P __7 #_/\ G_/_ -<_S_G_ #_]<_S_ )_S_P#7/\_Y_P _
M_7 #_/\ G_/_ -<_S_G_ #_]<_S_ )_S_P#7/\_Y_P __7 #_/\ G_/_ -<_
MS_G_ #_]<_S_ )_S_P#7/\_Y_P __7 #_//^?\_S7_/^?\^OI0.H(_S_ )S^
MOUI!V_#I^'_UOT]Z #_/I_G_ #Z4?Y_S_G^7 .V/\]/_ *W^>A_G_/Z?YZ !
M_G_/^?\ ZTUK_P ?D(_Z:#^?_P!;]/I4/;_/^?\ /MBIK7_C\A_ZZ#M[_P"?
M\B@#T>BBB@#"\5_\@N+_ *[#_P!!:N/_ ,_Y_P __6[#Q7_R"XO^NP_]!:N/
M_P _Y_S_ /6 #_/^?\__ %C_ #_G_/\ ]8_S_G_/_P!8_P _Y_S_ /6 #_/^
M?\__ %C_ #_G_/\ ]8_S_G_/_P!8_P _Y_S_ /6 #_/^?\__ %C_ #_G_/\
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M_P"L '^?\_Y_^L?Y_P _Y_\ K'^?\_Y_^L?Y_P _Y_\ K !_G_/^?_K'^?\
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M+'=3JHZ!96 'X9Q_G\:=_:-\/^7VYX_Z:M_C_G^57_/^?\_XT?Y_S_G_ .L
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M_D/\_P"><[_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\
M/_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7
M/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?
M\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP
M _S_ )_S_P#7/\_Y_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y
M_P __7/\_P"?\_\ US_/^?\ /_UP _S_ )_S_P#7/\_Y_P __7/\_P"?\_\
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M_/6H/\_Y_P __7/\_P"?\_\ UP"7[1/Y'D">3R2,>7O.W\NG?_/:+K^/]?\
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MG_/^?_K@!_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_ZX ?Y_P _Y_\
MKG^?\_Y_^N?Y_P _Y_\ KG^?\_Y_^N '^?\ /^?_ *Y_G_/^?_KG^?\ /^?_
M *Y_G_/^?_K@!_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_ZX ?Y_P _
MY_\ KG^?\_Y_^N?Y_P _Y_\ KG^?\_Y_^N '^?\ /^?_ *Y_G_/^?_KG^?\
M/^?_ *Y_G_/^?_K@!_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_ZX ?Y
M_P _Y_\ KG^?\_Y_^N?Y_P _Y_\ KG^?\_Y_^N '^?\ /^?_ *Y_G_/^?_KG
M^?\ /^?_ *Y_G_/^?_K@!_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_Z
MX ?Y_P _Y_\ KG^?\_Y_^N?Y_P _Y_\ KG^?\_Y_^N '^?\ /^?_ *Y_G_/^
M?7WR?Y_S_G_ZZ]\_Y_ST_P ]0!/\\_Y_SS[YFM?^/R'_ *Z+_/\ S^OOF'Z?
MY_SQ_GK-:\WD.!_RT7^?^?T]L@'H]%%% &%XK_Y!<7_78?\ H+5Q_P#G_/\
MG_ZW8>*_^07%_P!=A_Z"U<?_ )_S_G_ZP ?Y_P _Y_\ K'^?\_Y_^L?Y_P _
MY_\ K'^?\_Y_^L '^?\ /^?_ *Q_G_/^?_K'^?\ /^?_ *Q_G_/^?_K !_G_
M #_G_P"L?Y_S_G_ZQ_G_ #_G_P"L?Y_S_G_ZP ?Y_P _Y_\ K'^?\_Y_^L?Y
M_P _Y_\ K'^?\_Y_^L '^?\ /^?_ *Q_G_/^?_K'^?\ /^?_ *Q_G_/^?_K
M!_G_ #_G_P"L?Y_S_G_ZQ_G_ #_G_P"L?Y_S_G_ZP ?Y_P _Y_\ K'^?\_Y_
M^L?Y_P _Y_\ K'^?\_Y_^L '^?\ /^?_ *Q_G_/^?_K'^?\ /^?_ *Q_G_/^
M?_K !_G_ #_G_P"L?Y_S_G_ZQ_G_ #_G_P"L?Y_S_G_ZP ?Y_P _Y_\ K'^?
M\_Y_^L?Y_P _Y_\ K'^?\_Y_^L '^?\ /^?_ *Q_G_/^?_K'^?\ /^?_ *Q_
MG_/^?_K !_G_ #_G_P"L?Y_S_G_ZQ_G_ #_G_P"L?Y_S_G_ZP ?Y_P _Y_\
MK'^?\_Y_^L?Y_P _Y_\ K'^?\_Y_^L '^?\ /^?_ *Q_G_/^?_K'^?\ /^?_
M *Q_G_/^?_K !_G_ #_G_P"L?Y_S_G_ZQ_G_ #_G_P"L?Y_S_G_ZP ?Y_P _
MY_\ K'^?\_Y_^L?Y_P _Y_\ K'^?\_Y_^L '^?\ /^?_ *Q_G_/^?_K'^?\
M/^?_ *Q_G_/^?_K !_G_ #_G_P"L?Y_S_G_ZQ_G_ #_G_P"L?Y_S_G_ZP ?Y
M_P _Y_\ K'^?\_Y_^L?Y_P _Y_\ K'^?\_Y_^L '^?\ /^?_ *Q_G_/^?_K'
M^?\ /^?_ *Q_G_/^?_K !_G_ #_G_P"L?Y_S_G_ZQ_G_ #_G_P"L?Y_S_G_Z
MP ?Y_P _Y_\ K'^?\_Y_^L?Y_P _Y_\ K'^?\_Y_^L '^?\ /^?_ *Q_G_/^
M?_K'^?\ /^?_ *Q_G_/^?_K !_G_ #_G_P"L?Y_S_G_ZQ_G_ #_G_P"L?Y_S
M_G_ZP ?Y_P _Y_\ K'^?\_Y_^L?Y_P _Y_\ K'^?\_Y_^L '^?\ /^?_ *Q_
MG_/^?_K'^?\ /^?_ *Q_G_/^?_K !_G_ #_G_P"L?Y_S_G_ZQ_G_ #_G_P"L
M?Y_S_G_ZP ?Y_P _Y_\ K'^?\_Y_^L?Y_P _Y_\ K'^?\_Y_^L '^?\ /^?_
M *Q_G_/^?_K'^?\ /^?_ *Q_G_/^?_K !_G_ #_G_P"L?Y_S_G_ZQ_G_ #_G
M_P"L?Y_S_G_ZP ?Y_P _Y_\ K'^?\_Y_^L?Y_P _Y_\ K'^?\_Y_^L '^?\
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M?Y_S_G_ZQ_G_ #_G_P"L?Y_S_G_ZP ?Y_P _Y_\ K'^?\_Y_^L?Y_P _Y_\
MK'^?\_Y_^L '^?\ /^?_ *Q_G_/^?_K'^?\ /^?_ *Q_G_/^?_K !_G_ #_G
M_P"L?Y_S_G_ZQ_G_ #_G_P"L?Y_S_G_ZP ?Y_P _Y_\ K'^?\_Y_^L?Y_P _
MY_\ K'^?\_Y_^L '^?\ /^?_ *R_Y_S_ )_EBD_S_G_/I^!_GU_S_GUH /\
M/'^?\\>V3_/'^?\ /'ME>_\ D_Y_S^*?Y_S_ )_^N '^>/\ /^>/;)_G_/\
MGT]LG^?\_P"?_KK_ %_S_7]?K0 =3_G_ #_G\P?Y_3_/Y>])_GC_ #_G(]31
M_GC_ #_G(]30 =OZ]O\ /3_/1>_I_3_//Y>U)_GC_/\ GBC_ #Q_G_/RT =!
MK'_(O:9V^4<>GRUS_P#G_/\ G^M=#K''A_3.WRCI_N_Y_P \USW^?\_Y_P#K
M !_G_/\ G^M'^?\ /^?ZT?Y_S_G_ .L?Y_S_ )_^L '^?\_Y_K1_G_/^?ZT?
MY_S_ )_^L?Y_S_G^7  O^?\ /^?YXI/\_P"?\_\ UP_Y_7_/_P"HTIY_'/\
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M_P"N '^?\_Y_^N?Y_P _Y_\ KG^?\_Y_^N?Y_P _Y_\ K@!_G_/^?_KG^?\
M/^?_ *Y_G_/^?_KG^?\ /^?_ *X ?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_ZY_G_
M #_G_P"N '^?\_Y_^N?Y_P _Y_\ KG^?\_Y_^N?Y_P _Y_\ K@!_G_/^?_KG
M^?\ /^?_ *Y_G_/^?_KG^?\ /^?_ *X ?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_Z
MY_G_ #_G_P"N '^?\_Y_^N?Y_P _Y_\ KG^?\_Y_^N?Y_P _Y_\ K@!_G_/^
M?_KG^?\ /^?_ *Y_G_/^?_KG^?\ /^?_ *X ?Y_S_G_ZY_G_ #_G_P"N?Y_S
M_G_ZY_G_ #_G_P"N '^?\_Y_^N?Y_P _Y_\ KG^?\_Y_^N?Y_P _Y_\ K@!_
MG_/^?_KG^?\ /^?_ *Y_G_/^?_KG^?\ /^?_ *X ?Y_S_G_ZY_G_ #_G_P"N
M?Y_S_G_ZY_G_ #_G_P"N '^?\_Y_^N?Y_P _Y_\ KG^?\_Y_^N?Y_P _Y_\
MK@!_G_/^?_KG^?\ /^?_ *Y_G_/^?_KG^?\ /^?_ *X ?Y_S_G_ZY_G_ #_G
M_P"N?Y_S_G_ZY_G_ #_G_P"N '^?\_Y_^N?Y_P _Y_\ KG^?\_Y_^N?Y_P _
MY_\ K@!_G_/^?_KG^?\ /^?_ *Y_G_/^?_KG^?\ /^?_ *X ?Y_S_G_ZY_G_
M #_G_P"N?Y_S_G_ZY_G_ #_G_P"N '^?\_Y_^N?Y_P _Y_\ KG^?\_Y_^N?Y
M_P _Y_\ K@!_G_/^?_KG^?\ /^?_ *Y_G_/^?_KG^?\ /^?_ *X ?Y_S_G_Z
MY_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N '^?\_Y_^N?Y_P _Y_\ KG^?\_Y_
M^N?Y_P _Y_\ K@!_G_/^?_KG^?\ /^?_ *Y_G_/^?_KG^?\ /^?_ *X ?Y_S
M_G_ZY_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N '^?\_Y_^N?Y_P _Y_\ KG^?
M\_Y_^N?Y_P _Y_\ K@!_G_/^?_KG^?\ /^?_ *Y_G_/^?_KG^?\ /^?_ *X
M?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N '^?\_Y_^N?Y_P _Y_\
MKG^?\_Y_^N?Y_P _Y_\ K@!_G_/^?_KG^?\ /^?_ *Y_G_/^?_KG^?\ /^?_
M *X ?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N '^?\_Y_^N?Y_P _
MY_\ KG^?\_Y_^N?Y_P _Y_\ K@!_G_/^?_KG^?\ /^?_ *Y_G_/^?_KG^?\
M/^?_ *X ?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N '^?\_Y_^N?Y
M_P _Y_\ KG^?\_Y_^N?Y_P _Y_\ K@!_G_/^?_KG^?\ /^?_ *Y_G_/^?_KG
M^?\ /^?_ *X ?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N '^?\_Y_
M^N?Y_P _Y_\ KG^?\_Y_^N?Y_P _Y_\ K@!_G_/^?_KG^?\ /^?_ *Y_G_/^
M?_KG^?\ /^?_ *X ?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N '^?
M\_Y_^N?Y_P _Y_\ KG^?\_Y_^N?Y_P _Y_\ K@!_G_/^?_KG^?\ /^?_ *Y_
MG_/^?_KG^?\ /^?_ *X ?Y_S_G_ZY_G_ #_G_P"N?Y_S_G_ZY_G_ #_G_P"N
M '^?\_Y_^NO?_/\ G_/YI_G_ #_G_P"NO^?\_P"?YT )_G_/^?Z4?3_/^>/\
MXH_SZ_Y_SZT?Y]?\_P"?6@ ^GX?Y_+_.*/I^'^?R_P XH_SS_G_//O@_SS_G
M_//O@ /I^'^?R_SBIK7_ (^X?^NB_P __P!7^<5#_GG_ #_GGWQ-:\7D//\
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MVCI][S_H=QQG/[MO\/\ /X\G]G7W_/G<?]^F_P /\_S *O\ G_/^?_KG^?\
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MWZ;_  _S_)?[.OO^?.X_[]-_A_G^0!5_S_G_ #_]8_S_ )_S_P#6L_V?>_\
M/G<?]^F_P_S_ "/[/O?^?.X_[]-_A_G^0!6_S_G_ #_]8_S_ )_S_P#6M?V=
M??\ /G<?]^F_P_S_ "3^S[WM9W'M^Z;_  _S^6 "MV_S_G_(]:/\^O\ G_/K
M5G^S[T_\N=P<_P#3)O?V_P \^U+_ &?>G_ESN#_VR/\ A_G^8!5_SZ_Y_P ^
MM+_G_/\ G^?-C^S[W_GSN/\ OTW^'^?YG]GWO_/I<?\ ?H_X?Y_F 5^^1_G_
M #_GW3Z?Y_SQ_GK:_LZ][V=Q_P!^S_GO_GNG]GWO_/G<?C$W^'O_ #_$ K=/
M_K?Y_P X_,Z?AZ?Y]OY>]6AI]Z2/]$N/^_;?X?YP?Q0:?>\?Z)<#T_=GV]O\
MX]N0#8\2#_1-,'_3-N/P7_/^<5SW^?\ /^?_ *_2Z_:SRVFG"*WE<I&0P5"=
MO"\'_/\ A6'_ &?>_P#/I<?]^C_A_G^8!6_S_G_/_P!<_P _Y_S_ /7L_P!G
MWO\ SZ7'_?H_X?Y_F?V?>_\ /I<?]^C_ (?Y_F 5O\_Y_P __7/\_P"?\_\
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M?\_Y_G5G^S[W'_'G<=/^>3?X?Y_*@Z?>G_ESN/\ OTWO[?YY]J *W^?7_/\
MGUI>_P#G_/\ GWJS_9][_P ^=Q_WZ/\ A_G^:?V?>_\ /G<?]^F_P_S_ # *
MW^?\_P"?_KG^?\_Y_P#KV?[/O?\ GSN/^_3?X?Y_FO\ 9U]_SYW'_?IO\/\
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MU]_SYW'_ 'Z;_#_/\T_L^]_Y\[C_ +]-_A_G^8!6_P _Y_S_ /7/\_Y_S_\
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M_P"?.X_[]-_A_G^8!6_S_G_/_P!<_P _Y_S_ /7L_P!GWO\ SYW'_?IO\/\
M/\U_LZ^_Y\[C_OTW^'^?Y@%7_/\ G_/_ -<_S_G_ #_]>S_9][_SZ7'_ 'Z/
M^'^?YK_9U]_SYW'_ 'Z;_#_/\P"K_G_/^?\ ZY_G_/\ G_Z]G^S[W_GSN/\
MOTW^'^?YG]GWO_/G<?\ ?IO\/\_S *W^?\_Y_P#KG^?\_P"?_KVO[.OO^?.X
M_P"_3?X?Y_FG]GWO_/G<?]^F_P /\_S *W^?\_Y_^N?Y_P _Y_\ KV?[/O?^
M?.X_[]-_A_G^:_V=??\ /G<?]^F_P_S_ # *O^?\_P"?_KG^?\_Y_P#KV?[/
MO?\ GSN/^_3?X?Y_F?V?>_\ /G<?]^F_P_S_ # *W^?\_P"?_KG^?\_Y_P#K
MVO[.OO\ GSN/^_3?X?Y_FG]GWO\ SYW'_?IO\/\ /\P"M_G_ #_G_P"N?Y_S
M_G_Z]G^S[W_GTN/^_1_P_P _S/[/O3_RYW'_ 'Z;_#_/\P"M_G_/^?\ ZY_G
M_/\ G_Z]G^S[W_GSN/\ OTW^'^?YG]GWO_/G<?\ ?IO\/\_S *W^?\_Y_P#K
MG^?\_P"?_KVO[.OO^?.X_P"_3?X?Y_FG]GWO_/G<?]^F_P /\_S *W^?\_Y_
M^N?Y_P _Y_\ KV?[/O?^?2X_[]'_  _S_,_L^]_Y]+C_ +]'_#_/\P"M_G_/
M^?\ ZY_G_/\ G_Z]G^S[W_GTN/\ OT?\/\_S/[/O?^?2X_[]'_#_ #_, K?Y
M_P _Y_\ KG^?\_Y_^O9_L^]_Y\[C_OTW^'^?YG]GWO\ SZ7'_?H_X?Y_F 5O
M\_Y_S_\ 7/\ /^?\_P#U[/\ 9][_ ,^EQ_WZ/^'^?YG]GWN<&SN/^_3?X?Y_
MF 5O\_Y_S_\ 7/\ /^?\_P#U[/\ 9][_ ,^=Q_WZ;_#_ #_,_L^]/_+G<?\
M?IO\/\_S *W^?\_Y_P#KG^?\_P"?_KV?[/O?^?2X_P"_1_P_S_,_L^]_Y]+C
M_OT?\/\ /\P"M_G_ #_G_P"N?Y_S_G_Z]G^S[W_GTN/^_1_P_P _S/[/O?\
MGTN/^_1_P_S_ # *W^?\_P"?_KG^?\_Y_P#KV?[/O?\ GTN/^_1_P_S_ #/[
M/O?^?2X_[]'_  _S_, K?Y_S_G_ZY_G_ #_G_P"O9_L^]/\ RYW'_?IO\/\
M/\S^S[W_ )]+C_OT?\/K_GJ 5O\ /^?\_P#US_/^?\__ %[/]GWO>TN/^_1_
MP^O^>I_9][_SYW'_ 'Z;_#_/\P"M_G_/^?\ ZY_G_/\ G_Z]G^S[W_GTN/\
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MG_/^?_KV?[/O?^?.X_[]-_A_G^9_9][_ ,^=Q_WZ;_#_ #_, K?Y_P _Y_\
MKG^?\_Y_^O:_LZ^_Y\[C_OTW^'^?YI_9][_SYW'_ 'Z;_#_/\P"M_G_/^?\
MZY_G_/\ G_Z]G^S[W_GSN/\ OTW^'^?YK_9U]_SYW'_?IO\ #_/\P"K_ )_S
M_G_ZY_G_ #_G_P"O9_L^]_Y\[C_OTW^'^?YG]GWO_/G<?]^F_P /\_S *W^?
M\_Y_^N?Y_P _Y_\ KVO[.OO^?.X_[]-_A_G^:?V?>_\ /G<?]^F_P_S_ # *
MW^?\_P"?_KG^?\_Y_P#KV?[/O?\ GSN/^_3?X?Y_FO\ 9U]_SYW'_?IO\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUVL?_29:[>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *SM?O9=-\.:I?P!3-;6DLT>X9&Y4)&?;(K1K&\7_P#(E:]_V#KC_P!%
MM0!-X<OYM5\+Z3J-R%$]W90SR!!@!F0,<#TR:TZPO!/_ "(7AWC'_$LMNO\
MUR6MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_\ R$O&G_8P3?\ HJ*NVH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "N)\%_\ (W^.>G_(3BZ?]<$KMJXGP7_R-_CGG/\ Q,XO
M_1"4 =M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <1X5_Y*7X^X_P"6UC_Z3"NWKB/"O_)2_'W_ %VL?_285V] !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>+_^1*U[_L'7
M'_HMJV:QO%__ ")6O?\ 8.N/_1;4 1^"?^1"\.\8_P")9;=?^N2UNUA>"?\
MD0O#O&/^)9;=?^N2UNT %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$[TW_GUO?^^4_P#BJ/\ A.]-_P"?6]_[Y3_XJ@#J**Y?_A.]-_Y];W_OE/\
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M@O\ Y&_QSSG_ (F<7_HA*[:N)\%X_P"$P\<^O]I1<X_Z8)0!VU%%% !1110
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M@$'(/0BN'\7?%;0?!>O6^CZE;ZA+<31K(&MXD95#$@9)8'L>@-3_  M\1?\
M"2_#W2[QY-]Q%']GG]=Z<<_48/XUXK\??^2G:=_UZ1?^AM0!]&:QK%MHF@W>
ML7*R/;6L!G=8P"Q4#/ ) S^->7_\-'>#_P#H&ZY_WXA_^.UZP;>"[T_[/<PQ
MSP2Q[9(Y$#(X(Y!!X(]J\M^,/A3PYIGPSU*[L/#^E6ERC1;9H+..-URZYPP
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M@P + XQSGC'2K&G>/OBYI^CVVE6G@F5(X(5@CE;2;G> !@$DMMS^&*TOA?\
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MYKW,    8 Z 4 8?C7_D1M=_Z\)O_0#7*? G_DE&G?\ 7:?_ -&-7<ZWI_\
M:VA:AIP;:;JW>$,>Q92 :\8\ :SXX\#V4/A"?P'?7FRZ(2\1RL*JS<DL$*D#
MDYW"@"S\9[&WU+XB>!+*ZC\RWGF9)$_O*7CR/QKVJ**."%(HD5(T4*B*,!0.
M  /2O*OB;HVJ:A\2/ UW9Z==7-M;7!,\L,+,L0WH<LP&%& >OI7K% 'C'@7_
M )."\:_]<S_-*Z?Q9\3AHOB*/PUH>BW.N:ZX#-;POL2($9^9L'G&#TP >2*Q
MO!NC:I:_'+Q=J-QIUU#93Q_N;F2%ECDY7[K$8/X&J/B#2_$O@KXKW?C+2=!F
MUW3M0A$<T5MS+&<*"  "?X0> 0<GI0!S'Q<UCQUJ/A&./Q)X4M=,L1=(R3QW
M:2MOP<# 8GIGG%>F?$%V?X'Z@['+-IT1)]3E*X#XC77CWX@>&6,/A"\TW2K:
M57^SR(TEU<N3@8C"[@!DD\?B>E>C^-].O;KX.7MA;6D\UX;")!!%&6<L-N0%
M')/!H F^$G_)*_#_ /U[G_T-J[2N2^&%E=:=\-M#M+VVEMKF. AX9D*.AW,<
M$'!!KK: /%/@;EO$WCAI,^<;[YB>OWY,_K6G^T+_ ,DXC_Z_H_Y-6;X 3_A'
M?CKXNT63Y%OE-S"/[W._/Y.:W?CII6HZQX!2WTRQNKV<7D;&*VB:1L8;G"\X
MH [;PM86NF^%=+M;*WC@@2VC(1!@9*@D_4DDDUY?\.84M/CGXZ@A&V+&[:.F
M2X/]37K6D1O#HMA%(I5TMXU92,$$*,BO-O!6CZG:?&SQEJ%SIUU#9W" 0W$D
M++')ROW6(P>G8T 2ZSXK^#MMK5Y#J\&C/J,<I6X:31VD8N.N6\HY/ODU0_X3
M+X&?\^NA_P#@A;_XS7I-SX5\.WES)<W6@Z7//(=SRRV<;,Q]22,FHO\ A#/"
MW_0M:-_X 1?_ !- &1JGC?P]X8^'*>(M+ACDTK8%LH;>/R5<DD!0I VC(.>.
M,'BO-['X/W7Q"@F\4>([N'2KO4D$MO:Z?;*JQ@C(:3/+$]2,Y_VNP]&^(G@=
M?%?@270]-$-K+"5EM450L89<X7 Z @D>U<EHOC[QKX<TNWT?6OAWJ]W<6D2P
MK<V*F1) HP,[5(' '()S[4 ,\">(M8\$^+;?X<^)(+5HG3.G7EK$$#CDC(
M.<'G&<CG.<UV7Q8"'X6^(/,. +;(^NX8_6N1T#PYXH\9_$>T\:>)M,&C65@F
M+.Q=]TA/.">..2220#P,#O6Q\<]3%A\,;R ']Y>RQVZ+Z_-N/Z*: -'X/DGX
M5:%G_GDV/^^VKK]2G>VTN[N(QEXH7=?J%)%9/@C2FT/P/HNFNNV2"T0./1B,
MM^I-;S*'1D895A@CVH \<_9XM8I/#.K:O( ]]=WS+-*1\Q  .,_5B?QK;^.F
MGVUY\+[Z:=5\RTDCEA8]0VX*<?4$BN3L-+\9?!_7-2&C:!+X@\.7LGF)%;']
MY&>W"AF! X/RD' Z4_6AX[^+RVVD2^&YO#6A+,)+J6\8^8^.@"LJD^P"XSC)
M% &IKMU->?LS)<7!/FOIL.23U^91G\JZ?X1V%K9?#'13;6\<37$'G3%1R[D\
ML3W/3\J;\1-$D'PEU'1](LYIS%;1Q000H7<A2O  Y)P*T?AQ9W-A\.M"M;RW
MEM[B*U4212H59#SP0>0: . $*6W[4N81M\_3B\F/XCY?_P!B*I>.]5C\*?';
M3]?,$NIHFG$W%K:IOEMT 8;\= .<]1WZ5O2Z/J9_:/@U4:=='3AIQ0W?DMY0
M;81C?C&?;-8'B2;7+3X[33>!V@U'59;(+?V]RG[JW4 8#/N';:< CL.<T 0>
M./%\?Q=L[/POX2TN_N&:Z26>\FAV1P  CDY..O.<>V<UN_'R:?3OAC9V4<C;
M9+F*&4@_>"J3S^(%.O\ QG\5_#MK-J.L^$-)N-/MEWSM9W!5@OJ,NQP._P I
MK;UFRLOC'\+4>R8VS7($UN9?^64JDC:V.V<@_7- '7^'+"VTOPWIME:(JP0V
MR*H4  _*.?QZUY'XXB32_P!H7PG>V2A+B\55GV_QC+(<_P# ?Y"I-'\<?$+P
MCI=OH>K?#W4-4GM4$4=U:,Q5T'"Y*(ZYQWR/I6AX1\)^)?$/CT^.O&-LEBT*
M;-/T\,&,8P0"?3 )Z\DGM@"@"I\6?^2I_#X_]/)Z_P#72.IOVB5#>"],!Z'4
M5!&?]AJL?$W1M4U#XC^!KNRTZZN+:VN"9YHH6=(AO0Y8@8 X/7TJ7XZZ1J6L
M>$]/ATS3[J]E2_1FCMH6D(7:W)"YXZ=J /1=&L;73-&L[.R@C@MXH55(XQ@
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M)].E "[N<\\>WI1GMSZ4F?<_E2?B?RH =NX[_E1NYSSQ[>E)[9/ITHS[G\J
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M[QC_ (EEMU_ZY+6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^)_*E]LGTZ4 )^)_*E]LGTZ49]S^5)^)_*@!<^Y_*D_$_E2^V3Z=*,^Y_*@
M]LGTZ49]S^5)^)_*E]LGTZ4 )^)_*E]LGTZ49]S^5)^)_*@!<^Y_*D_$_E2^
MV3Z=*,^Y_*@ ]LGTZ49]S^5)^)_*E]LGTZ4 )^)_*E]LGTZ49]S^5)^)_*@!
M<^Y_*D_$_E2^V3Z=*,^Y_*@ ]LGTZ49]S^5)^)_*E]LGTZ4 )^)_*E]LGTZ4
M9]S^5)^)_*@!<^Y_*D_$_E2^V3Z=*,^Y_*@ ]N?2C\.O48I/KGZYH^O;J30
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MKQH?0LS+G\,T >DT5@:9XRT?6_"\WB#2I9+RSA1F=(HSYH*C)7:<?-7@]O\
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M].@$\UQ*J^40<8"X8L6^8<;:P=/^/7@R_P!52Q;^T+59&VI<W$ $39.!R&)
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M MKPVK^(X#(#C,<,KI_WVJE?UKF?CKJEY):Z'X5LI6C;6;H)*5.,H"HP?;+
MGZ5V5G\,_!MIHJ:7_P (]I\L:Q^6TLMNK2OQRQ?&[=[@\=L4 =)97UIJ5G'>
M6-S%<VTHW1RQ.&5A[$58KQ+X0M-X9^(GBGP29'>S@<SVX8_=P1_-67\J]MH
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M?8$D=ZN^$/B9X<\:7$EIITTT%]&"6L[N/RY0!U[D''?!..] '84444 %%%%
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MB2:W>9^.[#C],5Y[I%M+K.L:?8.Q9-P0#^ZF2Q_K7L/B !?#>H*. +=@/RH
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MS:OX1@6V7=- B2J@ZMA>0/?%<KX5\91^'[.33[^VG>-7+(8P-RD]002._O0
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M0 4444 %%%% !1110 4444 %%%% 'SQI>22/Z?2NJM?N=,?TKE=+QDY/'?\
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MVR?3I1GW/Y4 'MD^G2C/N?RI/Q/Y4OMD^G2@!/Q/Y4OMD^G2C/N?RI/Q/Y4
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MSW/2@<<9'I@4=3P?>DSQU.,?2@!W455N+<,IP.,<T33XX5NGI_G_ #FLB]O
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M5+,AR!WVQ#'^?2O;*\L^$?A35[2ZU?Q;XCMVM]5UB0L+=QAHDSGD'D$G'!Y
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M=1T:*S_L^X\DR,V\[%;.,<?,#0!V-%8GA+4+K5/#EO=7DGF3L6#/M S@D=
M*VZ "BBF2L4A=AU5210 ^BO(K#Q3XNU:\%M8WOF3."RH(H1P/<BMZU'Q#^V0
M_:&_<^8/,S]G^[GGIST]* ._HKB_'FO:EHS62Z?<^3YH;?\ NU;.,8^\#6[X
M8OKC4O#EG=W3AYY%;>P4#.&(Z#Z4 :]-DD2*-I)'5$499F. !ZDUQOCS7M2T
M9K-=/N?)\P,7/EJV<8_O UM>';F76?"MM-?,)9)T99#M W?,1T''04 :5K?V
M=\&-G=P7 0X8PR!\?7%6*\H\*3OH'C>33G.(Y7:W;/'.?E/\OSKU>@ HHHH
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M_/TKUM&#HK#HPS7D_P 12'\5!5^\+=!C\37JML,6D(]$7^5 $M%%% !1110
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M'[MN??\ ^O0)KTX_=MS[_P#UZ .I\TY^^!D_UI/-.,[ATS7+B:]./W;<^_\
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M@?[OY5U?C/3=4\2_"J_M#:A-5N+)7:V0])!AB@_(B@"3X6_\DP\._P#7FO\
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M>22)).PRP56("KZ#C)]3^%:^F _\,_0C;S_8)X/'_+(TSX% CX4:=D8S+/\
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M).>Y;CB@#V2O%/"W_)S'BC_KV_\ 98J[KQM\2=$\!36D6K0WLC72LT?V:)6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*X/P9X5U"QU>?4M6A$<H!$0+JQ+-U;@G_)KO* "BBB@ HHHH **** "BBB@
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M)H_X0C2O[UQ_WTO_ ,37244 <W_PA&E?WKC_ +Z7_P")H_X0C2O[UQ_WTO\
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M7;UQ'A7_ )*7X^_Z[6/_ *3"NWH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L;Q?\ \B5KW_8.N/\ T6U;-8WB_P#Y$K7O^P=<
M?^BVH C\$_\ (A>'>,?\2RVZ_P#7):W:PO!/_(A>'>,?\2RVZ_\ 7):W: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \GU71M4D_:+TG54TZZ;
M3DL-CW8A8Q*V)."V, \C\Z]8HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B?AC_ ,@?
M6O\ L.WW_HTUVU<3\,?^0/K7_8=OO_1IKMJ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KB?AQT\6?]C)>?^RUVU<3\..GBS_L9
M+S_V6@#MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#B?A__ ,A+QI_V,$W_ **BKMJXGX?_ /(2\:?]C!-_Z*BKMJ "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?!?\ R-_C
MGG/_ !,XO_1"5VU<3X+Q_P )AXY]?[2BYQ_TP2@#MJ*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B/"O_)2_'W'_ "VL>?\
MMV6NWKB/"N/^%E^/O7SK'_TF%=O0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %8WB__ )$K7O\ L'7'_HMJV:QO%_\ R)6O?]@Z
MX_\ 1;4 1^"?^1"\.\8_XEEMU_ZY+6[6%X)_Y$+P[QC_ (EEMU_ZY+6[0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% '$_#'_D#ZU_V';[_ -&FNVKB?AC_ ,@?6O\ L.WW_HTUVU !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/PXZ>+/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!^_W_-E<<?@:[JBB@#EO&FC:IJ\-FNF-M:-V+_O-G!QC^5<</!/BSC][Z?\
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M2.?I6Q110!YKK?A3Q+>:W>7%I*5MY92T?^D;<#Z9JA_PA?BX_P#+8C_M[/\
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MT?P_KFISZDE@^)+.\:WNLS[<RA5)/OP1S_A6F/!7BP8_>=/^GK_Z]=)\/_\
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M?\8Z9J&K:/';Z:V)EG5S\^S*X8'G\17044 >3?\ "$^+/^>WX_:O\_Y)I/\
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M56<&XSD CMGVKTRBB@#(\3V-WJ7AZYM+$XN7*;#OV]&!//;@&O//^$*\6?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#B?AC_ ,@?6O\ L.WW_HTUVU<3\,?^0/K7
M_8=OO_1IKMJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KB?AQT\6?]C)>?^RUVU<3\..GBS_L9+S_V6@#MJ*** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B?AC_ ,@?6O\ L.WW
M_HTUVU<3\,?^0/K7_8=OO_1IKMJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KB?AQT\6?]C)>?^RUVU<3\..GBS_L9+S_V6@#M
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B
M?A__ ,A+QI_V,$W_ **BKMJXGX?_ /(2\:?]C!-_Z*BKMJ "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB?!>/^$P\<\<_VE%_Z
M(2NVKB?!?_(W^.>/^8G%W_Z8)0!VU%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Q'A7_ )*7X^_Z[6/_ *3+7;UQ'A7'_"R_
M'WKYUC_Z3"NWH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "L;Q?_P B5KW_ &#KC_T6U;-8WB__ )$K7O\ L'7'_HMJ (_!/_(A
M>'>,?\2RVZ_]<EK=K"\$_P#(A>'>,?\ $LMNO_7):W: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRW[1JG_02O\ _O\ O_\ %4?:-4_Z"5__ -_W_P#BJ /4J*\M^T:I_P!!*_\
M^_[_ /Q5'VC5/^@E?_\ ?]__ (J@#U*BO'M8U35K.Q8QZI?K,S *?/?CN3R:
MZ[P/XWC\0PBPOF2/5HEY X$X'\2^_J/QZ= #LZ*** "BBB@ HHHH **** "B
MBB@ HHHH **** "N)\%_\C?XYZ_\A.+K_P!<$KMJXGP7C_A,/'/'/]I1?^B$
MH [:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH XCPK_R4OQ]Q_RVL>?^W9:[>N(\*_\ )2_'W_7:Q_\ 29:[>@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QO%_P#R)6O?]@ZX
M_P#1;5LUC>+_ /D2M>_[!UQ_Z+:@"/P3_P B%X=XQ_Q++;K_ -<EK=K"\$_\
MB%X=XQ_Q++;K_P!<EK=H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK3/'?AW5-9U"UFT^V\Y$B*M^\5<'.>Y% '2Z/G_A%K+L?LB]_P#9KSKX?_\
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MVR?3I1GW/Y4 'MD^G2C/N?RI/Q/Y4OMD^G2@!/Q/Y4OMD^G2C/N?RI/Q/Y4
M+GW/Y4GXG\J7VR?3I1GW/Y4 'MD^G2C/N?RI/Q/Y4OMD^G2@!/Q/Y4OMD^G2
MC/N?RI/Q/Y4 +GW/Y4GXG\J7VR?3I1GW/Y4 'MD^G2C\_7I2?B?RI?S].M "
M?@?SI<>Q_.CWP?7K2?@?SH 7WP?7K2?@?SI<>Q_.CWP?7K0 8]C^='O@^O6D
M_ _G2X]C^= "?@?SI<>Q_.CWP?7K2?@?SH 7WP?7K2?@?SI<>Q_.CWP?7K0
M8]C^='O@^O6D_ _G2X]C^= "?@?SI<>Q_.CWP?7K2?@?SH 7WP?7K2?@?SI<
M>Q_.CWP?7K0 8]C^='O@^O6D_ _G2X]C^= "?@?SI<>Q_.CWP?7K2?@?SH 7
MWP?7K2?@?SI<>Q_.CWP?7K0 8]C^='O@^O6D_ _G2X]C^= "?@?SI<=L&CWP
M?7K1^8_&@ [9SU]*3\3W[4?CZC/>ES[G\J #OU/7THYP.N<=Z3\S2\>@(S0
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ILDD<,;22NJ1J,LS'
M]S3JR?$__(KZISC_ $9^OTH NVNI6-\6%G>V]P5^\(95?'UP:GDDCAC:25U2
M-1EF8X 'N:\R^&/_ "%[W_K@/_0A7=>)_P#D5]3_ .O9_P"5 %RUU*QOBPL[
MVWN"OWA#*KX^N#5FO,/AC_R%[W_K@/\ T(5Z1>7MK86YGNYXX8A_$[8__6:
M)Z*Y^/QMX=EE$:ZDH8G&6B=1^9&*U;W4[+3[ WUS.J6PQ^\ +#G@=,T 6Z*\
MCL?%$R>,!<SZK=?V;Y[$J9)"FSG'R\^W:O3=+UFPUF%Y=/G\Y(VVL=C+@_\
M @* +]%9&H>*-%TN8Q7=_&D@ZJJLY'UV@XJ;3=>TO5R187D<S 9*8*MCUP<'
M% &C15#5-9T_1H4EU"X\E)&VJ=C-D_0 U5N?%>B6<,$L]^BK.@>,!&)*GH2
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M<D#A9U'\2^_J/QZ=.SKYTN+:6WGCN+>1HYXVWQR)PRL.X]Z]:\#^-H_$-O\
M8KTK'JL*_,HX$P_O+[^H[?2@#L:*** "BBB@ HHHH **** "N)\%_P#(W^.>
MO_(3BZ_]<$KMJXGP7C_A,/'/'/\ :47_ *(2@#MJ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B/"O\ R4OQ]Q_RVL>?^W9:
M[>N(\*_\E+\??]=K'_TF6NWH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "L;Q?_ ,B5KW_8.N/_ $6U;-8WB_\ Y$K7O^P=<?\
MHMJ (_!/_(A>'>,?\2RVZ_\ 7):W:PO!/_(A>'>,?\2RVZ_]<EK=H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K)\3_\
M(KZISC_1GZ_2M:LGQ/\ \BOJG./]&?K]* /*?#.I:MIEW/)I%B+J5X]KKY+R
M87/7"D=ZW-3\2^++K2[J"[T7RK:2-EDD^R2KM4CDY+8%+\,?^0O??]<!_P"A
M"NZ\3_\ (KZG_P!>S_RH X7X8_\ (7O?^N _]"%4/%VHC5/%S6]S<&.RMY!#
MN )"#^)L=SU^N!5_X8_\A>^_ZX#_ -"%9/B2TCT_QK-]MB9[5YQ*PR1O0G)Z
M?B* +^K0^"#I$@TVZD6]1<HQ64^81V.1CG\*T_ ?E:UHE[H^H(9[:-U=%+$8
M![9'/49_&K<>F?#^2$2K)9A2,X:\<-_WR6S6WX:@T"."XDT%5\MG"2L"YR0.
MF6^O;UH \UT[3+.X\<+ITD.;0W#IY>X_=&<#(Y[5W^L0V?A'PM?2:5 (&D(
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M_7OZT<<]1UI>]  "?_K4G_Z\4O;OBD]/KQQTH 7\SWHZ< TG^/'%&/;&>V*
M%_,9[4<_XBD/?('OZ4N#_P#7H 0$?WABE_//3)HSSU_2F.X1<\YQCK0 K2*@
MR:IW%X@!RF<=\U'<7 '4X_I_]>N=U+4PH(!H EU#5X$)_=9'^_UK)M+J[O-5
MMUTJWE%]Y@,!B?Y@W8]/K[51BCNM4OH[:WB>6XE;:D:CDFO>? W@>V\+68GG
M"RZI*O[R0\^6/[J^WKZXH Z;31>C3+8:DT37HC'G&(?*6[XJU110 4444 %%
M%% !1110 5Q/@O\ Y&_QSQ_S$XN__3!*[:N)\%_\C?XYZ_\ (3BZ_P#7!* .
MVHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M(\*X_P"%E^/O7SK'_P!)A7;UQ'A7_DI?C[C_ );6//\ V[+7;T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6-XO_Y$K7O^P=<?
M^BVK9K&\7_\ (E:]_P!@ZX_]%M0!'X)_Y$+P[QC_ (EEMU_ZY+6[6%X)_P"1
M"\.\8_XEEMU_ZY+6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !4%[:1W]C-:3%A',A1MIP<&IZ* ,+0O"EAX>GEFM);A
MWE4*?-8' SGC %:U[:17]C/:3;O*F0HVTX.#Z5/10!A:%X4T_P /3RS6DEP[
MR+L)E8' SGC %7-6T/3];A6.^MQ(5SL<'#+GT-:-% '&_P#"M-%W9^T7V/3S
M$_\ B:Z/2=&LM$M3;V,91&;<Q9B2Q]:OT4 <]K'@S2=:NC=3K-%.WWWA8#=]
M0015W1-!LM M'M[3S&61MSM*02QQCL!6I10!R]_X!T.^G:41S6S,<D6[@#/T
M(('X4VR^'VB65PD_^DSLC!E$L@P"/]T"NJHH RM=\/VGB&WBANWF18FW*8F
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M_E0 >V3Z=*,^Y_*D_$_E2^V3Z=* $_$_E2^V3Z=*,^Y_*D_$_E0 OY^O2D_
M_G2_GZ=:/?!]>M !CV/YT>^#Z]:3\#^=+CV/YT )^!_.EQ['\Z/?!]>M)^!_
M.@!??!]>M)^!_.EQ['\Z/?!]>M !CV/YT>^#Z]:3\#^=+CV/YT )^!_.EQ['
M\Z/?!]>M)^!_.@!??!]>M)^!_.EQ['\Z/?!]>M !CV/YT>^#Z]:3\#^=+CV/
MYT )^!_.EQ['\Z/?!]>M)^!_.@!??!]>M)^!_.EQ['\Z/?!]>M !CV/YT>^#
MZ]:3\#^=+CV/YT )^!_.EQ['\Z/?!]>M)^!_.@!??!]>M)^!_.EQ['\Z/?!]
M>M !CV/YT>^#Z]:3\#^=+W]_<T  Z8!X(X-)^.,]N^:.HZ'W'K[4N>V1GI0
MF/0?3VHR/7'?DT<'OG/OT%+G\?;% !TZY]3CFDZ=_J?6E_'C/;F@=>O/?- "
M>PX..!Z4<$$]OSS1]>W)ZTUW"<GMV_S]: !Y @R2/I6?/< #[W0>M+<7&!DG
MH/7I7.ZEJ87*AN?3- !J6I;5*@_0"L"..ZU2^CM[:)YIY6VHB\DGM_G_ ""*
M*ZU2]CMK6)YYY6"HB@DDG_.?\\>\>!O MOX6M!<7 2;5)%_>2CD1@_PK_C0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M5=2O1IVF7-Z8S(((R^P'&<>] %JBN8\+^+_^$DNIX#8_9C$F_/F[\\X]!6[J
M5Z-.TRYO3&9!!&7V XSCWH M45S'A?Q@/$=U/ ;'[,8DW@^;OSSC^Z,5T] !
M1110 4444 %%%% !1110 4444 %%%8OBN_N=,\.W-W9R>7,FW:VT'&2!T/%
M&U17(^ ];U'6;2\;4)_.:*10C;%7 (/' %==0 4444 %%%<]XSU2[TC0#<V4
MOE3>:J[MH; .>QXH Z&BN8\#ZM>ZQHTL]_-YTJ3% VP+Q@'L .]=/0 4444
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M]31]H7_)/X4 3>^#Z]:3\#^=1?:%_P DT?:%]/U- $V/8_G1[X/KUJ'[0O\
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M@ HHHH XCPK_ ,E+\?<?\MK'G_MV6NWKB/"O_)2_'W_7:Q_])EKMZ "BBB@
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M1@,TP;+'OC!&!^=+\4?^/G3?]R3^:UU/A#3[6V\,6ACA4-<1"25B,ER?7VH
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M]FJ'XGVP%S8707ED:-CZX.1_,U-\+O\ 5:I_O1?^S5/\3Q_Q+; X'^N;G\*
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M_P"M0!5_M>'T_44?VO#Z?J*M'P-?\XL[KV_=O[__ %J#X&O^<6=U[?NW]_\
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MC_CSNL_[C?Y_S]*7_A!;_/\ QYW/O\C?Y_S]* *G]L1^@_,4?VQ'Z#\Q5O\
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M/T'YBC^V(_0?F*M?\(+J&/\ CSNL_P"XW^?\_2E_X06_S_QYW/O\C?Y_S]*
M*G]L1^@_,4?VQ'Z#\Q5O_A!K_K]CN?\ OAO\_P"?I2?\(+J&/^/.ZS_N-_G_
M #]* *O]L1^@_,4?VQ'Z#\Q5O_A!;_/_ !YW/O\ (W^?\_2C_A!K_K]CN?\
MOAO\_P"?I0!4_MB/T'YBC^V(_0?F*M?\(+J&/^/.ZS_N-_G_ #]*7_A!;_/_
M !YW/O\ (W^?\_2@"I_;$?H/S%)_:\78#\Q5S_A!K_K]CN?^^&_S_GZ4G_""
MZAC_ (\[K/\ N-_G_/TH J?VO%V _,4O]L1YY[G)^85);^$9;MYEMD>8P2&*
M819;RW R5;'0X/3W''2I_P#A!K_K]CN?^^&_S_GZ4 4_[8B]!^=']KQ>@_,5
M;_X074,?\>=UG_<;_/\ GZ4O_""W^?\ CSN??Y&_S_GZ4 5/[8BST'YBD_M>
M+V_,5<_X0:_Z_8[G_OAO\_Y^E)_P@NH8_P"/.ZS_ +C?Y_S]* ,+4]4&TE&P
M#VS6!%%=:G>QVUK"\T\K;4C0<D_Y_P ^G9:CX#U5[1_L]C<M,,;5\MN?4?K^
MGXUZ-X&\"V_A>U%Q<A)M4D7]Y+CB,'JJ_P!3WH / W@6W\+6GVBX"3:I*O[R
M7&1&/[J_U-=C110 4444 %%%% !1110 4444 %%%% !1110 5Q/@O_D;_'/'
M_,3B[_\ 3!*[:N)\%_\ (W^.>O\ R$XNO_7!* .VHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .(\*X_X67X^]?.L?\ TF%=
MO7$>%?\ DI?C[C_EM8\_]NRUV] !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5C>+_\ D2M>_P"P=<?^BVK9K&\7_P#(E:]_V#KC
M_P!%M0!'X)_Y$+P[QC_B66W7_KDM;M87@G_D0O#O&/\ B66W7_KDM;M !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]3\(Q/I]YIS/'O+*DI,;*3UP<'([]*W]*\;ZEK.KVUO;Z2J6SOB5_F?:O<Y
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M_A%AD?\ +=\?I76T4 %>1>-$:P\;-<XX8QS#\,?U%>NUPOQ)THSV%OJ4:DM
M=DF/[IZ'\_YT =I*XDLW=>5:,D?E7DWP^1O^$LA^5AMB?((Z<=Z] \&WYU#P
MO:.Q)>(>2V?]G@?IBM^@".X_X]I?]P_RKR3X?(W_  EL.5.5BDR<=.*]?HH
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MB@ HHHH **** "BBB@ KB?!>/^$P\<\<_P!I1?\ HA*[:N)\%_\ (W^.>/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>*/!FEZPZA9;B$&51T#CAOU%6O$GAS3_ !7H<VD:HLC6DI5F$;E3E2".?J*
M.6\!>.=2\4^)O$^FWL%I'#I5QY4#0*P9AN8?-EB"?E'3%=_7S3\//AGX<\2^
M*_%>GZ@ET;?3;GR[<)-M(&YQR<<]!7=?&32K70O@LNEV(=;6UF@BC#L6.T'N
M>] 'KE<5XC\/>+-0\<:-J6DZ\MGHUMC[9:&1P9/FR?E *MD8')&*X;0OA3=^
M-M)LO$/BW7+Y+V2)&L[>S=5CMH@!M&"#R0 >,?4FI?B$"GQS\!(&)VA1R?\
M;- 'M-%<QXS\(S>,+:TM!KE_IEK'(6N%LFVM.I& I/;'7D$>U>8^)_A3X/\
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M_P#TP2NVKB?!?_(W^.>O_(3BZ_\ 7!* .VHHHH **** "BBB@ HHHH ****
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M*@<Y]S7=444 <MXUUW4M#@LWTY$8RLP?=&6Z 8Z=.M<=_P )_P")>/W,//\
MT[G_ !KUJB@#R;_A/_$HR3##@?\ 3 _XUZG9R/-96\LGWWC5FP,<D<U-10 R
M9BD$C+]X*2,_2O*?^$_\2_\ /&$?]NY_QKUFB@#R;_A/_$O_ #QA_P# <UU?
M@GQ!J>NM?#441?)$93;&4Z[L]_:NNHH *XGQGXFU;1-1@AL$C:-X=[;HRW.2
M.N?:NVHH \F_X3_Q*#CR8?\ P'/^-2VOCOQ'+=PQO%%L>0*2(#T)KU2B@ JA
MK=W-8Z)>75N 9HHF9 1D9[<5?HH \F_X3_Q+G_4P_P#@.U)_PG_B7'^IA_\
M <_XUZU10!SO@W5[[6M(FN-055F2X,8"IM&T*I_F371444 >>^*/%VMZ5X@N
M+.SCB,$80J6B)/*@GG/J:R/^$_\ $N3^ZAX_Z=S_ (UZS10!YOH/C+7M0UVS
MM+J*)899-KD0D$#![_A7I%%% &)XKU.[TG09+NQ"F=74 ,NX8)Q7 _\ "?\
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MG3= NKRT"F>,+L#+N'+ =/QKSO\ X3_Q+G'DP]?^>!_Q^M>LT4 >2_\ "?\
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M_I,*[>@#!\7:K>:/HGVJQ53-YJK\R;N#GM7!_P#"P/$N,^3#_P!^#_C7K5%
M'DW_  GWB;_GC#_X#G_&O1_#][<:CH-G=W043RIEPJX&<GMVK2HH *\NU'QS
MXAMM2NH(HHC'%,Z)F DD!B!WKU&B@#R;_A/_ !+VAA(/3$!_QK?\'^*=8UG6
M7M=0CC6$0,X*Q%?F# ?UKNJ* "N6\:Z[J6AP6;Z<B,968/NC+= ,=.G6NIHH
M \E_X3_Q+Q^YAY_Z=S_C1_PG_B7/^JA_[\'_ !KUJB@"&SE:>RMY7QO>-6;
MXR1FGRL4A=AU5213Z* /)?\ A/\ Q+Q^ZA_[\'_&E_X3_P 2Y/[J'C_IW/\
MC7K-% '(^"?$&IZZ;[^T411#LV;8RO7=GZ]*ZZBB@#B?&?B;5M$U&"&P2-HW
MAWMNC+<Y(ZY]JYS_ (3_ ,2@X\F'_P !S_C7K-% 'E=KX[\1RWL,;Q0[&D4-
MB ]"?K7=^+_^1*U[_L'7'_HMJV:QO%__ ")6O?\ 8.N/_1;4 1^"?^1"\.\8
M_P")9;=?^N2UNUA>"?\ D0O#O&/^)9;=?^N2UNT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY!_*N[HH AM;2WL;:.VM((H+>,;4BB0*JCT ' J:BB@ HHHH **** "BBB@
MHHHH **** "BBB@ K&OO"FB:EX@LM>N[+S=3L1BWF\UQLZ_P@[3U/4&MFB@
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MW*WS'GKSZ=S>^''B'Q'I7C[4_ 7B74&U)K>+S;6[D.791@\D\G((/)R"#R:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+V\*-C*S-$@/7 V\FM;Q^'/A72R/NAUW?]\<5J_#YD/A.()C(E<-CUSW_#%
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MI6 /K@K72V?A0?\ "'C1+^16;);S(NB-G((R!0!R6EV/BWQ%:MJ$&M2(F\J
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MKZT_XB:G?6.J62VM[<P(82Q6&5D!.3UQUJ.U\!:Y_:\%[>:A;RE)5=W,SNY
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M?[#;5]XLR#RN?OX/8MWZ;NV*]\\5_#R7Q)X7TSPY%KUQ::=:E!<;XO-EN54
M ,VX8]>AYQQQ73-X>TMO#?\ PCYM4_LS[/\ 9_( XV8Q^?OZT +:ZG::UX=3
M4K&42VMS;F2-QW!'\Z\J_9VOK1O#NK6 N(S>+>M,T.?F"%5 ;Z9&.]=CX(\$
M7/@3P[J&EMK3:C9L6DMT>#RS!D'(SN.<]>W.?6O)/A9\/;7Q9X5N]2@U&\TG
M6K:_=(-0M)"&"[5X(!&1R>A!YZT =9^T1=0R>&](T="K7UW?!HH^K8 ()_-@
M*ROCKIQAM/!;WDLJ6<,GV>XD0X9.$R0><'"MV[5U_AOX/P:;XABU[Q!KU[XB
MU*#_ %#W8(5".AP68DCMS@>E=MXB\.Z9XIT6;2M6@\ZUEP< X96'1E/8B@#@
M8_@AH<L:R1^*/%#HX#*RWZ$$'H1^[KH?!OPVTCP/=7]UIUWJ-S<7JA9)+V97
M/!)_A4=SU.:YFW^$7B#2XC::+\2-7L].'$=N\/F&,>@8. /P KM/"'A-_"MK
M<)-KFIZO<7+*TD]_,7(P, +GH/Q- 'FOP$E2SU;Q?I,[;+Y+P.T3=< NI/X'
M^8KVN2:*)HUDE1&D;:@9@"QZX'J:\\\6_"2RU_73K^D:O>:#K+?ZRYM"</QC
M) *D''<$9I?#7PJ.E:];:[KGB;5->U*TW?9WN7(2/(P<*68]">^/:@#G?BA\
MOQD\ LW"^9U/_705Z#\0[2:^^'?B"WM\^:]E)M [X&<?B!53X@?#RR\>V5JL
MMY-8WUFY>VNHAN*$XR",C(X!X(.1UJ3P5X/U'PO'>'5?$]_KTUSM >[+;8U&
M>%#,W7//- 'E/PO^&VB>+O!-OJ#:_KUO<+(\4\%I>*B1L#QA2AQD$'KWKM['
MX(>'[/6++4WU?7KN:SE66);JZ1UR#D9^0''T(J*^^#26VKSZEX2\3:CX<DN&
MW310 R1-W^[N7CV)(]*TO#_PYU33M;M]5UGQQK6KR6[%T@9C' 201\R;F!Z]
ML4 <E\09ETSX]^#=0N\+:,@C#L?E!W,OZ%U/Y5[)?W=O86$]U=S1P6\2%I))
M&PJCU)K!\;>!M)\=Z0MCJ0='C;?!<18WQ-[9Z@]Q7'V'P7E=XH?$GC+5];TR
M%@T>GR.T<1QT#9=LCZ8H SOV>9%ETOQ)(ARKZAN4^H*U[/7'^ ? <7@6'58H
MKX7*7UT;A56#RA$O9 -QSCUX^E=A0!XMQ_PU2?\ KP_]HU)\6?\ DJ7P^_Z^
M6Z_]=(Z[+_A !_PM/_A-O[2.?L_D?8_(_P!G;G?N_3%+XK\!#Q1XI\/:V=2^
MS?V/*9/)\C?YWS*<9W#;]WT- '7S?ZB3G'RGG\*\F_9^_P"14UC_ +";_P#H
M*UZTZ[XV3^\"*Y/X?^!QX$TJ\L1J'VW[3=-<;_)\O;D 8QN.>G6@#KJB@N;>
MY#FWGCE$;E'\MPVUAU!QT(]*EKS+7/@]'=:W=ZSX>\3:KH%]=OOG-NY9&)Z\
M J>3VW$>U &)^T'I.CP^&+76!%%;ZRMTB0S1@+)(N#D$CDXP#GM^-;?B>PU'
MQ1\ P+A7?4FTZ&Y92.6=0K'\2 :@TWX)VTFJPZCXK\1ZEXDG@.8DN25C ZX(
M+,2,]@0/4&O4P JA5   P .U 'G/P4\26FM_#VQLDF4WFFK]GFB+?, #\K8]
M",<^QKNM6U6RT32[C4M1G2"UMT+R.Q_3W)Z 5YWKWP1TJ]U>35_#^JWOA[4)
M"26M#F,$]2%!4C/H& ]JHCX%R:F0/%/C;6M9C3F)&8J$.,9^=G_3% %/X'6M
MQJVN>)_&<\;I%J$YB@W=QN+-]<?*/P->UUXKIMC\1OA;)'I]E9IXG\-!_P!V
ML0VS0@GT&6'7/1A]*]I4DJ"1@D<CTH YSQMXTTSP/H3ZC?MND/RV]NI&^9_0
M>WJ>U<1X!\&ZIKNO?\)]XT4MJ$OS6%DP^6V3^$X[''0?B>3Q?^(/PFF\<^(K
M75XO$<NFO;0B.-%MS)M(8G<IWK@\_I67_P *@\8?]%9US\IO_C] 'HGC*PDU
M3P5K=C$I:2>RE1 !U)4X%<1\ =4BO/ATMB''VBQN9(Y$[@,=P./Q(_"NR\&^
M'M1\-:*UCJ?B"ZUR<REQ<W(;< <?+\S,<<>O>N/UGX,PRZY/K'A?Q'?^'+JY
M),ZVH)1L\G #*1D\XR1["@#)^/\ ="_M- \,6I\R^OKU7$:\L%Y4<>Y;]#7L
M-I +6S@MUZ11J@Q[#%<'X2^%%CX?UK^WM5U6\U[6@,)=WAX3C&5!).<=R3CM
MBNF\6:)?^(-">PTW6[C1KEG5A=P*2P /(X93S]: /+_BM_R5_P !\9_>CI_U
MU%>V5XI>_ K7=1O;>]O?B-?7%U;',$TMHS/%SGY29LCGTKN_!/A#6O#$MX^K
M>+[W7EG"B-;E& B(SDC+MUS[=* +OCKQ+'X2\':AJ[$>;''M@4_Q2MPH_/GZ
M UR/P,\-R:7X/DUJ]RU_K,GVAW;[VS^'/UR6_P"!5N?$+P _CZ/3K676'L[&
MVF\V:!8-YG/UW#;QGL>M=A;V\5I;16\"!(8D"(HZ  8 H EHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P S72_\)WIP.#:7O_?"?_%4 =117+_\)WIO_/K>_P#?*?\ Q5'_  G>F_\
M/K>_]\I_\50!U%%<O_PG>F_\^M[_ -\I_P#%4?\ "=Z;_P ^M[_WRG_Q5 '4
M45R__"=Z;_SZWO\ WRG_ ,51_P )WIO_ #ZWO_?*?_%4 =117+_\)WIO_/K>
M_P#?*?\ Q5'_  G>F_\ /K>_]\I_\50!U%%<O_PG>F_\^M[_ -\I_P#%4?\
M"=Z;_P ^M[_WRG_Q5 '445R__"=Z;_SZWO\ WRG_ ,51_P )WIO_ #ZWO_?*
M?_%4 =117+_\)WIO_/K>_P#?*?\ Q5'_  G>F_\ /K>_]\I_\50!U%%<O_PG
M>F_\^M[_ -\I_P#%4?\ "=Z;_P ^M[_WRG_Q5 '445R__"=Z;_SZWO\ WRG_
M ,51_P )WIO_ #ZWO_?*?_%4 =117+_\)WIO_/K>_P#?*?\ Q5'_  G>F_\
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M]-_Y];W_ +Y3_P"*H_X3O3?^?6]_[Y3_ .*H ZBBN7_X3O3?^?6]_P"^4_\
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MB@ HHHH **** .(\*_\ )2_'W_7:Q_\ 29:[>N(\*X_X67X^]?.L?_285V]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>+_^
M1*U[_L'7'_HMJV:QO%__ ")6O?\ 8.N/_1;4 1^"?^1"\.\8_P")9;=?^N2U
MNUA>"?\ D0O#O&/^)9;=?^N2UNT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 -D021M&WW6!4X]ZY[P;X+TWP/IMQ
M8:9+=2Q3SF=FN75FW$ 8&%''%='10 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !14-S=VUG%YMU<101CJ\KA1^9J.UU.POG9+2
M^MKAE&6$,JN0/P- %JBBB@ HJO?7D=A8SW<P8QPH78*,G ]*S-!\4V/B)YDM
M(KB,P@%O.4#KZ8)]* -NBBB@ HHHH **** "BBB@ HHHH **** "BBH;NZCL
MK.:ZESY<2%VV]<#TH FHK"T'Q98>(;B6&TBN8VB7<?.50",XXP36[0 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKDGFW,+)/C'FQ-M8_7L?Q%4]/\!:)I]PL^R:X="&7SW! (]@ #^- '3T444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'SQI0^;IU/\ A756GW/KW_\
MK]ZY72_O'/K_ (5U5J,)SV_^M0!8?[WIDTG?J>OI2OPQ[<TWZ#@=,<4 '7K_
M "HX]CGG@?E2^PSZ9S1GW_#% "?7\>.]'U_'CO1_3CK0.V/PYZB@ ^OX\=Z/
MK^/'>@=L?ASU% [8_#GJ* #Z_CQWH^OX\=Z!VQ^'/44#MC\.>HH /K^/'>CZ
M_CQWH';'X<]10.V/PYZB@ ^OX\=Z/K^/'>@=L?ASU% [8_#GJ* #Z_CQWH^O
MX\=Z!VQ^'/44#MC\.>HH /K^/'>CZ_CQWH';'X<]10.V/PYZB@ ^OX\=Z/K^
M/'>@=L?ASU% [8_#GJ* #Z_CQWH^OX\=Z!VQ^'/44#MC\.>HH /K^/'>CZ_C
MQWH';'X<]10.V/PYZB@ ^OX\=Z/K^/'>@=L?ASU% [8_#GJ* #Z_CQWH^OX\
M=Z!VQ^'/44#MC\.>HH /K^/'>CZ_CQWH';'X<]10.V/PYZB@ ^OX\=Z/K^/'
M>@=L?ASU% [8_#GJ* #Z_CQWH^OX\=Z!VQ^'/44#MC\.>HH /K^/'>CZ_CQW
MH';'X<]10.V/PYZB@ ^OX\=Z/K^/'>@=L?ASU% [8_#GJ* #Z_CQWH^OX\=Z
M!VQ^'/44?3-  /7\^.M'\QU'K2X_SFD[9_*@ _I[TO?MD>]'&>O?UH'7_P"O
MTH 3'H,D=SZTN/;CV-)Z CTX[48]L?2@ [9Z\=12]>.O8X[4=^G.<TG^10 >
M^?H:.W3ZBESSG.,=<^E)Z9_'F@ Y_'^=''3IZ>WTH]/\.] /?\\T 'KV[D8Y
MI1QQ^5)^..G'>CISC@9/% #NHP:IW-N&!-233[?E!YZ9_P _YYK)N[[RU)+'
ML0"?I0!4OK+<K#;G\.M:7@[QC-X6NA97I:329&R>Y@)/WE']WU7\1SUX^_U.
M5V($C<?[5:O@OP??>+K[>\DL6FQ,!-.>_P#LKGC<>#[9Y[ @'T)#-%<01SPR
M+)%(H9'4Y# ]"#3ZKV-C;:;8PV5G$(K>% D:#L*L4 %%%% !1110 4444 %<
M3X+Q_P )AXY]?[2BYQ_TP2NVKB?!?_(W^.>G_(3BZ?\ 7!* .VHHHH ****
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M& Q=1C/7..WI7?T <]XH\4CPVMM_H9N6F)X\S8 !CV/K7-_\+2;_ * H_P#
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M/01/$V/4;B<UW]E>0:A9Q7=L^^&5=RF@">BBB@ HHHH **** "BBB@ HHHH
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MO0 O/OSS]*.??GGZ4GU_'CO1]?QX[T +S[\\_2CG'?U^E)]?QX[T#U_/CK0
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MMNO_ %R6MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"IKSQ'K?BS3FLK/3_)@"9N)58D, ,GG' ]N2: +'PO\ ]=J7^['_ %K&N_\
MDI1_[""_^A"MKX7@^;J1P<;4Y_.L:[5O^%ED8.?MZG&/]H4 =]XJU^QT.*W>
MXM5NKDL6@0@?*1_%D@XZ]JY.7QEXDU*PF\K1HWM)$96D6WD8 8Y.<XJ[\1]&
MN[IK;4;>)Y4C0QR! 25YR#CTK.A\:ZG>Z3'HUCI8:X,0@WH2W&,<+CCCWQ0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'EGA'PO
M::YIMW(K>1]EOI[,Y7>9/+?;OSQC..G;]:W_ /A7EM_S]C_OS_\ 94WX8_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1I5G-_ST@1^?=0:M54TJ(PZ191'JD"*<^RBK= !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q/PQ_P"0
M/K7_ &';[_T::[:N)^&/_('UK_L.WW_HTUVU !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Q/PW^YXK_P"QDO?YK7;5Q/PW^YXK
M_P"QDO?YK0!VU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Q/P__ .0EXT_[&";_ -%15VU<3\/_ /D)>-/^Q@F_]%15VU !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q/@O\
MY&_QST_Y"<73_K@E=M7$^"_^1O\ '/.?^)G%_P"B$H [:BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XCPK_ ,E+\??]=K'_
M -)EKMZXCPKC_A9?C[U\ZQ_])A7;T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !6-XO_P"1*U[_ +!UQ_Z+:MFL;Q?_ ,B5KW_8
M.N/_ $6U $?@G_D0O#O&/^)9;=?^N2UNUA>"?^1"\.\8_P")9;=?^N2UNT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56
MO[5;[3[BU;[LT;)^8JS10!Y5\/KAK#Q//8S?*TJ-&0?[ZG./T-=-JW@8:OKS
M:C/J)\MF7,/DY^4=L[OZ5)=>"UE\3+K5M?FW82+*T8BSEAUYSW^E=70 @
M P!T K&\2^'H_$5@ENT_D/&^]9-F['8C&16U10!REGX'MHM!DTF\O)+B-IO-
M1T788SC' R:R'^%L9DRFK,%[ V^3^>ZO0J* ,#0/".G: WG1;YKHK@S2=O7
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M^"\?\)AXY]?[2BYQ_P!,$KMJXGP7_P C?XYZ?\A.+I_UP2@#MJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B/"O_)2_'W'_
M "VL>?\ MV6NWKB/"O\ R4OQ]_UVL?\ TF6NWH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "L;Q?_R)6O?]@ZX_]%M6S6-XO_Y$
MK7O^P=<?^BVH C\$_P#(A>'>,?\ $LMNO_7):W:PO!/_ "(7AWC'_$LMNO\
MUR6MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M )\K[_OE,_\ H7^<UU&J:)IVM)$NH6_G+$24&]EP3UZ$5F?\()X:QC^S>/\
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MA_Q';>(H)I;:&:(1,%82@<DC/&":V*H:7HNGZ+')'I]OY*R'<XWLV3^)-7Z
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M7D9'8CU- ')_\+0TG_GRO?Q">_\ M>U'_"T-)[65[^2>_P#M>U:W_""^&_\
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MA><YZ8)]*K_\(+X;_P"@:/\ O])_\56EI>B:=HJRKI]OY(E(+_.S9QTZD^M
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MMQ'OAETFW1T)(R#$N1Q2_P#"">&O^@:/^_TG_P 50!D_\+0TKM97I].$Y_\
M'JZ/0->M_$-C)=VT4L<:2F+$@&20 <\$\<U2_P"$$\-?] T?]_I/_BJU=,TF
MQT:V:WL(/)B=_,9=S-EL 9Y)[ 4 7:Y;6?'6GZ)JDMA/:W4DD>TEHPI!R >Y
M'J*ZFL;4/"FB:I>/=WMB)9W #/YKKD 8' (% &!_PM#2?^?*]_)/_BO\YJWI
MGQ T[5=2@L8;2[629MJLP7'UX/2K?_"">&_^@;_Y'D_^*J:T\(:#8W<=U;6
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M34+7SFC&%/F,N!U[$4 <U_PM#2<?\>5[S[)_\53D^)NE.ZJ+*]^8@ [4[_\
M JU/^$$\-YS_ &;_ .1Y/_BJ5? WAM6##31D'.?.D_\ BJ .AJ"]NDL;"XO)
M%9D@B:5E4<D*"3CWXJ>H[B".ZMI;>9=T4J%'7)&5(P1Q0!Q?_"T-)_Y\KW\
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M '/?\+0TD]+*^/\ P%/_ (JI[+XC:9?7UO:1VEXKSR)&I8+@%CC/WNG(J_\
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M>=K>:YQD$'@G'0FMF@#*U_7;?P]8)>7,4LB-((P(P,Y()[D>E<Y_PM#2<?\
M'E>\^R?_ !5=9J6E66L6PMK^'SH@X<+N*\C([$>IK)_X03PWG/\ 9O\ Y'D_
M^*H R?\ A:&DY'^A7O/LG_Q5==IU]'J6FV][$CHDZ!PK]1GUK'_X03PW_P!
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MXGP7_P C?XY'/_(3BZ_]<$KMJXGP7_R-_CGC_F)Q=_\ I@E ';4444 %%%%
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M_1"4 =M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <1X5Q_PLOQ]Z^=8_P#I,*[>N(\*_P#)2_'W'_+:QY_[=EKMZ "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHIKNL:,[L%51DLQP * '456M=0LK[=]CO+>XV?>\F57Q]<&K- !1
M13)98X8FEED6.-1EF<X 'N: 'T56M-0LK\,;.\M[@+][R95?'UP:LT %%%%
M!1110 4444 %%%% !14<]Q#:Q&6XFCBC7J\C!0/Q--MKRVO8O-M+F&>/.-\3
MAAGZB@":BBHKBYM[2$S7,\<,0ZO(X51^)H EHJ&VO+:]B,MI<PSQ@X+1.&&?
M3(J:@ HHHH **** "BBB@ HJK-J=A;W"V\]];13-]V-Y55C] 3FK5 !1110
M4444 %%%% !1110!XSX8UV]MK6>"QNC;M+.]Q*NQ6WR.<LV6!ZD].W:MW_A(
M=?\ ^@BW_?F/_P")K@M(+)*'7(8'*G\J]$T<0:C" P"3* 2#P&]QS0!!_P )
M#K^?^0BW_?F/_P")H_X2'7_^@BW_ 'YC_P#B:VO[(C'/R>W/'\_I2_V/'T&W
M\Q_C]* ,3_A(=?Q_R$3_ -^8_P#XFC_A(=?S_P A%O\ OS'_ /$UM?V1'QC8
M!]1_C]*/[(C'/R>W/'\_I0!B_P#"0Z__ -!%O^_,?_Q-'_"0Z_C_ )")_P"_
M,?\ \36W_8\?0;?S'^/TI/[(CXQL ^H_Q^E &+_PD.OY_P"0BW_?F/\ ^)H_
MX2'7_P#H(M_WYC_^)K:_LB,<_)[<\?S^E+_8\?0;?S'^/TH Q/\ A(=?Q_R$
M3_WYC_\ B:/^$AU_/_(1;_OS'_\ $UM?V1'QC8!]1_C]*/[(C'/R>W/'\_I0
M!B_\)#K_ /T$6_[\Q_\ Q-'_  D.OX_Y")_[\Q__ !-;?]CQ]!M_,?X_2D_L
MB/C&P#ZC_'Z4 8O_  D.OY_Y"+?]^8__ (FC_A(=?_Z"+?\ ?F/_ .)K:_LB
M,<_)[<\?S^E+_8\?0;?S'^/TH Q/^$AU_'_(1/\ WYC_ /B:/^$AU_/_ "$6
M_P"_,?\ \36U_9$?&-@'U'^/TH_LB,<_)[<\?S^E &+_ ,)#K_\ T$6_[\Q_
M_$T?\)#K^/\ D(G_ +\Q_P#Q-;?]CQ]!M_,?X_2D_LB/C&P#ZC_'Z4 8O_"0
MZ_G_ )"+?]^8_P#XFC_A(=?_ .@BW_?F/_XFMK^R(QS\GMSQ_/Z4O]CQ]!M_
M,?X_2@#$_P"$AU_'_(1;_OS'_P#$U3TZYU#2/M?V&Z:+[7<O=S_(C;Y7QN;D
M'&<=!QQ73?V1'QC8!]1_C]*/['CQVZ8[<_K0!B_\)#K^<?VB?^_,?_Q-'_"0
M:_\ ]!$_]^H__B:V_P"R(_;_ #^-)_8\?J/T_/K0!B_\)!K_ /T$3_WZC_\
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M[(CSGCKG_/-']D)Q\PX]2/\ &@#$_P"$AU__ *")_P"_*?\ Q-'_  D.O_\
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MH *XGP7C_A,/'/'/]I1?^B$KMJXGP7_R-_CGC_F)Q=_^F"4 =M1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <1X5_P"2E^/N
M/^6UCS_V[+7;UQ'A7_DI?C[_ *[6/_I,M=O0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %8WB__ )$K7O\ L'7'_HMJV:QO%_\
MR)6O?]@ZX_\ 1;4 1^"?^1"\.\8_XEEMU_ZY+6[6%X)_Y$+P[QC_ (EEMU_Z
MY+6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !6=KFJIHND3WSIO\L?*OJ3P/UK1K&\4Z5)K/A^XM(?\ 7</&,]2#G'X]
M* ."T^7Q9XNGFEMM1>WCC/)65HD!]!MY-=#X=C\5Z=KD=GJCR7%BZMF5F\P
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MU6L;Q9_R*NI?]<37EWB?PLWAN:!3<)<1S D-LVD$=<C)]?YUV$&D)I/PXO\
MR[EIEN8?/!\O;M! XQD_G0!2^%_^OU+_ '4_F:]'KS3X;PK<IJ\#DA9(E0X/
M(!W"LOPK.^@>,_LL^5#.UM)[G. ?S H ]?HKB/B3J/D:3!8JWS7#[F'^RO\
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M@ZJ-<T"PU46\EN+N!9A%)]Y,C.#6%\2?%-[X/\$76MZ;';S7$3QJJSJ60AF
M/W2#T/K4\_B2[C^&C>)1%#]L&F_;/+(/E[]F[&,YQ^/XT =/17B^C?%KQ=XL
MTFWB\+^&(+_5DCW7T[YBM86SPHW."QQ_M?3/;:\%_$O5[_Q;+X2\7Z/%IFM*
MN^,P,3')QG&,MVY!#$'GI0!Z=17$>/OB WA*;3]+TW3FU/7-2;;:VJMM'IN8
M^F?Y'D8S7#^)?B!\6_"6F)J.K>'= CM"0K2QAW$;'H&Q-D?7I[T >WT5S?@G
M4/$6J: M[XCATZ*>8AX/L!8HT14%2=Q//)[UT9.%)P3@=!WH 6BO+#XH^+&J
MS/+I/@W3K&T!(3^TYCO?!QT#J1^(_&K?@OXC:IJ/BF?PGXKT>/3-<BC\U?(?
M='*.O')QQR/F.>>E 'I%%>;_ !'^)5QX#\1Z!;M#;MIEYO:[=XV:154K]S#
M9Y[@UB7OQ!^)S6+Z]8>![:/053S@MS)NN#$/XMH<$<<_<./<<T >QT5SO@CQ
M?:>-O#,&L6L30EB4EA8Y,;CJ,\9'3GWKB=9^*/B'4O%=WX=\ Z##J=Q8DBYN
M;E\1*0<$#YE'7C);D@X'% &E\9O%&L>$_!\%]HEY]ENGNUC+^4C_ "D,2,,"
M.P[5W]G(\MC;R2'+O&K,?<CFOF_XL>,]<U#PO#X?\5^'VTO6$N5G22)MT$Z
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M;E9/3/O[UA)X*\5I&(5UQ$@ P$6ZEP!],8H Z;POX67PVEP/M9N&G(R?+V
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M&?<_E2?B?RH 7/N?RI/Q/Y4OMD^G2C/N?RH /;)].E&?<_E2?B?RI?;)].E
M"?B?RI?;)].E&?<_E2?B?RH 7/N?RI/Q/Y4OMD^G2C/N?RH /;)].E&?<_E2
M?B?RI?;)].E "?B?RI?;)].E&?<_E2?B?RH 7/N?RI/Q/Y4OMD^G2C/N?RH
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MNH\+<6Y.3&WMZJ>Q_J#6]0 4444 %%%% !1110 4444 %<3X+_Y&_P <\?\
M,3B[_P#3!*[:N)\%_P#(W^.>O_(3BZ_]<$H [:BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH XCPK_P E+\??]=K'_P!)EKMZ
MXCPKC_A9?C[U\ZQ_])A7;T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'3I7?4 <?\.AXS_L&8^-R/[1,Y\L#RLB/ Q_JOEZY]ZXS]HW_D1M/_Z_U_\
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M =/\0XTE^'7B%)%#+]@E.#ZA21^M<O\ #;6(/#WP-L=7NHIY8+6&21T@3<Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_.@!,^^/8TI_+L,4<XR.<C\*3CM]!SR?:@ [Y]>F11^!_.EZ=/PI.![#Z]*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG^#_  _;Z/IH?R8LLSN<M(YZL?<UM444 %%%% !1110 4444 %%%% !1110
M4444 %<#I7@?4K'XO:MXMEN;5K"\MA%'$K-YH.$'(*XQ\IZ'\*[ZB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***J:K=BPTF[NS_RQB9Q]0.* .3D
M\97]QXP72-/@MGM_-$;.ZL6X^\<@XXY[5V<\\-M"TT\J11*,L[L !^)KS+X;
M6OVC7;J\DY:*+@X_B8]?RS^=3?$R^F-]:V(++ L?F$9X9B<?IC]: .K;QOX<
M63RSJ2[LXR(G(_/;BMJUN[>]@6>UFCFB;HZ-D5QV@^#/#]_X?MIW1IY9HPS2
MK*05;N !QP>.16]X=\/Q>';:>WAN'F267S!O4 KP!CCKTH $\5:*^I#3EO1]
MJ,GEA/+?[V<8SC'ZULUXU;C_ (N'$/\ J(C_ -#KV6@#'7Q5HKZD-.6]S=&3
MRPGE/][IC.,?K3+[Q;H>FWDEI=WOESQXW*(7;'&>H4BO-+?_ )*%%_V$1_Z'
M7IM]X4T34[M[J[LO,G?&YO-=<XXZ XH J_\ ">>&O^@B?_ >7_XFGQ>-O#T\
MR0QZ@6D=@JCR).2?^ UYEKUA:V7BV>QMXMELDR*J;B>"%SR3GO7IT7@OP];S
M)-'IX5XV#*3-(<$?5J -R26.&,R2R+&@ZLQP!^-8<WC;P[ Y1]24D?W(W<?F
M 17!^(-6O?%7B)=,M'/V<2^7"F>"1U8^O<_2NOL/A[HEO;JMU')=RX^9VD9!
MGV"D8'US0!KV'B71M3D$=IJ$3R,<!&RC'Z!@,UG^,-<U+0;."ZL8K>2-GV2>
M<C'!QQT(JK+\/-+%W#<V<TULT<BOLSO4X.>_/ZUJ^++1;WPQ?1D<K&9%^J\T
M 6-!U5=:T:WO@ K.,2*.BL."*TJ\\^&-\2M]8$\#$R_R/]*]#H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH 7WZX/ITI._7G^='H<_0^M';KCCZD4 '3V_&E]\'UZTAXR>G?Z_6E]?;WH
M/;G Q1WXXI/QSCU%'&/;/3% !^A/3)I>??TH[_6D[= ?;MF@!?4]!].M)TQT
M';B@_7\?2E[]AF@ _7!I.P[G'0T?PC&,=L<CVI>_3O0 G&#R,=< =J7O[XYX
MHZCU[YI/I]1DT ']/QI>_O\ SH_/V-'0\4 '/O1^>>U X([?X4>G4<>M "<8
MQC@C./6CU[]>AH]OTSR*7GZX]* #UZCFD ],#MQ1VXYXQUI>N#U]* #Z<#Z4
MGX$_C1Z^N.?4TO?H>OK0 =.QSVYH^F3UI.V.>1@9-!QU)X]CTH /S.*7^+M_
M]:CO^-'IR<8XXH 3/Z<T%MHY/3U%(S +DGW&?\*IW%QUYQ[9_P _Y% "3S_[
M0]/\_P">U8>HZB(P0#R!1J&HB,$ \]S7*W-TT\G'X<<_YXH +JY:=\=0>WK7
MKGP[^'?V+RM:UJ'-V<-;V[C_ %7<,P_O=P.W7KT3X=_#O[$(M:UJ'_2CA[>V
M<?ZKCAF'][T';OST]0H **** "BBB@ HHHH **** "N)\%_\C?XYZ_\ (3BZ
M_P#7!*[:N)\%X_X3#QSQS_:47_HA* .VHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .(\*X_X67X^]?.L?\ TF%=O7$>%?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!\\:4/FZ=3_ (5U5IG9GG(/7\JY72_O''K_
M (5U5H/DX&.?RH L/]XC\*3/N?RI7ZGL/RXI.?7';B@!.@]..@%+[9/ITH]^
MF3Z=:3\3^5 "Y]S^5)^)_*E]LGTZ49]S^5 ![9/ITHS[G\J3\3^5+[9/ITH
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MZ1QJ1PS 87)(Z]@:[CPOH4'AGPSI^CP?=M851F_O-U8_B<F@#7HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YYLK.\-MOB4IO^
MZ_MZ_I2?V1?_ -Y_S_S_ )'UKTWX=00WNDZLUU%'.T>LWD2&50Y5%D(51G.
M!P!VKL/[,L/^?&V_[]+_ (4 >!?V1??\]&_S_G]/K1_9%_\ WW_S_G_/->^_
MV98?\^-M_P!^E_PH_LRP_P"?&V_[]+_A0!X%_9%__??\/\_YXH_LB_\ [[_@
M?\_YQZU[Y_9>G_\ /C;?]^5_PH_LO3_^?&V_[\K_ (4 >!_V1??WV_/_ #_G
M%']D7W]]OS_S_G%>^_V;8?\ /E;?]^E_PH_LRP_Y\;;_ +]+_A0!X%_9%]_?
M;\#_ )_SCWH_LB^_OM^?^?\ .*]]_LVP_P"?*V_[]+_A1_9MA_SY6W_?I?\
M"@#P+^R+[^^WY_Y_SBC^R+[^^WX'_/\ G'O7OO\ 9EA_SXVW_?I?\*/[-L/^
M?*V_[]+_ (4 >!?V1??WV_/_ #_G%']D7W]]OS_S_G%>^_V;8?\ /E;?]^E_
MPH_LRP_Y\;;_ +]+_A0!X%_9%]_?;\#_ )_SCWH_LB^_OM^?^?\ .*]]_LVP
M_P"?*V_[]+_A1_9MA_SY6W_?I?\ "@#P+^R+[^^WY_Y_SBC^R+[^^WX'_/\
MG'O7OO\ 9EA_SXVW_?I?\*/[-L/^?*V_[]+_ (4 >!?V1??WV_/_ #_G%']D
M7W]]OS_S_G%>^_V;8?\ /E;?]^E_PH_LRP_Y\;;_ +]+_A0!X%_9%]_?;\#_
M )_SCWH_LB^_OM^?^?\ .*]]_LVP_P"?*V_[]+_A1_9MA_SY6W_?I?\ "@#P
M+^R+[^^WY_Y_SBC^R+[^^WX'_/\ G'O7OO\ 9EA_SXVW_?I?\*Y#P##'>#Q/
M]JC6?R?$%W%%YJ[MB#;A5ST4>@XH \Q_LB^_YZ-_G_/Z?6C^R+_^^_\ G_/^
M>:]]_LRP_P"?&V_[]+_A1_9EA_SXVW_?I?\ "@#P+^R+_P#OO^'^?\\4?V/?
M _?;^A_S_C7OG]EZ?_SXVW_?E?\ "C^R]/\ ^?&V_P"_*_X4 >!_V1??WV_$
M_P"?\Y]J/[(OO[[?3/\ G_.:]]_LRP_Y\;;_ +]+_A0=,L#UL;;_ +]+_A0!
MX%_8]_\ \]'_ ,_Y_G1_9%__ 'W_ ,_Y_6O??[,L/^?&V_[]+_A2?V7I_P#S
MXVW_ 'Y7_"@#P/\ LB__ +[_ .?\_K1_9%]_?;Z9_P _YS7OG]EZ?_SXVW_?
ME?\ "E_LRPQC[#;?]^E_PH \"_LB_P _??\ /_/^<T?V1?8_UC'W_P _YZU[
M[_9EA_SXVW_?I?\ "C^S+#_GQMO^_2_X4 >!?V1?Y^^_^/\ G_&C^R+_ /ON
M?\_Y_.O??[,L,8^PVW_?I?\ "D_LO3_^?&V_[\K_ (4 >!_V1??\]&/^?\_K
M1_9%]_?;\3_G_.:]]_LRP_Y\;;_OTO\ A0-,L!TL;;_OTO\ A0!X%_9%]_?;
M\3_G_.?:C^R+[^^WY_Y_SFO??[,L/^?&V_[]+_A1_9MA_P ^5M_WZ7_"@#P+
M^R+_ /OO_G_/ZT?V1??WV^F?\_YS7OG]EZ?_ ,^-M_WY7_"E_LRPQC[#;?\
M?I?\* / O['O_P#GH_\ G_/\Z/[(O_[[_G_G_)^E>^_V98?\^-M_WZ7_  I/
M[+T__GQMO^_*_P"% '@?]CWW9VY[_P"?\\4?V1?8_P!8X]>/S_S[5Z;X'@BO
M+_Q:MU$DZP:Y+%")5#"-!'&0JYZ#D\#UKK_[+T__ )\;;_ORO^% '@?]D7_/
MSN/Q^O\ A1_9%_S\[_X=?\*]\_LO3_\ GQMO^_*_X4?V7I__ #XVW_?E?\*
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M=M7$_#__ )"7C3_L8)O_ $5%7;4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7$^"_^1O\ '/'_ #$XN_\ TP2NVKB?!?\ R-_C
MGK_R$XNO_7!* .VHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .(\*_\ )2_'W_7:Q_\ 29:[>N(\*X_X67X^]?.L?_285V]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>+_^
M1*U[_L'7'_HMJV:QO%__ ")6O?\ 8.N/_1;4 1^"?^1"\.\8_P")9;=?^N2U
MNUA>"?\ D0O#O&/^)9;=?^N2UNT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_94 =Q_;^C?]!>P_\"4_QJ]%+'/$LL,B21N,JZ,""/8BO.?^%5-C_D+K_P"
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M.[  #W)I]4]6L?[3TFZL?,\OSXS'OQG&?:@"+^W]&_Z"]A_X$I_C1_;^C?\
M07L/_ E/\:X?_A5;YYU=/_ ;_P"RH_X54^/^0NN?^O;_ .RH ]#MKRVO8S):
M7,,\8.TM$X8 ^F1WY%35B>%O#Y\-Z9+9FY%P9)C+O";>JJ,8R?[OZUMT 4I]
M8TRUF:&XU&TAE7[R23JK#OR":C_M_1O^@O8?^!*?XUS?B'P"==UF;4!J(A\P
M*-GD[L8 '7/M67_PJM^/^)NG'_3M_P#94 =W#K.E7$JQ0ZG9R2,<*B3J23[
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MM_1O^@O8?^!*?XU3\4^'3XDL(;9;H6YCE\S<4W9X(Z9'K7*?\*LD_P"@PO\
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M2@#6_M_1O^@O8?\ @2G^-']OZ-_T%[#_ ,"4_P :XC_A5DG_ $&%_P# <_\
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M!&.H]: +/]OZ-_T%[#_P)3_&C^W]&_Z"]A_X$I_C7$?\*K;_ *"Z_P#@-_\
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M_P!!>P_\"4_QJCXJ\-'Q+:V\(NA;^3(7R8]^<C&.HKE?^%5/C_D+KG_KV_\
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MIXF$)EV_.4W8PP/3(]*XG_A53?\ 077'_7O_ /94 =Q_;^C?]!>P_P# E/\
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M >@VM_9WP8VEW!<!/O&*0/CZXJQ7.^%/"Y\,QW2&[%QYY4Y$>W&,^YSUKHJ
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M_P#LJT=#^'S:-K-MJ!U%9?)).SR-N<@CKD^M '<4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '$_#'_D#ZU_V';[_P!&FNVKB?AC_P @?6O^P[??^C37;4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$_#CIXL_[&2\_]EKMJ
MXGX<=/%G_8R7G_LM ';4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '$_#_\ Y"7C3_L8)O\ T5%7;5Q/P_\ ^0EXT_[&";_T
M5%7;4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7$^"S_Q5_CGO_P 3.+_T0E=M7$^"_P#D;_'/3_D)Q=/^N"4 =M1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_3!* .VHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** .(\*_\ )2_'W'_+:QY_[=EKMZXCPK_R4OQ]_P!=K'_TF6NWH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L;Q?_P B5KW_
M &#KC_T6U;-8WB__ )$K7O\ L'7'_HMJ (_!/_(A>'>,?\2RVZ_]<EK=K"\$
M_P#(A>'>,?\ $LMNO_7):W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,4 1^+"3X[F_ZZQ_R%==\2B?^$?@]#<#/Y&N1\6Y/CN;(_Y:Q?R6NM^)?_(
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M1110!Q/P_P#^0EXT_P"Q@F_]%15VU<3\/_\ D)>-/^Q@F_\ 145=M0 4444
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MPU>7/V>VT7Q%++G!1+6-B.<<@25R_P +?%GA_P &:YXHT[Q+>0VNJR7[$W;
MNLH!.5WJ#C!R>?[WK6AHNH6OC/X_1Z[X9C=M-L[,QWEX(RBRL00.H]P!QD[?
M04 >E^(?&^F>&=0T>SOX;HOJLGEPLBKMC/'+Y8$#GMGO7*ZE\>O!>GZ@UK&=
M0O41MK7-K K1 YQU9@2/< Y[9K!^/5G%J.M^#+&?/DW-X87*G!VLR X_ UZU
M!X>TJU\/_P!A6]C!'IOE&'R @VE2,'([D]SWH ?HFMZ=XBTF#5-*N5N+.<92
M0 CZ@@\@@\8K \6_$OPYX-G2UU">:>^< K9VD?F2D'IQD ?B1FN)_9_<V^A>
M(K4,3#;:B1&I/3Y?_K"N-^'WB^[L_$OB'Q"WA'5M?O[JY*BYLX&D$"\_)G!Q
MQCOT H ]:\.?%[PQXBU9=*'VW3K]SB.#4(!&9#Z @D9]B17:WU]:Z;8S7M[/
M'!;0J7DED.%4>IKP#XDZYK7CG2[-+7X=>([34;2<2PW3V4A*CN.%SUP?PKH/
MCC?7Y\ Z!ITI,,NHW,2W2^A"Y(/_  (_I0!J#]H#P4=0^SXU/[.&VF\^RCRA
M[XW;\?\  <UB^!+VVU+]H+Q3>6,\=Q:S6BO'+&P96&(^0:]8TK0--TSPY;Z+
M!9P_84A$;0E 5<8YW#OGJ?7->0?#K2++0?CWXHTW3XO*M(;<^5'G.P'8V.>W
M)H ]TKED\>Z4WCZ3P<\%Y%J*Q>:LCHOE.,!L ALYP>X'0UU->*_&2-O#GC3P
MIXUA&%@G%O<$?W0<\_\  2XH ]-\7>+=.\%Z"^KZFL[P*ZQA(%#.Q/3 ) _6
MKNA:S:>(=#L]7L2YMKN,21[QA@#V(&>0>#7E_P 5HT\7^+/"7@Z.1O(NW:\N
M"AZ1A3@_ENIGP?\ $']C>!O$&F:BQ63PY/-O#]=G)Q_WT&H [S2?'6EZUXPU
M/PU9PW;76G+F><HODYX& =V<Y..@Z&L3P1<^#9?&7BB/P_H]Q::K;R;=0GDY
M64EFSL^=N,@G@+VK'^ ^G2OH&J^);L$W6LWK/N(Y*J3_ .S%JJ?";_DJ7Q!_
MZ^5Z?]=)* ./\5_$*QOOB[X=UR/2M8CATX;)();=5FD.6^XN[!'/J*]J\-^-
M;3QEI>HRVFFZI9"W7:POX!&6RI^[ACGI7!^.C_QD%X*Y_P"6>/U>O8;O/V.?
M'7RV_E0!X%\)?'.@^"O 6HSZQ=%7EU%_*MXEWRR_*O0>GN3CWKTCPE\7/#'C
M'4O[-LVN[2^()2"\B"-)CKM*EA^&<UP_[/?A[3)+#4M?EMEDU%+MH(Y7Y\M=
MH/R^A.3DU:^,=G#:>//!&KVZB.\DODA>11RRATQGUQDC\: /::*** "BBB@
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MH XSQ?X1OM?U"&YM)K=%2/8PE9@<Y[8!KJ+.S$&DV]E+APD"POCH<+@U;HH
M\VD^'>K6E\TNE:G'$G.US(\<B@]LJ/ZUT&I>&;V\\'P:0+M)+J-@S2RDX;DG
MKR>_Z5U-% '->&_#<VEZ!=:;?21N9V8DPL2 " .X'-<Z? 6OV9>+3=91+=CR
M/-DCS]0H(KT>B@#E/"_@M-"N#>W,XN+L@JNT85 >OU/O75T44 %%%% 'SQI?
MWCQGGI^5=[H6HI"@AN!NAS\K==O_ -:N"TO[Q^O^%=5:9"Y';H>] '<YM<9
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M+7;5Q/PXZ>+/^QDO/_9: .VHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .)^'_\ R$O&G_8P3?\ HJ*NVKB?A_\ \A+QI_V,
M$W_HJ*NVH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "N)\%_P#(W^.><_\ $SB_]$)7;5Q/@O'_  F'CGU_M*+G'_3!* .VHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .(\*_\
ME+\?<?\ +:QY_P"W9:[>N(\*_P#)2_'W_7:Q_P#29:[>@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QO%__(E:]_V#KC_T6U;-
M8WB__D2M>_[!UQ_Z+:@"/P3_ ,B%X=XQ_P 2RVZ_]<EK=K"\$_\ (A>'>,?\
M2RVZ_P#7):W: "OE_P 4(_Q'^/RZ4RNUE!.MJRACQ%'RYR.F3NY]Q7U!10!Y
M_P#\*2^'G_0O?^3MQ_\ '*\.\=Z-'\+_ (L6EUI$+0V*-%=VR;BV%'#KEB2>
M0>I[U]8T4 ?*'QR\2W>M^-8[5MZZ?:V\;6R$$;A(H8O]3G'X5O:!\?K/PWH5
MGI%AX-VV]M&$7_B9<L>[']UU)Y-?2-% '"?#_P =1_$[0=3>72?L,<;FV>/S
M_-#JR\\[5QUKQ/\ LOQ=\$O&4^HVMA)>:6V4\X(3%-$3D!B,[&Z=>X[BOJ>B
M@#YH\1?&+Q'\0=)E\/:!X;E@:Z&R<V[M<2,G<#"C:#W//'I7I_P<\ 7/@CP[
M/)J85=3OG#RQJP81*/NKD=3R2?K7I%% 'S!K*,?VGT&TY.IP$<=MB<_2O9?B
M[X8_X2CX?7T44>^[M!]JMP!R64'('U7(KNJ* /#/V<_$CSZ;J/AR;<?LK?:8
M">RL<,OY\_B:\LT7Q4_@3XHW^L2:>UTT-Q<QFW:7RC\Q8==IQCZ5]C44 >"V
MO[2?VF\AMQX2(\V14R-1R1DXZ>5S7O7:BB@ KYX^(WQJ^UVWB#PE_P (\T>6
MDM/M37G/!QNV;.^.F?QKZ'HH ^1OAI\5/^%=V>H6_P#8W]H?:Y$?=]J\K9M!
M&/N-GK7U?IMY_:.EVE[Y1B^T0I+Y;')7< <?K5JB@#+\2C/A76!ZV4W_ * :
M\_\ V?1CX9#CK>R_^RUZI10 5XW\85)\?> , G_3>@'^W'7LE% #7^XW...U
M>0? -"_AWQ)'RA;5)%R.WR+7L-% 'SUX&\56_P (KO6=$\6:7?0S3W1EBNXH
M=RS+C  )(R.XQGJ<XIFJZ[J7BKXQ>#=8FT2ZTS36N!#9?:UVRS!6RS%><?>'
M^)[?1%% '$^,/B-!X)U2&+4]%U*73I8@WV^VCWHCY(VMG ''/7/M7F?B74[?
MXN>+= _X1+1[T-97 >ZU:2'RU1 0<;O;!(SSGI7T%10!Y=\8/"NKZB=&\3>'
MX#<:EHLWF>0HRTB9#<#O@KTZ\G%06_Q^\-I!Y>IZ;J]GJ*#$EF;<,P;N <C]
M<5ZQ10!@>$_$_P#PE>FR7Z:3J&G0B39$M]%Y;R# .X#GCG'4]*WZ** /FOXK
M>/X]8\<-X:U5KVU\.:=/MNH[-5:6Y8>N6 QZ<\=<$XQU6F_'WP'I&G06%AHN
MLV]K @2.-+>$!1_W]KVJB@#/T/6+?Q!H=EJ]HDJ6]Y$LL:S*%< ^H!(S^)K0
MHHH ^?-.\3K\)?B5XI'B#3;Y[/5)O.MIK>(-O^8L,;B 1AL<'@BNG^,>I#6O
M@HFIQVT]NES+!*(IUVN@)XW#L:]<HH Q_"8*^#]&!&#]BAXQ_L"O,?B<K'XR
M^ <*3F3CC_;%>S44 >/?&C2M036?#7BB#3I=2L-*FS=6T:[L#<K;L>G!&<8Z
M5'KOQ;A\7>&[[2?".A:G?WES;LDSRQ!(K9"IW%VSU _#W['V6B@#S;X&@CX2
MV&5ZR3X'K^\:L/\ 9]!_L[Q,3G_D)8R1[5[+10 5\_\ Q!N-:L_V@-.NO#]H
MMWJ$-@CK;N0!*H\S<H]]N:^@*\GU31M3D_:+TK54TZ[;3DL-KW8A8Q*V)."V
M, \CCWH S-;^-ZZGI-SHNB>'-:7Q'<1F$6\D _<L>">#N)&3CY1[XKK?AEX/
MN/!OP[^PWJ@7TX>>X5>=K,.%]R !^-=]10!Y!^SR"/!NIDJ1G47Z_P"ZM:WQ
MD\&ZAXI\.6MWHZF34],F\^*(=9%[@>_ (]<8KTFB@#QRS^/^FVEG':ZYH&LV
M^M(H26W2!<,_3C<P8?0CCWJ3X>:!KFO^/M0^(/B+3Y-.\Q##8V<RD.JX"[B#
MR, 8YZY)Z8KU^B@#QKXTV][I?B3PMXNALIKNSTR4_:5C7.P;E()],\C)[XKJ
MM"\6Z1\5M!UFQLK+4(+-H3 \MU$JABX(^7:QSCO]:[NB@#P#PEXSO_@]:W'A
MGQ?HM^;**=FL[VUC#(X)R<$D @]>#D9P14FNZGJGQOU+3-*T?2+ZR\-03">Z
MOKM-N_'&!@D9P3@ DY.3@5[W10!YK\7_  3>>(_"-HVB1;K_ $F02P0KC+H!
M@J/<8! ]L=ZQ;#X^V$=I%9:GX>UI==50DEK% I#2=.,L&&3_ +/&>]>R44 >
M;Z]I&L?$SX3RQ7^F?V5JLK&>WM)&(*E6.P,3T++UR!C/:N6\._&5/"&B6V@^
M,="U>VU*QC$"M'"I$JKPI^9EYP.V0<9S7N-% 'B>C6>L?$_XFV/BR^TJXTWP
M_I2@V272[7G/4''?).21QP!DU8^,*D^/O & 3_IO0#_;CKV2B@ KD?B9X6F\
M8>!;_2K7;]K^6:W#' +J<@9[9&1^-==10!X=X5^,J>']%M/#>O\ A_6O[=LX
MQ;K#!;@F7'"\$@@].@/MZ51\/S:_J'[0.FZGX@T];"XO+)Y8K13EH80K!0_^
MUQD_7MT'O]% 'D/Q+T/7-&\<Z3X_T'3Y-1^RIY-Y:Q#+E.1D#DD$,1P., U9
MC^/_ (3>,#[#K)N\[3:+:J9,^GWL?K7JM% ',+XKNYO \OB*#P[J/VA59TTR
M5"D[@-CH 3DCG&#7":M\:O"NLZ+=:7)H.K7=[<(T7]FRV@+,Q&,'D\9[CGVK
MV*B@#S;X1>'=3\.?#1[;587@GN'EG$#?>C5E  (['C.*QOV?U8^!M7&[9F_D
MP_3'R+SFO8JI:O9/J6BWUC'+Y+W,#Q+)_=+*1G]: /G?P3J5_I]AJFA+X"M?
M&=K;7\C&^0*8V<\$Y:-@QX![5WNA?%:PTN]LM%UGP;?>%8[E]EMNA"PY)_W5
MQSW /7FL3P?JWC'X8:1_PCM_X"OM2ACF=X[O3,RA\G/(53^9P<8&*FU:P\7?
M%S5M)CO?#<OAW0K"?SY);Q_WTAXX"D @X]L>IZ"@"Q\:E)\6> \#/_$R'3_?
MCKV6D    Z"EH \<^ 0_T/Q3D?\ ,3(Y^AK)TZYU'X*^+M:&H:1>7GAC4I?.
MBO+5-_E')QN[9YP02.F1FO>:* /,8/CCH&I7,=KHND:YJ=Q(0 MO: A?KSD?
MD:M_&/PC>^+/!8&F1F34+&87,,8^\^ 0RCWP<^^*]#HH \9TCXZ1'3H=*G\-
M:U/XFCC\IK.& $/(!]=P!ZGY>,]ZH?#--;_X7=X@G\00Q0ZE/8B::*+E8]Q3
M:N?88'X=:]UHH *XSXJZ ?$7PYU6TC3?/%']IA4#DLG.![D9'XUV=% '@/P-
M>]\4>*[GQ#J W?V9IL.G0L>1TQQ[X4D_[U8'Q7BU'PS\0-;L]/C/D>*+:-2.
M?F8NN<>^5(_X&:^G:* ,GPQHZ>'_  OIFDQ@ 6MND9QW;'S'\3DUYA\)U(^*
M/Q!.,#[2OT^_)7LM% 'BWQ>6\\/^/O"_C3[%/=:;8_)<F%<E,-W[#(;C/&17
M=>%?'5AX[TC4;K3+*_@MX!LWW42KYA*D_+ACG']:Z^B@#R#]GD$>#M4." =1
M?&?]U:;\:\GQ!X$QG_D*KT_WXZ]AHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BN(D\97]QXP72-/@MGM_-$;.ZL6X^\<@XXY
M[5U&J:SI^C1)+J%R(5<X7Y68G\ ": +]%9NEZ_I>M&1=/NQ,T?++L92/?# <
M5;O;VWT^TDNKJ3RX8QEFP3C\!S0!/15'2]8L-9@>?3Y_.C1MK'8RX.,_Q >M
M768(I9CA0,DGM0 M%<^GC?PZ\PB741N+;1^YDQGZ[<5T% !145Q<P6D+37$R
M11+U=V  K$_X3?PX)-G]I#.<9\I\?GMQ0!T%%16]S!=P+-;31S1-T>-@0:S+
M?Q5HMUJ0T^&]#W1<H$$;X)&<C.,=CWH V***QX/%6BW.I#3X;W?=%R@01/R1
MUYQC]: -BBN7\8Z_J7A^&VGLH;=XI&*N9E)P>HQAA[ULZ-J2:OI%M?( /-3+
M*#G:W0C\Z +]%%% !17/>,M;ET31/,MGV7,KA(VP#CN3@^U,\%7NIZEHK7FI
MS^<TDA\H[%7"CC^$#OF@#I***P[SQAH-A=/;7-^%FC.&41.V#]0"* -RBHK:
MYAO+:.XMY%DAD&5=>A%9^I^(])T:=(;^[\F1UW*OELW'_ 0: -6BD5@RAE.0
M1D4M !1110 4444 %%%% !1110 445R&D^.O[4U]=+_L[R@S,HE\_=TSVVCT
M]: .OHHHH **** "BBLGQ%K?]@:4;W[/Y_SA-F_;U]\&@#6HK&\-:_\ \)%I
MSW?V;[.5D*%/,W]@>N!ZULT %%%% !116'XG\0_\(Y8PW/V7[1YDGE[?,V8X
M)SG!]* -RBL;2O$"ZCX=.KO;F%55B8P^[[OH<"LSPYXW3Q!J;61L&MSL+JWF
M[\X]1@8H ZRBBB@ HHI"0JEB< #)- "T5SA\=^&P2#J/3T@D/_LM/B\;^'9I
MDACU EW8*H\B09)X'\- '04444 %%%% !1110 4444 %%%% !1110 4444 ?
M/&E?>/U_PKJK3_5Y_#.*Y72QEB/4_P"%=5:_<S_3_/M0!9;[QX[TW\3Z<BE?
M[QX[TGMT[#% !GW!^E&<=2>.?K1GUZ'\*.?I]* #\3Z<BDS_ +0_STH_$_E2
MY]P/K0 9]"#[4=\9Z]*.O'7L<=J.O3'/<4 )GW/XBES_ +0Q1GW/Y4>V?;D4
M '/OQQ]:.??CCZTGOC'IGUH^GX<=Z %Y]^./K2#'KGI1]![CBER><<X[4 +5
M>> .,@9/N?PJ?I]!QTI>HP: .;O+,-VS[XZTWPYXBO?"&I>9$&FL93_I%MTW
M=MR^C#]>A]MZX@#@GKGK6'>66>"#Z<]Z /;M-U*TU?3XKZQF6:WE&58?J".Q
M'<5;KP3PWXBO/"&I^8FZ33Y6 N8/7_:7T8?KC'ICW+3]0M=4L8KVRF6:WE&4
M=>_^!]J +-<3\..GBS_L9+S_ -EKMJXGX<=/%G_8R7G_ ++0!VU%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q/P_P#^0EXT
M_P"Q@F_]%15VU<3\/_\ D)>-/^Q@F_\ 145=M0 4444 %%%% !1110 4444
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M.F>,;C5(=.@NXVTZ;R)C<(JAFR1E<,<CCOBNFH **** "BBB@ HHHH ****
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MUO*)$TR,L.TCLX_)B10!SOPSTZ>**[OY%*Q3 )'G^+!.3].U<WH7_(_P\?\
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M29]< UTVG:)IFD@_8;..$D8+ 98CTW'FI=1TVTU6T-K>P^;"2&V[B.1[@@T
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M:9&6':1F<?DQ(H T].O/[0TVWO/+\OSHP^S.=N>V:FN/^/:7_</\J> %4*H
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M[9Q_JO\ :8?WNX';KUZ;/PW^[XL/_4R7O\UH [:BBB@ HHHH **** "BBB@
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M?H*-1_Y!EW_UQ?I]#5A55%"J J@8  X H(#*58 @C!![T >1_L[?\D_NN/\
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M^:[DMX_,D80.B@9QU8#-:6H>&- U:?S]1T/3+R;&/,N;2.1OS8$U=L["STZ
M06-I!:PCI'!&$7\A0!X=-J8^%GQNU34-8CF30]<0LMRJ%@IX/09)PP(QUP0<
M5:^)'Q0TOQ-X1U+1?"D-QJS20&2[N4A=(K6)2&+,6 .>,#M^/%>S7VGV6IVK
M6M_:6]W;M]Z*XB$B'Z@C%06^A:1::?)I]MI5C!8R@B2VBMT6-P>N5 P<T <W
M\)/^25^'_P#KW/\ Z&U=I4-I:6UA:QVMG;Q6]O$-L<4*!$0>@ X%34 %%%%
M!1110 4444 %%%% !1110!E77AS2;S4EU">S#W2D$2;V'(Z< XK5HHH ****
M "BBB@ HHHH **** "BBB@ HHHH S=3T'3-9>-]0MO.:($)\[+C/T(J_%%'!
M"D42!(T4*JCH *?10 55&F6"W9NUL;87).3,(EWY]<XS5JB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHJI%JFGSW1M8;ZVDN!G,23*7&.O&<T 6Z*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBJ]U?6EBJM>74%NK'"F:0("?;-
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M#B?A_P#\A+QI_P!C!-_Z*BKMJXGX?_\ (2\:?]C!-_Z*BKMJ "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUS>H>!=5TW4_MOA^?*[B442;'CSVR>"* &W7@7Q1>JJW>KPW"J<A9;F5P#[
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M$<A)]L8_K7KM>9?#*S+ZC>7I!VQ1B,''&2<_R'ZUZ;0 4444 %%%% !1110
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MRCTK4GU+5@LLD<G^BPDA@@SD,WJWI^?7&/2: "BBB@ HHHH *XCX;_=\6?\
M8R7O\UKMZXGX;_=\6?\ 8R7O?W6@#MJ*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#B?A_P#\A+QI_P!C!-_Z*BKMJXGX?_\
M(2\:?]C!-_Z*BKMJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KB?!?_(W^.><_\3.+_P!$)7;5Q/@O'_"8>.?7^THN<?\ 3!*
M.VHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.(\*_P#)2_'W'_+:QY_[=EKMZXCPK_R4OQ]_UVL?_29:[>@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *QO%_\ R)6O?]@ZX_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%<01W5M)!*H:.1
M2K ^AKA_"/A[6= \0S>=;@V,BLAE$B\XY4XSG_\ 77>T4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7,^-K'5-3TF.STRW\W?)F7YU7 '3J1WKIJ*
M,/PIHK:'H4=O*H%PY,DV#GYCVS[  5N444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '$_#'_D#ZU_V';[_ -&FNVKB?AC_ ,@?
M6O\ L.WW_HTUVU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5Q/PW^[XL_[&2][>ZUVU<1\-_N^+/\ L9+W^:T =O1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <3\/_P#D)>-/
M^Q@F_P#145=M7$_#_P#Y"7C3_L8)O_145=M0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %<3X+_ .1O\<]/^0G%T_ZX)7;5Q/@O
M_D;_ !SSG_B9Q?\ HA* .VHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .(\*X_X67X^]?.L?_285V]<1X5_Y*7X^X_Y;6//_
M &[+7;T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !6-XO\ ^1*U[_L'7'_HMJV:QO%__(E:]_V#KC_T6U $?@G_ )$+P[QC_B66
MW7_KDM;M87@G_D0O#O&/^)9;=?\ KDM;M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <3\,?\ D#ZU_P!A
MV^_]&FNVKB?AC_R!]:_[#M]_Z--=M0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %<3\-_N^+/\ L9+WO[K7;5Q/PW^[XL_[&2][
M>ZT =M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 <3\/_P#D)>-/^Q@F_P#145=M7$_#_P#Y"7C3_L8)O_145=M0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<3X+Q_P )AXY]
M?[2BYQ_TP2NVKB?!?_(W^.>G_(3BZ?\ 7!* .VHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** .(\*_P#)2_'W_7:Q_P#29:[>
MN(\*X_X67X^]?.L?_285V] !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5C>+_\ D2M>_P"P=<?^BVK9K&\7_P#(E:]_V#KC_P!%
MM0!'X)_Y$+P[QC_B66W7_KDM;M87@G_D0O#O&/\ B66W7_KDM;M !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P")YIW_ 'Q;_P#QJ@#VVBO$AIOQ[X_XGFG?]\6__P :H&F_'OC_ (GFG?\
M?%O_ /&J /;:*\2&F_'OC_B>:=_WQ;__ !J@:;\>^/\ B>:=_P!\6_\ \:H
M]MHKQ(:;\>^/^)YIW_?%O_\ &J!IOQ[X_P")YIW_ 'Q;_P#QJ@#VVBO$AIOQ
M[X_XGFG?]\6__P :H&F_'OC_ (GFG?\ ?%O_ /&J /;:*\2&F_'OC_B>:=_W
MQ;__ !J@:;\>^/\ B>:=_P!\6_\ \:H ]MHKQ(:;\>^/^)YIW_?%O_\ &J!I
MOQ[X_P")YIW_ 'Q;_P#QJ@#VVBO$AIOQ[X_XGFG?]\6__P :H&F_'OC_ (GF
MG?\ ?%O_ /&J /;:*\2&F_'OC_B>:=_WQ;__ !J@:;\>^/\ B>:=_P!\6_\
M\:H ]MHKQ(:;\>^/^)YIW_?%O_\ &J!IOQ[X_P")YIW_ 'Q;_P#QJ@#VVBO$
MAIOQ[X_XGFG?]\6__P :H&F_'OC_ (GFG?\ ?%O_ /&J /;:*\2&F_'OC_B>
M:=_WQ;__ !J@:;\>^/\ B>:=_P!\6_\ \:H ]MHKQ(:;\>^/^)YIW_?%O_\
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MH&F_'OC_ (GFG?\ ?%O_ /&J /;:*\2&F_'OC_B>:=_WQ;__ !J@:;\>^/\
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M\6__ ,;H ]MHKQ+^S?CW_P!!O3O^^+?_ .-T?V;\>_\ H.:=_P!\6_\ \:H
M]MHKQ+^S?CW_ -!O3O\ OBW_ /C=']F_'O\ Z#>G?]\6_P#\;H ]MHKQ+^S?
MCW_T'-._[XM__C5']F_'O_H-Z=_WQ;__ !N@#VVBO$O[-^/?_0;T[_OBW_\
MC=']F_'O_H.:=_WQ;_\ QJ@#VVBO$O[-^/?_ $&]._[XM_\ XW1_9OQ[_P"@
MWIW_ 'Q;_P#QN@#VVN)\%_\ (W^.><_\3.+_ -$)7$?V;\>_^@YIW_?%O_\
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MCW_T&]._[XM__C= 'MM%>)?V;\>_^@WIW_?%O_\ &Z/[-^/?_0<T[_OBW_\
MC5 'MM%>)?V;\>_^@WIW_?%O_P#&Z/[-^/?_ $&]._[XM_\ XW0![;17B7]F
M_'O_ *#FG?\ ?%O_ /&J/[.^/?/_ !.M._[XM_\ XW_G% ';>%?^2E^/N/\
MEM8\_P#;LM=O7@EIX8^-MGJNI:A;ZAI\=U?M&US*?((E*(%7 V'&!QT']:O?
MV;\>^G]N:=]=EOZ_]<J /;:*\2_LWX]_]!O3O^^+?_XW1_9OQ[_Z#>G?]\6_
M_P ;H ]MHKQ+^S?CWC_D-Z?T_N6__P ;H_LWX]\_\3O3N_\ !;__ !N@#VVB
MO$O[-^/>?^0WIW_?%O\ _&Z/[-^/>/\ D-Z?_P!\6_\ \;H ]MHKQ+^S?CW_
M -!O3O\ OBW_ /C=']F_'O\ Z#>G?]\6_P#\;H ]MHKQ+^S?CWC_ )#>G_\
M?%O_ /&Z/[-^/>?^0WIW_?%O_P#&Z /;:*\2_LWX]\?\3O3NW\%O_P#&Z/[-
M^/>/^0WI_3^Y;_\ QN@#VVBO$O[-^/?_ $&]._[XM_\ XW1_9OQ[_P"@WIW_
M 'Q;_P#QN@#VVBO$O[-^/?3^W-.^NRW]?^N5']F_'O\ Z#>G?]\6_P#\;H ]
MMHKQ+^S?CW_T&]._[XM__C=']F_'O'_(;T_I_<M__C= 'MM%>)?V;\>^?^)W
MIW?^"W_^-T?V;\>\_P#(;T[_ +XM_P#XW0![;6-XO_Y$K7O^P=<?^BVKRO\
MLWX]X_Y#>G_]\6__ ,;J&]T/XZW]A<6ESJVGR07$3121A8!N5@01D1\<'UH
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M_P!!S3O^^+?_ .-4?V;\>_\ H.:=_P!\6_\ \:H ]MHKQ+^S?CW_ -!S3O\
MOBW_ /C5']F_'O\ Z#FG?]\6_P#\:H ]MHKQ+^S?CW_T'-._[XM__C5']F_'
MO_H.:=_WQ;__ !J@#VVBO$O[-^/?_0<T[_OBW_\ C5']F_'O_H.:=_WQ;_\
MQJ@#VVBO$O[-^/?_ $'-._[XM_\ XU1_9OQ[_P"@YIW_ 'Q;_P#QJ@#VVBO$
MO[-^/?\ T'-._P"^+?\ ^-4?V;\>_P#H.:=_WQ;_ /QJ@#VVBO$O[-^/?_0<
MT[_OBW_^-4?V;\>_^@YIW_?%O_\ &J /;:*\2_LWX]_]!S3O^^+?_P"-4?V;
M\>_^@YIW_?%O_P#&J /;:*\2_LWX]_\ 0<T[_OBW_P#C5']F_'O_ *#FG?\
M?%O_ /&J /;:*\2_LWX]_P#0<T[_ +XM_P#XU1_9OQ[_ .@YIW_?%O\ _&J
M/;:*\2_LWX]_]!S3O^^+?_XU1_9OQ[_Z#FG?]\6__P :H ]MHKQ+^S?CW_T'
M-._[XM__ (U1_9OQ[_Z#FG?]\6__ ,:H ]MHKQ+^S?CW_P!!S3O^^+?_ .-4
M?V;\>_\ H.:=_P!\6_\ \:H ]MHKQ+^S?CW_ -!S3O\ OBW_ /C5']F_'O\
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M;:*\2_LWX]_]!S3O^^+?_P"-4?V;\>_^@YIW_?%O_P#&J /;:*\2_LWX]_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gemp20161231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHJ"XNX+4*9GV[NGRD_P J )Z*H_VO8_\ /?\ \<;_  H_
MM>Q_Y[_^.-_A0!>HJC_:]C_SW_\ '&_PH_M>Q_Y[_P#CC?X4 7J*H_VO8_\
M/?\ \<;_  H_M>Q_Y[_^.-_A0!>HJC_:]C_SW_\ '&_PH_M>Q_Y[_P#CC?X4
M 7J*H_VO8_\ /?\ \<;_  H_M>Q_Y[_^.-_A0!>HJC_:]C_SW_\ '&_PH_M>
MQ_Y[_P#CC?X4 7J*H_VO8_\ /?\ \<;_  H_M>Q_Y[_^.-_A0!>HJC_:]C_S
MW_\ '&_PH_M>Q_Y[_P#CC?X4 7J*H_VO8_\ /?\ \<;_  H_M>Q_Y[_^.-_A
M0!>HJC_:]C_SW_\ '&_PH_M>Q_Y[_P#CC?X4 7J*H_VO8_\ /?\ \<;_  H_
MM>Q_Y[_^.-_A0!>HJC_:]C_SW_\ '&_PH_M>Q_Y[_P#CC?X4 7J*H_VO8_\
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MKV[6\UC(#$(H_.4-AB<\^]2M'$EU;XA\M_.^4A57*_@>?K0!F'3;M2 8QDG
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MN##').I:./",Y8@$$\*<#(Z]: (Y?"\4EW).FI:C")]ANHX9$5;AE  9CMW
MD  ["N<56E\%6DERC+J.HQ6L=X+Y;)'3R1*&WYY3=@MDXW8Y.,5 =8\02ZE#
MHL3:4E^(Y9I;DH[Q%490H$8<%6.[D%CMQWS66WC/7+N"6XL8M.@2VTIKZ99X
MWD+.KNK(I#+A3L."0?H:+VL_Z_K0=KZ?UV_4Z_5M&BU;[,YN;BUN;:3S(+BW
M*AT)!!^\"I!!P00:RH/!%I:Q(;?4]2CO%GEF%Z'C,I,F-X.4*D' ."O&.,5S
M'B#6M:N4M[&Y&GM,\NGWML8T=%0O/C8^6.[&!\PVY]!6Q)XGUNVU(Z#,NGOJ
MKW$4<=RD3B (Z.^60MG(\MAC=SD<BFD[?A^0K_Y_G^AIMX.M!9QVEM?W]K"(
MFBF6-T;SU8EFW[U;DDL=PP>>M/C\(VEO-_HE[?VMJS(\EG#*!'(R  $DKO'"
MKG:P!QSGFI_#^J76H"_M[Y8?M=A<FWD>!2(Y/E5@P!)(X89&3@]ZV:-M?Z[@
M%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HS_ ,?*?[C?
MS6I*C/\ Q\I_N-_-: *>J:7_ &EY7[[R_+S_  YSG'O[5<@B\BVBAW;MB!<X
MQG Q4E% '%:IX:UK5X!87JZ7,J3;X=59F%U"H;<-J!,!P.,AP.^.U+/X;UQ+
MJZ>UDM6A?46NUC^UR0M*K1A<,Z(2A4@'C.[OBNFEUK2H-033YM3LX[U\;+=Y
MU$C9]%)R:LQ7$$SRI%-'(\+;)51@2C8!P?0X(.#ZBA?U^'^2!G#6G@_6K;R=
MSV#['OMQ$\G*W&"#RI.0>,$\CG/:IU\':@NA:Q8F:U\V]TJ"RC;<V Z1LI)^
M7[N3QU^E=O4<%Q#=0)/;S1S0N,I)&P96'L1UH#K<Y)O#.JKKRW=M+!;(;B.6
M2XANYE9T4*&1X,>6Y(&-Y(.,<<5V-%%%]+"L%%%-=UC1G=@J*,LS'  ]30,=
M13(I8YX4EAD62-U#(Z'(8'H0>XILMQ! \2331QM*^R,.P!=L$X'J< G'M0!+
M1110 4444 %%1Q7$,YD$,T<AB<I($8'8P[''0\CCWJ2@ HJ.>XAM8'GN)HX8
M4&6DD8*J_4FI* "BHH+F"YC,EO-'*@9D+1L& 93@C([@@@_2H[74+*])%I>6
M]P0H<^5*KX4YP>#T.#@^QH LT5''<02RRQ1S1O)"0)$5@2A(R,CMD<\U)0 4
M444 %%%% !4%E_QXV_\ UR7^53U!9?\ 'C;_ /7)?Y4 3T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 53U+2[/5K=8+V(NJN'0I(R.C#HRLI#*>O((ZU<HH Q'\(Z(]K#!]ED0
M0EF22.YE27+?>S(K!VW=\DY[U./#FD+')&MDJ1R6GV%E1F4>3S\F >/O'D<\
M]:MZC-';Z9=SRRM#''"[O(O5  22/I7F6AP7$4UO!I^EW>CWUUH[[))#&HOI
M R$R,59L/@Y!89^<^G(M7;^MF/5:_P!;K_ASO;WPKHNHX^UV7F8BCB'[UQ\L
M;;D'!['G/6D7PIHRV4EI]ED9)91,\CW$C2EQT;S2V\$#H=W%<[;:C/97:VNH
MR7T-I!<><L+,]U<<K^[A)CW,YR'D."V%"Y.#7;VUS#>6T=S;R"2&50Z.O0@T
M^@B'3M,M-)M?LUE$8XRQ=MSL[,QZLS,26)]22:MT44@"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "HS_Q\I_N-_-:DJ,_\?*?[C?S6@#/
MUB:_A\G[$)#G=OV1[O3';ZU?MFD:TA:7/F&-2V1@YQSQ4M% ' :0VC)X'U9]
M<B21Q<W!U%#_ *UI/,;:!R#NQMV\@],522YU'3YO$.K6=[/;QQ:G:J;.2)&#
MAXX%8.2"V<-_"PY'>NY.G:+>:LUTUA8S:A;$ SM K21G&0-V,@X/KWJTVGV3
MK,KV=NRSN))08E(D88PS<<D;5Y/H/2FG;7^N@,XLZ]JN[^TO[1X.L?V?_9?E
M)MV>9LSG&_?M^?.<8[=ZQ='US58='TW3[(7L4-OI:W7F6OV7YF+N/G,[#Y!M
M&=O//4<9]+_LG3?[1_M'^S[3[=C;]I\E?-QZ;L9_6J=Y8>'S%;6]UIUC,EO*
ML<,7V59!"S=,  [/KP*72W]=O^".^K?];W_X!RDWB36_,@O[BXEM[6.&V>X2
MS6WGCB9P"PE#'S"#GY3&>G/-4[34M7L/]!M[O4KHWFKWJ-+&+;S5$9X5/,VI
MD]3G/ . .WH4^CZ9<WL5[/IUI+=0_P"JGD@5G3Z,1D?A6=J:>&K87,&HV%IL
MG>.6</9;TE=WV(6.TAFW8'/(Z\"CK_7D);6_K9K]3G-.UKQ!J>IZ5;-?-;(8
M[N28(D$CSB*5%7)7<JL02&VG'7&.,0QZYJDVEZ;=3ZG]J&L6]QYUEY2 6V(F
M;Y2!N^4@*=Q/)[5W\5A9P-"T5I!&T$9BB*1@&-#C*KZ#@<#T%55T[1;34'9;
M"RAO+T,'=8%5YP.2&./FX[&B2O&W]=?Z_(:=G<Q4U!],^&VFW$<YAE:TMHHW
M$8<AGV*, D#//&>/7BN4OM2U*[U>UTZ?5Y8WM-8A2*ZN$@,L6^WD)!$8\LGL
M.._.:]0>RM)+'[%):PM:%/+\AHP8]O3;MZ8]JHGPSH!0(=#TTJ%V!?LD> HS
MQTZ?,?S/K5-WDY>9,5:*7E^ECD7UG7VEFTR#4)KI[:]>$W%LMNEQ.@C5_E$@
M$1*E\-@#IQWJ2'7]0U?:L.N-81V^EB[,YM8U-Q)N=6W*^X!5*<A3_%PV,5US
MZ!HTNGQZ?)I%@]E&=R6S6R&-3ZA<8%/N=%TJ]C@CNM,LITM_]2LL"L(_]T$<
M?A4]/Z[%?U^)P%QXD\0W.E:MJR:@;);/2;>[6U%NC 2R1L3DL"< @''M^%1^
M)+[4A;/IZ>(Y[R.6&WNC<1)"K1$SHFWY4QM;=D9Y^3J1D5WNLZ%;:MI6H66U
M('OH?)EG2,;B.@SZXR<9I\6@:/!:SVL>DV*07',\:VR!93ZL,8;\:;:O<E;?
MUY')1ZMJ<VL-I*ZD;1)=3GA^UK#%OVQQ(P097;N8DG)!X!_"*QU?7-:U/3]/
M36GMH]E\)+FW@B)N/)E1$<;E8#.><#'7VQVLNBZ5/:/:3:9926TC[WA>W4HS
M<#)!&">!S[5-'86<+0M%:01M#&8HBL8!C0XRJ^@X' ]!2_R_0?\ 7XG*2:Y?
M3_"L:PTB?;FM0Y?RU(+;@"=I!%4IM6UR*>^U :NY@M];BL4L_(B\LQ.T:G+;
M=V?G)!!'3O7;_P!GV7V'[#]DM_LFW;Y'E#R\>FW&,4'3[)D=&L[<J\HF<&)<
M-(""'/'+ @<]>!33]Z_];H'M8X#0KC4=-CLIXM0=K6[UVZM7LVB38%,DQW!L
M;MV5]<>U9>A7NI7EQ?:BNO+I\Z:/;W$F((L2E3-U!7 4=]N#SU%>IC3K%41%
ML[<+'*9D B7"R')+CCACD\]>3563PWH4IC,FBZ<_E8\O=:H=F,XQQQC)Q]:7
M3^NP[J_]=[G!3ZIJ>M>7))=SV+?VEIQ\N!(P5\R)&8$E23@D]?ITXK3M=>U5
MGL=1?4PXNM4DL6TSRD"QH&9>#C?O4*&.21C/ XKLI]*TZZ69;BPM9EF97E$D
M*L)&7[I;(Y(P,9Z8I$TG38]0;4$T^T6]<;6N5A42$>A;&:/Z_+_(FVGR_P _
M\S(\$3ZE?>&[;4=4U!KN:Z7>!Y2(L8R1@;0,^^?PQ71U'!;PVL"06\,<,*#"
M1QJ%51[ =*DIL84444@"H++_ (\;?_KDO\JGJ"R_X\;?_KDO\J )Z*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ5YJUG8\33#?
M_<7EORH NT$@#)[5R5WXKF?*VD*QC^\_)_+I_.L6YOKJ[/[^=W'H3Q^72G8#
MN9]9T^VR)+I,CLOS']*S9O%EHN1%!+)CUPH-<A1181T<GBZ<_P"KM8U_WF)_
MPJNWBG4&Z+ OT4_XUB44 =+INO7MU<2)(4PL3N,+W XJ7^VKSU3_ +YK'T7_
M (^YO^O>3_T&IZ -0:[=#JD1_ _XU*GB!OX[<'Z-BL:B@#H1K-G/&T<\;!6&
MU@RY!!ZBH=(TC0K"?S]/!\W9Y:>;<22&-.NU ['8O X7 X'I6)10!T4_A[3K
MF"2*6.0EYS<&1)GCD$A&,AT(8<?+P>G'2K]M;0V=M%;6\8CAB4(B+T '05S$
M&HW5O]R5BO\ =;D5J6^NQM@7$90_WEY%(9L44R*:.9-T;JZ^H-/H **** "B
ML_5-:L=&6 WCS W$GE1)#;R3.[8+8"HI/0$].U.TS6++5TE:SD<M"^R6.6%X
MI(SC.&1P&''J* +U%%% !114,5U%-<3P(6\R @291@,D9&"1@\>F: )J*9)-
M'$5#NJLV=H)Y; R<#O3;:YCO+6*YA+&*50Z;D*'!]00"/H10!+1110 4444
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M_3]/\B7K_7J6J***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1TN-1;=OZWL>D45P%SXZU$2W)M;1I!9)%YD$>FW$QN&:-7(65/DCP&P-V??
MYJQ)XHUQ+F[NMNG_ -G6^JQV'DF%_.97*+NW;\ @OTVG..U.SO;^NG^9-]+G
M;U!9?\>-O_UR7^5<+::CJL-G_:-]>K<26^OM: 1QE 8GD\HK@LV0"P8#MM'6
MNZLO^/&W_P"N2_RI+:_];)_J-Z.W];V_0GHHHH **** "BBB@ HHHH ****
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M([623S(U#-'-!)"VT]& =02IP>1Q4-SXGTBTU'[#/<NLPD6)B()&C1VQM5I
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M#Y9C52G5#\_)YZ5?_M>^_P">_P#XXO\ A1_:]]_SW_\ '%_PHZW_ *[B((]
MUV"SGTF%].%A)--,)W9FE/F%FV%-N!AFQOW9P.E9\GA#7[;0]0TRP;3)5U*R
MB@FDN)74PR+$(B5 0[E(4$9VX/K6O_:]]_SW_P#'%_PH_M>^_P">_P#XXO\
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M (XO^%']KWW_ #W_ /'%_P * .IHKEO[7OO^>_\ XXO^%']KWW_/?_QQ?\*
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MRK]UU##\:DK/T9)XM.6*="C(2 "><=:T*D855U&_@TS3YKVX)\N)<D*,ECV
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MH P*D,,HB$I1A&3@-BMF""W8,$@7:7/S$!P!Z'GC\*R))Y/+^S[P8E;@ <4
M0T444 %%%% !1110 5U]E_QXV_\ UR7^5<A77V7_ !XV_P#UR7^5(">BBB@8
M4444 %%%% !1110 4444 (S!5+$X &37FL\IGN))6ZNQ8_B:[[5Y?)TBZ?\
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M%OE+<":3^]_ /\:PKF[GNWWSR%CV'8?05J1Z-;IS-.\A](UVC\S5R.WM8?\
M56T8/J_S']: .>AM9[@_N87?W5>*NQZ)<'F:2.(=P3N/Y"MEI'88+''IVIM
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M_P"/6W_WS_*N3KL/%H_XET)])@/T-<?30@HHHI@%%%% !1110 4444 %%%%
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MBBB@ HHHH **** "BBB@#&\3IOT9F_N.K?T_K7$UZ#K,7G:/=)C/[LM^7/\
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M64L06R,*5XK<T/2?[&L)+7S_ #M]S-/NV;<>9(SXQD]-V,^U9LWAN_BN+_\
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MXV__ %R7^53U!9?\>-O_ -<E_E0!/1110 4444 %%%% !1110 4444 %%%%
M'(^*;'RKE+Q!\DORO_O#_$?RKGJ]'OK1+ZSDMWZ,.#Z'L:\\FA>WF>&08=#@
MBFA$=%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH *['1+C[1I$>22
MT1,9SZ=1^AQ^%<=6YX9N-EY+;$\3)D?[R\_RS2 Z6BBB@84444 8VNZ+]O4W
M-LH%TH^91_RT'^/\ZXT@@D$$$<$&O2ZP]=T3[:&N[5?]( RZ#_EI[CW_ )T
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M\R:C;K9/:S3L'B</B-E#')P%VDD%2-V2/0T ;U%4-,UJQUA939R2%HB!)'-
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M-(GEDBAD=I8;O4K@,^X  ^;EW&,?=Z'/:F_VO??\]_\ QQ?\*/[7OO\ GO\
M^.+_ (4K:6"^MSG-/T?Q#H7B+3;6VCTZ>YBM+UMTDLBQNCSHX^;:2K?-T^;I
MU]-K2?"%[IQN"]Q!(9]-:W8C</WS222-@8X3,F!WXZ59_M>^_P">_P#XXO\
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M_P".+_A0!U-%<M_:]]_SW_\ '%_PH_M>^_Y[_P#CB_X4 =317+?VO??\]_\
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MMU0!0_D[0^?^67E\^7C^_P#-71444 %%%% !6-X@_P!5!_O&MFL;Q!_JH/\
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M+B"5"\G1&VD8_.HQ>L'8^5"5;'R;.!CT[U%/.]Q,99"-Q]* (Z*** "BBB@
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MDWYC_"C^P;7_ )Z3?F/\*U** ,O^P;7_ )Z3?F/\*/[!M?\ GI-^8_PK4HH
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MXV__ %R7^5 $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[-RC/RJ<<$XR3STV^M;-<:WAG68VM7M;Q$=L27#+<R1".4MEF"*,2C;A KX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHH **** "BBB@ J"R_X\;?\ ZY+_ "J>H++_ (\;?_KDO\J )Z*** "BBB@
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M<E_E4]067_'C;_\ 7)?Y4 3T444 %%%% !1110 4444 %%%% !1110 4444
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MS?DG_P 30!/4%E_QXV__ %R7^5'D2?\ /W-^2?\ Q-20Q"&%(@S,$& 6QG%
M#Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gemp20161231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MD3U-'V1/4T7CV_K[@]XJ_P!O67_/.^_\ )__ (BFOXAT^-&>07B(HRS-8S
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M]T$?0D4&QC)R03]2?;_ ?E5NBE<9GC3($;=&A0C'W'*^GH?]E1]!CI4<4=Q
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M:RXO$^DS7RVB7.79S&KX.QG'8'UK7JI1E'="4E+9C/*7U?\ [[/^-'E+ZO\
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MCENX(W'57D (_"K%8>J;QJMAAC]]L?\ ?)IRDY/FEN$8J*LC5DO;2$(9;J%
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M^U,]HXF0$J& (#$>F>H]ZRKC4K 7DJIHMU=O&Y5IH;0,-PZC)QDBMTJ)(RK
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M*?3(?]0G^Z*?0 4444 %%%% !4;_ .MC^I_E4E1O_K8_J?Y4 24444 %%%%
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MZ/G8ZMCK@YKG-A-C?\]6_(?X5',C>4W[QC^ _P *GJ.;_5-0 NQO^>K?D/\
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M_P \G_3_ !ID3G:?W;_>;T]3[T 9^DZ:UCX:M[#RT@F%N$?RL##[<$\=_>N
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M\G_3_&@!],'^O?\ W1_6CS#_ ,\G_3_&F!SYS?NW^Z/3W]Z )J*9YA_YY/\
MI_C1YA_YY/\ I_C0 ^BF>8?^>3_I_C1YA_YY/^G^- #Z*9YA_P">3_I_C1YA
M_P">3_I_C0 LG^K;Z&E7[B_2HW<^6W[M^A]/\:D7[B_2@!:RO$O_ "+>I?\
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M!2T5)1QK:;?/8F+^SYRH-R(HV=<H[MF.3.[L,C/49KL(PRQ('.6"@$^IIU%
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M,4@$*#:_W1_":?YH_NO_ -\F@!]%,\T?W7_[Y-'FC^Z__?)H ?13/-']U_\
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MGTR'_4)_NBGT %%4+[5[2P<1.[27#?<MXEWR-^ _F>*J>3J^J?Z^3^S;4_\
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M0!)1110 4444 %%%% !3!_KW_P!T?UI],'^O?_=']: 'T444 %%%% !1110
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M_&Z/LNH?]!>__P"^(/\ XW6W11SO^D'*C$^RZA_T%[__ +X@_P#C='V74/\
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M!>__ .^(/_C='V74/^@O?_\ ?$'_ ,;K;HHYW_2#E1B?9=0_Z"]__P!\0?\
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51YKH:*.=ARH9$I6-0?2GT45)1__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gemp20161231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 3&!UP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&8*I9C@#J: %H)
M&37/7OB([BEHO /WV'\JR9=2O9OOW+_0''\J .R^TP;MOG1[O3>*EK@/-DSG
M>V?7-:5EK=S;NJS.98NX/4?C0!UM%,BE2:)9(SE6&0:?0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !169J6LQ6+>4HWS8
MSCL*P)M8OIL_OR@/\*C'ZT =>9HE.&E0'T+"G @C(.17!&>9CDN[$]RU6(-4
MO+<C;<,1_=;D4[ =M15#3-234(B<;9%^\M7Z0!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14%U>06<>^9]N>@ZDU
MB3>)6.1#!CG@L: .BHKE#XAO=P/R >F*LV_B1MP%Q$-O]Y: .BHJ.&:.XB66
M)@R-T-24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU=#E6&01W%(!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQR.Q^E<C2JS(P920PZ$4 >@45BZ1K G @N6 EZ*Q_B_^O6U2&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5R6OR%]3*D\*HQ76UR.OKMU1CZJ#0!F4444Q!1110 4444 %
M=AHDKRZ9&7SE3M!/>N/KN+" 6UE%$.<+0!9HHHI#"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Q?$O_'G%_P!=/Z5M5B^)!_H<7^__ $H YBBB
MB@ HHHI@%%%% !1112 U]#U)H+E;9S^YD/R_[)KJJX"-B)4V]G!%=[&28U)Z
MX&: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R?B$$:
MGDC@QC'YFNLKGO$L)S#..F"I_I0!S]%%%,04444 %%%% !1110 H)!!!P1T-
M=7HNI?:X?*E8><G_ (\*Y.I[.X-K=Q3 X"L,_3O0!W5%,CD26-9$8,K#((I]
M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<IXA;.HA?[J"NKKDO$'_ "%#_N"@#+HHHIB"BBB@
M HHHH .U=Y;,6M8V/=17!GI7=V@(M(@?[HI#)J*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *RO$ SIA/HPK5K.UQ=VDR^Q4_J* ./HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N9\21;;J&3^\I'Y5TU8GB5,VD+X^Z^/S'_ -:@#F:***8@HHHH ***
M* "N^B_U2?[HK@:[V%@T",.A44ADE%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %5[V'[1931?WE./K5BB@#S\C:V",XR"/>DK4UNR:UO3*
MH_=2\@XZ&LOGOUH ****8!1110 4444 %:>AW)AU%4)^67Y3]>U9E/A<Q3I(
M#@JP- '?44V-M\2/_> -.I %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4V1!)&R'HPP:=10!P#QM%(T;?>4X--K3UV#R=29L<2#<*S*8@HHHH
M**** "BBB@ HHHH **** .IT/4C<Q_9YF'FH.#_>%;%<):SM;74<RG[K9/N*
M[.QN/M=G'/C&[/Z$BD,L4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM3VQQSNB#R(S@!B!_#57_A8GBK_H*_\ DO%_\378L'4:O=&+KQ3L>\45X/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0/">FZ5=/$\]K#Y;M$25)R>F0#^E;=%%<TI.4G)]32,5&*BN@4445)04444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPY?UU1Y/'_K%^HK[<A_U$?\ NC^5?$<?^L7ZBOMR'_41_P"Z/Y5V8_X8_/\
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M *$:^OZ^0/'G_(_:]_U_2_\ H1KKP7\7Y?Y&=?\ A?-?J3?#S_D>=._[:?\
MHMJ]XKP?X>?\CSIW_;3_ -%M7O%7COC7I^K,L/LPHHHKB.@**** "BBB@ HH
MJ6W@:YN$A3 9SC)H \#^(G_([W__  #_ - %5O T/VCQSHL.[;OND7..G-:/
MQ2MOL?Q"U*#=NVB/G'_3-:J?#S_DH>@_]?B?SKV:.M&/H<.(TE(^M;:VBM(1
M%$N /UJ:BBO%.\**** "BBB@ HHHH **** /F/XN>"3X9\1&_LXMNEW[%TVC
MB*3^)/ZC_P"M7#:5J=UHVJVNI6;[+BVD$B'W';Z'I7UWXK\-VGBOP]<Z5=@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5J%'T1P5'[6=EU_K\CW>BBBO$/0"BBB@ HHHH *^>/C_ /\ (W:=_P!>(_\
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M#YD?7MGY.E>+7]E-IVH7%E<KMFMY&BD'H0<&M*=>%1VB3*E**NSZ<^$7B/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#_\ R-)_\51_PA?A_P#Z!_\ Y&D_^*HOB^T?O?\ D%L)WE]R_P S0_MS2/\
MH*6/_@0G^-']N:1_T%+'_P "$_QK/_X0OP__ - __P C2?\ Q5'_  A?A_\
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MR_S-#^W-(_Z"EC_X$)_C1_;FD?\ 04L?_ A/\:S_ /A"_#__ $#_ /R-)_\
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MA_\ Z!__ )&D_P#BJ+XOM'[W_D%L)WE]R_S-#^W-(_Z"EC_X$)_C1_;FD?\
M04L?_ A/\:S_ /A"_#__ $#_ /R-)_\ %4?\(7X?_P"@?_Y&D_\ BJ+XOM'[
MW_D%L)WE]R_S-#^W-(_Z"EC_ .!"?XT?VYI'_04L?_ A/\:S_P#A"_#_ /T#
M_P#R-)_\51_PA?A__H'_ /D:3_XJB^+[1^]_Y!;"=Y?<O\S0_MS2/^@I8_\
M@0G^-']N:1_T%+'_ ,"$_P :S_\ A"_#_P#T#_\ R-)_\51_PA?A_P#Z!_\
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MB^+[1^]_Y!;"=Y?<O\S0_MS2/^@I8_\ @0G^-']N:1_T%+'_ ,"$_P :S_\
MA"_#_P#T#_\ R-)_\51_PA?A_P#Z!_\ Y&D_^*HOB^T?O?\ D%L)WE]R_P S
M0_MS2/\ H*6/_@0G^-']N:1_T%+'_P "$_QK/_X0OP__ - __P C2?\ Q5'_
M  A?A_\ Z!__ )&D_P#BJ+XOM'[W_D%L)WE]R_S-#^W-(_Z"EC_X$)_C1_;F
MD?\ 04L?_ A/\:S_ /A"_#__ $#_ /R-)_\ %4?\(7X?_P"@?_Y&D_\ BJ+X
MOM'[W_D%L)WE]R_S-#^W-(_Z"EC_ .!"?XT?VYI'_04L?_ A/\:S_P#A"_#_
M /T#_P#R-)_\51_PA?A__H'_ /D:3_XJB^+[1^]_Y!;"=Y?<O\S0_MS2/^@I
M8_\ @0G^-']N:1_T%+'_ ,"$_P :S_\ A"_#_P#T#_\ R-)_\51_PA?A_P#Z
M!_\ Y&D_^*HOB^T?O?\ D%L)WE]R_P S0_MS2/\ H*6/_@0G^-']N:1_T%+'
M_P "$_QK/_X0OP__ - __P C2?\ Q5'_  A?A_\ Z!__ )&D_P#BJ+XOM'[W
M_D%L)WE]R_S-#^W-(_Z"EC_X$)_C1_;FD?\ 04L?_ A/\:S_ /A"_#__ $#_
M /R-)_\ %4?\(7X?_P"@?_Y&D_\ BJ+XOM'[W_D%L)WE]R_S-#^W-(_Z"EC_
M .!"?XT?VYI'_04L?_ A/\:S_P#A"_#_ /T#_P#R-)_\51_PA?A__H'_ /D:
M3_XJB^+[1^]_Y!;"=Y?<O\S0_MS2/^@I8_\ @0G^-']N:1_T%+'_ ,"$_P :
MS_\ A"_#_P#T#_\ R-)_\51_PA?A_P#Z!_\ Y&D_^*HOB^T?O?\ D%L)WE]R
M_P S0_MS2/\ H*6/_@0G^-']N:1_T%+'_P "$_QK/_X0OP__ - __P C2?\
MQ5'_  A?A_\ Z!__ )&D_P#BJ+XOM'[W_D%L)WE]R_S-#^W-(_Z"EC_X$)_C
M1_;FD?\ 04L?_ A/\:S_ /A"_#__ $#_ /R-)_\ %4?\(7X?_P"@?_Y&D_\
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M.\ON7^9H?VYI'_04L?\ P(3_ !H_MS2/^@I8_P#@0G^-9_\ PA?A_P#Z!_\
MY&D_^*H_X0OP_P#] _\ \C2?_%47Q?:/WO\ R"V$[R^Y?YFA_;FD?]!2Q_\
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M06PG>7W+_,T/[<TC_H*6/_@0G^-']N:1_P!!2Q_\"$_QK/\ ^$+\/_\ 0/\
M_(TG_P 51_PA?A__ *!__D:3_P"*HOB^T?O?^06PG>7W+_,T/[<TC_H*6/\
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M?O?^06PG>7W+_,T/[<TC_H*6/_@0G^-']N:1_P!!2Q_\"$_QK/\ ^$+\/_\
M0/\ _(TG_P 51_PA?A__ *!__D:3_P"*HOB^T?O?^06PG>7W+_,T/[<TC_H*
M6/\ X$)_C1_;FD?]!2Q_\"$_QK/_ .$+\/\ _0/_ /(TG_Q5'_"%^'_^@?\
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MM]MM/^?J'_OX*/MMI_S]0_\ ?P5U/_"%^'_^@?\ ^1I/_BJ/^$+\/_\ 0/\
M_(TG_P 51?%]H_>_\@MA.\ON7^9)IFIZ1:V$<9U.R#8RW^D)U/XU<_MS2/\
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M/\:/[<TC_H*6/_@0G^-9_P#PA?A__H'_ /D:3_XJC_A"_#__ $#_ /R-)_\
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M%+'_ ,"$_P :/[<TC_H*6/\ X$)_C6?_ ,(7X?\ ^@?_ .1I/_BJ/^$+\/\
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M /R-)_\ %47Q?:/WO_(+83O+[E_F:']N:1_T%+'_ ,"$_P :/[<TC_H*6/\
MX$)_C6?_ ,(7X?\ ^@?_ .1I/_BJ/^$+\/\ _0/_ /(TG_Q5%\7VC][_ ,@M
MA.\ON7^9H?VYI'_04L?_  (3_&C^W-(_Z"EC_P"!"?XUG_\ "%^'_P#H'_\
MD:3_ .*H_P"$+\/_ /0/_P#(TG_Q5%\7VC][_P @MA.\ON7^9H?VYI'_ $%+
M'_P(3_&C^W-(_P"@I8_^!"?XUG_\(7X?_P"@?_Y&D_\ BJ/^$+\/_P#0/_\
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M110 4444 %%58M2L)Y_(AO;:289_=I*I;CKP#5JDI)JZ&XM;H****8@HHHH
M**** "BBB@ HHHH **** "BBB@ HHIDLL<$32RR+'&HRSN< #W-#=M6"U'T5
M!;7MK>!C:W,,X7[QBD#8_*IZ2::NAM-.S"BBBF(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH Y'PE_R,'B7_KZ_P#9Y*ZZN1\)?\C!XE_Z
M^O\ V>2NNKCP/\!>K_-G7COX[]%^2"BBBNPY KD?B)_R+\'_ %]+_P"@/775
MR/Q$_P"1?@_Z^E_] >N/'_[M/T.O ?[S#U-_0_\ D7]-_P"O6+_T 5?JAH?_
M "+^F_\ 7K%_Z *OUT4OX<?1&%7^)+U84445H9A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1144]S!:Q>;<31PQ@
MXWR,%'YFDVDKL:3;LB6BHK>YM[N/S+:>*:/.-T;AAGZBI::=]4#33LPHHHH$
M%%%% !1110 4444 %%%% !1110 445!<WUI9[?M5U!!N^[YL@7/TS2;25V-)
MMV1/138Y$EC62-U=&&593D$>QIU,04444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!R/P[_Y%^?\ Z^F_] 2NNKD?AW_R
M+\__ %]-_P"@)775R8#_ ':'H=>/_P!YGZA11176<@5R/BW_ )&#PU_U]?\
ML\===7(^+?\ D8/#7_7U_P"SQUR8[^ _5?FCKP/\=>C_ "9UU%%%=9R!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%9-YX
MGT:PG,%Q?HL@."JJSX/OM!Q5K^U=/^RQW+7MNL$G"2/(%#?3-9JM3=[26GF:
M.C423<7KY%RBF1313Q++#(DD;?==&!!_$4^M#-Z!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6!XT_P"12OO^V?\ Z,6M^L#QI_R*
M5]_VS_\ 1BUSXO\ W>?H_P CHPO\>'JOS-#0_P#D7]-_Z]8O_0!5^J&A_P#(
MOZ;_ ->L7_H J_6E+^''T1G5_B2]6%%%%:&84444 %4-<_Y%_4O^O67_ - -
M7ZH:Y_R+^I?]>LO_ * :SJ_PY>C-*7\2/JC/\%_\BE8_]M/_ $8U;]8'@O\
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M444 %%%% !1110 4444 %%%% !1110!R/A+_ )&#Q+_U]?\ L\E==7(^$O\
MD8/$O_7U_P"SR5UU<>!_@+U?YLZ\=_'?HOR04445V'(%<C\1/^1?@_Z^E_\
M0'KKJY'XB?\ (OP?]?2_^@/7'C_]VGZ'7@/]YAZF_H?_ "+^F_\ 7K%_Z *O
MU0T/_D7]-_Z]8O\ T 5?KHI?PX^B,*O\27JPHHHK0S"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J*Y61K6983B4H0AST..*EHI-75AIV=SS/^Q_&_\
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M+\__ %]-_P"@)775R8#_ ':'H=>/_P!YGZA11176<@5R/BW_ )&#PU_U]?\
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MYQG)YX->FUOAL3#$0YXF.*PL\-+EEK<****Z#F"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K \:?\BE??\ ;/\ ]&+6_6!XT_Y%*^_[9_\ HQ:Y\7_N
M\_1_D=&%_CP]5^9H:'_R+^F_]>L7_H J_5#0_P#D7]-_Z]8O_0!5^M*7\./H
MC.K_ !)>K"BBBM#,**** "J&N?\ (OZE_P!>LO\ Z :OU0US_D7]2_Z]9?\
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MB2]6%%%%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >E>/\
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MK_V>.NNKD?%O_(P>&O\ KZ_]GCKDQW\!^J_-'7@?XZ]'^3.NHHHKK.0****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#FO'?\ R+$G_75/YUF?#?\
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MXSN<<?OUZ?05ZY7DGB3_ )'.Y_Z[)_(5ZW2RO>K_ (AYG_#H^G^04445ZQY
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MUQ1<V=K>*JW5M#.JG*B6,-C\ZGHHY8VY;:!S2OS7U&0PQ6\2Q0Q)%&OW410
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M3_GI-_WT/\*T+#PSHEPPCGFO8Y#P")$VG_QVCVN)_P"?:_\  O\ @![+#?\
M/Q_^ _\ !/1J*Y$?#S2",BYO?^_B?_$T?\*[TC_GYOO^^T_^)H]KB?\ GVO_
M  +_ ( >RPW_ #\?_@/_  3KJ*Y'_A7>D?\ /S??]]I_\31_PKO2/^?F^_[[
M3_XFCVN)_P"?:_\  O\ @![+#?\ /Q_^ _\ !.NHKD?^%=Z1_P _-]_WVG_Q
M-'_"N](_Y^;[_OM/_B:/:XG_ )]K_P "_P" 'LL-_P _'_X#_P $ZZBN1_X5
MWI'_ #\WW_?:?_$T?\*[TC_GYOO^^T_^)H]KB?\ GVO_  +_ ( >RPW_ #\?
M_@/_  3KJ*Y'_A7>D?\ /S??]]I_\31_PKO2/^?F^_[[3_XFCVN)_P"?:_\
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MX%_P ]EAO^?C_P# ?^"==17(_P#"N](_Y^;[_OM/_B:/^%=Z1_S\WW_?:?\
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M )^;[_OM/_B:/^%=Z1_S\WW_ 'VG_P 31[7$_P#/M?\ @7_ #V6&_P"?C_\
M ?\ @G745R/_  KO2/\ GYOO^^T_^)H_X5WI'_/S??\ ?:?_ !-'M<3_ ,^U
M_P"!?\ /98;_ )^/_P !_P""==17(_\ "N](_P"?F^_[[3_XFC_A7>D?\_-]
M_P!]I_\ $T>UQ/\ S[7_ (%_P ]EAO\ GX__  '_ ()UU%<C_P *[TC_ )^;
M[_OM/_B:/^%=Z1_S\WW_ 'VG_P 31[7$_P#/M?\ @7_ #V6&_P"?C_\  ?\
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M98;_ )^/_P !_P""==17(_\ "N](_P"?F^_[[3_XFC_A7>D?\_-]_P!]I_\
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M_P !_P""==17(_\ "N](_P"?F^_[[3_XFC_A7>D?\_-]_P!]I_\ $T>UQ/\
MS[7_ (%_P ]EAO\ GX__  '_ ()UU%<C_P *[TC_ )^;[_OM/_B:/^%=Z1_S
M\WW_ 'VG_P 31[7$_P#/M?\ @7_ #V6&_P"?C_\  ?\ @G745R/_  KO2/\
MGYOO^^T_^)H_X5WI'_/S??\ ?:?_ !-'M<3_ ,^U_P"!?\ /98;_ )^/_P !
M_P""==17(_\ "N](_P"?F^_[[3_XFC_A7>D?\_-]_P!]I_\ $T>UQ/\ S[7_
M (%_P ]EAO\ GX__  '_ ()UU%<C_P *[TC_ )^;[_OM/_B:/^%=Z1_S\WW_
M 'VG_P 31[7$_P#/M?\ @7_ #V6&_P"?C_\  ?\ @G745R/_  KO2/\ GYOO
M^^T_^)H_X5WI'_/S??\ ?:?_ !-'M<3_ ,^U_P"!?\ /98;_ )^/_P !_P""
M==17(_\ "N](_P"?F^_[[3_XFC_A7>D?\_-]_P!]I_\ $T>UQ/\ S[7_ (%_
MP ]EAO\ GX__  '_ ()UU%<C_P *[TC_ )^;[_OM/_B:/^%=Z1_S\WW_ 'VG
M_P 31[7$_P#/M?\ @7_ #V6&_P"?C_\  ?\ @G745R/_  KO2/\ GYOO^^T_
M^)H_X5WI'_/S??\ ?:?_ !-'M<3_ ,^U_P"!?\ /98;_ )^/_P !_P""==17
M(_\ "N](_P"?F^_[[3_XFC_A7>D?\_-]_P!]I_\ $T>UQ/\ S[7_ (%_P ]E
MAO\ GX__  '_ ()UU%<C_P *[TC_ )^;[_OM/_B:/^%=Z1_S\WW_ 'VG_P 3
M1[7$_P#/M?\ @7_ #V6&_P"?C_\  ?\ @G745R/_  KO2/\ GYOO^^T_^)H_
MX5WI'_/S??\ ?:?_ !-'M<3_ ,^U_P"!?\ /98;_ )^/_P !_P""==17(_\
M"N](_P"?F^_[[3_XFC_A7>D?\_-]_P!]I_\ $T>UQ/\ S[7_ (%_P ]EAO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDL4<T9CE174]
M0PS3Z* ,6X\.0.2T+M'[=163/HEY >%$@_V 3_2NPHH Y6ST&>9P9\)&#\P(
M()_2NI4!5"CH!BEHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *AN+6"Z3;/$KCW'2IJ* ,>X\/6KQX@S&WU)%9G
M_".WGF$;XL>O/^%=710!E:=HL5DPE<^9,.A[+]*U:** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  @$8(R*R[O0K
M6XRT8\ISW7I^5:E% '+2^';I!E)(V]N<_P JA70KUFQA![G/^%=?10!E:9HX
ML7\UI2TF.@/'_P!>M6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% "8HP*6B@!-HI-M.HH 9L%&RGT4 1[*0QU+10!!Y=(8ZL4F*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** #%)@4M% ";12;!3J* &>6*;Y*U+10! ;=:
M:;8&K-% %,V@IALZOT4 9ALZ8;,UJXHP* ,5K+/50?PJ)K ?W!^5;VT4GECT
MHN%CG6L%_N_K49L!_M#\:Z4PKZ4TVZGM3YF+E1S!LCV8_E49M)!T?]*Z@VJG
MM3#9J>U/G8N1'+FWE'<'\:88IA_#^M=.;!34;:>*?M&+D1S1$H_@;\J868=0
M172-IU1-IQI^T%[,Y_S#1YM;;:<?0'\*A;3?]@?E3]HNPO9LRO-H\VK[::/[
ME1-IWLPI^TB+DD5?-H\VIC8$=":C-FX_B_2JYXBY)#?-H\VFFVE'I3##*/X?
MUIWCW%:78E\VCS:@*2#^$TTEAU!_*GH3J6?-H\VJN^C?3Y0YBUYM'FU5WT;Z
M.4.8M>;1YM5=]&^CE#F+7FT>;57?1OHY0YBUYM'FU5WT;Z.4.8M>;1YM5=]&
M^CE#F+7FT>;57?1OHY0YBUYM'FU5WT;Z.4.8M>;1YM5=]&^CE#F+7FT>;57?
M1OHY0YBUYM'FU5WT;Z.4.8M>;1YM5=]&^CE#F+7FT>;57?1OHY0YBUYM'FU5
MWT;Z.4.8M>;1YM5=]&^CE#F+7FT>;57?1OHY0YBUYM'FU5WT;Z.4.8M>;1YM
M5=]&^CE#F+7FT>;57?1OHY0YBUYM'FU5WT;Z.4.8M>;1YM5=]&^CE#F+7FT>
M;57?1OHY0YBUYM'FU5WT;Z.4.8M>;1YM5=]&^CE#F+7FT>;57?1OHY0YBUYM
M'FU5WT;Z.4.8M>;1YM5=]&^CE#F+7FT>;57?1OHY0YBUYM'FU5WT;Z.4.8M>
M;1YM5=]&^CE#F+7FT>;57?1OHY0YBUYM'FU5WT;Z.4.8M>;1YM5=]&^CE#F+
M7FT>;57?1OHY0YBUYM'FU5WT;Z.4.8M>;1YM5=]&^CE#F+7FT>;57?1OHY0Y
MBUYM'FU5WT;Z.4.8M>;1YM5=]&^CE#F+7FT>;57?1OHY0YBUYM'FU5WTNXGH
M#18+EGS:/-JN YZ*?RIPCE/\/ZTM!ZDWFT>;3!;RGL!^-/%I(>XJ>:/<?++L
M'FT>;4@L6/\ $?RJ1=//^U2YXCY)%?S:/-JZNFC^Z?SJ5=-_V!2]I$?LV9OF
M4HD)Z9K7733_ '0/PJ9=.:E[3R'[/S,,>8>B-^5/"2G^$UO+IQJ1=.%+VC'[
M-& ()CV _&G"UE/5A71+8 4\62BESL?(CGA9MW?]*D%CZEJZ$6BCM3Q;*.U+
MF8^5'/K8#T)_&I5L%_N5NB%?2G>4M*['9&*MB.R#\JE6S-:VP4NT4AF8+,T\
M6=:&!2T 4A:"G"U%6Z* *XMUIP@6IJ* (Q$*7RQ3Z* $VBC:*6B@!,4M%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F*-HI:*
M &[!33$#4E% $)@4TPVJFK-% %,V2FHFT]36C10!E-I@-0MI=;=)@4 <^VE&
MHFTMZZ7:*38/2@#E6TQ_2H&TQO[@_*NP\M3V%-,"'L*+A8XQM.8?P5$U@P_A
M-=L;5#V%1FRC/\(JN:7<GECV.(-FP]:8;9QW_2NV;3HS_"/RJ)M+C/84_:2[
MB]G'L<687'I33&X[5V+:.A["H6T4>@JO:R)]E$Y/##M3?F]*Z=M$/8"H&T5O
M2G[9]A>Q7<Y_)HW5M/H\@[5 VDR#^&J]LNQ/L7W,S=1NJZVFRC^&HFL91_#5
M*M$7L9%?=1NJ0VL@_A-,,,@[&FJL"?93$W4;J0HP[&DP?0U2G#N3R3[#MU&Z
MF49]ZI.+ZBM)=!^ZC=3**=B;C]U&ZF446"X_=1NIE%%@N/W4;J9118+C]U&Z
MF446"X_=1NIE%%@N/W4;J9118+C]U&ZF446"X_=1NIE%%@N/W4;J9118+C]U
M&ZF446"X_=1NIE%%@N/W4;J9118+C]U&ZF446"X_=1NIE%%@N/W4;J9118+C
M]U&ZF446"X_=1NIE%%@N/W4;J9118+C]U&ZF446"X_=1NIE&?>BR'J/W4;J9
MFCGWJ;Q74:C+L/W4;J;M8]C3A&Y[&E[2'<I4Y]@W4;J<+>0]C4@LY3V-3[6
M_93(=U&ZK:Z?*?X:E72Y#_#4^VCV*5&7<S]U&36LND2'M4ZZ,_<5/M_(KV'F
M8>&]*78Y[5T2Z*>X%3+HH]!2]LQ^Q1S(B<^E.%NY[_I75KHRCL*F724'85/M
M9%>RB<D+1CZU(+%CV-=<NF1CL*D%A&/X12]I+N/V<>QR*Z>?[M3+IK?W!^5=
M8+2,?PBGBW0=A4\S[E<J['++IC_W1^53+I;UTOE*.PIP1?2D,YY=*:I5THUN
M[11@4 9"Z6*E73E%:>** **V*BGBT45;HH @%LHIPA45+10 P1@4NT4ZB@!,
M"EQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5<72YSV-2KHTIZ@U/UA=A^P?<SJ3(]:V%T)SU6ITT ]UJ?K#[%?5UW,#(H_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 )M'I1@4M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7F7BGX@^(M/\7W6B:%H\-W]EC1F_<R2NV55
MBV$(P/F [_7G ]-KS/3O^2Z>(/\ KP3_ -!@K:C:[;5[(SJ7T2?4R_\ A8/Q
M$_Z%0?\ @NN/_BJ/^%@_$3_H5!_X+KC_ .*KU.BG[:'\B)]G+^8\L_X6#\1/
M^A4'_@NN/_BJ/^%@_$3_ *%0?^"ZX_\ BJ]3HH]M#^1![.7\QY9_PL'XB?\
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MN/\ XJC_ (6#\1/^A4'_ (+KC_XJO4Z*/;0_D0>SE_,>6?\ "P?B)_T*@_\
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M1_PL'XB?]"H/_!=<?_%5ZG11[:'\B#V<OYCRS_A8/Q$_Z%0?^"ZX_P#BJ/\
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M'_Q5>IT4>VA_(@]G+^8\L_X6#\1/^A4'_@NN/_BJ/^%@_$3_ *%0?^"ZX_\
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M3_XNN'HH]C3_ )0]K/N=Q_PN7Q-_T#],_P"_,G_Q='_"Y?$W_0/TS_OS)_\
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M)_\ %T?\+E\3?] _3/\ OS)_\77#T4>QI_RA[6?<[C_A<OB;_H'Z9_WYD_\
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M_OS)_P#%UP]%'L:?\H>UGW.X_P"%R^)O^@?IG_?F3_XNC_A<OB;_ *!^F?\
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M2>V__72'_P!!-0I-PA?O^I;BE.5NS/$Z]K^&?_)/;G_KK-_Z"*\4KVOX9_\
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MM+T_R%4WCZG?T445D:!1110 4444 %%%% !1110 5Y_X_P#^1Q\#_P#80_\
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M!/\ T7)7H]><?&G_ )$ZS_[""?\ HN2E0_B(*WP,\:HHHKU3SPHHHH ****
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M;N5((P01Z<UH>)M7\2^*FMS?:7)&L .Q(+:0#)ZDYSSQ4_\ PM'Q3_S]0?\
M?A:/^%H^*?\ GZ@_[\+0U-M-I70)P2LFQ=#\1^*- T:72[32"T,C,Q:6UD+
ML,'&"!^E9N@W7B7PW>-<Z=9W:EQMD1[=BKCW&*T?^%H^*?\ GZ@_[\+1_P +
M1\4_\_4'_?A:.6=V^5:A>%DKO0U+CX@>-IS'MTL0A'#$16DGSX.<')/'TQ6'
MK>J^(]>UFUU2ZTETGM@HC6*VD"_*VX9SD]?>K'_"T?%/_/U!_P!^%H_X6CXI
M_P"?J#_OPM3&$HNZBBG--6<F,\3:YXE\516\=]I#1K Q9?(MI!DG'7)/I5'P
M]/KWAK4_M]EI4SR["FV:W<K@_3'I6C_PM'Q3_P _4'_?A:/^%H^*?^?J#_OP
MM4HS2Y5%6$W%N[;*.J7OB/5/$"ZV^GW$%XI4J8+=P%*],9S5_P 1>(O$WB>P
MCM+[1%58W#J\5I('!QCJ2>.:3_A:/BG_ )^H/^_"T?\ "T?%/_/U!_WX6ERR
MT]U:!S1U=WJ6]*\:^-M+M5MOL,EW&@VH;FU=F4>F1@G\<TS6O%WC'7+"6RFT
MYH+>48D6"T<;AZ9;)JO_ ,+1\4_\_4'_ 'X6C_A:/BG_ )^H/^_"TG3DW?E0
MU-)64F4_#NH^)O#%Q)+I]C<%90!)%+;.R-CIZ'\C4OBOQ'XB\0VT(U2P^S6\
M#;AY=NZ+N/&26)J?_A:/BG_GZ@_[\+5'5_'>O:WILEA?3Q/;R$%@L2J>#D<C
MW%5RR<E)Q1/-%1LFSFJ***W,@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "FR?ZMOH:=39/]6WT- CW_P"%W_).=*_[;?\ HYZZ^N0^%W_).=*_
M[;?^CGKKZ\FK_$EZL]*G\""O*XK^ST[XW:_-?7<%K$UDBAYY BD[83C)[\'\
MJ]4KG-4\!^&M:U&74-0TWSKJ7&^3SY%S@!1P& Z 44Y1C?FZH)Q;M;H'_"4^
M'O\ H/:7_P"!D?\ C1_PE/A[_H/:7_X&1_XU3_X5=X-_Z __ )-3?_%T?\*N
M\&_] ?\ \FIO_BZJU+N_P%^\\BY_PE/A[_H/:7_X&1_XT?\ "4^'O^@]I?\
MX&1_XU3_ .%7>#?^@/\ ^34W_P 71_PJ[P;_ - ?_P FIO\ XNBU+N_P#]YY
M%S_A*?#W_0>TO_P,C_QH_P"$I\/?]![2_P#P,C_QJG_PJ[P;_P! ?_R:F_\
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MM2[O\ _>>1<_X2GP]_T'M+_\#(_\:/\ A*?#W_0>TO\ \#(_\:I_\*N\&_\
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M:F_^+HM2[O\  /WGD7/^$I\/?]![2_\ P,C_ ,:/^$I\/?\ 0>TO_P #(_\
M&J?_  J[P;_T!_\ R:F_^+H_X5=X-_Z _P#Y-3?_ !=%J7=_@'[SR+G_  E/
MA[_H/:7_ .!D?^-'_"4^'O\ H/:7_P"!D?\ C5/_ (5=X-_Z _\ Y-3?_%T?
M\*N\&_\ 0'_\FIO_ (NBU+N_P#]YY%S_ (2GP]_T'M+_ / R/_&C_A*?#W_0
M>TO_ ,#(_P#&J?\ PJ[P;_T!_P#R:F_^+H_X5=X-_P"@/_Y-3?\ Q=%J7=_@
M'[SR+G_"4^'O^@]I?_@9'_C1_P )3X>_Z#VE_P#@9'_C5/\ X5=X-_Z _P#Y
M-3?_ !='_"KO!O\ T!__ ":F_P#BZ+4N[_ /WGD7/^$I\/?]![2__ R/_&C_
M (2GP]_T'M+_ / R/_&J?_"KO!O_ $!__)J;_P"+H_X5=X-_Z __ )-3?_%T
M6I=W^ ?O/(N?\)3X>_Z#VE_^!D?^-'_"4^'O^@]I?_@9'_C5/_A5W@W_ * _
M_DU-_P#%T?\ "KO!O_0'_P#)J;_XNBU+N_P#]YY%S_A*?#W_ $'M+_\  R/_
M !H_X2GP]_T'M+_\#(_\:I_\*N\&_P#0'_\ )J;_ .+H_P"%7>#?^@/_ .34
MW_Q=%J7=_@'[SR+G_"4^'O\ H/:7_P"!D?\ C1_PE/A[_H/:7_X&1_XU3_X5
M=X-_Z __ )-3?_%T?\*N\&_] ?\ \FIO_BZ+4N[_  #]YY%S_A*?#W_0>TO_
M ,#(_P#&C_A*?#W_ $'M+_\  R/_ !JG_P *N\&_] ?_ ,FIO_BZ/^%7>#?^
M@/\ ^34W_P 71:EW?X!^\\BY_P )3X>_Z#VE_P#@9'_C1_PE/A[_ *#VE_\
M@9'_ (U3_P"%7>#?^@/_ .34W_Q='_"KO!O_ $!__)J;_P"+HM2[O\ _>>1<
M_P"$I\/?]![2_P#P,C_QH_X2GP]_T'M+_P# R/\ QJG_ ,*N\&_] ?\ \FIO
M_BZ/^%7>#?\ H#_^34W_ ,71:EW?X!^\\BY_PE/A[_H/:7_X&1_XT?\ "4^'
MO^@]I?\ X&1_XU3_ .%7>#?^@/\ ^34W_P 71_PJ[P;_ - ?_P FIO\ XNBU
M+N_P#]YY%S_A*?#W_0>TO_P,C_QH_P"$I\/?]![2_P#P,C_QJG_PJ[P;_P!
M?_R:F_\ BZ/^%7>#?^@/_P"34W_Q=%J7=_@'[SR+G_"4^'O^@]I?_@9'_C1_
MPE/A[_H/:7_X&1_XU3_X5=X-_P"@/_Y-3?\ Q='_  J[P;_T!_\ R:F_^+HM
M2[O\ _>>1<_X2GP]_P!![2__  ,C_P :/^$I\/?]![2__ R/_&J?_"KO!O\
MT!__ ":F_P#BZ/\ A5W@W_H#_P#DU-_\71:EW?X!^\\BY_PE/A[_ *#VE_\
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M-_\ %T?\*N\&_P#0'_\ )J;_ .+HM2[O\ _>>1<_X2GP]_T'M+_\#(_\:/\
MA*?#W_0>TO\ \#(_\:I_\*N\&_\ 0'_\FIO_ (NC_A5W@W_H#_\ DU-_\71:
MEW?X!^\\BY_PE/A[_H/:7_X&1_XT?\)3X>_Z#VE_^!D?^-4_^%7>#?\ H#_^
M34W_ ,71_P *N\&_] ?_ ,FIO_BZ+4N[_ /WGD7/^$I\/?\ 0>TO_P #(_\
M&C_A*?#W_0>TO_P,C_QJG_PJ[P;_ - ?_P FIO\ XNC_ (5=X-_Z _\ Y-3?
M_%T6I=W^ ?O/(N?\)3X>_P"@]I?_ (&1_P"-'_"4^'O^@]I?_@9'_C5/_A5W
M@W_H#_\ DU-_\71_PJ[P;_T!_P#R:F_^+HM2[O\  /WGD7/^$I\/?]![2_\
MP,C_ ,:/^$I\/?\ 0>TO_P #(_\ &J?_  J[P;_T!_\ R:F_^+H_X5=X-_Z
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M?^@/_P"34W_Q='_"KO!O_0'_ /)J;_XNBU+N_P  _>>1<_X2GP]_T'M+_P#
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M'/?\++\(_P#07_\ ):7_ .)H_P"%E^$?^@O_ .2TO_Q-=#_PB?AS_H7]*_\
M ./_  H_X1/PY_T+^E?^ <?^%%Z79_@'[SR.>_X67X1_Z"__ )+2_P#Q-'_"
MR_"/_07_ /):7_XFNA_X1/PY_P!"_I7_ (!Q_P"%'_")^'/^A?TK_P  X_\
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M-HD*[F%^A(R!QY<E>A5Q?Q-_Y%NW_P"OQ?\ T!Z6'_BQ"M_#9XA]AN?^>?\
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M_P"+H_X5UX7_ .@?-_X&S_\ Q='UNEV8?5JG='@OV&Y_YY_^/"C[#<_\\_\
MQX5[U_PKKPO_ - ^;_P-G_\ BZ/^%=>%_P#H'S?^!L__ ,71];I=F'U:IW1X
M+]AN?^>?_CPH^PW/_//_ ,>%>]?\*Z\+_P#0/F_\#9__ (NC_A77A?\ Z!\W
M_@;/_P#%T?6Z79A]6J=T>"_8;G_GG_X\*/L-S_SS_P#'A7O7_"NO"_\ T#YO
M_ V?_P"+H_X5UX7_ .@?-_X&S_\ Q='UNEV8?5JG='@OV&Y_YY_^/"C[#<_\
M\_\ QX5[U_PKKPO_ - ^;_P-G_\ BZ/^%=>%_P#H'S?^!L__ ,71];I=F'U:
MIW1X+]AN?^>?_CPH^PW/_//_ ,>%>]?\*Z\+_P#0/F_\#9__ (NC_A77A?\
MZ!\W_@;/_P#%T?6Z79A]6J=T>"_8;G_GG_X\*/L-S_SS_P#'A7O7_"NO"_\
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MG_X\*/L-S_SS_P#'A7O7_"NO"_\ T#YO_ V?_P"+H_X5UX7_ .@?-_X&S_\
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MZV]P>/(NAY3Y].>"?H3735C*+B[-&JDGL%%%%2,**** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "L[Q!_R+>J?]><O_H!K1K.\0?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.\0?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HIK.%[UR&M?$'3-/N#8V*R:IJ)X%
MM:#=@_[3=!^I'I3C%RV$Y);G8%@*P]9\7Z%H.1J&HPQR#_EDIW/_ -\C)KCY
M+;Q=XD^;5-1&CV;?\NMD?WA'^T_;^7M6AI7A/1='(>VLD:;J9I?G<GUR>GX8
MI2G3AN[^G^9'-)[(CD^(&J:EQX?\-74R'I<7A$*?4#N/QJ!XO'6I\W>N6FFQ
MG_EG90;SCZMR/P-=+163Q3^RDOQ_,7*WNSE&\#077.J:SJVH$]1-<G;^7_UZ
MLP>!/#5O]W2XV/K([/\ S-=%16;Q%5_:8<D>QDIX8T%.FC6!^MNI_F*?_P (
MYH7_ $!=._\  5/\*TZ*CVD^['RKL9+^%]!?KHU@.,?+;J/Y"J5QX#\-7'+:
M6B'UC=D_D<5T=%-5JBVD_O#ECV.57P0EISI6MZO88& L5R2GY?\ UZF0>.],
MYMM:LM4C7_EG>0;"1]5Y)^IKI**T6)J=7?U%R+H8D?Q#OM.^7Q#X;O+91UN+
M0B:/ZGT'XFNFT?Q5H>O ?V;J4$SG_EEG:_\ WR<']*J5AZIX0T35F,DUFL5Q
MG(GM_P!VX/KD=3]<UI'$0E\2MZ?Y?\$/>7F=_17FD0\8^&>;&]77+%?^7:\.
M)@/]E^_X_E70Z%X_TC6)Q93^9IVI9P;2[&QL^BGH?T/M6JCS*\'=%*:V>AU5
M%%%26%%%% !1110 4444 %%%% !1110 4444 %<7\3?^1;M_^OQ?_0'KM*XO
MXF_\BW;_ /7XO_H#UMA_XL3*O_#9VE%%%8FH4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDEXMFL ,)N;=(_GW=MH&>,U:5WH0W9:GK-%%%(H**** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G>(/^1;U3_KSE_\
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MC_\ 5[U=T"7389;:*-&EO)0=[L.(^"<#_P"M7.S7$UPP:::20CH78G'YU?\
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MP_:QQ:3+?K")K@;MHQDC'0"L^[\0S7EK+;W-K"2PPK $%#^.:K:7K%QI;$(
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M<M>ISRTV6QG%-*[W"BBBL2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %%%% !1110 5G>(/\ D6]4_P"O.7_T UHUG>(/^1;U3_KSE_\
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M=AXA=[S2V.V'4 ,O%Z!^Y'OU^O0<U3#]8?<=$*W21Z-J#8B;Z5Y-X]<R:>(
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M9)&<XZ =N]8-Y:V?B3Q#J5CJ\CMIVEQ1#R3*T:N[#<7;!&<8&.W6IO <-O\
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M&M&(_BQ^7YBPWP/^NA\_5[9X7TI=;^$::>V,S)*$)[,)&*G\P*\3KW_X:?\
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MXD'^C0GI"G;\?\]ZVZ]"G35->9Q3FYOR"BBBK("BBB@ HHHH **** "BBB@
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M[R!9[6>*>%ONR1.&4_0CBA)+8&V]S)U?P?H6O7@N]3L?/G5 @;SI%PHSQA6
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MUW2-,_LTW7]HMM,GG[/+^8+TVG/7VJWXAE%YXG\/Z*>8Y)'O)U]5B *@_P#
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MO_#9VE%%%8FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNS]*XG7$W6LOM@_K4_:17V6>AT5#:3"XLH)@<B2-7'XC-359(4444@"BBB@
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M4445B:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBK58OA":ZN/!VCS7L(AN7LXS)&%VA3M';M]*VJUFK2:(@[Q3"BBBI*"BBB@
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MA#$D(X..*YFBJE&[3[$QE9,U-$U7^S+EMX+0R##@=1Z&M"XTS1[Z4W%OJD4
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M] -:-9WB#_D6]4_Z\Y?_ $ U4/B1,OA9F^!/^1,T_P#[:?\ HQJZ.N<\"?\
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MB,;L8Z@9 Y[FER:6^7R'SZW':;9KIVF6MDG*P1+&#ZX&*M445HW=W("BBBD
M4444 <]XD/VN[TW2UY\^;S)!_L+R<_7^E= O2N=TP_VEXEO]0ZQ0?Z-"?I]X
M_G_.NCJGV$@HHHJ1A1110 4444 %(S!5+,0 !DD]J6L#Q5(\UM::3&Q5]2G$
M#E>HC +/_P".@C\:3=EH-*[-./5;&33EU'[5&EFPW":4[%QZY;''O4UM=6][
M L]K<13PMTDB<,I_$5S/B;3,7FF7<FF?VCI5FCK+9(H8KD#:X0\/@ C'7GBE
M?6="\/Z!'?Z/#:I%?RCR4#""-I",$L3P@ 7GCMTS2YK7N/EO:QU=%<9I/BC5
M;RYO;21M'NY8[5YXIM.E:2-".B/GN?8]C6C_ ,)!<3:+HLUM'$U[J9BPA!*J
M"-TAQG. ,]^N*:DG_7R!Q:.BHKB=7\:3K?75OI=UH<*6CE)7U*ZVM(PZA$7G
MCID]\U=N?$U__9VARV>FA[S4SS;NQ&P;"2<]@#CG'3M24T]4'(T=317(ZCXE
MU'2+:VLKY](36;@.P9YS%;1H#PQ+?,>W Z\U<\*Z[=ZS'>)>?89)+:0)]HL'
M9H),C/RD\Y'>FI)NP.+2N=%1113)"BBB@ HHHH **** "L7Q&V(M.4 DO?PJ
M,?4G^E;59.JKYVK^'K89_>:I"3CT!Y_G3 ]F'2EI!TI:\H] **** "BBB@ H
MHHH **** "BBB@"&X&8S]*X?78\.QKNY1E#7'Z]%]XXH YGP#)Y5[KU@>"ER
M)P/9Q_\ 6%=M7GFBR_8/B"BDXCO[5H_JZ\_R'ZUZ'6&*7O\ -W2,H;6"BBBN
M<H**** "N3\)"0:EXL=QNF.JMQTX$2;?TQ7657@L+:UNKJYAB"373*\S GYR
M %!QTZ #CTIIVOYK]5_D/H<K9>%I[CX;R:/?IY6H7*232?,#LG9RX.0<<-CI
MZ51T[1?$R^#IK6:$6^K:Q>N][*DB'[-&W#,#GD[% &,\D>E>@44^;?S"YYEJ
M_P +I;;P[)%I&O\ B*ZFMU5K6QN+]3 S(057:5  XXY&*ZJ73K^[\;Z;J$L.
MVRL["0;BZG]](5!&,YX5>O3FNCHI\[Z_U=6$<SX]LM3U'PE<V>DVAN[B9XPT
M(D6/<@<%AN8X&0,?C5>'4_%>HZ-JL5QX5_LRX6U86@_M"*;S9"" .,!<<<DU
MUU%3?W6F-.S3/.=&;QY'X?M-"M_#=KI'D0)#]ON;])P   6$:#.[J1DXKM="
MT>#0=&M]-MV9UB4[I'^](Q.68^Y))K1HIRFY7\Q6Z'C_ /P@%U!XANFG\%V6
MJO/=RS+JL^I%8PKL2 \'<@'' ]/K75>*[/5K@Q:9;>$+#5=,"+Y,HO%MVM7'
M&X C(QVV<\5VU%',VDNP[ZW.#U'1O$=EHOA<PP#6[W2YA)<QO="(R'8R@[V'
M.W=WY.*ZV.ZU$ZI';2::%M#;^8]V)P0)<X\L)C)XYW<"K]%#E?<1@>,=)O-9
M\//;Z>8_M<4T5Q$LAPKF-PVTGMG%9=G:^(O$>LZ=?:]I$&D6FG2--';BZ%Q)
M+*5*@EE& H!/'7-=G124K ]3SRTM/&>A"_T;3-'LYX+FYFGAU62\"K%YC%OG
MCP68C/;CI6BOA6:R'A33;93+8Z=,UQ=3%E!:0(<$@G))=B>*[*BGS,'K_7<X
M9?"FHS^.[Z:X*#P])-%?A,C,MRJA0",YVC:&Y')Q[UK:3H]P=<\1WFIVZ&*^
ME2&%'VL'@2,#D<\$L_!KHZ*.9VM\OZ^ZP^M_Z_KJ<C:> -$CU_4;VXT31FM9
M4BCMH%M$(0*"68@K@$D]NP%/NU&L>/;"UB'^C:)$;B8CH)I%VQK]0NX_B*ZN
MJMEIUII_G_98MAN)6FE8L6+N>I)))]![  "A2=]0+5%%%2(**** "BBB@#F-
M;7[=XX\+:>.0L[W;^VP97]0:])'2O//#Z_VE\4-3N^L>FV:6RGMO<[C_ .S"
MO1*]"W+",?+\]10ZL****1H%%%% !7%_$W_D6[?_ *_%_P#0'KM*XOXF_P#(
MMV__ %^+_P"@/6V'_BQ,J_\ #9VE%%%8FH4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 450U/7-)T58VU75+*P60D(
M;JX2(-CKC<1FFZ;X@T76'9-+UC3[YE^\+6Y24CZ[2:%J&QHT444 %%%175U;
MV5M)<W<\5O;Q+NDEE<*J#U)/ % $M%1V]Q!=V\=Q;31S02*&22-@RL#T((X(
MJ2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K.\0?\BWJG_7G+_Z :T:SO$'_(MZI_UYR_\
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M;TW$T.R)XOE;<#G)!'0UFZYIUW#>7%W)%B!Y3M;<.<^V<U1&HWRJ%6\N H&
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M;D?.%RY]6/)K3I%&!2T %%%%( HHHH **** "N>U9&_X3'P_(Q_=@7"C_?*
MC] :Z&F/#%*T;21H[1MN0LH)4XQD>AP2/QH:N-,P+V'Q?_:$HL+S2/L4A^4W
M$3^;$/0!3AOQJA?^"Y#H^GP6<EI<W-G*\S#4(M\-PSYW%E'3DY&.E=C14\BM
M8?,S'\/Z=>V-B\5^NG1LQ^6#3X?+B0>V>235+PUX;N-*;S;^>*:2%6@M%CSM
MBAW9[C[QXS]!72T4[*]Q7=K'#Q>$=5LM5E:T306MY)WF%W<6A:[CW$D@'H<9
MP"3722Z=/+XDM=09T^S6]L\:KGYM[%<GIC&%]>]:E%$8J*20W)MW.3\2>&;S
M4-7CU.PATFYD$/D/!JD)DC R2&7'0\XK?TJVN+33HX;IX&F&=WV>+RXU] H]
M!5VBB,4MA.3>X4444Q!1110 4444 %%%% !5*UC-Y\1/#]N/NP^;</[87C]1
M5VCP-!]N\?ZM?8REE;);*?\ :8[C_(C\:F;M!LJ"O)(]1HHHKS3N"BBB@ HH
MHH **** "BBB@ HHHH 1AD5SNMP[HV..U='69J<.^)OI0!Y#XC+V$MIJD8.^
MQN%E('=<X(_'BO3(Y%EB61"&1P&4CN#7&ZY9+/'- X^612I_&KG@+4&N_#BV
MDQ_TBP<VT@]A]W]./PJ:\>:FGV_4R>D_4ZBBBBN(H**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*YN
M([6UEN)FVQQ(7<GL ,FI:Y?QS<2MI=OH]J?]+U2=;9!Z*2-Q^G0'ZU=*'/-1
M%)V5S3^&-I)_PC\^K7"XN-4N7N6SV7. /IP3^-=Q533K.+3]/M[2$8B@C6-!
M[ 8%6Z[IRYI-E15E8****DH**** "N+^)O\ R+=O_P!?B_\ H#UVE<7\3?\
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MSO$'_(MZI_UYR_\ H!JH?$B9?"S-\"?\B9I__;3_ -&-71USG@3_ )$S3_\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD9E1"S$*JC))/ %
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M\2);;4&M7<1B_%L?LVXG &_Z]\8JQJGBNQTO4'L#;WEU>+&L@@M8?,=@21P
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M?^7_  1.RO\ +_,WII4@@DFD.$C4LQ] .:VOA;8O%X8?49EQ/J5P]PV>N,X
M^G!/XUQWB(RW,%MI-J?])U&98%]ES\Q^GK]:]ATZSBT_3[>S@7$4$:QH/8#
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M )%NW_Z_%_\ 0'KM*XOXF_\ (MV__7XO_H#UMA_XL3*O_#9VE%%%8FH4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S
M'B#PA_;OBGP[K7V[R/['E>3R?)W>=N &-VX;<8]#73T44+16!ZNYQGBCP')K
M.OVWB'1];GT76[>(P"YCA69'CSG#(V >_?O5&W^&=P?$ND>(M3\37>I:I8R%
MGDF@54=2I&Q$4A8QDYSSFO0:*(^[L)J^YS'C7P;'XOL[,)?RZ??V,XN+2[B0
M,8W'JIZCVR.E1/X3U6^\$ZIH.L>)'U"[OT=#?-:)&(PP  $:D# QZ\DFNLHI
M65G'HQ]4^QA6/A>SA\%6_AB^(O;2.T6TD++M\P!<9QDX]>O%<O:?#WQ/H\26
M.B?$*]M=*CXCMI]/AN)$7^Z)&Y''3CBO1:*;=Y.3W8DDDDNADZ;HTMCX?.F3
MZG=7\S*X>[NB&=BV>PP !G@#H!BJ?@?PL/!GA.UT,7GVSR"Y\[RO+W;F+?=R
M<=?6NBHIWU;[A;;R.9\/^$1H7B?Q#K/V[SSK$J2>5Y6WR=H(QG)W=?05CWGP
M[U&+Q3?:UX>\57&C+J3*U];K:),)".,J6/R'KS@]:[ZBDM&FNFGR';?S.2U[
MPQXBOM3^W:'XTN](+(J/ ]I'<Q''<*V-I/'-2>$_!47AJZO]2N=1N-4UC4"I
MNKV=0I;:, *HX4>W-=310M-A-7"BBB@84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !6=X@_Y%O5/^O.7_T UHUG>(/^1;U3
M_KSE_P#0#50^)$R^%F;X$_Y$S3_^VG_HQJZ.N<\"?\B9I_\ VT_]&-71U5;^
M)+U8J7P+T"BBBLRPHHHH *\H^)=IX&\7^(+/POJFH36OB(86VD@@9RN_D*W&
M"#UQD8]17J]?-GQMU6TT3XF66I:4MQ;Z]:QQ2O*0#%(.=O'7( P>Q!]JB5N:
M*EM<:ORMQWL6/^&:M2^T;?\ A([3R<_?^S-N_P"^<X_6O7_ ?@#2O .ER6M@
MSSW$Y#7%S* &D(Z# Z >E>21?M+W@B02^&('D &YEO"H)]0-AQ^==U\,_BS)
M\0=6O+&31A8_9X!*'6X\P-\V,'Y1CK6L;[(B5M&STVBBBI*"BBB@ HHHH **
M** "BBB@ HHHH *0]*6B@#GM:CS&QQVKROQ0#:S66H ?\>MRI8^B'@_TKV'5
M(MT3<=J\V\16 NK6YMB/]8I SV/;]<5I2ERS3(G'FBT7 <C(HK)\-WOV[0X&
M8_O8AY4@/4,O'/X8/XUK5Z+.(****0'$^% ;'Q;XKL"OSM.MU&.FX,"?ZBMW
MPQ87.F^'XH[N,)>.SS3("#AW8L1D<=\5=_LNR_M?^U?)Q>^5Y/FAB,IG.",X
M//M5RIC&R2^14I79Q4WAK4+SP')I\L48OI[@W,L#285B9=Y0L.G'&13_  AH
M L+M[AO"MKH^U2%8W?VF5B<=&_A&/>NRHH4$G<'-M6,7PW8W5G:7<EZFRXNK
MR6=EW X!.%Z<?= H-A<S>,EOY(@+2WLC'$^X9,C-EN.O 4?G6U132M;R_P K
M"OOYF-)8W4WC&"]>,"SMK-D1]PYD=AD8Z\!1^=9GC^ZE_L:#2;9L7.JSK:K[
M*?O'\OYUUE0RVEM-/#/+;Q230Y\J1T!9,]=IZC/M2<;KE_K<:E9W,[4+&:V\
M)SZ?I<6Z9+4P0)D+SMVCD\47%E<6GA*2QT^(/<QV?DPH" "VW Y.!6O13DKW
MOU_K]1)VMY'*:AHVHVFGZ#)IEM%=3:4!FU>0()/W>WACP"/>I]/M=7U#54UC
M5[2*S:WA:.VLXYA(06QN9F  SP ,5TE%#C=MA?2QC>%K"YT[0((;U0MV[/+,
M 0<.[%CR..]):6%S_P );J&HSQ!8?L\5O;MD$L 2S'VY('X5M44[;>07W\S&
M@LKH^+KW49HPMNMK'! VX?-R6<X[<XZU7\/#[?J.J:Y_RSN9!!;'UBCR-WT+
M%C],5NSP)<V\D$H)CD4JP5BIP>O(Y'X40016T$<$"+'%&H5$4<*!T%)*PV[D
ME%%%,D*Y_P 6N8M"G"#,DV(D'J6./Y9KH*S8K4ZYXZTG30-T-GF]N/3C[N?Q
MQ^=#:2NQI7=D:)T;^S=-M;4 ?N8E0GU(&*Y2<OX=U4ZA&";&X.+I /N-V<?Y
M_F*]?U*P$D9P!7$:GIX(>.1 R,"&4]"*\^G4<)7.R<%*-AR.DD:R(P9&&58'
M((IU<KIUV_AZ]73;MB;"5O\ 1IF/^K/]UO\ /_UNJKT$TU='$TT[,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K!U#S]?U,:#8,0@&Z]F'1$_N_4_Y[U/J^HSI-%IFFIYNIW/$:C^
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M$9M)&_Y:Q^GU'\OI4UH>TCSK=;^G_ ,OA?DSMJ***XB@HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "L[Q!_R+>J?]><O_ * :T:SO$'_(MZI_UYR_^@&JA\2)
ME\+,WP)_R)FG_P#;3_T8U='7.>!/^1,T_P#[:?\ HQJZ.JK?Q)>K%2^!>@44
M45F6%%%% '%>*?BIX7\'ZO\ V7JL]R+KRQ(5B@+  YQS^%<O=_&3X8ZA*);V
MT:YD VAYM.#G'IDUU?B;X7^%O%VK?VGJ]G-)=>6(RR3L@(&<< ^]>(^*/ 7A
MQ_BSI?@K187L8V :ZN9)F=FRN[:H8X'RCCW-3&[:B]W_ %^0Y62<NB1W?_"U
MOA-_T"HO_!4G^%=7X%\9^"_$E_=6WAFU2WN(X@\H6S$.Y<XZ@<\UER_ 3P*]
MN\:6EW'(R%5D%TQ*G'7!XKEO@?\ 9-#\9^(O"\EO ]_:EPE\@PTL:O@J?Q(-
M7&SER^39$[J/-YH]WHHHI%!1110 4444 %%%% !1110 4444 %%%% %:ZCWQ
MD5P^M6VUV.*[]QE37.:U:;D8@4 >66+_ -D^*)K9CBWU >9'Z"0=1^/^%=/6
M'XCTQ[FV)A^6YA82PL.H8?Y_E5W1M235=-CN1P_W9%_NL.HKT*4^>'H<52/+
M(OT445H0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1S3)
M;P232MMCC4LQ/8"M+X8Z:[VEYX@N4Q/J4F8P>JQ+PH_SZ"N8U&*77M8M/#=J
MQ'G$27;K_P LX@<G\3_AZU[#96L5G:16\*!(HD"(HZ  8 K#$3M'E[FU&-WS
M=B26,.N,5SFJZ;N!(45U%03PB1<8KB.H\GU;2H[F![>=-R,/Q'N/>L?2]2FT
MJX72]4DRAXMKENC#^Z3V/^?2O2M4TO.2%%<7JVDQ74#V]Q'N1OS!]1[UM1J\
MCL]C*I3YM5N:%%<O8ZI<:),EAJK%[4_+!=^GLU=."& (((/(([UW:-71R;.S
M%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K*U?5S8F.UM8C<:A.=L,"\GZGVIFIZP\5PNG:;%]JU*7A8UZ)[MZ5U7
MA#P<NE[KV]<7.IS<RSMSC_97T'^?:IJ5%!794(.;T)/!GA'^R8WO+QO/U.Y&
M9Y3SC_97V'^>U=PJ!5Q38HPB\"I:\^4G)W9VQBHJR,S4;821M7":K9['8$9!
MZC%>ER+N4BN;UBPW*Q J1GEFF3'0=6.F2G%E<L6MF)X1NZ?Y]O6NIK+US24O
M;>2WER,G*L.JMV-5M!U664OIM^0M_ ,9/_+5>S"O0I5.>.NYQU(<C\C=HHHK
M0S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBCI0!%<7
M$5K;R3S.$CC7<S'L*G\ :-+J5])XHOXRID&RQB8?ZN/^]]3_ (^M8MC8R>-M
M;%NF1HEF^9W!QY[CHH]O\^E>PVL"01*B*%50  !@ 5A7J<JY%N;487?,R=1@
M4M%%<1U!1110 4444 %%%% !1110 4444 %%%% !1110 5#/$'0BIJ* ..UC
M3L[B!7":UI;SA)(7,-W V^"4=5;_  KV"[MA*A&.U<=JVFE2Q -.,G%W0FDU
M9D'A7Q*NNVC17"B'4K?Y;B'I_P "'L?\]JZ&O,M1L+F"]CU+39/)U"#[I[2#
M^ZW^?_K=GX=\1VWB"T+*/)NXOEN+9C\T;?U'O6%>BE[\-OR,TVGRLVJ***YB
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***PO$
M?B2+1(4AA0W&I7'RVULO)8^I]JJ$)3ERQ!M)79'XG\02::D>GZ<GGZO=_+;Q
M#G9_MM[#_/ -:_@[PPF@Z?AV,UY.?,N9SR9'/OZ#_P"OWK/\(>%IK6:35M6D
M^T:M<\R2'D1C^XOM7=(@50*[DE3CR1^?]=A1BV^9C@,"EHHI&@4444 %%%%
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M'=KI5\Y-JY_T6=CT_P!@UU->AHU='%JM&%%%% !1110 4444 %%%% !1110
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M>C6VD:?#9VL0CAB&%'\R?<UL#BD P*6N!N^K.S8**** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG&6?&#] >/2KA93YNMGI_78B=W'E\UJ=S1112*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"*:,.I&*YK5M,W!B%KJJ@G@612"* /)M7TF*ZA>WN(]R'
M\P?4>]8VG:K-HTZZ;JSEH2<6]V>A'HWI_GZUZ;JFE!@Q"UQ^IZ5'-$\,\0>-
MNH(K:E6<-'L95*:EJMRWUHKDXIM0\-G:0]YI8Z#K)"/ZC_/%='97]KJ-N)[6
M99$/7'4>Q':NY--71RM-.S+-%%% @HHHH **** "BBB@ HHHH **** "J]Y>
MV^GVS7%S*(XU[GO[#U-4M3UVWL'%O&K7-Z_"6\7+$^_I5S0_!]UJEXFI>(<2
M.IS%9K_JXOKZG_//93G&"O(J,7)V15T30+OQ?>1:AJD30Z5&=T%HW67T9O;_
M #TZ^M6MNL2  8 %-M;58E&!5SI7!4J.;NSKA!06@4445F6%%%% !1110 QT
M##D5FW>G)*#\HK5I",T </?Z,1DA:YK4=&BN(S%<P+(GH1T^GI7JTMLL@Y K
M)N](5P<**:;3N@:ON>1+9ZMHI_XEL_VFV'_+K.>0/]EO\_C5^S\3V4\GD78>
MQN>\<XP/P/3^5==>:*RYPM8-_HD5Q&8[B!9%[!AT^GI73#$O:6IA*@OLEH$$
M @@@]"*6N7_L*\TYBVDW\L S_J9?GC/Y]/UJ1==U2RXU'2FD4?\ +6T.X?\
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M+_Z ]=I7%_$W_D6[?_K\7_T!ZVP_\6)E7_AL[2BBBL34**** "BBB@ HHHH
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M,=*ECB5!P*EKE<G)W9NDDK( ,4444AA1110 4444 %%%% !1110 4A4&EHH
MKR6R..0*SKC24?/RBMFDP#0!R%SH?7"UE3Z*ZYPM>A-$I[5 ]FC?PB@#RV\\
M/P7/_'Q:QR>[*,_G60_A&WB??:O<VC>L$I'\\UZ_)I<;?PBJDFBH?X15QJ3C
MLR7"+W1Y3_9FNV__ ![ZW(P'\,T0;]32^;XIB_Z!TP]PP/\ 2O2WT)>RBH&T
M'_9K18F9#H0///[2\1*#G2K9SVVS8_G2_P!KZ]C_ ) *_P#@4M=__8/^S0-!
M_P!FJ^LR[(GV$>YP']I^(6)QHL2>FZX!_E1YWBF;[MOIT(_VBQ/Z5Z&N@C^[
M4Z:$H_A%+ZS+LA^PCW/-QIOB6Y_UNJQ0CTA@!_4\U*G@Q[H_Z=J%]<YZJTN%
M_*O38]&0?PBK<>F1K_"*EXBH^HU1@NAP.G^"M/MB#%8Q9'1F&X_F<UTEMH8&
M,J*Z1+5%Z**F$8':LG)RW9HDEL9EOI:)_"*OQVZH. *GQ12&( !2T44 %%%%
M !1110 4444 %%%% !1110 5&\88<BI** ,JZTU) >!7/WNB]2!^E=H1FHWA
M5QR!0!YE=:2=K*Z!E(P01D&N<G\,112F:QEFL9O[T+$ _4?TKV*?34?^$5E7
M&B*<X4?E51G*/PLF48RW1YBMSXCL.'2WU",=Q^[?_#^=2+XLMXN+^RN[0]V>
M/*_F/\*[:?0R.@JC)H[C^&NB.)?VD9.@NC,6'Q%H\XRFH0#_ 'VV?SQ5Y+JW
MD_U<\3_[K@U#/X:M9B3+90.3W,8S^=49/!6FN>;(#_==A_(U:Q,.J9#H2-GK
M2%E498@?4UA_\(-IO_/LW_?QO\:>O@33,_\ 'JQ_[:-_C5?6*?F+V,S1EU"R
M@&9;RW3_ 'I *H3^*=&@.#>+(W81J6S^7%6K?P1IJ8VV,9_WLM_.MJS\,PP8
M\FVBB_W$ _E4O$PZ(:H2ZLY/_A(KR[XTW1;J7/1YL1K_ /7J1-(\1ZI_Q]WZ
M6<1ZQVJ_-_WT>E>@V^A@=5%:L&E(G\(_*LY8F3V5BU0CU.'T;P/86<@E$'FS
M9R99CO;/KST/TKL[/2EC'*C\JU8[9$' %3!0*PE)R=VS912T1%' J#@"IJ**
MD84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %(5!I:* *LMJD@Z5E76D*^2!6_2%0: .%NM$(S@?I6/=:1N4I
M)&'4]59<@UZ:]NK#I5.73D?M0!Y!-X6MDF\ZU\ZSF[26TA0U-%<>*M/P+?6$
MND'1+R+/_CPY->E3:*C=OTJA+H7H/TJW4;^+7U(]G'IH<A'XR\0V^!=Z##<
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M-/\ ^VG_ *,:NCJJW\27JQ4O@7H%%%%9ED<L*S8W&08_N2,O\C4?V.+^]/\
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M7^QQ?WI_^_[_ .-'V.+^]/\ ]_W_ ,:L44 5_L<7]Z?_ +_O_C1]CB_O3_\
M?]_\:L44 5_L<7]Z?_O^_P#C1]CB_O3_ /?]_P#&K%% %?['%_>G_P"_[_XT
M?8XO[T__ '_?_&K%% %?['%_>G_[_O\ XT?8XO[T_P#W_?\ QJQ10!7^QQ?W
MI_\ O^_^-'V.+^]/_P!_W_QJQ10!7^QQ?WI_^_[_ .-'V.+^]/\ ]_W_ ,:L
M44 5_L<7]Z?_ +_O_C1]CB_O3_\ ?]_\:L44 5_L<7]Z?_O^_P#C1]CB_O3_
M /?]_P#&K%% %?['%_>G_P"_[_XT?8XO[T__ '_?_&K%% %?['%_>G_[_O\
MXT?8XO[T_P#W_?\ QJQ10!7^QQ?WI_\ O^_^-'V.+^]/_P!_W_QJQ10!7^QQ
M?WI_^_[_ .-'V.+^]/\ ]_W_ ,:L44 5_L<7]Z?_ +_O_C1]CB_O3_\ ?]_\
M:L44 5_L<7]Z?_O^_P#C1]CB_O3_ /?]_P#&K%% %?['%_>G_P"_[_XT?8XO
M[T__ '_?_&K%% %?['%_>G_[_O\ XT?8XO[T_P#W_?\ QJQ10!7^QQ?WI_\
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M +_O_C1]CB_O3_\ ?]_\:L44 5_L<7]Z?_O^_P#C1]CB_O3_ /?]_P#&K%%
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M%_>G_P"_[_XT?8XO[T__ '_?_&K%% %?['%_>G_[_O\ XT?8XO[T_P#W_?\
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MXO[T_P#W_?\ QH^QQ?WI_P#O^_\ C5BB@"O]CB_O3_\ ?]_\:/L<7]Z?_O\
MO_C5BB@"O]CB_O3_ /?]_P#&C['%_>G_ ._[_P"-6** *_V.+^]/_P!_W_QH
M^QQ?WI_^_P"_^-6** *_V.+^]/\ ]_W_ ,:/L<7]Z?\ [_O_ (U8HH K_8XO
M[T__ '_?_&C['%_>G_[_ +_XU8HH K_8XO[T_P#W_?\ QH^QQ?WI_P#O^_\
MC5BB@"O]CB_O3_\ ?]_\:S]>M(U\.ZFP:;(M)3S,Y'W#[UL5G>(/^1;U3_KS
ME_\ 0#50^)$R^%F;X# '@VQ//)D)R?\ IHU='7.>!/\ D3-/_P"VG_HQJZ.J
MK?Q)>K%2^!>@4445F6%%%% !117FVO?'+P9H5])9^==W\T3;'^Q1!E4]_F9E
M!_ FE=7L.S/2:*YJ_P#'>@:5X9L/$-_=20:=?!##(868_,,C(4''%=#!-'<P
M1SPN'BD4.C#HP(R#5---KL3=.WF24444AA1110 4444 %%%% !1110 4444
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M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9WB#_D6]4_Z\Y?\
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M K,U/2?M;QW=K*UKJ,!W0W$9P0?0^U:=%,#>\%^-/[:W:7JBBWUJW'SQG@3
M?QK_ %'XCCIV=>-ZMIDEUY5W92FWU*V.^WG4X(/H?8_Y[UWO@OQ6GB736$R"
M'4K8^7=0?W6]1['!_45QUZ/+[T=CII5+^Z]SIZ***YC<**** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ?Q-_P"1;M_^OQ?_ $!ZVP_\6)E7_AL[2BBBL34**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBO-/BKXHGL(HM%LI#&\Z>9.ZG!V= OXX.?_KU4(N4E
M%"DU%79U=_XW\-:;,8KG5H!(#@K&&DP??:#BK&E>*M#UIQ'I^I0RR'I&<HY^
MBM@U\UTY'>-U=&*NIRK*<$'U%=OU2-MSD>)E?8^JJCGN(;6%IKB:.&)!EGD8
M*H^I-<%\/_'J:O NF:K.JZ@G$<CG'GC_ .*_G5?XNZK;)HMOI:RJUS),)&0'
M)50#R?3)(KE=*2FH,Z(U(RBY([NTUG2[^7RK+4K.YD SLAG5SCZ U=) !)(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH.\':4^F:!&UQDWEV3<W#'J7;GGZ#'XYK?HHK@G-SDY/J2E96"BBBI&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <YXTTZ6[T/[7:$K?:
M>XNH&4<Y7DC\OU KL_#^K1ZWH=GJ,7"SQ!B,_=/<?@<C\*SR 001D'J#7/\
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M<?UKV*N;$Q4:FAKAY-PUZ!1116!N%%%% !1110 4444 %%%% !1110 4444
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MT#1;V74+ W$VT,7( 4< 5Q>J_P#(6N_^NK?SKJ_"W_(&'_71JY35?^0M=_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_0'K;#_Q8F5?^&SM****Q-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]9@%Q8RQ-T="I_$5Y+X2=CH$<+_?@D>)AZ$,3C]:[,,_=:.:NM4S<HHHKH,
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M5'8?SJUX]\$IXXTB"Q:^:S:&;S5D$7F \$8(R/7UHE*/NQCL@3O-R9R/P?\
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M-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7\3?^1;M_P#K\7_T!ZVP_P#%B95_X;.THHHK$U"BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW;_]?B_^@/7:5Q?Q-_Y%NW_Z_%_] >ML/_%B95_X;.THHHK$U"BBB@ HHHH
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MGJ^YFE[UUHA]%%%26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS6/&9>X;3?#L:WM[T>?K%#[D]S_GGI2>'O"S1W+7UY(]WJ$W,EQ)R?HOH/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 5Q?Q-_Y%NW_P"OQ?\ T!Z[2N+^)O\ R+=O_P!?B_\
MH#UMA_XL3*O_  V=I1116)J%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !6=X@_Y%O5/^O.7_ - -:-9WB#_D6]4_Z\Y?_0#50^)$R^%F;X$_
MY$S3_P#MI_Z,:NCKG/ G_(F:?_VT_P#1C5T=56_B2]6*E\"] HHHK,L****
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M:TH-+BC[5HX%+0!$D"(.!4N,444 %%%% !1110 4444 %%%% !1110 4444
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M ._#_P"%6** *_VR+^[/_P!^'_PH^V1?W9_^_#_X58HH K_;(O[L_P#WX?\
MPH^V1?W9_P#OP_\ A5BB@"O]LB_NS_\ ?A_\*/MD7]V?_OP_^%6** *_VR+^
M[/\ ]^'_ ,*/MD7]V?\ [\/_ (58HH K_;(O[L__ 'X?_"C[9%_=G_[\/_A5
MBB@"O]LB_NS_ /?A_P#"C[9%_=G_ ._#_P"%6** *_VR+^[/_P!^'_PH^V1?
MW9_^_#_X58HH K_;(O[L_P#WX?\ PH^V1?W9_P#OP_\ A5BB@"O]LB_NS_\
M?A_\*/MD7]V?_OP_^%6** *_VR+^[/\ ]^'_ ,*/MD7]V?\ [\/_ (58HH K
M_;(O[L__ 'X?_"C[9%_=G_[\/_A5BB@"O]LB_NS_ /?A_P#"C[9%_=G_ ._#
M_P"%6** *_VR+^[/_P!^'_PH^V1?W9_^_#_X58HH K_;(O[L_P#WX?\ PH^V
M1?W9_P#OP_\ A5BB@"O]LB_NS_\ ?A_\*/MD7]V?_OP_^%6** *_VR+^[/\
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M 'X?_"C[9%_=G_[\/_A5BB@"O]LB_NS_ /?A_P#"C[9%_=G_ ._#_P"%6**
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M+^[/_P!^'_PH^V1?W9_^_#_X58HH K_;(O[L_P#WX?\ PH^V1?W9_P#OP_\
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M@"O]LB_NS_\ ?A_\*/MD7]V?_OP_^%6** *_VR+^[/\ ]^'_ ,*/MD7]V?\
M[\/_ (58HH K_;(O[L__ 'X?_"N0^(TGVCPW%Y4<Q$=RKN3"P"C:PR21ZD#\
M:[>BKISY)J78F<>>+B<7_P +-T7_ )];_P#[]I_\71_PLW1?^?6__P"_:?\
MQ==I16G/2_E_'_@$<M3^;\#B_P#A9NB_\^M__P!^T_\ BZ/^%FZ+_P ^M_\
M]^T_^+KM**.>E_+^/_ #EJ?S?@<7_P +-T7_ )];_P#[]I_\71_PLW1?^?6_
M_P"_:?\ Q==I11STOY?Q_P" '+4_F_ XO_A9NB_\^M__ -^T_P#BZ/\ A9NB
M_P#/K?\ _?M/_BZ[2BCGI?R_C_P Y:G\WX'%_P#"S=%_Y];_ /[]I_\ %T?\
M+-T7_GUO_P#OVG_Q==I11STOY?Q_X <M3^;\#B_^%FZ+_P ^M_\ ]^T_^+H_
MX6;HO_/K?_\ ?M/_ (NNTHHYZ7\OX_\  #EJ?S?@<7_PLW1?^?6__P"_:?\
MQ='_  LW1?\ GUO_ /OVG_Q==I11STOY?Q_X <M3^;\#B_\ A9NB_P#/K?\
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MYOP.+_X6;HO_ #ZW_P#W[3_XNC_A9NB_\^M__P!^T_\ BZ[2BCGI?R_C_P
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M^;\#B_\ A9NB_P#/K?\ _?M/_BZ/^%FZ+_SZW_\ W[3_ .+KM**.>E_+^/\
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MS$MG )P .E+K8'H=O17#W'B^ZTNQU(Z=I[ZK8Z$ICO;V[O!')(R %P@"$2,
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M2#X9ZM?22ZQ)J-VUS):RM8W)C3>Y6(+-LV  %<8;%#>]M?U[??\ H):M)_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)Y+Q[VP687!D8L6VAEPPZ Y(_P!GTZG3-2M-8TVWU&PE\ZTN%WQ2;2NX>N"
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M[ 9K.TC7/M_A.UUVZMOLBRVHNGAW[_+7;NQG SQ["E=13?:WY-?E<;5W;O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML7"*9$!9?EVKAMH(PHJY,FB:3K,.C^(9WO-'T[1EFL(+U23=RLS%B(R/F=0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5\_PO_EI^H*^OI^-O\]3#MH](M/$5KI\NM>(SK&2VZ=[H0W.P M@,OD$8Z[
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M<>=$LMN9HW^0I@J&4]#P<\5T/;FJTUMW_"R$KZ7[?CJ%%%%(H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N>N/&.F0>,+3PPJ7,U_<(SEHD!CAPN[#L
M2,$CL 3TSC-:6LW%_:Z-=S:59?;;](R8+<NJ!W[9+$ #\:\W\,13Q?$6%+G2
M-2BEL=/DFO;FY>W),T[9,C;)6^4B/: ,D# P!S23]ZSV_P" Q2TC=?UJO\ST
M+0M:_MF.^W6_D26=[+:,H??G8>&S@=00<=JU:Y'X>*TVBWVJL %U749[R+WC
M+;4/XJH/XUUU-7LK[V5_6VOX@G=OU?W7T_ ****!A7+W_C*2PUR#2&\-:Q-<
MW/F&W,3VNV54QN89F! Y'W@#S745QT0^W_%RYE(S'I>E)&#Z/,Y)_P#'4'YT
MOM+Y_DP;M%OT_.QUEM*\]M'+);R6[NH+0RE2R'T.TD9^A(J6O')+?R_ _B3Q
MC%#NU.\OYFM[HKN>T@\P0EX\CY?D!)(]!Z4QYO#MAXAU#4?#L4/V71M!EF>X
MM_N7$TG"MN'#MA6R_.<D9XI.6E[=/TO;]/4.MO.WXI?\$]FHKR33=#L/"^L>
M$H(UDBN;;2[BZO[M5:25DV*NTX!)4,V0O0;>!6)+/96'A3Q#:6[VVH,\$=J-
M?L2Q-WY\FTK+C(>51SGG XXSBJEH[+^M6OS)C)-7]/\ ,]VHKQ:_\C3VU/5?
M ["2VL=#>&XO[<^9]HG9EVDOSYCHH9B>2,@>U26[^&K7Q/:WNA+#);Z/HMQ?
M75Y"25N)2 JLS='?[^6Y/)'M2<DE?U_"_P#E^(TV_P"O3]7;Y'LM%>,W6BCP
M[X&\,KYL%C+J,L8U75;F-GVHRF39(P96$9?"XW*.?<U+<Z%IDFCV>F:;J$4\
M&OZQ"LG]FP_9K9$B7>QA4$X!V<L&.2>O%59\SCYV_+_,7.K7\K_G^.A[#17C
M.I>7I+>*?[+!T[27U6RL;J2W^58DVJ9Y21T)# %OQ/-:GB%?"^BZ-I_B;0(8
MDLM.U6!YFLD/ER*08V*@?*W$G++G)ZDD5*::OZ?C;\-1W>W77\+_ .1ZE7/>
M'/&6F>)]0U6RL8[E)--F\J4S( LG++N0@G*Y5AGCI5#P^DVB^%M4\0:HACO;
MTRZC<(W6)=OR1G_=15'US7!Z>-5\.7&@6^G0L=4\0Z+Y0?'RQ3>9YC2/_NK*
MY]R .]&O-R]?U:;_ $:!M<M_ZLFK_G<]+TSQGI>K^*M0\/V2W$EQ81[YI]@\
MG.<%0V<D@Y!XQP>>*Z&O$[JV71;3Q ;*5[>Q2_LM'FO Q#) N&F=F[9:1LM[
MDTEX='BG\7WGAJVBM[.#3(=-MFMU*QO-.W+(.ASE/F'7&>>M"=XZ:_\ #77W
MW2"^NNG_  ]G]VK/5?$.N_V%;V3+;_:)KN\BM(X_,V<NV"<X/09.,=JV*\?\
M6^'YM(?0-'\+01IJ-K;RZA+-L#2S&*,1@ECU?]X=I;(!QQBH+U]'/_"/6UIJ
M-AIWANXLY;UI=7A:6&\N"0")OWB;Y -QPQ//;@8+]//^OQ3%=Z-]OQ_IH];O
M]4L],%M]LF\O[3.MO#\I;?(W0< ^AYZ5'KFL6V@:)=ZK=K(\%K&798@"[>R@
MD#)^M>87.A>&[74?!.G7QM;G3I9+FY2:_MUC1MP^2%5<?*I+@B/_ &174_$6
M!;G1-)T"!C;C4=1M[93$H_=HIWG (QP$[@CVIO;U=OQL-2Z]$K_F_P C7TKQ
M5!J.L-I$^G7VG:@+<7*P78C)>+.-P,;N.O&"0?:M^O'-5EU'3(?&.Z_GFU:"
M>UM3JLB_/%92;26VQ[54+E\E0O3/&,U8BTG08=&U:ZM?%>GVHNX4LFO=,M3#
M9HV2V]VWL&8XVLYD[XR"12YKQO\ UW_5+UN"O>W]?UN_2QZW17B3W<<FF:/:
MK'I>@:+<WEQ]JN&B=M.NO+4",[=Z ))R<;@&*_Q=[LMMI&E_\(_8SZA$?#.I
MW=Q<W3F+[/:.ZH D*H>!&S9(7)#8[YI_U_7;K_3%?^OO/8**\0M;*RU73);2
MPADM++7?$JPQ1QAHS';VXR<#JHS&W'&,]JW([7PPGC;6-)URULX+6V6%-*TY
MHP ^]2SS1(!EI"QP67)&.HI+6W]=$_UM\F#=K^7^;7Z'=6VO?:?%U]H26W%G
M:Q3O<;_XG+ )MQZ+G.>_2M>21(8GED8*B*69B> !U->+ZQI-C?:-XSUN:(SS
M2WR:;IV\EO)9-D*NN?XMQ/S=>.O6N\^(3RVWP\O;=)&WSK%:%\\XD=8R?R8T
M7;@FMW;\=5^:&G[UGM_EH_QN6[;Q?;MX1E\2WEL]M8C<\"@[I)H\X0A<##/Q
MA?<<UI:#K5MXAT.TU:T25(+E-ZI,H#KS@A@"<'(]:XW4Q?:QXEL]'T2RL[K3
M?#WER7*7-RT$;3[?W2 K&^=@^8C'4KSQ7(_;8O\ A&]+\/:Q.ME'%XEG2[:.
M9@L,4;-+]_ (7+(-Q X.>*::;T_I72O^-_\ AQ-M*[_IV;M^%O\ ACW&J%_J
M@T^XM(FL[N87#,IEABW)"%4MND.?E'&![D5Y+=6<%Y;:K:Z,OV71-=U:SL[/
M[.-B2!/FFECQV.T_,.N,^]:'B>&ST;5]6&E6D5LFDZ#(46)0 ;BY;:"?5CL&
M2>3FI;?+=?U[M_\ @#3UL_ZN['H7AK6SXA\-VFL&U-LMRAD6+?O(7)P<X'4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gemp20161231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"617AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A8VAS+"!3
M87)A   !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ_\  $0@"1 &V P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M3:<UK?Z9?!=ZVVHP>2[KZJ,G(K#T*%;GXQ^(;B\ :>WMH5@5OX4RW(^M.O\
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M3)"]:LPZY#)X@ETB13'.L7G1D])$SC(_&M.B[W[A9+3L%%%%(84444 %%%%
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M.MK>92/F,LI0@_@#6;:ZIK=VTXBT^SS!*8GS<'[P /'R].:0&_161]H\0?\
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MO4*\O_:%_P"21W/_ %]P?^AT ?*%%%%!04444 %%%% ';?"/_DHMM_U[S?\
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M<'_H= 'RA11104%%%% !1110!VWPC_Y*+;?]>\W_ *#7OM>!?"/_ )*+;?\
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M_P!QOY5DUK>&?^0['_N-_*@#MJ***D84444 %%%% !399(XHF>9U2-1EF8X
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M*** +.F_\A6U_P"NR_SKT.O/--_Y"MK_ -=E_G7H=)C"BBBD 4444 %>9_M
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ML9=1U)V'VN0O# PQY*#@#\<9_&L75_#5C/XBAL=,TF.V2Z;S]0NXXL>8J_\
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MUG<7T>=UM'.K2#'^R#FO)H;"?3VUG6?$OP]L]0M!?S2R7UT5\]8MV05C*DD
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M2WAF(,T22$="R@XK+T!5235%10JB^?  P!PM24;%%%% !1110 4444 %%%%
M!6-XI_Y C?\ 71?YULUC>*?^0(W_ %T7^= '&44450@HHHH **** +.F_P#(
M5M?^NR_SKT.O/--_Y"MK_P!=E_G7H=)C"BBBD 4444 %%%% !1110 4444 %
M%%% &/XH_P"0&_\ OK_.N+KM/%'_ " W_P!]?YUQ=-""BBBF 4444 %:WAG_
M )#L?^XW\JR:UO#/_(=C_P!QOY4 =M1114C"BBB@ HHHH ***S];LK[4-+D@
MTO4WTRX;[MPD2R%?P;BD]$,X+6['PR^KWC7/Q)U"PN#(V^W35E186_NA>V/2
MM[X93SS^#8_M%]/J!2:15NYVW-*H<X.>_%>=Z3X3OO$%WJ\FH^*+.":TNY(2
M9M*M_,DVG[[97O7HWPUNI[GP;"+JX2Y>*62/SHX5C1P'(!"J .U7!6B_1!/?
MY_HSK:***D04444 %%%% !61H7^NU7_K_?\ DM:]9&A?Z[5?^O\ ?^2T :]%
M%% !1110 4444 %%%% !6-XI_P"0(W_71?YULUC>*?\ D"-_UT7^= '&4445
M0@HHHH **** +.F_\A6U_P"NR_SKT.O/--_Y"MK_ -=E_G7H=)C"BBBD 444
M4 %%%% !1110 4444 %%%% &/XH_Y ;_ .^O\ZXNNT\4?\@-_P#?7^=<730@
MHHHI@%%%% !6MX9_Y#L?^XW\JR:UO#/_ "'8_P#<;^5 ';4445(PHHHH ***
M* "@G S161XGUW_A'="EOE@-Q*"%BB!QO8G 'ZTF!YAK\,?BCQ8MRVBZ-+ M
MU)9J;J-C,TB8 9B& VY/0BO2/!NIQZGX=C:.TCM/)=H6BB^X"K%?E]N*\MUS
M2M4U[Q)':7?A*.'6S^_)M=6EAMRO7)91][\*]5\)65[I_AR"WU.SMK.=,YAM
MI"Z+S_>(&2>I-5#2']?UO<)N\OZ_KM_3-NBBBD 53GU?3;6[2UNM0M8;A_N0
MR3JKM] 3DU0MO&&@7VIS:98:M:SW\(.ZW1\N,#/2O*H!=:IINLZO>>&+;4K9
M+R<3WT\Y6YB16/\ J1M.,#T(H6K\AVZ==CV>]U*QTZ-9-0O;>T1CA6GE5 3]
M2:FAGBN85FMY4EB<95T8,K#V(KSG3[+3?%?CL"^B%]86FF+]G@NAO7)(^8@\
M%N<9K4^'T?V"YUW2H2QM;6_?R%)XC4G[H]ABFEW_ *L[$W5KKR_%7.UK(T+_
M %VJ_P#7^_\ ):N7FJV.GNJ7MU' SC*AVQD50\-S1W U*:!Q)&]\Y5E/!&%I
M#-JBBB@ HHHH **** "BBB@ K&\4_P#($;_KHO\ .MFJ>IZ>-2LC;M(8P6#;
M@,]* //Z*ZC_ (0^/_G]?_OV/\:/^$/C_P"?U_\ OV/\:JXCEZ*ZC_A#X_\
MG]?_ +]C_&C_ (0^/_G]?_OV/\:+@<O174?\(?'_ ,_K_P#?L?XT?\(?'_S^
MO_W['^-%P,#3?^0K:_\ 79?YUZ'7/V_A1+>ZBF%V[>6X;&P<XKH*3&%%%%(
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M?$%AXDTT7^DR&6V+%5DQ@-@XR/4<52T5K?U>_P"H/>_];?\  -.BBBD!$MK
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MQ&*V'[O<&()7'KC-5'6'W#G\7]>?^3.GHHHI""BBB@ HHHH *R-"_P!=JO\
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M 4444 %%%% !1110 4444 %%%% !1110!C^*/^0&_P#OK_.N+KM/%'_(#?\
MWU_G7%TT(****8!1110 5K>&?^0['_N-_*LFM;PS_P AV/\ W&_E0!VU%%%2
M,**** "BBB@ H)P,FB@]* /,+GPW8^.M2U?4!HD(:QE:&U?[9+"9IE^\7"'
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MZ_K^KK^F2T444@"BBB@ HHHH *R-"_UVJ_\ 7^_\EK7K(T+_ %VJ_P#7^_\
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M9L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1ZUK>&2/[>C_ -QOY5V7V6W_ .>$?_? IR01(VY(D4^H4"BX#Z***0PHHHH
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MK2#XE7<^A:1<Z=H\MDGDM*[D3-ELMAB<=N#7K%-[)D=6E_6EPHHHJ1A1110
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M;:JR:E:Q:E#8228N9U+1I_> &37FEE$WBO6!8>+=198[2R$L7V.Y>%93D?O
MP() ST-5;31M*NOB-X<N(]2NM2 AE"7+3LF[8N5& >?Z]ZN*O))^?X7_ ,B'
M+W')>7XV_P SU^BN)\=,]WJVC:/<W,MKIM[+B=XI#&SGLFX8(S['M7':\9=(
ML/$&A:1?71TZ'[,T<IN&=X7:8*RAR<GCW[U"U1HE>27I^)[/7,^*?%5YH6H:
M=8:7HQU6[OV*HGVE80N 3DE@?2N;T33E\-?$C3-/TZZNWM[_ $Z2:X6XN'EW
MNNW##<3MZG@58\?/J:>-/##:'#:S7GFR;$NY&2,_(W4J"?TJW'6/G?\ "_ZH
MB_NM^GXV+\7CRZMAJ$.OZ"^FWMI:M=1VXNEE$ZJ"3AP, \5T^D:B-6T>VOUC
M,0N(PX0G.W/;-<%K&AZY<:;K6O>*?L<-Q%IDT,%O92,Z*"AR26 .>E9T=O9:
M]#IFF7,U\YMM,\WR8[AK>)3Q\Q="&)YZ=*GIKO\ _M?HD5;K_7V?U;/6J*\5
MLWO=>\/:18/J<=Q&MS.C69O)(9+A54;<2+\W'7DTV=C>Z;HVA->:C"(];2"=
M3.P8*P<[1(#EAQU)JE%MV1-TE=_UO_D>V45XT_AFV4^*+<7NI>5I(,MFOVZ7
M,;!<\G=EA['(J2!K?Q=9Q'4;J^GN;/2[>5_]*:VBC9DR6W(07)QT(J?L\WS^
M15M;?UT_S/8&)"$JNY@.!G&:X*_\=^)K#7;;2F\$[Y[S>;8C5H\.$P23\O'4
M5J?#2_N=2^'VFW-[,9YF5U+DY) =@/T JEXE_P"2I^%/^N5U_P"@K5N%JO(_
M/\F*+O%OR9UFGW%Y<::DU_9?8[EE)>W$PDVGTW#@T:;<W-W:"2]LS92[B/*,
M@?CUR*X+Q#IQUGXMPV=S>7<=I'I,DQA@G:,.P< 9P?>L/39KC6+;0-$U'4+F
M+3[R:?SY%F97EVJ"J[\Y'/O4J\FK=;_@_P#@ _=6O3_*YZ;XEUY?#FD_;GMV
MN!Y@38K;>OO6JC;XU;&-P!QZ5X;>0I8S>*=.MK^XN[2WN;98A-,TGEY0Y ))
MK1EU.]M]3E\#I=3_ &NZODEMY/,8LMN K'GWPPHCK;SV^Y?E=OY"EI)I]%K^
M/_#'L=%>4PV=CKD6MZIX@UB[T^YTRYDA@>.Y=1;HA(5B@.'R!GD&L_6X]<\1
M^*+JW22SN;.Q@5K=KG49K,D;0?,Q$/FY/>EV_KI<OE>OE^=['LU4]/NKJZ64
MWEB;,HY5 9 ^\>O'2O*(8-0U[6?!]CJVK,Z20W!D:PN'"3*JKCG@GZU''<W+
MV-KI$U_<Q:?=:P;:>7SFW^6 V%WYR.@YS3Y7>W>_YV)Z7?\ 6C?Z'IL/B)9?
M&=SX?^S,&@M4N?/WC#!B1C'X5M5X=?Q2>%?%7B.+PO=/.Z:=;JIN)FD\H-(P
M.7.3P.<U<T.TUO0M5MI&OM*L8[NV:24KJ<]TT@X^<+(,+U[>M*ZM?R_S*DK/
M^NR_S/9:*\>\/13:+K^C7UW/<,;^1TDN;>\>XBN3@XRCG"#IT%=CX[DMKF33
MM(N9KQ?MDA(BM7\OS N,AG!!4<]J<E:UO0E:_=<["BO"]0FN+#PWXNTFTOIH
MK>TNH4@V7;R/&&V9 D8[CU-;.J0S>"M7O(M N;LB;3))G$\[S8=5)WC<3CZ"
MET3[_P"5QM-.W];I?J>@^(/$2Z#/I<;6S3_VA>+:@J^WRR03N]^G2MJO%KW1
M=.L+GP5J-KJ=Q<75[?Q23K+<M('8H22%)(7!XP*]I'2J<;1\[L3:NK=OU844
M45(!1110 4444 %%%% $<]Q#:PM-<RI#$O+/(P51]2:='(DT:R1.KHPRK*<@
MCU!K@/BJ#K5KIWA*%RLFL2D.5."$3#']*S_#OC"7P_\ "^^<6_VJYT.=[7R"
M^"55B$Y^@HCJF_Z[?F[#DK6_KT_)GI=W:6]_:O;7D2S0R##(XR"*PK/X?>%-
M/\W['H=K%YPQ)A2=WYFLJW\=:EIUY'%XOTJ#3TN86EM7MK@R[\*6*G(&#@5'
M:>.M9#6%]J^B0VNBZE(D=M<1W!>4;_N%TV@+GZFFD[Z$WNC9U/P]X1UV^MWU
M.UT^[N82(X=SC<".=H //TK7&DV OH[P6L8N(H_+20#E5]![5YCX;U6WL-?,
M#Z=#<R7&I2&.=C@PXC8Y''MC\:U++XB:]/9QZO<^'[>+1?/\F29;HF5><;MF
MW&.>N:4=8Q\U?[_^'L&[?D[?=_PUSLQX;T==.^P+IT M?-,OE;?EWDDEOKDF
MJT_@OPY<ZTNKSZ1;/?J<B<J=P/\ *N<D^(]VNLZNHTJ/^R=)$;37AF(+*ZAA
MM7')Y'&:FM_&6OP7-L-<T.VM+;4 19R1W1<[\942 J-N>/6C7XOZU_5C?6_]
M=7^9N77@GPW>ZH^HW6CVTMW(NUI64Y8?RJI>^ ?!K6R&_P!%L5AA4*K2?*%&
M<XSGU-<=HGQ#U/1?"6H:CXI2U!_M*2UM6-P=I?>PPYQ\JC&,\U8M_BE::MIN
MH6NH6VEWT\$22^5971GA=2X&"Q488'G&*&K*RZ?U^I5GS6?>WZ'=W?AO0]4T
M6+3;O3[>XT] /+A(^4 =,8HA\+:);Z5%IL.FP)9PMO2$+\JMZURUSXTUW^V#
MI/AO0+2X\FRBN6:>Z,2J&7.WA3Z5'<?$V:72],ETRQMA=7R.Q%]<&&)-K%2-
MX!R<@XXIO2[\_P#/_)D6NDGV_-7_ "9VYTFP.H2WS6L9N98A%)*1RR#/RGVY
M-9N@^&/#&F74U_X>L+.*65B))K<[LG/(SD]ZL>'-7GUK0TO+NT^RRG(:/=N4
MX[J>Z^]<5!X[FLO#]@^A>'K82W^JRV:VXFV*&#/ER0.^W/XT6:=OZU'\4;]/
M^!_P#O-9T+3/$-@;+6K**\MB03'*,C(K)T_P!X2T*\74-/T:UM)X>1,"1M_,
MT>%O$E_JU[?:=K=A#9:A9D;T@F,J%3T(8@?RKF=6U;Q#+XTU_3I8+8Z8FG[A
M^_.Y>.NW'6HD^1779O[E<<4I:/NE^-CMH=!T.2UA%O96SP)*9X]G*A_[P]ZB
MU3P=X?UK48K_ %72K>ZNHL;)7!R,5Q7A'Q7JFD:3H-KJFE00Z9>;XH+B.<M)
MD;F^9,8 P/6H[OXT6EOJMP$;2O[/MYC%();TK=$@X)6+;@CTYK1QM/E7?_@?
MY$1;<.9]5^?Y]3M]?\,^&]7MXY/$5A:30VH^5YSM6,?7(Q3G\/\ AZ^BL+MK
M.TFCL!OM)@<K$/52#C'%8_Q)DCO_ (3ZK)'_ *NXM5*Y'9F7'\ZX[1-5GTWX
M.SZ'+*?MD;BPB(')23"JV/Q-1=I2MNK?>:<J:CV=U\M#U&]L='\4:6T%W';:
ME9.<$!@ZDCW!JJGACPWI6AMIPL+2VTXNK-$QPA8$8))/7(%>??#2[U'P[\*+
M:#2[ 7]X+Z:#]X_EQJ0[99VP<#CKBI?$/BFY\0>#]5L-3M+>WO;*YM]XM9C-
M$095Z,0/Y5<X\LG%?UL*'O-7[GIG]E:>^H0:A]FC-U!&8XIL<JAQD ^G IUQ
MIEE=7MO>7%NDEQ;$F&1ARA(P<?G7FNH?&"VTZ[>ULWTHP6*A+@7EZ8IF(X(C
M0*=W3U%>B6=\FN>'TO+"0JMU"3&_H2,9_.D[VYET_K\25T3Z_P!?@1WNIZ%<
MF72[_4+!VF!CDM9+A-S \%2N<U7OO!?AS4UM?MVD6TXM5VP;@?D'H,5P4NEZ
M+H6AR6?C316%S(6WZY%;A]N>CF7JI[UMR^+-7M]8MM \*Z=;ZL$L1<+=W-T8
MU900.H4\\TM+?UVO^!3NM.G]+\3=G\!>%KFS>TGT2U>"24RLFTX+GJ>O7BK5
MOX5T.TM;2VM],@CALY?.MT"_ZM_[P]^37*77Q*O?L>F+IFC+<ZA=W,EI-;M,
M5$,J $C..1SUJQK?C'Q)I1E==#LE@M8U:XDN;PQ[B1DB+Y3OQT[4[\JN%KV_
MKK;_ #.L.B::6NR;.(F]&+DX_P!:.G-9]QX'\-7<UI+<:-;.]F@2W)4_NU P
M *Q9/'E_J-Q:VOA728[ZYDM1=3"XF,2QH21C(!R<@\5#H'Q&NM7N+"&YTE;:
M2YNYK:1?-)\LQL%STYS1RN]OZ["O>/-T_P"!?\CL=+T?3]$M3;:3:1VL)8L4
MC&!GUI\^F65SJ%O?3VT<EU;!A#*1\T8;KCZXKD=4^)$&C_V\;^W6./2Y5BC8
MR?ZTL%//' ^:J/A[XMZ?>W[VFN7>D0-Y;2K+8WIGC50,G<Q48-).^J_K3_(<
MDX[_ -7.TO;?1[.].KZA]EMY_*,!NIG"?(3G;DGIQ7(Z[I^G:IIMO:>%[/2=
M<L8'9[G2X[A,R9Z$-NPISZTSQUJ&D^)?#.E7%A-;ZE837Z+N7#H_!R/>E\7Z
M3IWA=M*U;P_8P:=<+>10LMI$(UE5V"D,%QG />B*;:3[V_+]7^H-VV[7_-?H
M3^$? L%M%J4^KZ5;VR7\D;+IZG>L 1< 9!Y-6M.\/W=U\1+CQ#J5@EHEO;"T
MM1O#LX!)W\=.#C!YXJAKOC[6M$DN+R;1;:/2;>0JS3W12X< X++'M((].:;J
M_P 3Y=)TC5;EM*WW-E<K'#;B3F:,A27Z<8#'\J?-M+Y?DOOLQ<NZ.CU7PGX8
MN]0&L:OIMHUS#AOM,W&W'<G./SJ75_"?A_Q(8)=7TRWO?* ,3..@[8Q7$>,?
M%PU_PCJ]E:VRM!_9(N9I=^=A=,JN,<]Z74OBA#H+6ND64FE">VM8VN/[1O#;
M@?*#A,*=QP?:BUEKW_ICU;OY?Y?YGH0T73A=VMR+.(36:%+=PO,2D8(%03^%
M]$N--GL)]-@>TN'+RQ%>';U-<_I/Q&MM4O-. A1+.^MWD2XW]&099<8Z<CFM
MOPOKDWB+13J$MJ+96D=(UW9W*K$;OQQ0T[:_UK_FOU$GV_K3^OR,NPT_P#X:
MFN(;)M&L)9$\F=#<(K%?[I!;/>M'0_"GAO2?-NM!TZUA%T,O)#\PD!]\GBO,
MM%NM$M]0\3?VGX(O-<E_M28_:H-+2X4#:OR[SR,5O^#]6U#3?AW'/I%F+^6>
M^E6&%Y-B6RESA9&YVA1P>.*%K&[[+\>@-6=O/\NIUNF^"/#6CZFVH:9H]M;7
M;9S*@.>?QJ[K.@:5XALQ:ZU8Q7D .X)(.AKS_5?'>O77AG6(;>RLH=6L"A<P
M79>+:6 X?:,GGTKN](OKH>%+>]U>..*<6XDE6-]Z],]34MKE;>R_X<%\2MN[
M_P!?B5/^$+\*PQRYTFS1#&$ESP-H((!Y]0#4\$OAO5-4$UM<Z?=WJ1F/,4R.
MX4]1@'I7G]Q/=:KH^A0WD\JCQ%J3_:BKD?(H;"CT'R"MSQIX5T?2/#IU/1;&
MWTV\L765);6,1L^TYVL1C<#[U337Q]_^ _\ +S#1_#_7;\K_ '&W:_#[PI8Z
M@M]::%:Q72R>:LH4Y#^HY]ZZ.O/)/'?B*?4[JRT70K6Z%E;13S2W%T8LAD#$
M !3SSTJ/5?BW:6VFZ6]E]ABN]0@$X74KDP1HO(Y8 \Y![4=/Z\_\F&[O_71_
MJ>CT5Q6B?%'P_?:']OU74K*QV2^2[>=F-F_V6(&1QZ5V4,T=Q"DT#AXW&Y67
MH119BN/HHHI#"BBB@ HHHH XO5OAY:^)?&4FJ^)1%>V,<"QVMKEE,;9.6)!'
M4$5R?BSX?CPMH/B"3P\R6^F7\:8M$#,R2 8W G/'6O8*;)$DJ;945U]&&:%I
M:W]:W&W>]S@K7P7K.N36T_C"^LYHK6W*6J6:,I!9"I9MW?![4MMX+\0S+IVE
MZSJ-A)HNFRI)"($<3R>7]P.3\OUQ7? 8&!13N[_UZ_J2EH>?1> +RRU1-1:\
M@:."YDN#&JMDJ8V7'UYK$\)^&O$NL>&8;*;4+.+1)+DRR(8W^T8!!V _=P:]
M<(R,'D4V.-(4"1(J*.@48%*.EO)6"V]NKO\ G_F<?#X"4KXCM[R=&M-8,0C5
M 0T81 O.?<5#:>%?$=[?V"^)M0L)K#3FW0I:(ZR2G'!D+<<<=,5W%%._Z?AL
M-ZJWK^.YYY%\/=373+NTEO+)C'J3:CI[^6Q*N69L2 \$9/:K#>#M?U+3+]-9
MO].2XN$2.**R@*0(%8-N.?F+'IUQ7=T4GJK,KF=^;^NYRVF^%+FQ\0W6H/<Q
M-'-8Q6H0*<AD4@GZ<UB0>!O$6F:'86FF:CIL[6YE$MO>PLT#[W9@PV_,& ..
MN*]$HIMW_KU_S9/]?A;\D<]X/\-R^'-&FM[F=)9[B9YY!%GRXV;^% >0HQWK
M!LOA[>VMKI$37UNQL-6DOW(5OG5F<[1[_,*[^BGS.]_ZT#IR_P!?UJ8.E^'Y
M[#Q5JFJR3QO%>JH2-0=RX/>L[5/"NIW/BF\U"RNK1;6]M/L\J2JQ=3@ %2.,
M5U]%0XIJS]/T&G9MKK_G?]#C)/!%U)I?AVT:[A_XE,S/,=IQ("&&!_WUWJHO
M@K7K2ZFLM.OM-CTB:<S&1[<M=(&.2JG&W'U%=Y*Q2%V5=S*I(7/7VKBI/B,D
M7@6_\0/IY\ZSGDMOL@DR7D4XQG'<^U-RU<GZOYB4=(P7HOQ_X)M^*-!EUWP?
M=:-;3K%)-$J++(,@8(.2!]*YW_A7,_\ PENGZH;V/[+!:K%/;;3^\D7.UQ^)
MJ]<>/430="O[6R,TFL3+"D/F8V'!)YQSC!KL*;BXMW[_ (K_ (?[_07,I12Z
M6_!_\,><0_#K5[+0;6"SO[-[VUOY;M!,K^0X=V8!@.3C=39_A]X@O'U-KO4=
M.SJ'DNPCB<"-DD#$+_LX'UKTFL./Q&9/'$WA[[-@16:W7G[^N6(VXQ[=:-6R
MMO>[:_C_ )LYR7P3KMC<7$/A^\TR*RO#NF:Z@+S1,?O&,CCOWS79#35.BG3I
M9&=6B,;2< G(Z\5=K@K'QGXNU@3S:+X4LY[6.5HUDEU01LV.^W8<4M_=_KL&
MWO?U_6@T>%O&,.CMX?AU+29-'\LP++/%(UR(\8ZYVYQWQ6*N@:UI7Q$CL_"5
MS;Q&VTHH6OD=D?+C/W>^>:]1L)+J:PADU"W2VN60&2))-X1NX#8&?K4HBC$I
MD"+O(P6QSBGJGK_6C7ZDO5?UW3_0XBP^']S9W.CW)O8I)[:ZFN[QBI_>R2*
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? 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gemp20161231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A8VAS+"!3
M87)A   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,U.0  DI(
M @    ,U.0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( ED"/ ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
M     0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q
M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C
MY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&
M!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R
M@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR
M\_3U]O?X^?K_V@ , P$  A$#$0 _ /I&BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HH) !). .I-9#>+?#B.RMK^EJR'# WL>5/OS0!KT52M]9TN[LWN
M[74K2:VC.'FCG5D4^[ X%-LM>TC4YC%INJV-W(!DI!<I(1^ -'D!?HHHH **
M** "BBB@ HHHH **** "BJK:I8*C,U];!5D\HDS+@/\ W>O7D<5:H **** "
MBBB@ HHIDT\5M"TUQ*D42#+.[!54>I)H ?16/_PE_AHKD>(=*QZ_;8__ (JK
MIU;3AIZWQO[46;#*W!F7RS_P+.* +=%4K#6=,U4L-,U*TO"OWOL\ZR8^N":N
MT %%%% !1110 4444 %%%% !12,P52S$ #DDGI5=-2L93"([VW<W )A"RJ?,
MQUV\\_A0!9HHHH **** "BBB@ HJO>W]GIUN9]0NX+2$<&2>0(H_$\5G_P#"
M7^&N/^*ATKGI_IL?/_CU &Q152\U?3=/A6:_U"UM8GY5YYE16^A)YI]EJ-EJ
M4/G:=>6]W%G&^"577/U!H L4444 %%%% !1110 4444 %%%% !1110 4444
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M?:+K'AQ419;>PMG2>8,!AFW'IU[TH6LETT_)W_&U^X3=KOK=_==?IMVU*/\
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M &5+A!N0,AX8G'\)KO\ 1_$/B"^U!+?4?!]UIL!'-Q)>0R!?P4YK3>/+Y_\
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M?M_E9?<0V%HEAI\%K']R% @_"K%%%-MMW9*22L@HHHI#"BBB@ HHHH ****
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M% !1110![C\%O^1)N?\ K^?_ -!%>A5Y[\%O^1)N?^OY_P#T$5Z%5$,****
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MBBB@#PC]J#_D%>&_^OF?_P! 6OG>OHC]J#_D%>&_^OF?_P! 6OG>@I!1110
M4444 %>I? [_ )"6M?\ 7"+_ -"->6UZE\#O^0EK7_7"+_T(T">Q[#1115$A
M1110 4444 =%X0_X^;K_ '%_F:ZJN5\(?\?-U_N+_,UU5)C"BBBD 4444 %?
M+?[2/_)3;3_L&I_Z&]?4E?+?[2/_ "4VT_[!J?\ H;T#1Y)1110,**** "BB
MB@#W'X+?\B3<_P#7\_\ Z"*]"KSWX+?\B3<_]?S_ /H(KT*J(84444 %%%%
M!77^$O\ D%2?]=C_ "%<A77^$O\ D%2?]=C_ "%# W:***D84444 %%%% 'Q
MA\6?^2N>(_\ K[_]D6N/KL/BS_R5SQ'_ -??_LBUQ]!04444 %%%% !7T?\
M#W_DG6B_]>__ +,:^<*^C_A[_P DZT7_ *]__9C30F=)1113)"M/P[_R'[;_
M (%_Z":S*T_#O_(?MO\ @7_H)H [FBBBI&%%%% !1110 4444 %%%% !48MX
M5N&G6&,3, K2!1N('0$]:DHH IW.D:;>W"SWFGVMQ,GW9)8%9E^A(S5P# P*
M** "LGPO_P BW:_\#_\ 0VK6K)\+_P#(MVO_  /_ -#:@#6HHHH \(_:@_Y!
M7AO_ *^9_P#T!:^=Z^B/VH/^05X;_P"OF?\ ] 6OG>@I!1110 4444 %>I?
M[_D):U_UPB_]"->6UZE\#O\ D):U_P!<(O\ T(T">Q[#1115$A1110 4444
M=%X0_P"/FZ_W%_F:ZJN5\(?\?-U_N+_,UU5)C"BBBD 4444 %?+?[2/_ "4V
MT_[!J?\ H;U]25\M_M(_\E-M/^P:G_H;T#1Y)1110,**** "BBB@#W'X+?\
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M$-_\31_PSIXX_P">FE?^!#?_ !-?55% 7/E7_AG3QQ_STTK_ ,"&_P#B:/\
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MR3SQ[$GV[MGX=ZY30O"WC/0K>UL[?7]&6Q@(#1QZ459USSSYG4^M=W10M'=
M]58X:_\ !&M)J%Z?#VO1V%CJ)#74$EN9&![E&W#;GGL:ZS1]*M]$T>VTZS!$
M-NFQ<]:NT4+167]6V^X'J[A63X7_ .1;M?\ @?\ Z&U:U9/A?_D6[7_@?_H;
M4 :U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5\M_M(_P#)3;3_ +!J?^AO7U)7RW^TC_R4VT_[!J?^AO0-'DE%%% PHHHH
M **** /<?@M_R)-S_P!?S_\ H(KT*O/?@M_R)-S_ -?S_P#H(KT*J(84444
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M %_/_P"@BO0JYCP%X0U?P3X?ETWQ!%%%<R7#3JL4HD&T@#J/<&NGJB&%%%%
M!1110 5U_A+_ )!4G_78_P A7(5U_A+_ )!4G_78_P A0P-VBBBI&%%%% !1
M110!\8?%G_DKGB/_ *^__9%KCZ[#XL_\E<\1_P#7W_[(M<?04%%%% !1110
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M** "LO5?#>BZU(DNL:;:W;1C"M/&&VC\:U*YSQMH,NO:#)#'KEUHZH"SRP,
M&'HV0>/I4R=E<J.KL'_" ^$F7/\ 8&G%<=?LZ_X5O6L$%M:QPVB)'#&H5%08
M  Z 5X1:WNAP:4EC+\0?%<D:H8W%O9.8V'<*?+SC\:]I\-P6EOX;L8M.>62V
M6%?+>8$.PQU8'G-:6T=MC/M?<TZ***DH***8T\23)$\J+(^=B%@"V.N!WH ?
M156XU2PM)UAN[ZV@E?[L<DRJQ^@)JUUZ4 %9/A?_ )%NU_X'_P"AM6M63X7_
M .1;M?\ @?\ Z&U &M1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN9+&%[Z%(+ED!DC1]RHW< ]Z\+ACT6+6+V2#5YB\^D+</*T[;VN S$?+G@Y
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M&ZO8(90 2CN 157PL0?#5H1R"&(/K\YK3>"&1MSQ(S>I4&LWPO\ \BW:_P#
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M110 4444 %9/A?\ Y%NU_P"!_P#H;5K5D^%_^1;M?^!_^AM0!K4444 %%%%
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MDE&BBB@ K3\._P#(?MO^!?\ H)K,K3\._P#(?MO^!?\ H)H [FBBBI&%%%%
M!1110 4444 %%%% !1110 4444 %9/A?_D6[7_@?_H;5K5D^%_\ D6[7_@?_
M *&U &M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[7_@?_H;5-=ZY9V-R8)_.W@ G9 [#GW Q4'A8[O#-H1T(8C_ +[-(#7HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  FA\.?VIH'FBT%UY_V&7&"Q&W&_VK5U/Q-XA75K7PSHRV=SK7D^;>7;(1!
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M)Y)XJA)X!LI+/486NY]][="Z24 !H'  !7\N]&GY_P#I=_\ TG_(E7OKY?\
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M.!WI)VN^_P#7_ TZ7'+73^MT_P!/OL<!!&O]N:?IGEC^S5\0$(G\)_<LV/\
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M4WA:]EU[4-0^T7BO-'=SF10YB8Y0'[H]JVK;5]1;X6ZQ>/?3FYBFE$<Q<[E
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MCP\\=C*6MF!X!48 !^@KNJ3Z#3W"BBBD,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHKG=>UBXCU_2]&T]PD]TYEE8C.(5X;\>11U2#I<
MW;FVAO+:2WNHUEAD7:Z,."*P;7X?>%;)%2UT2WC"2B9<;CM<=",FN6NX$\0>
M--3M/$VM7^E+;N$L+>VO&MO-3 ^?Y3\W)(_"K-_K&N?#_P &3R:AYVKF.XV6
MDL2F5S$3QO\ ?'>DFDN;O;\QM._+_6QVD.AZ;;VMQ;P6<:0W1S,@'#GWJGJ/
M@WP]JNF6^G:AI4$]I:C;#$<@1CT&#FFZ-XJM-7G^RB&Y@NDMUGDCGBV%0<?X
MU7F\>Z-!HTVI-]H:..Y:U$2Q9DDD! PJYYZTVK:/^K:+_(F+3U7]7U-'1/#6
MC^'(Y4T/3XK)9B#((\_,0,#.:L2Z383ZI#J4UJCWD"E8IB/F0'@@5YU#X\CN
MOB*]ULU2WL[327DGL9XBCAMZX/EYZX/Y5VLWB_2X4TIMTLG]JMBU$:9+<9)/
MI56;L_ZZK] T5U_71_@;$\$5U;O!<()(I!M93T(K%O\ P/X;U.&UBOM(@F2T
MX@!R/+YSQ@^M:>J7DMAILMS!:RW<D:Y6&(99O85RG@WQ?J&L:#K.I:S;_9VL
MIW"VY7!C54!VGU-1IJ^VO]?>5V\]/Z^XVQX-\/+;W<"Z3;B*\4+<+@XD Z9_
M,TFF>#/#VCV4]IINE0007 Q*@R=X]#DUQT?B'Q?'HUMXLGOK9]*N'5SIOV<!
MHX6_B\SJ2!VQ6M>7OBK7M8NHM!O$T6QLT5A<3V@F^TDJ&XR1@<XS[4W?K\_^
M"'7^O0Z@Z'IC)9HUG&5L?^/88_U7T_*F3^'=(NI+U[BPAD:^4+<EA_K0!@ _
MA7,:7=^)/%OA^&XT[6XM(N+:5X+EOL2SK.5Q\RY(P.:7P9=>);SQ!J']HZ[#
MJNE6W[J.1+%8#))WP03D#!%.UVT_7^O4E.RNO3_@?(U[/P%X7T\0BST:WB\F
M3S(R-Q*MZ@DUT-<MXQUO4;*XTW2=#:.*_P!4E9(YY%W"(*-Q;;WXK&'BS6?"
MS:M9^)[B'4Y;.T-U;W,<0A\X <J5&<8R*5VU_6O>W]="N75?+\79?B=K8:/I
M^F/<O86L<#7<GFSE!_K&QC)_ 4R+0-+@T^ZL8K*)+6\9WGB XD+_ 'B?K7%)
MK'BW0SINJZ[J%M>:??N%DM4MA&;8-]TAQRW;TJY\1/&UUX<@AM-#C$VH2N"Y
M*[EAC[LW]*'V^7_ ^0D^J]?^"5_&/AVXDN[)(/"MOK^DP1;4M!,(9('!X8,S
M 8QVJUX0\$Q6VBSKK^GPB2ZOC>K:YW+ <@J,@\D$5V-G(TUC!*YRSQJQ('<B
MFWUP]I92SQ027#HI(BC&6;V%.[A?^NMP^.UCDAH5]K'Q,AUG4=-6UM-+@:*V
MD:16,[,0=P / &,<UNZYX2T+Q(T;:YIL-XT7W"^01^((K$\#>*M4\13:VVJV
M9L_L<RI%;,N'0;2>?4FLF?5O&C:/-XF:^AT^SC?<NE36BEF3..9"<@GTQ2>B
M2>UK_?K^O0:NVVN]ON_X8[*\\*Z'J&CQZ5>:;#+8QXV0D$!?ICFFVWA'0;/1
M7TBVTR".PD(+P '#$'(SSGJ!3Y?$$%KX3&O7<4H@6V%P\:)N< KG&.YJC-X\
MT2'5M(TUY9/M&KIYEL G&,$_,<\=#3L^9KK_ %_D)/W5);?U_F:\ND6$]U:7
M$MK&TUF"+=R.8P<9Q^0K&N_ASX1O]1DOKO0K:6YD.YW.[D^N,XI'\?Z*EI>7
M ^TN+2Z-IL2++S2@XVQC/S<U/I'C/3M6%PKQ7>G3VZ>9);ZA#Y,@3^]M)Z4O
M/^NX]5I\B75_!OA[7EA75]*AN1 -L>[(VCTX(J6[\+:)?:*FD7>FPR6"?=@(
M("_ES658?$32KZ^BA^R:E;0SML@O+FVV03'MM?/.:R=(\51:+)X@N=9N;B9$
MO5B@A4F1V)!^5%_I1OI\_P 4OOU%>UK>GX-_=H=?HOA[2O#MH;;1;*.TA)R5
M3)R?J>:TJYC5_'NG:1<1V[66I7EPT0F>"SM?,>%/5QGY:AF\5C[?HM_:3;])
MU)O(8,N&25L;?IWR*>LG_7]>0M$CK:***0PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N+O1Y/QCTYY?NRZ=*L9[ [DXKM*S-7T6/5)K.<
M2&&>SF$L<BCKC^$^QIK22?\ 6J:_4'K%K^NYR.K>+=+AO-1TGQ_8"VC+E;:6
M*WDD$\6.N5!(.<^E<U;VEW;_  WUMH([H:,+@2:?',"TBQ G)Q][&,8!YKV8
M=.:*E*R\_P#+]?\ @@[/T_X!Y9'XGT[0O%DNJ:@;A;/4-,06TJV\C>8PP-N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gemp20161231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M#EB>U+HGW_RN-JS:_K>QU=%>:2>,7U?7/!]Y$]S8PO/>QWUJ93@/''RK8X8
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MXQU/0<9ZT7_KT_X<=G_7]>1ER_#YKGPOK6FW.K&34-8F6:YO?( &05("H&X
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M,]>!26GW6_3\K_>.3O\ ??\ KY_D<IXW\,2^)-8\-AK%;O3[:Z=[Q7=0 A7
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M?V%J/_0V:S_WZL__ (Q6Y10!A_V%J/\ T-FL_P#?JS_^,4?V%J/_ $-FL_\
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MLP56FD" D] ">]6*X[Q!<:?9>,K.YUN6WBT[^SIHXI+D@1B4LN1D\;BO0=2
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M =%6'H7_ "&/$_\ V$T_])+>M#2M2@UC2;74;8,(;B,2*&'(SV/N.E9^A?\
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M**8';?"[_D9KG_KS;_T-*];KR3X7?\C-<_\ 7FW_ *&E>MTF,****0!1110
M4444 %%%% !1110!S'B/_D(1_P#7(?S-8];'B/\ Y"$?_7(?S-8],04444P.
MG\.?\@^3_KJ?Y"H_&?\ R(OB'_L&7/\ Z*:I/#G_ "#Y/^NI_D*C\9_\B+XA
M_P"P9<_^BFJ1FY1110 5SWB^UMFTEKVX>^W6PQ&EK>R6P=F(4!BA'&<<G.!F
MNAK)\3QSS>&=0CMFMUE,)P;D@18[[\@C;C.>*3V''<Y[PW8W>B^(H[74ED,U
MS;N\+)JT]RF%*[@4EZ'YAAA[]*[>N#\"RVDM[(]GINBP+)!N\ZRU%KARH8@
M!D&$R&Z'&17>53Z$HX[X@1W5SI8CM3<2JJ2>9!:7'E2;RG[MC\P)4-U&?3@X
MJ_X2-U):WLTR7$5O+<;[>&YE#R(-HW9P3@%MQ"YX![=*PO&EKX;34;;5+FU\
M/W$]O,4NH;QXHGF)0;078<LHP0K<8/L*T? *6)L=0N=.73(;:XNMZVNG2I(D
M!V*,%EXW'&<#@9I1V?\ 78J70ZZJNI:?!JNF76GW()@N8FB?:<'!&./>K5%
MEH<E-H7BB^M'TN^URP;39$\J66*S9;F2/H1G>5!(X)"_05U:(L<:QH,*H  ]
MA7G&M:UK%KXBNXOMNIQ3%)A:VL-IOB+ QF'!V'=O^<,2W'/W<9KT:(N8D,@
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M )&;5?\ K\F_]#->_P!> >(?^1FU7_K\F_\ 0S0@,VBBBF(*];^%W_(LW/\
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MK=)C"BBBD 4444 %%%% !1110 4444 <QXC_ .0A'_UR'\S6/6QXC_Y"$?\
MUR'\S6/3$%%%%,#I_#G_ "#Y/^NI_D*C\9_\B+XA_P"P9<_^BFJ3PY_R#Y/^
MNI_D*C\9_P#(B^(?^P9<_P#HIJD9N4444 %<[XQNK^+19+73K*_GGN1L62T>
M--G(X+,ZD%AD KDBNBKE?$VVUU_2=4OK2:ZTNU23<(H6F,$Q*[)2B@DX 89
M.,T>3&B'PK;VT>I2-%H^OV<BQE7>_O\ SXP<CY<><_S?@.]=A7'Z1/;:KXQ_
MM71K.XAM&MG6]N9+9X%N9"5\OAP"Q4!OFQP#C-=A3Z(74X?QW<"/[):ZC>Z1
M;VUS<'R)KZ E8MJ9Y82J0Q.<,/7'UN>"[+338B>WN=%OY()'2.XTV/ 3<%+
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MWG,ZR+:C9(Q5E/F!2I;(8\YR#5*'P?J%C*M_8:K;IJDAF^TRRVI:*02L&.U
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MG4/^V?\ Z,6O$J:$%%%%, KU*O+:]2H **** "N_K@*[^DQA1112 \D^*/\
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M^C%KQ*O;?'W_ ").H?\ ;/\ ]&+7B5-""BBBF 5[_P"'O^19TK_KSA_] %>
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M &%J/_0V:S_WZL__ (Q1_86H_P#0V:S_ -^K/_XQ0!N45A_V%J/_ $-FL_\
M?JS_ /C%']A:C_T-FL_]^K/_ .,4 ;E%8?\ 86H_]#9K/_?JS_\ C%']A:C_
M -#9K/\ WZL__C% &Y16'_86H_\ 0V:S_P!^K/\ ^,4?V%J/_0V:S_WZL_\
MXQ0!N45R4-CJTGB2^TX^*M6\F"SMYU80VFXM(\RD']QC&(EQQW/X:/\ 86H_
M]#9K/_?JS_\ C% &Y16'_86H_P#0V:S_ -^K/_XQ1_86H_\ 0V:S_P!^K/\
M^,4 ;E%8?]A:C_T-FL_]^K/_ .,4?V%J/_0V:S_WZL__ (Q0!N45A_V%J/\
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M/&&.1@D]JAN/%6I>18P)J5T21<^=+::=YER&C8!5DAVG:.2&8#&<8(S71_\
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gemp20161231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k008.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HI,CUZ49&<9% "T4@(/0BEH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)
M &2<"@!:*B>X1.^<>E5WO#T! H N$@=3BHS.@[Y^E9SW+$Y)_/FH&E)]^* -
M-KP=L?B:A-Z3WP#Z"J!8GOGZTPL,]<DF@"ZUXV.IYZ@GVJ-KIB3W]_2J9D/;
MN../\^U-WD]^O^?Z_P">M %TW+?_ *J/M#?Y%4B^1P3^=&\YZ]3T_/\ S_G@
M N_:6I1<\=*H[CV)_/Z?Y_'ZT!SGKZ?E_GG\?:@#36Z;.1N!^O\ GWJ5;MN/
MF)SVQFLD2<<_CD]*>' [X]J -9;OGJ#_ %_S_A4@N1CD#CK@UD"1AWIPDQCV
MZ<4 ; G0^OY4\.I[_G6.)SGKZ?Y_S[T]9SQC].O^>U &O168ESCOCO\ Y_SZ
M5.MT>FX<=<_Y]C0!<HJ 7([BI!(A[_Y_R* 'T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M95QXETBUU-=-FO MVS!1'Y;'D].0,?K4>L^*-*T+Y;N<F;&1#&-SG\.WXXH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7C%Q_R4!O\ K_'_ *%7L]>(:NL[
M^,;I;8D7!N\1D'!W9XZ^] 'M]<+\2-7ACTV/2XW#3RN'=1SM5>>?QQ^59!TK
MX@."K37BY'47B#^35:TKX<7$MR+C6KD%2VYHT8LS>S,>GX9_"@#4^&UA);:'
M-<NA7[3)E,]U P#_ #K&^*/_ !_Z?_UR?\.17I,44<$*11(J1H-JJHP *\V^
M*)_XF&G\_P#+)^_N* $\+^'7\3S-JVLEVMD BAC!*APHQU_NCVZG/O7:Z;X7
MTG2+\WEC;M#(4V$"1B,9Z\D\T_PTJKX:TX* !Y"\ >U:<C;8V;T!- 'E/C/5
MKG7?$(TFT):&)Q$B*>))#U)^G3\/>NNTOP%H]G:JMU#]KG(^=W8@9] !QBN&
M\(_Z5XYMWEP6,LDG)SS@FO8Z .!\5>!;&/3IKW2XS#)$"[Q!B5<#KC/0TSX;
MZW+*LND3N6$:>9 2<X'0K],UWTP#0R*>A4CFO'_ Y,7C.V5#P?,0XZ$;30!W
M_C;69-'T!C ^RXN&\I&'5?4_E7(^"/"-OJT#ZAJ*L]N"4CCW%=Y[DXYQ]*M_
M%%R)=-3_ &9&'/?Y:ZOP?$L7A/3@O\4>X_B2: ,S6?A_I5Y:L;"(6ER!\I4D
MJWL0?YBO.;:*YB\36L-X'^TQW,:.'.2,$#WSP*]UKR#7O^2DN#_S]PG]%H ]
M?KQZS_Y*4I[?;VYQ[FO8:\>L_P#DI:GCG4&/7WH ]AKCOB3_ ,BVG_7=?ZUV
M-<=\2?\ D6T_Z[K_ %H 7X;?\BP_.<7+X_):A^(FN/8V$6G0.4EN>793@A!^
M/?\ QJ;X; CPS)GK]J?^2UROQ&=F\4A!_!;ICZDGF@#7\'>"K*XTR/4=3B:5
MYANCB+$!5[$XZD]:U=7^'^DWENWV&/['<8^5E)*GZ@_TKIK"-8=.MHT VI$J
MC'I@58H YS3?#8E\)6VD:R#(8SDA9#Q@G&#]*\Y\7Z5:Z1X@^QV:LL7EH0"V
M3D^YY[5[37DGQ"_Y&[_MC'_,T =A'X \/O"C&WE^90?]<:Z5(8[6R6"%=L<4
M>Q%'8 8%.M_^/:+_ '!_*EE_U+_[IH \C\ _\CC'STCD_E7K%[=QV-C/=2G"
M0H7;\*\H\!?\CFG3A). ?K7=>/)#'X0NR.Y13SV+"@#@--M+SQQXD=[J9UC^
M_(P_@3/"KGC/_P!>O0X_!/A^.#RC8!\C!9Y&+'\<_P JY_X7Q*+749?XS(B'
MZ '_ !_2O0* /(_&/AD>';F"\L9)!;R/\I+<Q..1SU_'VKT'PIK#:WH$-S)_
MKU_=R^[#O^(P?QJE\08P_A&=CUCD1E.>AW8_K67\+V;^SM0C/W5F4@?4?_6H
M Q?B5_R,4'3_ (]UQ_WT:U=!\(2:V_\ ;/B%GD:8 QP9*_+VSZ#T K)^)G_(
MPP^OV8=NV37INF?\@JS_ .N"?^@B@#D?%7@O31H]Q>:?#]GG@0N0K':P')&"
M>N,U4^&6HRM]LTYV)C0"6,'^'G##\\5W.I#.E7@(!_</P?\ =->9_#,?\5!.
M?^G8]O\ :% 'JU%%% &)XP_Y%+4N<?NOZBN1^&**[:FK#AD0'Z<UUWC#_D4M
M2_ZY?U%<G\+L^;J7? 3)_.@#$MG?PEXXV,<0QRE&YZQMT_3GZU[%U&17G7Q,
MTK)M=411_P \93^J_P!:Z/P5JO\ :GAJ!G;,T \J0GVZ'\L4 9_Q%U86>B+8
MHV);LX.#T0=?Z"D\&Z5_9_A&XNG4":[1I"<<A<':/YG\:Y;5Y'\6>.A:QDF%
M9/)7'9%Y9N_OS]*]2N(TATN:*,;42 JH'8!: /+OAN,^)OI;M_,?Y[5ZI>W<
M=C8SW4IPD*%V_"O*_AN,^)OI;M_,?Y[5W/CERGA&]PQ7.T''IN% '":+87'C
MCQ)-<7\K^0OSR;3T&?E0>E>B?\(IH/V?R/[+M]GKCYO^^NOZUYCX9U37=-BN
M#H^G&Y60KYC"!I-N <#(/O6__P )3XW_ .@&W_@%)_C0!CZ[8R^#/$\,]C(X
MC/[R+<>V>4/J/\:]:M;E+NSANHS^[EC$BY]",UY)KC^)_$#PM>:/=*T(8*8K
M21<YP><_2O2-.CGL?!\,<R;)HK/E3V(7H: /-]7N[GQ=XN2UAD)A\WRH!SM5
M1U;],UWUKX%T"WM1$]GYS8PTCNV6]^#@?A7#_#A _B?>PRRP.03Z\"O6Z .'
M?P(;#Q#8W^DS%(4F#2([$E%[X/<'D8-:OCK_ )%&\Y(SM''^\*Z.N<\=?\BA
M>_\  >_^T* /.?#.A7OB&9K5)I([!7#SMGC/;ZMC\NM>C+X%\/BU$'V(DC_E
MH9&WY]<YK$^%_P#QY:E_UU7^1KOJ /&(EF\)^-%B67(AF5"1_'&<=?PQ^->S
MUY#X]'_%8R 9Y2/H*]<C_P!6OT% '&'P"E]KMW?ZI=M+')*7CCC)!*]@Q/3'
M3 _.MD^#_#Y@\K^RX=OKSG\\YK.\0^.[/1KAK2WB-U=+]\!MJ)]3W/M6$OC+
MQ==+YMKHRO$?NF.UE8'\<T 8>KV;>%/%ZBTD8K$R31$GG:3T)_,5[*C!T5AT
M89KP[Q#>ZGJ.J+/JML8+D1A0AB9/ER><-SWZU[;:_P#'I#QC]VO'X4 >1>+I
MI(/'5Q/#CS$DC9!C=R%&./Z5U.@^!8I%-_K^^YO)OF,;.<+GUQU/MT'2N7\6
M$?\ ">R]/];%_(5[#0!YSXV\(6-CI9U'38_(\L@2Q[CM()QD9/'6M3X<:C)=
MZ'+:R,6^RR!4).<*1D#\.:UO&(!\):CD _NN_P!17+_"[KJ?K^[_ /9J -KX
MA?\ (IR_]=8^^.]4_AE_R KKWN">G^R*N?$/_D49O^NJ?SJI\-/^0'=?]?!_
MD* *GQ.O9D@LK%6(AF+.X'?;C&?;G-:GAGPKHZZ':3SV4-S--&)'>90^,\X
M/  JSXP\-GQ#IRB%@MU 2T18\'/4&N#L-=U_P=(+.X@(@W9\B<<<_P!UO_UB
M@#NO^$)TR'6+74K(-:O ^]HUR5?CIR>*Z&X_X]I?]P_RKG_#_C/3]=98,-;7
MA&?)D_B_W3W_ $-=!/S;R?[A_E0!X=H,.HW=V]AIK,DETFR0C( 4$$DGL.GY
MUZ=8> ]#M;-8KBV^TRD?/)(QSGVP1@5Q?PW_ .1F)Q_R[O\ S'^%>MT >,:Y
M8R>$O%*FSD8",K- S<X4\8/KZ5TV@>%)-=<ZWXA9Y6G^:.'<5X]^X'H ?YUF
M?$W_ )#EK[0>GN:]&T48T+3P.UM'V_V10!QGC+P?IUII#ZAI\ @>$@R(I)5E
MZ'@]"/;%6/AGJ#SZ5<6,C9%LP,?LK9X_ C]:Z#Q9_P BIJ?_ %P-<C\+_P#7
M:E]$_#K0!WVHVS7FFW-LC;6EB9 3V)%>>^%/!^LZ?XBM[N\@6*&')+&56W<$
M8&,GTZXKTNB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBHY)508!R?8T /9@HY-5)K@]OPJ&2X+'@\G
M\C_GBJK/GH>?\_XT />7)Z\>Q]Z@+9Z_RI&;U_"HB<@9[CTH 4MG/;_/_P"J
MFD_A_3_//_UZ3/\ ^K_/^?RI/QX_+_/?_(X %.#[#^77_/YTA/4].^/\_7_/
M9,G\>W'?C_"FGV_#_/XT .SQP/I_G_/3\D)_'^7^?_K4W(SU_P \?Y[TWKVS
M0 XM_G]:,]C3<_TI,X]OH: '$^_^<4F3R".G:FYXQ10 /(L2,[L%51ECZ8[U
MX#X:TU?B1\1-;O[Q-]F(I2N1D+D;(OR'/U%>F?%'7/[$\#7A1]L]V/LT?.#\
MWWO_ !W->/>!/B+%X)L+J!=%^V37,@=Y?M/E\ 8"XV'U/?O0!O?!K4Y-'\7:
MCX>NCM,X9=OI+&3G]-WY"O8O$7B&R\,:++JE^S"&/&%499VZ!5'<U\TW?BL3
M>/%\3VEG]C/VA)S )-_(QNYP.O/;O7I/QNO1=>'-"D@<FVN)&E&#PWR#:?R)
M_.@"JGQ=\7ZDTESI'A>.6PB.'*P2S%._+K@ _A7H?AWQQ9ZWX-D\1749LH8"
MPN%=MP4J!G![YR/Y4?#F."+X?:*+8 *;<,2/[Y)W'\\UA?&!!:?#VX2UB2*.
M:[0R^6@7=DDDG'<D#- '/S?%_P 3:O=3'POX8:>UC)#%X)9VQS@MY9 7CMD_
M6NC\#?%$>)M2;1]3L?L.J#.T)G:Y&<C!Y4CT.>AZ=*\Z\%CXECP\G_"+!!IK
M2MC'V7)?H<[_ )OS_"M30O!7CN7XA6'B#6K)587*RW-QYT R ,'Y4/<#' H
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQBX_P"2@GK_ ,A!<_\
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MAP:]IK6LI*.#NBD'\#?X4 'AO4$U/P]97"L&;R@DGLP&#6HS*BEG8*H&22<
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M@@8 )]<]J /2Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6@#S7XJ> -0\5-9ZAI'EM>6Z&-X'<)O7.1@GC(.>N/K5SX?VGCVWN9?^$KG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_AMR93G'(^3//U/XUR.H_''2HLKINE75TW3,S+$I_+<3^0_"@#U4<X'<TO\
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M:QXZUM3/I]LEO 3\I$: $>QDZ_44K:IX]T@>=>6PNH@,MF)&&._^KY'XUZ*
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M:M:Z+XVU6]NV.Q3, JC+,2PP!_\ KK5E\;>)I(S=VFA 66-P9X)&^7UW @4
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M._\ A.?$6GE9M6T,);$XR(9(C^;$C\.*WM5UW57TJQOO#UBMVEQDL)$)*CZ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&8*N2: &33+$A)
M(S6!=7)DDZ]??I4U_>EV(#=.G^?PK.!Y]O\ "@!Z_P#U^/\ /M4@X7Z#J/\
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M]O7KQCZ&@WX YP/P-8V\YZD?T_S_ (T>8?\ ZWY<4 ;/V]1R2.OI2?;QZ_\
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M\,0!J6I8[1J!Q[FIOBE_S#>G_+3K^%1?#$[M2U)BN,QJ>>W)XJU\48&-I87
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MDX!XVQ'VKU7QC_R)6M\_\N,W?_8/O7!? 0?\4UJA Y^V#_T!?ZXH ]!L[_\
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M;5OL:W7VIY6ST!V[<XVXXZ9XZT[PU;S>*/@3J%C*QDDM6D$!;MLPZC^8^AH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]FW?V$ON%UY+>5CR0/OXQUXZU8^+GA[5+NXT?6M&M+FXNK=BC"VB,C+@AE.
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M!QSS748^)V<?\4?],7-'_%SCW\'D_P#;S0!S_P 4_"6LW6N:?XHT"W:YN;/
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M\-FE[;M=+UA$JEQ_P'.:LT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!13)98X(FEFD2.-!EG=@ ![DTRVO+6]B\VTN8;B,'&^)PPSZ9% $U%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQU_SC_/TI<]QGI_G_'_.:  ]3CU]/\_Y]:",_P#ZO\YI#W[#'Z4[D'ISW_\
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MQ.,_A0!Z/16=HFLV^NZ:MY;AE!)5T;JC#J#3=<UVST"R^TW;$Y.$C3[SGVH
MTZ*\Z7QOXFOLRZ;H2M #C)ADD_4$"K6E?$)FOELM;LA9R$[3(,@*?]I3R![Y
MH [NO,_A\/\ BK=4./\ EF_3M^\%>F=1D5YG\/A_Q5NJ''_+-^G;]X* /3**
MI:KJMIHU@]W=OM1> !U8^@]ZXV/Q?XGU,M+I.AH;8$X:5&;/XY49]A0!W]%<
M5I/CJ5M273=<L397#D . 0N3TR#R/KDUV%S<Q6=K+<SN$BB4L['L!0!+17 +
MXVU[5IW_ +"T59(%.-\RLV?J00 ?;)K5\/\ B35+W5&TW5]+^R3^69%=0P!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5.]G")M!YJS)(
M(T)) X[UAW4YD?J?8Y_S_D4 0.Q9L@Y]#FE49_#I35YY/^'^?_UU.JYX'3VH
M 2@_RJ;;D=>OO^'^/ZTUADYZ$^I]Z (0!TQQWS3J*#]<4 1L>?>H3TX_S_G'
M^>\K'H?QJ(]/PQ^@H :><\YX-+GYC['_ #_.CU_S_GC^7M3>,'T__50 X=N3
M[?E_G\Z.W&!WH[_J?UJI>ZC!90L\DB*JCYBQP!0!:8JJ_,<#H2?\_P"?Y4[K
M5;:T3?*ZHIZ&1@,]^_6N+U7QC+-(R6(*@?\ +9QS]5';\:YB6:6>3S)I'DD]
M6))__5_C0!W-YXWM4RL(EF/8J-BY^IYK'G\9WLAS';PH.P<L_P#A7-=OP[?Y
M^M+@L< 9)Z8[T ;!\3ZLYPLR#)X"Q#G\Z>VNZ]#S([@=M]NH_H,UI6K67AZU
MC=HDN-0D&1QT']!].M4=2\1WJ9\^&(QL/N@8X- #8O%VHQ_>6WE7/\2D'\P1
M6G;>-E!Q<6TB>\;AOT.*XB:_@>Z1X^(Y3C']TYZ5/W]/I_GZ?E0!Z;9:[8WY
MVQ7",_(V,=K?3!YK0W!N_7.??@UY#]0/?CI6OI_B*^L,(7\^$?P2'D#V;J.W
MM0!Z3SGT//X?YS1QU[<]/\^@_P YK*TS7;34UQ&Q$H&6B?AA_B/\:U 0>^?4
M_E_]8T *!C&?Q_S^OT%*!T_S_G_/2F]NF,C^G3_/M3OH<\\'^7^?YT '4=N1
MG\_\_P#ZZ><^_P"M-')P#_G'_P"NG#&?3&/;'6@!1CZ>WO3J0>F,>@QTI: '
M=OI^-*.W0X'ITIO.>G([=Q2]LXXSZ4 .Z\9Y/'/7K2$GOW]:,GU]N32<?Y'6
M@!><8QVSSVI>=W7_ #_GZTSC\?:E!YZ?@* %[=AQ_2E/1AC@$\4@SCCTX[49
M]OPSTH 7OV_/Z^]*,\=>.,4T=<8Z].M'?TSR./6@!0<=, ]?I2_3UZ4F>"!Q
M[9H!P>OTH 4G'].U&>V?\]J!CC/X_3BC..I_GUZT !Z'J*._^?\ /I0>#TP/
MI_GWI._/Y^M "]1['T'K2'D<^G0TGUQDYI?T]_UH 4]3^N/SI/QZD]>]*>^<
MX/7/^>:CDD6+[WY=Z '9 R21CN>U5)[^.!,Y"CL3G]!^%9M[JISM0AF'?L/\
M:R7=I&W.Q)]30!HW&K,YPBYQT+?T%49+B:7[\A/MTJ*E_0T )5JWT^:X7<H"
MKZFJN\))&#SN;I5^&[-WA%;$8. !W[9H I7:FT&YQE!U*\X_"HT=9$#HP92,
M@@]:IZ[*879(V^900<<Y]OTK!\/:IMUF2P9ODG4R1^S#J!]1S^% '7K))&<H
M[+]#5N'4YHS\WS>XX-4:.N23S0!TMKJJ2 #.2.<=#6BCJZ@HP//'X5Q/0Y%:
M%IJ;Q,!(QQC&_J1]?:@#I^,8YQCUH(]>?KVZ5!;W*SJ,$9/IR#4_^1S[_P"?
M\\4 )WR>_7]*!VX[_P"<?E2''Y]\4OU[^_\ G- #NP&<C%.7J/?K^8'^?_U4
MSG\__P!9I5Q^G^?TS^= %B,Y6G,..G7WJ-/<Y/>I\;EH I-G/'?N/\^]-)X^
MOK4LPY/?/O\ Y]ZKD_K[4 !.>Y/N:2FEN<#GZ&F\8SG\<?Y[]J )*=G(//YT
MP')Q3@2.Y_.@!YY)[Y]L]Z.^/?--Z#&#BC)^GT- #NW?\J3C ]3Z]Z3L#Z=.
M])VH =N'X"F^Q'-+GJ<__7IN: %Y'/3-(75>K >F:*\I^-6H7EG9:;':W<T
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M'AS3K?4?'UXMRN](9I90IP02'XS7JJNCE@K*Q4X8 ]#7FO@W_D?]4X_BF_\
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M!AE8=:XBZ^&%K).7M-2E@0DG:\0D(_'(KO:* .8T'P/INB7*W6^2YND^X[X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/U"WO(P/-MY5E0'U4@C]17U/X?\ %^A:_813VEW"6< M$S#S$/<,O7(_+TH
M^=-6'C'7!%_:EOJMT(<F/?;-\N<9Z#O@5Z)\$M%U.PU;4[F[L9[:!HEC4S1L
MFYLD\9'/ Y^M>HZAXG\/Z5&7O=2LX, G$DJ@GZ#J?H.:7P]XFTKQ-9RW>DR^
M;#'(8F?RV7Y@ 2.0#T8?G0!Y_P#'@_\ %-6 _P"GU?\ T"2O.OA2B-\0+(LH
M.V.5AD=#L/->B?'8_P#%-V'/'VU1_P".2?Y_&O/?A/G_ (3^S]HI<?\ ?!H
M^D6ZXZ#I36!SD]^IIQX8^W'Y?3Z4T@?CTXH C:H6 [CZ_P"?P_2IR,BH3_G_
M #_GJ?6@",$@Y].3_.I4 '!^F<>G']/U%1GV.?0^_/\ G]:<K<Y[?Y_S^% %
MF,X(/'X\5T6F-F(CT]17-(<?AW!KH-)/RD9[>E &G1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA@S'^(CL1TKUT <?Y_S_ /7^E. X% 'G_P *_"VJ^&[:^&IPI$\\BLJK(&(
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M.??J: (CC-0,.<$^@_D/\_YS9?IUSW'O5>3CG\: (2>,]\?X?XTX=?Q_J/\
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MCC_/^>/R'K12#M_GTH[4 +FC/^?\_P"?UIN:,T ._P _Y_S_ "X/\_Y_S_\
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M(/3Z_AS_ (T .[$?Y[C_  H//X_Y_K_G-(#[XSS_ )_G^ ]:.G^'^?I^GO0
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MK<363?$NRGTN2-H))X\M']W)X8?S_.O1=?\ ^1>U Y(_T=^1]*\YN[+3M/\
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M*<8Y(X8?B/YFI_AB!]MU,@<;4Q@<=3_GK70^.],_M#PW+(@S+;'S5^F,-^E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#$7FZ[$<9$2LY'X$?S(KT3H, _Y_S_GF@!2?\_Y_S_5,_P"?\_Y_J=P:.E
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M>< ]_P#/YUT.DC"'C''3\JP(P<@=.>.:Z'2QB(G'Z4 :%%%% !1110 4444
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M41D\,6"N"#L8_AN./TQ0!=O+8S.".,J5Q_G_ #Q64;V2U<HY((."0*Z$ E@
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M7^>[OR';% %:1><?RJ$#D>N>_P"'^?\ .:MR#Y?UJNPYS0 Z/^' SWYKI-.
M$/2N>C'SCVKH]/\ ^/>@"W1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB/\ /^>(_8U8N 0W7![<U7Z]/\^E #A[_I_^K_/X4[D]:9^'7V_^M3QS^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=>E0-C'6@")L^OX_Y_S_ %K7,$=S"\,JAHW&U@>A'^?\]ZG<\_Y_S_G\X6-
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M 7M_GG_/^'X-(],>G^'\J7D]LD^G^?\ /X\J?S_K_G_"@!T*_-QGTYKHX?\
M4K6! N7'&>@KH(N(E^E #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M .@R:Q[I]\WMGGFM2=ML3'UXK&SN<L>OK_DT  SCOG I#U_K_.G-QGCUZ^QI
MO?V'\J #D<\C'UXYIXZ_RIO0]N#ZTX<>O% #Q^G^?_K4X>U,';_/^?\ ]5';
M\/\ /^?I0 [/^3WHS_\ K_S_ )_2DSS_ /6ZTF?\Y_S_ )- #L_ATY]*3/3K
MQ^G3_/X49/4=?7_/^>::?T_S_P#6H :3Q^%1L?\ &GM_^HU$WY9H 0GWQ[U&
MQZG'0=#3_P#'C J,GZ=: &-]1D'KZ?YZU7?I4[YQW_S_ "Z5 _8T 0/_ )_S
M_GM5=S[5,Q_EVJ!^E $9/^?SIOF,AR"< TI/)Z]?\_Y]Q49//7_/^?Z>E &?
MJ&@V.I$R+FWN#U9!P?J.F>?K7,WOA[4+,L?),T8Z/%SQ].M=K^(]O;_/]:%F
M=?NMQV% 'FO3KZ\TG;'MZUZ-/!979/VFSC<_WL<_GUK/D\-:1+]QIHO97R!^
M>: .*_2DZ>QQ76GPA;?PZ@P]B@_QI!X/@'74<CVC _\ 9O\ .* .4/<8H[]Z
M[&/PKIR?ZVYF?_=( _D:NPZ7I-K_ *NS21AT,@W?S_PH XJTT^[OCBW@>0="
MP'RCIWZ5T5CX3CBQ)J,VX_\ /.,G]3U/X?G6^UPVT*@"J. !VJ MSDDT 3!X
MXHQ%;QB*-1@!0!0.M19]>*<#0!,#S3P>/7/^?\/\FH@?YY'^?PIX/''X?I_]
M;_/0 >/7U[_Y]Z<"1_@348(_S_G_ #_)P/;\J )1ZT4P-WZT[(H 6BC( R:*
M "BBB@ HHHH 7O2__K--IXH !TI<4 4X>M "CBG 4 <T\?Y_S^5  !_G_/\
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MP[?I_G_/ZT -;KBJ[]Q_6K#>W2H).^?Q_P _3- %=_?ZU&>_TJ1_\\U$QYH
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MC\*U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M36J;1CI@8XKP7XE>#9?A7KNG^,?",K6UJT_EM;DEEB<@G;UR8V .0>F.O(P
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MU"W820P,"A79P00S?W/7M4WAO4]*;XP^(M1\1WMM!-;LR6AO'"JN&V\%N,@
M>_)H ]"\/_$#0?$.C7FJ0S2VUM98^T&[0)Y?''()!SCL<_I6''\;/"4FH"U)
MOUB+;?M+0#R_KUW8Y/\ #7/_ !?U6TOO"NG/H\D7V'4;UC/<1IM65D^4%CCY
ML>O/3CC%9L&AW6O+IF@ZUX]T.?3A*JP66E!79B!P,(B[>_)S^- '0_$[XFRZ
M')'I6ASR0ZB"DLESY*.GEL,X&[.3T/3\:U[?XM:'_8UA?RVFJ"*ZN#:K(T48
M^=0N6.'QCD=/3I7-^.9[$?%7PGI=U<Q6UAIT2.SSR!43DD98\?P*.:U_C1%'
MJ/@&VU.W=94M[J.5)$.058$9!STY'Z4 =;XI\9:;X0AM)+Z.YG:[E\N**V16
M8GUP6''3\Q7#^*#_ &[\;_#6FX)CL8Q<.I'0\N0??Y5S53P_-)\2_']GJSQL
M-'T.W38''#SX!QS_ +7/T0>M3^%1<:Y\6_%^K6Q026L3VUL\@RJO]U?7^X<_
M_7H ]A']?2O'M?UC6OB!X]D\):%J,EAI5F#]LN(206QPV2#R,G:%X!.<^W1>
M']'^)D&MV\NN^)=-GTU"3-#!$N]^#C_EDO?'?M7%?"W7--\-^,/$MGKUS'8W
M<TN!+<N%4E7;<"QX'4'KS0!VN@?"33_#&M6>IZ9K6J1F(EIXI74I.,'@[0N!
MGGG/3\:75_C5X2TF_>S#7E\4)5Y+2-60'TRS+GZC(J3QKXMT^]\"^(AH.I0W
M<]O;JLKVS;U17./O#Y<XW=#Q7*^$?$?A'PU\('9KFR?4+B&7[1:[E::60DJH
M*]<8Q[ 4 >JZ#X@TWQ/I,>IZ7/YMNY(.5(*L.JD'D$<5XA\1[J[\=:SJ_P!@
M<_V1X<MV9F'*R29 ;'./7\%/K4^@:I<^ O@Q-<,K1ZCK-PPLHR,-M*A=^.O0
M$CZKZU!I6C?$?1/!]]I,/A:P-G>H[W$TTR&9PRX.?WHY Z#'ZT >E_#N\-[\
M/=&E8@LL'EG_ ("2O]*Z)CSZ?4UY]\%;OS_ A@)R;>[D3Z @-_4UZ _7_/\
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MC:5;:'HMEI5F"+>TA6&//4@#&3[GJ:O4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'BW[22R_\
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M0#F5SRS'_/3'I4FC>&M'\//=OI=D+=KM_,G;S'8NV3_>)QU[?X5J9XR3W_\
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M:<IH E'2E_SS31TIU #QGH*>.M1 ^_Y5)0!,AJ>-L\55!_QJ5#S_ )_S_D4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$(+NWN%4$X]\5K9]:\;\%6ECXQ\>^(M6UR.*[:V?9!;W #*JY(&5/'  'U-
M'J.F>)M&U;2Y-4L=2A>RBSYDQ)0)@9.[=C''KBLF/XF>#I!<%=<A_<*6?*.,
M_P"[E?G_ . YKAOB7'ING:-I6C:$MO:Z?JUZ99WMS^[?&T=0<8!P<=.*I?%/
M3O#.D:5I>A:38V:ZH9%R\2#S0F,9=AR23CKGO0!ZQ<^+]"LM.T_4+B^"6VH,
MJVKF)R9"1D< 9'X@5F:IXXT:X\/>()-*U!+B;3[=_,,:MA68$+AB,'GT-<-X
M^TU-0\2>#O!R$K#'&HE"]0O"D^W"-6I\3[/2_#'P\EL]*L;:S^V2Q0,88PK.
M%^;D]6.!U.>IH J_#7Q5X:\*>#;6WU35H8;R[F>8Q[6<J#PN[:#MX&><=?QK
MU674K&VT_P"WSW<$=GL#F=I $VGH<YQW_6O&?$WA_P ->&_A);@6]K-JEXD3
M1W/#2.YPS%6ZA0.,#C\ZIZ_%<2IX"\(ZC-)#:211-<@G;R[8 /T&1[9H ]4L
M/B/X2U2_2RM=;A:X=MJJZ.@8^@9E .3P.:T;_P 4:/IFL6FDWUYY-[>8,$9C
M<B3)Q]X+@<^I'\J\F^*^D:!9RZ)H^A:?:P:J\P&VU0!]AX7=CDDG&,\\'FKW
MQ@EADDT*QL6>;Q#;/YL:PC<R(!DD^G*@CZ&@#T>\\7Z%8ZR=)N+[%^(S*T,<
M3N54#)W%00O )YJ?1_$6E:_IK:CIMV)K1696D,;+@@#/# 'T-<#\(K.SU+0M
M1UJ>5KG5K^9XKN67JH_NCV((/Z=JX31O$K^&_!WB+PW#N.ISWOV:WC'WL-\K
M'\-N/JU 'IGB_P :Z3J?PTUN]T>\\],"SWB-TPS8&!N SP>U7/!<]AX2^&.D
MSZI=1VL/D^:[2' RYW8 ZDX(X%<#XUT<^'/A_P"&_"D8!N[RZ#SA>K/W_5@!
M]*T/%-K#K/Q4\.^$[M@-*LK=28<X5R%)Q^2@?G0!W"?$[P:]JMPFN1,ID$07
MRI-^XCCY-N['OC'Z5K:YXNT+PP$_M?4HK5G^XA5F<\]=J@G'OC%>1^(;'P_J
M/Q<T'2-#L;.);>0&\-K&%0E3N(('&0%YX[X-:'C_ $2\A\12>.+"/2M:T^WC
M$=S:70$BQ[?E88)P<>QR#VZT >J:3X@TG6],.I:=?136:YW2Y*A<#G<#R/QQ
M6-'\3/!LFH+8KKT!F+; =K["?]_&W]<5YCXQUNU;X6Z3'H.G+ID.M7+O<01-
MQN7@J#Z%@.P&!TJ(^ _$>K6MAI&H:)X;T"W$BJMVC(9YNV-P=V<GTXYH ^@0
M<@=P1Z=:\L^(M]<>)_%FE> K*1DBF99]0=#R$'./R&?KBO3+2!;6U@ME8LL2
M+&&;J< #GWXKRGX8_P#$Y^)'BW7Y3N9)##&3SP6/?Z(* .[\5ZY9>!_!DUS$
MBHMO$(;2$=VQA1^'4^P->7?#S5O$UG\1;;3?$&I7L_VVR,ZPSSNZIN&]?E/
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MI>/XUN;V(2 W5O.K%2G<+N9N>W05SWPXN(A\4/$POW5;^1Y%B#D G$GS >^
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M,\4A.*;N_7_ZU)UYH #U&?;Z4S^O%*3VZ=N:83D]1R.,_P"?\_S  G@G\?\
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M_A^M7H]7,LBHEODL<#YO_K5CR1F*1XVX9201_G_/(K3T>VRS7##I\J_7N?\
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MBHK:Y@O+:.YM9HYX)%W))&P96'J".M2T %%%% !1110 4444 %%%% !1110
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M4 %%%% !1110 4444 %%%8^O>*M"\+PQ2ZUJ<%FLK!8Q(<LQ]E&3@=SC [T
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MR33=P//YCO[_ .?>@"3/.!SZ?Y_S_@F<X_K_ )^GYTW)[YS29.!^IQ_GCI0
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M!7;_ #_G\/\ />/'-2M]:C- ""GK^5)3Q_G_ #_G_  <!4@&/3\J8M2J.0*
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M1:1:N5MX?KCJ>QQSQRQH 2]^)NM^+KR32OAOI37(4[)=8NTV6\7NH/7\>?\
M9-7M"^#VF+/)J?BZZD\2:Q.I$DMT3Y2 CHB^V3@GIQ@+7H=E96NG6<5I96T5
MM;1#;'%$@55'L!4] 'DES\.O$?@>ZDU+X<:D6M6;?+H=\^Z)_9&)X/3J0?\
M:/2MKPO\6=)U>]_L?6X)= UU#M>SO?E5F_V'.!SV!P3VS7H-8/BCP9H/C&R^
MS:U81SE01',/EEB_W6'(^G0]P: -ZBO'_L'Q ^%^6TV1_%?AJ,?\>LIQ=6Z_
M[)Y) XZ9'7Y5ZUV_A'X@^'O&L/\ Q*[S;=*,R6<XV31^OR]Q[C(H ZFBBB@
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MVSR6L1Q+>0(V.C.!_6F+-9.?W=_;ODX $BD_SKSE"K*K+RI (Q^%+U'?D>M
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MJ1?Y4 2*.G'2M72TS*IQ_2LM?Y5M:2GSY/4"@#9HHHH **** "BBB@ HHHH
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MVL:,&"IK5DN60=!YB\>W7!Z\M7IFA^(-)\2:<M_H]]#=VS<;HSRI]&!Y4^Q
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MGTP?9J:-:^(WQ'_T;2M/D\(Z3]R>\N=QN&/\0CR%/!XR .GWATH Z_Q?\2]
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M 2CIGKQS4@X]ZB4CC(S^%/![8Z?6@"3/KG'L:83V%&1]:::  FFY[4A:D.:
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MW$C_ ':DC^+.>G!Z5[GHFBV'AW1K;2M,@$-I;IM11U/J2>Y)Y)]30!H4444
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MT 5[J\C^)'[1FGR:8WG:?I31GST.5:.!BY;TVF0[0>^0>]=!^TG_ ,BSHO\
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MT , _.GTT=O:G4 .IX[Y_6F#I^M/'&: '?Y_S^O^>KOT_P _Y_SU;GGG_/\
MGG_.:</3U_S_ (_IZT ._ _YQ2@Y]Z9_7G'^?QIWZ_C0 \&DS[TW=QGTH)Q_
MG_/I0 I--)/3^5)2'I0 A_S_ )_'^5&3_P#6_P _YZ_B9[_Y_P ]:;0 N?\
M/^?\]:,TG^>G^?\ /X44 +[4E%+F@!.]'7_/^?\ /ZE H .OK1V[?R_S_P#7
MH/'X?Y_S]:/_ -5 "_Y_S_GVI,Y_'^M ]?Q_S_GZTO3\/\_Y_I0 $_\ UO\
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M?^3F(LG/_$QM>_\ LI7U!0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 52U;5K#0]+N-2U*Y2VM(%W22.>![>Y)X
M')-&K:M8:'I=QJ6I7*6UI NZ21SP/;W)/  Y)KR?3=.U+XRZS%K>MQ36?@VT
MDW6&GL=K7C#^-\=O?\!W) %TVPU/XR:M'K.M1367@VUEW6.GM\K7C#^.3'4=
M?U [FO88HHX(4AAC6.*-0J(@P% X  ["B**.&)(HD6.-%"HB# 4#H .PI] !
M1110 5Y[X^\ W.IWD7BCPM,+'Q39?-&ZX"W2C^!\\9QP">,<'CD>A44 <;X
M\?6WC*SEMKB$V.NV1V7U@^0R,#@L >=N?Q!X/8GLJ\]\?^ ;C5+R+Q3X8F%C
MXILANCD7 6Z4#&Q\\9QP">,<'CIH> ?'UOXPM);6YA-AKUE\E]82 AD8<%E!
MYVD_B.A[$@'94444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )#VJI>^)=;OYXK26./S&P"[0@$_7 _I4%]XDNY[B>S\UYP20 >26[8]^:]
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M#/R_+I_GC_/5W3..WK^/^?P- #OIT[=A_GC]/S/\X/\ GZ?G3<\\<'M[=?\
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M .7\A4R\]>?7_/\ GK40XP.PJ=1_^O\ *@"1.U2BHU'M_G_/^>*F0<C_  H
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M":KKX&\(HP9?"VB!@<@C3XL@_P#?- &\I#*&'0C/-+2    # '0"EH ****
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M@ HHHH ***YG1?'.F:_XJU;P_907?VC2^)YG11$3G&%(;)YSU Z&@#IJ***
M"BBB@ HHHH **** "BBB@ HK,U+Q%H>C3)#JFLZ?8RN-R)=721%AZ@,1FM)6
M5U#*05(R"#P10 M%%9<GB30HM3&F2:UIR:@6""U:Z02ECT&S.<GZ4 :E%%%
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MSZO/3..M1GI]?\_X4 &>WM_G^=,//^?\^O\ GL$_K_G_ #]?R0GGZ_Y_S]:
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M---  #_*ES33]*6@ SFBBC_/\J $YHI:* "BC_&C_P"M0 G4\=Z!U_&CVHH
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M'7I2'DYI5^\.,_A0!,@Q[>I_S_G^LZU$@_7O5@#/>@!X'X'&*=W_ ,^](/\
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M)X7_ +%\#G59X]MUJS^:,C!$2Y"#\?F;Z,*]6J*VMH;.UAM;>-8X(46.-%&
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M0"1T(.TL1W^4<BIOCKX5\,:7X*34+/2+2RU#[0D4+VD2Q;@<[@P7 88!]^E
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MCE.[.&QTSWQT_"MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG)_ =R<?2/B)X1TN/;;:3?0,P^>3RT9F^K%LGK6M_P +7\.8^[??3R1_C[T
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIDLT<$9DE=40=230
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M_/M4=  >II"?6E)IIH 0GW]J3MZ"EY]_>FYYH #G/^?\_P#ZZ3.12MQ31UH
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MF\F&8[:+&2#D D]@<>Y]O2EHOCZ6_P!8@TS5O#]]I4UT2(#,&*N0,XY53Z]
M>M<YIRI?_'&]-U@M;(WD*QX!55 Q^9->IO'&X7S(U<(=R[ESM..H]#S0!,#[
M\_Y_S^/TIXZ?RKR6QD\2?$+6-2EM=>GT?3[.79&MONR3SC.TKGIDY/&>!6KX
M#UK6(O$NI^%]:N_MC6:EHYVY; P.3WR"#SSVS0!J^,_B#'X1N[>U33S?32HT
MK*)MGEJ#@$_*?0_E74:'JD6MZ-::E" ([B(/MSG:>XZ=CG\J\JT^^TCQ#XW\
M27^KZC9V]N(&L;9;B94R#E<KN//0GC^]6Q\&]5\S2[_1))4D>RF+1E6!#(WI
MZC(//^U0!ZK$.G^?\]*F&<=< ^]11]C_ $_S_G-2B@!*8:>:C8\4 1&D%#')
MI5H 9)T_^O\ 7_/_ .NL^3)8C.<G_/>KTQXZ]LU1(RQ^O0GZT 1@9Q4Z+D=\
M#V_S_GZT@7M_/_/^?RJ5!SG'XT 6(AS^-3K_ $'?_/\ G](XA_G_ #]:L*,4
M ,(XQS_G_/Z5&P_#^7^>GZ58QZ 5$PX_#_/^?\@ KLM1U.PYQ43"@!G\Z6EH
MH :>H^M-_P _Y_2G\?\ ZJ;CC'7'_P"J@!O^?\_E3>@_#_/]:=_G_/X_SIIZ
M''^?\\4 -^O^?\\T[\/PIN>:/:@"0=?\_P"?_P!=2*>.<^AJ$?7_ #_G_/-2
MITQ_2@"U&?7_ #_G%3C-5H^OU[X_S[U8'-  ::>G/3O2FN7\8^-].\'6<<ER
M&GNIL^3;1L S>I)_A'O0!Y%\1_$5[/XT@>_TC[/_ &=<'[.9%(\^(,#DYX8$
M@X([''->Q^'O&.B>)X<Z=>(9MN6MY/ED7ZJ>HZ<C(KSQ?BWX?\0*;#Q)X?V6
M;G[V\3A3TSC:I7'JN33-4^$D%Y%'J_@S5!L?]Y#$\AQ_P"0<CZ'\30!Z7-X3
MT.XU]=<ETZ-]13&V9F;J,@$KG&>G./Y5NJ*S]#LKJPT6SM+ZZ:ZNXH@LL[')
M=^YR?RR>3@5IB@!0.U/'3MFD4?C4BC/&3SU/^?\ /6@"U9J#)DG !R2>PKS_
M %*Z-_J-Q=$9$LF0,=NP_P"^<#\*[35;@V>@W,@X>1?*7'7+=?TR?PK@>N#C
M//Y_YS0 N??)QC/\OZ?YS7H^FRQZ!X<M8V -Q(OF>7T.6YY^G _"N L8/M%T
MBD9C4Y;/3&>GX_Y]3Z%I>GM>2_;[P;MW**1P?P]/04 4V1I]M[JDK+&Q_=QK
M]YO91V%*WBNRTE=DE@\4 ZLC G'J1Q7,^/M<GL]9N57(\F)%CSTYY)'Y_I7E
MFJ:VZRK*DK&0C+DL26_QH ZC7?$5R[_-(569FDD()^8D^OI7%R:LQO@FYO*W
MAL9^[SU^M=SX0TQ?&^BW,<D#B2R<(7 QNW X(]^,$?3UJ/\ X5REEJP2].V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.&!!S]T=,=ZA\1^$-,\4/;27[7"M;DA3"X&0><'(/M6_WQW_ ,G_  H_R,4
M8^O>'+'Q#IL5C=--%#$XD3R'"D$# '((QSZ5<O-,L]0T\V%Y;K/;,H4H_?'
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M\ZF0?G40&>O<?Y_F?SJP@R>GX4 68E]NO/\ G_/Y5849[9J&/ &1_GBI<]J
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M_P#C]'_"L/%?_16-<_\ (O\ \?H ]JS]?RHS_G%>*_\ "L/%?_16-<_\B_\
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M_D7_ ./T >U9^OY49^OY5XK_ ,*P\5_]%8US_P B_P#Q^C_A6'BO_HK&N?\
MD7_X_0![5G_.*,_7\J\5_P"%8>*_^BL:Y_Y%_P#C]'_"L/%?_16-<_\ (O\
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MN?\ D7_X_0![5G_.*,_7\J\5_P"%8>*_^BL:Y_Y%_P#C]'_"L/%?_16-<_\
M(O\ \?H ]JS]?RHS_G%>*_\ "L/%?_16-<_\B_\ Q^C_ (5AXK_Z*QKG_D7_
M ./T >U9^OY49^OY5XK_ ,*P\5_]%8US_P B_P#Q^C_A6'BO_HK&N?\ D7_X
M_0![5G_.*,_7\J\5_P"%8>*_^BL:Y_Y%_P#C]'_"L/%?_16-<_\ (O\ \?H
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M_P"%8>*_^BL:Y_Y%_P#C]'_"L/%?_16-<_\ (O\ \?H ]JS]?RHS_G%>*_\
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M_P#C]'_"L/%?_16-<_\ (O\ \?H ]JS]?RHS_G%>*_\ "L/%?_16-<_\B_\
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M2HZ "O,_$VI?#'2M0FMM2TZSFO2VZ5;>VW,">>6&!GVSGVKT2\D>.RN)(O\
M6)&Q4=>0,UX)X5T#0]6^'_B+7=03[7JT(F<;I3F/Y<AL CDG/)STH [5?#OP
MSO/#\>O/IT4&GRG DDEFBP<XQ@,,<U=7X7>"+F&.:#3B8I '1X[N0AEZ\98\
M8_G7.2M;V_[/D2W!53+%\@/\3&4D8]?7_P#4:[/X?F0^ -&\W.[[./;*Y./T
MQ^M '0HBPQ)$@VJBA57T & *0]/6E--;I0 TGGJ.O%1G\/\ ./\ /X4X]:8?
M3_/^>/\ /8 0GC\/\_Y]OK32<<>WK_GZ4I/\^W^?\_A3>G3_ #UH :33"?7]
M:<>M1D\]?UH 7CIQTQ2=Z.W-%  >E-[?2E]J,<"@!._XT[L*:.N*7],T )CG
M'_UJ,Y]Z*!F@ !X^E+[&@<4IZ?2@!O<$]<BD["E^G;THZ8]O>@!/\/\ /\_P
MI>_XT@_S_*CIV_S_ )Q0 =A2<=21_G_]5+CKWI.A[_7\J *MW=_92N8]RMWW
M8_"LR:[\V[CFV8\O'&<YP2:UKF'S[=HSUZCZ\?X&L @C(.<C]/\ .* ->#4#
M-,L:PGGN#T_3V'Z5=Q_G_/\ GIZU1TRW\N/S6'+'Y1Z '/\ 0_E5\<8]O_K?
MX?J* &]\CU_/_./TI.W^?\_Y_-2,+_GT_P _Y-'?_/O0 A']<TH(ZTA]:3OQ
MU!XH <32@?S_ ,_SIO;_ #_G_/M3A0 _'\J</KFD]J<.>,]: %]_QI1THYI1
MTH *6DI: $[TX=OTHQ1V_G0 4"EI* #M12_I1B@!**7'THH 2CM11B@!:2DH
MH 4_YXI,TO6D[4 )2TE+0 444=J "DHHH 7G%)110 [-,FD\J"20@'8I;&<=
M!2D C!'!ZUS%U$]O/)$68@=#GJ.W^?:@#?L[K[9$TFS9ABN,YJQ7)C.<#J3T
M'-=):0_9K9(R1NZL??O0!8I<TVE% #UIPY_'_P"O31TI1C.: '@DC/<^WU_Q
M_EZT\5&/\YZ_Y_S[T\'_ #_G_/\ 0 D%2+UJ(5*O6@"Q'Z''O_G\ZG!J!/R_
MS_\ JJ7_ ".* 'GI4+G_ #G_ #[U*3@&H7/)_P _Y_S^  Q>O3-.<X4_3_/^
M?>D4<\_C22GY?\_Y]: *<G)Q_GH?\:3J>?\ /7_Z]!.6^O\ ]:D'3V_^L/\
M&@!ZCG./\_\ ZZGC&?Q]JA7J>F:L1CVQ_G_/YT 6%_S_ )_&C)X- I,_Y]:
M)0<TUO3UIH)^O?Z\?2D8_P"?\_Y_G0!&YYSZU&?\_P"?SI[4TT ,Z_\ ZJ/\
MFEQ2=_Z4 -Z'!IK?Y]J=2&@"-N_X_P"?Y4P^W^>O^?\ ]7$AY_$_Y_E4>/\
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M]/\ /]: '$X7KCZU YY_S_G_ #^4SDC^G^?PJ ]>/\_YXH 5>E13GCKV/?\
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MFB\T&VB1E5<D<[F'IVS6YKWBS3/#GA9O$5\939!$<"-07;?C: "1SR.]?/\
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MI_&BVKHT2):K<VC7"YR=QVA6P>!R?6OJ[3$LH]+M5TV...Q\I3 L:[5"8^7
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MV.WNKTVZ[,#Y@05+'.1U[=* ,6VN-'TGXQZ=-X.O)'TS[?"+=V5@0KD!E^8
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MK<:$V]Y;(4D[%T."/RVF@#TC1_@+X.B\/0V^HVL]SJ+Q#S;L7#J5<CG:H(7
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M(9 I)7!3'08P>*X'X8^'_$GB'7YH?#6L?V9<0Q"2:3[1)%O3</ER@.?H>.*
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MPL=.BM[*29?.P&DD"9^8EN@'?I^->LMS_P#KH 8>E,/]:DIAH C_ )=_T_\
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M%MV,YSFLS2K26*ZDED)_U83_ #_GO0!K\9_&@9&,9XZ8H_S_ )_2C^O//?\
MS_2@#<:ST76M/#7%RMM=HN"KG&?<'H:YQ=-M[.Z_<NL@7A6 XK1TZQ.H7JV^
M=@/+-C.T5J:O9:):0F.WN2UP 3RV<^WI0!@=O\_Y_P#UUN>'-3:SO!:RD_9I
MS@Y_A8\ _CQ^8K AF2>/>A!&<'OSW_K3\9XQ^G^?\B@#T&:/RI67MV^G^?Y>
MU1_Y_P _Y[46-R=0T.VN6):11L<GJ2./\/SI: $Q_G_/^?SIPI*<!_\ KH >
MHXQQ3@*:#UY]^M/[T */6C\Z7\/THQZB@ 'KQ3AT_3BD[]NM)^M #OR_S_\
M7H]\]NN:3K^5.Z'TYH 3],?XT#KBC_./\_A2@9[Y_'K0 >]'3I2_YZ8_S_\
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M@=^PJ,>E2 ]* )%X^G^?_K?YQ4J],5$O^?U_P_7VJ1>N<]J )5JRG Z'\O\
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MUKQ-' \-EY?E@'N3M"@X[X7)KI-0\)^!M0UU+2_L;--5FC\[R8I7B+CG)PI
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M)Z]":S[[2XO$R!9=OVU$\IU?CS4!S^8_STKGM"LOM^M6MOC*%\M[J.3^@_\
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M^']#M/#6@V>C6+2M;6B;$,I!8\DY)  SD^E:=% '!0_"3P_!X[/B];G43?\
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MH **** "BBB@ HHHH **** $/2N5^('_ "(GB+_L%W/_ **:NJ/UQ7*^/_\
MD1/$?_8,N?P_=-0!S_P4'_%K-%[<S\_]MY*]*'TQFO-?@H/^+6:+VYGY_P"V
M\E>E#^= "T444 %%%% !112$A5+,0 !DD]J %HK)NO$6GVSE-[2L/^>>/ZGG
M\*SI/&$<;*/LH&3CYY"O_LM &[J?_(*O/^N#_P#H)KYA';&.G^?Y?YZU]"76
MOM)9S0S:?/'YL;)N!W $COWQS7EEG\.-1O@%M=4TIW'_ "S,LBMQ_LE ?QH
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M*P3?M+')Z< 9H O'.W/J.W^?KZTC?Y[_ .?_ *U<>/BMX*;_ )C.#Z&UF_\
MB*M1?$/PC/C9KUJ,C/SDI_Z$![?YYH UHM7TR>_DT^*_M9+R,?/;+,ID4#'5
M<Y]/\]+1]^?QZUY#X&GAU/XPZ]>P2":%DE9)%.0P+* ?I7KYY_'^M $;?7/O
MCK3#S3SR.OZ]:;VH 8>.:8>O/T_S_GUIYZTT_AQQ0!&W^?\ /^>]1GOBI2/Q
M^O\ G_.?SC;T_F?\^M $1Z4TCJ*>:8?;% "#_P"O3OIZTG]:<.: $ XZ=.HI
MU)C]*6@ I1R:2G 8- !CBC%+2XY(YH ;],XI,4[J*/XO?K0 W'/M2XYZ4N/R
M-* ./\_Y[T (T(N;2XMCTEC*_F/_ -5<%8($U!/.7_5MRI]1_A7H",4<$?E7
M+Z_:#3M7COT3=!.V6 '?O^?7\Z ,S7?&EQAE4JL:N5$1'4=ZP=(U W%W,SCY
M$<,N1V.?_KUTFK:+H%];"Z@O8U=N3&QP0?<=:P[>VCM@VSJQR2!C- &SK'A6
M]OK<WEC*LD,BC.&]!U_2N8M='DLKU6FR&C&.?4UTFEVNIW9:.P>9%_C9)"JY
M]\5%J.GW&G2[;DKEC]X-G- %:*)YY%CB0N[<!5&2?\_TK1N] OK* 33*@7KA
M6R1_GBFZ/*UO=-*B;G5>!Z?YZ5B:MXDOY)5W2S%V.&5F.WZ8Z"@"R,$9 XZT
M>]4-(:5[-_-'21L<=NO^-;6FV+ZC?Q6RYPQR[ ?=7N?Z4 =7H4!M?#VY@=UP
MY;\. /T7/XU9!Z'^7^?\\5-<%%VPQJ%CB&T+C@ "H/K_ (_Y[_Y- #AV_#%.
M7!_PIM.6@"2G+^?M3.OTIXX'U_PH > ,8/3_ #_G_"CD@^O]?\XH'?L<_P"?
MZTO^0/\ /^>: &CZ_E2]N?\ ZW^>E&,#KTX_S_GTH_"@!>^/7U_S_GBCGMR?
M_P!7^?\ /*=/\/\ /^>:4>^?\_Y/^<T )QV_S_GBE ]OT^G^?QI<=O7_ #_G
M_P#71UY'?_/]1^=  .@[_P"11CBE&./T_P _E_GJO:@!AZTG^?\ /^>]/Z?Y
M_P _Y%)CB@!*0BE/6DH ,?K3L<\?A^G_ -:D'^?>E'Y_Y_\ K_Y[@!C_ #_G
M_/\ 0_S_ )_SZTH_S_G_ #U_-.W;W_3_ #^/Y@"?G1W_ ,]J7OW_ ,_Y'YFD
M[9^GY4 -/^?\_A24[&?7K_7_ /53>U "'I2S#?IS_P"R:2GP%26C8_*XQ0!D
MU&;[[%<AMNXA<CC/-6)8VBD:-AR/UIB+"TJ^<I*=#CTH YKQ5XB,Z^4K[\KS
MQT/X5>T)GU70K">[)$A4AF/?!*Y_3.:EU?PYI]U*K6\N 1@_*<C\ZNP01VUN
MD,2A8XP%44 9.O\ A2X*H\4GFH<X&1CZ58T/2QI.F+;Y!=F,CG_:/_Z@*VX;
M*6:)I1@*H[U0%U$;IK8L!,HSM/<>HH NV]K+=/M0?4FJMW-'8SK%.X7>=JMV
M)]/:H#?W%HTA52%W\D ]/\XKB/$NIW%ZUPJ!@A) '3Z'ZT >@UI68VV4C8^\
MW%9%B)9+*V$F3,T2;O7=@9K;EQ##' #G:,GB@"''\Z</6DI10!(./PJ7I^'^
M?Z5$/\_Y_P ]JD7GMS_G_/X>U %A!R/TJRO ^G^?Z"JR<_CZBK/;Z_Y_S_\
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M7HH_$.C_ -G1VDDT5F1;R1^<FX?-EB0W0<KQS7US7SO^TOG^TO#OIY,_\TH
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M-9UWH^G3W@G2%L [@K=_K5U5+L% R2<# J]#9K"OFW/X)C- "6<*Q1_:9?\
M@(Q36<O)N/4_Y_QI9YFF;V . *C/<]A^O7_/^30!(IJ05"O!/MUJ0=!0!(#U
M'^>AJ91S_G_/_P"K\H5X_P ]ZE4CMT['_/X?D: +$?;_ #^%6B.#G^7^?4_Y
MZ58NH&,=@*M\;<_C_6@"&0^_-9TY^8]ZT)*S)CS0 T?Y-/6H5.>E2@_K0!*M
M2 _Y_P _Y_I$I_S_ )_SQ3\_Y_/_ #_DT /S[]!Z^U+GMS_G^O\ A3,_7C_#
M_P"M2GC./_U8)_E0 ]2>GI3L@_\ UQ47MT_S_P#J_&GKUSTH D%/_/\ S_\
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M .CM+F.]LX+J$YBGC61#Z@C(_G4U4])TZ/2-'LM,ADDDBLX$@1Y""Q5%"@G
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M8)SR<$8SS6C\-=.OM<U[4-8U"5Y(;&)F4N<#S60J,#IP-QXQ@XH Y/.1]?\
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MRR:\T/38]/F9&DE60;EC/.0#*3G!]/PKO&Y_^O\ _7_#\J (S4;=*>Y !/8
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M8<<UMIV].OT_SQ_GH 6HNH_.K70?3^E4);F*RLIKJ4A8H(S(^>P')KSOP?\
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MXB6NH2_V4=/:T=%V^?YH<,#SG:N.GI0!W=%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 45S/B/X@^%O"=]%9ZYJHM+B5/,1/)D?*YQG*J0/QKI$=
M9(U=#E6 (/J#0 ZBBB@ HHHH **** $-<K\0/^1$\1>VF7/_ **:NKKE/'__
M "(?B+VTRY_#]TU '/\ P4'_ !:S1>W,_/\ VWDKTH?3&:\U^"@_XM9HO;F?
MG_MO)7I0_G0 M%%% !1110!P_BOP]=07W]N:.%6<*1.A^[(IZ@^QSG/8\_3S
MZ_\ #LVIVWVV&9PT0Q+N)W+CJ#Z'_/->\$ @@C(/4&N>U/PK!<2FXLF-O/CJ
MAZ^Q[$>Q% 'G-MK*6Z10C$<2@8VGH.@_2L1O$-SJ6L1P-*7!R47:.",^W/&:
MZ_4/!4N#')E2O 8<!A7*6?@R<:]$9VDCMHI59Y0/FP#_  ^_U_&@!;[5KBW@
MFC96+$=3VKGO#]K<:SXWTBWR55KH,W^ZN2WX8!KU:_T_2+I#%%%,^X_*&09'
MY&N,@OM*T&X;['*[22+L>6)0[!"0< 9 ].YZ=* -_7?#UGJ.JIINF1BXO6.?
MD/R*O=G/91ZXY/3->A:7H5IX<\,O86JC"Q,TC@8,CXY8_P"> !7G^F_$;0=$
MMV33]&O7D?!DFGD4/(>.6;G_  YIE_\ %^ZN()(K;2(8MZE=TDQ?] !0!YK_
M  _\!-6+/_D(6^0#^^3@_7_/YU!^/ZU/9<7]O[2IT^N/\\=Z /J"J%Z.3[U?
MJI>]/PH QI>.O'O7"^,OB+IO@R_M[.]M+N=IH_,!A"X49QW(]*[N0>^,=_2L
M/5?#NCZU*DFI:7:74B#:C31!F49Z9/\ GF@#@!\=/#1.6L-6!/\ TRC/_L]5
M]8^,/AK4O#^H6L*7\<\T#QQK)".25P.0QP.:ZR;X:>#9_O:#;CDGY'=/Y,*J
M/\)?!1'&C%<_W;J;_P"+H Q_@FFWP/-)_>O7SSZ*M>B-UYSGV_S_ )XJGHNA
M:?X<TU=/TR$Q6ZLS[2Y8Y/4Y-7FZXZ\_UY_K^= $3?\ ZL4P_3\:<W09].?Z
M_P"?QJ,^G<4 (>E,.?S]Z?T.#2$=Z (S_+I[5"P]/\_Y_I4YX/?U_P _E4#=
M,''3_#_/^> "/Z4E*:;F@ Q1]:!TI: % IWU'UX_^M31[4X#N/PH <.G-/'3
MZ?Y_S_G#>G^?\^E.'^?\_A0 N,?AZ_C_ (?J:7!YZG_/^?UH_P X_P _C3N.
M_P"/ZT )SU]3FO-?BS_K?#O_ %^?_$UZ9CUQ[U7NM/LKXQ_;;*WN3&P:,S1*
M^QN.1D<'_"@#R?XEFZ\,>+X=?T_Y6O;9X)#_ +6W;_(J1_NU'K6C_P!C?!&U
MC<8FGN([B7/7+9(_3%>MWEA9:E&J7]G;7<:G<JSQ+(%/K@YQ3KJQL[VW^S7=
MG;W%OD?NI8PZ<=/E(Q0!Y'\0;:Y3PYX/U%&=+>W@C6214W>6Q5"&QT/0U0O)
MM/U^\TV"Y\=W>I2"X411)I)0JQ(&<E@/Y_2O;_(A^S_9Q#'Y.T)Y80!=O3&W
MIC'&*HVFB:383>=9Z78VTO\ ?AMT1OS !_R: /.O'S'PMX\TGQ/&A,4JM%.J
M]3@8_,JP_*I/ <-Y9^$-<\3K%YNHWIEFB!&2VW<1^;$_E7I%YI]EJ,2PWUG;
MW42MN"3Q+(H/(SAA[_SIT$$-I;QP6T,<,,8PD<:A54>@ Z=_\B@#P&YUV/5?
M#-U<:EXJU675IL@:>BLL)&?XL?*1CGM]*W-1S_PHNP_Z[+_Z,>O5!HNE+<23
MC3+)9I 0\@MT#,#P03C)SS3GTO3C8"P:PM#9@\6Y@7RQSG[N,=3Z4 >4^*E>
MQM_!>LRPM)96\$0E 7.#A6_49_*G>//$VF^+K33])T,R7ET]P'XB9=O!&.0,
MGG]*]6-M;FV^S>1%Y&W;Y6P;-OICICVJO::3ING.SV.G6EJ[##-! J$_D!0!
MYYK4/E_%?PW"^',<"*>.,C=S3_&'_)3?#!'=T!]QOKT&6QLYKJ.[EL[>2ZB_
MU<SQ NGT)&139;"RN+F*YFL[>6>(CRIGB5G3Z,>1^% 'EFJ>(9KGQ9J=KK?B
M#4-'M;5BL$5HK O@\<KZCGG]*N?"8J][KKQM)(&9"KR?>89;D^Y'O7HEUI>G
MWTR37=A:W$J ;9)8$=E^A(XJ6"SM;>62:"U@BEF.9'CC"LYSW('/^>E 'F'P
MZUJPTC6=7T^]F:*ZN[Q(X8]C$L0S#' XY(ZUD123Z%XNUJ"\\03:(\DS.)19
MF;S@6)'3D=<U['_9FGO>K>M86K78Y$YA4R<?[77_ /73[O3;'40HO[&VN@O3
MSX5?'TR* .(^'4%D^M:Q?VNLS:G)($$TK6GD*223D9))/![#\:]'7KR/KQ5:
MUM+>SA$-K;Q01#D)$@5?R%65'&* )0,__7_S_G^:_P"?\_Y[T _H<_SI1TQ^
M'^?SH 0^OX_R_P /\]DQQG_/^?\ /I3CZY^N/\^U-/OCCC_/ZT *1V_S_G_/
MT7\_\G_/_P!:D'7GL<G\_P#/^>JCC_ZWU_S_ /6H 7';O^5'7G\?\_E1V]O:
ME]S0 WH/2D(IQ_EUHH 9^/X_Y_"D_3_/^?RIQ%)C!_SZ_P"?\]0!N.?\_P">
MU+2XXHQS]* %':E[9]NO^?I1V_S[4?Y_S_GL*  \_P"?\^M'X]^O^?\ /\J#
M]?\ /^?Y4=: #'0=,UY]\8/^1-C][I/Y-7H6,'TKEO'?AN[\4Z EA92P1RK,
MLF9V(7 !X^4'GGTH Q_#6H^/I)=,AO=%L(]**HKS+(-XCP,''F'G&.U<UXJM
M_#FH>*+V.]U#7M4N@^1;:=$K+;# ROS9S@^E>N6,#6NGVMNQ4O#"D9*]"0N.
M*\_N/ _B33=?U"^\-ZY;VEMJ$A>82H2ZY)) ^5L\DX.10!C> H#XC\,:YH5_
M/=FQCD3RLMAXQDG'(('W1Q]?6J?PQ\+V.I/-JL\MP)K*X"QJC*$88_BXYZ]C
M7:>"_!]YX7DU07=W%<K=.I1TW;B!G)8$<'GL36;X?\&>(/#FMO\ 9M7MAHTD
MWF21;?WC@#@<J<?@U ''V'@K3;GXA7^@2378M+>/>K!U\PG"GD[<?Q'M6]?Q
MCPI\3[&Z0E;/4HQ$Y)[X"G/X[3^-:6L^#M;/BV77= U2WM9;A0LHG7)7@ X&
MU@>@ZXI?B;9Q3>#1+<3#[1:R(R.>-['@@?7K^% &;I4ZZI\0=:\02AGL])B:
M.,J,YP".,^P<]>XK;T3XB:1KNJQ:?;6]ZDL@)#2H@4 #)R0Q]#VIWPZTLZ=X
M3AED!\^\8W#ENO/ S^ S^)KK'02Q-&V=KJ5/7H>#_2@#Q/5+;P]>37LHO=?U
M6]3<?M-O$IA0\X!W<[1Z@_2M[2_$FH6OPDN+WSW:ZBF-M%*S9902,'/J 3C\
M*L6O@+Q/IJ7.F:=X@@ATBX<E_D/FD$8Z;>N .C"M;1?!#V_@J[\/ZE-$_GRM
M()("6"\+M/('(*T 9&@?#V*ZT_3];DU:^75)0EP90P(Y.<<\GCC.[O26Q_X1
M?XKW$+'99:LI=3T&XY(_'<"/Q%6-.\)>,;!8;!/$ENFE0OD! ?,VYSC[N1WX
MW4GQ:M(6T6SOO,$=S#/L3GE@V<@?0C- &=HBG6[SQ=XD?E/)D@MSG(QM_P#B
M0OYU9\&:_:>&_ATE]>1S21&\>/$*J6R<>I'O71>&_#[6G@!-,7"7%U;LSENF
M^0=^,\# _"K/@O0;KPWX>%A=RPO+YK2;X6.W!]R : .6\1^+[7Q1X$UAM-AN
MHO(:$2^<JC(9^V&/I75_#_R?^$&TOR,8\L[O][<<_K6Q>V<&I64]E=)YD,Z%
M'7/8_3_/%<%:>"/%V@L\'A[Q%;I9.=P6X3E<^VUAGW&,T :OQ-UN\TG0;>*Q
MF:&:\F\HRJ<,J@9.#V[<US7B'P$OA;P[_;^GZO?+J5N4:60N '+$ [2,$<GN
M3G%=1<^"+O6/"?\ 9FL:NUQ?B<W"76W(C;&-H']WKZ=>E9C> O&&KPPZ;K?B
M2W;2HR,K"I+L!T!RBY_$GUYQ0!+XT\4R2?"FPDD91=ZM&B-CTQESCWQ^M<QX
MIUSP[%IGA>3P_J(GO]'VHRB&1,@88G+* ?F!_P"^J[_4O ,NJ^)M#D9K0Z!I
M<*QBU?<SN1ZC;M(.%SD]C6WKO@/0M3T*\M+32-,M+F6(B*>.U1#&W8Y5<@9Z
M^U &O:7L6I:;;7L))BN(Q(I]B :IW/?ZU2\':-J7A_PO!I>IS6\LT#,(V@9B
M-AY ^8 YR35RXY+'KD]: *XZ_P"?\^M3*>*@'7M4J<_3% $XYJ5><?Y[U$*E
M7C_/^?2@ [9QVSQ_GW_2GCKSZ\_G_P#6/Z_B@'3_ #_GH/\ )J11CH#Q_G^E
M #DZ9(Y[_E4Z+TR/\_Y_G4:KV%657GCKTX'U_P#K?Y% #E&?2G@>U(!Z4\ 4
M &*<!T_2@?RI1C.>/SQ0 H!' !SU'^?PI>HX^G04@&>.@/!XYI3S@?I_G_/2
M@!A^N:BE=(XWDD8*BC+$G@ =<U*>M8OBJTO+_P *:I9Z>";R:W=(AN"Y)'3)
MX% 'DVI?$SQ=JFHSWGAK3Y6TBU?!9;,R!@.<N><>N!CBM+2?BEX>\368TSQ7
MI\4!< %G7S(&/3/JA_E_>%)=K>>#/@@;=K=K2_N',4HS\P+L<DGUVC KGO%6
MC^%8/ ?A]M.DMI-4E,:L\#@O+D9?<!Z$XR1D8Q[4 =WHWPO\/V?B2T\0Z9=N
M]G'F6*W#"1"W\+*^>@]#GZUZ#CC^=97AGP_:>&=$ATRR\SRT8N6E(WLQ)))_
MEP*V * $QUX]<UPOCGXF6_@W4;>P2Q^W7#IYD@\[9Y8SQV/)YKO .GL:\T^)
MOP[DUQO[>T8'^U(5'F0@_P"N"]"/]H?K0!7M/CMHKJ#>:3J$+=Q"4D'ZE:U7
M^*7P_P!;L&M=4E/D/]Z&[LV<?^.AAGWS7,^$-:\%>(=)N+?Q)H>F6VI6<322
MNMNL/GJHR6!4 AN.1_D9/P^^'6G^.9M4U.[2YL=*64QVL5L_.<YQEPV0!@?4
MT 7[OX:>'/$[R7?@#7X/M$8$ALI9&^7W5C\Z_B#SW%:OA35/']E->:#XEAF-
MM'%@37*%I,DCA)!PXQG).?J*]!\%^ ]*\$0W::?)/,]RX+RSE2X '"\ #'4_
MC69K5[]OU"1Q_JURD?TZ?J>?Q% % 'D?7/UZ_P"?_P!1KIM+L/M8L;, %'8-
M)Q_"/F/Y]/QKF<Y)Q^'?U]_\X_+T;PQ$OFSR8&44*#W /;_QT4 6=4U^*UDD
MMXA&[(/WCR'Y%XZ>Y_QKSF]O]$FF"7B6YMG?!E0Y$7N1UQ_+WK \2:G>)*1/
MN&96,F>[9YSZUQ%YJ#RW;B+@,#D>U 'IOE:5X6NKF2%8[B17VQNHX/ )P?3G
MKU-8>H>,+J.ZSF..3JCQ@<>F<\$4^T\-WUSX2T]W.99(1(@_V<\ YQC@?ECK
M7*WFAZ@;T)*C$YZ+R2?PH [Y/%LK:;%?R0PK<RH% C'R@_WL'UZX]ZYG6/$U
MQ)*R3RB6-^?3;FNAM?!TLGARWAGG595C#$KD[,DD+SC/&,^^?K7(7?A6[&JK
M;(_G2'[JIR3W_E_*@!8/[1U73/MT*/+Y;&%CCGCH?R(J+P]:2)K:W%S&W[O)
M13ZUZ5X=LX-'\.161D5F&78QCEF8\^^ ,#\.G-4['6]+M]7;3KN&+[+J+K"\
M^T;XG)&T[O[NX#- $-WKX-I-YCY(^Y@^_P#A_*N&_M6Y_M^SD@+;A+M)]5/!
M'Y']*]-U7PE;7"3;9XVD0D%E/!_I6/X:\.:3:7MU<ZE=#[7;)FWMQ_&2<;L]
M^_';.: ,#7=7FG5(U4C:N!GOSUK9^'FARZCH&L7MS(J6T,X W\#[H+?^R\?6
MM;7-*TJXB\X J5.6P!^56/#VNQ7WA_4?"EO&L<T,#3VWECF5 X9P?5N>W7)]
M* ,76?"<+E9+2=&R<D9[59\$ZY:>%-;M].=@;:\E\IY.ZR-@*3_LY"CVZ^U4
M+NXO;-7(4G<N,CZ8KD([&[UO6+2R0,S3SH@ '3)&3WZ=>G:@#ZJHHHH *^6?
MAYG_ (:&FSU^W7G_ +/7U-7":-\)?#^A^,Y/%-K/J#7KR22>7+*AB5GSG V@
M]SU- &[XUT ^)_!NJ:.C!9+F B(GH''*Y]L@5\^?"+QY%\/-9U+0?$B2VEK-
M)\[,A)MYEX.Y1S@CN/0=J^H:Y;Q3\._"_C%A+J^FJ]T%VK<Q,8Y0/<C[V/0Y
MH P/B#XY\*77P[UN&U\1:9<37%D\<44-TCNS,, ;0<_I7'_LT_\ 'AX@_P"N
ML/\ )JW(OV=?!L<P=KS69%!R8WN(]I]N(P?UKT'PUX1T+PA9R6NAZ>EK'(VZ
M0[F=G/NS$D_3H* -NBBB@ HHHH **** "BBB@ HHHH **** "BBB@"M<?=Z=
M>,'O_GBO'/A)_P C_P#$8]?^)F/_ $;/7L=SRH[Y'YUXY\)/^1_^(QZ_\3,?
M^C9Z /:4^Z!VI],3A0.>!TI] !T&36=8^(-%U2ZDM=/U>PN[B+_616]RDCIV
MY .17$_'&ZU&T^&5XVGM(H>6..X9.HB)Y_ G /L:^6O#MS?V?B339],:5;U+
MA/),7WBV<8_'ICWH ^[**:F[RUW?>P,_6G4 %%%% !1110!YK\6OB;_P@NG1
M6FGI'+K%VI,>_E84'5R.Y]!_A7F&@?#3QM\3[-=9\1>(9[:RG^> W&Z5G'JL
M0(55].1[#'-8WQ9D;5_C9<6=P6\M9K>U&>R$+T_[Z-?1GC+Q)'X$\&S:K%I_
MVJ.T$<:6R/Y8P2%'.#@#Z4 >0S? 'Q-H2&Y\,^+LW0YP ]H3QV96;GZX^M>V
M^%DU>/PMIJ:\V[55@471R#\_?)'!/TXKQ?\ X::_ZE'_ ,J7_P!JKTC5?'R6
M_P )V\8P0>6\MHLD,+MG;(WR@$\9P3^E '3ZEKNCZ-L_M35;&QW_ '?M5PD6
M[Z;B,U+I^JZ=JT'GZ;?VM[#G'F6TRR+GZJ2*^5_!'AW0O'5UJ&L^.?&,=G(9
M-JK+>Q1SRM@'=F3/RCH,#\L5%JCVOPM^(%G>>$/$<6I6+*KLT4Z2_+G#1R;.
M#TST'4<<9H ^J]2UC3-&A2;5-2L[&)VVJ]U.L2L?0%B,FF76NZ18V,=]=ZK8
MV]G* 8[B:X1(WSTPQ.#FO'?VC95G\*>'YD^[)<LZ_0IFL7P)\)I/B!X9M];\
M3:U>^48O(T^&W9?W4:?*,Y! &1]T >I.30!]!6&I6&JVPN=.O;:\@)P);>59
M%_-2151_$^@1:A_9\FN:8E[NV_9FNXQ)GTVYSFODG1++Q%I?CF[\(Z)J[6EQ
M=W#6$LR,45U#'DXY'3/'/4=Z['XE?!C3_!?@Z/6=/U&[N)89$CN5G"[6W<;E
MP 5YQP2>O6@#Z:JM?:C9:9;-<ZA>6]I O66XE6-1^).*\Z^"?B&XU'X8K+J,
MKR?V?))#YKG),:@,.?8''X"O'=.AU/XV_$Z1+Z]DBL5WRX4Y$$ ( 5 >,GY>
M?Q/3% 'U#INN:1K(<Z5JMC?!/OFUN$EV_7:3BKDTT5O"TL\J11H,L[L% 'N3
M7D%I\"(/#WB;2=9\.:W=)]EN%>>.\()=,_,%9%';(P1SGJ*TOB-\-;KQMXAM
MKR_\0BP\/VL WPY)(DR<D D*N01\QR>.E ';6_B_PS=W*VUMXBTB:X8X$4=[
M&S$^F V:VJ^6O'OP^\!:%X9FOO#OBZ.]U"%U!M7OX)6D4G!PJ $$9SWZ5ZI\
M!=:O=7^'QCO97F-E<M;Q.YR=@52!^&<4 >1_"'_DMB?[]S_)J^EQXH\/MJ']
MGC7=,-[NV?9A=Q^9N]-N<Y]J^0_#FC:IXB^(4FE:3=FTN+F:9'G#$;(^=_0Y
M/RYX[]*[GXG?!>Q\&^%5UK2;^\N/)D5+I+DJ>&X#+M QSC@YZ^U 'TS56_U/
M3]*M_M&HWUM9P@X\RXE6-?S8@5YE\&_&LNH_#6[FU6=Y9=&+K)*YRS1A=RY/
M<XR/PKQ_27@^*GCFZO?&/B6'2[%%+KYUPD>%S\L<6\X'J>OZT ?4VFZ_HVLE
MQI>K6%\8_OBUN4EV_7:3BK5Y>VFG6KW5]=0VMO&,O+/($1?J3P*^4?'/AW0/
M UYINK>"/%R7T@D(98[R*6:%@,ALQX^4\CD?GFO7/&NN-XD_9XDUAP%DNK6%
MY .!O\Q0WZ@T >E0ZYI%SIK:E!JMC+8*2&NDN$:(8ZY<''ZTW3=>T;62XTK5
MK"^,?W_LMRDNWZ[2<5\S?"SP#=?$2QEM]1U>XM_#^GS$_9H& 9I6'49! X[D
M$]A6=XPT*X^$?Q(M6TB^F:.-4N;>5\;]I)#(V.#T(Z<@T ?7=9>H>)=!TB<0
M:EK>FV4Q&1'<W<<;8^C$5Q_Q;\:7/A;P +NP?RKZ_9889 >8\C)8>X _6O'/
M W@3P;XAT5M6\7>-8+6]N9&9;==0ACE7DY:3S,DDGG_]? !]0VEY:W]LES9W
M,-Q _P!V6%PZM]".#4U?*W@[5&^'OQ>CTC2=:BU+1;JY2!Y(9 \<JOC:?E)&
MY21R/0^M?5- '(_$KPYIWB?P;/8:IJT>DVZR)*+R4KLC8<#=N(&.?450^%'A
M/2/"GAVYBTG7H-;6XN-\MU;E=F0  H"LP&/KWJG\=L_\*HU#_KM!_P"C%K!_
M9Y9H_A]JLD:9<7KE>.I$:XH ]8U+7=(T8(=4U6QL0_"&ZN$BW?3<1FG:=K&E
MZQ$TFF:E9WL:G!:VG60#\5)KY)\-0Z3XX\>7C^.]=GL#/N;S3(JYDSPF]@54
M 9QGC@"O?? WPGTKP5XA;6M(U:ZN;>:U,0BFV/G)!W!U !Z>G?K0!Z-7EWQC
M\?S>&-!2/0-;M(-9%RBRPJ8I)5C*D\HV<#ISBO4:^??C]X(TNRMW\712W7]H
M7ES'%+&TBF+ 0C(&W.?E'?% '<?#'XB6FL^#[%_$7B/33K4TKQF*2>**1OG(
M0>6,<D8Q@<UYK^TE_P C7H__ %XG_P!#-7_A1\)- \1>&-+\37MUJ*WBW#/Y
M44B"(^7(<#!0G!QSS5#]I+_D:]'_ .O$_P#H9H ]LT37-(T;P9H1U75+*P$E
MC#L^U7"1;OD'3<1FNBM;JWO;9+FTN(KB"0926)PZL/8C@UX-H?P*'B/PI#JV
MNZ[>OJUS;*UL(V#1PIM'EJVX9; QP"N.@]:Q/@!K-[IOCJZ\//(QM;F.0M'_
M  B5/XOR!'Y4 ?3)(498@ =2:QE\8>&'NQ:KXCTAKDML$(OHBY;TQNSFO$/C
MUXPOKGQ#!X0L[S[/9JB-='?L5W8\!S_= P?3GVJG??"WX>0^&Y7MOB#92:Q'
M 67.H6_DNX&=H3[P!Z#YOSH ^E>HR**\,_9X\67NH6NH>';V=YDLT6:U+G)1
M"<%<^@XP/<U[G0 R66.")I9I$CC499W8  >Y-9$'C#PQ=7(MK?Q'I$L[' BC
MOHF8GTP&S7&?$CX;WGCC6[.XO/$ L- M8,RQ9)/F9.6P<*.#C<>GI7E7CKX>
M> =$\,7%]X?\81W>I0%?]%DOH)3("0" J ,",Y[]/QH ^HJK7VHV6F6S7.H7
MEO:0+UEN)5C4?B3BO+?@-X@NKWX=W0U"=Y(],G:.-W;)6,(&Q]!DXKRK3H=3
M^-OQ.D2^O9(K%=\N%.1! " %0'C)^7G\3TQ0!]0Z;KFD:R'.E:K8WP3[YM;A
M)=OUVDXKRCXS?$J^\.K80>%M?M$NQ+(EY'%Y,SI@# 96#;><]A4MI\"+?P]X
MFTG6?#FMW:?9+A7GBNR"73/S!611VR,$8.>HK@_CMX(TSPWJ%OK-E/=O<ZM<
MRR3I,ZE%/!^7 !ZD]2: /9_ /CG3M<\,:,M_X@TV;7+B$>; +B)96?G(\L$$
M'V KC/'OPV\,:[\0!J.I>-;/3;B?RO,T^9H_,DQ@#:6<$9 P/E--^%OPD\/G
M2_#OB]KK46U#8MSY7F)Y._GMLW8_&O/_ (T?\EH;Z6W\A0!]+7VOZ%H1BMM2
MUG3[%RGR)=721,RCC(#$9K31TEC62-U=' 964Y!!Z$&O"_VB_#_G:/I/B"),
MM;M]EF(_NMROY$'_ +ZKLO@_XD34_A99SW,F&TU7MYF8] G()_X#B@#L9?$>
MA0ZF-,EUK3H]09@HM7ND$I)Z#9G.3]*OSSPVT+37$L<42#+/(P55'N37RY\-
M[:3QW\;)=9G4M#%-)?R>@ .$'YE?RI_Q"\0S>/?BC_PCUQK$6G:';7)MQ)-+
MMA0KG?(V2 6X(&?8=S0!]&V7BOP[J5R+:PU_2[JX/(B@O(W8_@#FM>OEOQM\
M/? FC>&I=1\->-8+O4+<JQMGOX)3*,@'8$P01G/?I^->M_!+Q5>>*/ W_$QF
M,]W8S&W:5OO.N 5)/<X.,^U 'I-17%Q!:0//<S1PPH,M)(P55'N3TJ6OEOQS
MJFJ_$[XLKX7MKHQV,5T;:"/)*)MSOD('4\-^ Q0!](:?XET'5IS!INMZ;>S
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M[$C:<'IQD_6@#SWN.WO_ )_.D[8_#']*])C^#VHG_6:I:H,_PHS?X>M:%O\
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M]+[4N/;VI0* &_I2X]OR_P _YQ3L?I[4G:@!!2]*/XJ*  _A33S2GK_3_/\
MGFD[_C0 AIC'IS^M//W?P_S_ )]JB<\]2.?RY- $9/2H6/&:E8\=<>GM41ZT
M ,/UK-U;1-.URW2WU*W\^)'WA#(R@-S_ '2/4]?\:TNW^?\ /^?:F]?\_P"?
M\CVH ;'&L,21QH$1% 51T  X'Z?Y[2CCCTX_H/Y4T#(^H_I_]<5$U[;QR,K2
M893TP?<T 6.PZ?Y%+UQCV_I67!?_ .ERB67]S\P3Y??CMFM"&YAG8B)MQ')&
M#0 [L.?\\5F:KH.F:V8#J5J)_LY+1@NP"GZ @'IWK4/]/\_Y_P#KTT_7_/\
MD4 .  [8'H.G>D[CU/\ G_/^< Z]/K_G_/2G8)]_6@ '/7TYJ0=*8,YZ5**
M'+4\=1@>U3*.?\_Y]* +$6,_Y_S_ )_.QCCGZ?3FH(QQFK&,>U %:7D5D7![
MUL2].E9%SU_Q- %0<FITJ(#)J>,4 2CK4@'^?\_Y_JU!WJ51^'^10 \#G/\
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M]KVIV_F.$03WD";V)X49C&2?04[Q!^SIH>HWCW&CZI<:6)&W&%HA/&OLHRI
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M2/A1X0\$^$7OH-:OI-58HMO!--$1+DC<0H4' &3G/'%=I^SD/^*&U#WOV_\
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M\B_:)!_X5];'' OTR?\ @+5Z[61XF\-Z?XLT"XT?4T8V\X'S(<,C#D,I]0:
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M-I[6Q<S7$EN)Y+@MC[Q#+C&. ..:]>MXA;VT4(.1&@0'UP,4 24444 %%%%
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M\XH 0<GKWX_.@'C([^](#BEQV[\CG\* $[9Z_P"?_K?K3QUYZ4G7\?6G#K0
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MT >+>)O$%WXI\1WNM7I_?74F[:#D(O15'L  /PKZ?^"/BW_A)? D5I/+NO\
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MT 2"I%'/3]/\^E1"I4/?_/\ GI0!,G^?U_S_ )YDZ#'2HE[?X?Y_SBI1T]*
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MA:46V[!D%\"^WUV[,9]MWXUZ]X4\6Z3XST5-4TB9GB)VR1NNUXF[JP]?ID4
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M[G&0"> P'^ _04 = >GZ4G7WX[?Y]J5UVL4..#BF]?0YY_2@!WN/_K>U.''
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MY[ "CK_G_/\ G\[*)';Q":89_NKZTRVB\R;_ &5Y/^?\]ZA>[@EOQY[8B49
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M'3''^?RH 0+Z8]JDQ0%]!3N /K[T  'M]:P/$VI>3"+&)OGDYDQP0O8>Q/\
M3WK7O;M+"TDN)!]T?*H');TK@)IY+B=YI6S([;V/^'MC'^>* (^N._\ (_\
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M3_:2L;:'7M%O(H42>X@D65P,%]I7;GZ;C4?[-O\ R->L?]>(_P#0Q5S]I?\
MY"7AW_KC/_-* /3_ (;>&='L_AIIUO%81;-0LUDN]Z[C,SKSN)'(YX'85X?\
M$@;7XQ_9X25B\NYC(ZY4 X'Z"OH;P!Q\/?#W&/\ B7P_^@"OGGX-_P#);/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>],'3^E.!H 6F$\&G$_A3><]\]: #O[_ .?_ *])V_SZ4=,"D_#MZ?Y_SF@
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ME3.WU_S_ %H :??_ #_G^M1GK4A]:C- #33"??WIYZTPT -IC'TIYZ5$Q]*
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MPJY"N3G&?7B@">)<<XQ^%2TBCC%/P.]  !_]?-#?IZ4\ _CZ?X4U@0/;K[4
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MCP-!I>GVEC"S;FCM85B4GU(4#FHM2T#1M9*'5-)L+XI]TW5LDNWZ;@<5HT4
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MT._&<CZUIT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX ]!Z5,%XZ9XQDU%+P._7_/XT 9-\W)'X52C3)%3W3;GZGFFPK[?Y_S_ #H
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M=JDHH **** "N=\9^#-+\<Z'_9>J>:BK()8IH2 \;C(R,@C!!(((_7!'144
M<YX+\$Z5X%T5M-TOS7$DAEFFF(+R-@#G  P .!_4DUXE^T%X(CT_48/%=C%M
MAO7\J\51PLN/E?\ X$ <^XSU-?2%9'BCP_;>*?#-_HMUCR[J(J&Q]Q^JM^#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7*>/_\ D0_$7MIES^'[IJZHUROQ _Y$3Q%[:9<_^BFH Y_X*#_B
MUFB]N9^?^V\E>E#Z8S7FOP4'_%K-%[<S\_\ ;>2O2A_.@!:*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K.O1AB?Z^U:-5+U> : ,B0?>'X5"^,Y
M]\G_ #^=6'';VJN_X]/7_/\ G\: (_;T'&?R_P#K4I]SCMSZ>E!&3C/7I[\T
M=QQU]NG^- $;#.3C'>HV'>I3TQT_S_\ KJ,]* *S<?3OS]/>H&[\GZ]:LOUX
MY]._^>OZ_6JS<\_CP: (6'!X'T'L*8W4]^?SZ_Y_&I#R?7^O^?Z4PX[]/K_G
MU/Y_2@!A[\]C^O\ G_/6@]3P?\BC!_'U_P _C1GO[Y_S_GO0 4?C^.?\_P"1
M1QC/I_A1T_\ K_2@!1[<9]/\_P"<"G=LCI_G_/Y4G^>?Q_S^=. Y[^G^?R_G
M^  '@\]NO;U_P_EZ4?7CZ#_/I^E'Z?3_ #_GB@?A_G_/\J %[=N.?\_Y[4'C
M\/7\O\:3G'^?3_Z]+[_C_G\Z #\O3T_SW_R*5CP?Q[?C7*MJU^&(^T$X/]U?
M;VI/[7OA_P O!^I5?\/:@#J3C!XXY_K_ (4'O^.?U_\ KU# Y:WA9C\Q123C
MO@$_Y_R) <?A_P#6_P !^M "G\SG_/\ *HR.,#^5//''3''7_/I3#^'% "JY
M1]P__6*Q]7\.QZ@6N;(A)V.71N%<^OL?T^E:M)G!X."/2@#S^ZM+BSE,5S$\
M;_[0[8[=ORJ'^M>E&;>A25%D0]0PX-4WTO2),[[!!G^[E?Y&@#@:UM,FUJ:'
M['8R2F$\$$ JH^IZ5U*:?I,1REA&2.FX9_GFK1N#MV(H1>P':@#.TO1(=*Q/
M.?.O#G#9R%^G^/\ *KC.TC%R<DGUI"V3DGK3: %^G\Z3GWY]_I1UX/3_ #_G
M\:7W_/\ 2@ Y/3GO3Z9@'K@^M.[T +3U]:9WIZ^G7- $J\=\>_\ G_/7\9EX
M]OPZ5"IYS[Y_E_G_ /74R].G- $X_P C\Z>!_GK_ )ZG_)Y8,8^O^?\ /TIX
M_//^?ZG\_P @!V,\>O\ ];_'_/<'/)Z=?\_G_GNG4>O]?\Y_7\CK^/\ G^OZ
M_D .&<^^?UX_^O\ G2@8Z4T=?3/^?\_3\GK]/_K4 */2GT@IV.,T )2$9I^.
MWTI,=QTH BQS32.,>WY_Y_S[S=:8?YT 0GKU_'/^?\X_&%OP!J=ATZ_YQ_G_
M "*A;I0!$QQ_.HC_ )_S^%2-V/OC]:B)X_S_ )__ %T (:C/7K3B?TK'U6\G
MMYT6*3:"F<8!]?\ "@#2/I4?/XUA'4KP_P#+8]^BK_A5_3;B6Y$QE?=@KC@#
M'6@"\!3NWYTWK_A3OJ: %Y_PJ<;)XO)E_P" GWJ$"EQB@"I/;20'YAE<\,!U
MJ+\JU5G8#:XWKZ&FM!:2<_-&3Z"@#+I0<'(['BK_ /9\.?\ 7\?A3OLEI%DO
M(7]!VH IW&[4D2*6".0J>#LY_'MVJ_#"EBG8RD?@!2^>J#;"H0=\5'U/.22?
MQH 7!)RV3ZU,@Y]__P!9_P _3\XP!CD#UZ=N?\_YXGC7GZ?Y_P _2@"S$O/
M^E7$ P!V]15:%?P)]O\ /M5I<'% $@R?IUQQQ_A4R#CZBHU''^>/\]?PJ<#U
M%  <#D?7K56? 4Y QBK;<#KC%4;DX5N<8'Y4 9,V2Y.<GK_G\J6-0/P_S_2A
MA\_7M4L8SC _#% %B)>G'>KD8R>W^%5XA@9_(U:B&0!Z_P"?\_6@"PF<>]2+
MR:C7I4B?A0!*.F:>/0_YXIH]QC_/^?\ .:>!0 HY_.E"]/\ "E'..].'3ZT
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MHG0<_A3Z\=7]HWPB$Q_9VN>G^HB_^.T[_AH[PA_T#M=_[\0__': /8**\?\
M^&C?"'_0.UW_ +\0_P#QVC_AHWPA_P! [7?^_$/_ ,=H ]@HKQ__ (:.\(?]
M [7?^_$/_P =H_X:-\(?] [7?^_$/_QV@#V"BO'_ /AHWPA_T#M=_P"_$/\
M\=H_X:.\(?\ 0.UW_OQ#_P#': /8**\?_P"&C?"'_0.UW_OQ#_\ ':/^&C?"
M'_0.UW_OQ#_\=H ]@HKQ_P#X:.\(?] [7?\ OQ#_ /':/^&C?"'_ $#M=_[\
M0_\ QV@#V"BO'_\ AHWPA_T#M=_[\0__ !VC_AH[PA_T#M=_[\0__': /8**
M\?\ ^&C?"'_0.UW_ +\0_P#QVC_AHWPA_P! [7?^_$/_ ,=H ]@HKQ__ (:.
M\(?] [7?^_$/_P =H_X:-\(?] [7?^_$/_QV@#V"BO'_ /AHWPA_T#M=_P"_
M$/\ \=H_X:.\(?\ 0.UW_OQ#_P#': /8**\?_P"&C?"'_0.UW_OQ#_\ ':/^
M&C?"'_0.UW_OQ#_\=H ]@HKQ_P#X:.\(?] [7?\ OQ#_ /':/^&C?"'_ $#M
M=_[\0_\ QV@#V"BO'_\ AHWPA_T#M=_[\0__ !VC_AH[PA_T#M=_[\0__':
M/8**\?\ ^&C?"'_0.UW_ +\0_P#QVC_AHWPA_P! [7?^_$/_ ,=H ]@HKQ__
M (:.\(?] [7?^_$/_P =H_X:-\(?] [7?^_$/_QV@#V"BO'_ /AHWPA_T#M=
M_P"_$/\ \=H_X:.\(?\ 0.UW_OQ#_P#': /8**\?_P"&C?"'_0.UW_OQ#_\
M':/^&C?"'_0.UW_OQ#_\=H ]@HKQ_P#X:.\(?] [7?\ OQ#_ /':/^&C?"'_
M $#M=_[\0_\ QV@#V"BO'_\ AHWPA_T#M=_[\0__ !VC_AH[PA_T#M=_[\0_
M_': /8**\?\ ^&C?"'_0.UW_ +\0_P#QVC_AHWPA_P! [7?^_$/_ ,=H ]@H
MKQ__ (:.\(?] [7?^_$/_P =H_X:-\(?] [7?^_$/_QV@#V"BO'_ /AHWPA_
MT#M=_P"_$/\ \=H_X:.\(?\ 0.UW_OQ#_P#': /8**\?_P"&C?"'_0.UW_OQ
M#_\ ':/^&C?"'_0.UW_OQ#_\=H ]@HKQ_P#X:.\(?] [7?\ OQ#_ /':/^&C
M?"'_ $#M=_[\0_\ QV@#V"BO'_\ AHWPA_T#M=_[\0__ !VC_AH[PA_T#M=_
M[\0__': /8**\?\ ^&C?"'_0.UW_ +\0_P#QVC_AHWPA_P! [7?^_$/_ ,=H
M ]@HKQ__ (:.\(?] [7?^_$/_P =H_X:-\(?] [7?^_$/_QV@#V"BO'_ /AH
MWPA_T#M=_P"_$/\ \=H_X:.\(?\ 0.UW_OQ#_P#': /8**\?_P"&C?"'_0.U
MW_OQ#_\ ':/^&C?"'_0.UW_OQ#_\=H ]@HKQ_P#X:.\(?] [7?\ OQ#_ /':
M/^&C?"'_ $#M=_[\0_\ QV@#V"BO'_\ AHWPA_T#M=_[\0__ !VC_AH[PA_T
M#M=_[\0__': /8**\?\ ^&C?"'_0.UW_ +\0_P#QVC_AHWPA_P! [7?^_$/_
M ,=H ]@HKQ__ (:.\(?] [7?^_$/_P =H_X:-\(?] [7?^_$/_QV@#V"BO'_
M /AHWPA_T#M=_P"_$/\ \=H_X:.\(?\ 0.UW_OQ#_P#': /8**\?_P"&C?"'
M_0.UW_OQ#_\ ':/^&C?"'_0.UW_OQ#_\=H ]@HKQ_P#X:.\(?] [7?\ OQ#_
M /':/^&C?"'_ $#M=_[\0_\ QV@#V"BO'_\ AHWPA_T#M=_[\0__ !VC_AH[
MPA_T#M=_[\0__': /8**\?\ ^&C?"'_0.UW_ +\0_P#QVC_AHWPA_P! [7?^
M_$/_ ,=H ]@HKQ__ (:.\(?] [7?^_$/_P =H_X:-\(?] [7?^_$/_QV@#V"
MBO'_ /AHWPA_T#M=_P"_$/\ \=H_X:.\(?\ 0.UW_OQ#_P#': /8**\?_P"&
MC?"'_0.UW_OQ#_\ ':/^&C?"'_0.UW_OQ#_\=H ]@HKQ_P#X:.\(?] [7?\
MOQ#_ /':/^&C?"'_ $#M=_[\0_\ QV@#V"BO'_\ AHWPA_T#M=_[\0__ !VC
M_AH[PA_T#M=_[\0__': /8**\?\ ^&C?"'_0.UW_ +\0_P#QVC_AHWPA_P!
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M:Z?^V$/_ ,=K%\3_ !V\,:UX9U73;:QU=)KNSF@C,D,84,Z%03B0X'(['\:
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M]1CE7SD@YYP2:[)%XZ?I]: )%&!5I .AQ@^GXU HY&.,=_2IUXXXSCI_GZT
M3+4B5&.#3Q0!.I^G^?\ /Z5(O/\ ]?\ S[57!X_"IE.#_G_/_P"J@"0=!R>@
M[T^F>W\Z4MCV^M #J0D"F,U-W9XZ4 2%O\BD)_'GZ_Y[TPG)^O\ 6DSSG\:
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M?3M^O^<"C?+ZD?3M^O\ G K2\A?3]?\ /^31Y"^GZ_Y_R: ,W?-ZD?3M^O\
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MA?3]?\_Y-'D+Z?K_ )_R: ,W?-ZD?3M^O^<"C?+ZD?3M^O\ G K2\A?3]?\
M/^31Y"^GZ_Y_R: ,W?-ZD?3M^O\ G HWS>I'T[?K_G K2\A?3]?\_P"31Y"^
MGZ_Y_P F@#-WR^I'T[?K_G HWS>I'T[?K_G K2\A?3]?\_Y-'D+Z?K_G_)H
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M31W( 7SH)-K$#H#D$?IFF>'O 6A^&[K[5:1S37.,+-<2!F4'KC  'Y9H S?
M_A_5-%UC7I[^W$,=U/OA82*V\;F.>"2.HZXZUP^O^'7/Q*.B6TA%IJ$\=Q)&
MF,*.2<CV^;&?45[?^585KX3L+;Q//X@$EQ+?3 C$CAD0$ ?*,9'''4T 97CG
MPE<Z]964VEO'%?6#;H0QV@CC@'L1@$4_0&\<WVHHNOVEC:Z>L;K*L3*6F)7
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M'Y9KV.3P(FLZ'!J%U:"VGE@65U9B#'D9PV<'CZ5R^G6FE>'I1<8%S=,I6%,
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MM 'F%?</@AMW@#PXWKI=L?\ R$M?#U?;_@3CX>^&L_\ 0*M?_12T =!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%1SSPVT$D]Q*D4,:EGDD8*
MJ@=22>@KD_%7CH>';SPY%:V"ZC%K=R($F2XVA =N&&%.X8;/;I0!V%%0)>VD
ME[)9I<PM=1('DA5P713G!*]0#@_E65XE\7Z#X0MH+C7=0%I'.Y2(^6[EB!D\
M("?QH W**X*/XT_#V618U\1*"QP"UI.H_$E,"NTL-0LM4LX[S3[J&ZMI/N2P
MN'5OH10!9HHHH **** "BBB@ HHHH **** "BBB@ HK"\3>,M!\'6\$^NWXM
M4G<I%B-G+$<GA03@>M;,$T=S;QSQ-NCD0.A]01D4 24444 %%<M\0/&D?@3P
MRVL/:?;',R1)!YOE[B?]K!Z $]*V]&OY-4T2QU"6W^SR7,"3-#NW;-P!QG S
MU]!0!>HHHH **** "BBB@ HHHH **XG4?B$+/XG:?X+@TO[1)<Q"66Z$^T0C
M#'[NTYX7U'45VU !1110 4444 %%%% !117$W?Q"$/Q1M/!-OI9G:6'S9KOS
M]HB^5FQLVG/ '<=: .VHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBL3Q+XMT3PA917>N7HM899/+0[&<LV,\!030!MT5#
M9W<-_907EL^^">-9(VP1E2,@X/M4U !1110 4444 %%9/B?78O#/AG4-:FB\
MU;2$R>6&V[SV7/.,G Z55\%>)9/%WA2SUR2P^P_:MQ6'S?,P Q .[:.N,]*
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MY _QH ;8SWMU.9)%VP8QCICTQGK6F!C_ #_GVI1Z?U_S_GZTH'Z]?\_YZ_F
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M>JW$"8CO%$D=O%@;(U0\9 Q].@Q7-^"]-MK+]I'6X-%B6WT^U@D$D42X09"
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M,,$_3_"OJR@ HHHH **** "BBB@ HHHH 9,,Q-]*QIA\QK;(RI'J*QK@?,:
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M9,_-C^2BM:TTFWL1E%WR8YD;D_\ UNU6"/I0!7C@CMXPD2!5'845*1S3".*
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MCOE?R+B8X0!BK+ECT! QGID8KN_''Q7\/Z%H$W]EZG::GJDZF.U@LYEE^8\
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M2-& _O;1G]<T>(?"6A^*A:#6K$78M)/,A!E= K<<_*1GH.#FMD    8 Z 4
M>(^&<>(?VDM>U$_-%ID#1(?<!8__ (JNT^,>I_V7\+M88/M>X1;9>>3O8 C\
MLUT.B^$M#\/7^H7VEV(@N=0D\RZD\UW,C9)_B)QR3P,=:D\0^&=(\5:<MAK5
MI]JM5D$@C\UT^8=#E2#WH Y7P'HDUI\%+/3X5*W-SITC@=/GE#,/_0A7#_ ?
MQ7H6B>'M0T75]1M=.OH[QI"MW(L6X$ <%L9(*D8ZU[I!!%:V\5O @2&) B(.
MBJ!@#\JYG7?AMX/\2WAN]5T*WFN6.6EC9XF<^K%"-WXT >>_%/QM%XMBA\#>
M#Y4U.]OY%%Q-;-OC1 0<;AQ[D]  :Z'QC:Q> _@5=Z9;R\PV2V@D_ONY"L?Q
MW,:[+0/"6@>%X3%HFE6UGN&&=%R[C_:<Y8_B:D\0>'-)\4Z6=-UFU^TVA<2&
M/S'3YAT.5(/ZT <O\)M*?3OA-I<*+LFN8'N,^\A)!_(BO,/@Y/X/LH]:TCQ=
M#I,>J1WA96U2*,9  4J&D[A@>,]Z^AK6U@LK2&UMHUB@A01QHO15 P!7.Z_\
M.O"/B>Z^U:OH=O/<G[TR,T3M_O,A!;\: "T\7>"K6[M=*TW5M*,US((H;>P9
M7RWN(\X^IP*X_P#:$MKB?X=1R0JQCAO(WFP,X7# $_B17::#X \*>&)A/I&B
M6MO.N=LQ!DD7(P<.Y+#CT-;]Q;PW=O);W,,<T$JE9(Y%#*P/4$'J* .&\*_$
M?P<W@S39'U_3K4PVD:26\TZI(C*H!&PG)Y'8'/:MW1O%=EXI\.7FK:(LTD"&
M6.%Y$*>:RCJH/.,\<X/!K(7X/^ 5O?M8\.0>9NW;3+(4S_N;MN/;&*[*UM+:
MQMH[:SMXK>WC&$BA0(JCT ' H \&^ _B?P]H^BZW_;&K6=C?RW8D<74HC+)M
MXQNZ\[N!S6)\2_%TGQ'\1Z+I>DPS'03>K!#.ZE1<S$@,P![*&QZ\GUKVF^^%
M?@C4M6?4[KP_;O=.^]RKNJLWJ45@ISWR.:TY_!?ARYOM+O'TJ$2Z5_QXB-F1
M(.<\(I"]NXH P?BYJ"Z+\*=5"-L,D2VL>./O$+@?AFG_  PTF33/A-I5LJ[9
MIK5I\?[4F6'\Q72>(?#6D>*M-&G:U:?:K02"3R_-=/F&<'*D'N:T+:WAM+6*
MVMXQ'#"@2-%Z*H& * / _@/XFT3P]9ZYIFN:A:Z=?_:@[&[E$8< ;2,M@9!S
MQUYK,^,?Q 'C&.VT?P^'ET>.Z"2WFTA)Y\?*JYZ@#)_$=L9]GUCX8^#-?U1M
M2U+0H);MCEY%D>/>?5@C ,?<@U<O/ WAF_ATV&?1X!#ILOG6D41:)(WR#G:I
M /('4&@#)\8RKX4^#]_'&<&VTT6R=N2H0?SJE\$=+_LWX7:<Y7#W;/<-GOEB
M!^@%=EKN@:9XFTF32]7MOM-E*59XO,9,D'(Y4@]1ZU9L+"UTO3[>PLH1#:V\
M8CBC!)"J!@#F@"S1110!\_\ P[\0Z3:?%[QIJ6O:E;6$SR/'";N41@@2$$ M
MQG"KQFNR^,THU?X/7=YIDHN+5VAF\R+D/'O'/TZ&NAUGX8^#-?U1M2U+0H9;
MQSEY%DDCWGU8(P#'W(KI8[&TBL%L$MH5LUC\H0!!LV8QMQTQCM0!YOX&^(W@
M_3?AGI)NM;L[9[.T6*:V:0><&48.$'S-D\Y [UY]I6KWGQ$^/VDW]S:RV]E
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M8^_L/<^W2LC2;8:I=1VMQ<NL:*=BY_,#L/\ ZU=U9VEM90^3;1JJCK@<M^-
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M3S-XNU;4",K;60B^C.X(_1#7TM0 4444 %%%% !1110 4444 %%%% !1110
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M #UI*4]32&@!.]%(>M+0 4AH-'X_A0 WV_G2C_\ 70/I[4HH 6CO13@,>E
M*,=?:E I>G7'O0 G0]J*.?\ /?\ SS1_^N@#+N]*DN9FE^T Y_A9> /3_(]:
MHOI%XG0*^.,JWN/7'^?6NB'7^E*,^O\ G_/\J ,;21/;7#0S1.B2=,J<!O\
MZXX_ 5M]?QI.!_G_ #VI?\_Y_P _SH K:A<&WM=P/WW"D^QZ_I6==:\OV*0L
MVP*.%]:U[J".>U=).%ZY],?Y_6L74?"3W%J\T3X)'W0<<T <9;:G]H\6:<CC
MS8Y9Q%*&&05;C)]<<'_ZV:[>\U'3H;I8+V%);>5@I95P4)Z''I_GVKC;'3TL
M-9BDG(::/+*O7YNF?PZUV?\ PCUE<0M=ZC(S3,=X56(4>@XYXH L:7-86-N8
M[2"-&DY( ]3^>:JV%Q9:I?S64\/ ^82*<KG/Z=ZPKZ58]02WMYN9&"1DG^(]
M!^=-TA+JUDNE(82!LGU H NZCX8LK>Y:<S(8NJH!G)'8Y[=*TYM!;5+4W%[<
M?9\)@1Q=N/?^7ZUD/=7E[Y2K;2-%"V9'"D@=,9_*K,VMO CB7LIV ]!Q0!9T
MJXT_3KA+&["RS ;8I"!AR.WL>/QYJ74M4N[BXEACR\:+@K@'GGO7FFIWES=7
M""W!$OF*R$==V01^O\Z['3)[N*YNI)H=[A\L'';Z]N] %/6=8F:T6'8>,\XZ
MTG@9KHZG=SW%U(MFL80Q;CLSG/3IQ@_G790V^DZDD=Q<6<:K@?NV.XY_K7/:
MW-9::6^R1+%@Y9 , CI0!M:WJ$%O"KQ Q$#Y)%.&!]<]?_U5F:)XF&H64T5X
MWGW$+;"S8R5ZJ>@^GKQ7.:G->75E!(N[R)(\HP[@U<\)^&YY;2XG.%>X8&($
M\E4W G'IDD?A0!T=U:Z-J5IM+>7<,O\ $#C/UKB+J]&@7'VG3I?])CY1^N<=
ML>A]*[?^P!+<1Q2RM%M'SA3SQ_+\JS/$/AC18[=Q$\BR8X;?G)^AXH ]$LKE
M;[3[6[5=B7$2RJ&Y(#*#U]LU-6;X?U*TU+1H9+/Y4B A9.\;*!\OY8_,5H,>
MPH Q-<LK_472& (MNO)+-C<?_K?UK+3PK=G[T\"_B3_2NL_S]/\ /^?<[$4
M<W%X8EAF247VUT.X%8\X(^IKIUD.,$^W%1L3G\:9F@"ZLF>I&/\ /_U_UJ3J
M/I_G_/U_*@KXR<C_ #_^NK"2Y[<=_P"5 #V7K^E,(Q[BI=P*YR.G>D<8)]\Y
M]Z ("/3/YU#@ _AZ_P"?2K!'./ZTPCKS0!$%QQ_D]/\ /XT]5]NU.V\_CTIR
MCT[T *%S^'-2!<#OCUQP:55[=1G\_P#.*D"YY_7K0 JJ1V.?;_/^<5,H _\
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MEE4'T)4GFKE<SX)\#:7X#TN>PTJ:[EBGF\YVNG5FW8 XVJ!C ]*Z:@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M W'/M_\ 7_\ U4H& ,<\^E'Y?Y_S_GNH'^'^?\__ %P!0/3\/\_E_G-*!P*
M/\_E_G\/QIP'3_/^>G^>* *&K2/#8AD'.\ _3_\ 6!6!>:YMM9A(,MC _P _
M2NNDA6>$QL/O'(X[YXK'U3P[826A>:98V/ +''- 'G%O>R3^([,J&P)#CG/8
MUUMQJ<]HCA@Q)CP,\XXJKINE6VFR27\DL;R0J1&!T!/!.?Q_6I8/%^F230Z?
MJ%BS--*(UEB(P,]"0?YYH XR_EN+V[C"95FE7:1ZYKTK4M8BC\N=$A+.W*E>
MHSZ_C_.L]M)TRWOT)E"M(3L+D*!^-0:MX6U-7B$67)8!5/'\Z .BM]4B$)@
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M''_UJ:K]OTJ4,#P<=>M #/+;VSZ4]8_3/(_S_6GAN_\ G_/_ ->G\9QCMZ4
M(B=/;U-2A<#U]Z9O_E2[O04 .)P*K2.6.,_AZT]VZ$XHMX6FE48_*@"[IEKN
M;>?NCFMKH,"HX8A#$$';K4E !33&C#!44ZB@"+[/$?X!3EAC7HH_&GT4
MP!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ^U?0%?$GP]D\KXC^&V]=2@7\W _K7VW0 4444 %%%% !1110 4444 %%%%
M$%VNZ'I6#-P>O2NBE&8F^E8-P,.V/7UH K=#R.AST_S_ )%-/IU_S_G\Z=VX
M''MWZ_XTC'OP?QZT 5WX%59/K_G_ #_.K;C&>>AZYJI)U.?\_P">: (#^/YT
MPYY]1_G_ #]*D-,P,X[>E #/\\_Y]Q^M!_K_ )_K^M+U]SWYZ_YX_P XI/J?
MU_S_ )_"@!!QCVQU_#_#^?I2CIT_SC_/ZT<#_/\ G_.*!^'^?\_RH =_G/\
MGZ4O;Z?Y_P ]*3//O2C[OTZ4 !]/YTT^GK_G_/\ G#F//T--/3_/^?\ /M0
MAZ_Y_P _Y_)IZ?Y_S_G\@^F<?Y__ %?Y%!^F/\_Y_+VH 9S2'FE--H .U(:7
MK1[T -I/Q_"EI!Z<T ';GZ]:3O2G_/-'M0 <^OZ4X=:;BG#K0 X<DX[_ .%.
MQW]O\_Y]*0=.?3!I_?\ ']?\X_SF@!,?_6_S_G^5+CG\?_U?Y]_IDP/T_/\
MS_6G]<]^/S_S_7WH ;MXX'^?\_S]Z![?_KZ?_6_ST=COP1Z_Y_SS1CU!_P _
MY_SF@!GIC_/^>/\ /11T&/T_S[?Y[+CI_GTH 'ID?Y_I_GU %_7^O^?\^E.
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M2BL./UJLPFTZ-HHP1$C<$8^O/X&N;U_5)KR8X4J>./:@"M]BBLIA.[K(T9.
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M'_\ 0J:'_P""Z'_XFN@HH IZ=I.FZ/ T&EZ?:6,+-N:.UA6)2?4A0.:N444
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M;R[68RHV]MF,!02PY9SR!^M>HT4 %%%% !1110 4444 %%%% !1110 4444
M%>?ZMX#OO%7C^'5?$4MK)H.G+_H&GQNS&1^,O*" /P&>@'U] HH 0    8 Z
M 4M%% !1110 4444 %%%% !1110!FZ_<:G:Z%>2Z-9?;=1$9^SP&14#.>F2Q
M P.O7M7*?"[P1<^%-(N+W6")=?U.0S7LA8,5SR$R.N,DDCN?85WM% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5S'Q&C,GPV\2*.VG3-^2D_TKIZPO&L?G> _$4?\ ?TRY7_R$
MU 'QMX1D\GQIH4N<;-1MVS])%K[FKX-TB7R-;L)?[ES&WY,#7WE0 4444 %%
M%% !1110 4444 %%%% !6%>+\YSSQ6[63J*_/WYS0!EGWQ[_ .?QI#U/)X')
M'UIW?_/^?7_/5#TY_G]/\_E0!"_],54DSG/KWJX_).:JR\_C_G_/^< %5NG?
M'M3?P[\BGL 3T_*F''0_E0 WMZ_UI/KSC_/^?\Y4^YY]:3O_ )]Z $[^O]?\
M_P!:7'4'TZ^O^?ZT?3]/QHQZ?Y_S_GI0 OK_ )]:/I1_04O?G]?K0 F??C_&
MF$_A_D?_ %_\BG'('^??_P#72'CIQC_/]/T_, 9R*0G'X4O:D_'_ #_DT -S
M^%)T-!_SBDH =29/8_K29]:#_GF@!*04M(0/2@ /^>*/\:3KZ?G2X- "T\#Z
MY_G31WIWKQV_S^M #AZ=>W\Z<.??/^?Z_K[4T#DT\>HZ_P"?_K?F: '>_OG]
M12@=OPI!QT_#^7^?K3AV_P ^E "=<?6@>OY_K3]N1U[<9HQWH 8: /\ )_S_
M )Q3L?EZ4!>*  #M4BC+8]?6D YP*E5>V.W2@!Z#/X_Y_J?\XJ9?6F(.<_Y_
MS_GZR@8H 41JQRP4]N:XDZE:R7BSR6\22 \/C[H[5W:@]N.U<QJ/A/[1)(T1
MPK,75L\C/.* /.?$^L&0R!)&)!^4]QC^M5X/#]WJIM]R%//C20L1P@89S^&:
MWU^'U_>ZH8=I6#(WS., #OCW]O?\:NW5EJ-DH"*V8EV$,?NX_P * '_:-"^:
MUO9A:H@^5G^[C_>']:S[SPBMQ<J;6>.6&4 JR,"#GN,=N]=#H]GI]I;!I(EG
MO'4,S. 2#[>@ZC\*ABU6.VN)GC15&0!CH/\ /^% &3J=C?Z1ISP*JB$*!\K=
M /UK.\*VD;7D]]=1&7:"B#;G;GJ1Z'''XFM37-3-Y<QVZS9\S 8GWZ_E70VE
MS:66GFVM(T147GC@<?K0!2DTW2]1A -P$G881/XC@=A5)_!UGIGE7?VHM.AW
M ' 7/;_.:PM2\1?8=5CND &&VN,9^4D#CWJ_J^N$V6QMV_/)/6@"S:^(8H)'
M-Q 9T7"LH/S#'I61JFHZ?J]]:V^F:=,MQ/*L0\P+M!8@=CSU]JM?#;2YO$'B
M74HI@/LXM-S;CQO#J%_'!:O5?#OP_P!/T/4O[1=O/NE)\KC"QY!''J<$T =-
M::=:V5K%;6\02&) B*.P'055OM-5U+1C'J*U** .,>-T?!% YKHK_3UF4LJ@
MGTKGYHFB<Y'?\_\ /% "'VI":3=FD[4 !_\ UTPY-/S_ #I#TH CHIVWVI,"
M@ 'KZ5*HI@'_ -:I%H =3QCM35X(.<<T]>GT'/\ G\: '#IVX]_\_P"?K3CC
MG\C_ )_SW^M-'3&<$"@M@].A]: '$^_U_P _Y_PFMH6ED  Z]/I4$2-(X &1
MTZ5T%E;"&,$_>- $T,0AC"@#WQ4E%% !1110 445XM\4?BUK'A/Q+'I.DVMJ
M^(!+(]PKGJ3@ *R]AU]_:@#VFBOE[_A?OC#_ )]-)_[]S?\ QVK%M^T%XG20
M&YT[3I8^ZQ>8AQ]2[8_*@#Z9HZ#)KS?P+\8-'\83BRF1K#43]VWE;(?UV-QN
MZ=, ^QQFO19#^Y<@C[IYH ISZUIMK(L<]Y#&[= \@!/YFKD<J3+NC;<*^+O'
M7S^/_$!;YO\ B83 9.3@.>*^E/@MG_A5ND<D\2_^CI* /0**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[7]431/#NI:J^"M
MG;23X/<JI('XXQ6C7DW[07B!=,\!)I*,!/JLX3'.?+C(=B/QV#Z-0!\Z>&-(
MF\5>,=.TPEG>]NE$K=]I.7;\%W'\*^XT18T5$4*JC  Z 5\S?LZ:"+[Q=?ZU
M(JE-.MPD>>HDER 1_P !5Q_P*OIJ@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"J>K6;:AH]]9*5#7%O)$"QX!92.?SJY10!\Q6_[.?BW<KR:GHT>#GB61B/\
MR'7T[110 4444 %%%% !1110 4444 %%%% !6?J2_*#6A5:^7=!0!@'K]/\
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M_P#G_)IZ_A2#K_GVIPH 6BJ]G?6>H"0V=W!<")MDAAD#[&]#CH?:K6W\?I0
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M5^BB@ HHHH **** "OE;XZ<_$AAZV<?\VKZIKY5^.F/^%D-G_GTC_FW^?\:
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ML4;E'4]00>W4$?6OK7X8>(IO$W@:POKH@W6TQS'U="5)]LX#?\"H [&BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_G_/_P"N@!5'?_)X_P#U_P"<U*O_ .NF 9Z]ZE7..E #P.AJ10<\<]^OY4T
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M!(W:NA33(5ZY-6$MHDZ(/QH PX-.D=NAX/<5I0::D?WL?05?Z=** $551<*
M![4M%% !1110 4444 %%%% !7RM\<_\ DI+$=?LD9_5J^J:^5?CI_P E(?\
MZ](^OU:@#A],U[5]%65=+U.ZLEEVF3[/(4W[>F<=>I_,TL]UKGB2YC2XN=0U
M2X&1&CR/,1TX4<_I7L/[/-K;W*Z^L\,<@WP8W(&Q_K?;Z5[S%9V\*[8HE1?1
M>!0!\]?#;X-ZA<:G!JOB.W-K:0L)([1_OR,.F\?PK['DU]$.H2W91P IIX
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M_KZE[8_NT >IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1110 4444 %%%% !1110!B:@F)&';WJ@3^?7TK6U)/GSZ]ZRCZ#G_/\ ]?\
ME0!$XY/M^M02^N>G^?Z58;H>O^?\BJ\O^?\ /Y4 5F_^MR:B-2M^N,4P]30!
MD:CJ-W82C]Q&\3?<;)_(USD\QGGDE*X+L6P/SKM98DEB:*10R-P5KE-1TU["
M7@[H6X1_Z&@"C].<?Y_H*UK'5;E(XK2"W61AD+SR>_:LN*)YY%CC0LS= /\
M/^<5U>G::EC&>C3-]Y^N/8>G]: +D9;8OF%-W?:>/PKR;XO>)7DD@\,V+%G<
MJ]R$ZDG[J?U_*O6^17(Q?#O18O%#:_)->W%V9C-LFD4QANW&T'CMR>U '!V'
MPU\;V%KLLM>@LXW^=H8KR9.2.X5<9XQ^%<KXATW6/#7BJV.L7HO+P&.?SQ*\
MF0&P!N8 \;:^D#^N?3_/^0*Y7Q/X&TKQ5=07-_)=QR0Q^6OD2*H(SGG*GUH
MY;XQZ@!HNFVB-@7$QE(]55>/_0JN>"_$_AS2_ ]JDFI6\4D"$S1.P$A8DDX7
MJWMBN3^)I^U^+]-T>$LZP01PKN.3ECW]\8KL[SX4^&[FX\X"[M_[T<$H"$_1
ME)'X$4 <7X/AG\6_$J76S$5MX93<-D9V]HU^O3\C52ZNHK#XP27.I-LBBO\
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MX?T76GC?5=(L+]HP0C75LDI4'TW XJY;6T%G;1VUK!'!!$H6.*) JH!T  X
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MJ/) %8I@,0),X/MD?Y->\4Q(TC^ZN*?0 4R7_5/_ +II]% 'Q;X[1X_'^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\P_M&V_E^/M/G  6
M734'U(DD_H176_LU7.[0-=M<G]W=1R8S_>4CI_P"LG]I>VVZCX=N1UDBGC_[
MY*'_ -GJ3]FSSX+SQ!#)!*D<\4+J[(0I*%P0#_P.@#Z#HHHH **** "BBB@
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M_P#"^N7.B:@?#VL955;;"['[A[#_ '3V/;/IT] H **0$'H0<''%+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%9
MGB'7;/PUH%[K%^X6WM8RY&<%CT51[DX ^M 'D?[0?C86.E0^%+*7_2+P"6\*
MGE(@?E7_ ($1GZ#WKY]T72;K7=:LM*LUW7%W,L2>@)/4^PZGV%2^(=<O/$OB
M"]UF^;-Q=REV /"CHJCV   ]A7L7[.OA+S]1O/%5S'^[M@;:T)'5V'SL/HI
M_P"!GTH ][T32+70-#LM)LUQ;VD*Q)QR<#DGW)R3[FK]%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 A1696*@E>A(Z4M%% !1110 4444 %%%
M% !1110 4444 %%%% $<XS$WM7/RC:_O_G_/XUT;#*,/45S]T,2-]<]: *C=
M/P_#_/-0/]W_ #Z58;@],8_#'/\ G_/6N_"YSC\_2@"L_4_Y_P ]:A/4U,W4
MX]>/UX_E41_#\* &9I,X_"E/6D- !GC&:7]#VIG?]:<./RY]Z '"FL>/7/;U
MIU-;KW% $9/^?\_7]?RC/3C\_P!:>W';_/\ D?I^;#U_''3_ #Z4 ,)I#_\
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M=.O+>60O)',)"S')(<?KRI[GK7:5Y7\/[PV_B3R"3MN8F3'N/F';V;\Z]4H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX_\  ?2@#TS2-*M-#T>TTNPC\NUM8EBC7O@=SZD]2>Y)J[110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEO(\4TD#2J T<+E1Q[>OO67J/C5K*Z'VN5[BV4X??R\?N#U/T_K6=/)>V>)
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MT_57C=;."X661LXW(#\P'KG&#VYYZT 9FK6&J0_N98G&#@'''/\ /I70^$=
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M\+>&[+PGX<M-&L%_=6Z89R,&5S]YS[D_X=JV* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"$V*.4_LX'!QGS^O\ X[74H.!C\,5Y3+_K7SS\QH ZT^.N/^0:!Q_SW_\
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MZK< _-Z=\4 =+;7LWB^R74MW^EX\B?:#]].,^G*[2<=R:SQI][;:GY]URT8
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ME,JT4JJ>)$(((Q],X]P#5F:"]2%)[4%T9 05R!C''X8Q0!>!##(Z$D]>F?\
M/ZUU_@;4XX;B:QE< S8>,GNPX(^I_IBO-=#OI"S6=R&#@GRR1Z]16X">&!([
MCO\ C0![56=K.KP:/8M-(09",11YY9NWX5Y_!XKUFWB\H718*, R*&(X]2/Y
MY_PS+J\N+R<RW4SRR$?><\CCMTQ_GWH W+'QGJ5O<%[EUN86.60@ CG^$]OH
M?3%>@V=W%?6D=S"28Y!D9&#7F&A:+/K%\J+E8$YED_NCT'N>WTSBO4X88[>!
M(84"1QJ%51T % #Z*** "BBB@ HHHH **** "F2RQP0O--(D<4:EG=V 50.I
M)/05C>)_%VB>#].-[K-ZD"G/EQCF24^BKU/\AW(KY@^(WQ9U7QQ,UI;[['15
M/RVRM\TOH9".OTZ#W/- '5_%;XU-JR3:#X6G>.Q.4N;Y?E:<=U3N$]3U/TZ^
M(444 /BBDGF2&&-I)9&"HB#)8G@ #N:^N?A-\.H_ V@>==HK:U>J&N7Z^4.H
MB4^@[^I]@*Y3X*?"O^RX(O%.O6W^GR#=96T@_P!0I_C8'^,]O0>YX]NH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IDG^J;Z4^D;E2/:@#FKL?O#Z9-4G
M^[CUXK0O.)#]2:SI3\M %60@]#U_S_6J[<DC\O\ /^?Y5,QR>M5V(/T[_P"?
MI_GU $)S_/\ S_GO3?\ /'^?\Y^E+S^/?CO_ )S_ )/*>_\ 7_/^?U %_P _
MY_/_ #W4?Y_3_'_/=O\ G_/^?ZTO3_/^?\_C0 \=.O\ G%'MT!IN<?\ ZO\
M/^>*7O[>O^?\]: $//\ G_/O3#US3R>Y_'_/^?TJ,GUZ_7O0 QOZ4G>E)_S_
M )_SQ2'W]?2@ HHI: $[4"BE'<^U "X]NW^-. XQCU&*;W[4Y?UH D'J._\
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M(VT#=R2>U>E_#3P^N@^'YE;!N9YR\K#IP   <=!_,F@#,;P1JR/A?L[#L5?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS2]/SH ;3OK28['/O1_.@!1U^A_*G@=NOM_GZTT=/Y"G]CW'//Y__7H <HY
M'/\ D?\ UJF1>@_IVJ-5Y_'_ #_G_P"O5B-><X_3B@"S$O?'/>K,8R./6H8U
MX  ]O\^]6D!]/P(H E3_ "*X[Q)X;,&^^L4_<]9(A_![CV]NWTZ=DO2IHAN<
M#]* .'\)>$WUB1;R[5DL%/3H93Z#V]3^'TI?$?X3Z[XV\6V-U;WFG0:+:PQP
MK"[NKJN<OA0I&?3D=!7K\,:PP)&B!%0 !5& !3Z (X(([:WB@B4+'$@1%'8
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M8S[U[E80"UL((0,;$ (]^] %FBBB@ HHHH *\:_:*U_[#X0LM$C?$FHW&^0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!\F?'G3#I_Q1NI\86^MXKD#_@/EG]8R?QKU/]G74S=>!;S3W;+65ZVT>B.H
M(_\ '@]8'[2NF<:!JRC_ )ZVTA_)E_\ 9ZROV;M3\CQ3J^F%L+=VBS >K1M@
M#\I&_*@#Z4HHHH **** "BBB@ HHHH **** "BBB@##U%?WI[^N:R)/NUMZD
M#YAZ\UBR_P 7/'OWH SY.IYJLW<_Y[?_ %_\BK<HY/OUJJW/X_\ UJ &=\9^
MOY?Y_P#K4=?ZY_'_ #^=!]/\]O\ ZU)GGCM0 O;/YT[///K_ )_S_D-&/\BE
M'^'^?\__ %J %'/_ -;\/\_E1G/X^G^?\\>E'7KW]_I_C^M!Z<_C_G\_SH 3
M/^?R_P#K4PGFG'J<TPYR<T (:2EI* %S2CV^E-I1GTH <>YY'^?I[T'TS^M
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ME;2W#RK<VH\TN&8G)4?,#SSQ7UQ10!\#W5E=6,GEW=M-;R?W98RA_(U  20
M,D] *^_B 1@C(IJ11Q_<15SUVC% 'P]IW@[Q+J[ 6&@ZC< ]&2V;;_WUC'ZU
MZ!H'[/?BO4F5]5FM=)A)^8.WG2X]E7Y?S85]244 >>^%/@SX2\+LL[6IU.]7
MD3WH#A3_ +*8VCZX)'K7H5%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIZ=: #IS[?Y_E0>/SQP/>E/K_G_/^--/O^/% "9XIAIQII_2@ I*6CM0 "E
MXH%+U'J>M  ,4?X?TH_S_.G?0XZ]Z #U_P _Y_S^$R#/N/Z?Y_E4.,>W]/\
M//\ ^NK"#!Z8H L1+S]?\_Y^E68U_ ]*AA7'KQ5N->F.<8% $J# X!]0,?Y_
MR*G!"C/M4: 42OM7ZC_/^?\ &@"-3YDP[@5TMM'Y<"COCK6!IT9EN <=^IKI
M0,#'I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX_SZ?Y_^M0 PTA(Y_K_G_/Z4[^73_/\ G^E,_K_A_P#7H 3VZTTTX]Z/\\4
M-_6C]:,<T4 .'YTX#G_/^?6FCG\J?C_/I_G'Z>] "@<<?K_G_/-2#UP<=:0#
MBI O>@!RKT ^E68QD=_\.E0HOZ^W^?\ (JTB^N0??_/^<T 3(,\?TJR@_7!Z
M_E4*+QR.U3CIGKWH BN&PG ]\ 4[2X#+< ]1GK5:<[VQZ]:W=(M]L1D8<GVH
M TP, #TI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 4444 %%%% &3XEO)]/\.WEU;2>7-&H*-@'!W =^*\T_X33Q%_T$B?\
MMC'_ /$5Z+XQ_P"12U#_ '!W_P!H5XX><_Y/^>: .MT7Q9KMUKEC;SWY>&2=
M4=?)09!..H6O4J\3\.<^)=-XS_I"'/X_2O;* "N8\>^+)?!7A>36X],.H+%(
MB21";RMJL<;L[6[X[=ZZ>LOQ)HT?B'PUJ6D2@;;NW:,$]F(^4_@<'\* ,/X=
M>/8/B!H,VHQV?V*6&8PR0>;YFW@$'=M'4'TKH=<U:#0M"OM5N>8;2!IF&<9P
M,X_'I7SO\ -6ET7QUJ/AZZRGVJ-EV'M+$3_3=^5=Y^T%K_\ 9O@:+2XWQ-J4
MX4@?\\T^9OUVB@#6^'GQ1E\>0:K<'0C806"*V_[5YN]B"=OW%QP/UJ'X<?%L
M?$'6;O3QHAL/L\'G!_M7F[AN QC8N.OK1\)_#W_"/_"5&D39<7\4EW+N']Y?
ME_\ '0M>9?LX?\CEJG_7C_[.M 'TQ7A^N?M$KH^O7^FIX7,ZVEP\'FF_V;]I
M(SCRSCIZFO<*^8/ O/[1]SSG_3KS^3_6@#J;']I:PDG"ZAX:N+>'N\%TLS?D
M57^=>O\ ASQ-I/BO2EU+1[M;BW)VMP0R-W5@>0:C\3^%-(\7:3+8:K:1RAE(
MCE*C?"W9E/4$5\[_  7U"[\,_%B;P^\I\FX:6UF3LSQ[BI^ORG\S0!ZKXZ^,
M"^"O%UOH)T,WGFQQR&?[5Y>W<Q'W=ASC'J*]-!RH)&,CI7S#\=/^2NV.#_R[
M6_\ Z&U?3L?^K7Z"@!U<M\0/&2^!/##:RUB;T^<D*PB7R\EL\EL'' /8UU->
M5_M!?\DS_P"WZ+^34 <I_P --?\ 4H_^5+_[57;>!?C/H?C34$TQK:?3M2D&
M4BE8.DF 20KC'.!W K!^"OBKPYI'PTBMM3US3+2=;B9FAN+I$?!/7:3GFO,M
M.BM?$7QZAF\*PD6!U%)XS%&558U(+OC^%203^- 'UI17"_$?XFZ?\/[.$/ ;
MS4KCF&U5]H"CJS'G _ Y/XFO-'^-WQ!L(TU+4O!L4>D,01(UI/$&4],2L2O/
MKB@#Z%HKD]$\=6?B7P'<^)-,3#0P2,\$O6.1%)*GID=.>X/:O*-'_:%UB[T^
M:";08;W6Y90EG!91N$(P<EAEF)SC '7VH ^@Z*^?](_:!UFQU_[!XQT*&SB#
M;9?(ADBE@XSED<DGMQQ3=7^/7BHI_:FD>%5BT'?L6ZO()7#G./OJ0BGMCGGN
M: /H*BN3^'OCFV\>^'/[2B@-M/%(8KB MNV-C/![@@UY58?M"ZC%?ZI;ZII%
MM.T;&.QALU=6D??@!R6;C'H.M 'T#17ST/CWXLT;6HH?$_A:&UM9/F\GR98)
M@A/W@7)#8Y[#..HKV77?%,.E>![KQ/:P->PQVHN8HP=OF XQSC@<\\4 =!17
MS^_Q?^*%RANK'P*/L9&Y6;3KF0;>N=X8 _7%=C\+_BXOCRZGTR^L$L]2AB\T
M>4Y,<J@@' /*D$CC)^M 'I]%>->,/C-?>$?B6VBW-G:/HT*JTKK&QG.4SP=V
MW.<=17/:E\>/&=MY6I)X2AMM%F8>3)=03'S![2Y"DGV!_&@#Z&KF-*^(?A77
M-?DT/3=5$^I1EPT(@D7[GWOF*A3CV-8,GQ%U#6OA<WBCPGI+7>I"18VL6B>8
MHVX!QA,%L YR*^<_"6O>(M)\>/JNC:3]LU@M,3:?9I),%L[_ )%(;CGOQWH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC_TQ@_F]:_PF\P? CQ 6SMS=;?\ OT,UD?LT#_B9^(C_ -,8/YO0!]$T444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S-13Y\UIU6O$W(/RH
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M(6FW7,2*N 0",J['//I7?UE:=X9T#2+DW.F:'IME.5*F6VM(XVP>V5 .*U:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(ID_NR(&'Y&I:* *UKI]E99^R6=O;[NOE1!,_D*LT44 %%%% !1110 4444
M%-DC25"DB*ZGJK#(-.HH H+HFDI('32[)7'1A;H#_*K_ $&!110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!>6D&H6-Q97
M48DM[B-HI4/1E88(_(U/10!\)>(-&G\/>(=0T>X.Z6SG:$MC&X \-CT(P?QK
M[ ^&GB,>*?A_I6H.Y:Y6(07))R?-3Y6)^N W_ J\6_:*\-_8O$]CX@A3$6HQ
M>5,0#_K8\ $GW0J!_N&KG[.'B3R=2U/PW-)A+A/M=N">-ZX5P/4E2I^B&@#Z
M*HHHH **** "BBB@ HHHH **** &2+D<=?I5.9>">@/-7ZJ3#!QB@#,E&#5:
M3]1WZ?Y[5;F'/XU58$<\<>E %211SBJS)C/7_.?_ *_^>MR0#\O6HF7/;- %
M-UP:CQ[5;=< \] 3_/\ S_DU"T?IZT 0$8'^?>FX[=1Z5)BC'- " ?0GUQ4B
M#FF@=A4R+Q_(_G_@* 'JOKVZ_P"?\]/K3PI';G_/^/KZTJKSQV_3J*>%&.0.
M1C%  J]L?2ID&/7L>#3% /<9J90.N,#V[_Y_S[ #AD 9S_G%/BC,TN/4_P"?
M\_XTS;GC'U_PK8T^VV+YC#D].* +<,8BB"BI*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KR+XC_  1M/%%S<ZSHMR;35I<O+'*Q:*X;
MZ]4/TR/8=:]=HH YSP-X3MO!7A2TT>WVM(H\RYE _P!;*0-S?H /8"NCHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ,*T)T*L?8X_S^E4I!U^E %8Y]?U_P _YS413_/K4[<'\>Y]Q3,8Q[8Z]O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 50UG6+'0-'NM5U&80VELA>1C^@'J2< #N2*OU\L?''QOJ>M>)YO#[0
M3V6G:=)M$,@P9W_YZG_9(^[[<]^ #C_'GC6]\=>))=3N08X%'EVMOG(BC[#Z
MGJ3Z^V*]Z^"7PV_X1O2AX@U6#&K7J#R8W7FVB/;!Z,W?T&!QS7#_  1^&)UF
M[C\4:U!G3H&S:0NO$\@_B(/\*G\S]#GZ5H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .3^(ER8/"SQJ<&:54//;K_2G_#^V2#PK%(!\\\CNY/7.
M<?TI_CRR:\\+3E%W- RRX]0.OZ&J?PXU&.XT%K+=^]MG/'^RW(/YYH U=?\
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MIO%\D^JZO=S^67*KM/S,>IQD$!1GM^E:E]\/9+&2.\T"\E2YC8$+*P!//4$
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MN/SKOJ\M'_%,?$K&"EO/)CM]Q_\  _RH ZWQUJ7]G>&9PK8DN#Y*?CU_2H_
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ML .ODG'YFO-O#.BRZWJ]U;)?O92HI<LBDD_, 1U'K[T =Q-\.-$>V\N-KE)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \+_ &BO"/VG3[/Q5;1DR6V+6[P/^69)*-[88D>^\>E>=?!?QDOA/QO'
M#=2A--U,"WN"W1&_Y9O^#'![88GM7U?J>G6VKZ7=:;>Q^9:W430RKG&588//
M8^]?$'B?0+KPMXEO]%N^9;24H'QC>O56'L5(/XT ?=-%<%\(O&/_  F'@>W>
MXEWZC8XMKO)Y8@?*Y_WEQSZAO2N]H **** "BBB@ HHHH **** "D(##!Z4M
M% &5>VA7++R.]9K94G()SV_S^%=,0&&",@UFWFG@@M&!CN#0!E;O?OUS_G_)
MI#_D?Y_SUHDB9#R#QZ^E1[B.N3]10 ,O;C.>PIF#Z4_.>.WKZ9H W$<=_IG_
M #F@!H7MU^E/4<Y QSV_S[5(D+-CY?TJE?:I!8Y15:>;(&Q%+'MV'TH T(XF
M8C ^GM5R#['!S/=0)CC#2 5S%]_:$-M#<7\JP+.VV*%&#,1U)/\ #_/K7.:A
MXCTZVC(CDF.T8\Q3\N?SH ]<BO+24A(;F!SG ".#4]>1:!XETO6;2XL[F%3J
M$6,,!A'C(^\??/!&?3'?%B7Q4ND2'[#JA+Y_U4A+Q-[<].>XP: /5:*Y3PGX
M[T_Q.OD'%M?HQ5H6.0Q SE3WXYQUKJZ "BBB@ HJO>7D%C;F:=L*.@'5CZ#W
MKD;C7=0U;4!96[Q6,3D!7F;;N]AW8_D/K0!UT]]:VW^NG1#Z9Y_+K51O$&F*
M<-<D?]LWQ_*O/M3O['1[NXBDD>X,#>7\Q WOW..@_6N6U'QB;:Y+VT:P3+R
M3O5AZ$>] 'N$&KZ?<OLBO(6?^Z6P>W8\]Q5VO*F\4:1JVEV]^;40Q3+Q""'<
MMT89]B#60/B+)H4H:Q=GMHS^\LYCP1_LGJO7MQ]: /;**R=!\0V7B"T,UJQ5
MT \R)^&0D9'X'L:UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BF2RQP0O--(D<4:EG=V 50.I)/040S17,
M$<\$J2PRJ'CD1@RNI&001P01WH ?7,^+O 6@>-HK==8M2TENP,<T3;) N<E<
M]U/0CWR,'FNFHH BMK:"RM8K6UA2&WA0)''&N%10,  =A4M%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M   P:]-HH Y;P3X<DT/3I)+I0+NX(++G.Q1T7Z\DU1\;^&+N^GAU?3 S74(
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M0R-_%].@XZD9KU']GJ]\2R:+<6EY:LWA^/+6ES*V"KY^9$'\2]3GL<]<\5O
M/P BM6CU'Q>Z3R@ADT^)LH/^NC?Q?0<>YKW*&&*V@C@@C2*&-0B(BX55'  '
M84 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M 5O[.LOM?VO[';_:<Y\[REW^GWL9JS110 4444 %%%% !1110 4444 %%%%
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M:2$F48P-^< @]N_U_*NEU72M*@LC$I RO)SU/7N?6@#G]9\427S+:O;Q/YV
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MC<I)JMBCCJK7" C]: -"BF1RQS1B2)U=#T93D&EDD2*-I)'5(U&69C@ >I-
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M_F:W?B-_R*C?]=T_K0!TEA?VVIV:7=G)YD$F=K;2,X..AYJS7.^!O^10LO\
M@?3_ 'S714 %<%J'CK49]5DL- TY+DQ,59W1GW8XR I&!GO78:AJ5C8QE;J]
MM[=W0[%EE5"WTR1FO._AU?6-G=7\U[=V\#NBA6FE5<\DGKU[4 =IX:U74]3@
MN!JNG_8YX6 QM90X/< _XFMVHK>X@NX5FMIHYHFZ/&P93^(IEU?V=D ;N[@M
MP>AED"9_.@"Q152UU/3[YMMI?6UPP&2(IE<_H:MT <AKOBJ^TSQ7::5!%;-!
M,(RS2*Q;YFP<$'';TKH]5NGL=)N[J(*9(8F=0PX) [UY_P"+O^2BZ=_NP_\
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MSAAP1T96'H1D&@#[JHK!\'^+-.\9^'H-6T]QAQMFA+9:"3'*-]/7N,'O6]0
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M]W 7_P#0<UGS>#O%%N,S^&]8B'^W8RK_ #6@#[=M;VTOHS)9W4%P@."T,@<
M_45/7D/[/.G7-CX*U(W5M+!*^HL-LJ%20(X^<'MR:]>H ***^>/CWXIUW1/&
MNG6VDZS?V,9T]96CMKAXU8F209(!P3\M 'T/17Q=#\4?'$!RGB;4#_OR;_\
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M"H*_=(XQ0!X[XHT+4/#T45HURT^FM(7@)X"M@Y&.Q_0UZEH'_(NZ;_U[1_\
MH(KE?B?_ ,@NP_Z[G_T&NJT#_D7=-_Z]H_\ T$4 <%X0'_%P]0X[S_\ H?\
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MP5<:XO\ :7B*[G,THS'$A *+VSD''^[BH?BAS)I@'/$G'Y5Z#;?\>D/^XO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ]#8QEFM;=_+R,XPO+G^GY5Z@ %4*H  & !VH 6BBB@ HHHH **** "BBB@
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M;NTM[^TFM+N&.>WF0I)%(N5=3U!%?,'Q.^#-YX5,^L:$LEWHO+R1]9+4>_\
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MNEBQ\[S]O[SS=NW<<=-IKI:\T\9_\CYIF?2+_P!#- 'I=%%% !1110 4444
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MQQ=OH6X.,] .]>AT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<T[1?&4NFVLEKKENENT2M&NYAM7' ^YZ4MYX3\8:A;&WN]9M982<E&D;&?\
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MVG8=&EB5B/S% 'F=K'>>.O%:WDD#1V,9&[NJH,X7..23_.O0/$P_XI?4P/\
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MY'-6*** .+^)>/\ A'[?_KX&!Z\&L?1/%5[X9M;>SUBUDELWB$EO+'C(4C(
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M<CI-Y0W_ /?6,T 6:\SN?^2N18_YZJ?_ "'7IE5CI]DUV+LV=N;D=)C$N_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!G'7]&4D'5[ $<$&Y3_ !H_X2#1?^@OI_\ X$I_C7BDY_?R\_Q-W]S[
M_P"?Y,/?K^!^M 'OR.LB*Z,&1AE64Y!'J*6J>DY_L:QSU^SQ_P#H(JY0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!FSZ!I=SJL>IS6@>
M\CVE9-[<8Z<9Q^E:5%% !1110 4444 %%%% !1110 4444 %(RAE*L,@C!I:
M* ,[3-"TW1FE.GVHA,OW\.QS^9-:-%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% &=JFAZ;K(C&H6WG>6<I\[+C\B*O0PQV\*0Q($CC4
M*JCH .E/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ,W4- TO5+J*YO;42S1 !&WL,<Y['UK2HHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***XK
M7/%NL:#?&"XTZW:-N8I0S8D']#ZC_$4 ><S$FXE.3]\^_<U$1\N,=L>P_P .
M]/=R\K,PY9B<$^__ ->F<=/PYQ_G_P#70![II7_('L>,?Z/'Q_P$5<KSW0O%
M^K7K6NFV6FV\A2-4WM(V%  &YL#BO05W;1NP6QSCIF@!:\PU3XP+IOQ,3P<-
M#,NZXC@-W]JQ@N <[-AZ9]:]/KY?\4_\G+Q9_P"@C:]_]E* /J"O-/B1\7%^
M'VKVFGC1#J#3P><7^U>5MY(QC8V>GM7I=?,_[2'_ "..E_\ 7C_[.U &W'^T
MRAD42>$F5,_,5U#) ^GEC^=>D^"?BAX=\<LT%A+);WZKN:TN5"N1ZJ02&'T.
M1W KIH;6VOM%@M[N".>"2!0\<J!E8;>X-?+?Q(T4?#/XH6]YH1:WA.R\MD5O
M]7R0R#VX/X'% 'T#\1O'@^'^A0:D=.-^9K@0B/S_ "L9!.<[3Z>E:?@SQ+_P
MEWA6RUP6AM/M(8^29-^W#$?>P,]/2O-/V@;E+SX<:/=1XV3W<<B\]C&QKK/@
MQ_R2G1O]V3_T8U '>T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %4]4TNUU>P>TNX]T;<@]U/8CWJ
MY10!XGKNAW6@WQMY_F1LF*4# D']#[9[_0U!IFEW6KWRVEHA9SU/15'<D]O_
M *_>O9]4TRVU>Q>TNDW(W((ZHW8CWJOH>A6F@V7D6XW.W,DI'S.?Z =A_P#7
MH -#T*UT*R\B ;I&YEE(^9S_ (#L*U*** "OE_Q1_P G,18Y_P")C:\#G^%*
M^H*^>/B!\.O'EY\4;KQ'X>TT2H)(IK:?[1"-K*JC[LC=B.XQ0!]#U\S_ +2'
M_(XZ7_UX_P#L[5N0?\-!_:(_-_U>X;L_8.F>>G-6OC5\//%/BW7M-O=$TX7D
M<5IY4I^T1H5;<3_&PSU[4 >TZ?\ \@VU_P"N*=?H*^9/COJ,6N_$FVTW3R)Y
M;:%+8[#G,K,3MX[\@?6M\Z=\?KRW%C+,]O R[-Z36D94?[T?SCZCFNB^'7P1
M/AW5TU[Q)>17VHQMOAAB):-'_OLS %F_#@\\]@"K\>K7[!\,-"L\_P"HN8HO
M^^8F']*[#X,?\DIT7C^&3_T8U5/C3X4UGQ=X2M;/0[47-S%=K*T7FJF5VL,Y
M8@=Q7G&BZ+\=O#VDPZ7I=O\ 9[. $1Q[[%L9.3RQ)/)[F@#Z/HKD?AW_ ,)C
M_P (])_PFQ_XF?GML_U/^KP,?ZKY>N?>NNH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gemp20161231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M?\)FO_/@?^_O_P!:N3HHL!Z3!<WEQ;Q3I;0!9$#@&<YP1G^Y1#<WDR%EMH
MS+S.>JD@_P 'M3M+_P"039?]<$_]!%6Z0S)GU:XMYFB>TB++UQ.<?^@U'_;D
MW_/FG_?X_P#Q-5]3_P"0C+^'\A52F(T_[<F_Y\T_[_'_ .)H_MR;_GS3_O\
M'_XFLRB@#H8Y[V2-9!;6^& (S.W?_@%)#<WDR%EMH  S+S.>JD@_P>U3VO\
MQYP?]<U_E4U(9R6J>.$TG49;&>P9I8L;C'+E>0#W ]:J?\+)MO\ H'2_]_!_
MA7,^-?\ D;K[_MG_ .BUK IB/1?^%DVW_0.E_P"_@_PH_P"%DVW_ $#I?^_@
M_P *\ZHHL![1I>JW&K:=%?06D2Q2YVB2<AN"1V4^E7K:>28S++&J/$^PA7W
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MX(ZT^2UMI@1+;Q/E#&=R _(>J_0X''M0M &6EY%>V?GVC&1?F4>8K(=P)!#
MC(.1SD5''<WDCRJ+:#,;;3F<]< _W/<58M[>"T@2"VACAA086.-0JK] *CM?
M^/B]_P"NP_\ 1:4 96I>(9-+N%@GLU9F3>"DV1C)'=1Z53_X3-?^? _]_?\
MZU4_&'_(6B_ZX#_T)JY^F(ZS_A,U_P"? _\ ?W_ZU'_"9K_SX'_O[_\ 6KDZ
M*+ >@:;JMQJENT\%I$JJ^PAYR#G /93ZU9%S>&=X?LT&Y%5B?/.,$D#^#_9-
M9G@__D$R_P#7<_\ H*UT%(9FW6H75IL\RUA.[.-LY[?\ JO_ &Y-_P ^:?\
M?X__ !-/UO\ Y8?\"_I633$:?]N3?\^:?]_C_P#$T?VY-_SYI_W^/_Q-9E%
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M"[3_ *XI_P"@BK-5M._Y!=I_UQ3_ -!% 'GNJ?\ (6O?^N[_ /H1JI5O5/\
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MTJS5:U_X^+W_ *[#_P!%I0!'>:18W\PENH/,<+M!WL./P/O5?_A&M(_Y]/\
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M6@GJ8.H^&S=S336ET+.5\;3%&R@<Y<DHRL2V%R0P^Z.O.=JWC:&VBB>5I61
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M_P!%I0!9HHHH **** "BBB@#(UO_ )8?\"_I636MK?\ RP_X%_2LFF(****
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M;FV\(6:&YM[@,7=9+:=IH\,Y( =OF. <<^E='5RW(6P4445(PJMIW_(+M/\
MKBG_ *"*LU6T[_D%VG_7%/\ T$4 6:*** "BBB@ HHHH YW4_P#D(R_A_(54
MJWJ?_(1E_#^0JI3$%%%% '3VO_'G!_US7^535#:_\><'_7-?Y5-2&>0^-?\
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M?3?^@)7F->G?#G_D7KC_ *^F_P#0$I,#ID_Y"EQ_UQC_ /0GJS59/^0I<?\
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M^1NOO^V?_HM:P*W_ !K_ ,C=??\ ;/\ ]%K6!5""BBB@#U[P5_R*-C_VT_\
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M!9HHHH **** "BBB@#(UO_EA_P "_I636MK?_+#_ (%_2LFF(**** -S1O\
MCS?_ *Z'^0K1K.T;_CS?_KH?Y"M&D,X#XE_\PO\ [:_^R5P-=]\2_P#F%_\
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M"_\ MK_[)7 UWWQ+_P"87_VU_P#9*X&FA!1113 [[X:?\Q3_ +9?^SUVS_\
M(4M_^N,G_H25Q/PT_P"8I_VR_P#9Z[9_^0I;_P#7&3_T)*0RS1112 **** "
MN(^(OA_4M<M[!K P2B!V)M9YS$KL<%7!'!*X/!]3Z5V]<)X^N8;36- G;4K2
MQN5:?R7U! UM]T [OF4AL=",]2.])C6IT/A2PN=-\/007<D;2%WD"Q2%TC5F
M+*BL>2%! S[5M5SW@FSMK#PM;06FHV]_#ND836V/*R7)*H 3A03@#/:NAJI;
MDH****0PJMIW_(+M/^N*?^@BK-5M._Y!=I_UQ3_T$4 6:*** "BBB@ HHHH
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M>&)H_P#A++&6+P_!!JT\LXU0+IKQ?9U.2K+*?E/0 X^]NS7J;8V-GICFO'O
M6K7\.L6-DNI7G]C/.T=M;NL!W*R.Z[@%W*/E;@$XP >M$?B!_">Q4444 %%%
M% %9_P#D*6__ %QD_P#0DJS59_\ D*6__7&3_P!"2K- !1110 4444 %%%%
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M_P"8I_VR_P#9Z[9_^0I;_P#7&3_T)*XGX:?\Q3_ME_[/7;/_ ,A2W_ZXR?\
MH24#+-%%%( HHHH *\W^*+37,^E6-JZSREF<V<$T:W#GC:0K$$IPV0.O%>D5
MYOXD\'^(K[Q!J%[IT&CR1W$]K/%-<RNLL1AVG:,(< D'OWI=4/HSJ_"%K>V?
MAR&&^A:&7?(R1.5+I&7)0,5X+!2,XK=JGI;:B^GQMJL=M'>9.];9V:,<\8+
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MSCJ3ZFIW_P"0I;_]<9/_ $)*;'JFGS7\EA%?6SWD0S);K,ID0>I7.1UIS_\
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M&\/Z+H^FV_VK2R9S<J";R2=IWF7M\[$DCV!Q6S52W)04444AA5;3O^07:?\
M7%/_ $$59JMIW_(+M/\ KBG_ *"* +-%%% !1110 4444 %%%% !1110 445
MDZ[JUQI26*VEG'=3WER+=$DG\I5)5FR6VMQ\OI0!K45SUOXMM6A2.YA==2,D
MD7V&WS,Y:-L,5( ^7I\S;1R,XK+FUS5&O+F^\V:VAM=0MK(Z<R1D,)!'N+,
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M _\ \C1__%5W?@O2[S2='F@OH?*E:X9PNX-QM49X)]#2&;2?\A2X_P"N,?\
MZ$]6:K)_R%+C_KC'_P"A/5FD 5YA\2M<U2PU<6]KJ.HV<(LUDC%G 7$CM+M<
M,P4XP@)'3FO3ZY/XAV[3>'$D<126<%PDMW;37(@6XB&<H7) ')!P3@XQ2>Z8
MUU1%\/+U[NPU-4NKZZL8;TK9S7P?S6B*(>2X#$;BW6NQKC_AU;F+1+J>%(8+
M"YN3)9VD-TMPMO'M *[U)')!. <#-=A5R_R_(E!1114C"JUK_P ?%[_UV'_H
MM*LU6M?^/B]_Z[#_ -%I0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5C_S^V__ ']7_&C^TK'_ )_;?_OZO^-6:* *W]I6/_/[;_\ ?U?\:/[2L?\
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M1+'441?#"WUS!;H[-;VL):")3\GWRIP"IPJY/R].E,%SX%-G>PO_ &%%;?:
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ML;,[("R+Y[%2<Y^ZO&1QTK2TK7+[5_&6DM]HD2VBM9+>Y@5CM:Y"J7R.AV\
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M0))^]<2AT/W>P'/Z9JOIMI?+XKM;,V)%O97ES<M=-%("PD#\;B@0\L -KL2
M,A<8ID?B77KFYA@ED@A\JY>*=39M$94^SF0#'F,4.1USGH>.ALZ)XBUBXEL&
MF-E]AGN5M!&L<AE!^S^9O,C.<\@C!&>^:I7>G;]0E*ZL_-_U\C=GTF[D\2V^
MHKJ5PMO'"Z&$"/&2R':,IG!VG/.?0BMFBBIZ6 **** "BBB@ HHHH **** ,
MS6[2ZO+2-+:"SN=L@9[>[)5)!@_Q!6*D'!! /3\:YL>%];$+8GM69[:XA6.:
MX>80;V1E56="7 V'EAQD8! Q6CKNLWUI>WB61C#VMM"RK,I*.\TI0%@"#A0I
MZ'^*HH?%KV+W-KJP@EN;>X,7F0216ZN-JL#LEER/O8X)Z?A0OZ_()=G_ %U,
M@>#-<;[>9)+,F\AN4)DO))&4RQ1*,L8QNP8O0<-TXP=^U\/W%O=VDQ:#]UJ$
M]T^TG)5T=1VZ_,,_2J\][J<NN'[#J+.BLIDM_*3[/!$4SF23&[S,\@*W0CC'
M-5K?4-6ALIK\W]Q=V<;P,DT\"1^:2^V01A54F/:1M+#.>Y%--A)W5F=I7.Z_
MH^H:K>0)$+?[*LD4GF&XDC>-D;/**"LH/& Q !YYKHJ*0'&2^%M4G2.!WM%B
MLM[6CB1BTK&59!Y@V_*!LP<%LYSQTJ^^A7UUH6L0W'V:.\U*0R,B2,\4?RHH
M&XJ">$SG:.O2F>(XI;B^ CENI4M[8R/:VEZ]M*"3Q(""H?H1M9@/SK$@\4ZN
MT-P]K>PW*22Q"T\RP9I/+^SK(Q*JZ@DEADEE YZY  G9-_UN-IO3^OZU+VM>
M%KJ>VOG0Q$/-<3[4!9F5X0@&,#)R.1GI5OPJ+V\DU>_N+0V!NWC6,)&ZD;4"
ME@)8U)Y]4 X[CDXG_"5:O):'4G>W,3);S0VX1U\LM;O(065QO&1T(Q73Z!J.
MI7-U<VFIM:22QP0SJ]M$T:XDW?*0S-G&WKD9ST%.VZ[:$Z*S[ZDVA:7=:9%<
M+<WTUSYD\DBAPF &<D'Y57D@\]O2M61!)&R, 58$$'OFG44GJK#ZW.'MO">L
MQR)=27$+S68C2S@>Y+1E$;."PB4KP,='([EJD?PMJQAO K61?5(I(KS,S@0!
MI';,?R?/@.1SMS@'CI7:5YS?WUWI-G)?Q7]V;FY@N7MKP7+3VTI".Z@PL0(R
M O&U<?+@DYP1.W]?UN-*[LNMO^!]QTFO>'Y]5EF:)H KV#VP\PG[Q=6]#QA:
MQ=:T^^TF]DOXK-;W[1)<J(EBED55E6,9(C1B&^0]MI!.6%2W'B;6(M4BLTDM
M)$8BW>5;1\+*8?,W;C(!UQ\@#<?Q>E?2M>U^Z6RMX[BR^UW7E&6XG@D=<&V$
MA(C$@ .>."!U.*&M'Y?KJ2K)I_/[M#;?1+V?P59:8EU):W,5K%&X39@D* 02
MRMZ=JZ""-HH5C>:29E',D@4,WUV@#\A530[]]4T*QOY45)+B!)&5>@)&3CVJ
M_52OS.X)65@HHHJ1A1110 4444 %%%% !1110 4444 4K?2[:WGFE"*QDD:0
M;E!\LL!N"^@)&3[FK20Q1P+!'$B0JNQ8U4!0N,8 Z8QVI]% &,OA'PTD<D:^
M'M)6.3&]191@-CID;>:L6FB6%A<126=M%;1PQM'%#!&J1IN(+$ #J<#\JT:*
M "D) !). .II:K:A;O=:;=6\;;7EA=%;T)!&:3=E=#6K,=+GPG-J]M=L=(35
MKE0T#RB-;EU/W2,_.01T]JMS:%X>MX_M,^E:7&D*']Z]O&!&N=QY(X&>?KS6
M'_PCUUJ6FS21B*WDN8[$*LFX-&87W.#CGUQ@_B.M;>EZ1<6+3?:;P7*R+C:3
M,0/^_DKC\@*IJU[$IW5V4SJ7A:QM;2_CAMQ%< SP26]DSG:"2TGR*2J@N26.
M!\W)YK8L9K-Q-#:*B"&0AT1=H#-\^?QW9SWS7)ZAX.O;G2=+M5\B5K6VDMY$
M^V2VZ_/M^8,BDL!M^X0 <\]*W=&M9XM3U"64L5$<%N&*[1(R*=S@>AW8_P"
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MAD/&.6(STXJ)/"^BVZA;+3+.R4R))(+6W2/S-AW*&V@9 .#^%;%%"T ****
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gemp20161231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M:@"E_:EO_P \[O\ \ Y?_B:/[4M_^>=W_P" <O\ \35VB@"E_:EO_P \[O\
M\ Y?_B:/[4M_^>=W_P" <O\ \35VB@"E_:EO_P \[O\ \ Y?_B:/[4M_^>=W
M_P" <O\ \35VB@"E_:EO_P \[O\ \ Y?_B:/[4M_^>=W_P" <O\ \35VB@"E
M_:EO_P \[O\ \ Y?_B:/[4M_^>=W_P" <O\ \35VB@"E_:EO_P \[O\ \ Y?
M_B:/[4M_^>=W_P" <O\ \35VB@"E_:EO_P \[O\ \ Y?_B:/[4M_^>=W_P"
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M[&,X&,T 0?VI;_\ /.[_ / .7_XFC^U+?_GG=_\ @'+_ /$U=HH I?VI;_\
M/.[_ / .7_XFC^U+?_GG=_\ @'+_ /$U=HH I?VI;_\ /.[_ / .7_XFC^U+
M?_GG=_\ @'+_ /$U=HH I?VI;_\ /.[_ / .7_XFC^U+?_GG=_\ @'+_ /$U
M=HH I?VI;_\ /.[_ / .7_XFC^U+?_GG=_\ @'+_ /$U=HH I?VI;_\ /.[_
M / .7_XFC^U+?_GG=_\ @'+_ /$U=HH I?VI;_\ /.[_ / .7_XFC^U+?_GG
M=_\ @'+_ /$U=HH I?VI;_\ /.[_ / .7_XFC^U+?_GG=_\ @'+_ /$U=HH
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MDZ7D0_WFQ_.K"7=M+_J[B)_]UP:K/HNFOULXA_NC'\JKOX:TQND+I_NR'^M
M&O16%_PB]LO,-S<QGV8?X4?V'?(<PZS<#V;)_K0!NT5A?8M?C_U>I1/[.O\
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M\K<=I(.,D=J +]%1+/&_1L'T-2T %%%% !1110 4444 %%%% !1110 4444
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M%*T+-C@LO!QZX/'U!H CU?\ Y M__P!>\G_H)J[5+5_^0+?_ /7O)_Z":NT
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MQE:TEX=-OF2> 0^0_P AA);&TY^;=C]*U:I:O_R!;_\ Z]Y/_035VD,****
M"BBB@ HHHH **** "BBB@ KDO$EC/IE\GB+35_>1\7,8Z.OK_C^![5UM(RAU
M*L 5(P0>] %?3[^#4[&*[MVS'(,^X/<'W%3R1I+&T<BAD88(/>N,C+>#=>\I
MR?['O6RK'I$W^?T^E=KU&10!@1O)H-WY,I9K&4_(Q_@-;P(8 @@@\@BH[BWC
MNH&AE7*M^GO6197$FE70T^[;,+?ZF4]/I_GI0!N4444 %%%% !1110 4444
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MBD 4444 4M7_ .0+?_\ 7O)_Z":NU2U?_D"W_P#U[R?^@FKM !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JM8?\>[_ /7:7_T8U6:K6'_'N_\
MUVE_]&-0!9HHHH ***S/$.MV_AS0;K5KJ*:6"V4,Z0@%B"0.,D#OZTF[(:5W
M9'D%MHNE)XOB@L]5T.:XBU!$GFDMW\Q6\YI%VO@JTC?,AYQP.]>Y5X'X;$&K
M^(()-/37YM%EN(V%N+*$A-LID4/()"0H=B3QG'%>^525H)?UT%*SFV@HHHI
M%%%% %+5_P#D"W__ %[R?^@FKM4M7_Y M_\ ]>\G_H)J[0 4444 %%%% !11
M10 4444 %%%% !1110 4444 <=K5O+X;UA=>LD)M93MNX5Z<]_Q_G]:ZRVN8
MKNVCN('#Q2+N5AW%.FACN('AE0/&ZE64]"#7'Z7-)X6UPZ/=.387+;K65C]T
MGM_0^^#WH [.BBB@ J.2"&88EB1Q_M*#4E% &=+H>GR_\L-A]4)'_P!:J_\
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M4?V;XNM/^/?5[>Y0?PS)@G]#_.@#JZ*Y3^U/%MKG[3HT-PH_BA?D_J?Y4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!3N-)TZZ_U]C;R'U:($_G67/X+T*?)%JT1/>.1A^G2N@H
MH Y/_A"?LX_XE^LWUMZ?-G^6*7^R_%MI_P >^LP7"C^&9,$_H?YUU=% ' ^(
MM7\06>EI!>1QQO*2&EA' 'IG)Y/7M_A#X:U37;RPDL;)ANCQLGE7(7V/^3^M
M=Y>V4%_:O;W"!XW&"#3-.TZWTRT6VMD"JHY/<TP.>_X1?5[XYU37YF4_>C@&
MU3_(?I5RT\%Z):X)MFG8?Q3.3^@P/TKH**0$,%K;VJ;+>"*%?2- O\JFHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *K6'_'N__7:7_P!&-5FJUA_Q[O\ ]=I?_1C4 6:*
M** "H+RRM=0M)+6]MXKBWDX>*5 RMSGD'WJ>B@#$A\&^&+>>.>#P]I<<L;!T
M=+1 5(Y!!QP:VZ** "BBB@ HHHH I:O_ ,@6_P#^O>3_ -!-7:I:O_R!;_\
MZ]Y/_035V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "JUA_Q[O_UVE_\ 1C59JM8?\>[_ /7:7_T8U %FBBB@
M HHHH **** "BBB@ HHHH I:O_R!;_\ Z]Y/_035VJ6K_P#(%O\ _KWD_P#0
M35V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "JUA_Q[O_ -=I?_1C59JM8?\ 'N__ %VE_P#1C4 6:*** "BB
MB@ HHHH **Y#Q%XCOH-;T^PTHH(DO8(]0F(!VB0X$:Y'WB.3Z#'J*KZIJFN2
MOX@U#3]06WM]$;:EKY*,MR5C61][$;A][ VD8QGFA:J_]=/\QVUM_7]:';T5
MQ2^,[@ZZL#-9);F55-HRM]H\HQ[S<;LXV#_=[?>SQ72:+=75_I_VVY7RUN&,
MD$>W!2(_<W>Y')],X[4[$W)-7_Y M_\ ]>\G_H)J[5+5_P#D"W__ %[R?^@F
MKM(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ._2_P"%']G6/_/E;_\ ?I?\*LT4 5O[.L?^?*W_ ._2_P"%']G6/_/E;_\
M?I?\*LT4 5O[.L?^?*W_ ._2_P"%']G6/_/E;_\ ?I?\*LT4 5O[.L?^?*W_
M ._2_P"%']G6/_/E;_\ ?I?\*LT4 5O[.L?^?*W_ ._2_P"%']G6/_/E;_\
M?I?\*LT4 5O[.L?^?*W_ ._2_P"%']G6/_/E;_\ ?I?\*LT4 5O[.L?^?*W_
M ._2_P"%']G6/_/E;_\ ?I?\*LT4 5O[.L?^?*W_ ._2_P"%']G6/_/E;_\
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M>P%9VD^(8=5NI+5K*]LKA(Q*L5W&JEXR<!EP3QGL<$=P* +_ /9UC_SY6_\
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M.])X/-A/!>WEMK4&L7EQ*&N[F C:&"@*JJ"=J@=!DGO72T4(&%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0.<<FLP:3_:7B'QUI%U_K-1MX7A)[QF,H"/HX-<M;?#OQ)-#H+WL 6:>X?\
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MJ-W>Z##<O<?;&@UJ&.QO=BJ;F,R(I?Y0!]UI%R  0,T)7=O/_+_,'M?^NO\
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M9Z8;.#5V.1)8UDC=71AE64Y!'J#7G-G>6-MX@76;F:"/09+N[-O<28$(=DA
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M,E;.YOL<EKGD_P#+.0EE_$\]:QO#ME;:=X@\1QVZE(S-"[;G+')C&3DDFAZ
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M1)'&H5$4*H'8#I3J** "JUE8PV$<D<&X1O*TNTGA2QR<>V23^-6:* "BBB@
MJM9V4-BDJQ;B996E=F.2S,>?Z >P%6:* "BBB@ HHHH **** "BBB@ HHHH
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M/MUM':R[6'"H6((XZ_.>N>U<[=^'M2N=>$,=O>PV/]I1WI9;B(VQVL&+;?\
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MFY(KO:*35]QIVV,%/"UJ=%_L^2><.3%)Y\; .DD:J%9>,#&P<$'OG.:K'P5
M4F9M8U1KJ6ZCNS=,T1D$B+M7 \O9C';;73T53=W<E*RL4["RGM(7CN-2NK\L
M<A[E8@5'H/+11CZBLS1]!^R16"W!</IAEAMBK#:\3?=)[Y"@#MR#6_12&84?
MA+3HX(XOM&J 1@@>5J4\(Y8M]V-U7J3SC-7[C2H+B*QC9YMMG*DL9,A9B5!
MW,V2W7DDY]ZO44 8=WX7M[R\DDEOK_[++*LTMEYBF%W7&"<J6 R =H8 XY'6
MK&DV,UO<:E=W(VS7ER7"YSM15"(/Q"Y_X%6I10M "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gemp20161231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M<-^;07$"1N8XH98'3<#E623)X(X8$@^U7+?Q<D>O0Z%JUFUGJ,^?($<@FCE
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MK^]EEBV"<(/E+<''>K-SXK\0:/JVK"]CM'U#R;...))93;1R2R,H.">@&,D
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MJ[R3/*Q5>BY<D@#L!Q4.EZ"-(D<V2Z?"LK[Y62T;S).>=SF0DGW.:VZ*/,#
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M'T444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME-81!R!+=\'_ )^Y?_BJ3[#'_P ]KO\ \"Y?_BJMO]]OK3:8%;[#'_SVN_\
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M[_R )_\ KZ;_ -!2NLJ1E330RV95G9]LTJ@NQ8X$C <GD\8JW5:P_P"/=_\
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M]*BI@5OL,?\ SVN__ N7_P"*H^PQ_P#/:[_\"Y?_ (JK-% %;[#'_P ]KO\
M\"Y?_BJ/L,?_ #VN_P#P+E_^*JS10!!'I\32 &6[Q_U]R_\ Q53_ -EV_P#S
MTN__  ,E_P#BJ?%_K5JU2 SETI?M4C--=&$HH1?M<N0V6W'[WIM_*I/[+M_^
M>EW_ .!DO_Q57:* /,/$VI:AI_B&ZM;6_NXX4V;5\]SC* GDG/4UD_V_J_\
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M"D,O:%_R&;?_ (%_Z":[*N-T+_D,V_\ P+_T$UV5# ****0%>?[X^E15+/\
M?'TJ*F 4444 %%%% #XO]:M6JJQ?ZU:M4@"BBB@#R;QE_P C9>_]L_\ T!:P
MJW?&7_(V7O\ VS_] 6L*J$%%%% !1110!UGP]_Y#\_\ UZM_Z$E>E5YK\/?^
M0_/_ ->K?^A)7I5)C*R?\A2X_P"N,?\ Z$]6:K)_R%+C_KC'_P"A/5FD 444
M4 %%%% !1110!YG\0+F;5M5M+/1[N&\N+)SY^F)?K;R>9N1E<AB-X !&/]K-
M=CX2LM1T_P .06^J,?M(9VV&7S3$A8E4W_Q;00,^U>4?$J;[1XEGM;^[TN\L
M]P5+*P1#?@D#@DQ.0?H1Q7J/@>.&'PC8QV]IJ-I$ VV'43^^7YC][^GMBB'P
M7_K^OO"6]C3.D6"O>36]G;075VA6:XCA4._&/F(Y;\366_ANYBM=*%AJ*07E
MA:FT\Z2W\Q9$(4'Y=PP<HI'/'O7144?U_7WAUN8R^'XTTS3=,2=Q9V:J&!^]
M(4'R9/LV&^H%1^'_  Y_8MO<PRW$=PD^ 42'RT( (+,"S;G;/S-QN]!6[13O
MN^X&=9VT%KJ]VEO#'"A@A)6- HSNDYXK1JE%_P AJZ_Z]X?_ $*6KM( HHHH
M **** "BBB@ HHHH **** *C_?;ZTVG/]]OK3:8!1110 4444 36_P#%^%3U
M!;_Q?A4]( HHHH \)HHHJA!1110 4444 >E?#W_D 3_]?3?^@I765R?P]_Y
M$_\ U]-_Z"E=94C*UA_Q[O\ ]=I?_1C59JM8?\>[_P#7:7_T8U6: "BBB@ H
MHHH YGQQ)-+H$MA8W&+Z4HWV>.<1331!QYBH21R5R,^]8_PWL]8MQ<O>V=]9
M6?D0Q1P7CY9I%W!G R<#;L'OC-5?BQ%.UK:2+IVA7$"AA+-J+(LL8)'^KW.@
M_#/I3/A#<64]C??8]3UB["E0T=\N(HCSQ%AF&/\ @1Z"B'4):)'H,VFV%S>0
M7D]E;2W4&?)GDB5GCS_=8C(_"LJ3PV6T^Y@CO=DSWYOH9O*R(WWA@"N?F'&#
MR,@]JWZ* ,2WT.X@TJ]@-\&O+Z8RW%RD>P<X4[%R=N%4 9)QUYJ+3O# T[7I
M-0BN$$)4JD2P[7P< *S[OF5<?*-HQD\FN@HH S+FSMH=2L)XK:%)7N&W2*@#
M-F*0G)^M:=4KW_C[TW_KX/\ Z*DJ[0!'+;PSX\Z&.3;TWJ#C\ZC^P6?_ #Z0
M?]^Q_A5BB@"O]@L_^?2#_OV/\*/L%G_SZ0?]^Q_A5BB@"O\ 8+/_ )](/^_8
M_P */L%G_P ^D'_?L?X58HH A2SMHG#QV\*,.C*@!%3444 %%%% %>?[X^E1
M5+/]\?2HJ8!1110 4444 /B_UJU:JK%_K5JU2 **** /)O&7_(V7O_;/_P!
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MO_0DKTJDQE9/^0I<?]<8_P#T)ZLU63_D*7'_ %QC_P#0GJS2 **** "BBB@
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M;N$M%<]4U&R74M-N;%YIH5N(VC:2%@'4$8R"0<'\*R8_"JC3?L$VKW\\";#
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M=0)2>FTD_-^%+-JNG6]_%8S:A:QWDW,=N\RB1_HI.3^%,">%&7=N&,U+112
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M*([0%88Q]U/EV].G3(_$U'INCV.D+(ME$Z>9C<7E>0X'106)(4=E' ["K]%
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M*([0%88Q]U/EV].G3(_$U'INCV.D+(ME$Z>9C<7E>0X'106)(4=E' ["K]%
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M* "BBB@ HHHH KS_ 'Q]*BJ6?[X^E14P"BBB@ HHHH ?%_K5JU56+_6K5JD
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M=2SW#>7;S*5A\TQ>2F0"K+C]YE0'9]W&%XKI=*OK:^LE-M/)-Y6(W:5&1]P
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M4M7:I1?\AJZ_Z]X?_0I:NT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!6L/^/=_P#KM+_Z,:K-5K#_
M (]W_P"NTO\ Z,:K- !1110 4444 >=_$D:K>7>GZ=I6@:3JKNC.YO!&TL0R
M!F,,ZGUY'I3OA_:7^A/>)K:W]D;EXUMX[Z_BDC9LGY8D4_+V[G/'I72>)K3P
MW?PV]IXACM9!*S>0LO#Y R2A'S# '45D^#=.\"-<S77AE;:YN80 \^]Y70'H
M SDD=#THAI<);':4444 (0#U /.>:6BB@"E>_P#'WIO_ %\'_P!%25=JE>_\
M?>F_]?!_]%25=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"LG_(4N/^N,?_H3U9JLG_(4N/\ KC'_
M .A/5F@ HHHH **** "BBB@#SBZM]6M]=U<:/H]AK]M-J"7#B2Z$+VEPJ+@-
MD?,!A2,>M=9X3TBYT3P]#:7CQM<M))-*(ON*SN7*K[#.!6#_ ,*_:\US6;^[
MU?5;1;NZ\R%-/OFB4IL498 ?>R#^&*ZS2=-32-.CLDN;NY6,DB6[F,LAR<\L
M>M-:1MZ?D#U8^_U*PTNW%QJ-[;6<);:)+B58USZ98@9JL/$>AM9"]&LZ<;0O
MY8G%TGEE_P"[NSC/M4.J:K?Z78:E>3V=MY%O&6MC'<,SRMT 92@"Y.!PS5@W
M4-IX>U+1Y-6FC6U%G=+-<3$!7N',;')/&6^? _ 5/]?U_75#L=L"&4,I!!&0
M1WH5E==RL&'J#FO,[#P_=V5CHU^MP4U">VCCCC-OF>/$.UAOW?ZM5^;9MY?'
M/-=5X4UF+4],DAL[6.-;1%2-4G\Q>1PK,!\KC'S+@X)[U36K783TL:T7_(:N
MO^O>'_T*6KM9T::B+V:Y:WM?WD:1[1<,<;2QS]S_ &OTJQOOO^?:W_[_ +?_
M !%("S15;???\^UO_P!_V_\ B*-]]_S[6_\ W_;_ .(H LT56WWW_/M;_P#?
M]O\ XBC???\ /M;_ /?]O_B* +-%5M]]_P ^UO\ ]_V_^(HWWW_/M;_]_P!O
M_B* +-%5M]]_S[6__?\ ;_XBC???\^UO_P!_V_\ B* +-%5M]]_S[6__ '_;
M_P"(HWWW_/M;_P#?]O\ XB@"S15;???\^UO_ -_V_P#B*-]]_P ^UO\ ]_V_
M^(H LT56WWW_ #[6_P#W_;_XBC???\^UO_W_ &_^(H LT56WWW_/M;_]_P!O
M_B*-]]_S[6__ '_;_P"(H LT56WWW_/M;_\ ?]O_ (BC???\^UO_ -_V_P#B
M* +-%5M]]_S[6_\ W_;_ .(HWWW_ #[6_P#W_;_XB@"S15;???\ /M;_ /?]
MO_B*-]]_S[6__?\ ;_XB@"S15;???\^UO_W_ &_^(HWWW_/M;_\ ?]O_ (B@
M"S15;???\^UO_P!_V_\ B*-]]_S[6_\ W_;_ .(H LT56WWW_/M;_P#?]O\
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MXS]X\<UN^'=7(UBXTF>!/MC,\UQ(LP9P_&2R8RJ8(5#DY"]J8C?O?^/O3?\
MKX/_ **DJ[6=<1W\MU ZP6PC@E+@F=LL-K*.-G'WL]35C???\^UO_P!_V_\
MB*0RS15;???\^UO_ -_V_P#B*-]]_P ^UO\ ]_V_^(H LT56WWW_ #[6_P#W
M_;_XBC???\^UO_W_ &_^(H LT56WWW_/M;_]_P!O_B*-]]_S[6__ '_;_P"(
MH LT56WWW_/M;_\ ?]O_ (BC???\^UO_ -_V_P#B* +-%5M]]_S[6_\ W_;_
M .(HWWW_ #[6_P#W_;_XB@"S15;???\ /M;_ /?]O_B*-]]_S[6__?\ ;_XB
M@"S15;???\^UO_W_ &_^(HWWW_/M;_\ ?]O_ (B@"S15;???\^UO_P!_V_\
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MFN=C#!022,X&.Q 84+;^N[#K_7;_ #-*[M+>_M)+6ZB$L,@PR'O4>G:9::5
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M =Q61D#'/&%(P,=:Z.BB@+!1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gemp20161231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M=@Y+?P^_7BNCLX8H/C/>)#&D:G1$.$4 9\T^E=U133V^?XW_ ,P>M_E^%O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>(=7N=4M1=?8C9W5[=6D<<4+K(GE%\,6+D'(3IM'7.>U;H\/Z*  -'T\ ;L
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MR"-VS9CH!\^[MM&,TUK;^NO^6HGLVOZT_P ]#T*BBBD 4444 %%%% !1110
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M+V.:-0L$Q$<B@8 ;^$_TK0J*Y@6YMI(6Z.,9]/>H["=I[53)_K4)20?[0X-
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M'RCJIZG!&:DTKPW)IU[;R2WJ36ME')%90K!L,:N03N;<=Q   P%X]:Z"BDM
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M!Y!%+61X>F86<EA*Q,UB_DDGJ4ZHWXKC\JUZ0!1110 4444 %%,D#E>"*$#
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M+7&L';%I=C=:D_PL.L?Z\>V!714 %%%% !1110 4444 %%%% !1110 4444
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MC %DF%!YYQV]3CN>];-E?6^H6RSV[[D/!!X*GN".QH L4444 %%%% !1110
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M10 4444 %%%% !5":&2SE:YME+(QS-"._P#M+[_SJ_10!%#<PW"JT4BL",@
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MY,!_.KKZ=92?>M8?J$ J/^R[8?ZOS8S_ +$K#^M %;^VW3_7Z3J,?N(A(/\
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M\ YO_B: +M%4O[5M_P#GG>?^ <W_ ,335UBT8L%6Z)0X8"TEX. <'Y?0C\Z
M+]%4O[5M_P#GG>?^ <W_ ,31_:MO_P \[S_P#F_^)H NT52_M6W_ .>=Y_X!
MS?\ Q-']JV__ #SO/_ .;_XF@"[15+^U;?\ YYWG_@'-_P#$TUM8M%*AEN@7
M.%!M)>3@G ^7T!_*@"_15+^U;?\ YYWG_@'-_P#$T?VK;_\ /.\_\ YO_B:
M+M%4O[5M_P#GG>?^ <W_ ,31_:MO_P \[S_P#F_^)H NT52_M6W_ .>=Y_X!
MS?\ Q-']JV__ #SO/_ .;_XF@"[15!-8M)$5T6Z9&&59;24@CU'RT[^U;?\
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M._M6W_YYWG_@'-_\30 ?V;&/]7/<Q^RS'^N:/LERO^KU"7_@:*W]*/[5M_\
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MZ3[VDO\ \!L)1_):C_LOP\!\FGWD?NEO<+_(4 =+17,_V?IBG]U+K</IY:W
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gemp20161231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !     %$2
M  0    !             8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,
M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_  !$( ;$"?@,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M )_+/_P%;_XY5VB@#+O'U2TL;BY^TV;^3&TFW[*PS@9QGS*G\K5/^?RS_P#
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MZI>ZA;6GV>S3SY5CW;&.W<0,XW>]=OY6J?\ /Y9_^ K?_'*\?T+_ )&'3?\
MKZB_]#%>VT,92\K5/^?RS_\  5O_ (Y1Y6J?\_EG_P" K?\ QRKM%("EY6J?
M\_EG_P" K?\ QRCRM4_Y_+/_ ,!6_P#CE7:* *7E:I_S^6?_ ("M_P#'*;%+
M>1ZC';W$L$B20NX,<)0@J4'=C_>_2K]5G_Y"EO\ ]<9/_0DH LT444 %%%%
M!1110 4444 %%%% !5+5?^/2/_KY@_\ 1J5=JEJO_'I'_P!?,'_HU* +M%%%
M !1110 4444 <_XP_P"03%_UW'_H+5Q-=MXP_P"03%_UW'_H+5Q--""BBBF
M4444 %%%% !6KX:_Y&"U_P"!_P#H!K*K5\-?\C!:_P# _P#T T >@T445(PH
MHHH **** "BBB@ HHHH **** "N8NO\ C\G_ .NC?SKIZYBZ_P"/R?\ ZZ-_
M.@"&BBBF(**** "BBB@ HHHH Z+3/^0=%^/\S5NJFF?\@Z+\?YFK=(84444
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M"&W!%NP:,-L6,!G4+(3M)+';@'FA:[?UO_DPZV_KI_F=W5+5?^/2/_KY@_\
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M\C#IO_7U%_Z&*]MKQ+0O^1ATW_KZB_\ 0Q7MM)C"BBBD 4444 %5G_Y"EO\
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M .<2;N%8G<R[3D\YKIJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKF+K_C\G_P"NC?SKIZYBZ_X_)_\ KHW\Z (:***8@HHHH **** "BBB@#HM,
M_P"0=%^/\S5NJFF?\@Z+\?YFK=(84444 %%%% !1110 4444 %%%% !7(?$;
M_D7K?_KZ7_T!ZZ^N0^(W_(O6_P#U]+_Z ] 'F-%%%4(**** "BBB@ HHHH T
M-"_Y&'3?^OJ+_P!#%>VUXEH7_(PZ;_U]1?\ H8KVVDQA1112 **** "JS_\
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M%>VTF,****0!1110 56?_D*6_P#UQD_]"2K-5G_Y"EO_ -<9/_0DH LT444
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M_P!&I3OH'6Y=HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY@_]&I5VJ6J_\>D?_7S!_P"C4H NT444 %%%% !1110 4444 %%%% !1110
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M9W MV@NH95N%+PM&X82*.I!'4<CGWJ/5?^/2/_KY@_\ 1J4 7:*** "BBB@
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M4RW*-.$QOM)0$9P"JNVW:K'(PI()R,=10!J?99O^?^X_[YC_ /B:/LLW_/\
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MZ#O69?>(]4TK3;ZXO]%C6:W1'C\F[+PR[F"X\PQ@J03R-O3IF@#<^RS?\_\
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M*Y8' Z=!6Y0!6^RS?\_]Q_WS'_\ $T?99O\ G_N/^^8__B:LT4 5OLLW_/\
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M#'RY..M>JT4=/ZZJPT[._I^#N>3_ -CR:K?++I_AJ_TVS@T>:SO(_*6W>=F
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M]K%J,^H)"!=3HL<DA))*KG &>@Y/3UJU1>ZU_K6XK6V"BBBD,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gemp20161231x10k014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k014.jpg
M_]C_X  02D9)1@ !  $ D "0  #_X0!V17AI9@  34T *@    @  8=I  0
M   !    &@       9*&  <   !     +     !53DE#3T1%  !, $4 00!$
M "  5 !E &, : !N &\ ; !O &< :0!E ', ( !) &X 8P N "  5@ Q "X
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M]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$
M @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S
M4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC
M9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.T
MM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H
M# ,!  (1 Q$ /P#[+H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * ,V76K""\CTR2YMTOIT,D5JTT:W$B .2Z0EA(Z@1N2
MRJ0 C\_*< %+5?%FBZ#*+?5+^RL9F02+'<W4$#E"64.%D=6*EE90P&"589R#
M0!<TK6K#78C<:7<V]]"KF-I+::.9 X"L4+QLRA@K*2I.0&4XP10!IT % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M&29MQ2ZD896-@,(<L0#@9( /<Z "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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ME756+1N% .LH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H S-;TJ+7=/N=+N"ZPWUO-;2-&0'"31M&Y0LK*&"L
M2I96 .,J1Q0!\@:/\/\ 3_AO\5=%TO2Y+B:&:RN+EFN6C=P[V^I1D QQ1+MV
MQ*0"I.2WS$$  'VE0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M5XQ/BG0-5US3$L;;0M,;37E2ZM90Z16]Y'!(8TGDD#,)XXW"AP75I1L1MD;
MZ"_\#>(? ?C2X\6>%+"+6;/5XI5NK0W*6LL,LC12RLLMQ(5/FW$8G5E610K3
M0>3$%AE* \G\;_!_QMXYNKWQ1<V,5M?7=U#%'IL=S;NRVT<&SSWN&G6'Y!%!
M'A6WS2/+)Y,$:(KFP'V5X,T^?2=!TVPNU\NXM;"T@F3*MLDBMXT==REE;:RD
M95BIQD$CF@#C/AM\2I_'=UJEA=Z?_95QHDT<$J?:EN<R,UPCKN2&)1Y;0$95
MI%?=D$ 9(&QP/_"O]=_X6O\ \)5]F_XD^/\ CY\Z#_H%?9O]5YOG_P"N^3_5
M?[7W/FH QO"OP@OKGQ?K]SXEL=VA:O\ ;/+;[3&/.WZE;W<'%O.+B/(B\SD)
MC;L?!.TG2P'I'_#/G@3_ *!G_DY?_P#R50!YKJWP<U+P%XGL_%'@*RBO+6W
M633I;LI(#)'-#.T<MP5"QM$RE6>>:1+B0MY+P+Y:@&UX(^'GB#4_&T_C[Q1;
MQ:40)%M[**X2:0-]GCM8FD:,2QO%]F,@9A+%(UP@<0QPD(0#Z6H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^9O%'_)9="_[!4O_
M *+U>@#Z9H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M&&DWFLS^&X)]VJ640GG@\N8;(V$1#>:8Q"V1/%PDC-\W(^5L '2T % !0 4
M<UKGC#2?#=U96&I3^1<:M+Y%FGES/YLNZ)-NZ.-UC^::,9E9%^;.<!B #&@^
M)_ANYNK^PBO-USHL5S/?)Y%R/)CM&V7#;C"%D\MCC$32,_5 PYH Z7P_X@L?
M%-A%JNE2_:+.XW^7)LDCW;)&B?Y)51QAT9?F49QD9!!(!LT % !0 4 >=>)O
MBUX5\'WATW5[]+>[5%=HEBN)B@<94.8(95C9EPP1RK[&1]NQT9@#LM&UFS\0
M6<6I:9*ES:7*;XI4Z,,D$$$!E96!5T8*\;JR.JNK* #3H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H ^9O%'_)9="_[!4O\ Z+U>@#Z9H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H S-;EO8-/N9=+C2>_2WF:UBD("27"QL84<EXP%>0*K$R(
M "?G7[P /D#1[_Q-J/Q5T67QA:6^GWXLKA8XK9E9&MQ;ZD4<E;FZ&XR&52/,
M!PJ_(/O, ?:5 !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'G?@C4+6TL72>:*)C.Q"O(JG&R,9PQ!QD$9]C38'8_VU8?\_-O_P!_H_\
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M_OB9!O+;6QMQM& #?MK:*SB2WMT2&&%%CCCC4(B(@"JB*H"JJJ JJH
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M (EG@_3/]'U+4K?C[5_$]A8.V[S/-W%KJZ8OYV\RRF2&15U$ /V5/^15NO\
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MPWMO:ZXMOB:PU622QLX!&K1F87<'VFS,<2V_F/OR&AN%93)<6[K)& >-:_\
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M.:GIOVKPB+5-/DE?<+2!;91,H57\R$1Q,DNT(?WD:NT?EN,QLA(!V5 !0 4
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M6UW\3/#%W?PI:Q>*+:?+:;.US8VGV10TX1;J(06;7$K*87F6,I'\NV*8%VV
M''>&?A+XO\"^&3+X<NXK3Q%=S?:+R$^2\3VZ0OY-FK3PW$9N8I"=LJ-;P%KB
M9)998XH)@; 3>*O!'BKXR:OI\?B'34\.:1IRRO(ZWEO>7$K2M'O2,Q':K.L<
M:QEX0D0$LKO,3' 0#Z*\5Z5+KNC7^EVY19KZRN;:-G)"!YH7C4N55F"AF!8J
MK$#.%)XH ^5O!/A7_A:'P[;PB[_V=JGAZ_F"I(WS"<-/(GVJ$H)H(G-S<6_
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M@IJGQ%UC5/$GC.)-(DO$:&SLX95N#&XMU@@N9I(I=LBVZK&WEK)&;F=&+K!
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MP?:)O.@3R_)OY9I?W<DJRMMB96^1&W9PN6!% '8']GWP(3DZ9_Y.7_\ \E4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MJ-UY.HWW]H?9X?)N'W^?810Q?O(XFB7=*K+\[KMQN;"D&AB/9?V5O^15N?\
ML*3_ /I+9TP/I:D 4 % !0 4 % !0!\S>*/^2RZ%_P!@J7_T7J] 'TS0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MV[8E(!4G);YB"  #[2H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H XSQ=\/
MM!\=^1_;UK]K^Q^9Y/[Z>+9YOE^9_J)8MV[RD^]NQM^7&3D XS_AGSP)_P!
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@#QG]H/_D1-3_[<_\ TOM: /9J "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /&?V
M?/\ D1-,_P"WS_TONJ /9J "@ H * "@ H * ,W6=+BURPN=,N"ZPWMO-;R-
M&0'"31M&Q0LK*&"L2I*L <94CB@#Y;^&M[KWP8BN/#FL:#J>H0R7$MW%>Z5'
M]M1]PB@5=BA%166!Y<RRI.H:,/:J&W4 ;7@;PAJGB?QW<_$+4[*XT>RV$6,%
MRRI=2.(!8;I[?:7B7R4DE9',9$DD'E/<1!W8 ^G* (;FYBLXGN+ATAAA1I))
M)&"(B("S.[,0JJJ@LS,0  22 * .2_X6/X5_Z#.E?^!]I_\ ': .SH * "@
MH * "@ H * /F;Q1_P EET+_ +!4O_HO5Z /IF@ H * "@#QG]H/_D1-3_[<
M_P#TOM: /9J "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M*\'PG4"X6ZGFN;6-S)F*V<(J +(JA%ED26Y01YC=)UF#%I&P >[T % !0 4
M% !0 4 ?,WBC_DLNA?\ 8*E_]%ZO0!],T ?,W[5?_(JVO_85A_\ 22]H ^ *
M "@ H * "@ H _3+]GS_ )$33/\ M\_]+[J@#V:@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MI/C:T:_T.?[5;1RM"S^7-%B151V7;-'&QPLB'(4KS@'(( !TM !0 4 % !0
M4 9FMRWL&GW,NEQI/?I;S-:Q2$!)+A8V,*.2\8"O(%5B9$ !/SK]X 'R!H]_
MXFU'XJZ++XPM+?3[\65PL<5LRLC6XM]2*.2MS=#<9#*I'F X5?D'WF /M*@#
MYF_:K_Y%6U_["L/_ *27M 'P!0 4 % !0 4 % 'Z9?L^?\B)IG_;Y_Z7W5 '
MLU !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MJ7@'QI:^/]&@UJS'E>;N26 NCO!,AQ)$Y0_1XRRHSPO%(8TWA0; =E0 4 %
M!0 4 % !0!\S>*/^2RZ%_P!@J7_T7J] 'TS0!\S?M5_\BK:_]A6'_P!)+V@#
MX H * "@ H * "@#],OV?/\ D1-,_P"WS_TONJ /9J "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#C/B/_P B
MKK/_ &"K_P#])): /EGX6^&_[5\-6>N>-[B*'PEH'GRV5D3^ZN9C<S&2ZO5!
M8R[)I'MK:VVEYV'EK"$DD6_ /0/^2B?\5MXV_P")9X/TS_2--TVXX^U?PI?W
MZ+N\SS=P6UM5#^=O$40DAD9M1 #_ )*)_P 5MXV_XEG@_3/](TW3;CC[5_"E
M_?HN[S/-W!;6U4/YV\11"2&1FU$ /^2B?\5MXV_XEG@_3/\ 2--TVXX^U?PI
M?WZ+N\SS=P6UM5#^=O$40DAD9M1 #_DHG_%;>-O^)9X/TS_2--TVXX^U?PI?
MWZ+N\SS=P6UM5#^=O$40DAD9M1 #_DHG_%;>-O\ B6>#],_TC3=-N./M7\*7
M]^B[O,\W<%M;50_G;Q%$)(9&;40#,_9RU6+7=:\5ZI;AUAOKV"YC60 .$FGU
M*1 X5F4,%8!@K, <X8CF@#ZLH * "@ H X'4?BAX;TG4YM#N[SR]0M8I)Y8?
M(N6VQ16IO';S$A:)MMLIDVJY8XV &3"T ?+-IK'A/PM=2R^#/&-UHEG/O9[*
M72[N_A61W!9HUFA1%PB11J[QR7(5"&N'#E0 >C?"74O!RZ]+=0:W<>(/%&L)
M(DD\UK=6R,B;IV2&)H%BA010QC:\SA1 J6XA1O)(!]/4 ?/G[0'@C4?&UE9P
M:/ISZA=P/*R7"WD%L+4,8=R/#.56X6X53]QHWA>%&W[&>.0 HZUK?Q*US0;G
M1[CPU;I=WMO-;27*:E:"$)-N1BEJUPSAA"Q52UTP$N)2"G[F@#,^&EOXS^'&
MC)HT/A7[0YEDFGN/[:LH_-DD( ?RCYHCVPI%%M1]K>7OP&=L@'U)0 4 % !0
M 4 % !0!\S>*/^2RZ%_V"I?_ $7J] 'TS0!\S?M5_P#(JVO_ &%8?_22]H ^
M * "@ H * "@ H _3+]GS_D1-,_[?/\ TONJ /9J "@ H * "@ H * "@ H
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M[/J6GK;.Q%ND7EK-Y+L93=OYX3[3S"C\X7RB ?15 !0 4 % !0 4 % !0 4
M% &9K>JQ:#I]SJEP':&QMYKF18P"Y2&-I'"!F52Q52%#,H)QE@.: /D#1_B!
MI_Q'^*NBZII<=Q###97%LRW*QHY=+?4I"0(Y95V[95 )8'(;Y0 "0#[2H ^9
MOVJ_^15M?^PK#_Z27M 'P!0 4 % !0 4 % 'Z9?L^?\ (B:9_P!OG_I?=4 >
MS4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M_P EET+_ +!4O_HO5Z /IF@#YF_:K_Y%6U_["L/_ *27M 'P!0 4 % !0 4
M% 'Z9?L^?\B)IG_;Y_Z7W5 'LU !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!XSX)_Y'OQ=_W O_ $@DH ]FH * "@ H * "@ H * . \5_\)I]J3_A%
M_P"Q?L?E+O\ [2^V^=YV]]VW[-\GE;/+VY^??OSQMH YC_BZ?_4J_P#E5H Y
MGP=XK^)/C;28-<L$\-16UWYFQ9UU-91Y4TD+;E1Y%&6C8C#G*D$X.0 #T#P]
M_P )_P#;XO[>_P"$?_L[Y_.^P_VA]I_U;^7Y?G_NO];LW[O^6>_;\V* /3*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#C
M/B/_ ,BKK/\ V"K_ /\ 226@#Y9^%OAO^U?#5GKGC>XBA\):!Y\ME9$_NKF8
MW,QDNKU06,NR:1[:VMMI>=AY:PA))%OP#T#_ )*)_P 5MXV_XEG@_3/](TW3
M;CC[5_"E_?HN[S/-W!;6U4/YV\11"2&1FU$ /^2B?\5MXV_XEG@_3/\ 2--T
MVXX^U?PI?WZ+N\SS=P6UM5#^=O$40DAD9M1 #_DHG_%;>-O^)9X/TS_2--TV
MXX^U?PI?WZ+N\SS=P6UM5#^=O$40DAD9M1 #_DHG_%;>-O\ B6>#],_TC3=-
MN./M7\*7]^B[O,\W<%M;50_G;Q%$)(9&;40 _P"2B?\ %;>-O^)9X/TS_2--
MTVXX^U?PI?WZ+N\SS=P6UM5#^=O$40DAD9M1 ,S]G+58M=UKQ7JEN'6&^O8+
MF-9  X2:?4I$#A690P5@&"LP!SAB.: /JR@ H * "@#-UF6\@L+F33(TFODM
MYFMHI" DDXC8PHY+Q@*\@56)D0 $_.O4 'RK^SYX=T/6[741XCMK2^\0G4)S
M<1:BB3WBQQK#N=H+G?)'_I,TJRR[%9Y3LE=F1 IZ 1?#VU3PS\4]0T/PLJ#1
M5M]MW$L[RI%Y5O"2X+S$O/%?O]G(;S7A$UQ&$0;C& ?8- 'R[^U+IFFW&BVE
M]=77V>_M)G6SML!OM0F,(N%VCYD\E423SL^6O^I<&2>$J =AIWQN^W6L-U_P
MCOB5O/BCDS!IWG0G>@;,,WFQ^=$<_NY?+3S$P^Q<X !Z;X5\2_\ "4VC7GV+
M4-+V2M%Y.I6_V:=MJHWF+'O?,1W[5?/+(XQ\O(!TM !0 4 % !0!\N>,O'VM
M7/CB?PU9:U:^%M.T^TC>:XNTLY5FE>-)@8Q=1I^];[1''Y/GJHC@DG!+9C(!
M[CX%2\&F^;>ZO%XD\Z5WBO8(+>"/R@%C\I1:N\3[)4D)DW;MS%#C8* /&/%'
M_)9="_[!4O\ Z+U>@#Z9H ^9OVJ_^15M?^PK#_Z27M 'P!0 4 % !0 4 % '
MZ9?L^?\ (B:9_P!OG_I?=4 >S4 % !0 4 % !0 4 % !0 4 % !0 4 % 'S;
M<_M3>$X)7B2#4YT1V598X( D@4D!T$EU'(%<#<HDC1P"-Z*V5 !!_P -5^%?
M^?75?^_-I_\ )M !_P -5^%?^?75?^_-I_\ )M 'G_AW]H#0-(\2Z[KDUOJ#
M6VM?V;]G5(K<RI]CMGAE\U3=*J[F8&/8\F5R6VGB@#T#_AJOPK_SZZK_ -^;
M3_Y-H /^&J_"O_/KJO\ WYM/_DV@#NOA_P#&O1?B/J$FEZ7#>PS0V[7+-<QP
M(A1)(HR 8[B5MVZ52 5 P&^8$ $ ]?H * "@#,UG6;+P]92ZGJ<J6MI;)OEE
M?.%&0   "S,S$(B(&>1V5$5G95(!Y9_PT'X$_P"@G_Y)W_\ \BT '_#0?@3_
M *"?_DG?_P#R+0 ?\-!^!/\ H)_^2=__ /(M 'F?P=^,7A/PKX3L=)U6^^SW
MEO\ :?,C^S7<FWS+NXE3YXK=T.4=6^5CC.#@@@ 'IG_#0?@3_H)_^2=__P#(
MM !_PT'X$_Z"?_DG?_\ R+0!Z-X9\4Z7XPLAJ6BW"7=J7:/>H92KH?F1XY%2
M2-L$,%D1249) "CHQ .@H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@#C/B/_P BKK/_ &"K_P#])): /EGX6^&_[5\-6>N>-[B*
M'PEH'GRV5D3^ZN9C<S&2ZO5!8R[)I'MK:VVEYV'EK"$DD6_ /0/^2B?\5MXV
M_P")9X/TS_2--TVXX^U?PI?WZ+N\SS=P6UM5#^=O$40DAD9M1 #_ )*)_P 5
MMXV_XEG@_3/](TW3;CC[5_"E_?HN[S/-W!;6U4/YV\11"2&1FU$ /^2B?\5M
MXV_XEG@_3/\ 2--TVXX^U?PI?WZ+N\SS=P6UM5#^=O$40DAD9M1 #_DHG_%;
M>-O^)9X/TS_2--TVXX^U?PI?WZ+N\SS=P6UM5#^=O$40DAD9M1 #_DHG_%;>
M-O\ B6>#],_TC3=-N./M7\*7]^B[O,\W<%M;50_G;Q%$)(9&;40#,_9RU6+7
M=:\5ZI;AUAOKV"YC60 .$FGU*1 X5F4,%8!@K, <X8CF@#ZLH * "@ H IZC
MI\&K6LUA=KYEO=120S)EEW1RH4==RE67<K$95@PSD$'F@#XHUZ_^"^B7;6<6
MFW>H["5>:SGNV@#AV0H))M0@\S[NX21"2%T92DK<@ '<>!_!?PM\>2W-G9Z7
M<6=]8.5GLKVXO8;E0I",_EK>R HLF8I/FWQ2 +*B;XBX&Q]#>%?!^D^";1M/
MT.#[);22M,R>9-+F1E1&;=-)(PRL:# 8+QD#))(!X1^TOX;E\065@;*UU*]O
MK=YS"+*T-S $<VXE6Z*'S(68*C6[JL@8QRQLGS"2,V ["V^,TK1(UQX:\41S
M%%,B1Z89$5R!N5)&DB9U#9"NT<98 ,40G: #T?PKXE_X2FT:\^Q:AI>R5HO)
MU*W^S3MM5&\Q8][YB._:KYY9'&/EY .EH * "@ H * /E7Q!XC\':-XVOX_&
MNCV]M,]NC)J5P;K4(;M,0)!Y=DUHT43^4A1YHU81RP30"60LS, 8'PP^%X\?
M:!?6VKQW>D:%<ZJFHZ7:1';-'FWD4L)KFV<W%K);SV\<4N6\QK=G'EY?S0"M
MH_P_T_X;_%71=+TN2XFAFLKBY9KEHW<.]OJ49 ,<42[=L2D J3DM\Q!  !]I
M4 ?,W[5?_(JVO_85A_\ 22]H ^ * "@ H * "@ H _3+]GS_ )$33/\ M\_]
M+[J@#V:@ H * "@ H * "@ H * "@ H * "@ H ^!O@IXKO;'19O#GA.V2;Q
M/JM[(QN7C AL;&."W5;NYE*,'6*1YA;PD2*LKN6C=Y([>[ /8/\ DGW_ !1/
M@G_B:^,-5_TC4M2N/G^S[_F>_OW;S-NWS2UK:L9-OF"643S3JM^ '_)/O^*)
M\$_\37QAJO\ I&I:E<?/]GW_ #/?W[MYFW;YI:UM6,FWS!+*)YIU6_ #_DGW
M_%$^"?\ B:^,-5_TC4M2N/G^S[_F>_OW;S-NWS2UK:L9-OF"643S3JM^ 9D5
MC+HE[)\-_!<S_P!NW:"\\1>(+C/VA$<(SR1;F\R2=Q<+Y*QN1;B<$3&YEN;V
MW -/R+7X:?\ %!?#B+[7XDU#][=7=P4D^PPG[MU?RK&$'DI(!:VPB"#>)6AD
MDN$BO@#F?A-X;_X1+XGZMI)N);YX=*#RW,YS+/-.=,N)Y6Y)^>:5V 9G<*0'
MDD8%V /K^@ H * /&?V@_P#D1-3_ .W/_P!+[6@#PSPUX:LOBS9:?HFB:?:6
M&F6%I9#6];%E EW<7:01-+964K1;_-W\W-R<DD[FS"8X]0 .@G\)Z+\3KT>'
M?"&GV5CX=TMTCU'7(K6!KBY>(*19Z?<NCR2,0%,]XSN7!\QV>%D340 G\)Z+
M\3KT>'?"&GV5CX=TMTCU'7(K6!KBY>(*19Z?<NCR2,0%,]XSN7!\QV>%D340
M G\)Z+\3KT>'?"&GV5CX=TMTCU'7(K6!KBY>(*19Z?<NCR2,0%,]XSN7!\QV
M>%D340 G\)Z+\3KT>'?"&GV5CX=TMTCU'7(K6!KBY>(*19Z?<NCR2,0%,]XS
MN7!\QV>%D340 G\)Z+\3KT>'?"&GV5CX=TMTCU'7(K6!KBY>(*19Z?<NCR2,
M0%,]XSN7!\QV>%D340#H/V5/^15NO^PK-_Z265 'TS0 4 % !0 4 % !0 4
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M\@'2T % !0 4 % !0 4 ?,WBC_DLNA?]@J7_ -%ZO0!],T ?,W[5?_(JVO\
MV%8?_22]H ^ * "@ H * "@ H _3+]GS_D1-,_[?/_2^ZH ]FH * "@ H *
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M\SS=Q:ZNF+^=O,LIDAD5=1 #]E3_ )%6Z_["LW_I)94 ?3- !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <9\1_^15UG_L%7_P#Z
M22T ?+/PM\-_VKX:L]<\;W$4/A+0//ELK(G]U<S&YF,EU>J"QEV32/;6UMM+
MSL/+6$))(M^ >@?\E$_XK;QM_P 2SP?IG^D:;IMQQ]J_A2_OT7=YGF[@MK:J
M'\[>(HA)#(S:B '_ "43_BMO&W_$L\'Z9_I&FZ;<<?:OX4O[]%W>9YNX+:VJ
MA_.WB*(20R,VH@!_R43_ (K;QM_Q+/!^F?Z1INFW''VK^%+^_1=WF>;N"VMJ
MH?SMXBB$D,C-J( ?\E$_XK;QM_Q+/!^F?Z1INFW''VK^%+^_1=WF>;N"VMJH
M?SMXBB$D,C-J( ?\E$_XK;QM_P 2SP?IG^D:;IMQQ]J_A2_OT7=YGF[@MK:J
M'\[>(HA)#(S:B 9G[.6JQ:[K7BO5+<.L-]>P7,:R !PDT^I2('"LRA@K ,%9
M@#G#$<T ?5E !0 4 % 'F?B'_A/OMTG]@?V!_9WR>3]N_M#[3]Q?,\SR/W7^
MMW[-O\&W=\V: /#9M3\5>+O%5UX7O],\'WNJ:9:I*]Q=V=W-%Y)\B18XI7,D
MW!NU.PQH@;S"#T+ ;'LW@[3?&FD3P6>H0^&K31HO,WPZ5'>Q2)N5W7R8W"P+
MNG8-)D#*ER/G(- 'K% 'S'^TOXCE\/V6GBQNM2LKZX><0FRNC;0%$-N96N@@
M\R9E#(MNBM&%,DLC/\HCD )?$7PJU70/#EYJ'_"4>()M1L;6>YW_ &V5+9_(
M5YMGV?S&E7=$OE[OM3;9#YNTJ/)(!X3X8^)NK^$TTCQ'+J>I:C;W5Q=V6J6=
M[*US'BW>VD>2S\R<88VUW 8BWE.ES%(&D>VE,=,#]#:0!0 4 % !0 4 % 'S
M-XH_Y++H7_8*E_\ 1>KT ?3- 'S-^U7_ ,BK:_\ 85A_])+V@#X H * "@ H
M * "@#],OV?/^1$TS_M\_P#2^ZH ]FH * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0!^F7[/G_(B:9_V^?\ I?=4 >S4 % !0 4 % !0 4 % !0 4 %
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MSP?IG^CZEJ5OQ]J_B>PL';=YGF[BUU=,7\[>993)#(JZB '_ "43_BB?!/\
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M<+)JM[IL%MIL/-N7QNBCGG=$F;S(1Y,Z8$L45S'P0#ZJH * "@ H * "@ H
M^9O%'_)9="_[!4O_ *+U>@#Z9H ^9OVJ_P#D5;7_ +"L/_I)>T ? % !0 4
M% !0 4 ?IE^SY_R(FF?]OG_I?=4 >S4 % !0 4 0W#2I$[6ZI),$8QI(YC1G
M .U7D5)&12V SB.0J,D(Y&T@'YX?''Q3K]QK-KI?BF'2II=(/G*E@]P894N1
M [1SYN!<1Y$2J5_T:8*QD0E)(92 ?97PJ\2:YXMT9-7UV/3XQ=_O+8V$KO\
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M)_Q1/@G_ (EG@_3/]'U+4K?C[5_$]A8.V[S/-W%KJZ8OYV\RRF2&15U$ /\
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MSP?IG^CZEJ5OQ]J_B>PL';=YGF[BUU=,7\[>993)#(JZB '_ "43_BB?!/\
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M)9X/TS_2--TVXX^U?PI?WZ+N\SS=P6UM5#^=O$40DAD9M1 #_DHG_%;>-O\
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M/^2B?\43X)_XEG@_3/\ 1]2U*WX^U?Q/86#MN\SS=Q:ZNF+^=O,LIDAD5=1
M#_DHG_%$^"?^)9X/TS_1]2U*WX^U?Q/86#MN\SS=Q:ZNF+^=O,LIDAD5=1 #
M_DHG_%$^"?\ B6>#],_T?4M2M^/M7\3V%@[;O,\W<6NKIB_G;S+*9(9%740
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MUX2UG6-7BE;7=*?1)HW C0W=M>)*A'WED@(965@0Z/&HP49'D)=8P#K* "@
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M8;Z]@N8UD #A)I]2D0.%9E#!6 8*S '.&(YH ^K* "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H ^9O%'_)9="_[!4O_HO5Z /IF@#YF_:K_P"15M?^
MPK#_ .DE[0!\ 4 % !0 4 % !0!^F7[/G_(B:9_V^?\ I?=4 >S4 % !0!4N
M-0M;1MD\T43$9"O(JG'(SAB#C((S[&@"O_;5A_S\V_\ W^C_ /BJ #^VK#_G
MYM_^_P!'_P#%4 >/>--4LW\<>$Y%GA*1_P!M[V$B%5W6,87<0V%W'@9QD\"@
M#V'^VK#_ )^;?_O]'_\ %4 ']M6'_/S;_P#?Z/\ ^*H >FKV,C!$N(&9B JB
M5"23P  &R23P .M &A0 4 % !0!\#?!3Q7>V.BS>'/"=LDWB?5;V1C<O&!#8
MV,<%NJW=S*48.L4CS"WA(D597<M&[R1V]V >P1A/AO!!\/O <<5]XIN8@;R^
M:*)%M8BS2&]U!T1L^7YY^Q6TIF:.)X@_G%X(KT /^2??\43X)_XFOC#5?](U
M+4KCY_L^_P"9[^_=O,V[?-+6MJQDV^8)91/-.JWX ?\ )/O^*)\$_P#$U\8:
MK_I&I:E<?/\ 9]_S/?W[MYFW;YI:UM6,FWS!+*)YIU6_ ,RVT]O#TJ?"SP*Z
M0:L+=9=<UQX4AFAMV(D)C";))Y\7:K;8D<VL4L423^;YMU: '03ZO:^#((?A
M[\,DBN]:D\SSI]R2Q6&UA%<WVI2JK*UTK+M$+*=C".,P;!:V=P <-\'?"<7@
M7XDZGH,$KW"6>CH#*X"EWD_LN:1@JY"*9)'V)ERB;59Y&!=@#[%H * "@#QG
M]H/_ )$34_\ MS_]+[6@#RSPG/>_$[1=/\(>'0^E^';&RM8M<U&-!$]S<- C
MW.GV8*@;I)'=KR<J0Y=GDW0NB:B =!_R43_BB?!/_$L\'Z9_H^I:E;\?:OXG
ML+!VW>9YNXM=73%_.WF64R0R*NH@!_R43_BB?!/_ !+/!^F?Z/J6I6_'VK^)
M["P=MWF>;N+75TQ?SMYEE,D,BKJ( ?\ )1/^*)\$_P#$L\'Z9_H^I:E;\?:O
MXGL+!VW>9YNXM=73%_.WF64R0R*NH@!_R43_ (HGP3_Q+/!^F?Z/J6I6_'VK
M^)["P=MWF>;N+75TQ?SMYEE,D,BKJ( ?\E$_XHGP3_Q+/!^F?Z/J6I6_'VK^
M)["P=MWF>;N+75TQ?SMYEE,D,BKJ( ?LJ?\ (JW7_85F_P#22RH ^F: "@ H
M QM7\1Z5X?V?VK>6EAYV[R_M5Q%!YFS;OV>:Z[MNY=VW.W<N<9% &+_PL?PK
M_P!!G2O_  /M/_CM !_PL?PK_P!!G2O_  /M/_CM 'DWQ7\:Z!J/]@?8]3T^
MX^S^)=,GF\J\MY/*AC\_S)I-DAV1)D;Y&PBY&2,B@#UG_A8_A7_H,Z5_X'VG
M_P =H /^%C^%?^@SI7_@?:?_ !V@ _X6/X5_Z#.E?^!]I_\ ': .MMKF*\B2
MXMW2:&9%DCDC8.CHX#(Z.I*LK*0RLI(((()!H FH * "@ H * "@#QG_ )JG
M_P!RK_[E: /9J "@ H * "@ H XSXC_\BKK/_8*O_P#TDEH ^6?A;X;_ +5\
M-6>N>-[B*'PEH'GRV5D3^ZN9C<S&2ZO5!8R[)I'MK:VVEYV'EK"$DD6_ /0/
M^2B?\5MXV_XEG@_3/](TW3;CC[5_"E_?HN[S/-W!;6U4/YV\11"2&1FU$ /^
M2B?\5MXV_P")9X/TS_2--TVXX^U?PI?WZ+N\SS=P6UM5#^=O$40DAD9M1 #_
M )*)_P 5MXV_XEG@_3/](TW3;CC[5_"E_?HN[S/-W!;6U4/YV\11"2&1FU$
M/^2B?\5MXV_XEG@_3/\ 2--TVXX^U?PI?WZ+N\SS=P6UM5#^=O$40DAD9M1
M#_DHG_%;>-O^)9X/TS_2--TVXX^U?PI?WZ+N\SS=P6UM5#^=O$40DAD9M1 ,
MS]G+58M=UKQ7JEN'6&^O8+F-9  X2:?4I$#A690P5@&"LP!SAB.: /JR@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * /F;Q1_R670O^P5+_P"B]7H
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M9=-OM11+JU?RY42"ZF". -R&2&"2,LA.UU#DQN&C<*ZLH ,S_AH/P)_T$_\
MR3O_ /Y%H /^&@_ G_03_P#)._\ _D6@#S/_ (7%X3_X3_\ M[[=_P 2[_A'
M_L/G?9KO_CY_M#S_ "_+^S^;_JOFW[/+_AW[N* /3/\ AH/P)_T$_P#R3O\
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M"33ZE(@<*S*&"L P5F .<,1S0!]64 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!\S>*/^2RZ%_P!@J7_T7J] 'TS0!\S?M5_\BK:_]A6'_P!)+V@#
MX H * "@ H * "@#],OV?/\ D1-,_P"WS_TONJ /9J "@ H X>__ .1EM/\
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M(TW3;CC[5_"E_?HN[S/-W!;6U4/YV\11"2&1FU$ /^2B?\5MXV_XEG@_3/\
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MK^)["P=MWF>;N+75TQ?SMYEE,D,BKJ( ?LJ?\BK=?]A6;_TDLJ /IF@ H *
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M AL;&."W5;NYE*,'6*1YA;PD2*LKN6C=Y([>[ /8/^2??\43X)_XFOC#5?\
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M&_\ A$OB?JVDFXEOGATH/+<SG,L\TYTRXGE;DGYYI78!F=PI >21@78 ^OZ
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M^I2('"LRA@K ,%9@#G#$<T ?5E !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M3_BMO&W_ !+/!^F?Z1INFW''VK^%+^_1=WF>;N"VMJH?SMXBB$D,C-J( ?\
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M4_\ 4R_$3Q+^/7_OW]FTNV\O_IA]H\C_ )=[>W_T  /^24_]3+\1/$OX]?\
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MT_\ DV@ _P"&J_"O_/KJO_?FT_\ DV@ _P"&J_"O_/KJO_?FT_\ DV@#YS\
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MC-P8HT/V:-8$M0 \+?&O1?"5E=ZLL-[JWC'4TW7%]>QP);[R5Q!&8KAI([.
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MC7HOC77A>>*8;V30=.</IVE01P.D\PW#[3J7F7$2NP7[MNHDB <Q%S&+@WH
M:K\:]%\:Z\+SQ3#>R:#ISA].TJ".!TGF&X?:=2\RXB5V"_=MU$D0#F(N8Q<&
M] #5?C7HOC77A>>*8;V30=.</IVE01P.D\PW#[3J7F7$2NP7[MNHDB <Q%S&
M+@WH :K\:]%\:Z\+SQ3#>R:#ISA].TJ".!TGF&X?:=2\RXB5V"_=MU$D0#F(
MN8Q<&] #5?C7HOC77A>>*8;V30=.</IVE01P.D\PW#[3J7F7$2NP7[MNHDB
M<Q%S&+@WH GPX^->B^#]:\0:I>PWLD.NWHN;988X&=$$]Y)B8/<1JK;;A!A&
MD&0WS8 + 'L'_#5?A7_GUU7_ +\VG_R;0!W7P_\ C7HOQ'U"32]+AO89H;=K
MEFN8X$0HDD49 ,=Q*V[=*I *@8#?," " >OT % !0 4 % !0 4 % !0 4 %
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MVM%#A)%5BI964,!@E6&<@T ?0U !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'R5?>,-0^'.KRZ_8:LWC#PO</&NHH+N"ZN--DE9MCJ("L-NDC[_LXCC@MI.;
M.1(W6VN" ?4>CZQ9^(+.+4M-E2YM+E-\4J=&'((((#*RL"KHP5XW5D=5=2
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M8#W'X=?$33OB/IHO[ ^5/%M2ZM&8&6VE(/!X&^)\,89@H65000DJ2Q1@'?4
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M&@_!WPAX9NUO].TV)+E,%'E>:X\ME975XUN995CE5D4I*BK(O(5@&8$ ]+H
M* "@ H * "@ H ^=OC=X\\0>%M1T>P\)MY]Y<_:9I[".!+F2>*+R6C#1!&N$
MB8+<C?"T3,J2D.#%E ""^CTO]HC08=2T:X?3-=TA_,@_>,'LKIMK&.79AF@F
M:%6ANXT$BF,2( \=Q:DV YGQC<^,?&'AI/!^L^'[B;7YFB=;U/LIL%2%B_VH
MW*R-!;7DB1R0/;[X@5E9XV59DM2!L?3WAW2?[ TNSTK?YWV"U@MO,V[/,\B)
M(M^S<VW=MW;=S;<XW'&: -B@ H * "@ H * "@ H * "@ H * "@ H * "@
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MI]H\.;Z&."YO;GRFBS)!O$J8BNMJ3XG1DM%C\Q6;RX0#Z6H * "@ H * "@
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M,6SO$;YG:18D=M\C "90H$K;;E7ANHS+*; >[4 % !0 4 % !0 4 % !0 4
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M)HE5K-2TA=/-#MYOF;D+;4AC$BO*D2M-)0!Z70 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MEHI,DR1NVTJ >UT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M&D=NB(K,Q"@D 'V#0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
+ !0 4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gemp20161231x10k015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *H E$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \)T#Q=X8TOX?:CH%]IT\FJ:
MA/=K%9I9.YU%FE9596 (.#A>3D%/I796?P]O!IF@Z@+^.#7[&TMT?[;:QWD0
M:-<%1N^>/TS&ZYZX)YKJ_"V@?\(SH,>E_:?M.R663S/+V9WR,^,9/3=CKVK9
MI+1>>GX?\.#U;[:_BSS7Q._B<>'=-UC6=+@^UZ%JT5U<+ILAE2XMPN'DC5@&
M& Y^4\_*3G%+I?B"R\??$;2]2T%IKC2=&M)_.NVA:-#-+M41C< 20H)/'I7I
M-%-:/^NU@>O]>=SS_P :ZE'J6@:7XET<2WUMHVKK<7"PQ'>8XR\<N%8 DKD_
MD?K533M>L?B#\0]-O]!>:XTG2+.X$UX86C0S3!5$8W $D*"3QZ5Z7122Z/\
MJZL#_K[[GA\7BN+2/AW=?#R:"[;Q8L<VFP6*V['S@Y8)(K8V[-C9R2.AKUVW
MLSIWA:*R8[C;60A)]=J8_I6G11*\HM/=_P!?J-.TD^W]?H<I\,_^29^'?^O&
M/^5=71152=VV3%6204444AA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!E^(]6FT+P_>:E;Z9=ZG/ @,=
MG:(6DE8D    G&3DG!P 3@XQ7F?_  M_QA_T2;7/SF_^,5[!10!X_P#\+?\
M&'_1)M<_.;_XQ1_PM_QA_P!$FUS\YO\ XQ7L%% 'C_\ PM_QA_T2;7/SF_\
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M,/\ HDVN?G-_\8H_X6_XP_Z)-KGYS?\ QBO8** /'_\ A;_C#_HDVN?G-_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&O0__!C#_P#%4+=/^MFOU![-?UO<QO#+W&@1^(99]*U!Q<^(9?*2&W)8I(4
MEP<?(.26'8&LGXEZ=!+K=A?S:#XF>2*(I#JWAF7-U&<G,3)V0@YW<\\<9.>O
M_P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*I6T2[?Y6'?5^?\
MG<P/ -[KUAI,%MK=KK=Q'>7TB6$E[&'N(+?;N4W1!^4Y!&3DY(''%=_7/_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6$,ELL*Q,1M+N5)\QMO )YY)[US'_"/?'/\ Z'/0_P#ORO\ \CT?\(]\<_\
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M]^5_^1Z/^$>^.?\ T.>A_P#?E?\ Y'KV"B@#Q_\ X1[XY_\ 0YZ'_P!^5_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<"[4C<\E!\S9V],[CG&>,XK0HHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %>?_%/_F2O^QKL?_9Z] KS_P"*?_,E?]C78_\ L] 'H%%%% !1110
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M.A\6?]@I/_0;6O8* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[=WM7UO7@GP8^$VKZ3K</BG7TDL7@0_8[,D;WWH06D'.T!6(VG#9ZXQAO>Z
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M@ HHHH **** "BBB@ KS_P"*?_,E?]C78_\ L]>@5Y_\4_\ F2O^QKL?_9Z
M/0**** "BBB@ HHHH **Y_Q-XJ_X1G[+_P 2'7-5^T;_ /D%6?G^7MQ]_D8S
MNX]<'TKG_P#A:?\ U(7CG_P3_P#V= 'H%>?_ !M_Y)#KO_;O_P"CXZ/^%I_]
M2%XY_P#!/_\ 9UR'Q2\??VW\.-6T_P#X1+Q78>=Y/^DW^F^5"F)D;YFW'&<8
M'N10![?17G__  M/_J0O'/\ X)__ +.C_A:?_4A>.?\ P3__ &= 'H%%>?\
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MH8=1P<C'(&1G<K+T'Q!IOB6PDO=+N(YX([B6W9D=6^9'*Y^4D8( 8>JLI[T
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M++5VTH?:((""B8-N%P0S=5VGJ>OX5[O7C_A[_DZ'Q9_V"D_]!M:]@H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/_ (P^,O\
MA$/ UQ]FF\O4]0S:VFUL.F1\\@PP8;5Z,,X9DSUKT"O%_BE\+O&'C[Q0MY;:
MAI46F6T2Q6D,TTRL,C+LRA&7<6XR.JJF>E '$? 'QE_8WBB3P]>3;;'5?]3O
M;"QW 'RXRP WC*\ EF$8KZ?KYD@_9X\;6MQ%<6^KZ-#/$X>.2.YF5D8'(((C
MR"#WKZ3L/MG]G6W]H^1]N\I?M'V?/E^9@;MF[G;G.,\XH X?XP^,O^$0\#7'
MV:;R]3U#-K:;6PZ9'SR##!AM7HPSAF3/6O(/@#XR_L;Q1)X>O)MMCJO^IWMA
M8[@#Y<98 ;QE> 2S",5V_P 4OA=XP\?>*%O+;4-*BTRVB6*TAFFF5AD9=F4(
MR[BW&1U54STKC(/V>/&UK<17%OJ^C0SQ.'CDCN9E9&!R""(\@@]Z /INBJ]A
M]L_LZV_M'R/MWE+]H^SY\OS,#=LW<[<YQGG%6* "BBB@ HHHH *^,/B;X1_X
M0OQS>Z;$NVQE_P!)LN<_N7)POWB?E(9,DY.W/>OL^N'^)/P[M_B!9Z7')-Y$
MUE=JYD!()@8@3(O4!B ""5/* < DT <O\ ?!O]C>%Y/$-Y#MOM5_U.]<-';@
M_+C*@C><MP2&41FO8*C@@AM;>*WMXHX8(D"1QQJ%5% P  .  .U24 %%%% !
M1110 5\J?'/Q+XCU#QC-HNJ6\ECIMD^ZSM@<K.O($Y/1BPSC^[RO7<3]5UR_
MCKP+I?CS0S87X\JXCRUI=HN7MW/<>JG RO?'8@$ 'Q14AGF:W2W:60P1NSI&
M6.U68 ,0.@)"KD]]H]*^C/\ AG;3O^$&^R?;/^*F_P!;]MW-Y.['^JV_\\_]
MK&[/S=/DJG\0OA-X<\*?!^6XMTDDU33GCD:^SM:=I)$1PPY&S!^5?X<=3EBP
M!\_R3S3)"DLLCI"FR)68D(NXMA?0;F8X'<D]ZCKZ3U;]G72)?#^GVVE:A)!J
MD#J+J\F!9;E21O.S.%*C)4#TPQ.=XDUK]G;0KJ\TDZ1>3V-K%B/4%=C(\Z@$
M[U)X60G@\;><@#;M8 C_ &?/$OB/5=+NM*O[>2XT>P0+;7[GF-N/W'/WP%.1
M_<  /#*![95/2M*L=$TNWTS3+:.VL[=-D42#A1_,DG))/)))/)JY0 4444 %
M>$?M+WUQ'IWAVP63%K-+/-(FT?,Z! ISUX$C_G["O=ZYOQQX,L?'7AJ31[Z2
M2$AQ-;SIR890" V.C##$$'J"<8." #XDKWCX5ZG>7/P/\<Z=-#.;6SM+EK>=
MV)0[X&+1J",#:5W$ _\ +7.!G)S_ /AF[Q)_:.S^V=*^P^;CSLR>9Y>?O;-N
M-V.=N[&>-W>O6[[PIIO@SX.>(-&TL2&"/3+QVDEV^9(S1N<N5 !.,*#CHH':
M@#R3XN7UQ'\+/AO8+)BUFT])I$VCYG2"(*<]>!(_Y^PKQ>OKM?!ECXZ^#'A[
M1[Z22$C3+2:WG3DPRB$ -CHPPQ!!Z@G&#@CRS_AF[Q)_:.S^V=*^P^;CSLR>
M9Y>?O;-N-V.=N[&>-W>@#J_V;]2U*Y\-:M87"R-I]I<(;61@Q 9P3(BDG&!A
M6P.AD)/WA7ME8?A+PIIO@SP_%HVEB0P1NSM)+M\R1F.<N5 !.,*#CHH':MR@
M HHHH **** "BBB@!#T.:X/3++X>ZKX2_P"$H_X172;?3O+DF=I]+AWJJ$AB
M0H;^Z>F:[QONGZ5X3IOB#4;#X33^$I/!7BYK]K2X@$J:4QBW.7(.<YQ\P[5+
M>CMO_P .5%7M?:YZC9>$/!-_96][:^&-#>WGC66)_P"S8AN5AD'!7(X/>NF
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M6?\ 8*3_ -!M:]@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI/\ T&UKV"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\G;C_P".4 <)X \!?#Z[2;PUXDL(SXMT^XE@N8Y;J:$W(W,R20KN7>AC .0
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M:Y_W_A_^-4?\,X^#_P#H):Y_W_A_^-5[!10!X_\ \,X^#_\ H):Y_P!_X?\
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M#_\ H):Y_P!_X?\ XU7L%% 'C_\ PSCX/_Z"6N?]_P"'_P"-5[!110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !12.ZQHSNP5%&69C@ >M<G-
MXFTSQCH.NZ?X4UNUN-3C@FA3RWP5?;@,,XRN2,.,KZ&DV[.PTM5<YGQIXP\
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M;@Y^[C#,<8YX/8[NM9.F_$KQ5I5WJ%GJ6ECQ1I^FR^3<:OHD1#(<,3N0C:S
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M5CXDN+.^F\1!)+'5DB @U*)4$?EXZ*XQS&>A9AZ9W-&\.ZWX%\3QV>B0M?\
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M^O\ AOR?J%]4_P"OZ_,K>'/#(\3Z'?>']4O9C?>&-3:VTW6(&Q/&JA67YO4
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M;[_43:U[?U^-_N&:;X,T?QA$?%&FW/B7PM=:A_Q^VUC<&U+RJ2"74KR0<\C
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M/,_M!>[!L#$H['!S^89NG^';/Q5>/XT\ >))= N[Y3%J,?V-)P7!!(>)CA)
M>IYSU'4DJR;_ *_JS[[A>R_K^O,V?!-Q<>'M3C\!7<]U?W%EIRWAOYI 0=S[
M?+4?>"KVW'/;H!7>5SGA;PI_8#7=[>ZC-JNLWI!N[^9 A<+]U50<(HST'K],
M='5-WWW)2ML%%%%(84444 %,FD$,$DI#$(I8A1DG [4^N/\ 'GC:+PK91VMF
M]K+KUX56QM;AB%<EU3)(QP-V<9!.#CH<)]D-$OA[XB>'O$RV\-A=_P#$RFB=
MSI\@Q-&4^\KCHI!/<\]LX->7W>D6.N^$$O\ 6M-FO_&OBB5XK**[WQFU 8[2
M@_ABC4;R1][/.0:Z>[\#Z[X:9?%WAV4S>(FS+J]B9F>'4,G+*FX J1SLXZ8'
M7KGOXD_X3GQ?I&J^![Z"/Q!8VDL=UI^K6DPAB1B-P9T7APV!P<'U[%JS?GU_
M/3R>U]T*[2_+_@_Y=?RJ)#>:GJ)\">*9+Q]<TMU?1?$MG [,"1N7S",D' YR
M<$ Y.0&/LFEQ7T.EVT6IW,5S?+&!--%'Y:NW<A<G'^>!TK+\+:!/HMM=7&HW
M@O=6U"7S[VX5=J%L!0J+V15  [GJ>M;].[MK_7]?B)=_Z_K\@HHHI#"BBB@
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MAU7# (I;N0.,G'I7IMO!%:VT5O @2&) B*.BJ!@#\JDHIW;%9!1112&%%%%
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MYTN0$G>JGK'G=QQCGI@A>OU^:^\'6WB#Q?!(@NM>>S@M(+R,*UHQ4)^\;)&
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MJX'G^F?"V+1?%>G:M8:_J0L;!9!!I\["41AQ@HKGYA&!C"G/(SG->@444=+
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M%<-!\,=>M(/[+MOB)K,>@[EQ;>4AN50 #:MQG*CCH% QQCK26UNW^=QO>_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gemp20161231x10k016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *R E0# 2(  A$! Q$!_\0
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M+4P;/.\^Y1/+W9V[LGC.#C/7!J[!<0W5O'<6\T<T$JAXY(V#*ZGD$$<$'UH
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M37;>"?3#II/[]IF9D7$?WCG<#D#'/UKVJL]]!T>755U632;%]17&V[:V0S#
MP,/C/3CK0U=6>S_K]6"=G==/Z_R(-*$5EI&FZ+/<PK?+8HODEQO(50K,%SD@
M''/O7EEGXITG3?@G>^';JZMTUVW@GTPZ:3^_:9F9%Q']XYW Y QS]:]D:TMF
MO$O&MX3=(AC28H-ZJ2"5#=0"0./:JKZ#H\NJKJLFDV+ZBN-MVULAF&!@8?&>
MG'6G+WF[]=_Z^8H>XE;IL<!!<VW@WQ]I+:Y<06=K<^'8K-+J=@D8FA;+(7/
MR#GD]JP]3+:_X?\ B#K^EQ_:K*2_M7MV1"5N%MMGF,O]X<-R.#@U[!J&EZ?J
M]M]FU.PM;VWW!O*N85D7(Z'# C-36UK;V5K':VD$4%O$NV.*) J(/0 < 4[M
MN_7_ (-Q))6^7X*QYSKOB71_%VO>#;'0=0MM0F_M%=0E^SMO,,4<;$E\?<.6
M PV#GM6QXV_Y&+P5_P!A@_\ HB6NCT_0='TB6673=)L;*2;_ %KVULD9?O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >,Z;_P ( ?$WC;_A+#I?VL:E)M&H
ME?\ 5;%_U6[^+.[.SYON^U:OAOP_J>O?"K2K>VU&>TB7SC!#<&15N+<LXB60
MQND@&S;C#XP>0W%='I?@FT%UK4FN6&FZ@MWJDE[:B6$2^4K(B_QKPV4[>W-=
M=22]Q)]E^0V_>;7=_P!?UY=CS.+3+Z#PMKOA9?!=MI$TVF2B*ZTQEDMKMQ&%
MY;"N');@."3@\G%9.L>*M'\1_#+1-!TV\MIM7OGL[86,9S+"Z.A?<G50NQN3
M@<=:]BK/@T'1[74Y-3M])L8;^7/F74=LBROGKEP,G/UJD_>N_+\";*UEY_C_
M ,,4/$ZIKGA'Q#IVGS17%U]DFMVCC<,4D,9PK =#R.#ZUYYK'BK1_$?PRT30
M=-O+:;5[Y[.V%C&<RPNCH7W)U4+L;DX''6O7(+2VMI)I+>WAB>=_,F:- ID;
M &YB.IP ,GTJK!H.CVNIR:G;Z38PW\N?,NH[9%E?/7+@9.?K2CH[^GX#>J^_
M\?\ ACG/B=_R*</_ &$[+_TH2NSJ&ZL[:^A$5W;0W$897"2H'&Y3E3@]P0"#
M4U"T5O/]%_D#WO\ UU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KW_ -L_
MLZY_L[R/MWE-]G^T9\OS,';OV\[<XSCG%>3_ /"0_'/_ *$S0_\ O\O_ ,D5
M[!10!X__ ,)#\<_^A,T/_O\ +_\ )%'_  D/QS_Z$S0_^_R__)%>P44 >/\
M_"0_'/\ Z$S0_P#O\O\ \D4?\)#\<_\ H3-#_P"_R_\ R17L%% 'C_\ PD/Q
MS_Z$S0_^_P O_P D4?\ "0_'/_H3-#_[_+_\D5T>I^(_&%SXQU;P_P"&[#2&
M^QPV\PNM0:140.&RK!#EB<<8  P<GI4=M\3#:^'I)M;TPP:Q;73V-Q;QS)'
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M17L%% 'C_P#PD/QS_P"A,T/_ +_+_P#)%'_"0_'/_H3-#_[_ "__ "17L%%
M'C__  D/QS_Z$S0_^_R__)%'_"0_'/\ Z$S0_P#O\O\ \D5[!10!X_\ \)#\
M<_\ H3-#_P"_R_\ R11_PD/QS_Z$S0_^_P O_P D5[!10!X__P )#\<_^A,T
M/_O\O_R11_PD/QS_ .A,T/\ [_+_ /)%>P44 >;^%M9^*UWXCM(/$OAG2K+2
M&W_:)X)%+IA&*X F;JVT=#U_&O2*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBL>^\6>&],O)+._\0:5
M:74>-\,]['&ZY (RI.1D$'\: -BBN?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A._!_
M_0UZ'_X,8?\ XJ@#H**Y_P#X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA
M_P#BJ ..N(?%#?%+Q-/X7NM,2=+6R66WU)',4@(?#;D^8,N#CL=QST%=;X3\
M,S:+I%W'JMS'J&HZE.]S?R[,1N[  JJG^ * HSUQVSBFIXO\#17<UU'XB\.I
M<S!5EF6]@#R!<[0QW9.,G&>F:F_X3OP?_P!#7H?_ (,8?_BJ%HK ]7?^MK$$
M'P_\/V4]^]A;264&H6[V]U:6TA2WD# #=Y7W58 8!4#[QSG-<Q:^!_&%Q%IN
M@:UJ^E3>&=-FCD1H(W%W<I$<Q))D; .!DKS\O?.:Z[_A._!__0UZ'_X,8?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KB]5^$W@?6M4N-2O]!C>[N7WRNEQ+&&;N=J,!D]2<<G)/)-=I
M10!Y_P#\*2^'G_0O?^3MQ_\ '*/^%)?#S_H7O_)VX_\ CE9=IXS^(6IZ%)KN
MGZ)HCV%I+,)HI))%FNECD8'R0"0ORC'S$Y8$@8P#T&J_$:RLM*TRZM;0W$VI
MVRW%LEQ<1VL6&QPTLI W<_=3<W^S@@T+57!Z.W]:%/\ X4E\//\ H7O_ "=N
M/_CE9^G_  P^$FKRRQ:;:6-[)#_K4MM5ED*=OF"RG'XU)XR?Q9;^ M<FUK4-
M/A>\:&U@@T]6"6\;RA68RMAG8J^#PH&W@<FEUWPUH_A'7O!M]H.GVVGS?VBN
MGR_9UV&:*2-@0^/OG*@Y;)SWH6K_  ^?]- ]$_O^[^F6_P#A27P\_P"A>_\
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M),$5+_PI+X>?]"]_Y.W'_P <K5^&?_),_#O_ %XQ_P JZNM)*TFB8NZ3//\
M_A27P\_Z%[_R=N/_ (Y1_P *2^'G_0O?^3MQ_P#'*] HJ1GG_P#PI+X>?]"]
M_P"3MQ_\<H_X4E\//^A>_P#)VX_^.5Z!10!Y_P#\*2^'G_0O?^3MQ_\ '*/^
M%)?#S_H7O_)VX_\ CE>@44 <OX<^'?A7PCJ,E_H>E_9+J2(PL_VB63*$@D8=
MB.JC\JZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF*E1)+N& 0"3A>,GVKG_ /A'OCG_ -#GH?\ WY7_ .1Z/^$>^.?_ $.>A_\
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M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<AXD\:7FB^([?0M.\/SZM>W5F]Q"L4PC!96 PQ881<9.
MXGK@8)-=?7FWBFYUNS^*^GW.A:?!J-Q'HLQDM)9Q"94\Y!A7.0K [3SQ@$=Q
M2^TEZ_DQ]&_ZW1MZ%X[@O;'5&UVR?0K[2F5;ZVN)1($#?<977[X;H,#D\#/&
M7)XEUW5M1AAT7PU<16 FVSZAJV;8! 5W>7"?WC$J6P6"C..M0>%-&U>YU#6M
M>\3V-O:W.JI';KIJR"988$# *[#ARQ9LXXQCZ"=/ =IINHPWGAV_O=%59O,F
ML[:3=:3@E=X,+9525! *;<9SSBJ^TK_U_7]7)Z:')6O@RQ^(5SXCUO6FNGOH
M=0GL],DCN&3[&D/"L@4XW;LL<YY_7M? &K7.N> ]&U"]<O=2VX$SG^)E)4M^
M)&?QKEI[#QMX8O\ 7+'PYH=KJ=AJ]R]W!=R7BP_8I)!APZ'EU!^8;>WY#J?#
M.F7?AG3M'\.QV@GLK:R(FU 2A<2@CY?+ZG=ECGMCWI0^&WI]]G?^NHY?%?U^
MZZM_70XJU\&6/Q"N?$>MZTUT]]#J$]GIDD=PR?8TAX5D"G&[=ECG//ZT-%5O
MBA<Z!IWB1IKC3K;11>7,"RF,7%R9&B#/M()P$8C!')_"MN>P\;>&+_7+'PYH
M=KJ=AJ]R]W!=R7BP_8I)!APZ'EU!^8;>WY!J^$=>\$R:'J/AJQAUJ:UTW^S;
MVT:=;<RC=O$B,W PY;(.>#^(4;65]M/OL_UMK\QRO=VWU^ZZ_3I\C+DO=0\)
M^%?&GA[3+J<#3;NWM]-DD?<]O'<A,*&//R[FQGD<5?D\(:=\.?$/AF^\/_:8
M1?7JZ=J*O<-(+H.C$.P8_>#+G(QU/%6X? VK:WX2\2G63!9:UKTRW(CC;>EJ
M8PODH6'WL;1DCCDXIUI:>,O%6OZ))XDT*VT>QT>7[4[)>+.;N<*57:%^XHR6
M^;)Z<U4=U??2_I97_4E_"[>?W]/ZZ$/Q,L_$$J17<VJ0P:+!J5D(+.VC(><M
M+&"9G)Z [L*HQT)Y%>FUS/CO2KW6?#T5KI\'G3+?6LQ7>J_(DR,QR2!P 373
M4E\-O/\ 1#>_R_5A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 <OXWL?&-]IULG@W5['3KI9<SM=Q;MZ8. "58#GMMYXY&"&\[;P1\9F
MUJ/5SXLT,W\=NULLNP<1E@Q7'V?'4#G&:]LHH \?_P"$>^.?_0YZ'_WY7_Y'
MH_X1[XY_]#GH?_?E?_D>O8** /'_ /A'OCG_ -#GH?\ WY7_ .1Z/^$>^.?_
M $.>A_\ ?E?_ )'KV"B@#Q__ (1[XY_]#GH?_?E?_D>C_A'OCG_T.>A_]^5_
M^1Z]@HH \?\ ^$>^.?\ T.>A_P#?E?\ Y'H_X1[XY_\ 0YZ'_P!^5_\ D>O8
M** /'_\ A'OCG_T.>A_]^5_^1ZU/#FB_%RV\06<VO>*=&N=+1R;F&.W!9UP>
M!B)"#G'.[CKAL;3Z910 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 445RWB7QM#H>HPZ-8:==:QKMQ'YD5A:X
M&U<X#R.>(TSQN.?I0!U-%>>R?$#Q+I$;7GB3X?WMAIB#]Y<V=]%>-'_M,BX(
M4#)+=L5W5C?6NIV%O?64RSVMQ&)(I%Z,I&0: +%%%% !1110!SOBRX\2):+;
M^'+>U626-S+J%S)\MH!C!$>"9&(+8' ! SQ3/A[=W%]\/=!NKN>2>XELT>26
M5BS.2.I)ZFMZ\4M8W"J"6,;  #D\5RW@^2X\/_"G29+O3;Y[BTL$,EG% 3.2
M!]T(<'=[4+9_+]0?2WG^A>\4Z-K&O?8K&QU>72]/9V:^GM)-ETP ^18VP0N6
MZG@X&.YKG?#<L_AKQKJFA/XBOM4T>TTY;VZN-5G$CV4I;HTN!A2@+8/0#/<U
M;^(GB;7-'TVRM]!TG5;BXOF(EN;.Q-RUG&,9.S[I<YX!('!]*I^"YM(U'3KW
MPROA/Q/96UU!(U[=:S:&(WA?"N7EW9,C;CZ< XQ@4X[O^OZM^82V_K^O^ =+
M_P )WX/_ .AKT/\ \&,/_P 5705\\?&OX=^%?"/@VSO]#TO[)=2:@D+/]HED
MRACD)&'8CJH_*OH>D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K'\1^(/^$<L([K^R-6U3?((_)TRV
M\^1>"=Q&1A>.ON*V** /(?!?Q'NY-1UJ"Y\/>+KL7&L.(6^Q&1;-"$ C<EOW
M>WDE1T!S76_"^]NM0\ V=S>W,US.TUP&EFD+L0)G Y//  'X5N:-H%KH<FIO
M;23.=1O'O9O-8':[  A< <?*.N?K1X=T"U\,Z+%I5E)-)!$\CJTS MEW+GH
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MO:GK?B'0?$=OIJ:AH[VY,VG%_*D69"X&'YR,<GOGIQD]I7G_ (2_Y*]\1?\
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M6+SKA]\DFT ;G;NQQDGN:KZ/H>E^'[-[32+""RMWE>9HX4V@NQR3_0>@  P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4<T$OBB_22.10RNI" @@\$$=J\D^(GP1U32-<BE\*64]_IE]*$CA3YGM'/\
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M)SO(X &?6*Y_QW_R3SQ-_P!@JZ_]%-0 >!/^2>>&?^P5:_\ HI:Z"N?\"?\
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M9W5M#/:NNUX98PR,/0J>"*CT_2]/TBV^S:;8VUE;[BWE6T*QKD]3A0!FK=%
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MW,D>W=G;]]1G.T]/2@#H**** "J>JZK8Z)I=QJ>IW,=M9VZ;Y97/"C^9).
M.22 .35RJ>JZ58ZWI=QIFIVT=S9W";)8G'##^8(."".00".10!\J>-_C#KOB
M/Q1;:AI-S/IECITOF6$*L-V[!'F2=0S$$C:<J%)7G+%O>_AG\3+'Q_I91Q';
M:U;H#=6@/!'3S(\\E">W52<'J"WSI\3?AW<?#[7(XA-]HTR\W/93,1O(7&Y'
M _B7<O(&#D$8Y I_#GQFW@7QC;ZNT<DMHR-!=Q1[=SQ-C.,]PP5NHSMQD F@
M#Z3^%G_,Z_\ 8UWW_LE<_P#$3XXV_A37(M(T2V@U*XMY1_:#.Q"(!UB4C_EI
MZGD+TPQR%D\ RPZ]X*\>W%AK<FF6]YKM]-%J:80PQLJ,)/GQM&WK]T@9P5."
M/F">-8;B6))HYT1RJRQA@K@'[PW '!Z\@'U H ^X_#'B?2_%VAPZOI$_FV\G
M#*W#Q..J..S#/Z@@D$$[%>$? 'P1KNF^9XFO+J>RT^\BVPV.!_I:_P ,C@CA
M1D[2,,<DY"GY_=Z "BBB@ HHHH Q_$>@?\)'IT=G_:^JZ7LE$OG:9<^1(V 1
MM+8.5YSCU ]*Y?\ X59_U/OCG_P<?_85Z!10!XOH?@^\U/QWXKT.;QQXR6UT
MC[']G=-6(=O-B+MN)7!P1Q@#\:ZC_A5G_4^^.?\ P<?_ &%'A+_DKWQ%_P"X
M;_Z(:NH\0^*M"\*6:W6N:G!91M]P.27DP0#M099L;AG .,Y/% &A86OV'3K:
MS^T3W'D1+%YUP^^23: -SMW8XR3W-6*Y/0/B7X/\4:HNF:/K4<]XR%UB:&2(
MN!UV[U )QS@<X!/0&NLH **** "BBB@ KE?B3;7EW\/=8@L4E>9H1N2$$N\8
M8&15 ZDIN&/>NJK%\6Z]_P (SX7OM76#SY($ CBSC>[,%4$]AN89-*6PX[H\
MLM;WPCXBUN[\0R64<_@KP[IJ6=M&]@6B:>1@6VQE<D@%1TX)!Z<UZ'\.+6]L
MO 6EP7T$UO(JN4@GSOBB+L8T;/.0A48]JQU\/_$UHQ?-XXL$NC^]_LT:2AMP
MW7RO-SYFSMN^]CWKIO"&O/XE\+V6J2P"">0,DT2G(61&*.![;E./:KZ6_KK^
MI/;^NAN4445(PHHHH **** "BBB@#Q_]H[_DGFG_ /85C_\ 14M>P5X_^T=_
MR3S3_P#L*Q_^BI:]@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "O,_$?P0\/>*?$%YK6I:IK)N[IPS^7)"JJ  JJ!Y70* .<GC
MDD\UZ910!X__ ,,X^#_^@EKG_?\ A_\ C54/%GP*\-V/A[7-<_M77+B^@M)[
MS?<7$;^9(J,^7/EY.2.><GUKV^N?\=_\D\\3?]@JZ_\ 134 >8>$_@5X;OO#
MVAZY_:NN6]]/:07F^WN(T\N1D5\H?+R,$\<Y'K7M]<_X$_Y)YX9_[!5K_P"B
MEKH* "BBB@ HHHH **** "O$/VB?"/VS1[3Q7;+^^L<6UWSUA9OD;EOX7;&
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M7XT=#';:U;^*+\6MV1P1\A\N3')0GOU4G(ZD-T_PF^$T/@VW36-82.;Q!*G
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M4DXR1S[BO<Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Y_QW_P D\\3?]@JZ_P#135T%<_X[_P"2>>)O^P5=?^BFH /
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MV/HPR<-VSW!(/V?877V[3K:\^SSV_GQ++Y-PFR2/< =KKV89P1V- %BBBB@
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M##."/0_H:-X1N=#\.7]I::W*VM7[M//JTT*NS3$ ;_+)QM   7. *(Z+Y/\
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M ]@* -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N.\5>)?#DFG:YI5[X@OM,?3TA>]GL
M1(DUNKLI0JX0YSD#C/!.<5V-<S\0FU!/ FJ-I1U 7X13!_9\9>8MO7@!2#@]
M"1R!D\]*3*CN>1R:K\.)HGBE^+7C=XW4JRM=3D,#U!'D]*]D\%R:!)X1T_\
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M@KQ_]H[_ ))YI_\ V%8__14M>P4 %%%% !1110 4444 %%%% !1110 4444
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M#_[_ "__ "10![!17C__  D/QS_Z$S0_^_R__)%'_"0_'/\ Z$S0_P#O\O\
M\D4 >P45X_\ \)#\<_\ H3-#_P"_R_\ R11_PD/QS_Z$S0_^_P O_P D4 >P
M45X__P )#\<_^A,T/_O\O_R11_PD/QS_ .A,T/\ [_+_ /)% 'L%%>$>'/B5
M\6O%VG27^A^&=#N[6.4PL^3'AP 2,/.#T8?G6O\ \)#\<_\ H3-#_P"_R_\
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M>>*[[1II?&&F6FGZ@+AECBM6#*8MJX8X=^=Q8=>PXH Z2BBB@ HHHH ****
M"BBB@ HHHH Q?$?A/0O%MG':Z[I\=Y%$^^/+,C(?9E((]QGFEB\)Z%;^&&\-
MPZ?''I#QF-K=&8;E/7+ [B3ZYS[ULT4 9FL^'M)\0Z0VE:M91W5D<?NW)&".
MA# Y!]P<U'X>\,:+X4T\V.B6$=G;LY=E5F8LQ[EF))_$UKT4 %%%% !1110
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M\NM+KWBZ\L)M0@B:"TMM.5Q;P*V-[Y?YF=L <\ #CK32M_6_GZW^:M\@;O\
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MW']C^-='N?#EW/F/9?*);68$X(68#:PP1DD!1G&:L7GB"V\(+9_\([X*FO\
M0;P&5KKP_%$XWD<8B3[V0HRY('3D]*YOPFNK?%BWMKOQ.B6^C:8XADTU'R;R
MZ0#<\WHH/1#WZY'7K-#^&6A^&=?;5-$N=3L8WY>PBNS]F<X(RR'))Y/4X&>
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M'-=7##%;01P01)%#&H1(T4*JJ.  !T%/HTT\@_4;'&D4:QQHJ(@"JJC  '0
M4ZBB@ HHHH *S-2\1Z'HTR0ZIK.G6,KKN5+JZ2)F'3(#$9%:0(.<'IUKR_PS
MIFAZMXW\7:?XETRROM<2^,\/VZW24FS*J(O+W#[HZ''<C-&[L'2Y;\:^+8[S
M4]&\+:;J5WIYUB:,_P!JP)A)("K$B"7H7.$&1TWC&:S7@U3X3:U+JL]]J6N>
M%[\HM]<7<AFN;*0?*LA./F3'' XX]!G+\9^#+3PA&Q*RR^![R91=6JL2^E3,
M<+<P-R5&3R/?&"",=YX0_P"$B%O>:#XHM5OH;= L&JC:8[Z%A@!U)SOQUX(/
M<]V([76_]:?UZK6Z![V>W]:_UZ;"2^$K+4?$^G^,O#^J?8IY%7[4]NHDBU"
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M-I'<I!,MQ$'_ (9%^ZP]Q65K(\)Z7X@M-;URYT^UU'RFAM9KZX"!5!RVP.<
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MC:L9YWYX& ?4<<USBM)XLE?Q=X13^R_&VF_N=4TF?Y1< =8I!QG./E?V ."
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M&%H\;?-M*$;MISR"<\T[7B[?\-I_37S%?57Z?C_77Y%7P=X#T77=+T_Q+/\
MVC%#J&V_ET7[2?L'GG!WB(C)&1N )(Z=N*]2ID44<$*0PQK'%&H5$08"@<
M=A3Z;:V6PDGN]PHHHI#"BBB@ HHKS[XD2FZU;POX>O+F2VT75[N2*^>.0QF7
M:F4A+#D!V.#C!/2CK9 :'Q&EU)M)T[3-/-W$NJ:A%9W5Q:(6EAA8$N5QTX7&
M[L,FO.[[0%LO$5YJOPTMK?3E\,6K1W<Q+M'?R AFMV&?FVJ"2W7<5&1@$=]/
MI>A?"CPEJNJ^'M!+*@66>%+ELN <9W2$X !)P/RYK TKP1XI:PN=&AUG3T\(
MZG,]T\HC<7[12_,T7]P9R5+<G!S[!*]WR_T]E?RW?]6'=:7_ *[_ #V0G@SP
MWX3\8:K)XP30WM9IXPM[IE]8*T0G//F(SI^.4(SD$@$D'U>F0PQV\$<$2A8X
MU"(H[ # %/JG;9;$I/=[A1112&%%%% !117#_%34[G3O"]JD-Y)8V]YJ$%I>
M7D3;6MX'.'8-_">V>V:/)#1/\1I=2;2=.TS3S=Q+JFH16=U<6B%I886!+E<=
M.%QN[#)KSN^T!;+Q%>:K\-+:WTY?#%JT=W,2[1W\@(9K=AGYMJ@DMUW%1D8!
M'HFF^"_#?@&SU#5_#NAG[6+9B46Y=FE"C<%!D8A<D#FN+\(>&_$^M^%Q;0:I
M86_A+67>[E(1S?A)#EX<X"8)W+OZXYXZ!*]_=W_I+Y;O^M2ZT;V_IOY[+^M-
M'1-!\,?$K4K+QE)I$UE?1+Y=_97=DK13DKP#YB%6QP0Z\X(SCC'J,,,5M!'!
M!$D4,:A$C10JJHX  '040PQV\$<$2A8XU"(H[ # %/JG;9;$I/=[A1112&%%
M%% !17/^*O%UGX0BLKG4;:Z-C<3B&6[BCW1VV>C2=P"<#I_0'FOBGXEN=.\-
MPQVT%TNE:@8X[C6;.52+:-G7) &3ADW?-T!*]2>%Z>@UOJ7O&6I>+;K58_#O
M@XV=K>&V^UW%_>Y*1)OVJJ#:V6)#=00 /4@UR4WVKQ=JWV*^$7A[XE:,#):7
M$61#>1<_=SG?&1G(.2.?]I:NW?P_7P;);^*OAO "\47^DZ=Y[21W\!Y^5F)(
M;H1C@\8]#T M?#?Q6T+3M8B>Y@GM9@\-Q WE7-I*I&Z,G!QZ$<@\$=C32_X/
M==FOZUZB;Z_T^Z?]>ABZ3X>@^(4L^H>)(O$&G7T!6TU/2?M+QV5PR9(( 'SI
MSD8;CWSEO3H88K:".""-(H8U")&B@*JC@  =!3QTZYHIB"BBBD,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*[[%K*.-YE4Y59)@2S#@9[GVKT, *H50 H& !VI0,# Z44KA8****!A1110
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M7GAWPNT@-W-?82[NU&#Y:Q_\LP3U)SD8(/53Z;!#%;01P0HL<42A$11@*H&
M!3Z*.ED'6X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gemp20161231x10k017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemp20161231x10k017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M\C35B4#S%</A7Y;Y.<GG/4=* -R#XD:=YM\FH:?J&G&UL/[1'VF-<RP9V[E
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M_P!#%J'_ ($"MS0-$BT=;CRM0N+P2E<F:0-MQGI^=9U;&C_ZF3_>H TJ***
M"BBB@ HHHH **** "BBB@ J&Z_X])O\ </\ *IJANO\ CTF_W#_*@#FZ***
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M ;^K Y' .>9O$-K>#6S=V*7AG.G21HT)?&=ZD@?PABN[&>IQZ5U=% &!X?\
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M=;:(2PR21LF5W[E>0XW!0/EQC.>>, '0)KNGS362P0,4N;IK1C+ T+Q2")I
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M]\]Z /<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM)D?^@4/XFUN7;YG@V=]IR-TF<'U^Y7944 <8_B36I2#)X,G<@$ M)G&>O\
M!0?$NM-#Y)\&3F+&-AD^7'IC979T4 <7%XBUB ,(?!4L8;J$?&?R2E_X236A
M#Y(\%S>5C&SS/EQ]-E=G10!YYJ]]J^KZ?):'PMJ5GO96\ZSNC%)D=.=F",<8
M((]JAT"34?#UG<V\'A/4+AKJ8SW$UU<;WE<@#)^0#H!P !7I-% '')XGUV-
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M/DXKLZ* .+'B+6!C'@J48;>/GZ-Z_<ZTH\2ZV)&D'@R?>PPS>9R1[G979T4
M<6/$>LJ(PO@N8"/[@$GW?I\G%9]U=ZE>:GI]])X/O ;%WEBA68",R,-N]AY>
M2P&<<]S[8]$HH Y#_A*]?_Z%"Z_[_'_XBC_A*]?_ .A0NO\ O\?_ (BNOHH
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MN?\ GN_YT?;+G_GN_P"=044 3_;+G_GN_P"='VRY_P">S_G4%% $_P!LN?\
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M,W=O3- '2?;+G_GL_P"='VRY_P">[_G7,:O/=21Z7<QRW=D/MT226YV#S 7
M^8C)Q]#WYJ.]6>YUJ2&QGO)+A)XFD<3,D%J@VDH5SAV89.,$_.,X&* .K^V7
M/_/=_P Z/MES_P ]G_.N/UK5-0T[6;IHKF/R1:P!(Y4^1'DF\O>QSG SD^PK
M2TJ^NWN=1L[N2*YDLV3$L";-VY<[2"3AA]>A% &]]LN?^>[_ )T?;+G_ )[O
M^=<MJEPUR]L/)U(7,D<GEV$4WDL3D?O'=&P%'U_BZ$\5D73ZCIWVB[O;E+Y;
M..))EBU&6%]RQ!GQ&OREF.2 >N1TH ] ^V7/_/=_SH^V7/\ SW?\ZXR[DU'3
MKB5;J\)CG+$F*1F?9O\ O!<#8<,L8"D\MN[5TEE>1W]L)X@ZC<R,KC#*RDJP
M/T((H O_ &RY_P">S_G1]LN?^>[_ )U!6/XH>:/P_.T$GER^9$%;G@F11V[4
M ;_VRY_Y[O\ G1]LN?\ GN_YUQT^K:Q"]Q9))!-<1W:1AXX@&:,Q;SM1G 9@
M??IDX..66%S'KFHO_:-RVQ+**6)(Y'@4DEQ(^,@Y!4#DG;QZY(!VGVRY_P">
M[_G1]LN?^>[_ )UP(9K_ %>U%K'/J=O_ &:KHT]R8F;]XP#G Y) '..F#533
M#=W]Q9JUO)?,-/RR2WC1^6WG.,;AG<1C;GJ<9H ])^V7/_/=_P Z/MES_P ]
MW_.N177O^$?M;73M2$MU=Q0+YLJSP@,<?]-)%8_4CFL'5+^\T[3O%%X;F8V<
MYN(!ES_HTHB'ELI[!B=O'?;ZF@#TS[9<_P#/=_SH^V7/_/=_SKBM<OY7@:"-
M[D_;+B.S5;?);RT&Z9U YSC<F?4"MCPS>O?^'[5Y=_GQ P3!QAO,0E6R.Q)&
M?QH W?MES_SV?\Z/MES_ ,]G_.H*9)&LT3Q.,HX*L,XR#0!:^V7/_/=_SH^V
M7/\ SW?\ZX-+>.VM=9ECEEA\O4TM_-\YLQ0L8@^"3Q@,QSVZU9DU&UT#7&A$
M%X$:W9U7[8CI* 5^?#OE3SC)(!YZ\8 .S^V7/_/=_P Z/MES_P ]G_.N?LO$
M4>H02R6UC<R&-E4HDD+GG//RR$8X[FLRTGN+?7DFN)%N8KN^F@B:*_D;R\!L
M Q?<X"$$=0>?H =G]LN?^>[_ )T?;+G_ )[/^=<?K&I:C9>(O)@NHDBGB@C0
M2QY2)GD8%SR,G"X XY(K3TB_N9X+]+DI<365PT.^!=HFPBMP"3@_-M//4'I0
M!N_;+G_GL_YT?;+G_GN_YUP?B+4+^*/4+N.&]1X[)9+:-+E4\B0%^9$#_,&(
M7'#9P0.>MJ_DU+3;B=[B\Q#,LIS'(S,L>X-N"XPA1?D&"=S.I- '9?;+G_GL
M_P"='VRY_P">[_G6?8W<=[;^9&DB;6*,D@^96!P0>O\ .K- $_VRY_Y[/^='
MVRY_Y[/^=044 3_;+G_GN_YT?;+G_GL_YU!10!/]LN?^>S_G1]LN?^>[_G4%
M% $_VRY_Y[O^='VRY_Y[/^=044 3_;+G_GL_YT?;+G_GL_YU!10!92\N"Z@S
M/U]:Z&N73_6+]1744 %%%% !1110 4444 %%%% !1110 5#=?\>DW^X?Y5-2
M,H="K#*L,$4 <M170?V=:?\ /$?]]&C^SK3_ )XC_OHT <_170?V=:?\\1_W
MT:/[.M/^>(_[Z- '/T5T']G6G_/$?]]&C^SK3_GB/^^C0!S]%=!_9UI_SQ'_
M 'T:/[.M/^>(_P"^C0!S]%=!_9UI_P \1_WT:/[.M/\ GB/^^C0!S]%=!_9U
MI_SQ'_?1H_LZT_YXC_OHT <M>Z?9:E"L-_9V]U$K;PD\2NH;D9P1UY/YU3/A
M?P^8UC.A:88U)*J;2/ )QD@8[X'Y"NU_LZT_YXC_ +Z-']G6G_/$?]]&@#DH
M=(TRVN$N(-.M(IT01I(D"JRJ!@*"!D#'&*1=%TI-^S3+)?,#A\0*-P?&_/'.
M[ SZX&:Z[^SK3_GB/^^C1_9UI_SQ'_?1H Y0Z7I[*X:QMB'18V!A7YE7[JGC
MH.P[5'+H>DSQB.;2[*1 S,%>W0@%CEC@CJ3U]:Z_^SK3_GB/^^C1_9UI_P \
M1_WT: .3ETG39_(\[3[63[. (=\*GRL=-N1Q^%)J6F1:D+8N[1RVTZSQ2+U5
MA_0@D'V-=;_9UI_SQ'_?1H_LZT_YXC_OHT <9;^'-"M)UGMM%TZ&9<[9([5%
M89&#@@>AJ1=$TE;22T72[(6TIW20BW38Y]2N,&NO_LZT_P">(_[Z-']G6G_/
M$?\ ?1H Y%]&TJ7_ %FF6;_O/.^:!3\^ -W3[V !GKP*A@T"Q@OI+E88]C6P
MM$@$:B..+))4*!CYB>?H*[3^SK3_ )XC_OHT?V=:?\\1_P!]&@#GD18T5$4*
MJC"J!@ >E9R>'=$C+E-&T]3(I5]MJ@W ]0>.0:[+^SK3_GB/^^C1_9UI_P \
M1_WT: .2@T?2[:WFM[?3;.*"<;98XX%59!C&& &#QZTZRTK3M-+FQL+6U,F-
M_D0JF['3.!SUKJ_[.M/^>(_[Z-']G6G_ #Q'_?1H Y4Z98-?B^:QMC> 8%P8
ME\P#_>QFK5=!_9UI_P \1_WT:/[.M/\ GB/^^C0!SDD4<P42QHX5@Z[E!PPZ
M$>XJE+H6CSWWVZ;2K&2[W!O/>W0R9'0[L9R,#\J[#^SK3_GB/^^C1_9UI_SQ
M'_?1H YB6RM)Y?-FM89)#&8BSQ@G8>JY/8^E%I96EA (+.UAMH0<B.&,(N?H
M*Z?^SK3_ )XC_OHT?V=:?\\1_P!]&@#DK[1M+U-T?4--L[MD&%:X@60J/09'
M%!T;2S-#,=-L_-@54B?R%W1JO0*<< 8&,5UO]G6G_/$?]]&C^SK3_GB/^^C0
M!S,EK;RF0R0QOYJ".3<H(91G@YZCD_G3H((;:%8;>)(HD&%2-0JJ/8"ND_LZ
MT_YXC_OHT?V=:?\ /$?]]&@#GZ9+%'/&8YHTD0D$JZ@C@Y''UKH_[.M/^>(_
M[Z-']G6G_/$?]]&@#EKC3;&[5UN;*VF61@SB2)6#$# )R.2!3+C2=-NX88;G
M3[2:*'_5))"K*G^Z"./PKK/[.M/^>(_[Z-']G6G_ #Q'_?1H YL00K-YPB02
M[ F\*,[>N,^GM3(;*UMWWP6T,38(RD84X)+$<>Y)^I)KI_[.M/\ GB/^^C1_
M9UI_SQ'_ 'T: .?J![&TE@F@DM8'AG),T;1@K(3U+#OT'6NG_LZT_P">(_[Z
M-']G6G_/$?\ ?1H YE;6W61)%MX@\>[8P097<<M@]LGD^M/C@BA,ABB2,R-O
M?:H&YO4^IX'-='_9UI_SQ'_?1H_LZT_YXC_OHT <_170?V=:?\\1_P!]&C^S
MK3_GB/\ OHT <T+:!5E40QA9B6D 0?.2,$GUX '-0VNE:=8G-G86MN02?W,*
MIUZ]!75_V=:?\\1_WT:/[.M/^>(_[Z- '/U633K&.]>]2SMUNW&'G6)1(P]"
MV,FNI_LZT_YXC_OHT?V=:?\ /$?]]&@#E[BPL[LL;FT@F+1F-C)&&RA.2ISV
MR <>U/MK6WL[=;>U@B@A3[L<2!57Z <5TO\ 9UI_SQ'_ 'T:/[.M/^>(_P"^
MC0!R\]A9W-Q%<3VD$LT)S%))&&9/H3R/PI[VT$CNTD2.73RVW#.5]/I72_V=
M:?\ /$?]]&C^SK3_ )XC_OHT <U;VT%I L%M#'#"OW8XU"J/H!4M=!_9UI_S
MQ'_?1H_LZT_YXC_OHT <_170?V=:?\\1_P!]&C^SK3_GB/\ OHT <_170?V=
M:?\ /$?]]&C^SK3_ )XC_OHT <_170?V=:?\\1_WT:/[.M/^>(_[Z- '/T5T
M']G6G_/$?]]&C^SK3_GB/^^C0!S]%=!_9UI_SQ'_ 'T:/[.M/^>(_P"^C0!@
MI_K%^HKJ*K#3[4'(B''^T:LT %%%% !1110 4444 %%%% !1110 5D2S78\7
MVT"M)]C-C(S#'R[PZ8Y]<9K7K.?4V3Q'!I?E K):O<>9GD%65<8_X%0!B37&
MB6^LO)-XQFCE2<LUHU]&$!!R4*XS@=,9HU'5/#VI3QRKXQ^R878$M;Z-58\G
M/(//^%/T;_CWO6+2;DO[O:WE9:+,S_ZOY3NSWZXK3V(I(5%3R\L@CCW"(D/E
MHOD^=SW';/Y@&;>:UX>O;&&V7Q8EN4(Q-!>QJ[X!&"><^I^E%KK7AZVTV6T_
MX2Q)C*643RWL9D4D8^4^HQD<=:T75$5]J"/RPS)Y,>[R21)EHOD^=SW7MGWY
M5T16<"-$VEI (TW!&)?,B'9\TI[K[^_(!DZ;JGA[3IVE/C$W88;-EU?1NH.>
MV .>*8NH^'UU,WG_  FCD>:6^SF_C\K)_AQC./;-;.Q-V/+3&[S,;.-V?]9G
M9_K?]FD55RORCYOWAS']YOE_>-\G$H[+_AP 9.HZGX?U"Y\X>,FM  $,=M?1
MJN?H0>>?Y5+?:UX>O+*.V_X2R.W,17,T%[&KMQC#$YZYST]*TD1"R QHVYED
M(=,!V!3$CG9\LH[+_D(BHX3<@D\P*[^;'M\X@1X>7Y/D<=E]O;@ SK;6O#UK
MITUFWBR.4N&!GFO8S*F1C@]L=1Q3--U;P_IDDCMXO%WN4 K=WT;!?<8 Q6IM
M1U^9!)Y@^?SH]OG8 QYOR?(1V]:5E5_O+YOF9#":/:)<$X$GR?*!_#ZT 8J7
M_A^+4#=GQK(P5_,,#W\?E@>A&.GXT_4M2\/W]SYW_"9-:;4 ,=M?1HN.>2"#
M_D5K.J.K[D$GF@J_G1[?. #_ "R_)\JCL>_X\K(JNSEEWE]T;&2/!D4&3]W)
M\GRQ#LW?WS\P!FWNM>'KRRBMAXL2W,>&,L%[&LC #'S$YX/7IUHAUKP]%I;V
M7_"6)(64G[0][&95![@]..W%:1"EB<9)/EDF+DKD_NS\G^J_VJ38@VX11P(^
M(_X>?W?W/]5_M4 9>F:MX?TZ5V/B\7F]>%NKZ-P!ZC %117_ (?34%NQXUD<
M%S((&OXS&1Z8Q]WGUK:4*&4@;2I$8*19*KE?W:_)S%ZMV_DB*J",JHC\L*B&
M*/)A4^7\D7R?-&>[=O;'R@&1J&I^']1N5F7QDUJ"F!':W\:J<=\$'GFIK_6O
M#VH00Q+XL2VV\A[:]C5GX[DYS6BJH@7:BQ^6 $\J/=Y((&1%\GS ]SV_D!41
M5VH(_* ">3'N\D$#B+Y/G![GM_( SH=:\/1:6UE_PEB2&3<!</>QF49]#TX^
ME,TS5O#VG2.Y\7B\\SY0MU?1N 1Z8 YK49413M01^6"4\F/=Y)(;)B^3YV/<
M=OYK(B+O 14$>YU$<>X1,?-R\?R?-(><KVS[_, 8T&H^'X=1%Y_PF;R#S&/D
M/?QF/)S\N,=!Z9[47^H^'[^Z,X\:/:@X7R[:_C5,CV(/-;+JJ[\+LVAY!Y<>
M[:QW?O%^3F4]U]^_<9$#$"-  3( J9"MEOW@.SF7U7_) ,W4-:\/7\$40\6)
M:^6V"]M>QJS'I@DYHBUKP]#I<ED?%D;DY4W+WL9E4GT;IGGCBM((A91Y:$$B
M0ADP"V1^\)V<2_[/^0(B-L!17#[782Q[1*P\O#R?)\L@XPO?'M\H!F:;K'A[
M3#,6\7+=[]HQ=WL;[#[8QC.?Y5!;7_A^UOA='QK)*$8DPRW\9CY[$8]_7TK9
MC5'*;E$N\*[>='L\P@QX>3Y/ED'\*]_PX%5'1=R"3S &?SH]OG$!<-+\GR,.
MP[_R ,?4-1\/WUTT_P#PFCVH"@&.WOXU0>^"#4^HZUX>OH$B_P"$L2T\KYF>
MWO8T8C'\1.>*T2J.AW()?-&'\Z/;YV >)?D^0#MZT.JN)-RB3S R/YL>WSE
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M(7/A9!M2?1@N_LT(!8$X3'J/[].6]\-(\<BW.D(Z956$D61NSNB'IG)RW?-
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M2"2.?6H @,8^?]UC:7"CH&"GKG/4U<>_\.>=/*+K27EF1HG;S8@;A<./))[
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M5-.0H!$&$\9\L97]SUY!_O5!:7_ANR<26UWI-HX 5GCDBS#GR_W?'W\_WNU
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M<_=]Z -+RQOQY2]?-V[1CK_KON??_P!FD$8(4^4IR?-R4&6X7]\?DX<?W?\
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MM\'*P6K*V>W)8BMRB@#!N=/UDW[-;/I"VFX;4DM6+X[\AL9Z]JGU.QOW:/\
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ME6(!&6^4?-P_O_D(Y/S_ 'NASMST^;[G^WZTK$Y;GU^[G&,GI_MT &\Y^_\
M[.=QQC/W?O??]ZS==<CPYJ7S[=MG(H+L2%!4?*WS<N>Q_P G2R<__KQC_P"+
MK.UTG_A'-2_Z\Y,;\XQM'WO]OTH W:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#6[N!Q8P :C*$B_LB5YE7<=OES [>>.=O%>@L" ^5(V@D[ 3M'S<IQRWJ/\
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MYAG(/[[@<=:CTA09M67RP=]_)\O_ #UP%Z^F*U.&R>'\S*Y( \W&[Y3Z8]:
M,\CQ(0=FHZ4=V1'G391N89R#^^^4<=?\D(\29.W4M*(.57.FRC+#.0?WW XZ
M_P"3?;#AN!)Y@*\@#SL!OE/'&/6G-AF8\/N)3) &_EOW?L!ZT 9V/$F?^0EI
M6/NY_LV7[WI_KNGO1CQ)WU'2O[K?\2V7A^./]=R.>M:/&<\==F<#U_U?T]Z0
M 9' &/DZ#Y>G[OIT/K0!G@>),C=J6E@#Y6(TV4X8XX'[[D<]: /$@QOU'2AM
MP),:;*=K'& /WWS#GK_D:*X!4\+M(3.!\G*_N_<'UK(\2ZG-H7A;4M3MHE,]
MC:L\:$9$1"KA?<=R: )L>) /GU'2AM_UF--E.WTQ^^^:C'B5?OZCI0V_?QIL
MIQZ8_?<_TKD(VUG2=*BO9O%D5R\^F33FWFCB5DD\K>&M]H&0,\CD8.:J^#8M
M:UK3(9;S4_$EGYEE'*+J46WE!GVMNBPI;GG[PZ$]Z .Y(\2*#OU'2ALYDQIL
MIP.<8_??,>.E!'B5<AM1TH%<L^--E.$YP1^^Y/'3W_/RU-4UNV^',.N-XAU*
M6YDU 6[!4C)A3SV0L@"9+%0?7K6E8:SKMK<Q1W<VK)I[ZU;Q6<NH6ZPSLKQR
MF0LNP97<!C@'KS0!Z!M\2YQ_:.E9'S'_ (ETOW/7_7=?:C'B3MJ.E?WO^0;+
M]SU_UW7VIFK7]QI6@ZA?20PM-;I+-%&IRIP6V.3CJ>,CMS6)J[:E!=0VUIJL
M\U\JPM;VT,2LI&?GGG)4X#<]QT^7F@#>"^)20!J.E9/S#.G2_<XY_P!=P>>E
M 'B1L;=1TH[\-'G391E>,D_ON#ST]OR@U/4;^/4K;3],LK:XGFB>Z8W,WEIM
M1D&[A2=Q+#C'&#["LKPQJMWKFO75U(/]$DLK66*V+]6;EF(QC<",9]AB@#<
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MWC_[[%'VJW_Y[Q_]]BN8=UC7<[!5R!EC@<\"G4 =+]JM_P#GO'_WV*/M5O\
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M '7?:K?_ )[Q_P#?8H^U6_\ SWC_ .^Q7-4V21(E#2.J*6"@L<#). /J20*
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MA;3KRVU:\N+RSU6-98K55:ZN=[EU$N\DASE<MT/J..F.VVMZ'\J-K>A_*@#
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M)G<Y\M@PSYBL!NV]#@''&,U8MX+^!;F&XTDW,UY+%-YCNK1J0B [VSG*%3C
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M+?WUK.%M?LLZ0+)+*@$S,N0%YSGV/- $!\/W*7%Y):ZU=6Z7,IE,:QQL$8@
M[25R.E..C:D2W_%0W0W#'$$0QUY'R\'FM*/4+*6U:ZCN[=[=<[IED!08ZY.<
M5);W$%U"LUM-'-$WW7C8,I^A% &2VBZDV_\ XJ&[&X8X@B&.O(^7@\]:&T;4
MF+'_ (2&Z&Y<<01#'7D?+P>>M1:#XPTS7-)74#*EFK22H$N955B(VVLW7I_C
M5RZUN*"]TN"*/[0FH.RI-'(FU0%W9Y.6!]LT 0?V-J6<_P#"0W73'^HB_/[O
M7WH_L74N/^*AN^%V_P"HBY]_N]>.M:D-]:7,TL,%U!++$<2(D@9D/N!TJCJ/
MB32=,TR^OYKV%X;%2TXBD5F7VQGJ>F* (1HVI J?^$ANCM7',$7/3D_+R>.M
M"Z+J2[/^*ANCM&.8(CGIR?EY/'6K4&O:5<6-I>"_MDANT#PF255+Y[#GJ.A'
MK5-?%>GCQ+?Z+.PMY+.**1IIG54?S,X R>O% #AHNI#;_P 5#=G;ZP1'/U^7
MF@:+J0V_\5#=G&>L$1SGU^7FG1^([9_%-WH1C=);6T6[>9B FUB1C]*T(]1L
M9;1KN.\MWMESNF652@QZMG% &:-%U(;?^*ANSM)/,$1SUZ_+SUH_L74N/^*A
MNSABW,$7.<\'Y>1STK6M[B"ZA6:VFCFB;[KQL&4_B*Y34_B#9Z?87=[%875W
M#!J*Z:AB*CSICUVY/0'Y<^H- &K_ &+J7_0PW?WMW^HB_+[O3VH_L74O^AAN
MOO9_U$7Y?=Z>U8\/Q'TZ.+5?[8L;W2)],A6>:&Y52S(QPI3:2#DX'U(J32_B
M!97M^;+4-,U'1YVMVNH1?Q!1+$HRQ&">0.2.M &I_8NI?]##=_>W?ZB+\ON]
M..E']BZEAO\ BH;L9(/$$7&,<#Y>!QTK'TSXBVVHW6GA]%U6TL=1?R[.^GB7
MRY6/W<X8E<XXR*;_ ,+*TUK,-#974]]+?R6%O8Q[3+,R'#,.<!1U)/2@#:.B
MZD=W_%0W0SCI!%Q]/EXH.BZD=W_%0W8W8Z01#'T^7BLVZ^(.EV>KR:?-:W["
M"6*"ZNXH=UO;2R8VH[Y]2!D CFNE^W6?VS[']J@^U8SY/F#?CUV]: ,QM%U)
MM_\ Q4-V-PQQ!$,?3Y>*&T;4FW_\5#=#<N.((ACKR/EX//6M6YNK>SA,UU<1
M01 X+RN%4?B:BDU33XD1Y+ZV19$+HS3* RCJ1SR/>@#/;1=2;=_Q4-V,KMX@
MB&/<?+U]Z#HVI$D_\)#=<KC_ %$7Y_=Z^]:;W]G';QW$EW D$A 25I %8GI@
M]#FJ'AOQ!!XETDZA;PR11B:2';)C.48J3Q]* (QHVI @_P#"0W7"X_U$7Y_=
MZ^]"Z-J2[?\ BH;H[5QS!$<].3\O)XZU1M/'>F7GCNY\*)',+J!"1.<>6[ *
MS(.^0&Y^AK>&J:>9Q +ZU,QD,8C$R[BXZKC/4>E &>NBZDNW_BH;L[5Q\T$1
MSTY/R\GCK0NBZDNS_BH;L[1CF"(Y^OR\U4N/'&F*^HQ6@:ZN-/N([>>)'1>7
M(Y!8@$#//N,5O?;K/[9]C^U0?:L9\GS!OQZ[>M &8-%U(;?^*ANSMSU@B.?K
M\O-']BZE\O\ Q4-V<$GF"+G.>#\O(YZ5J+?6C7;6BW4!N5&6A$@W@>NWK4<&
MJ:?=2)';WUK+(ZED6.96+ '!( /(R#0!G_V-J7'_ !4-UPQ/^HBYSG@_+R.>
ME']BZE_T,-W]XM_J(N>O'W>G/2M2*^M)KF2VBNH))XO]9$D@+)]1U%5+S6[6
M#3;Z[M62^>RC9Y(+>16?@9(Z\'@\&@"M_8NI?]##=_>W?ZB+\ON]/:HKGP[?
M7=I/;3>(+PQ3*5<+#$#@C! .W@>U:]A?6^IZ=;W]I()+>XC66-QW4C(JS0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !4<_FBWE,"HTVP[ YPI;'&?;-25C:[H]YJQ@^R:Q<:?Y>[=Y(/SYQC.".F/
MUH X"+0]3\6>,[6\U'1=2TZ(V;PZH+B16B!^78MMR<#<N21@'GUY[I?"6G)X
M@36$DNEF2X:Y$(F_<^:T9C9MOJ5/Y_CG-_X0_6/^ANU#\F_^+H_X0_6/^ANU
M#\F_^+H Q--U34O#'B3Q,)?"^N7L5[J'GPS6<"LA78HZEAZ5D:SX7U+4=?OO
M-TF>6SN?%%C.X:/*O;B,K(Q_V1G!KLO^$/UC_H;M0_)O_BZ/^$/UC_H;M0_)
MO_BZ .'UKP9JNWQ);:7I3Q:<-9M+M+6&%=D\*H?,"(<*WS$';T.W%=A\-M&N
M=*LM4EEMKJUAN[KS8H+B&.$CY0"PC0D(#QQ[58_X0_6/^ANU#\F_^+H_X0_6
M/^ANU#\F_P#BZ .'\,^#;R;5/#4>LZ&\EG ^HM.ES#N12SYCW \<]1FJ]II.
MH6$7@S2GCDLKO[?J2P+)D&,,C["!Z<@UZ!_PA^L?]#=J'Y-_\7567X>W4VH0
MW\OB*XDO(%*PSM%EXP>H5MV1GVH XCPIX+UR">%$L+W3KZUT^ZMY;AH(88WD
M="J_O%):7YL,">F*GM/"\ESX4N-/@\"36>I0:));37LK*GGSX'"J"1)EAN#'
MI@8[5W7_  A^L?\ 0W:A^3?_ !='_"'ZQ_T-VH?DW_Q= 'G&M>']4U*P$<7A
M2YBQHB00%;*-W,BYWAM[8B^;)&T;FSG.35J_T&[.HZC/?^#[S5OM.AVUK;R>
M4K&*?RL'.X@J0>K#E<>]=[_PA^L?]#=J'Y-_\71_PA^L?]#=J'Y-_P#%T <!
MJ7@OQ/+9WMHMO-+.-!L8'<'B9HY 9(PQX)P/Q_&IE\)7LWAC6C'I.J1QW%W:
MR);K:6\+ Q@[G%N#L8<KE21NQFNY_P"$/UC_ *&[4/R;_P"+H_X0_6/^ANU#
M\F_^+H K?#*QU.PTW4DO]-2RCDNS)"WD"W:;*C+M$&94Y&,#'TKCX='U'4?A
M5I^D6L<[:E9:^R7;0KEXF$[L7_ ,I_*NY_X0_6/^ANU#\F_^+J&'P)J%O-/-
M#XGNXY)V#S.B$&1@, M\_)P /PH R?$7PSN)_#^K36VHW6J:[<^2RRWK* RQ
M,&$8   !Y_''2MJPUWQ-KUS+%_PC']GV*6CB4:D1F6<C"HNT_<SU8CD>E._X
M0_6/^ANU#\F_^+H_X0_6/^ANU#\F_P#BZ .-T'1]8L]<T=-$T37=",=RIU."
M>Z#Z>8N=XC!8EB>V.F?QJGI?A#7O#US<>,-.LKJ34X=5N%FT]Q_Q\V;L/N#L
M>X_^M@]]_P (?K'_ $-VH?DW_P 71_PA^L?]#=J'Y-_\70!QWB/PYJNI:U?V
MNEV.M6UKK%Q;7,H_=_9F(*EG<GYXRH'*=V [<5%)X<UFW^()NK30YYEDUG[6
MS7=M&412>9$N5<.!CI&01[&NV_X0_6/^ANU#\F_^+H_X0_6/^ANU#\F_^+H
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M .+H_P"$/UC_ *&[4/R;_P"+H ["BN/_ .$/UC_H;M0_)O\ XNC_ (0_6/\
MH;M0_)O_ (N@#L**X_\ X0_6/^ANU#\F_P#BZ/\ A#]8_P"ANU#\F_\ BZ .
MPHKC_P#A#]8_Z&[4/R;_ .+H_P"$/UC_ *&[4/R;_P"+H ["BN/_ .$/UC_H
M;M0_)O\ XNC_ (0_6/\ H;M0_)O_ (N@#L**X_\ X0_6/^ANU#\F_P#BZ/\
MA#]8_P"ANU#\F_\ BZ .PHKC_P#A#]8_Z&[4/R;_ .+H_P"$/UC_ *&[4/R;
M_P"+H ["BN/_ .$/UC_H;M0_)O\ XNC_ (0_6/\ H;M0_)O_ (N@#L**X_\
MX0_6/^ANU#\F_P#BZ/\ A#]8_P"ANU#\F_\ BZ .PHKC_P#A#]8_Z&[4/R;_
M .+H_P"$/UC_ *&[4/R;_P"+H ["BN/_ .$/UC_H;M0_)O\ XNC_ (0_6/\
MH;M0_)O_ (N@#L**X_\ X0_6/^ANU#\F_P#BZ/\ A#]8_P"ANU#\F_\ BZ .
MPHKC_P#A#]8_Z&[4/R;_ .+H_P"$/UC_ *&[4/R;_P"+H ["BN/_ .$/UC_H
M;M0_)O\ XNC_ (0_6/\ H;M0_)O_ (N@#L**X_\ X0_6/^ANU#\F_P#BZ/\
MA#]8_P"ANU#\F_\ BZ .PHKC_P#A#]8_Z&[4/R;_ .+H_P"$/UC_ *&[4/R;
M_P"+H ["BN/_ .$/UC_H;M0_)O\ XNC_ (0_6/\ H;M0_)O_ (N@#L**X_\
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M/W,:QJKQ;1UW,&/''SY/(K9U>PN+E Q\VYC699%ABE\AT !'RN,$G)'4CZT
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M_P#GM_XZ/\*/[1N_^>W_ (Z/\* )?[(N/[T?YG_"C^R+C^]'^9_PJ+^T;O\
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M7_QT?X4?VC=_\]O_ !T?X4 =!17/_P!HW?\ SV_\='^%']HW?_/;_P ='^%
M'045S_\ :-W_ ,]?_'1_A1_:-W_SV_\ '1_A0!T%%<__ &C=_P#/;_QT?X4?
MVC=_\]O_ !T?X4 =!17/_P!HW?\ SV_\='^%']HW?_/;_P ='^% '045S_\
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M;E\RUA61[<R$^6)OWFT#C<%/89Y)'->@_P!DW']Z/\S_ (4?V3<?WH_S/^%
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M9_PH M:/_P >\G^__2M&JEA;/;1,LA7);/!JW0 4444 %%%% !1110 4444
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M =I_;/\ TP_\?_\ K4?VS_TP_P#'_P#ZU<U-KFFQ0M(+V"4A-X2*169QG:,
M'G+8 ]SBL?\ X26];3S<K;6X:W@FN+E"Y/RQN5VJ1W(4\GC@<<\ '>_VS_TP
M_P#'_P#ZU']L_P#3#_Q__P"M7'0Z[.;UX+JV6TC#_P"MF)4;06'5@ 3G9T)'
MS]\&IM=N=1L[>&:QFM4#3PPLL\#29\R54R"'7&-V<<Y]J .K_MG_ *8?^/\
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M='%L5P<$JS93CYB0"3Z5"NI:/=3">-X&EAD*1LL6YHBY;YT.W)W8R<<8!.<
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M0ZA;ZGI$UK +HRL\39:QG *K(&*_<]!UH T9/$6F0+"SM<J\B%EB6QE:94!
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MLW'VI8@)'CL9V57QAF'R<@GGVS5K^W[# VB\3DE?] G/EGYOF^YSG(XH TW
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MMN96 QN4G'![<=*[3^R[7T;_ +ZH_LNU]&_[ZH Y.]T>TU!F:X5RQP,JY4@
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M#3_#<-O!X<O[R-2V)HL;3R:]#UCG2+D#^X:P/AQ&\7@^V21&1@S95A@CYC0
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MT4 <A_PF&K?]"?JGZ?X4?\)AJW_0GZI^G^%=?10!R'_"8:M_T)^J?F/\*/\
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MSU^8\\FM]$6*-8T4*B@*J@< #M0 ZBBB@ HHHH **** "BBB@ HHHH ****
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M*P]01P14M<WX AEM_A_H4,T;Q2I9H&1U(93CH0>E=)0 4444 %%%% !1110
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M4E%/+$[20/3'/-(?$EQ#XCN8BTLEK;P7SO"WEC<T1M=NUL# Q*_4_P 7)X&
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>23
<FILENAME>gemp-20161231.xml
<DESCRIPTION>EX-101.INS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/20/2017 8:19:33 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:gemp="http://www.gemphire.com/20161231" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="gemp-20161231.xsd" />
  <!--Context Section-->
  <context id="As_Of_3_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_3_15_2017_To_3_15_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_ThreeBoardMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:ThreeBoardMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-03-15</startDate>
      <endDate>2017-03-15</endDate>
    </period>
  </context>
  <context id="Duration_3_15_2017_To_3_15_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_OneBoardMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:OneBoardMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-03-15</startDate>
      <endDate>2017-03-15</endDate>
    </period>
  </context>
  <context id="Duration_9_8_2016_To_9_8_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-09-08</startDate>
      <endDate>2016-09-08</endDate>
    </period>
  </context>
  <context id="Duration_3_31_2015_To_3_31_2015_us-gaap_CounterpartyNameAxis_gemp_PfizerInc.Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_gemp_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gemp:PfizerInc.Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gemp:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-31</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_11_1_2014_To_11_1_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2014-11-01</startDate>
      <endDate>2014-11-01</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_4_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_gemp_MembersEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gemp:MembersEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_8_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-09-08</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gemp:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_TitleOfIndividualAxis_gemp_OfficersDirectorsAndEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:AmendmentAndRestatementOf2015EquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:OfficersDirectorsAndEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_TitleOfIndividualAxis_gemp_OfficersDirectorsAndEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:AmendmentAndRestatementOf2015EquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:OfficersDirectorsAndEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gemp:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_gemp_EquityIncentivePlan2015Member_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:EquityIncentivePlan2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_gemp_EquityIncentivePlan2015Member_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:EquityIncentivePlan2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PlanNameAxis_gemp_InducementPlanMember_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:InducementPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:AmendmentAndRestatementOf2015EquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2016_us-gaap_PlanNameAxis_gemp_InducementPlanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:InducementPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="As_Of_4_30_2016_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:AmendmentAndRestatementOf2015EquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-04-30</instant>
    </period>
  </context>
  <context id="As_Of_4_30_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-04-30</instant>
    </period>
  </context>
  <context id="As_Of_4_30_2015_us-gaap_PlanNameAxis_gemp_EquityIncentivePlan2015Member_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:EquityIncentivePlan2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-04-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_gemp_OfficersDirectorsAndEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:AmendmentAndRestatementOf2015EquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:OfficersDirectorsAndEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_gemp_OfficersDirectorsAndEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:AmendmentAndRestatementOf2015EquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:OfficersDirectorsAndEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_InducementPlanMember_us-gaap_TitleOfIndividualAxis_gemp_OfficersAndEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:InducementPlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:OfficersAndEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:OfficeRentalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:OfficeRentalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:OfficeRentalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToThreeDirectorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:InvestorsRelatedToThreeDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoBoardMembersInvestorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:TwoBoardMembersInvestorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="Duration_2_1_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-02-01</startDate>
      <endDate>2016-02-29</endDate>
    </period>
  </context>
  <context id="Duration_12_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-12-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_11_1_2014_To_2_18_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-11-01</startDate>
      <endDate>2015-02-18</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:OfficeRentalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:LlcOwnedByTwoOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:OfficeRentalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:LlcOwnedByTwoOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_9_8_2016_To_9_8_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-09-08</startDate>
      <endDate>2016-09-08</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_11_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-11-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_11_1_2014_To_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2014-11-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_10_31_2014_us-gaap_StatementEquityComponentsAxis_gemp_MembersEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gemp:MembersEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_10_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_CounterpartyNameAxis_gemp_PfizerInc.Member_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_gemp_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gemp:PfizerInc.Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gemp:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_CounterpartyNameAxis_gemp_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_gemp_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gemp:PfizerInc.Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gemp:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_5_1_2016_To_5_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2016-05-01</startDate>
      <endDate>2016-05-31</endDate>
    </period>
  </context>
  <context id="Duration_10_31_2014_To_10_31_2014_us-gaap_StatementScenarioAxis_us-gaap_PredecessorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-10-31</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <context id="Duration_10_31_2014_To_10_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2014-10-31</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gemp:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">gemp:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_IncomeStatementLocationAxis_gemp_InterestIncomeExpenseNetMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gemp:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_IncomeStatementLocationAxis_gemp_InterestIncomeExpenseNetMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gemp:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_IncomeStatementLocationAxis_gemp_InterestIncomeExpenseNetMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gemp:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_IncomeStatementLocationAxis_gemp_InterestIncomeExpenseNetMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gemp:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_IncomeStatementLocationAxis_gemp_InterestIncomeExpenseNetMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">gemp:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201517Member_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201517Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:NewAccountingPronouncementEarlyAdoptionAxis">us-gaap:NewAccountingPronouncementEarlyAdoptionEffectMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201517Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201517Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_8_10_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <instant>2016-08-10</instant>
    </period>
  </context>
  <context id="As_Of_7_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-07-31</instant>
    </period>
  </context>
  <context id="As_Of_11_1_2014_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-11-01</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-04-30</instant>
    </period>
  </context>
  <context id="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-29</instant>
    </period>
  </context>
  <context id="As_Of_10_31_2014_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-10-31</instant>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:TwoOfficersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-31</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:InvestorsRelatedToBoardMemberAndOfficersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-31</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_DebtConversionByUniqueDescriptionAxis_gemp_ConversionOfInterimNotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">gemp:ConversionOfInterimNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_DebtConversionByUniqueDescriptionAxis_gemp_ConversionOfConvertibleNotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">gemp:ConversionOfConvertibleNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_11_1_2014_To_11_1_2014_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-11-01</startDate>
      <endDate>2014-11-01</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_DebtConversionByUniqueDescriptionAxis_gemp_ConversionOfRelatedPartyPromissoryNotesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">gemp:ConversionOfRelatedPartyPromissoryNotesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_8_10_2016_To_8_10_2016_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-08-10</startDate>
      <endDate>2016-08-10</endDate>
    </period>
  </context>
  <context id="Duration_8_10_2016_To_8_10_2016_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-08-10</startDate>
      <endDate>2016-08-10</endDate>
    </period>
  </context>
  <context id="Duration_8_10_2016_To_8_10_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-08-10</startDate>
      <endDate>2016-08-10</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_ConversionOfStockByUniqueDescriptionAxis_gemp_ConversionOfSeriesPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">gemp:ConversionOfSeriesPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2016_To_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2016_To_9_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_3_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2015_To_6_30_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementScenarioAxis_us-gaap_PredecessorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:PredecessorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_8_3_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <instant>2016-08-03</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gemp:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleNotesPayableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">gemp:EmployeeConsultantsAndDirectorsStockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_3_31_2015_To_3_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-31</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_gemp_MembersEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">gemp:MembersEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_3_31_2015_To_3_31_2015_us-gaap_CounterpartyNameAxis_gemp_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_gemp_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gemp:PfizerInc.Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gemp:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-31</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_EquityIncentivePlan2015Member_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:EquityIncentivePlan2015Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">gemp:EmployeesDirectorsAndConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_gemp_EquityIncentivePlan2015Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">gemp:EquityIncentivePlan2015Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_8_4_2016_To_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-08-04</startDate>
      <endDate>2016-08-04</endDate>
    </period>
  </context>
  <context id="As_Of_3_15_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-03-15</instant>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToTwoOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:InvestorsRelatedToTwoOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-04-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:OfficeRentalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:LlcOwnedByTwoOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_12_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndFourBoardMembersInvestorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:TwoOfficersAndFourBoardMembersInvestorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-12-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_12_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToThreeOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:InvestorsRelatedToThreeOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-12-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndThreeBoardMembersInvestorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:TwoOfficersAndThreeBoardMembersInvestorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2015_To_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:TwoOfficersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-31</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:InvestorsRelatedToBoardMemberAndOfficersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-31</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:OfficeRentalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:LlcOwnedByTwoOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:InvestorsRelatedToBoardMemberAndOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:OfficeRentalMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:LlcOwnedByTwoOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToTwoOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:InvestorsRelatedToTwoOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-04-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToThreeOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:InvestorsRelatedToThreeOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToThreeDirectorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:InvestorsRelatedToThreeDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-04-30</instant>
    </period>
  </context>
  <context id="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoBoardMembersInvestorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:TwoBoardMembersInvestorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-02-29</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndFourBoardMembersInvestorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:TwoOfficersAndFourBoardMembersInvestorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndThreeBoardMembersInvestorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:TwoOfficersAndThreeBoardMembersInvestorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:InvestorsRelatedToBoardMemberAndOfficersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">gemp:DebtIssuedToRelatedPartiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:InvestorsRelatedToBoardMemberAndOfficersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_15_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_ThreeBoardMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:ThreeBoardMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-03-15</instant>
    </period>
  </context>
  <context id="As_Of_3_15_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_OneBoardMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">gemp:OneBoardMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-03-15</instant>
    </period>
  </context>
  <context id="As_Of_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-08-04</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-31</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:SeriesaPreferredConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-03-31</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_7_31_2015_To_7_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">gemp:FinancingConvertibleDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-07-31</startDate>
      <endDate>2015-07-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_10_1_2015_To_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_CounterpartyNameAxis_gemp_PfizerInc.Member_us-gaap_OtherCommitmentsAxis_gemp_MilestonePaymentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_gemp_LicenseAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">gemp:PfizerInc.Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">gemp:MilestonePaymentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">gemp:LicenseAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_3_15_2017_To_3_15_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-03-15</startDate>
      <endDate>2017-03-15</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_8_5_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <instant>2016-08-05</instant>
    </period>
  </context>
  <context id="As_Of_3_3_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <instant>2017-03-03</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit19">
    <measure>gemp:segment</measure>
  </unit>
  <unit id="Unit18">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit17">
    <measure>gemp:person</measure>
  </unit>
  <unit id="Unit16">
    <measure>gemp:item</measure>
  </unit>
  <unit id="Unit15">
    <measure>gemp:director</measure>
  </unit>
  <unit id="Unit14">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit13">
    <divide>
      <unitNumerator>
        <measure>gemp:Vote</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag contextRef="Duration_1_1_2016_To_12_31_2016">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2016_To_12_31_2016">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2016_To_12_31_2016">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2016_To_12_31_2016">2016</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2016_To_12_31_2016">2016-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2016_To_12_31_2016">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2016_To_12_31_2016">0001638287</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_3_3_2017" unitRef="Unit1" decimals="INF">9272582</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2016_To_12_31_2016">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2016_To_12_31_2016">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="As_Of_8_5_2016" unitRef="Unit12" decimals="-5">30300000</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2016_To_12_31_2016">Gemphire Therapeutics Inc.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="Duration_1_1_2016_To_12_31_2016">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="Duration_1_1_2016_To_12_31_2016">No</dei:EntityWellKnownSeasonedIssuer>
  <gemp:AccruedOfferingCostsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">575000</gemp:AccruedOfferingCostsCurrent>
  <gemp:AccruedOtherGeneralAndAdministrativeExpenses contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">47000</gemp:AccruedOtherGeneralAndAdministrativeExpenses>
  <gemp:AccruedOtherGeneralAndAdministrativeExpenses contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">94000</gemp:AccruedOtherGeneralAndAdministrativeExpenses>
  <gemp:AccruedOtherResearchAndDevelopmentExpenses contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">759000</gemp:AccruedOtherResearchAndDevelopmentExpenses>
  <gemp:AccruedOtherResearchAndDevelopmentExpenses contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1259000</gemp:AccruedOtherResearchAndDevelopmentExpenses>
  <gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">53000</gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">53000</gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">131000</gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">131000</gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">1498000</gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">1498000</gemp:AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <gemp:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">8318000</gemp:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity>
  <gemp:AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">153000</gemp:AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <gemp:AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">153000</gemp:AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <gemp:AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">220000</gemp:AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <gemp:AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">220000</gemp:AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <gemp:AmortizationOnConvertibleNotesDiscount contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">5000</gemp:AmortizationOnConvertibleNotesDiscount>
  <gemp:AmortizationOnConvertibleNotesDiscount contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">261000</gemp:AmortizationOnConvertibleNotesDiscount>
  <gemp:AmortizationOnConvertibleNotesDiscount contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-276000</gemp:AmortizationOnConvertibleNotesDiscount>
  <gemp:AmortizationOnConvertibleNotesToRelatedPartiesDiscount contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">7000</gemp:AmortizationOnConvertibleNotesToRelatedPartiesDiscount>
  <gemp:AmortizationOnConvertibleNotesToRelatedPartiesDiscount contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">62000</gemp:AmortizationOnConvertibleNotesToRelatedPartiesDiscount>
  <gemp:AmortizationOnConvertibleNotesToRelatedPartiesDiscount contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-17000</gemp:AmortizationOnConvertibleNotesToRelatedPartiesDiscount>
  <gemp:BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">55000</gemp:BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes>
  <gemp:BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">842000</gemp:BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes>
  <gemp:BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">505000</gemp:BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes>
  <gemp:ClassOfWarrantOrRightWarrantsOrRightsExercisable contextRef="Duration_3_15_2017_To_3_15_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">P5Y</gemp:ClassOfWarrantOrRightWarrantsOrRightsExercisable>
  <gemp:CommonStockVotingRightsPerShare contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit13" decimals="INF">1</gemp:CommonStockVotingRightsPerShare>
  <gemp:ContingentLiability contextRef="As_Of_3_31_2015_us-gaap_CounterpartyNameAxis_gemp_PfizerInc.Member_us-gaap_OtherCommitmentsAxis_gemp_MilestonePaymentsMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_gemp_LicenseAgreementMember" unitRef="Unit12" decimals="-6">37000000</gemp:ContingentLiability>
  <gemp:ConvertibleNoteExtinguishmentLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-1047000</gemp:ConvertibleNoteExtinguishmentLoss>
  <gemp:ConvertibleNoteExtinguishmentLoss contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">-106000</gemp:ConvertibleNoteExtinguishmentLoss>
  <gemp:ConvertibleNoteExtinguishmentLoss contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-941000</gemp:ConvertibleNoteExtinguishmentLoss>
  <gemp:ConvertibleNotesPremiumUponSubstantialModificationValue contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">1047000</gemp:ConvertibleNotesPremiumUponSubstantialModificationValue>
  <gemp:ConvertibleNotesPremiumUponSubstantialModificationValue contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">1047000</gemp:ConvertibleNotesPremiumUponSubstantialModificationValue>
  <gemp:CumulativeDividendsDeclared contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="0">0</gemp:CumulativeDividendsDeclared>
  <gemp:DebtInstrumentAutomaticConversionEquityOfferingThreshold contextRef="Duration_7_31_2015_To_7_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="-5">5000000</gemp:DebtInstrumentAutomaticConversionEquityOfferingThreshold>
  <gemp:DebtInstrumentConvertedPercentInExcessOfPrincipal contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember" unitRef="Unit14" decimals="2">1.25</gemp:DebtInstrumentConvertedPercentInExcessOfPrincipal>
  <gemp:DebtInstrumentConvertedPercentInExcessOfPrincipal contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit14" decimals="2">1.25</gemp:DebtInstrumentConvertedPercentInExcessOfPrincipal>
  <gemp:DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount contextRef="Duration_7_31_2015_To_7_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit14" decimals="2">2.00</gemp:DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount>
  <gemp:DeferredTaxAssetsAcquiredIntangibles contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">345000</gemp:DeferredTaxAssetsAcquiredIntangibles>
  <gemp:DeferredTaxAssetsAcquiredIntangibles contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">351000</gemp:DeferredTaxAssetsAcquiredIntangibles>
  <gemp:DeferredTaxAssetsConvertibleNotes contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">460000</gemp:DeferredTaxAssetsConvertibleNotes>
  <gemp:DeferredTaxAssetsTaxCreditCarryforwardsState contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">0</gemp:DeferredTaxAssetsTaxCreditCarryforwardsState>
  <gemp:DeferredTaxAssetsTaxCreditCarryforwardsState contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">24000</gemp:DeferredTaxAssetsTaxCreditCarryforwardsState>
  <gemp:DeferredTaxLiabilitiesRestrictedStockAwards contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">11000</gemp:DeferredTaxLiabilitiesRestrictedStockAwards>
  <gemp:EffectiveIncomeTaxRateReconciliationConvertibleNotes contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit14" decimals="4">0.0120</gemp:EffectiveIncomeTaxRateReconciliationConvertibleNotes>
  <gemp:EffectiveIncomeTaxRateReconciliationConvertibleNotes contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="4">0.0060</gemp:EffectiveIncomeTaxRateReconciliationConvertibleNotes>
  <gemp:EffectiveIncomeTaxRateReconciliationConvertibleNotes contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="4">0.0110</gemp:EffectiveIncomeTaxRateReconciliationConvertibleNotes>
  <gemp:ExerciseOfPremiumConversionDerivative contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">685000</gemp:ExerciseOfPremiumConversionDerivative>
  <gemp:FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">0</gemp:FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount>
  <gemp:FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">0</gemp:FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount>
  <gemp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="Unit12" decimals="-3">-182000</gemp:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal>
  <gemp:IncreaseDecreaseInPrepaidExpensesAndDeposits contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">2000</gemp:IncreaseDecreaseInPrepaidExpensesAndDeposits>
  <gemp:IncreaseDecreaseInPrepaidExpensesAndDeposits contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-10000</gemp:IncreaseDecreaseInPrepaidExpensesAndDeposits>
  <gemp:IncreaseDecreaseInPrepaidExpensesAndDeposits contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-55000</gemp:IncreaseDecreaseInPrepaidExpensesAndDeposits>
  <gemp:JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Jumpstart Our Business Startups Act Accounting Election&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As an emerging growth company under the Jumpstart Our Business Startups Act (JOBS Act), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has irrevocably elected not to avail itself of this exemption and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</gemp:JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock>
  <gemp:LiquidationPreferencePercentageOfChangeInVoting contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit14" decimals="2">0.50</gemp:LiquidationPreferencePercentageOfChangeInVoting>
  <gemp:MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="INF">0.5</gemp:MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits>
  <gemp:NoncashInterestOnConvertibleNotes contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">1000</gemp:NoncashInterestOnConvertibleNotes>
  <gemp:NoncashInterestOnConvertibleNotes contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">100000</gemp:NoncashInterestOnConvertibleNotes>
  <gemp:NoncashInterestOnConvertibleNotes contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">256000</gemp:NoncashInterestOnConvertibleNotes>
  <gemp:NoncashInterestOnConvertibleNotesToRelatedParties contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">5000</gemp:NoncashInterestOnConvertibleNotesToRelatedParties>
  <gemp:NoncashInterestOnConvertibleNotesToRelatedParties contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">40000</gemp:NoncashInterestOnConvertibleNotesToRelatedParties>
  <gemp:NoncashInterestOnConvertibleNotesToRelatedParties contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">145000</gemp:NoncashInterestOnConvertibleNotesToRelatedParties>
  <gemp:NonCashInterestOnPromissoryNotesToRelatedParties contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">19000</gemp:NonCashInterestOnPromissoryNotesToRelatedParties>
  <gemp:NumberOfBoardMembers contextRef="As_Of_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit15" decimals="INF">3</gemp:NumberOfBoardMembers>
  <gemp:NumberOfBoardMembers contextRef="As_Of_3_15_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_OneBoardMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit15" decimals="INF">1</gemp:NumberOfBoardMembers>
  <gemp:NumberOfBoardMembers contextRef="As_Of_3_15_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_ThreeBoardMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit15" decimals="INF">3</gemp:NumberOfBoardMembers>
  <gemp:NumberOfBoardMembersInRelatedPartyTransaction contextRef="As_Of_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember" unitRef="Unit16" decimals="INF">1</gemp:NumberOfBoardMembersInRelatedPartyTransaction>
  <gemp:NumberOfBoardMembersInRelatedPartyTransaction contextRef="As_Of_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">1</gemp:NumberOfBoardMembersInRelatedPartyTransaction>
  <gemp:NumberOfBoardMembersInRelatedPartyTransaction contextRef="As_Of_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" unitRef="Unit16" decimals="INF">3</gemp:NumberOfBoardMembersInRelatedPartyTransaction>
  <gemp:NumberOfBoardMembersInRelatedPartyTransaction contextRef="As_Of_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndFourBoardMembersInvestorsMember" unitRef="Unit16" decimals="INF">4</gemp:NumberOfBoardMembersInRelatedPartyTransaction>
  <gemp:NumberOfBoardMembersInRelatedPartyTransaction contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoBoardMembersInvestorsMember" unitRef="Unit16" decimals="INF">2</gemp:NumberOfBoardMembersInRelatedPartyTransaction>
  <gemp:NumberOfBoardMembersInRelatedPartyTransaction contextRef="As_Of_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToThreeDirectorsMember" unitRef="Unit16" decimals="INF">3</gemp:NumberOfBoardMembersInRelatedPartyTransaction>
  <gemp:NumberOfDebtInstrumentsIssued contextRef="As_Of_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember" unitRef="Unit16" decimals="INF">4</gemp:NumberOfDebtInstrumentsIssued>
  <gemp:NumberOfDebtInstrumentsIssued contextRef="As_Of_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" unitRef="Unit16" decimals="INF">4</gemp:NumberOfDebtInstrumentsIssued>
  <gemp:NumberOfDebtInstrumentsIssued contextRef="As_Of_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" unitRef="Unit16" decimals="INF">5</gemp:NumberOfDebtInstrumentsIssued>
  <gemp:NumberOfDebtInstrumentsIssued contextRef="As_Of_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToThreeOfficersMember" unitRef="Unit16" decimals="INF">5</gemp:NumberOfDebtInstrumentsIssued>
  <gemp:NumberOfDebtInstrumentsIssued contextRef="As_Of_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndFourBoardMembersInvestorsMember" unitRef="Unit16" decimals="INF">6</gemp:NumberOfDebtInstrumentsIssued>
  <gemp:NumberOfDebtInstrumentsIssued contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoBoardMembersInvestorsMember" unitRef="Unit16" decimals="INF">2</gemp:NumberOfDebtInstrumentsIssued>
  <gemp:NumberOfDebtInstrumentsIssued contextRef="As_Of_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToThreeDirectorsMember" unitRef="Unit16" decimals="INF">3</gemp:NumberOfDebtInstrumentsIssued>
  <gemp:NumberOfDebtInstrumentsIssued contextRef="As_Of_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToTwoOfficersMember" unitRef="Unit16" decimals="INF">2</gemp:NumberOfDebtInstrumentsIssued>
  <gemp:NumberOfEmployeesInRelatedPartyTransaction contextRef="As_Of_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" unitRef="Unit16" decimals="INF">1</gemp:NumberOfEmployeesInRelatedPartyTransaction>
  <gemp:NumberOfInvestorRelatedToBoardMembers contextRef="As_Of_3_15_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_OneBoardMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit17" decimals="INF">1</gemp:NumberOfInvestorRelatedToBoardMembers>
  <gemp:NumberOfInvestorRelatedToOneOfCompanysDirectors contextRef="As_Of_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit17" decimals="INF">1</gemp:NumberOfInvestorRelatedToOneOfCompanysDirectors>
  <gemp:NumberOfInvestorsRelatedToOfficers contextRef="As_Of_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit17" decimals="INF">14</gemp:NumberOfInvestorsRelatedToOfficers>
  <gemp:NumberOfOfficers contextRef="As_Of_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit17" decimals="INF">5</gemp:NumberOfOfficers>
  <gemp:NumberOfOfficersInRelatedPartyTransaction contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember" unitRef="Unit16" decimals="INF">2</gemp:NumberOfOfficersInRelatedPartyTransaction>
  <gemp:NumberOfOfficersInRelatedPartyTransaction contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember" unitRef="Unit16" decimals="INF">3</gemp:NumberOfOfficersInRelatedPartyTransaction>
  <gemp:NumberOfOfficersInRelatedPartyTransaction contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember" unitRef="Unit16" decimals="INF">2</gemp:NumberOfOfficersInRelatedPartyTransaction>
  <gemp:NumberOfOfficersInRelatedPartyTransaction contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">3</gemp:NumberOfOfficersInRelatedPartyTransaction>
  <gemp:NumberOfOfficersInRelatedPartyTransaction contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit16" decimals="INF">2</gemp:NumberOfOfficersInRelatedPartyTransaction>
  <gemp:NumberOfOfficersInRelatedPartyTransaction contextRef="Duration_7_1_2015_To_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" unitRef="Unit16" decimals="INF">3</gemp:NumberOfOfficersInRelatedPartyTransaction>
  <gemp:NumberOfOfficersInRelatedPartyTransaction contextRef="Duration_7_1_2015_To_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" unitRef="Unit16" decimals="INF">2</gemp:NumberOfOfficersInRelatedPartyTransaction>
  <gemp:NumberOfOfficersInRelatedPartyTransaction contextRef="Duration_12_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToThreeOfficersMember" unitRef="Unit16" decimals="INF">3</gemp:NumberOfOfficersInRelatedPartyTransaction>
  <gemp:NumberOfOfficersInRelatedPartyTransaction contextRef="Duration_12_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndFourBoardMembersInvestorsMember" unitRef="Unit16" decimals="INF">2</gemp:NumberOfOfficersInRelatedPartyTransaction>
  <gemp:NumberOfOfficersInRelatedPartyTransaction contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember" unitRef="Unit16" decimals="INF">2</gemp:NumberOfOfficersInRelatedPartyTransaction>
  <gemp:NumberOfOfficersInRelatedPartyTransaction contextRef="Duration_4_1_2016_To_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToTwoOfficersMember" unitRef="Unit16" decimals="INF">2</gemp:NumberOfOfficersInRelatedPartyTransaction>
  <gemp:NumberOfSharesIssuedPerUnit contextRef="As_Of_3_15_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit1" decimals="INF">1</gemp:NumberOfSharesIssuedPerUnit>
  <gemp:NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany contextRef="As_Of_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="INF">47000</gemp:NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany>
  <gemp:NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector contextRef="As_Of_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="INF">500000</gemp:NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector>
  <gemp:NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers contextRef="As_Of_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="INF">154450</gemp:NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers>
  <gemp:PeriodForTestingPercentageOfOwnershipChange contextRef="Duration_1_1_2016_To_12_31_2016">P36M</gemp:PeriodForTestingPercentageOfOwnershipChange>
  <gemp:PreferredStockRedemptionRequestedByPercentageOfShares contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit14" decimals="2">0.80</gemp:PreferredStockRedemptionRequestedByPercentageOfShares>
  <gemp:PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">182000</gemp:PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment>
  <gemp:ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany contextRef="Duration_8_4_2016_To_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit12" decimals="-5">500000</gemp:ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany>
  <gemp:ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector contextRef="Duration_8_4_2016_To_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit12" decimals="-5">5000000</gemp:ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector>
  <gemp:ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers contextRef="Duration_8_4_2016_To_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit12" decimals="-5">1500000</gemp:ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers>
  <gemp:ProceedsFromRelatedPartyPromissoryNotes contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">94000</gemp:ProceedsFromRelatedPartyPromissoryNotes>
  <gemp:RedemptionPricePercentageOfLiquidationPreference contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit14" decimals="2">1.50</gemp:RedemptionPricePercentageOfLiquidationPreference>
  <gemp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_gemp_EquityIncentivePlan2015Member" unitRef="Unit1" decimals="INF">104907</gemp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross>
  <gemp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_EquityIncentivePlan2015Member_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember" unitRef="Unit1" decimals="INF">276248</gemp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross>
  <gemp:SharesIssuablePercentageOfOffering contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_CounterpartyNameAxis_gemp_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_gemp_LicenseAgreementMember" unitRef="Unit14" decimals="2">0.15</gemp:SharesIssuablePercentageOfOffering>
  <gemp:StockEffectDuringPeriodShareUponMerger contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">1987817</gemp:StockEffectDuringPeriodShareUponMerger>
  <gemp:StockEffectDuringPeriodValueUponMerger contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_gemp_MembersEarningsMember" unitRef="Unit12" decimals="-3">388000</gemp:StockEffectDuringPeriodValueUponMerger>
  <gemp:StockEffectDuringPeriodValueUponMerger contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">-6000</gemp:StockEffectDuringPeriodValueUponMerger>
  <gemp:StockEffectDuringPeriodValueUponMerger contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">6000</gemp:StockEffectDuringPeriodValueUponMerger>
  <gemp:StockEffectDuringPeriodValueUponMerger contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-388000</gemp:StockEffectDuringPeriodValueUponMerger>
  <gemp:StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">827205</gemp:StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities>
  <gemp:StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">8319000</gemp:StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities>
  <gemp:StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">1000</gemp:StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities>
  <gemp:StockRestrictionDuringPeriodShares contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">-556589</gemp:StockRestrictionDuringPeriodShares>
  <gemp:StockRestrictionDuringPeriodValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">2000</gemp:StockRestrictionDuringPeriodValue>
  <gemp:StockRestrictionDuringPeriodValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">-2000</gemp:StockRestrictionDuringPeriodValue>
  <gemp:TemporaryEquityConversionOfStock contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">8319000</gemp:TemporaryEquityConversionOfStock>
  <gemp:TemporaryEquityConversionOfStockShares contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="INF">745637</gemp:TemporaryEquityConversionOfStockShares>
  <gemp:TemporaryEquityDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;7. Convertible Series&amp;nbsp;A Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March 31, 2015, the Company issued 745,637 shares of Series&amp;nbsp;A preferred stock at a per share price of $6.70585, as adjusted for the Reverse Stock Split, or $5.0&amp;nbsp;million in the aggregate, consisting of $1.5&amp;nbsp;million in cash and $3.5&amp;nbsp;million representing 125% of the principal and accrued and unpaid interest on the Convertible Notes, all of which converted into shares of Series&amp;nbsp;A preferred stock. On August 10, 2016, immediately prior to the closing of the IPO, the Company&amp;#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Prior to their conversion into shares of common stock, the Series&amp;nbsp;A preferred stock had the following rights and preferences:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Dividend Rights&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Dividends effectively accrued on a daily basis at a simple rate of 8% per annum on the sum of the original per share issue price. Dividends were effectively deemed declared daily and were payable upon the occurrence of certain events. In addition, the holders of the Series&amp;nbsp;A preferred stock had rights to participate in common stock dividends, entitling holders of Series&amp;nbsp;A preferred stock to a dividend payable at the same time as the dividend paid on common stock based on the number of shares of common stock each share of Series&amp;nbsp;A preferred stock would convert into if such shares had converted on the record date. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;There were no dividends deemed payable and accrued as of December 31, 2016 due to the conversion of the Series A preferred stock, together with accrued dividends thereon, on August 10, 2016 immediately prior to the closing of the IPO. There were no dividends deemed payable and accrued as of December 31, 2015, but unpaid dividends were $0.3&amp;nbsp;million as of December&amp;nbsp;31, 2015. See Note&amp;nbsp;5&amp;nbsp;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="display:inline;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Voting Rights&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Each share of Series&amp;nbsp;A preferred stock was entitled to vote together with the common stock on all actions to be taken by the stockholders of the Company, based on the number of shares of common stock into which each share of Series&amp;nbsp;A preferred stock could be converted. A separate vote of a majority of the outstanding shares of Series&amp;nbsp;A preferred stock was required to (1)&amp;nbsp;issue or authorize any class or series of equity securities or equivalents, (2)&amp;nbsp;effect any transaction that results in a change in control, (3)&amp;nbsp;change the principal business of the Company, enter new lines of business, or exit the current line of business, (4)&amp;nbsp;issue of convertible debt above a certain threshold, or (5)&amp;nbsp;materially sell, transfer, license, pledge or encumber technology or intellectual property. A management stock option plan approved by the board of directors, however, was not subject to a separate vote of the Series&amp;nbsp;A preferred stockholders, but any subsequent increases to the authorized option pool were subject to approval by the Series&amp;nbsp;A preferred stock holders via a separate vote.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Liquidation Rights&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In the event of any liquidation, dissolution, or winding&amp;#8209;up of the Company, whether voluntary or involuntary, merger, consolidation or transaction in which over 50% of the Company&amp;#x2019;s voting power was transferred, or a sale, lease, transfer, exclusive license or disposition of all or substantially all of the assets of the Company, the Series&amp;nbsp;A preferred stock holders were entitled to the assets of the Company legally available for distribution before any distribution or payment was made to the holders of common stock. The distribution amount would have been equal the original issue price of the Series&amp;nbsp;A preferred stock (as adjusted for any stock dividends, combinations, splits or other recapitalizations since issuance), plus any accrued or declared but unpaid dividends thereon. After payment of the full liquidation preference to the Series&amp;nbsp;A preferred stock holders, the remaining assets legally available for distribution would have been distributed to the holders of common stock and holders of the Series&amp;nbsp;A preferred stock pro rata based on the number of shares of common stock each share of Series&amp;nbsp;A preferred stock would convert into if such shares had converted immediately prior to such liquidation, dissolution, or winding&amp;#8209;up.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Conversion Rights&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Shares of Series&amp;nbsp;A preferred stock, at the option of the holder, could have been converted at any time into shares of common stock. The conversion rate would have been obtained by dividing the Series&amp;nbsp;A preferred stock original issue price of $6.70585 per share, as adjusted for the Reverse Stock Split, by the conversion price per share in effect at the time of conversion. The Series&amp;nbsp;A conversion price was initially equal to the original issue price, but could be adjusted on a broad&amp;#8209;based weighted average basis in connection with certain dilutive events. The Series&amp;nbsp;A holder was also entitled to receive additional shares of common stock for any unpaid Series&amp;nbsp;A dividends (whether or not declared).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Shares of Series&amp;nbsp;A preferred stock would have automatically converted into common stock based upon the then&amp;#8209;effective Series&amp;nbsp;A conversion price upon the affirmative vote or consent of the holders of at least a majority of the outstanding shares of the Series&amp;nbsp;A preferred stock, or at the closing of a firmly underwritten public offering. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The conversion price for the Series&amp;nbsp;A preferred stock was $6.70585 per share (as adjusted for the Reverse Stock Split) at the time of the conversion of the Series A preferred stock, together with accrued dividends thereon, immediately prior to the closing of the IPO on August 10, 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Redemption Rights&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The holders of at least 80% of the outstanding shares of Series&amp;nbsp;A preferred stock could have required the Company to redeem all outstanding shares of Series&amp;nbsp;A preferred stock at any time on or after December&amp;nbsp;31, 2020 at a redemption price equal to the greater of 150% of the liquidation preference of the Series&amp;nbsp;A preferred stock or the fair market value per share plus any unpaid declared dividends. The liquidation preference of the Series&amp;nbsp;A preferred stock was defined as an amount per share equal to $6.70585, as adjusted from time to time for any stock dividends, combinations, splits or recapitalizations, plus any accrued or declared but unpaid dividends thereon.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The redemption value for redeemable preferred stock could have at times been based on fair market value. The assumptions used in calculating the estimated fair market value at each reporting period represented the Company&amp;#x2019;s best estimate, however, inherent uncertainties were involved. As a result, if factors or assumptions changed, the estimated fair value could have been materially different. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company recognized changes in the redemption value immediately as they occurred and adjusted the carrying amount of the instrument to equal the redemption value at the end of each reporting period since it was probable that the instruments would have become redeemable. In the absence of retained earnings, these charges were recorded against additional paid&amp;#8209;in&amp;#8209;capital, if any, and then to accumulated deficit.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company evaluated the Series&amp;nbsp;A preferred stock and determined that it was considered an equity host under ASC 815&lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;, &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Derivatives and Hedging.&lt;/font&gt;&lt;font style="display:inline;"&gt; In making this determination, the Company&amp;#x2019;s analysis followed the whole instrument approach that compared an individual feature against the entire Series&amp;nbsp;A preferred stock instrument that included that feature. The Company&amp;#x2019;s analysis was based on a consideration of the economic characteristics and risks of the Series&amp;nbsp;A preferred stock. More specifically, the Company evaluated all of the stated and implied substantive terms and features of the Series&amp;nbsp;A preferred stock, including: (1)&amp;nbsp;redemption features and their underlying exercisability, (2)&amp;nbsp;existence of any protective covenants, (3)&amp;nbsp;nature of dividends rights, (4)&amp;nbsp;nature of voting rights, and (5)&amp;nbsp;the existence and nature of any conversion rights. As a result of the above, the Company concluded that the Series&amp;nbsp;A preferred stock represented an equity host, and as such, the redemption and/or conversion features of the Series&amp;nbsp;A preferred stock were considered to be clearly and closely related to the associated Series&amp;nbsp;A preferred stock host instrument. Accordingly, the redemption and/or conversion features of the Series&amp;nbsp;A preferred stock were not considered an embedded derivative that required bifurcation.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</gemp:TemporaryEquityDisclosureTextBlock>
  <gemp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="INF">745637</gemp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <gemp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">745637</gemp:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
  <gemp:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit12" decimals="-5">5000000</gemp:TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross>
  <gemp:ThresholdPercentageOfShareholdersOwnershipChange contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="INF">0.05</gemp:ThresholdPercentageOfShareholdersOwnershipChange>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;3. Accrued Liabilities&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:27.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued offering costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;575
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Legal costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;54
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;234
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued compensation costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;706
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,259
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;759
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other general and administrative expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;94
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;47
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,113
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,617
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">531000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">2008000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">1617000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">2113000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">234000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">54000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">47674000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">11444000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">4168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">4168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">53000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3">53000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">284000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3">284000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">1718000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3">1166000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">552000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">994613</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="INF">302842</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleNotesPayableMember" unitRef="Unit1" decimals="INF">828751</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">745637</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">348093</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="INF">2242800</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">4009</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">4490000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">24754000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">3643000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">24746000</us-gaap:AssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2013" unitRef="Unit12" decimals="-3">3000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">317000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">3620000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">24033000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">314000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">3303000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">20413000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of 90&amp;nbsp;days or less at the time of deposit to be cash equivalents. The Company invests excess cash in readily available checking and savings accounts and highly liquid investments in money market accounts.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_15_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit18" decimals="2">10.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="As_Of_3_15_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit1" decimals="2">0.75</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;6. License Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April 2011, the Company entered into the Pfizer Agreement for a worldwide exclusive license to certain patent rights to make, use, sell, offer for sale and import the clinical product candidate gemcabene. In exchange for this license, the Company agreed to issue shares of its common stock to Pfizer representing 15% of the Company&amp;#x2019;s fully diluted capital at the close of its first arms&amp;#8209;length Series&amp;nbsp;A financing, which occurred on March 31, 2015.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company agreed to make milestone payments totaling up to $37&amp;nbsp;million upon the achievement of certain milestones, including the first regulatory submission in any country, regulatory approval in each of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of gemcabene or any product containing gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company also agreed to pay Pfizer tiered royalties on a country&amp;#8209;by&amp;#8209;country basis based upon the annual amount of net sales, as specified in the Pfizer Agreement until expiration of the last valid claim of the licensed patent rights including any patent term extensions or supplemental protection certificates. Under the Pfizer Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize gemcabene.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March 31, 2015, upon the closing of the Series&amp;nbsp;A preferred stock financing, the Company issued 675,250 shares of its common stock, at a fair market value of $0.9&amp;nbsp;million, to Pfizer in connection with the first equity payment, pursuant to which Pfizer became the owner of more than 5% of the Company&amp;#x2019;s capital stock. The transaction was recorded as acquired in&amp;#8209;process research and development expenses based on the fair market value of the common shares issued since no processes or activities that would constitute a &amp;#x201C;business&amp;#x201D; were acquired and none of the rights and underlying assets acquired had alternative future uses or reached a stage of technological feasibility. None of the other milestone or royalty payments were triggered as of December 31, 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Pfizer Agreement will expire upon expiration of the last royalty term. Either party may terminate the Pfizer Agreement for the other party&amp;#x2019;s uncured material breach or upon specified bankruptcy events. Pfizer may terminate the Pfizer Agreement if the Company or any of its sublicenses challenge the validity, enforceability or ownership of the licensed patents. Upon termination of the license agreement for cause by Pfizer, we must grant Pfizer a non-exclusive license to use any intellectual property rights arising from the development or commercialization of gemcabene. Additionally, Pfizer may revoke the license if the Company is unable to adequately commercialize gemcabene by April 2021.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Pfizer has a non&amp;#8209;exclusive, sub licensable, royalty&amp;#8209;free right and license for non&amp;#8209;commercial research or development purposes to intellectual property rights relating to gemcabene that are developed by us after the effective date of the license with Pfizer.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2015" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2016" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;5. Commitments and Contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Pfizer License Agreement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April 2011, the Company and Pfizer&amp;nbsp;Inc. (Pfizer) entered into an exclusive license agreement (the Pfizer Agreement) for the clinical product candidate gemcabene. In exchange for this worldwide exclusive right and license to certain patent rights to make, use, sell, offer for sale and import the clinical product gemcabene, the Company agreed to certain milestone and royalty payments on future sales (See Note&amp;nbsp;6&amp;nbsp;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;License Agreement)&lt;/font&gt;&lt;font style="display:inline;"&gt;. As of December 31, 2016, there was sufficient uncertainty with regard to both the outcome of the clinical trials and the ability to obtain sufficient funding to support any of the cash milestone payments under the license agreement, and as such, no liabilities were recorded related to the license agreement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Series&amp;nbsp;A Preferred Stock Dividends&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Holders of the Series&amp;nbsp;A preferred stock were entitled to cumulative accruing dividends at a simple rate of 8% per year on the original issue price of the preferred stock of $6.70585 per share, as adjusted for the Reverse Stock Split. The dividends effectively accrued daily on each share of preferred stock. The dividends were payable upon the earliest to occur of (1)&amp;nbsp;the date determined by the Board, (2)&amp;nbsp;the liquidation of the Company (including a deemed liquidation event) or (3)&amp;nbsp;the conversion or redemption of at least a majority of the outstanding shares of Series&amp;nbsp;A preferred stock. If the board reasonably believed that the Company was not legally able to pay the dividends in cash at the payment date, or if elected by the majority of the Series&amp;nbsp;A preferred stockholders or if issued in connection with an IPO, the dividends were to be paid in shares of common stock at the conversion price for the Series&amp;nbsp;A preferred stock in effect at that time, which was the original issue price of the Series&amp;nbsp;A preferred stock as adjusted from time to time for any stock dividends, combinations, splits or recapitalizations. Since the dividends were payable upon a contingent event, the Company did not record them in the accompanying financial statements as of December 31, 2015; however, cumulative unpaid dividends for the Series&amp;nbsp;A preferred stock totaled $0.3&amp;nbsp;million as of December&amp;nbsp;31, 2015. On August 10, 2016, immediately prior to the closing of the IPO, the Company&amp;#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock, and as such, there were no cumulative unpaid dividends for the Series A preferred stock as of December 31, 2016. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Other Agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Both cancellable and non-cancellable facility agreements were in place that provided for fixed monthly rent for the years ended December 31, 2016, 2015 and 2014. The total rent expense was $58,000,&amp;nbsp;$23,000 and $6,000 for the years ended December 31, 2016, 2015 and 2014, respectively. In May 2016, the Company entered into a new lease agreement for its headquarters location, commencing in August 2016. The initial term of the agreement is 3 years with an initial monthly base rent of approximately $8,400. In conjunction with entering into the new lease agreement, the Company cancelled its original Northville, Michigan lease agreement, as amended, effective August 31, 2016 and renegotiated a new cancellable lease agreement for limited use of office space in the Northville location that expires in September 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Future minimum lease payments under fixed non-cancellable operating leases that expire on various dates through August 2019 consist of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;101
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;101
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;58
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;260
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2015" unitRef="Unit18" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_8_3_2016" unitRef="Unit18" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2016" unitRef="Unit18" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">17674419</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_8_3_2016" unitRef="Unit1" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">3758488</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">9270255</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">3758488</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">9270255</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2016_us-gaap_StatementScenarioAxis_us-gaap_PredecessorMember" unitRef="Unit1" decimals="INF">0</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">12000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">17000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-320000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-2279000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-9029000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="-3">-1611000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">-2569000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-2570000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">-2103000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-14586000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-1391000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">-3878000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-7214000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ConversionOfStockAmountIssued1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_ConversionOfStockByUniqueDescriptionAxis_gemp_ConversionOfSeriesPreferredStockMember" unitRef="Unit12" decimals="-3">8319000</us-gaap:ConversionOfStockAmountIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="Duration_8_10_2016_To_8_10_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit1" decimals="INF">1656807</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="Duration_8_10_2016_To_8_10_2016_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">827205</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="Duration_8_10_2016_To_8_10_2016_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">827205</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConvertibleNotesPayableCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">4629000</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:CostsAndExpenses contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">266000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">1589000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">8076000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="-3">1610000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">2366000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">2511000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">2226000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">14696000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1840000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">3402000</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">7228000</us-gaap:CostsAndExpenses>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_DebtConversionByUniqueDescriptionAxis_gemp_ConversionOfRelatedPartyPromissoryNotesMember" unitRef="Unit12" decimals="-3">359000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Duration_11_1_2014_To_11_1_2014_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" unitRef="Unit12" decimals="-5">400000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_DebtConversionByUniqueDescriptionAxis_gemp_ConversionOfConvertibleNotesMember" unitRef="Unit12" decimals="-3">2778000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_DebtConversionByUniqueDescriptionAxis_gemp_ConversionOfInterimNotesMember" unitRef="Unit12" decimals="-3">11445000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">516421</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">63967</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">68649</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit12" decimals="-5">3500000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:DebtDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;4. Debt&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Promissory Notes to Related Parties&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company issued promissory notes to related parties (the Promissory Notes) at a compound interest rate of 8% per annum for an aggregate principal amount of $0.3&amp;nbsp;million on various dates from March 2009 through October 2014 with maturity dates through October&amp;nbsp;31, 2014. The Promissory Notes along with accrued interest were exchanged for convertible notes (the Convertible Notes) on November&amp;nbsp;1, 2014, in the amount of $0.4&amp;nbsp;million inclusive of accrued interest.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Convertible Notes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company completed a series of convertible note financings with certain investors beginning on November 1, 2014 and ending on February&amp;nbsp;18, 2015 (the Convertible Notes), whereby a total of $2.7&amp;nbsp;million was loaned to the Company, of which $2.0&amp;nbsp;million was loaned in 2015. Interest for the Convertible Notes compounded on a daily basis at a rate of 8&amp;nbsp;percent per annum. The Convertible Notes converted into shares of the Company&amp;#x2019;s Series&amp;nbsp;A preferred stock upon close of the Series A preferred stock financing on March 31, 2015. The conversion equaled 125% of the unpaid principal plus unpaid accrued interest on the Convertible Notes.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;At the time of their issuance, the Convertible Notes contained a conversion premium with regard to the conversion into the Series&amp;nbsp;A preferred stock. The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Convertible Notes. The discount was amortized to interest expense over the term of the Convertible Notes using the straight&amp;#8209;line method. The embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium conversion derivative associated with the Convertible Notes to interest expense that amounted to $0.4&amp;nbsp;million and $18,000 for the years ended December 31, 2015 and 2014, respectively. As a result of their conversion into shares of Series A preferred stock on March 31, 2015 as described above, there were no Convertible Notes outstanding during 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Interim Notes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On July&amp;nbsp;31, 2015, the Company entered into a convertible interim note financing (collectively with the notes issued in December 2015, February 2016 and April 2016, the Interim Notes), pursuant to which certain investors agreed to loan the Company approximately $2.8&amp;nbsp;million. On August 10, 2016, immediately prior to the closing of the IPO, the Company&amp;#x2019;s Interim Notes, together with accrued interest thereon, converted into 1,656,807 shares of common stock. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Interim Notes accrued interest at a rate of 8% per annum, compounded annually, and would automatically convert into shares issued to investors in the Company&amp;#x2019;s next equity financing round that results in gross proceeds of at least $5.0&amp;nbsp;million (a Qualified Financing). The conversion would be equal to unpaid principal at 115% plus any unpaid accrued interest. The investors would be paid out principal at 200% if a change of control occurred before the next financing round. In the event that a Qualified Financing, change of control, or an IPO did not occur before July&amp;nbsp;31, 2016, the parties would then negotiate a price for conversion into a new round of stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In December 2015, the Company amended the Interim Notes and certain investors agreed to loan the Company an additional $2.7&amp;nbsp;million for a revised financing total of $5.5&amp;nbsp;million. The Interim Notes continued to accrue interest at an 8% rate per annum compounded annually, but were amended to automatically convert into shares of the same class of the Company&amp;#x2019;s next convertible preferred stock financing round (the Preferred Stock Financing). The conversion into shares issued in the Preferred Stock Financing would be equal to unpaid principal at 115% plus unpaid accrued interest. In the event that either a change of control occurs or the Company completes a public transaction which results in the Company&amp;#x2019;s stockholders holding securities listed on a national securities exchange, including an IPO, before the Preferred Stock Financing, the Interim Notes, as amended, would automatically convert into shares of the Company&amp;#x2019;s common stock at a conversion price of $6.70585 per share (which represents the original issue price of the Series&amp;nbsp;A preferred stock) based on 100% of outstanding principal and unpaid accrued interest. Lastly, if a Preferred Stock Financing, change of control, or public transaction did not occur before December&amp;nbsp;31, 2016, the parties agreed to then negotiate a conversion price into a new round of stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February 2016, certain investors agreed to loan the Company an additional $0.2&amp;nbsp;million for a revised financing total of $5.6&amp;nbsp;million. The Interim Notes continued to accrue interest at an 8% rate per annum compounded annually, but were amended to automatically convert into shares of the same class of the Company&amp;#x2019;s next Preferred Stock Financing. The conversion into shares issued in the Preferred Stock Financing would be equal to unpaid principal at 115% plus unpaid accrued interest. In the event that either a change of control occurs or the Company completes a public transaction which results in the Company&amp;#x2019;s stockholders holding securities listed on a national securities exchange, including an IPO, before the Preferred Stock Financing, the Interim Notes, as amended, would automatically convert into shares of the Company&amp;#x2019;s common stock at a conversion price of $6.70585 per share (which represents the original issue price of the Series&amp;nbsp;A preferred stock as adjusted for the Reverse Stock Split (as defined below)) based on 100% of outstanding principal and unpaid accrued interest. Lastly, if a Preferred Stock Financing, change of control, or public transaction did not occur before December&amp;nbsp;31, 2016, the parties agreed to then negotiate a conversion price into a new round of stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April 2016, the Company amended the Interim Notes and certain investors agreed to loan the Company an additional $5.0&amp;nbsp;million for a revised financing total, including Interim Notes previously issued, of $10.6&amp;nbsp;million. The Interim Notes continued to accrue interest at an 8% rate per annum compounded annually, but were amended so that 125% of the unpaid principal and accrued interest, would automatically convert into shares of the same class of the Company&amp;#x2019;s next convertible preferred stock financing round of at least $5.0&amp;nbsp;million (the Qualified Financing). In the event that either a change of control occurs or the Company completes a public transaction which results in the Company&amp;#x2019;s stockholders holding securities listed on a national securities exchange, including an IPO, before the Qualified Financing, 100% of outstanding principal and unpaid accrued interest on the Interim Notes, as amended, would automatically convert into shares of the Company&amp;#x2019;s common stock at a conversion price of $6.70585 per share, as adjusted for the Reverse Stock Split. Lastly, if a Qualified Financing, change of control, or public transaction did not occur, the Interim Notes would become payable on demand anytime after December&amp;nbsp;31, 2016. The Company incurred issuance costs related to the April 2016 financing in the amount of $10,000. The Interim Notes were discounted for the issuance costs, and the discount was amortized to interest expense over their remaining term using the straight&amp;#8209;line method.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On August 10, 2016, immediately prior to the closing of the IPO, the Company&amp;#x2019;s Interim Notes, together with accrued interest thereon, converted into 1,656,807 shares of common stock. At the time of their issuance, the Interim Notes contained a conversion premium with regard to the conversion into shares at the time of the next Qualified Financing. The Company determined that the redemption feature under the Interim Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Interim Notes. The discount was amortized to interest expense over the term of the Interim Notes using the straight&amp;#8209;line method. The embedded derivative was accounted for separately on a fair market value basis. The fair value of the derivative associated with the Interim Notes was $0.3 million at December 31, 2015 and was included as premium conversion derivative on the accompanying balance sheets. As a result of the conversion of the Interim Notes, together with accrued interest thereon, into common stock immediately prior to the closing of the IPO, there was no premium conversion derivative outstanding as of December 31, 2016. The Company recorded the fair value changes of the premium conversion derivative associated with the Interim Notes to interest income (expense) that amounted to $0.2 million, $(0.1) million and zero for the years ended December 31, 2016, 2015 and 2014, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As a result of their conversion to common stock on August 10, 2016 as described above, there were no Interim Notes outstanding as of December 31, 2016.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">372000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">372000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="As_Of_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit18" decimals="INF">6.70585</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="Duration_7_31_2015_To_7_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit14" decimals="2">1.15</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="Duration_4_1_2016_To_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit14" decimals="2">1.25</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_10_31_2014_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" unitRef="Unit12" decimals="-5">300000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="-5">5500000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_2_29_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="-5">5600000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="-5">10600000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="0">0</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember" unitRef="Unit12" decimals="0">0</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_10_31_2014_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" unitRef="Unit14" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_11_1_2014_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember" unitRef="Unit14" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_7_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit14" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DeferredCosts contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">847000</us-gaap:DeferredCosts>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">11000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredOfferingCosts contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-5">800000</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredOfferingCosts contextRef="As_Of_8_10_2016" unitRef="Unit12" decimals="-5">4200000</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredOfferingCosts contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">0</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">4000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
  <us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">12000</us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">3668000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">9320000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">5254000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsNet contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">11000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">2723000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">2289000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-5">2400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">2100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-5">300000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">95000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">768000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">41000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">633000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">13000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">3657000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">9320000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilitiesCurrent contextRef="As_Of_12_31_2016_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201517Member_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember" unitRef="Unit12" decimals="0">-10000</us-gaap:DeferredTaxLiabilitiesCurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="As_Of_12_31_2016_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201517Member_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember_us-gaap_StatementScenarioAxis_us-gaap_ScenarioAdjustmentMember" unitRef="Unit12" decimals="0">10000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DepositsAssetsNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">8000</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;9. Share&amp;#8209;Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Share-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying statements of comprehensive loss (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&lt;font style="display:inline;font-size:11pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="middle" style="width:50.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="middle" style="width:50.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,166
				&lt;/td&gt;
				&lt;td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;284
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;53
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;552
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total share-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,718
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;284
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;53
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Restricted Stock Awards&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During the year ended December 31, 2016, the Company did not grant any restricted stock awards (RSAs). During the years ended December 31, 2015 and 2014, the Company granted an aggregate of 44,657 and 1,605,008 RSAs, respectively, to certain of its employees, members of its board of directors and consultants subject to a 2014 Shareholders Agreement (the Agreement). The RSAs are subject to various vesting schedules and generally vest ratably over a six to twenty four month period coinciding with their respective service periods. During the years ended December 31, 2016, 2015 and 2014,&amp;nbsp;no RSAs were forfeited.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;A summary of RSA grant activity is as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:8pt;"&gt;Weighted-Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:8pt;"&gt;Fair Value (per share)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Non&amp;#x2011;vested at December&amp;nbsp;31, 2013 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,605,008
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(610,395)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Non&amp;#x2011;vested at December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;994,613
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,567
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(691,087)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Non&amp;#x2011;vested at December&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;348,093
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(344,084)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Non&amp;#x2011;vested at December&amp;nbsp;31, 2016 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,009
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;There were no RSAs granted during the year ended December 31, 2016. The grant&amp;#8209;date fair value of the RSAs issued during the years ended December 31, 2015 and 2014 was $9,000 and $140,000 respectively. Grant date fair market value in prior years was based on traditional valuation techniques and methods in determining the fair value of the Company&amp;#x2019;s equity as a private company including market, income, and cost valuation approaches. A number of objective and subjective factors were considered including contemporaneous and retrospective valuations of its common stock performed by an unrelated valuation specialist, sales of the Company&amp;#x2019;s convertible preferred stock to unrelated third parties, valuations of comparable peer public companies, the lack of liquidity of the Company&amp;#x2019;s capital stock and general and industry&amp;#8209;specific economic outlook. The fair value of the Company&amp;#x2019;s common stock was determined by the Company&amp;#x2019;s board of directors prior to the IPO.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Stock Options&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April 2015, the Company adopted a 2015 Equity Incentive Plan (the 2015 Plan) under which 320,615 shares of the Company&amp;#x2019;s common stock were reserved for issuance to employees, directors and consultants. The 2015 Plan permits the grant of incentive and non&amp;#8209;statutory stock options, appreciation rights, restricted stock, restricted stock units, performance stock and cash awards, and other stock&amp;#8209;based awards. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;"&gt;Amendment and Restatement of 2015 Equity Incentive Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April 2016 the Company&amp;#x2019;s board of directors approved the Company&amp;#x2019;s amended and restated 2015 Plan (the A&amp;amp;R 2015 Plan). The A&amp;amp;R 2015 Plan became effective immediately upon the execution and delivery of the underwriting agreement related to the IPO. The A&amp;amp;R 2015 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and other forms of equity awards, as well as performance cash awards. The Company initially reserved 2,400,000 shares of common stock for issuance under the A&amp;amp;R 2015 Plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During the years ended December 31, 2016 and 2015, the Company granted an aggregate of 1,825,700 and 305,278, respectively, of stock options under the A&amp;amp;R 2015 Plan or the 2015 Plan to its officers, directors, employees and consultants, generally vesting over a three or four-year period. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;"&gt;Inducement Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;In September 2016 the Company&amp;#x2019;s board of directors approved the Company&amp;#x2019;s Inducement Plan (the Inducement Plan). The Company initially reserved 300,000 shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual&amp;#x2019;s entry into employment with the Company within the meaning of Rule&amp;nbsp;5635(c)(4)&amp;nbsp;of the NASDAQ Listing Rules. The Plan was approved by the Company&amp;#x2019;s board of directors without stockholder approval pursuant to Rule&amp;nbsp;5635(c)(4), and the terms and conditions of the Plan are substantially similar to the Company&amp;#x2019;s stockholder-approved A&amp;amp;R 2015 Plan. During the year ended December 31, 2016, 198,000 stock options to newly-hired officers and employees were granted under the Inducement Plan, generally vesting over a four-year period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table summarizes the Company&amp;#x2019;s stock option plan activity for the year ended December&amp;nbsp;31, 2016 and 2015 as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Weighted&amp;#x2011;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Contractual&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Term (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Value(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding at December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;305,278
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercised &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,436)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Forfeited/Cancelled &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding at December&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;302,842
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.43
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.60
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,031,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,023,700
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.07
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercised &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Forfeited/Cancelled &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(83,742)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.12
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding at December 31, 2016 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,242,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.07
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.48
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,759,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested and exercisable at December&amp;nbsp;31, 2016 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;373,158
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.86
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.06
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;740,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested and expected to vest at December 31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,242,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.07
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.48
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,759,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 23.00pt; display: inline;"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;sup style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (1)&lt;/sup&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:13pt;"&gt;&lt;p style="width:13pt;width:13pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of December 31, 2016 and 2015 of $7.84 and $5.83 per share, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The weighted average fair value per share of options granted during the years ended December&amp;nbsp;31, 2016 and 2015 was $6.37 and $1.50, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company measures the fair value of stock options with service&amp;#8209;based and performance&amp;#8209;based vesting criteria to employees, consultants and directors on the date of grant using the Black&amp;#8209;Scholes option pricing model. The fair value of equity instruments issued to non&amp;#8209;employees is re&amp;#8209;measured as the award vests. The Company does not have history to support a calculation of volatility and expected term. As such, the Company has used a weighted&amp;#8209;average volatility considering the volatilities of several guideline companies.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;For purposes of identifying similar entities, the Company considered characteristics such as industry, length of trading history, and stage of life cycle. The assumed dividend yield was based on the Company&amp;#x2019;s expectation of not paying dividends in the foreseeable future. The average expected life of the options was determined based on the mid&amp;#8209;point between the vesting date and the end of the contractual term according to the &amp;#x201C;simplified method&amp;#x201D; as described in Staff Accounting Bulletin 110. The risk&amp;#8209;free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to the expected life assumed at the date of grant. As a result of the early adoption of &lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;ASU 2016-09, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;"&gt;Compensation &amp;#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="display:inline;"&gt;, the Company has made an accounting policy election to record forfeitures when they occur. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The weighted&amp;#8209;average assumptions used in the Black&amp;#8209;Scholes option&amp;#8209;pricing model are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year&amp;nbsp;&amp;nbsp;Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="middle" style="width:17.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="middle" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:17.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected stock price volatility &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;71.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;71.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected life of options (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected dividend yield &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Risk free interest rate &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During the years ended December 31, 2016 and 2015, 276,248 and 104,907 stock options vested, respectively. The weighted average fair value per share of options vesting during the years ended December 31, 2016 and 2015 was $4.59 and $1.05, respectively. During the year ended December 31, 2016, 83,742 stock options were forfeited. During the years ended December 31, 2015 and 2014, no stock options were forfeited. As of December 31, 2016, 457,200 shares were available for future issuance under the A&amp;amp;R 2015 and Inducement Plans.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Unrecognized share&amp;#8209;based compensation cost for the RSAs and stock options issued under the Company&amp;#x2019;s 2014 Shareholders Agreement, A&amp;amp;R 2015 Plan and Inducement Plan was $11.2&amp;nbsp;million as of December 31, 2016. Approximately $11.2 million of the unrecognized compensation cost was related to the stock options and under $1,000 related to the RSAs. The non&amp;#8209;employee portion of the unrecognized compensation cost was estimated utilizing the Company&amp;#x2019;s fair market value for its common stock as of December 31, 2016. The unrecognized share&amp;#8209;based expense is expected to be recognized over a weighted average period of 3.2 years for the stock options and 0.1&amp;nbsp;years for the RSAs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;"&gt;Adoption of 2016 Employee Stock Purchase Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April 2016 the Company&amp;#x2019;s board of directors approved the 2016 Employee Stock Purchase Plan (the ESPP) in order to enable eligible employees to purchase shares of the Company&amp;#x2019;s common stock at a discount following the effective date of the IPO. The Company&amp;#x2019;s stockholders also approved the ESPP in April, 2016 and the ESPP became effective immediately upon the execution and delivery of the underwriting agreement related to the IPO. The Company initially reserved 150,000 shares of common stock for issuance under the ESPP. As of December 31, 2016, no shares were purchased under the ESPP. &amp;nbsp; &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-5">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
  <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit18" decimals="2">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit18" decimals="2">-2.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit18" decimals="2">-4.54</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit18" decimals="2">-0.60</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit18" decimals="2">-0.87</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit18" decimals="2">-1.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit18" decimals="2">-0.65</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit18" decimals="2">-2.57</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit18" decimals="2">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit18" decimals="2">-0.56</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit18" decimals="2">-0.78</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;10. Net Loss Per Common Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Basic earnings or loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The holders of the Series&amp;nbsp;A preferred stock had rights to participate in common stock dividends, entitling the holders of Series&amp;nbsp;A preferred stock to a dividend payable at the same time and rate per share as the dividend paid on common stock based the number of shares of common stock each share of Series&amp;nbsp;A preferred stock would have converted into if such shares had converted on the record date. The Series&amp;nbsp;A preferred stock, however, did not have a contractual obligation to share in the losses of the Company, and as such, no losses were allocated to the Series&amp;nbsp;A preferred stock for the purposes of the basic loss per share calculation while they were outstanding. Prior to the Company&amp;#x2019;s incorporation, no common shares were outstanding when the Company operated as MLT.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&amp;#x2019;s RSAs, stock options, shares of Series&amp;nbsp;A preferred stock, Convertible Notes and Interim Notes are considered common stock equivalents while outstanding for this purpose. Diluted earnings is computed utilizing the treasury method for the RSAs and stock options, and in the case of the Series&amp;nbsp;A preferred stock, either the two&amp;#8209;class method or the if&amp;#8209;converted method, whichever was more dilutive. Diluted earnings with respect to the Convertible Notes and Interim Notes utilized the if&amp;#8209;converted method, but was not applicable during the years ended December 31, 2016, 2015 and 2014 as no conditions required for conversion had occurred during these periods while the instruments were outstanding. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti&amp;#8209;dilutive given the net loss reported for the years ended December 31, 2016, 2015 and 2014. The following table sets forth the computation of basic and diluted loss per share as of December 31, 2016, 2015 and 2014 (in thousands, except share and per share amounts):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:36.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,586)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(9,029)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(320)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Adjustment to redemption value on Series&amp;nbsp;A convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(366)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,968)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Premium upon substantial modification of convertible notes with certain stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,047)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss attributed to common stock holders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,952)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(13,044)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(320)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted weighted average common shares outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,809,396
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,875,053
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,521,703
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2.57)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4.54)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.21)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti&amp;#8209;dilutive:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:29.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Restricted stock awards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,009
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;348,093
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;994,613
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,242,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;302,842
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Series&amp;nbsp;A&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;745,637
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;828,751
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit14" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit14" decimals="4">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="4">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="4">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit14" decimals="4">0.3680</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="4">0.3820</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="4">0.4020</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="4">-0.0080</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="4">0.0140</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit14" decimals="4">-0.0400</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="4">-0.0400</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="4">-0.0470</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="4">-0.0400</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">345000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="As_Of_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="-5">300000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="As_Of_12_31_2015_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">345000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">345000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="As_Of_12_31_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="-5">0</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_IncomeStatementLocationAxis_gemp_InterestIncomeExpenseNetMember" unitRef="Unit12" decimals="-5">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_IncomeStatementLocationAxis_gemp_InterestIncomeExpenseNetMember" unitRef="Unit12" decimals="0">18000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_IncomeStatementLocationAxis_gemp_InterestIncomeExpenseNetMember" unitRef="Unit12" decimals="-5">-100000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_IncomeStatementLocationAxis_gemp_InterestIncomeExpenseNetMember" unitRef="Unit12" decimals="-5">-400000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_IncomeStatementLocationAxis_gemp_InterestIncomeExpenseNetMember" unitRef="Unit12" decimals="-5">200000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">2000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">706000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-5">11200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">P1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit12" decimals="0">1000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="-5">11200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:ExtinguishmentOfDebtAmount contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">1426000</us-gaap:ExtinguishmentOfDebtAmount>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;11. Fair Value Measurements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company follows accounting guidance that emphasizes that fair value is a market&amp;#8209;based measurement, not an entity specific measurement. Fair value is defined as &amp;#x201C;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&amp;#x201D; Fair value measurements are defined on a three level hierarchy:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Level&amp;nbsp;1 inputs:&lt;/font&gt;&lt;font style="display:inline;"&gt; &amp;nbsp;Unadjusted quoted prices for identical assets or liabilities in active markets;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Level&amp;nbsp;2 inputs:&lt;/font&gt;&lt;font style="display:inline;"&gt; &amp;nbsp;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, weather directly or indirectly, for substantially the full term of the asset or liability;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Level&amp;nbsp;3 inputs:&lt;/font&gt;&lt;font style="display:inline;"&gt; &amp;nbsp;Unobservable inputs that reflect the Company&amp;#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December 31, 2016 and 2015, the fair values of cash and cash equivalents, other assets, accounts payable and accrued liabilities approximated their carrying values because of the short&amp;#8209;term nature of these assets or liabilities. The estimated fair value of the Company&amp;#x2019;s Interim Notes was based on amortized cost which was deemed to approximate fair value. The derivative liability associated with the conversion premium on the Interim Notes was based on cash flow models discounted at current implied market rates evidenced in recent arms&amp;#8209;length transactions representing expected returns by market participants for similar instruments which were based on Level&amp;nbsp;3 inputs. There were no transfers between fair value hierarchy levels during the years ended December 31, 2016 and 2015.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value of financial instruments measured on a recurring basis is as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:39.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;As of December&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Description&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Level&amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Premium conversion derivative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total liabilities at Fair Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table provides a roll&amp;#8209;forward of the Company&amp;#x2019;s premium conversion derivative liabilities measured at fair value on a recurring basis using unobservable level&amp;nbsp;3 inputs (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 92.80%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;For&amp;nbsp;the Year Ended December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Balance as of beginning of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Issuance of underlying convertible notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;505
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;842
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;55
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Change in fair value of premium conversion derivative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(850)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;297
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Reversal of premium conversion derivative associated with note extinguishment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(182)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Redemption of underlying convertible notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(685)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Balance as of end of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;There were no financial instruments measured on a recurring basis as of December 31, 2016 and on a non&amp;#8209;recurring basis for any of the periods presented.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">18000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">297000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-850000</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The fair value of financial instruments measured on a recurring basis is as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:39.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;As of December&amp;nbsp;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Description&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Level&amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Level&amp;nbsp;2&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Level&amp;nbsp;3&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Premium conversion derivative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total liabilities at Fair Value&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table provides a roll&amp;#8209;forward of the Company&amp;#x2019;s premium conversion derivative liabilities measured at fair value on a recurring basis using unobservable level&amp;nbsp;3 inputs (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 92.80%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;For&amp;nbsp;the Year Ended December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Balance as of beginning of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Issuance of underlying convertible notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;505
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;842
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;55
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Change in fair value of premium conversion derivative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(850)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;297
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Reversal of premium conversion derivative associated with note extinguishment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(182)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Redemption of underlying convertible notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(685)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Balance as of end of period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;73
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="Unit12" decimals="-3">18000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="Unit12" decimals="-3">297000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="Unit12" decimals="-3">-850000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="Unit12" decimals="-3">55000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="Unit12" decimals="-3">842000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="Unit12" decimals="-3">505000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="Unit12" decimals="-3">685000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="As_Of_12_31_2014_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="Unit12" decimals="-3">73000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="As_Of_12_31_2015_us-gaap_FairValueByLiabilityClassAxis_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" unitRef="Unit12" decimals="-3">345000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s financial instruments include principally cash and cash equivalents, other current assets, accounts payable, accrued liabilities and debt. The carrying amounts for these financial instruments reported in the balance sheets approximate their fair values. See Note&amp;nbsp;11&amp;nbsp;&amp;#x2014; Fair Value Measurements, for further discussion of fair value.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2014_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember" unitRef="Unit12" decimals="-3">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember" unitRef="Unit12" decimals="-3">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">345000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">345000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember" unitRef="Unit12" decimals="-3">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2016_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-3">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-198000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-198000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">214000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">475000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">3177000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="-3">658000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">997000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">1047000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">1050000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">5956000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1051000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">1466000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">2389000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-320000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-2279000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-9029000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="-3">-1611000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">-2569000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-2570000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">-2103000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-14586000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-1391000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">-3878000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-7214000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;12. Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The effective tax rate for the years ended December&amp;nbsp;31, 2016, 2015 and 2014 was zero percent. MLT was treated as a partnership for federal and state income tax purposes. Accordingly, no provision was made for income taxes for periods prior to the merger, since the Company&amp;#x2019;s net loss (subject to certain limitations) was passed through to the income tax returns of its members. Upon the incorporation of Gemphire on October&amp;nbsp;30, 2014, the Company became taxed as a corporation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying statements of comprehensive loss is as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:40.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;For the Year Ended December 31, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Income tax (benefit) provision at federal statutory rate &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Valuation allowance &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;40.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;38.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;36.8
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;State income tax, net of federal benefit &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4.7)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible notes &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.8)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Effective tax rate &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Significant components of the Company&amp;#x2019;s deferred tax assets and liabilities are summarized in the tables below as of (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:36.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year Ended December 31, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:17.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:16.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Federal and state operating loss carryforwards &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,289
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,723
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development costs deferral election&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,254
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Acquired intangibles &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;351
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accruals&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible notes &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;460
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Charitable contributions &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Stock-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;633
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development credit carryforwards &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;768
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;95
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,320
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,668
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Valuation allowance &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(9,320)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,657)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total deferred tax assets, net of valuation allowance &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Restricted stock awards &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total deferred tax liabilities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net deferred tax assets &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
			&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2016 and 2015, the Company had gross deferred tax assets of approximately $9.3 million and $3.7&amp;nbsp;million, respectively. Realization of the deferred assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre&amp;#8209;tax losses since its inception. The Company has not yet generated revenues and faces significant challenges to becoming profitable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance of $9.3 million and $3.7&amp;nbsp;million as of December&amp;nbsp;31, 2016 and 2015, respectively. U.S. net deferred tax assets will continue to require a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As of December&amp;nbsp;31, 2016 and 2015, the tax effect of the Company&amp;#x2019;s federal net operating loss carryforwards was approximately $2.1 million and $2.4&amp;nbsp;million, respectively. The Company had federal research credit carryforwards as of December&amp;nbsp;31, 2016 and 2015 of approximately $0.7 million and $95,000, respectively. The federal net operating loss and tax credit carryforwards will begin to expire in 2034 if not utilized. As of December&amp;nbsp;31, 2016 and 2015, the Company had state net operating loss carryforwards with a tax effect of approximately $0.2 million and $0.3&amp;nbsp;million, respectively. The Company had state research credit carryforwards of $24,000 as of December&amp;nbsp;31, 2016 and no state research credit carryforwards as of December 31, 2015. The state net operating loss carryforwards will begin to expire in 2026, if not utilized, and the state research credit carryforwards will begin to expire in 2023 if not utilized.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section&amp;nbsp;382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more &amp;#x201C;5-percent shareholders&amp;#x201D; increase their ownership, in the aggregate, by more than 50&amp;nbsp;percentage points over a 36&amp;#8209;month time period testing period, or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of December&amp;nbsp;31, 2016 and 2015, and as such, no interest or penalties were recorded to income tax expense.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s corporate returns are subject to examination for the 2014 and 2015 tax years for federal and subject to examination for the 2015 tax year in various state jurisdictions. Prior to this period, the Company filed partnership returns, resulting in its income being passed through to its members.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_10_31_2014_To_10_31_2014" unitRef="Unit12" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_10_31_2014_To_10_31_2014_us-gaap_StatementScenarioAxis_us-gaap_PredecessorMember" unitRef="Unit12" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilizes the liability method of accounting for income taxes as required by Accounting Standards Codification (ASC) 740, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="display:inline;"&gt;. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is no provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. MLT was treated as a partnership for federal and state income tax purposes. Accordingly, no provision was made for income taxes for periods prior to November&amp;nbsp;1, 2014, since the Company&amp;#x2019;s net loss (subject to certain limitations) was passed through to the income tax returns of its members. Upon incorporation on October&amp;nbsp;30, 2014, the Company became taxed as a corporation.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-6000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">444000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">1477000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">21000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">1012000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">496000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Acquired In&amp;#8209;Process Research and Development Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company includes costs to acquire or in&amp;#8209;license product candidates in acquired in&amp;#8209;process research and development expenses. The Company has acquired the right to develop and commercialize its product candidate gemcabene. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &amp;#x201C;business&amp;#x201D; as defined under GAAP or provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-55000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-690000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-762000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">-209000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">137000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">127000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">114000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">449000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">-475000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">13000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestOnConvertibleDebtNetOfTax contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">649000</us-gaap:InterestOnConvertibleDebtNetOfTax>
  <us-gaap:InterestPaid contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">2000</us-gaap:InterestPaid>
  <us-gaap:LeaseAndRentalExpense contextRef="Duration_5_1_2016_To_5_31_2016" unitRef="Unit12" decimals="0">8400</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Duration_5_1_2016_To_5_31_2016">P3Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">8917000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">4122000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2016_us-gaap_CounterpartyNameAxis_gemp_PfizerInc.Member_us-gaap_TypeOfArrangementAxis_gemp_LicenseAgreementMember" unitRef="Unit12" decimals="0">0</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">4490000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">24754000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAssumed1 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" unitRef="Unit12" decimals="-3">642000</us-gaap:LiabilitiesAssumed1>
  <us-gaap:LiabilitiesAssumed1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherAssetsMember" unitRef="Unit12" decimals="-3">205000</us-gaap:LiabilitiesAssumed1>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">8917000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">4121000</us-gaap:LiabilitiesCurrent>
  <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="As_Of_3_31_2015_us-gaap_CounterpartyNameAxis_gemp_PfizerInc.Member_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_gemp_LicenseAgreementMember" unitRef="Unit14" decimals="2">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">509000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">8736000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">31456000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-195000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-5433000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-11043000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2014_To_10_31_2014" unitRef="Unit12" decimals="-3">-124000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2014_To_10_31_2014_us-gaap_StatementEquityComponentsAxis_gemp_MembersEarningsMember" unitRef="Unit12" decimals="-3">-124000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-320000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_11_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-196000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_11_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-196000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-2279000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-9029000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-9029000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="-3">-1611000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">-2569000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-2570000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">-2103000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-14586000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-14586000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-1391000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">-3878000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-7214000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-320000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-4796000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-13044000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="-3">-1760000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">-2721000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-3767000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">-2252000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-14952000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-1541000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">-3945000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-7214000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In May 2014, the FASB issued ASU 2014&amp;#8209;09, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Revenue from Contracts with Customers&amp;nbsp;&amp;#x2014; Topic 606&lt;/font&gt;&lt;font style="display:inline;"&gt;, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In 2015, the FASB agreed to allow companies to delay the implementation of this standard for one year effective for annual reporting periods beginning after December&amp;nbsp;15, 2017, including interim periods within that reporting period. Early application is permitted only for periods beginning after December&amp;nbsp;15, 2016. The Company plans to adopt this standard on January&amp;nbsp;1, 2018 and to select the modified retrospective transition method. The Company plans to modify its accounting policies to reflect the requirements of this standard however, the planned adoption will not affect the Company&amp;#x2019;s financial statements and related disclosures for these periods or future periods until the Company generates revenues.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In August 2014, the FASB issued Accounting Standards Update No.&amp;nbsp;2014&amp;#8209;15, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Presentation of Financial Statements&amp;nbsp;&amp;#x2014; Going Concern (Subtopic 205&amp;#8209;40): Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern&lt;/font&gt;&lt;font style="display:inline;"&gt; (ASU 2014&amp;#8209;15), which requires management to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events that, considered in the aggregate, raise substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable) and provide related disclosures. ASU 2014&amp;#8209;15 is effective for the annual period ending after December&amp;nbsp;15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company elected to adopt this standard early as of December 31, 2015 and did not have a material impact on the Company&amp;#x2019;s financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In November 2015, the Financial Accounting Standards Board (FASB) issued ASU 2015&amp;#8209;17, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="display:inline;"&gt; (ASU 2015&amp;#8209;17). The new guidance simplifies the presentation of deferred income taxes by requiring that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015&amp;#8209;17 applies to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax&amp;#8209;paying component of an entity be offset and presented as a single amount is not affected by this ASU. For public entities, ASU 2015&amp;#8209;17 is effective for financial statements issued for annual periods beginning after December&amp;nbsp;15, 2016 with earlier application permitted. The new guidance may be applied either prospectively or retrospectively to all periods presented. The Company &lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;adopted this standard effective April 1, 2016 on a retrospective basis for each period presented. &lt;/font&gt;&lt;font style="display:inline;"&gt;The adoption of this standard did not have a material impact on the Company&amp;#x2019;s financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In January 2016, the FASB issued ASU No.&amp;nbsp;2016&amp;#8209;01, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Financial Instruments&amp;nbsp;&amp;#x2014; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.&lt;/font&gt;&lt;font style="display:inline;"&gt; The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in the first quarter of fiscal 2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently evaluating the impact of the new guidance on its financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Leases (Topic &lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;842). The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The Company is currently evaluating the new guidance to determine the impact it may have on its financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;In March 2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;"&gt;Compensation &amp;#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;. This ASU simplifies the accounting for share-based payment award transactions including: income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December&amp;nbsp;15, 2016, including interim periods within those fiscal years. Early adoption is permitted. &lt;/font&gt;&lt;font style="display:inline;"&gt;The Company &lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;adopted this standard effective July 1, 2016 on a retrospective basis for each period presented. &lt;/font&gt;&lt;font style="display:inline;"&gt;The adoption of this standard did not have a material impact on the Company&amp;#x2019;s financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;background-color: #FFFFFF;"&gt;In November 2016, the FASB issued ASU No.&amp;nbsp;2016-18, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;background-color: #FFFFFF;"&gt;Statement of Cash Flows (Topic 230): Restricted Cash&lt;/font&gt;&lt;font style="display:inline;color:#000000;background-color: #FFFFFF;"&gt;. The objective of this ASU is to eliminate the diversity in practice related to the classification of &lt;/font&gt;&lt;font style="display:inline;"&gt;restricted cash or restricted cash equivalents in the statement of cash flows. &lt;/font&gt;&lt;font style="display:inline;color:#000000;background-color: #FFFFFF;"&gt;For public business entities, this ASU is effective for annual and interim reporting periods beginning after December&amp;nbsp;15, 2017, with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&amp;#x2019;s financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1 contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="-3">908000</us-gaap:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1>
  <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">1795000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
  <us-gaap:NumberOfOperatingSegments contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit19" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">-266000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-1589000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-8076000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="-3">-1610000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">-2366000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">-2511000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">-2226000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-14696000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-1840000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">-3402000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-7228000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">260000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">101000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">58000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">101000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;1. The Company and Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On November&amp;nbsp;10, 2008, Michigan Life Therapeutics,&amp;nbsp;LLC (MLT) was organized as a limited liability company (LLC) in Michigan. On October&amp;nbsp;30, 2014, Gemphire Therapeutics&amp;nbsp;Inc. (Gemphire) was incorporated as a C corporation in the state of Delaware. On November&amp;nbsp;1, 2014, MLT entered into a merger agreement with Gemphire whereby MLT was merged with and into Gemphire with Gemphire as the surviving entity; all outstanding membership interests of MLT were exchanged for shares of Gemphire&amp;#x2019;s common stock. The purpose of the merger was to change the jurisdiction of MLT from Michigan to Delaware and to convert from an&amp;nbsp;LLC to a corporation. All financial results presented prior to November 1, 2014 are from the operations of MLT. MLT and Gemphire are collectively referred to as the &amp;#x201C;Company&amp;#x201D; in the accompanying notes to the financial statements. The Company&amp;#x2019;s headquarters are located in Livonia, Michigan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company is a clinical&amp;#8209;stage biopharmaceutical entity focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease and NAFLD/NASH (nonalcoholic fatty liver disease). The Company&amp;#x2019;s primary activities have been conducting research and development activities, planning clinical trials, performing business and financial planning, recruiting personnel and raising capital. The Company is subject to certain risks, which include the need to research, develop, and clinically test potentially therapeutic products, initially one product candidate gemcabene (also known as CI&amp;#8209;1027); obtain regulatory approval for its products and commercialize them around the world; expand its management scientific staff; finance its operations; and, find collaboration partners to further advance development and commercial efforts.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;color:#000000;"&gt;Initial Public Offering and Capital Requirements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;On August 4, 2016, the Company&amp;#x2019;s Registration Statement on Form S-1 (File No 333-210815) relating to its IPO of its common stock was declared effective by the Securities and Exchange Commission (SEC). Pursuant to such Registration Statement, on August 10, 2016, the Company closed its IPO whereby 3,000,000 shares of its common stock were issued and sold at a public offering price of $10.00 per share. On September 8, 2016, the Company closed the sale of 27,755 shares of its common stock at the public offering price of $10.00 per share, representing a partial exercise of the underwriters&amp;#x2019; over-allotment option, following which, the IPO terminated. The Company received net proceeds of approximately $26.1 million after deducting underwriting discounts and commissions of $2.1 million and other offering expenses of $2.1 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Immediately prior to the IPO, the Company amended and restated its certificate of incorporation and bylaws to, among other things, change its authorized capital stock to consist of (i) 100,000,000 shares of common stock and (ii) 10,000,000 shares of undesignated preferred stock.&lt;/font&gt;&lt;font style="display:inline;color:#000000;background-color: #FFFFFF;"&gt; Both the common stock and the preferred stock have a par value of $0.001 per share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company has sustained operating losses since inception and expects such losses to continue over the next several years. Management plans to continue financing the operations with equity issuances. The Company&amp;#x2019;s management believes the cash and cash equivalents on hand are adequate to fund the Company&amp;#x2019;s operations for at least the next 12 months. If adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate part or all of its research and development programs.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;background-color: #FFFFFF;"&gt;Certain prior period balances have been reclassified to conform to the current period presentation. Specifically, the Company reclassified all current deferred tax liabilities as long term in the amount of $10,000 on its December 31, 2015 balance sheet in conformity with the adoption of&lt;/font&gt;&lt;font style="display:inline;"&gt; Accounting Standards Update (ASU) 2015&amp;#8209;17, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="display:inline;"&gt; (ASU 2015&amp;#8209;17).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;color:#000000;background-color: #FFFFFF;"&gt;Reverse Stock Split&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;background-color: #FFFFFF;"&gt;In April 2016, the board of directors approved an amendment to the Company&amp;#x2019;s certificate of incorporation to effect a 1-for-3.119 reverse stock split (the Reverse Stock Split) for all common and Series A preferred stock. The Reverse Stock Split became effective on April 27, 2016 upon the filing of the amendment to the certificate of incorporation. The authorized shares and par value of the common stock and Series A preferred stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common and Series A preferred stock, options for common stock and per share amounts contained in the financial statements were retroactively adjusted to reflect the Reverse Stock Split for all periods presented.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">1000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">7000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="-3">-1000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">6000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">2000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">-4000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-4000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">-1000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">1000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
  <us-gaap:PaymentsForUnderwritingExpense contextRef="Duration_9_8_2016_To_9_8_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit12" decimals="-5">2100000</us-gaap:PaymentsForUnderwritingExpense>
  <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Duration_4_1_2016_To_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="0">10000</us-gaap:PaymentsOfDebtIssuanceCosts>
  <us-gaap:PaymentsOfFinancingCosts contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">10000</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">205000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">3963000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="Duration_9_8_2016_To_9_8_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit12" decimals="-5">2100000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">2968000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">1130000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">1838000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">366000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">285000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">81000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:PreferredStockAmountOfPreferredDividendsInArrears contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-5">300000</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
  <us-gaap:PreferredStockAmountOfPreferredDividendsInArrears contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit12" decimals="-5">300000</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
  <us-gaap:PreferredStockAmountOfPreferredDividendsInArrears contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit12" decimals="0">0</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
  <us-gaap:PreferredStockDividendRatePercentage contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit14" decimals="2">0.08</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit12" decimals="INF">6.70585</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2015" unitRef="Unit18" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_8_3_2016" unitRef="Unit18" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2016" unitRef="Unit18" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_8_3_2016" unitRef="Unit1" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_12_31_2015" unitRef="Unit12" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_12_31_2016" unitRef="Unit12" />
  <us-gaap:PrepaidExpenseCurrent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">23000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">713000</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidRent contextRef="As_Of_12_31_2015_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember" unitRef="Unit12" decimals="0">3000</us-gaap:PrepaidRent>
  <us-gaap:PrepaidRent contextRef="As_Of_12_31_2016_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember" unitRef="Unit12" decimals="0">0</us-gaap:PrepaidRent>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">390000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_11_1_2014_To_2_18_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember" unitRef="Unit12" decimals="-5">2700000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember" unitRef="Unit12" decimals="-5">2000000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_gemp_SeriesaPreferredConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToBoardMemberAndOfficersMember" unitRef="Unit12" decimals="-5">300000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">5560000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_7_1_2015_To_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="-5">2800000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_7_1_2015_To_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" unitRef="Unit12" decimals="-5">300000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_7_1_2015_To_9_30_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" unitRef="Unit12" decimals="-5">500000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_7_31_2015_To_7_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="-5">2800000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_12_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="-5">2700000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_12_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToThreeOfficersMember" unitRef="Unit12" decimals="-5">200000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_12_1_2015_To_12_31_2015_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoOfficersAndFourBoardMembersInvestorsMember" unitRef="Unit12" decimals="-5">600000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">2651000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="-5">200000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_TwoBoardMembersInvestorsMember" unitRef="Unit12" decimals="0">81000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_2_1_2016_To_2_29_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" unitRef="Unit12" decimals="0">20000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_4_1_2016_To_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit12" decimals="-5">5000000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_4_1_2016_To_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember" unitRef="Unit12" decimals="-5">5000000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_4_1_2016_To_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToThreeDirectorsMember" unitRef="Unit12" decimals="-5">2300000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_4_1_2016_To_4_30_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember_us-gaap_RelatedPartyTransactionAxis_gemp_DebtIssuedToRelatedPartiesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_InvestorsRelatedToTwoOfficersMember" unitRef="Unit12" decimals="-5">200000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">30278000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">3000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">1522000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Duration_8_4_2016_To_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit12" decimals="-5">26100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">25000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">1856000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">2500000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;13. &lt;/font&gt;&lt;font style="display:inline;font-weight:bold;color:#000000;"&gt;Supplementary Data &amp;#x2014; Quarterly Financial Data (unaudited)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;The following table presents certain unaudited quarterly financial information for each of the eight fiscal quarters in the period ended December 31, 2016. This quarterly information has been prepared on the same basis as the audited financial statements and includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the information for the periods presented. The results for these quarterly periods are not necessarily indicative of the operating results for a full year or any future period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Three Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;June 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016 (B)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(in thousands, except per share amounts)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Operating expenses:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,389
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,466
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,051
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,050
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,839
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,936
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;789
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,176
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total operating expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,228
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,402
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,840
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,226
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss from operations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,228)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,402)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,840)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,226)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Interest income (expense)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(475)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;449
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;127
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other income (expense)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss before income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,214)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,878)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,391)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,103)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Provision (benefit) for income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,214)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,878)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,391)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,103)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other comprehensive loss, net of tax&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Comprehensive loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,214)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,878)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,391)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,103)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,214)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,878)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,391)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,103)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Adjustment to redemption value on Series&amp;nbsp;A convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(67)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(150)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(149)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss attributable to common stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,214)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,945)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,541)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,252)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss per share:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted (A)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.78)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.56)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.42)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.65)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Three Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;June 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(in thousands, except per share amounts)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Operating expenses:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,047
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;997
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;658
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;475
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,464
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,369
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;952
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;206
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Acquired in&amp;#x2013;process research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;908
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total operating expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,511
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,366
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,610
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,589
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss from operations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,511)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,366)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,610)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,589)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Interest income (expense)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;137
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(209)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(690)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss on convertible note extinguishment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(198)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other income (expense)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss before income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,570)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,569)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,611)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,279)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Provision (benefit) for income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,570)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,569)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,611)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,279)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other comprehensive loss, net of tax&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Comprehensive loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,570)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,569)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,611)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,279)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,570)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,569)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,611)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,279)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Adjustment to redemption value on Series&amp;nbsp;A convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(150)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(152)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(149)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,517)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Premium upon substantial modification of convertible notes with certain stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,047)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss attributable to common stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,767)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,721)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,760)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,796)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss per share:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted (A)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1.14)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.87)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.60)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2.27)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 23.00pt; display: inline;"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
				&lt;sup style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (A)&lt;/sup&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:13pt;"&gt;&lt;p style="width:13pt;width:13pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Net loss per share for the year does not equal the sum of the four historical quarters loss per share due to changes in weighted-average shares outstanding.&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 23.00pt; display: inline;"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
				&lt;sup style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (B)&lt;/sup&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:13pt;"&gt;&lt;p style="width:13pt;width:13pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Activity for the quarterly period ending December 31, 2016 reflects activity post IPO depicting a ramp-up of research and development expenses given the additional IPO proceeds and an increase in general and administrative expenses attributed to becoming a public company.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember" unitRef="Unit12" decimals="0">6000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember" unitRef="Unit12" decimals="0">6000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember" unitRef="Unit12" decimals="0">23000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember" unitRef="Unit12" decimals="0">23000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember" unitRef="Unit12" decimals="0">58000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_RelatedPartyTransactionAxis_gemp_OfficeRentalMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_LlcOwnedByTwoOfficersMember" unitRef="Unit12" decimals="0">21000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;14. Related Party Transactions&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company rented an office in Northville, Michigan from an&amp;nbsp;LLC owned by two officers under short&amp;#8209;term agreements during the years ended December 31, 2016, 2015 and 2014. The original facility lease, as amended, was cancelled and replaced with a cancellable lease agreement in August 2016 for limited use of office space in the same Northville location. The new lease agreement became effective in August 2016 and expires in September 2017. Rent expense under the related party agreements was $21,000,&amp;nbsp;$23,000 and $6,000 during the years ended December 31, 2016, 2015 and 2014, respectively. A prepaid rent balance related to the short&amp;#8209;term agreements amounted to zero and $3,000 as of December&amp;nbsp;31, 2016 and 2015, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During the first quarter of 2015, the Company issued $2.0&amp;nbsp;million of additional Convertible Notes (the 2015 Notes) as part of the Convertible Notes described in Note&amp;nbsp;4&amp;nbsp;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Debt&lt;/font&gt;&lt;font style="display:inline;"&gt;. The 2015 Notes included four notes in the aggregate of $0.3&amp;nbsp;million issued to investors who were related to one board member and three officers of the Company. On March 31, 2015, all of the Convertible Notes (including the 2015 Notes) were converted into 516,421 shares of Series&amp;nbsp;A preferred stock. The conversion included a total of 68,649 shares of Series&amp;nbsp;A preferred stock issued to two officers of the Company, and 63,967 shares of Series&amp;nbsp;A preferred stock issued to investors related to one board member and three officers of the Company.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;During the third quarter of 2015, the Company issued $2.8&amp;nbsp;million of Interim Notes as described in Note&amp;nbsp;4&amp;nbsp;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Debt&lt;/font&gt;&lt;font style="display:inline;"&gt;. Such Interim Notes included five notes issued to two officers and three board members (or entities they control) in the amount of $0.5&amp;nbsp;million. In addition, such Interim Notes included four notes to investors who were related to three of the Company&amp;#x2019;s officers and to one of the Company&amp;#x2019;s key employees in the amount of $0.3&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In December 2015, the Company issued an additional $2.7&amp;nbsp;million of Interim Notes, as described in Note&amp;nbsp;4&amp;nbsp;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Debt,&lt;/font&gt;&lt;font style="display:inline;"&gt; which included six notes issued to two officers and four board members in the amount of $0.6&amp;nbsp;million. The December 2015 Interim Note issuances also included five notes to investors who were related to three of the Company&amp;#x2019;s officers in the amount of $0.2&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In February 2016, the Company issued an additional $0.2 million of Interim Notes, as described in Note&amp;nbsp;4&amp;nbsp;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Debt,&lt;/font&gt;&lt;font style="display:inline;"&gt; which included two notes issued to two board members (or entities they control) in the amount of $81,000. The February 2016 Interim Note issuances also included a $20,000 note to an investor who is related to an officer of the Company.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In April 2016, the Company issued an additional $5.0 million of Interim Notes, as described in Note&amp;nbsp;4&amp;nbsp;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Debt,&lt;/font&gt;&lt;font style="display:inline;"&gt; which included two notes to investors who were related to two of the Company&amp;#x2019;s officers in the aggregate amount of $0.2&amp;nbsp;million. The April 2016 Interim Notes issuances also included three notes to investors who were related to three of the Company&amp;#x2019;s directors in the aggregate amount of $2.3 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The IPO included 154,450 shares sold to 5 officers and 3 board members, totaling $1.5 million. In addition, 500,000 shares were sold to 1 investor who is related to 1 of the Company&amp;#x2019;s directors, totaling $5.0 million, and 47,000 shares totaling $0.5 million were sold to 14 investors who are related to 5 officers of the Company.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">908000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
  <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">908000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">52000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">206000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">3991000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="-3">952000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">1369000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">1464000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">1176000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">8740000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">789000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">1936000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="Duration_10_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">4839000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and development expenses consist of costs incurred in performing research and development activities, including compensation for research and development employees, costs associated with preclinical studies and trials, regulatory activities, manufacturing activities to support clinical activities, license fees, non&amp;#8209;legal patent costs, fees paid to external service providers that conduct certain research and development, clinical costs and an allocation of overhead expenses. Research and development costs are expensed as incurred.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">-12392000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">-27059000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:27.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;As&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued offering costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;575
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Legal costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;54
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;234
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accrued compensation costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;706
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other research and development expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,259
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;759
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other general and administrative expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;94
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;47
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,113
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,617
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:29.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Restricted stock awards&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,009
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;348,093
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;994,613
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,242,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;302,842
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Series&amp;nbsp;A&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;745,637
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible notes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;828,751
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Significant components of the Company&amp;#x2019;s deferred tax assets and liabilities are summarized in the tables below as of (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:36.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year Ended December 31, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:17.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:16.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Federal and state operating loss carryforwards &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,289
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,723
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development costs deferral election&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,254
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Acquired intangibles &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;351
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;345
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Accruals&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible notes &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;460
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Charitable contributions &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;12
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Stock-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;633
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;41
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development credit carryforwards &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;768
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;95
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,320
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,668
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Valuation allowance &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(9,320)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,657)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total deferred tax assets, net of valuation allowance &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;11
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Restricted stock awards &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total deferred tax liabilities &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(11)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net deferred tax assets &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The following table sets forth the computation of basic and diluted loss per share as of December 31, 2016, 2015 and 2014 (in thousands, except share and per share amounts):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:36.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Numerator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,586)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(9,029)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(320)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Adjustment to redemption value on Series&amp;nbsp;A convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(366)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,968)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Premium upon substantial modification of convertible notes with certain stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,047)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss attributed to common stock holders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(14,952)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(13,044)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(320)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Denominator:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted weighted average common shares outstanding&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,809,396
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,875,053
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,521,703
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted net loss per share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2.57)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4.54)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.21)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="bottom" style="width:40.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;For the Year Ended December 31, &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Income tax (benefit) provision at federal statutory rate &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(34.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Valuation allowance &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;40.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;38.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;36.8
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;State income tax, net of federal benefit &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4.7)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Convertible notes &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research credits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4.0)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.8)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Effective tax rate &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Share-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying statements of comprehensive loss (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;"&gt;
						&lt;font style="display:inline;font-size:11pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="middle" style="width:50.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="8" valign="middle" style="width:50.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="middle" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,166
				&lt;/td&gt;
				&lt;td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;284
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;53
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;552
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total share-based compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,718
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;284
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;53
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:17.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;101
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;101
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;58
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;260
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Three Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;June 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016 (B)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(in thousands, except per share amounts)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Operating expenses:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,389
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,466
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,051
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,050
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,839
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,936
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;789
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,176
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total operating expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;7,228
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,402
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,840
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,226
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss from operations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,228)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,402)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,840)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,226)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Interest income (expense)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;13
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(475)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;449
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;127
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other income (expense)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss before income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,214)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,878)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,391)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,103)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Provision (benefit) for income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,214)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,878)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,391)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,103)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other comprehensive loss, net of tax&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Comprehensive loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,214)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,878)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,391)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,103)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,214)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,878)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,391)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,103)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Adjustment to redemption value on Series&amp;nbsp;A convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(67)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(150)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(149)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss attributable to common stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(7,214)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,945)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,541)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,252)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss per share:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted (A)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.78)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.56)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.42)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.65)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Three Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;September 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;June 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(in thousands, except per share amounts)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Operating expenses:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,047
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;997
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;658
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;475
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,464
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,369
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;952
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;206
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Acquired in&amp;#x2013;process research and development&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;908
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Total operating expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,511
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,366
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,610
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,589
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss from operations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,511)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,366)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,610)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,589)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Interest income (expense)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;137
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(209)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(690)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss on convertible note extinguishment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(198)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other income (expense)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Loss before income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,570)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,569)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,611)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,279)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Provision (benefit) for income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,570)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,569)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,611)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,279)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Other comprehensive loss, net of tax&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Comprehensive loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,570)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,569)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,611)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,279)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,570)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,569)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,611)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,279)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Adjustment to redemption value on Series&amp;nbsp;A convertible preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(150)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(152)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(149)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,517)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Premium upon substantial modification of convertible notes with certain stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,047)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss attributable to common stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,767)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,721)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,760)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(4,796)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Net loss per share:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Basic and diluted (A)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1.14)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.87)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(0.60)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2.27)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 23.00pt; display: inline;"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
				&lt;sup style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (A)&lt;/sup&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:13pt;"&gt;&lt;p style="width:13pt;width:13pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Net loss per share for the year does not equal the sum of the four historical quarters loss per share due to changes in weighted-average shares outstanding.&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 23.00pt; display: inline;"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
				&lt;sup style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (B)&lt;/sup&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:13pt;"&gt;&lt;p style="width:13pt;width:13pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Activity for the quarterly period ending December 31, 2016 reflects activity post IPO depicting a ramp-up of research and development expenses given the additional IPO proceeds and an increase in general and administrative expenses attributed to becoming a public company.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:8pt;"&gt;Weighted-Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Times;font-weight:bold;font-size:8pt;"&gt;Fair Value (per share)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Non&amp;#x2011;vested at December&amp;nbsp;31, 2013 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,605,008
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(610,395)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Non&amp;#x2011;vested at December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;994,613
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;44,567
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(691,087)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Non&amp;#x2011;vested at December&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;348,093
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(344,084)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.09
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Non&amp;#x2011;vested at December&amp;nbsp;31, 2016 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4,009
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.21
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Weighted&amp;#x2011;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Weighted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Average&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Remaining&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Aggregate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Contractual&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Intrinsic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Term (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Value(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding at December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;305,278
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercised &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,436)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.34
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Forfeited/Cancelled &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding at December&amp;nbsp;31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;302,842
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.43
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.60
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,031,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,023,700
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;10.07
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Exercised &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt; &amp;nbsp;-&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Forfeited/Cancelled &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(83,742)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.12
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Outstanding at December 31, 2016 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,242,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.07
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.48
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,759,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested and exercisable at December&amp;nbsp;31, 2016 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;373,158
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.86
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.06
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;740,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Vested and expected to vest at December 31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,242,800
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.07
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9.48
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(2,759,000)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 23.00pt; display: inline;"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;sup style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"&gt; (1)&lt;/sup&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:13pt;"&gt;&lt;p style="width:13pt;width:13pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of December 31, 2016 and 2015 of $7.84 and $5.83 per share, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;Year&amp;nbsp;&amp;nbsp;Ended &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;December 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="middle" style="width:17.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="middle" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:17.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected stock price volatility &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;71.4
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;71.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected life of options (years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.5
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Expected dividend yield &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;Risk free interest rate &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.2
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.7
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td colspan="16" valign="bottom" style="width:99.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;SCHEDULE II&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td colspan="16" valign="bottom" style="width:99.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;VALUATION AND QUALIFYING ACCOUNTS&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="14" valign="bottom" style="width:68.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Beginning &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:34.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Additions&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Ending &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Balance of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:18.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Charged to &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Charged to&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Balance of&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Description&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:18.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Costs and Expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Paid in Capital&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Releases&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;"&gt;Period&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td colspan="16" valign="bottom" style="width:99.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;(in&amp;nbsp;thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;For the Year Ended December 31, 2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;Valuation allowance for deferred taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;For the Year Ended December 31, 2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;Valuation allowance for deferred taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;72
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,447
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;138
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,657
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-weight:bold;font-size:8pt;"&gt;For the Year Ended December 31, 2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;Valuation allowance for deferred taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,657
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5,937
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(274)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;9,320
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Segment Information&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&amp;#x2019;s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company&amp;#x2019;s chief operating decision maker is its Chief Executive Officer. The Company&amp;#x2019;s Chief Executive Officer views the Company&amp;#x2019;s operations and manages its business in one operating segment, which is the business of development and commercialization of therapeutics for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease and NAFLD/NASH. Accordingly, the Company has a single reporting segment.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;General and Administrative Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;General and administrative expenses consist primarily of personnel&amp;#8209;related costs, including salaries and share&amp;#8209;based compensation costs, for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">53000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">284000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">1718000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_InducementPlanMember_us-gaap_TitleOfIndividualAxis_gemp_OfficersAndEmployeesMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RangeAxis_us-gaap_MaximumMember">P24M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_RangeAxis_us-gaap_MinimumMember">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TitleOfIndividualAxis_gemp_OfficersDirectorsAndEmployeesMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TitleOfIndividualAxis_gemp_OfficersDirectorsAndEmployeesMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">1605008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">44567</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit18" decimals="2">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit18" decimals="2">0.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">994613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">348093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">4009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit18" decimals="2">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit18" decimals="2">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit18" decimals="2">0.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">610395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">691087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit1" decimals="INF">344084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit12" decimals="0">140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit12" decimals="0">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit12" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit18" decimals="2">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit18" decimals="2">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="Unit18" decimals="2">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2014_To_12_31_2014">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2015_To_12_31_2015">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2016_To_12_31_2016">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="3">0.710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="3">0.714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit14" decimals="3">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit14" decimals="3">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_4_30_2015_us-gaap_PlanNameAxis_gemp_EquityIncentivePlan2015Member_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember" unitRef="Unit1" decimals="INF">320615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_4_30_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember" unitRef="Unit1" decimals="INF">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_4_30_2016_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember" unitRef="Unit1" decimals="INF">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_9_30_2016_us-gaap_PlanNameAxis_gemp_InducementPlanMember" unitRef="Unit1" decimals="INF">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember" unitRef="Unit1" decimals="INF">457200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_12_31_2016_us-gaap_PlanNameAxis_gemp_InducementPlanMember_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember" unitRef="Unit1" decimals="INF">457200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="INF">83742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">9.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_PlanNameAxis_gemp_EquityIncentivePlan2015Member_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember" unitRef="Unit1" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_gemp_EquityIncentivePlan2015Member_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember" unitRef="Unit1" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_EquityIncentivePlan2015Member_us-gaap_TitleOfIndividualAxis_gemp_EmployeesDirectorsAndConsultantsMember" unitRef="Unit1" decimals="INF">83742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="INF">7.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="INF">5.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="INF">305278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_TitleOfIndividualAxis_gemp_OfficersDirectorsAndEmployeesMember" unitRef="Unit1" decimals="INF">305278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="INF">2023700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember" unitRef="Unit1" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_us-gaap_TitleOfIndividualAxis_gemp_OfficersDirectorsAndEmployeesMember" unitRef="Unit1" decimals="INF">1825700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_PlanNameAxis_gemp_InducementPlanMember_us-gaap_TitleOfIndividualAxis_gemp_OfficersAndEmployeesMember" unitRef="Unit1" decimals="INF">198000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">6.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="0">1031000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="0">-2759000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="INF">302842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="INF">2242800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">2.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">9.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">P9Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="0">740000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="INF">373158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">5.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">P9Y22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit12" decimals="0">-2759000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="INF">2242800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">9.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">P9Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">1.05</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">4.59</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">1.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">2.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit18" decimals="2">10.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Share&amp;#8209;Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company accounts for share&amp;#8209;based compensation in accordance with the provisions of ASC 718, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Compensation&amp;nbsp;&amp;#x2014; Stock Compensation&lt;/font&gt;&lt;font style="display:inline;"&gt; (ASC 718). Accordingly, compensation costs related to equity instruments granted are recognized at the grant&amp;#8209;date fair value. Additionally, as a result of the early adoption of &lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;ASU 2016-09, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;"&gt;Compensation &amp;#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="display:inline;"&gt;, the Company has made an accounting policy election to record forfeitures when they occur. Share&amp;#8209;based compensation arrangements to non&amp;#8209;employees are accounted for in accordance with the applicable provisions of ASC 718 and ASC 505, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Equity&lt;/font&gt;&lt;font style="display:inline;"&gt;, using a fair value approach. The compensation costs of these arrangements are subject to re&amp;#8209;measurement as the equity instruments vest and are recognized as expense over the related service period (typically the vesting period of the awards).&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharePrice contextRef="As_Of_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit18" decimals="INF">10.00</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="As_Of_9_8_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="Unit18" decimals="INF">10.00</us-gaap:SharePrice>
  <us-gaap:SharesIssued contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">3036236</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">3758488</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">9270255</us-gaap:SharesIssued>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_3_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" unitRef="Unit18" decimals="INF">6.70585</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_3_15_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit18" decimals="2">9.47</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;2. Summary of Significant Accounting Policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of 90&amp;nbsp;days or less at the time of deposit to be cash equivalents. The Company invests excess cash in readily available checking and savings accounts and highly liquid investments in money market accounts.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company&amp;#x2019;s financial instruments include principally cash and cash equivalents, other current assets, accounts payable, accrued liabilities and debt. The carrying amounts for these financial instruments reported in the balance sheets approximate their fair values. See Note&amp;nbsp;11&amp;nbsp;&amp;#x2014; Fair Value Measurements, for further discussion of fair value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;General and Administrative Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;General and administrative expenses consist primarily of personnel&amp;#8209;related costs, including salaries and share&amp;#8209;based compensation costs, for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Research and development expenses consist of costs incurred in performing research and development activities, including compensation for research and development employees, costs associated with preclinical studies and trials, regulatory activities, manufacturing activities to support clinical activities, license fees, non&amp;#8209;legal patent costs, fees paid to external service providers that conduct certain research and development, clinical costs and an allocation of overhead expenses. Research and development costs are expensed as incurred.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Acquired In&amp;#8209;Process Research and Development Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company includes costs to acquire or in&amp;#8209;license product candidates in acquired in&amp;#8209;process research and development expenses. The Company has acquired the right to develop and commercialize its product candidate gemcabene. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &amp;#x201C;business&amp;#x201D; as defined under GAAP or provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company utilizes the liability method of accounting for income taxes as required by Accounting Standards Codification (ASC) 740, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="display:inline;"&gt;. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is no provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. MLT was treated as a partnership for federal and state income tax purposes. Accordingly, no provision was made for income taxes for periods prior to November&amp;nbsp;1, 2014, since the Company&amp;#x2019;s net loss (subject to certain limitations) was passed through to the income tax returns of its members. Upon incorporation on October&amp;nbsp;30, 2014, the Company became taxed as a corporation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Share&amp;#8209;Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company accounts for share&amp;#8209;based compensation in accordance with the provisions of ASC 718, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Compensation&amp;nbsp;&amp;#x2014; Stock Compensation&lt;/font&gt;&lt;font style="display:inline;"&gt; (ASC 718). Accordingly, compensation costs related to equity instruments granted are recognized at the grant&amp;#8209;date fair value. Additionally, as a result of the early adoption of &lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;ASU 2016-09, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;"&gt;Compensation &amp;#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="display:inline;"&gt;, the Company has made an accounting policy election to record forfeitures when they occur. Share&amp;#8209;based compensation arrangements to non&amp;#8209;employees are accounted for in accordance with the applicable provisions of ASC 718 and ASC 505, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Equity&lt;/font&gt;&lt;font style="display:inline;"&gt;, using a fair value approach. The compensation costs of these arrangements are subject to re&amp;#8209;measurement as the equity instruments vest and are recognized as expense over the related service period (typically the vesting period of the awards).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Common Stock Valuation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Due to the absence of an active market for the Company&amp;#x2019;s common stock prior to the close of the IPO, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants&amp;#x2019; Technical Practice Aid, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Valuation of Privately&amp;#8209;Held Company Equity Securities Issued as Compensation&lt;/font&gt;&lt;font style="display:inline;"&gt;, to estimate the fair value of its common stock. The valuation methodology included estimates and assumptions that required the Company&amp;#x2019;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biopharmaceutical industry sector, and the likelihood of achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Convertible Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March 31, 2015, the Company issued 745,637 shares of Series&amp;nbsp;A convertible preferred stock (the Series&amp;nbsp;A preferred stock). On August 10, 2016, immediately prior to the closing of the IPO, the Company&amp;#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock. The Series&amp;nbsp;A preferred stock prior to conversion was classified outside of permanent equity, in mezzanine equity, on the Company&amp;#x2019;s balance sheet. The Company initially records preferred stock that may be redeemed at the option of the holder, or based on the occurrence of events outside of the Company&amp;#x2019;s control, at the value of the proceeds received. Subsequently, if it is probable that the preferred stock will become redeemable, the Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying amount of the instrument to equal the redemption value at the end of each reporting period. If it is not probable that the preferred stock will become redeemable, the Company does not adjust the carrying value. In the absence of retained earnings, these charges are recorded against additional paid&amp;#8209;in&amp;#8209;capital, if any, and then to accumulated deficit See Note&amp;nbsp;7&amp;nbsp;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Convertible Series&amp;nbsp;A Preferred Stock&lt;/font&gt;&lt;font style="display:inline;"&gt; for further discussion. As a result of their conversion to common stock on August 10, 2016 as described above, no shares of Series A preferred stock were outstanding as of December 31, 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Segment Information&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&amp;#x2019;s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company&amp;#x2019;s chief operating decision maker is its Chief Executive Officer. The Company&amp;#x2019;s Chief Executive Officer views the Company&amp;#x2019;s operations and manages its business in one operating segment, which is the business of development and commercialization of therapeutics for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease and NAFLD/NASH. Accordingly, the Company has a single reporting segment.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Jumpstart Our Business Startups Act Accounting Election&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;As an emerging growth company under the Jumpstart Our Business Startups Act (JOBS Act), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has irrevocably elected not to avail itself of this exemption and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In May 2014, the FASB issued ASU 2014&amp;#8209;09, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Revenue from Contracts with Customers&amp;nbsp;&amp;#x2014; Topic 606&lt;/font&gt;&lt;font style="display:inline;"&gt;, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In 2015, the FASB agreed to allow companies to delay the implementation of this standard for one year effective for annual reporting periods beginning after December&amp;nbsp;15, 2017, including interim periods within that reporting period. Early application is permitted only for periods beginning after December&amp;nbsp;15, 2016. The Company plans to adopt this standard on January&amp;nbsp;1, 2018 and to select the modified retrospective transition method. The Company plans to modify its accounting policies to reflect the requirements of this standard however, the planned adoption will not affect the Company&amp;#x2019;s financial statements and related disclosures for these periods or future periods until the Company generates revenues.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In August 2014, the FASB issued Accounting Standards Update No.&amp;nbsp;2014&amp;#8209;15, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Presentation of Financial Statements&amp;nbsp;&amp;#x2014; Going Concern (Subtopic 205&amp;#8209;40): Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern&lt;/font&gt;&lt;font style="display:inline;"&gt; (ASU 2014&amp;#8209;15), which requires management to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events that, considered in the aggregate, raise substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable) and provide related disclosures. ASU 2014&amp;#8209;15 is effective for the annual period ending after December&amp;nbsp;15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company elected to adopt this standard early as of December 31, 2015 and did not have a material impact on the Company&amp;#x2019;s financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In November 2015, the Financial Accounting Standards Board (FASB) issued ASU 2015&amp;#8209;17, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="display:inline;"&gt; (ASU 2015&amp;#8209;17). The new guidance simplifies the presentation of deferred income taxes by requiring that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015&amp;#8209;17 applies to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax&amp;#8209;paying component of an entity be offset and presented as a single amount is not affected by this ASU. For public entities, ASU 2015&amp;#8209;17 is effective for financial statements issued for annual periods beginning after December&amp;nbsp;15, 2016 with earlier application permitted. The new guidance may be applied either prospectively or retrospectively to all periods presented. The Company &lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;adopted this standard effective April 1, 2016 on a retrospective basis for each period presented. &lt;/font&gt;&lt;font style="display:inline;"&gt;The adoption of this standard did not have a material impact on the Company&amp;#x2019;s financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In January 2016, the FASB issued ASU No.&amp;nbsp;2016&amp;#8209;01, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Financial Instruments&amp;nbsp;&amp;#x2014; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.&lt;/font&gt;&lt;font style="display:inline;"&gt; The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in the first quarter of fiscal 2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently evaluating the impact of the new guidance on its financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;In February 2016, the FASB issued ASU 2016-02, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Leases (Topic &lt;/font&gt;&lt;font style="display:inline;color:#000000;font-size:10pt;"&gt;842). The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The Company is currently evaluating the new guidance to determine the impact it may have on its financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;In March 2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;"&gt;Compensation &amp;#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;. This ASU simplifies the accounting for share-based payment award transactions including: income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December&amp;nbsp;15, 2016, including interim periods within those fiscal years. Early adoption is permitted. &lt;/font&gt;&lt;font style="display:inline;"&gt;The Company &lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;adopted this standard effective July 1, 2016 on a retrospective basis for each period presented. &lt;/font&gt;&lt;font style="display:inline;"&gt;The adoption of this standard did not have a material impact on the Company&amp;#x2019;s financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;color:#000000;background-color: #FFFFFF;"&gt;In November 2016, the FASB issued ASU No.&amp;nbsp;2016-18, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;color:#000000;background-color: #FFFFFF;"&gt;Statement of Cash Flows (Topic 230): Restricted Cash&lt;/font&gt;&lt;font style="display:inline;color:#000000;background-color: #FFFFFF;"&gt;. The objective of this ASU is to eliminate the diversity in practice related to the classification of &lt;/font&gt;&lt;font style="display:inline;"&gt;restricted cash or restricted cash equivalents in the statement of cash flows. &lt;/font&gt;&lt;font style="display:inline;color:#000000;background-color: #FFFFFF;"&gt;For public business entities, this ASU is effective for annual and interim reporting periods beginning after December&amp;nbsp;15, 2017, with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&amp;#x2019;s financial statements.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013" unitRef="Unit12" decimals="-3">-264000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2013_us-gaap_StatementEquityComponentsAxis_gemp_MembersEarningsMember" unitRef="Unit12" decimals="-3">-264000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">-531000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">44000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">9000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-584000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">-12380000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">12000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-12392000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">20632000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">47674000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">17000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="Unit12" decimals="-3">-27059000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;8. Stockholders&amp;#x2019; and Members&amp;#x2019; Equity (Deficit)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The membership interests of MLT were converted to 1,431,228 shares of the Company&amp;#x2019;s common stock on November&amp;nbsp;1, 2014. The MLT members&amp;#x2019; deficit was transferred to stockholders&amp;#x2019; deficit on the accompanying balance sheets upon conversion to a C Corporation at that time.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Common Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Company had &lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;9,270,255&lt;/font&gt;&lt;font style="display:inline;"&gt; and 3,758,488 shares of its common stock issued and outstanding as of December 31, 2016 and December&amp;nbsp;31, 2015, respectively. Voting, dividend and liquidation rights of the holders of the common stock are subject to the Company&amp;#x2019;s articles of incorporation, corporate bylaws and underlying shareholder agreements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Dividend Rights&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Common stock holders are entitled to receive dividends at the sole discretion of the board of directors of the Company. There have been no dividends declared on common stock as of December 31, 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Voting Rights&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The holders of common stock are entitled to one vote for each share of common stock along with all other classes and series of stock of the Company on all actions to be taken by the stockholders of the Company, including actions that would amend the certificate of incorporation of the Company to increase the number of authorized shares of the common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;font-style:italic;"&gt;Liquidation Rights&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In the event of any liquidation, dissolution, or winding&amp;#8209;up of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution post preferential distributions made to holders of the Company&amp;#x2019;s preferred stock.&amp;nbsp;&amp;nbsp;There was no preferred stock outstanding as of December 31, 2016. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Deferred Offering Costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;IPO offering costs of $4.2 million, consisting of &lt;/font&gt;&lt;font style="display:inline;color:#000000;"&gt;underwriting discounts and commissions,&lt;/font&gt;&lt;font style="display:inline;"&gt; legal, accounting and other direct fees and costs, were initially capitalized and subsequently offset against the Company&amp;#x2019;s IPO proceeds upon the close of the offering in August 2016. There were no deferred offering costs capitalized as of December 31, 2016. As of December 31, 2015, offering costs of $0.8 million were capitalized.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Convertible Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March 31, 2015, the Company issued 745,637 shares of Series&amp;nbsp;A convertible preferred stock (the Series&amp;nbsp;A preferred stock). On August 10, 2016, immediately prior to the closing of the IPO, the Company&amp;#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock. The Series&amp;nbsp;A preferred stock prior to conversion was classified outside of permanent equity, in mezzanine equity, on the Company&amp;#x2019;s balance sheet. The Company initially records preferred stock that may be redeemed at the option of the holder, or based on the occurrence of events outside of the Company&amp;#x2019;s control, at the value of the proceeds received. Subsequently, if it is probable that the preferred stock will become redeemable, the Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying amount of the instrument to equal the redemption value at the end of each reporting period. If it is not probable that the preferred stock will become redeemable, the Company does not adjust the carrying value. In the absence of retained earnings, these charges are recorded against additional paid&amp;#8209;in&amp;#8209;capital, if any, and then to accumulated deficit See Note&amp;nbsp;7&amp;nbsp;&amp;#x2014; &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Convertible Series&amp;nbsp;A Preferred Stock&lt;/font&gt;&lt;font style="display:inline;"&gt; for further discussion. As a result of their conversion to common stock on August 10, 2016 as described above, no shares of Series A preferred stock were outstanding as of December 31, 2016.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
  <us-gaap:StockholdersEquityPolicyTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Common Stock Valuation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Due to the absence of an active market for the Company&amp;#x2019;s common stock prior to the close of the IPO, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants&amp;#x2019; Technical Practice Aid, &lt;/font&gt;&lt;font style="display:inline;font-style:italic;"&gt;Valuation of Privately&amp;#8209;Held Company Equity Securities Issued as Compensation&lt;/font&gt;&lt;font style="display:inline;"&gt;, to estimate the fair value of its common stock. The valuation methodology included estimates and assumptions that required the Company&amp;#x2019;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biopharmaceutical industry sector, and the likelihood of achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="Duration_4_1_2016_To_4_30_2016">0.320615582</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Duration_11_1_2014_To_11_1_2014" unitRef="Unit1" decimals="INF">1431228</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">1656807</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Duration_8_10_2016_To_8_10_2016_us-gaap_DebtInstrumentAxis_gemp_FinancingConvertibleDebtMember" unitRef="Unit1" decimals="INF">1656807</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">677685</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_CounterpartyNameAxis_gemp_PfizerInc.Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_gemp_LicenseAgreementMember" unitRef="Unit1" decimals="INF">675250</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">3027755</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_8_4_2016_To_8_4_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="Unit1" decimals="INF">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_9_8_2016_To_9_8_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="Unit1" decimals="INF">27755</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_15_2017_To_3_15_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit1" decimals="INF">1324256</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_15_2017_To_3_15_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_OneBoardMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit1" decimals="INF">52798</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_3_15_2017_To_3_15_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_ThreeBoardMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit1" decimals="INF">56678</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">1605008</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">44567</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_AwardTypeAxis_gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" unitRef="Unit1" decimals="INF">-2436</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">11445000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">911000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">908000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_3_31_2015_To_3_31_2015_us-gaap_CounterpartyNameAxis_gemp_PfizerInc.Member_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_gemp_LicenseAgreementMember" unitRef="Unit12" decimals="-5">900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">30278000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">30275000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_3_15_2017_To_3_15_2017_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit12" decimals="-5">12500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_3_15_2017_To_3_15_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_OneBoardMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit12" decimals="-5">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Duration_3_15_2017_To_3_15_2017_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_gemp_ThreeBoardMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="Unit12" decimals="-5">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="Unit12" decimals="-3">-5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="Duration_1_1_2014_To_12_31_2014_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="Unit12" decimals="-3">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:SubsequentEventsTextBlock contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;15. &lt;/font&gt;&lt;font style="display:inline;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;On March 10 2017, the Company entered into a securities purchase agreement for a private placement with a select group of accredited investors whereby, on March 15, 2017 the Company issued and sold 1,324,256 units at a price of $9.47 per unit for gross proceeds of approximately $12.5 million. Each unit consists of one share of the Company&amp;#x2019;s common stock and a warrant to purchase 0.75 shares of common stock. The warrants have an exercise price of $10.40 per share and are exercisable for a period of five years from the date of issuance. The private placement included 56,678 units sold to 3 board members, for aggregate proceeds totaling approximately $0.5 million and 52,798 units sold to 1 investor who is related to 1 board member, for proceeds totaling approximately $0.5 million.&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The securities were issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company have agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the private placement and issuable upon exercise of the warrant issued in the private placement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">2968000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
  <us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">366000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">2517000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">2968000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="Duration_4_1_2015_To_6_30_2015" unitRef="Unit12" decimals="-3">149000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="Duration_7_1_2015_To_9_30_2015" unitRef="Unit12" decimals="-3">152000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="Duration_10_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">150000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="Duration_1_1_2016_To_3_31_2016" unitRef="Unit12" decimals="-3">149000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">366000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">150000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="Duration_7_1_2016_To_9_30_2016" unitRef="Unit12" decimals="-3">67000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">7953000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit12" decimals="-3">7953000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit12" decimals="-3">0</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit18" decimals="INF">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit18" decimals="INF">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">2325581</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued contextRef="As_Of_3_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">745637</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued contextRef="As_Of_12_31_2015" unitRef="Unit1" decimals="INF">745637</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued contextRef="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">745637</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued contextRef="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="As_Of_12_31_2015_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">745637</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="As_Of_12_31_2016_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">4985000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="0">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UseOfEstimates contextRef="Duration_1_1_2016_To_12_31_2016">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">72000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">3657000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesBalance contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">9320000</us-gaap:ValuationAllowancesAndReservesBalance>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit12" decimals="-3">72000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">3447000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">5937000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
  <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit12" decimals="-3">138000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
  <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit12" decimals="-3">-274000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="INF">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="INF">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="INF">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2014_To_12_31_2014" unitRef="Unit1" decimals="0">1521703</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2015_To_12_31_2015" unitRef="Unit1" decimals="0">2875053</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="0">5809396</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>24
<FILENAME>gemp-20161231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/20/2017 8:19:58 PM-->
<!--Modified on: 3/20/2017 8:19:58 PM-->
<xsd:schema targetNamespace="http://www.gemphire.com/20161231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:attributeFormDefault="unqualified" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:gemp="http://www.gemphire.com/20161231">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementStatementsOfComprehensiveLoss" id="StatementStatementsOfComprehensiveLoss">
        <link:definition>00200 - Statement - Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementCondensedStatementsOfComprehensiveLossCalc2" id="StatementCondensedStatementsOfComprehensiveLossCalc2">
        <link:definition>00205 - Statement - Condensed Statements of Comprehensive Loss (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureAccruedLiabilitiesDetails" id="DisclosureAccruedLiabilitiesDetails">
        <link:definition>40301 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesOtherAgreementsDetails" id="DisclosureCommitmentsAndContigenciesOtherAgreementsDetails">
        <link:definition>40503 - Disclosure - Commitments and Contigencies - Other Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationUnrecognizedDetails" id="DisclosureShareBasedCompensationUnrecognizedDetails">
        <link:definition>40904 - Disclosure - Share-Based Compensation (Unrecognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails">
        <link:definition>41101 - Disclosure - Fair Value Measurements - Financial Instruments Measured On Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails">
        <link:definition>41202 - Disclosure - Income Taxes - Reconciliation of income tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitieDetails" id="DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitieDetails">
        <link:definition>41203 - Disclosure - Income Taxes -Significant components of deferred tax assets and liabilitie (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficit" id="StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficit">
        <link:definition>00300 - Statement - Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitTemporaryEquity" id="StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitTemporaryEquity">
        <link:definition>00305 - Statement - Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit - Temporary Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation" id="DisclosureCompanyAndBasisOfPresentation">
        <link:definition>10101 - Disclosure - The Company and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureAccruedLiabilities" id="DisclosureAccruedLiabilities">
        <link:definition>10301 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>10401 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10501 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureLicenseAgreement" id="DisclosureLicenseAgreement">
        <link:definition>10601 - Disclosure - License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureConvertibleSeriesPreferredStock" id="DisclosureConvertibleSeriesPreferredStock">
        <link:definition>10701 - Disclosure - Convertible Series A Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockholdersAndMembersEquityDeficit" id="DisclosureStockholdersAndMembersEquityDeficit">
        <link:definition>10801 - Disclosure - Stockholders&#x2019; and Members&#x2019; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>10901 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShare" id="DisclosureNetLossPerCommonShare">
        <link:definition>11001 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>11101 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11201 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnaudited" id="DisclosureSupplementaryDataQuarterlyFinancialDataUnaudited">
        <link:definition>11301 - Disclosure - Supplementary Data &#x2014; Quarterly Financial Data (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11401 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11501 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts" id="DisclosureScheduleIiValuationAndQualifyingAccounts">
        <link:definition>11601 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureAccruedLiabilitiesTables" id="DisclosureAccruedLiabilitiesTables">
        <link:definition>30303 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>30503 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>30903 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareTables" id="DisclosureNetLossPerCommonShareTables">
        <link:definition>31003 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>31103 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31203 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedTables" id="DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedTables">
        <link:definition>31303 - Disclosure - Supplementary Data &#x2014; Quarterly Financial Data (unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationIpoAndCapitalRequirementsDetails" id="DisclosureCompanyAndBasisOfPresentationIpoAndCapitalRequirementsDetails">
        <link:definition>40101 - Disclosure - The Company and Basis of Presentation (IPO and Capital Requirements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationBasisOfPresentationDetails" id="DisclosureCompanyAndBasisOfPresentationBasisOfPresentationDetails">
        <link:definition>40102 - Disclosure - The Company and Basis of Presentation (Basis of Presentation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureDebtDetails" id="DisclosureDebtDetails">
        <link:definition>40401 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPfizerLicenseAgreementDetails" id="DisclosureCommitmentsAndContigenciesPfizerLicenseAgreementDetails">
        <link:definition>40501 - Disclosure - Commitments and Contigencies - Pfizer License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPreferredStockDividendsDetails" id="DisclosureCommitmentsAndContigenciesPreferredStockDividendsDetails">
        <link:definition>40502 - Disclosure - Commitments and Contigencies - Preferred Stock Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureLicenseAgreementDetails" id="DisclosureLicenseAgreementDetails">
        <link:definition>40601 - Disclosure - License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureConvertibleSeriesPreferredStockDetails" id="DisclosureConvertibleSeriesPreferredStockDetails">
        <link:definition>40701 - Disclosure - Convertible Series A Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureStockholdersAndMembersEquityDeficitDetails" id="DisclosureStockholdersAndMembersEquityDeficitDetails">
        <link:definition>40801 - Disclosure - Stockholders&#x2019; and Members&#x2019; Equity (Deficit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationDetails" id="DisclosureShareBasedCompensationDetails">
        <link:definition>40901 - Disclosure - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationRestrictedStockDetails" id="DisclosureShareBasedCompensationRestrictedStockDetails">
        <link:definition>40902 - Disclosure - Share-Based Compensation (Restricted Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationStockOptionsDetails" id="DisclosureShareBasedCompensationStockOptionsDetails">
        <link:definition>40903 - Disclosure - Share-Based Compensation (Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareDetails" id="DisclosureNetLossPerCommonShareDetails">
        <link:definition>41001 - Disclosure - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareEarningPerShareDetails" id="DisclosureNetLossPerCommonShareEarningPerShareDetails">
        <link:definition>41002 - Disclosure - Net Loss Per Common Share - Earning Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesDetails" id="DisclosureNetLossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>41003 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" id="DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails">
        <link:definition>41102 - Disclosure - Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41201 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>41204 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedDetails" id="DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedDetails">
        <link:definition>41301 - Disclosure - Supplementary Data &#x2014; Quarterly Financial Data (unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsRentalAgreementDetails" id="DisclosureRelatedPartyTransactionsRentalAgreementDetails">
        <link:definition>41401 - Disclosure - Related Party Transactions - Rental agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsConvertibleNotesDetails" id="DisclosureRelatedPartyTransactionsConvertibleNotesDetails">
        <link:definition>41402 - Disclosure - Related Party Transactions - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsInterimNotesDetails" id="DisclosureRelatedPartyTransactionsInterimNotesDetails">
        <link:definition>41403 - Disclosure - Related Party Transactions - Interim Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41501 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gemphire.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails" id="DisclosureScheduleIiValuationAndQualifyingAccountsDetails">
        <link:definition>41601 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="gemp-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gemp-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gemp-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gemp-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock" name="JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_AccruedOtherResearchAndDevelopmentExpenses" name="AccruedOtherResearchAndDevelopmentExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_AccruedOtherGeneralAndAdministrativeExpenses" name="AccruedOtherGeneralAndAdministrativeExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" name="EmployeeConsultantsAndDirectorsStockOptionsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember" name="AmendmentAndRestatementOf2015EquityIncentivePlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_EquityIncentivePlan2015Member" name="EquityIncentivePlan2015Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NoncashInterestOnConvertibleNotesToRelatedParties" name="NoncashInterestOnConvertibleNotesToRelatedParties" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NoncashInterestOnConvertibleNotes" name="NoncashInterestOnConvertibleNotes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount" name="AmortizationOnConvertibleNotesToRelatedPartiesDiscount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_AmortizationOnConvertibleNotesDiscount" name="AmortizationOnConvertibleNotesDiscount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits" name="IncreaseDecreaseInPrepaidExpensesAndDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ExerciseOfPremiumConversionDerivative" name="ExerciseOfPremiumConversionDerivative" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes" name="BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_AccruedOfferingCostsCurrent" name="AccruedOfferingCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" name="AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" name="AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" name="DebtInstrumentConvertedPercentInExcessOfPrincipal" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold" name="DebtInstrumentAutomaticConversionEquityOfferingThreshold" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount" name="DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_FinancingConvertibleDebtMember" name="FinancingConvertibleDebtMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_PfizerInc.Member" name="PfizerInc.Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_LlcOwnedByTwoOfficersMember" name="LlcOwnedByTwoOfficersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_OfficeRentalMember" name="OfficeRentalMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" name="TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_LiquidationPreferencePercentageOfChangeInVoting" name="LiquidationPreferencePercentageOfChangeInVoting" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_PreferredStockRedemptionRequestedByPercentageOfShares" name="PreferredStockRedemptionRequestedByPercentageOfShares" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_RedemptionPricePercentageOfLiquidationPreference" name="RedemptionPricePercentageOfLiquidationPreference" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_SeriesaPreferredConvertibleDebtMember" name="SeriesaPreferredConvertibleDebtMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_MilestonePaymentsMember" name="MilestonePaymentsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_SharesIssuablePercentageOfOffering" name="SharesIssuablePercentageOfOffering" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ContingentLiability" name="ContingentLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_CumulativeDividendsDeclared" name="CumulativeDividendsDeclared" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_CommonStockVotingRightsPerShare" name="CommonStockVotingRightsPerShare" nillable="true" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfOfficersInRelatedPartyTransaction" name="NumberOfOfficersInRelatedPartyTransaction" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_TemporaryEquityDisclosureTextBlock" name="TemporaryEquityDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_OfficersDirectorsAndEmployeesMember" name="OfficersDirectorsAndEmployeesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_TwoOfficersMember" name="TwoOfficersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_InvestorsRelatedToBoardMemberAndOfficersMember" name="InvestorsRelatedToBoardMemberAndOfficersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_DebtIssuedToRelatedPartiesMember" name="DebtIssuedToRelatedPartiesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfDebtInstrumentsIssued" name="NumberOfDebtInstrumentsIssued" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfBoardMembersInRelatedPartyTransaction" name="NumberOfBoardMembersInRelatedPartyTransaction" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" name="TwoOfficersAndThreeBoardMembersInvestorsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" name="ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_TwoOfficersAndFourBoardMembersInvestorsMember" name="TwoOfficersAndFourBoardMembersInvestorsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_InvestorsRelatedToThreeOfficersMember" name="InvestorsRelatedToThreeOfficersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_TwoBoardMembersInvestorsMember" name="TwoBoardMembersInvestorsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_InvestorsRelatedToTwoOfficersMember" name="InvestorsRelatedToTwoOfficersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_InvestorsRelatedToThreeDirectorsMember" name="InvestorsRelatedToThreeDirectorsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfEmployeesInRelatedPartyTransaction" name="NumberOfEmployeesInRelatedPartyTransaction" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_EmployeesDirectorsAndConsultantsMember" name="EmployeesDirectorsAndConsultantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_LicenseAgreementDisclosureAbstract" name="LicenseAgreementDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_InterestIncomeExpenseNetMember" name="InterestIncomeExpenseNetMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount" name="FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers" name="NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfOfficers" name="NumberOfOfficers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfBoardMembers" name="NumberOfBoardMembers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers" name="ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector" name="NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors" name="NumberOfInvestorRelatedToOneOfCompanysDirectors" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector" name="ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ConversionOfSeriesPreferredStockMember" name="ConversionOfSeriesPreferredStockMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ConversionOfInterimNotesMember" name="ConversionOfInterimNotesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ConversionOfConvertibleNotesMember" name="ConversionOfConvertibleNotesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_InducementPlanMember" name="InducementPlanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NonCashInterestOnPromissoryNotesToRelatedParties" name="NonCashInterestOnPromissoryNotesToRelatedParties" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue" name="ConvertibleNotesPremiumUponSubstantialModificationValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_MembersEarningsMember" name="MembersEarningsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_StockEffectDuringPeriodValueUponMerger" name="StockEffectDuringPeriodValueUponMerger" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_StockEffectDuringPeriodShareUponMerger" name="StockEffectDuringPeriodShareUponMerger" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_StockRestrictionDuringPeriodValue" name="StockRestrictionDuringPeriodValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_StockRestrictionDuringPeriodShares" name="StockRestrictionDuringPeriodShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ConvertibleNoteExtinguishmentLoss" name="ConvertibleNoteExtinguishmentLoss" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ProceedsFromRelatedPartyPromissoryNotes" name="ProceedsFromRelatedPartyPromissoryNotes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment" name="PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ConversionOfRelatedPartyPromissoryNotesMember" name="ConversionOfRelatedPartyPromissoryNotesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes" name="EffectiveIncomeTaxRateReconciliationConvertibleNotes" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_DeferredTaxAssetsAcquiredIntangibles" name="DeferredTaxAssetsAcquiredIntangibles" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_DeferredTaxAssetsConvertibleNotes" name="DeferredTaxAssetsConvertibleNotes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_DeferredTaxLiabilitiesRestrictedStockAwards" name="DeferredTaxLiabilitiesRestrictedStockAwards" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ThresholdPercentageOfShareholdersOwnershipChange" name="ThresholdPercentageOfShareholdersOwnershipChange" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits" name="MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_PeriodForTestingPercentageOfOwnershipChange" name="PeriodForTestingPercentageOfOwnershipChange" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_DeferredTaxAssetsTaxCreditCarryforwardsState" name="DeferredTaxAssetsTaxCreditCarryforwardsState" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_OfficersAndEmployeesMember" name="OfficersAndEmployeesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_TemporaryEquityConversionOfStock" name="TemporaryEquityConversionOfStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_TemporaryEquityConversionOfStockShares" name="TemporaryEquityConversionOfStockShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities" name="StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities" name="StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity" name="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfSharesIssuedPerUnit" name="NumberOfSharesIssuedPerUnit" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable" name="ClassOfWarrantOrRightWarrantsOrRightsExercisable" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfInvestorRelatedToBoardMembers" name="NumberOfInvestorRelatedToBoardMembers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ThreeBoardMember" name="ThreeBoardMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_OneBoardMember" name="OneBoardMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfInvestorsRelatedToOfficers" name="NumberOfInvestorsRelatedToOfficers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany" name="NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany" name="ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>25
<FILENAME>gemp-20161231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/20/2017 8:19:58 PM-->
<!--Modified on: 3/20/2017 8:19:58 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementBalanceSheets" roleURI="http://www.gemphire.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementStatementsOfComprehensiveLoss" roleURI="http://www.gemphire.com/role/StatementStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementCondensedStatementsOfComprehensiveLossCalc2" roleURI="http://www.gemphire.com/role/StatementCondensedStatementsOfComprehensiveLossCalc2" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.gemphire.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureAccruedLiabilitiesDetails" roleURI="http://www.gemphire.com/role/DisclosureAccruedLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCommitmentsAndContigenciesOtherAgreementsDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesOtherAgreementsDetails" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureShareBasedCompensationUnrecognizedDetails" roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationUnrecognizedDetails" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitieDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitieDetails" />
  <calculationLink xlink:role="http://www.gemphire.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636256379967540626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_636256379967540626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636256379967560626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636256379967540626" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636256379967560626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_636256379967560626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636256379967540626" xlink:to="us-gaap_PrepaidExpenseCurrent_636256379967560626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts_636256379967560626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredCosts_636256379967560626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent_636256379967560626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent_636256379967560626" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636256379967640626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_636256379967640626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636256379967640626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636256379967640626" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636256379967640626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636256379967640626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636256379967640626" xlink:to="us-gaap_LiabilitiesCurrent_636256379967640626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636256379967640626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636256379967640626" xlink:to="us-gaap_AccountsPayableCurrent_636256379967640626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636256379967640626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636256379967640626" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636256379967640626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_636256379967640626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636256379967640626" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_636256379967640626" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_636256379967640626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636256379967640626" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_636256379967640626" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_636256379967650626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636256379967640626" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_636256379967650626" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_636256379967650626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_636256379967650626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_636256379967650626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_636256379967650626" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636256379967650626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_636256379967650626" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_636256379967650626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636256379967650626" xlink:to="us-gaap_AdditionalPaidInCapital_636256379967650626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636256379967650626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636256379967650626" xlink:to="us-gaap_CommonStockValue_636256379967650626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636256379967650626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636256379967650626" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636256379967650626" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/StatementStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_636256379967660626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636256379967660626" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636256379967660626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636256379967660626" xlink:to="us-gaap_OperatingIncomeLoss_636256379967660626" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636256379967660626" xlink:to="us-gaap_CostsAndExpenses_636256379967660626" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_636256379967660626" xlink:to="us-gaap_GeneralAndAdministrativeExpense_636256379967660626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_636256379967660626" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_636256379967660626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_636256379967660626" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_636256379967660626" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636256379967660626" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_636256379967660626" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636256379967660626" xlink:to="us-gaap_InterestIncomeExpenseNet_636256379967660626" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636256379967660626" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_636256379967660626" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636256379967660626" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636256379967660626" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_636256379967660626" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConvertibleNotesPremiumUponSubstantialModificationValue" xlink:label="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_636256379967660626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_636256379967660626" order="3" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/StatementCondensedStatementsOfComprehensiveLossCalc2" xlink:type="extended" xlink:title="00205 - Statement - Condensed Statements of Comprehensive Loss (Calc 2)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636256379967670626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_636256379967670626" order="1" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636256379967670626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="us-gaap_NetIncomeLoss_636256379967670626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636256379967670626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="us-gaap_ShareBasedCompensation_636256379967670626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NoncashInterestOnConvertibleNotesToRelatedParties" xlink:label="gemp_NoncashInterestOnConvertibleNotesToRelatedParties_636256379967670626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="gemp_NoncashInterestOnConvertibleNotesToRelatedParties_636256379967670626" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NonCashInterestOnPromissoryNotesToRelatedParties" xlink:label="gemp_NonCashInterestOnPromissoryNotesToRelatedParties_636256379967670626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="gemp_NonCashInterestOnPromissoryNotesToRelatedParties_636256379967670626" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NoncashInterestOnConvertibleNotes" xlink:label="gemp_NoncashInterestOnConvertibleNotes_636256379967670626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="gemp_NoncashInterestOnConvertibleNotes_636256379967670626" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount" xlink:label="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount_636256379967670626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount_636256379967670626" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AmortizationOnConvertibleNotesDiscount" xlink:label="gemp_AmortizationOnConvertibleNotesDiscount_636256379967670626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="gemp_AmortizationOnConvertibleNotesDiscount_636256379967670626" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_636256379967670626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_636256379967670626" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_636256379967680626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax_636256379967680626" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_636256379967680626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_636256379967680626" order="10" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_636256379967680626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_636256379967680626" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits" xlink:label="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits_636256379967680626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits_636256379967680626" order="12" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_636256379967680626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_636256379967680626" order="13" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_636256379967680626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379967670626" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_636256379967680626" order="14" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379967680626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379967680626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_636256379967680626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379967680626" xlink:to="us-gaap_ProceedsFromConvertibleDebt_636256379967680626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636256379967680626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379967680626" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636256379967680626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_636256379967680626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379967680626" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_636256379967680626" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_636256379967690626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379967680626" xlink:to="us-gaap_PaymentsOfFinancingCosts_636256379967690626" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromRelatedPartyPromissoryNotes" xlink:label="gemp_ProceedsFromRelatedPartyPromissoryNotes_636256379967690626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379967680626" xlink:to="gemp_ProceedsFromRelatedPartyPromissoryNotes_636256379967690626" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636256379967690626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379967680626" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636256379967690626" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_636256379967690626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379967680626" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_636256379967690626" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_636256379967690626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379967680626" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_636256379967690626" order="8" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/DisclosureAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Accrued Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AccruedOtherGeneralAndAdministrativeExpenses" xlink:label="gemp_AccruedOtherGeneralAndAdministrativeExpenses_636256379967690626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="gemp_AccruedOtherGeneralAndAdministrativeExpenses_636256379967690626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AccruedOtherResearchAndDevelopmentExpenses" xlink:label="gemp_AccruedOtherResearchAndDevelopmentExpenses_636256379967700626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="gemp_AccruedOtherResearchAndDevelopmentExpenses_636256379967700626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_636256379967700626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_636256379967700626" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_636256379967700626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_636256379967700626" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AccruedOfferingCostsCurrent" xlink:label="gemp_AccruedOfferingCostsCurrent_636256379967700626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="gemp_AccruedOfferingCostsCurrent_636256379967700626" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesOtherAgreementsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Commitments and Contigencies - Other Agreements (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636256379967700626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636256379967700626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636256379967700626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636256379967700626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636256379967700626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636256379967700626" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/DisclosureShareBasedCompensationUnrecognizedDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Share-Based Compensation (Unrecognized) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_636256379967710626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_636256379967710626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636256379967710626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636256379967710626" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Fair Value Measurements - Financial Instruments Measured On Recurring Basis (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_636256379967710626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_636256379967710626" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Reconciliation of income tax (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636256379967710626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636256379967710626" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636256379967710626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636256379967710626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_636256379967710626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_636256379967710626" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636256379967710626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636256379967710626" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes" xlink:label="gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes_636256379967720626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes_636256379967720626" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636256379967720626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636256379967720626" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitieDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes -Significant components of deferred tax assets and liabilitie (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_636256379967720626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_636256379967720626" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DeferredTaxLiabilitiesRestrictedStockAwards" xlink:label="gemp_DeferredTaxLiabilitiesRestrictedStockAwards_636256379967720626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_636256379967720626" xlink:to="gemp_DeferredTaxLiabilitiesRestrictedStockAwards_636256379967720626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_636256379967720626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_636256379967720626" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_636256379967720626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_636256379967720626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636256379967720626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636256379967720626" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636256379967720626" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DeferredTaxAssetsAcquiredIntangibles" xlink:label="gemp_DeferredTaxAssetsAcquiredIntangibles_636256379967720626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636256379967720626" xlink:to="gemp_DeferredTaxAssetsAcquiredIntangibles_636256379967720626" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DeferredTaxAssetsConvertibleNotes" xlink:label="gemp_DeferredTaxAssetsConvertibleNotes_636256379967720626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636256379967720626" xlink:to="gemp_DeferredTaxAssetsConvertibleNotes_636256379967720626" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_636256379967720626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636256379967720626" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_636256379967720626" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_636256379967730626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636256379967720626" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_636256379967730626" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_636256379967730626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636256379967720626" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_636256379967730626" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636256379967730626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636256379967720626" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636256379967730626" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_636256379967730626" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_636256379967720626" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_636256379967730626" order="8" use="optional" weight="1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>26
<FILENAME>gemp-20161231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/20/2017 8:19:58 PM-->
<!--Modified on: 3/20/2017 8:19:58 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.gemphire.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficit" roleURI="http://www.gemphire.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.gemphire.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCompanyAndBasisOfPresentationIpoAndCapitalRequirementsDetails" roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationIpoAndCapitalRequirementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCompanyAndBasisOfPresentationBasisOfPresentationDetails" roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureDebtDetails" roleURI="http://www.gemphire.com/role/DisclosureDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCommitmentsAndContigenciesPfizerLicenseAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPfizerLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCommitmentsAndContigenciesPreferredStockDividendsDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPreferredStockDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCommitmentsAndContigenciesOtherAgreementsDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesOtherAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureLicenseAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureConvertibleSeriesPreferredStockDetails" roleURI="http://www.gemphire.com/role/DisclosureConvertibleSeriesPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureStockholdersAndMembersEquityDeficitDetails" roleURI="http://www.gemphire.com/role/DisclosureStockholdersAndMembersEquityDeficitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureShareBasedCompensationRestrictedStockDetails" roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationRestrictedStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureShareBasedCompensationStockOptionsDetails" roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureShareBasedCompensationUnrecognizedDetails" roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationUnrecognizedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureNetLossPerCommonShareDetails" roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureNetLossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureRelatedPartyTransactionsRentalAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsRentalAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureRelatedPartyTransactionsConvertibleNotesDetails" roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsConvertibleNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureRelatedPartyTransactionsInterimNotesDetails" roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsInterimNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.gemphire.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://www.gemphire.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636256379968030626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_636256379968030626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficit" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636256379968090626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_636256379968090626" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_MembersEarningsMember" xlink:label="gemp_MembersEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="gemp_MembersEarningsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockEffectDuringPeriodValueUponMerger" xlink:label="gemp_StockEffectDuringPeriodValueUponMerger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gemp_StockEffectDuringPeriodValueUponMerger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockEffectDuringPeriodShareUponMerger" xlink:label="gemp_StockEffectDuringPeriodShareUponMerger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gemp_StockEffectDuringPeriodShareUponMerger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockRestrictionDuringPeriodValue" xlink:label="gemp_StockRestrictionDuringPeriodValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gemp_StockRestrictionDuringPeriodValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockRestrictionDuringPeriodShares" xlink:label="gemp_StockRestrictionDuringPeriodShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gemp_StockRestrictionDuringPeriodShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities" xlink:label="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities" xlink:label="gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities" xlink:to="gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities" xlink:to="gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConvertibleNoteExtinguishmentLoss" xlink:label="gemp_ConvertibleNoteExtinguishmentLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gemp_ConvertibleNoteExtinguishmentLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_636256379968130626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain_636256379968130626" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfSeriesPreferredStockMember" xlink:label="gemp_ConversionOfSeriesPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="gemp_ConversionOfSeriesPreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_636256379968130626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_636256379968130626" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfInterimNotesMember" xlink:label="gemp_ConversionOfInterimNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="gemp_ConversionOfInterimNotesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfConvertibleNotesMember" xlink:label="gemp_ConversionOfConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="gemp_ConversionOfConvertibleNotesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfRelatedPartyPromissoryNotesMember" xlink:label="gemp_ConversionOfRelatedPartyPromissoryNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="gemp_ConversionOfRelatedPartyPromissoryNotesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_636256379968140626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_636256379968140626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NonCashInterestOnPromissoryNotesToRelatedParties" xlink:label="gemp_NonCashInterestOnPromissoryNotesToRelatedParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gemp_NonCashInterestOnPromissoryNotesToRelatedParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NoncashInterestOnConvertibleNotesToRelatedParties" xlink:label="gemp_NoncashInterestOnConvertibleNotesToRelatedParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gemp_NoncashInterestOnConvertibleNotesToRelatedParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NoncashInterestOnConvertibleNotes" xlink:label="gemp_NoncashInterestOnConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gemp_NoncashInterestOnConvertibleNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount" xlink:label="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AmortizationOnConvertibleNotesDiscount" xlink:label="gemp_AmortizationOnConvertibleNotesDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="gemp_AmortizationOnConvertibleNotesDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits" xlink:label="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromRelatedPartyPromissoryNotes" xlink:label="gemp_ProceedsFromRelatedPartyPromissoryNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="gemp_ProceedsFromRelatedPartyPromissoryNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ExerciseOfPremiumConversionDerivative" xlink:label="gemp_ExerciseOfPremiumConversionDerivative" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="gemp_ExerciseOfPremiumConversionDerivative" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes" xlink:label="gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment" xlink:label="gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_LiabilitiesAssumed1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationIpoAndCapitalRequirementsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - The Company and Basis of Presentation (IPO and Capital Requirements) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636256379968240626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636256379968240626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsForUnderwritingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationBasisOfPresentationDetails" xlink:type="extended" xlink:title="40102 - Disclosure - The Company and Basis of Presentation (Basis of Presentation) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_636256379968250626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_636256379968250626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingStandardsUpdate201517Member" xlink:label="us-gaap_AccountingStandardsUpdate201517Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201517Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_636256379968280626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_636256379968280626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_636256379968280626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_636256379968280626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="us-gaap_ScenarioAdjustmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioAdjustmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PredecessorMember" xlink:label="us-gaap_PredecessorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_PredecessorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636256379968300626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_636256379968300626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_NotesPayableOtherPayablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SeriesaPreferredConvertibleDebtMember" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gemp_SeriesaPreferredConvertibleDebtMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_FinancingConvertibleDebtMember" xlink:label="gemp_FinancingConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gemp_FinancingConvertibleDebtMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636256379968310626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_636256379968310626" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InterestIncomeExpenseNetMember" xlink:label="gemp_InterestIncomeExpenseNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="gemp_InterestIncomeExpenseNetMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" xlink:label="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold" xlink:label="gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount" xlink:label="gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPfizerLicenseAgreementDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Commitments and Contigencies - Pfizer License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636256379968320626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636256379968320626" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PfizerInc.Member" xlink:label="gemp_PfizerInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gemp_PfizerInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636256379968330626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636256379968330626" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LicenseAgreementMember" xlink:label="gemp_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gemp_LicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPreferredStockDividendsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Commitments and Contigencies - Preferred Stock Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesOtherAgreementsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Commitments and Contigencies - Other Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_636256379968340626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_636256379968340626" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OfficeRentalMember" xlink:label="gemp_OfficeRentalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="gemp_OfficeRentalMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureLicenseAgreementDetails" xlink:type="extended" xlink:title="40601 - Disclosure - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PfizerInc.Member" xlink:label="gemp_PfizerInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="gemp_PfizerInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LicenseAgreementMember" xlink:label="gemp_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="gemp_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_636256379968350626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_636256379968350626" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_MilestonePaymentsMember" xlink:label="gemp_MilestonePaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="gemp_MilestonePaymentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636256379968360626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_636256379968360626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SharesIssuablePercentageOfOffering" xlink:label="gemp_SharesIssuablePercentageOfOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gemp_SharesIssuablePercentageOfOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ContingentLiability" xlink:label="gemp_ContingentLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="gemp_ContingentLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureConvertibleSeriesPreferredStockDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Series A Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SeriesaPreferredConvertibleDebtMember" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gemp_SeriesaPreferredConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" xlink:label="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LiquidationPreferencePercentageOfChangeInVoting" xlink:label="gemp_LiquidationPreferencePercentageOfChangeInVoting" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="gemp_LiquidationPreferencePercentageOfChangeInVoting" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PreferredStockRedemptionRequestedByPercentageOfShares" xlink:label="gemp_PreferredStockRedemptionRequestedByPercentageOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="gemp_PreferredStockRedemptionRequestedByPercentageOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_RedemptionPricePercentageOfLiquidationPreference" xlink:label="gemp_RedemptionPricePercentageOfLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="gemp_RedemptionPricePercentageOfLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersAndMembersEquityDeficitDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders&#x2019; and Members&#x2019; Equity (Deficit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_CumulativeDividendsDeclared" xlink:label="gemp_CumulativeDividendsDeclared" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="gemp_CumulativeDividendsDeclared" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_CommonStockVotingRightsPerShare" xlink:label="gemp_CommonStockVotingRightsPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="gemp_CommonStockVotingRightsPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Share-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureShareBasedCompensationRestrictedStockDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Share-Based Compensation (Restricted Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379968430626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379968430626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureShareBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Share-Based Compensation (Stock Options) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636256379968450626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_636256379968450626" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember" xlink:label="gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EquityIncentivePlan2015Member" xlink:label="gemp_EquityIncentivePlan2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="gemp_EquityIncentivePlan2015Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InducementPlanMember" xlink:label="gemp_InducementPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="gemp_InducementPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636256379968450626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636256379968450626" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OfficersDirectorsAndEmployeesMember" xlink:label="gemp_OfficersDirectorsAndEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gemp_OfficersDirectorsAndEmployeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OfficersAndEmployeesMember" xlink:label="gemp_OfficersAndEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gemp_OfficersAndEmployeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EmployeesDirectorsAndConsultantsMember" xlink:label="gemp_EmployeesDirectorsAndConsultantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="gemp_EmployeesDirectorsAndConsultantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureShareBasedCompensationUnrecognizedDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Share-Based Compensation (Unrecognized) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss Per Common Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PredecessorMember" xlink:label="us-gaap_PredecessorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_PredecessorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636256379968580626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636256379968580626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Fair Value Measurements - Financial Instruments Measured On Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_636256379968590626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_636256379968590626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636256379968590626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636256379968590626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount" xlink:label="gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636256379968600626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636256379968600626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal" xlink:label="gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsRentalAgreementDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Related Party Transactions - Rental agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636256379968600626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_636256379968600626" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LlcOwnedByTwoOfficersMember" xlink:label="gemp_LlcOwnedByTwoOfficersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_LlcOwnedByTwoOfficersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OfficeRentalMember" xlink:label="gemp_OfficeRentalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="gemp_OfficeRentalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfOfficersInRelatedPartyTransaction" xlink:label="gemp_NumberOfOfficersInRelatedPartyTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfOfficersInRelatedPartyTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidRent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsConvertibleNotesDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Related Party Transactions - Convertible Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToBoardMemberAndOfficersMember" xlink:label="gemp_InvestorsRelatedToBoardMemberAndOfficersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_InvestorsRelatedToBoardMemberAndOfficersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoOfficersMember" xlink:label="gemp_TwoOfficersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_TwoOfficersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtIssuedToRelatedPartiesMember" xlink:label="gemp_DebtIssuedToRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="gemp_DebtIssuedToRelatedPartiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SeriesaPreferredConvertibleDebtMember" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gemp_SeriesaPreferredConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfDebtInstrumentsIssued" xlink:label="gemp_NumberOfDebtInstrumentsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfDebtInstrumentsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfBoardMembersInRelatedPartyTransaction" xlink:label="gemp_NumberOfBoardMembersInRelatedPartyTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfBoardMembersInRelatedPartyTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfOfficersInRelatedPartyTransaction" xlink:label="gemp_NumberOfOfficersInRelatedPartyTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfOfficersInRelatedPartyTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsInterimNotesDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Related Party Transactions - Interim Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" xlink:label="gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" xlink:label="gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoOfficersAndFourBoardMembersInvestorsMember" xlink:label="gemp_TwoOfficersAndFourBoardMembersInvestorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_TwoOfficersAndFourBoardMembersInvestorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToThreeOfficersMember" xlink:label="gemp_InvestorsRelatedToThreeOfficersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_InvestorsRelatedToThreeOfficersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoBoardMembersInvestorsMember" xlink:label="gemp_TwoBoardMembersInvestorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_TwoBoardMembersInvestorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToTwoOfficersMember" xlink:label="gemp_InvestorsRelatedToTwoOfficersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_InvestorsRelatedToTwoOfficersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToThreeDirectorsMember" xlink:label="gemp_InvestorsRelatedToThreeDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_InvestorsRelatedToThreeDirectorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtIssuedToRelatedPartiesMember" xlink:label="gemp_DebtIssuedToRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="gemp_DebtIssuedToRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_FinancingConvertibleDebtMember" xlink:label="gemp_FinancingConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gemp_FinancingConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SeriesaPreferredConvertibleDebtMember" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="gemp_SeriesaPreferredConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfDebtInstrumentsIssued" xlink:label="gemp_NumberOfDebtInstrumentsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfDebtInstrumentsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfBoardMembersInRelatedPartyTransaction" xlink:label="gemp_NumberOfBoardMembersInRelatedPartyTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfBoardMembersInRelatedPartyTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfOfficersInRelatedPartyTransaction" xlink:label="gemp_NumberOfOfficersInRelatedPartyTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfOfficersInRelatedPartyTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfEmployeesInRelatedPartyTransaction" xlink:label="gemp_NumberOfEmployeesInRelatedPartyTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfEmployeesInRelatedPartyTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfBoardMembers" xlink:label="gemp_NumberOfBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfBoardMembers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfInvestorsRelatedToOfficers" xlink:label="gemp_NumberOfInvestorsRelatedToOfficers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfInvestorsRelatedToOfficers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors" xlink:label="gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfOfficers" xlink:label="gemp_NumberOfOfficers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfOfficers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany" xlink:label="gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector" xlink:label="gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers" xlink:label="gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany" xlink:label="gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector" xlink:label="gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers" xlink:label="gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.gemphire.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636256379968680626" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_636256379968680626" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ThreeBoardMember" xlink:label="gemp_ThreeBoardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_ThreeBoardMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OneBoardMember" xlink:label="gemp_OneBoardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="gemp_OneBoardMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesIssuedPerUnit" xlink:label="gemp_NumberOfSharesIssuedPerUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gemp_NumberOfSharesIssuedPerUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:label="gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfBoardMembers" xlink:label="gemp_NumberOfBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gemp_NumberOfBoardMembers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfInvestorRelatedToBoardMembers" xlink:label="gemp_NumberOfInvestorRelatedToBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="gemp_NumberOfInvestorRelatedToBoardMembers" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>27
<FILENAME>gemp-20161231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/20/2017 8:19:58 PM-->
<!--Modified on: 3/20/2017 8:19:58 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DocumentAndEntityInformationAbstract" xlink:label="gemp_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="gemp_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, convertible preferred stock and stockholders&#x2019; equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes to related parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Embedded Derivative, Fair Value of Embedded Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium conversion derivative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No liabilities were recorded related to the license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 5)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A convertible preferred stock, $0.001 par value; no shares authorized as of December 31, 2016 and 2,325,581 shares authorized as of December 31, 2015, no shares issued or outstanding as of December 31, 2016 and 745,637 shares issued and outstanding as of December 31, 2015, aggregate liquidation preference as of December 31, 2016 and 2015 of zero and $7,953, respectively.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders&#x2019; equity (deficit):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2016 and no shares authorized as of December 31, 2015, no shares issued or outstanding as of December 31, 2016 and 2015.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value; 100,000,000 and 17,674,419 shares authorized as of December 31, 2016 and 2015, respectively, 9,270,255 and 3,758,488 shares issued and outstanding at December 31, 2016 and 2015, respectively.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders&#x2019; equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities, convertible preferred stock and stockholders&#x2019; equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Par Value (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, share authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, balance at end of period (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary equity, balance at beginning of period (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred stock, share issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred stock, share outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, liquidation preference</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par Value (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par Value (in dollar per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, share authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, share issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, share outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Asset Acquired Other than Through Business Combination, Written-off</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired in-process research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash acquisition of in-process research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income (expense)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash loss on extinguishment of convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on convertible note extinguishment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (expense) income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to redemption value on Series A convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption value change of Series A preferred stock</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConvertibleNotesPremiumUponSubstantialModificationValue" xlink:label="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue" xlink:to="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease to net income for premium upon substantial modification of convertible notes to derive net income apportioned to common stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Premium upon Substantial Modification Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium upon substantial modification of convertible notes with certain stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted (Note 10)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares used in per share calculations:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and diluted weighted average common shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period (shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period (shares)</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockEffectDuringPeriodValueUponMerger" xlink:label="gemp_StockEffectDuringPeriodValueUponMerger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_StockEffectDuringPeriodValueUponMerger" xlink:to="gemp_StockEffectDuringPeriodValueUponMerger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_StockEffectDuringPeriodValueUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of stock effect during the period upon merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_StockEffectDuringPeriodValueUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Effect During Period Value Upon Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_StockEffectDuringPeriodValueUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of merger</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockEffectDuringPeriodShareUponMerger" xlink:label="gemp_StockEffectDuringPeriodShareUponMerger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_StockEffectDuringPeriodShareUponMerger" xlink:to="gemp_StockEffectDuringPeriodShareUponMerger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_StockEffectDuringPeriodShareUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares effect during the period upon merger.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_StockEffectDuringPeriodShareUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Effect During Period Share Upon Merger</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_StockEffectDuringPeriodShareUponMerger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of merger (in shares)</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockRestrictionDuringPeriodValue" xlink:label="gemp_StockRestrictionDuringPeriodValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_StockRestrictionDuringPeriodValue" xlink:to="gemp_StockRestrictionDuringPeriodValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_StockRestrictionDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of stock restriction for issuance during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_StockRestrictionDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Restriction During Period Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_StockRestrictionDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restriction of initial common stock issuances</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockRestrictionDuringPeriodShares" xlink:label="gemp_StockRestrictionDuringPeriodShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_StockRestrictionDuringPeriodShares" xlink:to="gemp_StockRestrictionDuringPeriodShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_StockRestrictionDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock restriction for issuance during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_StockRestrictionDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Restriction During Period Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_StockRestrictionDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restriction of initial common stock issuances (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Accretion of Redemption Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption value adjustment - Series A preferred stock</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities" xlink:label="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities" xlink:to="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gross value of stock issued during the period upon conversion of convertible equity securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Conversion of Convertible Equity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock to common stock, amount</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities" xlink:label="gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities" xlink:to="gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued during the period as a result of the conversion of convertible equity securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Equity Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock to common stock, shares</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity" xlink:to="gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to additional paid in capital resulting from the conversion of convertible equity securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Equity Component of Convertible Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred stock to common stock, additional paid in capital amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible notes to common stock, amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible notes to common stock, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Membership interest converted into shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible notes to common stock, additional paid in capital amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Separation of beneficial conversion feature associated with convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock (shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs of offering</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConvertibleNoteExtinguishmentLoss" xlink:label="gemp_ConvertibleNoteExtinguishmentLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ConvertibleNoteExtinguishmentLoss" xlink:to="gemp_ConvertibleNoteExtinguishmentLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ConvertibleNoteExtinguishmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of convertible note loss extinguishment during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ConvertibleNoteExtinguishmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Note Extinguishment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_ConvertibleNoteExtinguishmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Note Extinguishment Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents the amount of recognized equity-based compensation related to employees during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital Employee Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation - employee</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents the amount of recognized equity-based compensation related to non-employees during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital Nonemployee Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation - non-employee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of convertible Series A preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of new stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of convertible Series A preferred stock (shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Accretion to Redemption Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption value adjustment - Series A preferred stock</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityConversionOfStock" xlink:label="gemp_TemporaryEquityConversionOfStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_TemporaryEquityConversionOfStock" xlink:to="gemp_TemporaryEquityConversionOfStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_TemporaryEquityConversionOfStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of temporary equity converted to permanent equity during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_TemporaryEquityConversionOfStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Conversion of Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gemp_TemporaryEquityConversionOfStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series A preferred stock, amount converted</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityConversionOfStockShares" xlink:label="gemp_TemporaryEquityConversionOfStockShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_TemporaryEquityConversionOfStockShares" xlink:to="gemp_TemporaryEquityConversionOfStockShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_TemporaryEquityConversionOfStockShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of temporary equity converted into permanent equity during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_TemporaryEquityConversionOfStockShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Conversion of Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gemp_TemporaryEquityConversionOfStockShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series A preferred stock, shares converted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NonCashInterestOnPromissoryNotesToRelatedParties" xlink:label="gemp_NonCashInterestOnPromissoryNotesToRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NonCashInterestOnPromissoryNotesToRelatedParties" xlink:to="gemp_NonCashInterestOnPromissoryNotesToRelatedParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NonCashInterestOnPromissoryNotesToRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of noncash interest on promissory notes to related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NonCashInterestOnPromissoryNotesToRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Cash Interest On Promissory Notes To Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_NonCashInterestOnPromissoryNotesToRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest on promissory notes to related parties</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NoncashInterestOnConvertibleNotesToRelatedParties" xlink:label="gemp_NoncashInterestOnConvertibleNotesToRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NoncashInterestOnConvertibleNotesToRelatedParties" xlink:to="gemp_NoncashInterestOnConvertibleNotesToRelatedParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NoncashInterestOnConvertibleNotesToRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of noncash interest on convertible notes to related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NoncashInterestOnConvertibleNotesToRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Interest On Convertible Notes To Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NoncashInterestOnConvertibleNotesToRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest on convertible notes to related parties</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NoncashInterestOnConvertibleNotes" xlink:label="gemp_NoncashInterestOnConvertibleNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NoncashInterestOnConvertibleNotes" xlink:to="gemp_NoncashInterestOnConvertibleNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NoncashInterestOnConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of noncash interest on convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NoncashInterestOnConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Interest On Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NoncashInterestOnConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest on convertible notes</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount" xlink:label="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount" xlink:to="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of noncash expense to amortize debt discount associated with the convertible notes to related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization On Convertible Notes To Related Parties Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash discount amortization on convertible notes to related parties</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AmortizationOnConvertibleNotesDiscount" xlink:label="gemp_AmortizationOnConvertibleNotesDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_AmortizationOnConvertibleNotesDiscount" xlink:to="gemp_AmortizationOnConvertibleNotesDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_AmortizationOnConvertibleNotesDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of noncash expense included in interest expense to amortize debt discount associated with the convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_AmortizationOnConvertibleNotesDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization On Convertible Notes Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_AmortizationOnConvertibleNotesDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash discount amortization on convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revaluation of premium conversion derivative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on Convertible Debt, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash interest upon conversion of convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits" xlink:label="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits" xlink:to="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase (decrease) of consideration paid in advance that provide economic benefits in future periods and deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Prepaid Expenses And Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of convertible notes to related parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Financing Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs related to convertible notes</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromRelatedPartyPromissoryNotes" xlink:label="gemp_ProceedsFromRelatedPartyPromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ProceedsFromRelatedPartyPromissoryNotes" xlink:to="gemp_ProceedsFromRelatedPartyPromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ProceedsFromRelatedPartyPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from a promissory note made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ProceedsFromRelatedPartyPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Related Party Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_ProceedsFromRelatedPartyPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of promissory notes to related parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of Series A convertible preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds from issuance of Series A preferred</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other offering expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental non-cash financing transactions:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series A preferred stock to common stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of debt instrument to stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory notes converted</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ExerciseOfPremiumConversionDerivative" xlink:label="gemp_ExerciseOfPremiumConversionDerivative" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ExerciseOfPremiumConversionDerivative" xlink:to="gemp_ExerciseOfPremiumConversionDerivative_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ExerciseOfPremiumConversionDerivative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise of premium conversion derivative.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ExerciseOfPremiumConversionDerivative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of premium conversion derivative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for acquisition of in-process research and development</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes" xlink:label="gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes" xlink:to="gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the bifurcation of premium conversion derivative related to convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bifurcation of premium conversion derivative related to convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extinguishment of Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible note extinguishment</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment" xlink:label="gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment" xlink:to="gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the premium conversion derivative reduction upon convertible note extinguishment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium Conversion Derivative Reduction Upon Convertible Note Extinguishment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium conversion derivative reduction upon convertible note extinguishment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Assumed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Company and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Company and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LicenseAgreementDisclosureAbstract" xlink:label="gemp_LicenseAgreementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_LicenseAgreementDisclosureAbstract" xlink:to="gemp_LicenseAgreementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_LicenseAgreementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_LicenseAgreementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Series A Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityDisclosureTextBlock" xlink:label="gemp_TemporaryEquityDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_TemporaryEquityDisclosureTextBlock" xlink:to="gemp_TemporaryEquityDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure relating to temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_TemporaryEquityDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Series A Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders&#x2019; and Members&#x2019; Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders&#x2019; and Members&#x2019; Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Common Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Common Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplementary Data &#x2014; Quarterly Financial Data (unaudited)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplementary Data &#x2014; Quarterly Financial Data (unaudited)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:to="us-gaap_ValuationAndQualifyingAccountsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research and Development, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired In-Process Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Valuation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock" xlink:label="gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock" xlink:to="gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policies for Jumpstart Our Business Startups Act Accounting Election.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jumpstart Our Business Startups Act Accounting Election [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Jumpstart Our Business Startups Act Accounting Election</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of RSA grant activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option plan activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted-average assumptions, option-pricing model</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of computation of basic and diluted loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potential common shares not considered in computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of fair value of financial instruments measured on recurring basis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of premium conversion derivative liabilities measured at fair value on recurring basis using unobservable level 3 inputs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of statutory federal income tax rate to the provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:label="us-gaap_QuarterlyFinancialDataAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_QuarterlyFinancialDataAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialDataAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Data [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly Financial Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of unaudited consolidated quarterly financial information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForUnderwritingExpense" xlink:to="us-gaap_PaymentsForUnderwritingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Underwriting Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting discounts and commissions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements or Change in Accounting Principle</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesCurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity, Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares converted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:to="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information, Additional Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segment</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AccruedOfferingCostsCurrent" xlink:label="gemp_AccruedOfferingCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_AccruedOfferingCostsCurrent" xlink:to="gemp_AccruedOfferingCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_AccruedOfferingCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for stock offering costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_AccruedOfferingCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Offering Costs Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_AccruedOfferingCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued offering costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation costs</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AccruedOtherResearchAndDevelopmentExpenses" xlink:label="gemp_AccruedOtherResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_AccruedOtherResearchAndDevelopmentExpenses" xlink:to="gemp_AccruedOtherResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_AccruedOtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for other research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_AccruedOtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Other Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_AccruedOtherResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other research and development expenses</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AccruedOtherGeneralAndAdministrativeExpenses" xlink:label="gemp_AccruedOtherGeneralAndAdministrativeExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_AccruedOtherGeneralAndAdministrativeExpenses" xlink:to="gemp_AccruedOtherGeneralAndAdministrativeExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_AccruedOtherGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for other general and administrative expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_AccruedOtherGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Other General And Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_AccruedOtherGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible debt, interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing total</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" xlink:label="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" xlink:to="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount by which the convertible debt's conversion value exceeds the amount of principal and unpaid accrued interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Converted Percent In Excess Of Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price percentage of principal and unpaid accrued interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of embedded derivative</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold" xlink:label="gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold" xlink:to="gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum gross proceeds received in an equity offering which would trigger the automatic conversion of the debt instrument into equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Automatic Conversion Equity Offering Threshold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Qualified Financing threshold for debt conversion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion ratio</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount" xlink:label="gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount" xlink:to="gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the redemption price as a percentage of the principal amount at which the debt instrument may be required to be redeemed in the event of a change of control.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Redemption Price Due To Change Of Control As Percentage Of Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt redemption price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Series A Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Original issue price, per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per issue and sold units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:to="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Amount of Preferred Dividends in Arrears</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative unpaid dividends</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Leasing Arrangements, Operating Leases, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monthly base rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum lease payments of operating leases:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SharesIssuablePercentageOfOffering" xlink:label="gemp_SharesIssuablePercentageOfOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_SharesIssuablePercentageOfOffering" xlink:to="gemp_SharesIssuablePercentageOfOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_SharesIssuablePercentageOfOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares of preferred stock offering that agreement required to be issued to the licensor.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_SharesIssuablePercentageOfOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issuable Percentage Of Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_SharesIssuablePercentageOfOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shares of common stock offering issued to Pfizer</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ContingentLiability" xlink:label="gemp_ContingentLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ContingentLiability" xlink:to="gemp_ContingentLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ContingentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents a contingent liability to make payments if certain conditions are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ContingentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ContingentLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential payments upon achievement of certain milestones</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership by Pfizer</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" xlink:to="gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of new stock classified as temporary equity issued during the period, before deduction of related offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Stock Issued During Period Value New Issues Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate consideration, cash and noncash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Original Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash consideration received, debt converted into stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends deemed payable and accrued</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LiquidationPreferencePercentageOfChangeInVoting" xlink:label="gemp_LiquidationPreferencePercentageOfChangeInVoting" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_LiquidationPreferencePercentageOfChangeInVoting" xlink:to="gemp_LiquidationPreferencePercentageOfChangeInVoting_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_LiquidationPreferencePercentageOfChangeInVoting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of the change in voting power of the reporting entity, which triggers a liquidation preference to holders of preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_LiquidationPreferencePercentageOfChangeInVoting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation Preference Percentage Of Change In Voting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_LiquidationPreferencePercentageOfChangeInVoting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation preference upon transfer of voting power, percentage</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PreferredStockRedemptionRequestedByPercentageOfShares" xlink:label="gemp_PreferredStockRedemptionRequestedByPercentageOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_PreferredStockRedemptionRequestedByPercentageOfShares" xlink:to="gemp_PreferredStockRedemptionRequestedByPercentageOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_PreferredStockRedemptionRequestedByPercentageOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of the outstanding shares of convertible preferred stock needed to require mandatory redemption at a specified future date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_PreferredStockRedemptionRequestedByPercentageOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Redemption Requested By Percentage Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_PreferredStockRedemptionRequestedByPercentageOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of outstanding shares which may require the Company to redeem shares</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_RedemptionPricePercentageOfLiquidationPreference" xlink:label="gemp_RedemptionPricePercentageOfLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_RedemptionPricePercentageOfLiquidationPreference" xlink:to="gemp_RedemptionPricePercentageOfLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_RedemptionPricePercentageOfLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price calculated as percentage of liquidation preference.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_RedemptionPricePercentageOfLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption Price Percentage Of Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_RedemptionPricePercentageOfLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price, as a percent of liquidation preference</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Liquidation Preference, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation preference, per share</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_CumulativeDividendsDeclared" xlink:label="gemp_CumulativeDividendsDeclared" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_CumulativeDividendsDeclared" xlink:to="gemp_CumulativeDividendsDeclared_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_CumulativeDividendsDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cumulative cash dividends declared.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_CumulativeDividendsDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Dividends Declared</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_CumulativeDividendsDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No dividends declared</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_CommonStockVotingRightsPerShare" xlink:label="gemp_CommonStockVotingRightsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_CommonStockVotingRightsPerShare" xlink:to="gemp_CommonStockVotingRightsPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_CommonStockVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the voting rights per share for common stock of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_CommonStockVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Voting Rights Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_CommonStockVotingRightsPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, vote per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Offering Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred offering costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value (in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSA grant activity [Rollforward], Number of Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non&#x2011;vested , Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non&#x2011;vested , Begining Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSA grant activity [Rollforward], Weighted-Average Fair Value (per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non&#x2011;vested , Ending Balance (per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non&#x2011;vested , Begininng Balance (per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Number, Ending Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Number, Beginning Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased under the ESPP</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Weighted Average Exercise Price, Beginning Balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/Cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options, Additional Disclosures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Outstanding, Weighted Average Remaining Contractual Term (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options, Outstanding, Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock reserved for issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock aggregate intrinsic value of exercise price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value per share of options granted</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:to="gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares under options that were vested during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value per share of options vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available for future issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected stock price volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life of options (years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation cost - RSA</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation cost - Stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized share-based compensation - Weighted average period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Common Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Participating Securities, Distributed and Undistributed Earnings (Loss), Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss allocated to preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Diluted Shares Outstanding Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental common stock equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computation of basic and diluted loss per share:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount" xlink:label="gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount" xlink:to="gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of transfers of assets and liabilities measured on a recurring basis between levels in fair value hierarchy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets (Liabilities) Transfers Between Levels Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers between levels</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities at Fair Value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Roll-forward of the company's premium conversion derivative liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of underlying convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of premium conversion derivative</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal" xlink:label="gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal" xlink:to="gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of reversal of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement with Unobservable Inputs Reconciliation Recurring Basis Liability Reversal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal of premium conversion derivative associated with note extinguishment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption of underlying convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of income tax:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax (benefit) provision at federal statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income tax, net of federal benefit (as a percent)</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes" xlink:label="gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes" xlink:to="gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research credits (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant components of deferred tax assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal and state operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development costs deferral election</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DeferredTaxAssetsAcquiredIntangibles" xlink:label="gemp_DeferredTaxAssetsAcquiredIntangibles" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_DeferredTaxAssetsAcquiredIntangibles" xlink:to="gemp_DeferredTaxAssetsAcquiredIntangibles_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_DeferredTaxAssetsAcquiredIntangibles_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from acquired intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_DeferredTaxAssetsAcquiredIntangibles_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Acquired Intangibles</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_DeferredTaxAssetsAcquiredIntangibles_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired intangibles</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DeferredTaxAssetsConvertibleNotes" xlink:label="gemp_DeferredTaxAssetsConvertibleNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_DeferredTaxAssetsConvertibleNotes" xlink:to="gemp_DeferredTaxAssetsConvertibleNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_DeferredTaxAssetsConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_DeferredTaxAssetsConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_DeferredTaxAssetsConvertibleNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Charitable Contribution Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Charitable contributions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal research credit carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets, net of valuation allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DeferredTaxLiabilitiesRestrictedStockAwards" xlink:label="gemp_DeferredTaxLiabilitiesRestrictedStockAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_DeferredTaxLiabilitiesRestrictedStockAwards" xlink:to="gemp_DeferredTaxLiabilitiesRestrictedStockAwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_DeferredTaxLiabilitiesRestrictedStockAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_DeferredTaxLiabilitiesRestrictedStockAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities Restricted Stock Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gemp_DeferredTaxLiabilitiesRestrictedStockAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DeferredTaxAssetsTaxCreditCarryforwardsState" xlink:label="gemp_DeferredTaxAssetsTaxCreditCarryforwardsState" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_DeferredTaxAssetsTaxCreditCarryforwardsState" xlink:to="gemp_DeferredTaxAssetsTaxCreditCarryforwardsState_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_DeferredTaxAssetsTaxCreditCarryforwardsState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state tax credit carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_DeferredTaxAssetsTaxCreditCarryforwardsState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Credit Carryforwards State</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_DeferredTaxAssetsTaxCreditCarryforwardsState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State research credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Uncertainties [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax:</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ThresholdPercentageOfShareholdersOwnershipChange" xlink:label="gemp_ThresholdPercentageOfShareholdersOwnershipChange" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ThresholdPercentageOfShareholdersOwnershipChange" xlink:to="gemp_ThresholdPercentageOfShareholdersOwnershipChange_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ThresholdPercentageOfShareholdersOwnershipChange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold percentage of shareholders ownership change.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ThresholdPercentageOfShareholdersOwnershipChange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage Of Shareholders Ownership Change</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_ThresholdPercentageOfShareholdersOwnershipChange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage of shareholders ownership change</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits" xlink:label="gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits" xlink:to="gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the minimum increase in ownership percentage annual limitation may result in expiration of net operating losses and credits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Increase In Ownership Percentage Annual Limitation May Result In Expiration Of Net Operating Losses And Credits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum increase in ownership percentage annual limitation may result in expiration of NOL and credits</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PeriodForTestingPercentageOfOwnershipChange" xlink:label="gemp_PeriodForTestingPercentageOfOwnershipChange" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_PeriodForTestingPercentageOfOwnershipChange" xlink:to="gemp_PeriodForTestingPercentageOfOwnershipChange_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_PeriodForTestingPercentageOfOwnershipChange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for testing percentage of ownership change</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_PeriodForTestingPercentageOfOwnershipChange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period For Testing Percentage Of Ownership Change</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="gemp_PeriodForTestingPercentageOfOwnershipChange_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for testing percentage of ownership change</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest or penalties</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfOfficersInRelatedPartyTransaction" xlink:label="gemp_NumberOfOfficersInRelatedPartyTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfOfficersInRelatedPartyTransaction" xlink:to="gemp_NumberOfOfficersInRelatedPartyTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfOfficersInRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of officers in related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfOfficersInRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Officers In Related Party Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfOfficersInRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of officers</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid rent</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfDebtInstrumentsIssued" xlink:label="gemp_NumberOfDebtInstrumentsIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfDebtInstrumentsIssued" xlink:to="gemp_NumberOfDebtInstrumentsIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfDebtInstrumentsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of debt instruments issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfDebtInstrumentsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Debt Instruments Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfDebtInstrumentsIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of notes issued to related party</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfBoardMembersInRelatedPartyTransaction" xlink:label="gemp_NumberOfBoardMembersInRelatedPartyTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfBoardMembersInRelatedPartyTransaction" xlink:to="gemp_NumberOfBoardMembersInRelatedPartyTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfBoardMembersInRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Board members in related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfBoardMembersInRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Board Members In Related Party Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfBoardMembersInRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of board members who were issued debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of shares issued in conversion</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfEmployeesInRelatedPartyTransaction" xlink:label="gemp_NumberOfEmployeesInRelatedPartyTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfEmployeesInRelatedPartyTransaction" xlink:to="gemp_NumberOfEmployeesInRelatedPartyTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfEmployeesInRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of employees in related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfEmployeesInRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Employees In Related Party Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfEmployeesInRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of employees</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfBoardMembers" xlink:label="gemp_NumberOfBoardMembers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfBoardMembers" xlink:to="gemp_NumberOfBoardMembers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of board members</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfInvestorsRelatedToOfficers" xlink:label="gemp_NumberOfInvestorsRelatedToOfficers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfInvestorsRelatedToOfficers" xlink:to="gemp_NumberOfInvestorsRelatedToOfficers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfInvestorsRelatedToOfficers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of investors related to officers of the company during the period of the transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfInvestorsRelatedToOfficers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Investors Related to Officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfInvestorsRelatedToOfficers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of investors related to 5 officers of the company</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors" xlink:label="gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors" xlink:to="gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of investor related to one of the Company&#x2019;s directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Investor Related To One Of Company&#x2019;s Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of investor related to 1 of the Company&#x2019;s directors</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfOfficers" xlink:label="gemp_NumberOfOfficers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfOfficers" xlink:to="gemp_NumberOfOfficers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfOfficers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfOfficers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfOfficers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of officers</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany" xlink:label="gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany" xlink:to="gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares sold to fourteen investors who are related to 5 officers of the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares Sold To Fourteen Investors Related To Five Officers of Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares sold to 14 investors who are related to 5 officers of the Company</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector" xlink:label="gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector" xlink:to="gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares sold to one investor who is related to one of company's director.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares Sold to One Investor Related To One Of Comapny's Director</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares sold to 1 investor related to 1 of the Company&#x2019;s directors</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers" xlink:label="gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers" xlink:to="gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shares sold to 3 officers and 5 board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares Sold to Three officers and Five Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares sold to 3 officers and 5 board members</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany" xlink:label="gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany" xlink:to="gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The proceeds from issuance of shares to investors related to 5 officers of the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Shares To Fourteen Investor Related To Five Officers Of Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of shares to 14 investors who are related to 5 officers of the Company</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector" xlink:label="gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector" xlink:to="gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The proceeds from issuance of shares to a investor related to one of the Company&#x2019;s directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Shares To One Investor Related To One Of Comapny's Director</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of shares to 1 investor related to 1 of the Company&#x2019;s directors</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers" xlink:label="gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers" xlink:to="gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The proceeds from issuance of shares to officers and board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Shares To Three officers and Five Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of shares to 3 officers and 5 board members</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesIssuedPerUnit" xlink:label="gemp_NumberOfSharesIssuedPerUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfSharesIssuedPerUnit" xlink:to="gemp_NumberOfSharesIssuedPerUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfSharesIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Describes te number of shares made available per units issued under the arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfSharesIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Issued Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfSharesIssuedPerUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares per unit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants per unit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrant</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:label="gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:to="gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period over which the warrant is exercisable, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Warrants or Rights Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable period</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfInvestorRelatedToBoardMembers" xlink:label="gemp_NumberOfInvestorRelatedToBoardMembers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_NumberOfInvestorRelatedToBoardMembers" xlink:to="gemp_NumberOfInvestorRelatedToBoardMembers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_NumberOfInvestorRelatedToBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors related to board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_NumberOfInvestorRelatedToBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Investor Related to Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_NumberOfInvestorRelatedToBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of investor</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation and Qualifying Accounts Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAndQualifyingAccountsDisclosureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation and Qualifying Accounts Disclosure [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="us-gaap_MovementInValuationAllowancesAndReservesRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="us-gaap_MovementInValuationAllowancesAndReservesRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MovementInValuationAllowancesAndReservesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Movement in Valuation Allowances and Reserves [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MovementInValuationAllowancesAndReservesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VALUATION AND QUALIFYING ACCOUNTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances and Reserves, Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending Balance of Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning Balance of Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances and Reserves, Additions for Charges to Cost and Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions Charged to Costs and Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowances and Reserves, Additions for Charges to Other Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions Charged to Paid in Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_MembersEarningsMember" xlink:label="gemp_MembersEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_MembersEarningsMember" xlink:to="gemp_MembersEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_MembersEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cumulative amount of the member's undistributed earnings or deficit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_MembersEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_MembersEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members' Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Conversion Description [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Stock Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfSeriesPreferredStockMember" xlink:label="gemp_ConversionOfSeriesPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ConversionOfSeriesPreferredStockMember" xlink:to="gemp_ConversionOfSeriesPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ConversionOfSeriesPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the conversion of Series A preferred stock into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ConversionOfSeriesPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Series Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ConversionOfSeriesPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Series A Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion Description [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfInterimNotesMember" xlink:label="gemp_ConversionOfInterimNotesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ConversionOfInterimNotesMember" xlink:to="gemp_ConversionOfInterimNotesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ConversionOfInterimNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the conversion of Interim notes to common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ConversionOfInterimNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Interim Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ConversionOfInterimNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Interim Notes</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfConvertibleNotesMember" xlink:label="gemp_ConversionOfConvertibleNotesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ConversionOfConvertibleNotesMember" xlink:to="gemp_ConversionOfConvertibleNotesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ConversionOfConvertibleNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the conversion of convertible notes into Series A preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ConversionOfConvertibleNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ConversionOfConvertibleNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfRelatedPartyPromissoryNotesMember" xlink:label="gemp_ConversionOfRelatedPartyPromissoryNotesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ConversionOfRelatedPartyPromissoryNotesMember" xlink:to="gemp_ConversionOfRelatedPartyPromissoryNotesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ConversionOfRelatedPartyPromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to conversion of related party promissory notes to convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ConversionOfRelatedPartyPromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion Of Related Party Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ConversionOfRelatedPartyPromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of related party promissory notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable And Accrued Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Overallotment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for New Accounting Pronouncements [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Adoption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Adoption [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingStandardsUpdate201517Member" xlink:label="us-gaap_AccountingStandardsUpdate201517Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201517Member" xlink:to="us-gaap_AccountingStandardsUpdate201517Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201517Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update201517 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201517Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASU 2015-17</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncement, Early Adoption [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Principles Early Adoption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Principles, Early Adoption [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncement Early Adoption Effect [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Early Adoption</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="us-gaap_ScenarioAdjustmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioAdjustmentMember" xlink:to="us-gaap_ScenarioAdjustmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario Adjustment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioAdjustmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adopted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PredecessorMember" xlink:label="us-gaap_PredecessorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PredecessorMember" xlink:to="us-gaap_PredecessorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PredecessorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Predecessor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PredecessorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">MLT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableOtherPayablesMember" xlink:to="us-gaap_NotesPayableOtherPayablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes Payable Other Payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promissory Notes</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SeriesaPreferredConvertibleDebtMember" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_SeriesaPreferredConvertibleDebtMember" xlink:to="gemp_SeriesaPreferredConvertibleDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing which can be exchanged for Series A preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Seriesa Preferred Convertible Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_FinancingConvertibleDebtMember" xlink:label="gemp_FinancingConvertibleDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_FinancingConvertibleDebtMember" xlink:to="gemp_FinancingConvertibleDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_FinancingConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing which can be exchanged for common stock or preferred stock at the time of the the reporting entity's next round of financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_FinancingConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Convertible Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_FinancingConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InterestIncomeExpenseNetMember" xlink:label="gemp_InterestIncomeExpenseNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_InterestIncomeExpenseNetMember" xlink:to="gemp_InterestIncomeExpenseNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_InterestIncomeExpenseNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption in which reported facts about interest income (expense), have been included.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_InterestIncomeExpenseNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income Expense Net [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_InterestIncomeExpenseNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income (expense)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PfizerInc.Member" xlink:label="gemp_PfizerInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_PfizerInc.Member" xlink:to="gemp_PfizerInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_PfizerInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Pfizer Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_PfizerInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pfizer Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_PfizerInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pfizer, Inc.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LicenseAgreementMember" xlink:label="gemp_LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_LicenseAgreementMember" xlink:to="gemp_LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exclusive worldwide license to certain patent rights to make, use, sell, offer for sale and import product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A Convertible Preferred Stock.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OfficeRentalMember" xlink:label="gemp_OfficeRentalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_OfficeRentalMember" xlink:to="gemp_OfficeRentalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_OfficeRentalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rental of office in Northville, Michigan from an LLC owned by two officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_OfficeRentalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Rental [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_OfficeRentalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office Rental</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Domain]</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_MilestonePaymentsMember" xlink:label="gemp_MilestonePaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_MilestonePaymentsMember" xlink:to="gemp_MilestonePaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_MilestonePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment to make milestone payments contingent upon achieving specified goals.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_MilestonePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_MilestonePaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:to="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An arrangement whereby an employee, consultant, or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Consultants And Directors Stock Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember" xlink:label="gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember" xlink:to="gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to amendment and restatement of 2015 equity incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment And Restatement Of2015 Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A &amp; R 2015 Plan</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EquityIncentivePlan2015Member" xlink:label="gemp_EquityIncentivePlan2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_EquityIncentivePlan2015Member" xlink:to="gemp_EquityIncentivePlan2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_EquityIncentivePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to equity incentive plan 2015.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_EquityIncentivePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan2015 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_EquityIncentivePlan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Plan</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InducementPlanMember" xlink:label="gemp_InducementPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_InducementPlanMember" xlink:to="gemp_InducementPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_InducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the Inducement Plan, an equity incentive plan used by the reporting entity targeted at individuals not previously employees or directors as an inducement into employment with the Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_InducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_InducementPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OfficersDirectorsAndEmployeesMember" xlink:label="gemp_OfficersDirectorsAndEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_OfficersDirectorsAndEmployeesMember" xlink:to="gemp_OfficersDirectorsAndEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_OfficersDirectorsAndEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents officers, directors and employees of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_OfficersDirectorsAndEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Officers Directors And Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_OfficersDirectorsAndEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Officers, directors and employees</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OfficersAndEmployeesMember" xlink:label="gemp_OfficersAndEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_OfficersAndEmployeesMember" xlink:to="gemp_OfficersAndEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_OfficersAndEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to officers and employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_OfficersAndEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Officers And Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_OfficersAndEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Officers and Employees</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EmployeesDirectorsAndConsultantsMember" xlink:label="gemp_EmployeesDirectorsAndConsultantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_EmployeesDirectorsAndConsultantsMember" xlink:to="gemp_EmployeesDirectorsAndConsultantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_EmployeesDirectorsAndConsultantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents employees, directors and consultants of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_EmployeesDirectorsAndConsultantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees Directors And Consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_EmployeesDirectorsAndConsultantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees, directors and consultants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESPP</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Notes Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Nonrecurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonrecurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Embedded Derivative Financial Instruments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Premium conversion derivative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LlcOwnedByTwoOfficersMember" xlink:label="gemp_LlcOwnedByTwoOfficersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_LlcOwnedByTwoOfficersMember" xlink:to="gemp_LlcOwnedByTwoOfficersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_LlcOwnedByTwoOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LLC owned by two officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_LlcOwnedByTwoOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Llc Owned By Two Officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_LlcOwnedByTwoOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LLC owned by two officers</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToBoardMemberAndOfficersMember" xlink:label="gemp_InvestorsRelatedToBoardMemberAndOfficersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_InvestorsRelatedToBoardMemberAndOfficersMember" xlink:to="gemp_InvestorsRelatedToBoardMemberAndOfficersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_InvestorsRelatedToBoardMemberAndOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors related to one Board member and three officers of the reporting entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_InvestorsRelatedToBoardMemberAndOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors Related To Board Member And Officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_InvestorsRelatedToBoardMemberAndOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors Related To Board Member And Officers</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoOfficersMember" xlink:label="gemp_TwoOfficersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_TwoOfficersMember" xlink:to="gemp_TwoOfficersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_TwoOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to two officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_TwoOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_TwoOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Officers</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtIssuedToRelatedPartiesMember" xlink:label="gemp_DebtIssuedToRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_DebtIssuedToRelatedPartiesMember" xlink:to="gemp_DebtIssuedToRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_DebtIssuedToRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to debt issued to related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_DebtIssuedToRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issued To Related Parties [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_DebtIssuedToRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issued To Related Parties</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" xlink:label="gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" xlink:to="gemp_TwoOfficersAndThreeBoardMembersInvestorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_TwoOfficersAndThreeBoardMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors comprised of two officers and three Board members of the reporting entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_TwoOfficersAndThreeBoardMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Officers And Three Board Members Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_TwoOfficersAndThreeBoardMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors - 2 officers and 3 Board members</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" xlink:label="gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" xlink:to="gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors related to three officers and one key employee of the reporting entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Three Officers And One Key Employee Members Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors - 3 officers and 1 employee</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoOfficersAndFourBoardMembersInvestorsMember" xlink:label="gemp_TwoOfficersAndFourBoardMembersInvestorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_TwoOfficersAndFourBoardMembersInvestorsMember" xlink:to="gemp_TwoOfficersAndFourBoardMembersInvestorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_TwoOfficersAndFourBoardMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors comprised of  two officers and four Board members of the reporting entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_TwoOfficersAndFourBoardMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Officers And Four Board Members Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_TwoOfficersAndFourBoardMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors - 2 officers and 4 Board members</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToThreeOfficersMember" xlink:label="gemp_InvestorsRelatedToThreeOfficersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_InvestorsRelatedToThreeOfficersMember" xlink:to="gemp_InvestorsRelatedToThreeOfficersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_InvestorsRelatedToThreeOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors related to three officers of the reporting entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_InvestorsRelatedToThreeOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors Related To Three Officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_InvestorsRelatedToThreeOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors related to 3 officers</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoBoardMembersInvestorsMember" xlink:label="gemp_TwoBoardMembersInvestorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_TwoBoardMembersInvestorsMember" xlink:to="gemp_TwoBoardMembersInvestorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_TwoBoardMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors comprised of two Board members (or entities they control) of the reporting entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_TwoBoardMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Two Board Members Investors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_TwoBoardMembersInvestorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investor - 2 Board members</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:to="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immediate Family Member Of Management Or Principal Owner [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investor related to an officer</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToTwoOfficersMember" xlink:label="gemp_InvestorsRelatedToTwoOfficersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_InvestorsRelatedToTwoOfficersMember" xlink:to="gemp_InvestorsRelatedToTwoOfficersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_InvestorsRelatedToTwoOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investor related to two officers of the reporting entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_InvestorsRelatedToTwoOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors Related To Two Officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_InvestorsRelatedToTwoOfficersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors related to 2 officers</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToThreeDirectorsMember" xlink:label="gemp_InvestorsRelatedToThreeDirectorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_InvestorsRelatedToThreeDirectorsMember" xlink:to="gemp_InvestorsRelatedToThreeDirectorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_InvestorsRelatedToThreeDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors related to three Directors of the reporting entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_InvestorsRelatedToThreeDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors Related To Three Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_InvestorsRelatedToThreeDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investors related to three directors</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private placement</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ThreeBoardMember" xlink:label="gemp_ThreeBoardMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_ThreeBoardMember" xlink:to="gemp_ThreeBoardMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_ThreeBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to three board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_ThreeBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Three Board [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_ThreeBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Three Board Members</label>
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OneBoardMember" xlink:label="gemp_OneBoardMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gemp_OneBoardMember" xlink:to="gemp_OneBoardMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gemp_OneBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to one board member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gemp_OneBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One Board [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gemp_OneBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One Board Member</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>28
<FILENAME>gemp-20161231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Merrill Bridge  6.4.50.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/20/2017 8:19:58 PM-->
<!--Modified on: 3/20/2017 8:19:58 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.gemphire.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementBalanceSheets" roleURI="http://www.gemphire.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.gemphire.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementStatementsOfComprehensiveLoss" roleURI="http://www.gemphire.com/role/StatementStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficit" roleURI="http://www.gemphire.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitTemporaryEquity" roleURI="http://www.gemphire.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitTemporaryEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.gemphire.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCompanyAndBasisOfPresentation" roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureAccruedLiabilities" roleURI="http://www.gemphire.com/role/DisclosureAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureDebt" roleURI="http://www.gemphire.com/role/DisclosureDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureLicenseAgreement" roleURI="http://www.gemphire.com/role/DisclosureLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureConvertibleSeriesPreferredStock" roleURI="http://www.gemphire.com/role/DisclosureConvertibleSeriesPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureStockholdersAndMembersEquityDeficit" roleURI="http://www.gemphire.com/role/DisclosureStockholdersAndMembersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureShareBasedCompensation" roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureNetLossPerCommonShare" roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureIncomeTaxes" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureSupplementaryDataQuarterlyFinancialDataUnaudited" roleURI="http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureSubsequentEvents" roleURI="http://www.gemphire.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureScheduleIiValuationAndQualifyingAccounts" roleURI="http://www.gemphire.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureAccruedLiabilitiesTables" roleURI="http://www.gemphire.com/role/DisclosureAccruedLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureNetLossPerCommonShareTables" roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedTables" roleURI="http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCompanyAndBasisOfPresentationIpoAndCapitalRequirementsDetails" roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationIpoAndCapitalRequirementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCompanyAndBasisOfPresentationBasisOfPresentationDetails" roleURI="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureAccruedLiabilitiesDetails" roleURI="http://www.gemphire.com/role/DisclosureAccruedLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureDebtDetails" roleURI="http://www.gemphire.com/role/DisclosureDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCommitmentsAndContigenciesPfizerLicenseAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPfizerLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCommitmentsAndContigenciesPreferredStockDividendsDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPreferredStockDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureCommitmentsAndContigenciesOtherAgreementsDetails" roleURI="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesOtherAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureLicenseAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureLicenseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureConvertibleSeriesPreferredStockDetails" roleURI="http://www.gemphire.com/role/DisclosureConvertibleSeriesPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureStockholdersAndMembersEquityDeficitDetails" roleURI="http://www.gemphire.com/role/DisclosureStockholdersAndMembersEquityDeficitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureShareBasedCompensationRestrictedStockDetails" roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationRestrictedStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureShareBasedCompensationStockOptionsDetails" roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureShareBasedCompensationUnrecognizedDetails" roleURI="http://www.gemphire.com/role/DisclosureShareBasedCompensationUnrecognizedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureNetLossPerCommonShareDetails" roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureNetLossPerCommonShareEarningPerShareDetails" roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareEarningPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureNetLossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" roleURI="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitieDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitieDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.gemphire.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedDetails" roleURI="http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureRelatedPartyTransactionsRentalAgreementDetails" roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsRentalAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureRelatedPartyTransactionsConvertibleNotesDetails" roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsConvertibleNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureRelatedPartyTransactionsInterimNotesDetails" roleURI="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsInterimNotesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.gemphire.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gemp-20161231.xsd#DisclosureScheduleIiValuationAndQualifyingAccountsDetails" roleURI="http://www.gemphire.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <presentationLink xlink:role="http://www.gemphire.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DocumentAndEntityInformationAbstract" xlink:label="gemp_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_636256379968840626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_636256379968840626" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_636256379968850626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_636256379968850626" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_636256379968860626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_636256379968860626" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_636256379968860626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_636256379968860626" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_636256379968860626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_636256379968860626" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_636256379968860626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_636256379968860626" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_636256379968860626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus_636256379968860626" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_636256379968860626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers_636256379968860626" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_636256379968860626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_636256379968860626" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_636256379968860626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_636256379968860626" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_636256379968860626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat_636256379968860626" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_636256379968860626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_636256379968860626" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_636256379968860626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_636256379968860626" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_636256379968870626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_636256379968870626" order="14" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_636256379968870626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_636256379968870626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_636256379968880626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636256379968870626" xlink:to="us-gaap_AssetsCurrentAbstract_636256379968880626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636256379968880626" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636256379968890626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636256379968880626" xlink:to="us-gaap_PrepaidExpenseCurrent_636256379968890626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636256379968880626" xlink:to="us-gaap_AssetsCurrent_636256379968890626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636256379968880626" xlink:to="us-gaap_DeferredCosts_636256379968890626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636256379968870626" xlink:to="us-gaap_DepositsAssetsNoncurrent_636256379968890626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636256379968870626" xlink:to="us-gaap_Assets_636256379968890626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636256379968890626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636256379968890626" xlink:to="us-gaap_LiabilitiesCurrentAbstract_636256379968890626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636256379968890626" xlink:to="us-gaap_AccountsPayableCurrent_636256379968890626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636256379968890626" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636256379968890626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636256379968890626" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_636256379968890626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636256379968890626" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_636256379968890626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636256379968890626" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_636256379968890626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636256379968890626" xlink:to="us-gaap_LiabilitiesCurrent_636256379968890626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636256379968890626" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636256379968890626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636256379968890626" xlink:to="us-gaap_Liabilities_636256379968890626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_636256379968890626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636256379968890626" xlink:to="us-gaap_CommitmentsAndContingencies_636256379968890626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_636256379968910626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636256379968890626" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_636256379968910626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_636256379968910626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_636256379968910626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_636256379968910626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636256379968910626" xlink:to="us-gaap_PreferredStockValue_636256379968910626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636256379968910626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636256379968910626" xlink:to="us-gaap_CommonStockValue_636256379968910626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_636256379968910626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636256379968910626" xlink:to="us-gaap_AdditionalPaidInCapital_636256379968910626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636256379968910626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636256379968910626" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636256379968910626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636256379968910626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636256379968910626" xlink:to="us-gaap_StockholdersEquity_636256379968910626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_636256379968910626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636256379968910626" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_636256379968910626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_636256379968920626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636256379968920626" xlink:to="us-gaap_StatementClassOfStockAxis_636256379968920626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636256379968920626" xlink:to="us-gaap_ClassOfStockDomain_636256379968920626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636256379968920626" xlink:to="us-gaap_ConvertiblePreferredStockMember_636256379968920626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636256379968920626" xlink:to="us-gaap_StatementLineItems_636256379968920626" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_636256379968920626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_636256379968920626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_TemporaryEquitySharesIssued_636256379968920626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_636256379968920626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_636256379968920626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_636256379968920626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_636256379968920626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_PreferredStockSharesAuthorized_636256379968920626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_636256379968930626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_PreferredStockSharesIssued_636256379968930626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_636256379968930626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_PreferredStockSharesOutstanding_636256379968930626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636256379968930626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636256379968930626" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636256379968930626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_CommonStockSharesAuthorized_636256379968930626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_636256379968930626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_CommonStockSharesIssued_636256379968930626" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_636256379968930626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968920626" xlink:to="us-gaap_CommonStockSharesOutstanding_636256379968930626" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/StatementStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_636256379968930626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_636256379968930626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_636256379968930626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636256379968930626" xlink:to="us-gaap_GeneralAndAdministrativeExpense_636256379968930626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_636256379968930626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636256379968930626" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_636256379968930626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636256379968930626" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_636256379968940626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636256379968930626" xlink:to="us-gaap_CostsAndExpenses_636256379968940626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_636256379968940626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet_636256379968940626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_636256379968940626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_636256379968940626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636256379968940626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636256379968940626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_636256379968940626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_636256379968940626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_6362563799689406261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_6362563799689406261" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_636256379968940626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConvertibleNotesPremiumUponSubstantialModificationValue" xlink:label="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_636256379968940626" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636256379968940626" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636256379968940626" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636256379968940626" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636256379968940626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_636256379968940626" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636256379968940626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_636256379968940626" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636256379968940626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficit" xlink:type="extended" xlink:title="00300 - Statement - Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_636256379968950626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636256379968950626" xlink:to="us-gaap_StatementEquityComponentsAxis_636256379968950626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_MembersEarningsMember" xlink:label="gemp_MembersEarningsMember_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636256379968950626" xlink:to="gemp_MembersEarningsMember_636256379968950626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636256379968950626" xlink:to="us-gaap_CommonStockMember_636256379968950626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636256379968950626" xlink:to="us-gaap_AdditionalPaidInCapitalMember_636256379968950626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636256379968950626" xlink:to="us-gaap_RetainedEarningsMember_636256379968950626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636256379968950626" xlink:to="us-gaap_EquityComponentDomain_636256379968950626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636256379968950626" xlink:to="us-gaap_StatementLineItems_636256379968950626" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968950626" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="us-gaap_StockholdersEquity_636256379968950626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="us-gaap_SharesIssued_636256379968950626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockEffectDuringPeriodValueUponMerger" xlink:label="gemp_StockEffectDuringPeriodValueUponMerger_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="gemp_StockEffectDuringPeriodValueUponMerger_636256379968950626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockEffectDuringPeriodShareUponMerger" xlink:label="gemp_StockEffectDuringPeriodShareUponMerger_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="gemp_StockEffectDuringPeriodShareUponMerger_636256379968950626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockRestrictionDuringPeriodValue" xlink:label="gemp_StockRestrictionDuringPeriodValue_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="gemp_StockRestrictionDuringPeriodValue_636256379968950626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockRestrictionDuringPeriodShares" xlink:label="gemp_StockRestrictionDuringPeriodShares_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="gemp_StockRestrictionDuringPeriodShares_636256379968950626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_636256379968950626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities" xlink:label="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities_636256379968950626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities" xlink:label="gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities_636256379968950626" xlink:to="gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities_636256379968950626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities_636256379968950626" xlink:to="gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity_636256379968950626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_636256379968950626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_636256379968950626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_636256379968950626" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636256379968960626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_636256379968950626" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_636256379968960626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_636256379968960626" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_636256379968960626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_636256379968960626" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636256379968960626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_636256379968960626" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConvertibleNoteExtinguishmentLoss" xlink:label="gemp_ConvertibleNoteExtinguishmentLoss_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="gemp_ConvertibleNoteExtinguishmentLoss_636256379968960626" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_636256379968960626" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_636256379968960626" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_636256379968960626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_636256379968960626" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue_636256379968960626" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="us-gaap_NetIncomeLoss_636256379968960626" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636256379968960626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="us-gaap_StockholdersEquity_636256379968960626" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_636256379968950626" xlink:to="us-gaap_SharesIssued_636256379968970626" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="8" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitTemporaryEquity" xlink:type="extended" xlink:title="00305 - Statement - Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit - Temporary Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_636251160117120233" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_636251160117120233" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636256379968970626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636256379968970626" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_636256379968970626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636256379968970626" xlink:to="us-gaap_TemporaryEquitySharesIssued_636256379968970626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636256379968970626" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_636256379968970626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_636256379968970626" xlink:to="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_636256379968970626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636256379968970626" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_636256379968970626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityConversionOfStock" xlink:label="gemp_TemporaryEquityConversionOfStock_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636256379968970626" xlink:to="gemp_TemporaryEquityConversionOfStock_636256379968970626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityConversionOfStockShares" xlink:label="gemp_TemporaryEquityConversionOfStockShares_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_TemporaryEquityConversionOfStock_636256379968970626" xlink:to="gemp_TemporaryEquityConversionOfStockShares_636256379968970626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6362563799689706261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636256379968970626" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6362563799689706261" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_6362563799689706261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_636256379968970626" xlink:to="us-gaap_TemporaryEquitySharesIssued_6362563799689706261" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable_636256379968970626" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636256379968970626" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis_636256379968970626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_636256379968970626" xlink:to="us-gaap_ConversionOfStockNameDomain_636256379968970626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfSeriesPreferredStockMember" xlink:label="gemp_ConversionOfSeriesPreferredStockMember_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockNameDomain_636256379968970626" xlink:to="gemp_ConversionOfSeriesPreferredStockMember_636256379968970626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636256379968970626" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_636256379968970626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_636256379968970626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis_636256379968970626" xlink:to="us-gaap_DebtConversionNameDomain_636256379968970626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfInterimNotesMember" xlink:label="gemp_ConversionOfInterimNotesMember_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain_636256379968970626" xlink:to="gemp_ConversionOfInterimNotesMember_636256379968980626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfConvertibleNotesMember" xlink:label="gemp_ConversionOfConvertibleNotesMember_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain_636256379968970626" xlink:to="gemp_ConversionOfConvertibleNotesMember_636256379968980626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConversionOfRelatedPartyPromissoryNotesMember" xlink:label="gemp_ConversionOfRelatedPartyPromissoryNotesMember_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain_636256379968970626" xlink:to="gemp_ConversionOfRelatedPartyPromissoryNotesMember_636256379968980626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636256379968970626" xlink:to="us-gaap_BalanceSheetLocationAxis_636256379968980626" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_636256379968980626" xlink:to="us-gaap_BalanceSheetLocationDomain_636256379968980626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_636256379968980626" xlink:to="us-gaap_OtherAssetsMember_636256379968980626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_636256379968980626" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_636256379968980626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636256379968970626" xlink:to="us-gaap_StatementLineItems_636256379968980626" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968980626" xlink:to="us-gaap_NetIncomeLoss_636256379968980626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968980626" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="us-gaap_ShareBasedCompensation_636256379968980626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NonCashInterestOnPromissoryNotesToRelatedParties" xlink:label="gemp_NonCashInterestOnPromissoryNotesToRelatedParties_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="gemp_NonCashInterestOnPromissoryNotesToRelatedParties_636256379968980626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NoncashInterestOnConvertibleNotesToRelatedParties" xlink:label="gemp_NoncashInterestOnConvertibleNotesToRelatedParties_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="gemp_NoncashInterestOnConvertibleNotesToRelatedParties_636256379968980626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NoncashInterestOnConvertibleNotes" xlink:label="gemp_NoncashInterestOnConvertibleNotes_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="gemp_NoncashInterestOnConvertibleNotes_636256379968980626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount" xlink:label="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount_636256379968980626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AmortizationOnConvertibleNotesDiscount" xlink:label="gemp_AmortizationOnConvertibleNotesDiscount_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="gemp_AmortizationOnConvertibleNotesDiscount_636256379968980626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_636256379968980626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_636256379968980626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_636256379968980626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax_636256379968990626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_636256379968990626" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636256379968990626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits" xlink:label="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636256379968990626" xlink:to="gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits_636256379968990626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636256379968990626" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_636256379968990626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636256379968990626" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_636256379968990626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636256379968980626" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636256379968990626" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968980626" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="us-gaap_ProceedsFromConvertibleDebt_636256379968990626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_636256379968990626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="us-gaap_PaymentsOfFinancingCosts_636256379968990626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromRelatedPartyPromissoryNotes" xlink:label="gemp_ProceedsFromRelatedPartyPromissoryNotes_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="gemp_ProceedsFromRelatedPartyPromissoryNotes_636256379968990626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636256379968990626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636256379968990626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636256379969000626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636256379969000626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_636256379969000626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_636256379969000626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_636256379969000626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_636256379969000626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379969000626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636256379969000626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636256379969000626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636256379969000626" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636256379969000626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636256379969000626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6362563799690006261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_636256379968990626" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6362563799690006261" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_636256379969000626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968980626" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_636256379969000626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid_636256379969000626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_636256379969000626" xlink:to="us-gaap_InterestPaid_636256379969000626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379968980626" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1_636256379969010626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" xlink:to="us-gaap_ConversionOfStockAmountIssued1_636256379969010626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_636256379969010626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_636256379969010626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ExerciseOfPremiumConversionDerivative" xlink:label="gemp_ExerciseOfPremiumConversionDerivative_636256379969010626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" xlink:to="gemp_ExerciseOfPremiumConversionDerivative_636256379969010626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_636256379969010626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_636256379969010626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_636256379969010626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1_636256379969010626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes" xlink:label="gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes_636256379969010626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" xlink:to="gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes_636256379969010626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_636256379969010626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_636256379969010626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment" xlink:label="gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment_636256379969010626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" xlink:to="gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment_636256379969010626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_636256379969010626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_636256379969010626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1_636256379969020626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636256379969000626" xlink:to="us-gaap_LiabilitiesAssumed1_636256379969020626" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - The Company and Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_636256379969020626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_636256379969020626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_636256379969020626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_636256379969020626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureAccruedLiabilities" xlink:type="extended" xlink:title="10301 - Disclosure - Accrued Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_636256379969020626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_636256379969020626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureDebt" xlink:type="extended" xlink:title="10401 - Disclosure - Debt" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_636256379969020626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_636256379969020626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10501 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636256379969020626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636256379969020626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureLicenseAgreement" xlink:type="extended" xlink:title="10601 - Disclosure - License Agreement" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LicenseAgreementDisclosureAbstract" xlink:label="gemp_LicenseAgreementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_636256379969020626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_LicenseAgreementDisclosureAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_636256379969020626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureConvertibleSeriesPreferredStock" xlink:type="extended" xlink:title="10701 - Disclosure - Convertible Series A Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityDisclosureTextBlock" xlink:label="gemp_TemporaryEquityDisclosureTextBlock_636256379969030626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="gemp_TemporaryEquityDisclosureTextBlock_636256379969030626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersAndMembersEquityDeficit" xlink:type="extended" xlink:title="10801 - Disclosure - Stockholders&#x2019; and Members&#x2019; Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_636256379969030626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_636256379969030626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="10901 - Disclosure - Share-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_636256379969030626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_636256379969030626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureNetLossPerCommonShare" xlink:type="extended" xlink:title="11001 - Disclosure - Net Loss Per Common Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_636256379969030626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_636256379969030626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="11101 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_636256379969030626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_636256379969030626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11201 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_636256379969030626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_636256379969030626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnaudited" xlink:type="extended" xlink:title="11301 - Disclosure - Supplementary Data &#x2014; Quarterly Financial Data (unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_636256379969030626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_636256379969030626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11401 - Disclosure - Related Party Transactions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_636256379969030626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_636256379969030626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11501 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_636256379969040626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts" xlink:type="extended" xlink:title="11601 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:to="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_636256379969040626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_636256379969040626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_636256379969040626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_636256379969040626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_636256379969040626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_636256379969040626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_636256379969040626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_636256379969040626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_636256379969040626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_636256379969040626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_636256379969040626" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_636256379969040626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock" xlink:label="gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock_636256379969040626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock_636256379969040626" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636256379969050626" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureAccruedLiabilitiesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Accrued Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_636256379969050626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30503 - Disclosure - Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_636256379969050626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - Share-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636136307231956399" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636136307231956399" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636256379969050626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636136307231956399" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_636256379969050626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636136307231956399" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_636256379969050626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636136307231956399" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_636256379969050626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareTables" xlink:type="extended" xlink:title="31003 - Disclosure - Net Loss Per Common Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_636256379969050626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636256379969050626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="31103 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_636256379969050626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_636256379969050626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31203 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_636256379969050626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_636256379969050626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_636256379969060626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedTables" xlink:type="extended" xlink:title="31303 - Disclosure - Supplementary Data &#x2014; Quarterly Financial Data (unaudited) (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:label="us-gaap_QuarterlyFinancialDataAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_636256379969060626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationIpoAndCapitalRequirementsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - The Company and Basis of Presentation (IPO and Capital Requirements) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_636256379969060626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_636256379969060626" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636256379969060626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636256379969060626" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969060626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969060626" xlink:to="us-gaap_IPOMember_636256379969060626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969060626" xlink:to="us-gaap_OverAllotmentOptionMember_636256379969060626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_636256379969060626" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_636256379969060626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_636256379969060626" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636256379969060626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_636256379969060626" xlink:to="us-gaap_SharePrice_636256379969060626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_636256379969060626" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_636256379969060626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_636256379969060626" xlink:to="us-gaap_PaymentsForUnderwritingExpense_636256379969060626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_636256379969060626" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_636256379969060626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_636256379969060626" xlink:to="us-gaap_CommonStockSharesAuthorized_636256379969060626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_636256379969060626" xlink:to="us-gaap_PreferredStockSharesAuthorized_636256379969060626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_636256379969060626" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_636256379969060626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636256379969060626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_636256379969060626" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636256379969060626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationBasisOfPresentationDetails" xlink:type="extended" xlink:title="40102 - Disclosure - The Company and Basis of Presentation (Basis of Presentation) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_636256379969070626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_636256379969070626" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_636256379969070626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_636256379969070626" xlink:to="us-gaap_TypeOfAdoptionMember_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingStandardsUpdate201517Member" xlink:label="us-gaap_AccountingStandardsUpdate201517Member_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_636256379969070626" xlink:to="us-gaap_AccountingStandardsUpdate201517Member_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionAxis" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_636256379969070626" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_636256379969070626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPrinciplesEarlyAdoptionMember" xlink:label="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementEarlyAdoptionAxis_636256379969070626" xlink:to="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember" xlink:label="us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPrinciplesEarlyAdoptionMember_636256379969070626" xlink:to="us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_636256379969070626" xlink:to="us-gaap_StatementScenarioAxis_636256379969070626" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_636256379969070626" xlink:to="us-gaap_ScenarioUnspecifiedDomain_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="us-gaap_ScenarioAdjustmentMember_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_636256379969070626" xlink:to="us-gaap_ScenarioAdjustmentMember_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_636256379969070626" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_636256379969070626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesCurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesCurrent_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_636256379969070626" xlink:to="us-gaap_DeferredTaxLiabilitiesCurrent_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_636256379969070626" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_636256379969070626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_636256379969070626" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_636256379969070626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_636256379969070626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636256379969070626" xlink:to="us-gaap_StatementScenarioAxis_636256379969070626" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_636256379969070626" xlink:to="us-gaap_ScenarioUnspecifiedDomain_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PredecessorMember" xlink:label="us-gaap_PredecessorMember_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_636256379969070626" xlink:to="us-gaap_PredecessorMember_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636256379969070626" xlink:to="us-gaap_StatementClassOfStockAxis_636256379969070626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636256379969070626" xlink:to="us-gaap_ClassOfStockDomain_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636256379969070626" xlink:to="us-gaap_ConvertiblePreferredStockMember_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636256379969070626" xlink:to="us-gaap_StatementLineItems_636256379969070626" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_636256379969070626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379969070626" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_636256379969070626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_636256379969070626" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636256379969080626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379969070626" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636256379969080626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636256379969080626" xlink:to="us-gaap_TemporaryEquitySharesIssued_636256379969080626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636256379969080626" xlink:to="us-gaap_ConversionOfStockSharesIssued1_636256379969080626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_636256379969080626" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_636256379969080626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationAdditionalInformationAbstract" xlink:label="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379969070626" xlink:to="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_636256379969080626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationAdditionalInformationAbstract_636256379969080626" xlink:to="us-gaap_NumberOfOperatingSegments_636256379969080626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureAccruedLiabilitiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Accrued Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_636054634929106134" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AccruedOfferingCostsCurrent" xlink:label="gemp_AccruedOfferingCostsCurrent_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_636054634929106134" xlink:to="gemp_AccruedOfferingCostsCurrent_636256379969080626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_636054634929106134" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_636256379969080626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_636054634929106134" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_636256379969080626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AccruedOtherResearchAndDevelopmentExpenses" xlink:label="gemp_AccruedOtherResearchAndDevelopmentExpenses_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_636054634929106134" xlink:to="gemp_AccruedOtherResearchAndDevelopmentExpenses_636256379969080626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AccruedOtherGeneralAndAdministrativeExpenses" xlink:label="gemp_AccruedOtherGeneralAndAdministrativeExpenses_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_636054634929106134" xlink:to="gemp_AccruedOtherGeneralAndAdministrativeExpenses_636256379969080626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_636054634929106134" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636256379969080626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureDebtDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Debt (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_636256379969080626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636256379969080626" xlink:to="us-gaap_DebtInstrumentAxis_636256379969080626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636256379969080626" xlink:to="us-gaap_DebtInstrumentNameDomain_636256379969080626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="us-gaap_NotesPayableOtherPayablesMember_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636256379969080626" xlink:to="us-gaap_NotesPayableOtherPayablesMember_636256379969080626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SeriesaPreferredConvertibleDebtMember" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember_636256379969080626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636256379969080626" xlink:to="gemp_SeriesaPreferredConvertibleDebtMember_636256379969080626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_FinancingConvertibleDebtMember" xlink:label="gemp_FinancingConvertibleDebtMember_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636256379969080626" xlink:to="gemp_FinancingConvertibleDebtMember_636256379969090626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636256379969080626" xlink:to="us-gaap_IncomeStatementLocationAxis_636256379969090626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636256379969090626" xlink:to="us-gaap_IncomeStatementLocationDomain_636256379969090626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InterestIncomeExpenseNetMember" xlink:label="gemp_InterestIncomeExpenseNetMember_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636256379969090626" xlink:to="gemp_InterestIncomeExpenseNetMember_636256379969090626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636256379969080626" xlink:to="us-gaap_DebtInstrumentLineItems_636256379969090626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_636256379969090626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="us-gaap_DebtInstrumentFaceAmount_636256379969090626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_636256379969090626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="us-gaap_ProceedsFromConvertibleDebt_636256379969090626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" xlink:label="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal_636256379969090626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_636256379969090626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="us-gaap_ConversionOfStockSharesIssued1_636256379969090626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold" xlink:label="gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold_636256379969090626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_636256379969090626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount" xlink:label="gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount_636256379969090626" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_636256379969090626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_636256379969090626" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_636256379969090626" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636256379969090626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636256379969090626" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636256379969090626" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPfizerLicenseAgreementDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Commitments and Contigencies - Pfizer License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969100626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969100626" xlink:to="us-gaap_CounterpartyNameAxis_636256379969100626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636256379969100626" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636256379969100626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PfizerInc.Member" xlink:label="gemp_PfizerInc.Member_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636256379969100626" xlink:to="gemp_PfizerInc.Member_636256379969100626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969100626" xlink:to="us-gaap_TypeOfArrangementAxis_636256379969100626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636256379969100626" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636256379969100626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LicenseAgreementMember" xlink:label="gemp_LicenseAgreementMember_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636256379969100626" xlink:to="gemp_LicenseAgreementMember_636256379969100626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969100626" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636256379969100626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636256379969100626" xlink:to="us-gaap_Liabilities_636256379969100626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPreferredStockDividendsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Commitments and Contigencies - Preferred Stock Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_636256379969100626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636256379969100626" xlink:to="us-gaap_StatementClassOfStockAxis_636256379969100626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636256379969100626" xlink:to="us-gaap_ClassOfStockDomain_636256379969100626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636256379969100626" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_636256379969100626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636256379969100626" xlink:to="us-gaap_TemporaryEquityLineItems_636256379969100626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_636256379969100626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969100626" xlink:to="us-gaap_PreferredStockDividendRatePercentage_636256379969100626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_636256379969110626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969100626" xlink:to="us-gaap_SharesIssuedPricePerShare_636256379969110626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_636256379969110626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969100626" xlink:to="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_636256379969110626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_636256379969110626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969100626" xlink:to="us-gaap_ConversionOfStockSharesIssued1_636256379969110626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesOtherAgreementsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Commitments and Contigencies - Other Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_636208801556036008" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969110626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_636208801556036008" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969110626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_636256379969110626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969110626" xlink:to="us-gaap_RelatedPartyTransactionAxis_636256379969110626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_636256379969110626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_636256379969110626" xlink:to="us-gaap_RelatedPartyTransactionDomain_636256379969110626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OfficeRentalMember" xlink:label="gemp_OfficeRentalMember_636256379969110626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_636256379969110626" xlink:to="gemp_OfficeRentalMember_636256379969110626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_636256379969130626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969110626" xlink:to="us-gaap_RelatedPartyTransactionLineItems_636256379969130626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_636256379969130626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969130626" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_636256379969130626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_636256379969130626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969130626" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_636256379969130626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense_636256379969130626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969130626" xlink:to="us-gaap_LeaseAndRentalExpense_636256379969130626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636256379969130626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969130626" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636256379969130626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636256379969130626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636256379969130626" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_636256379969130626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636256379969130626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636256379969130626" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_636256379969130626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636256379969130626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636256379969130626" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_636256379969130626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_636256379969130626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_636256379969130626" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_636256379969130626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureLicenseAgreementDetails" xlink:type="extended" xlink:title="40601 - Disclosure - License Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LicenseAgreementDisclosureAbstract" xlink:label="gemp_LicenseAgreementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gemp_LicenseAgreementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969140626" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969140626" xlink:to="us-gaap_CounterpartyNameAxis_636256379969140626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_636256379969140626" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636256379969140626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PfizerInc.Member" xlink:label="gemp_PfizerInc.Member_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_636256379969140626" xlink:to="gemp_PfizerInc.Member_636256379969140626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969140626" xlink:to="us-gaap_TypeOfArrangementAxis_636256379969140626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636256379969140626" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636256379969140626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LicenseAgreementMember" xlink:label="gemp_LicenseAgreementMember_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636256379969140626" xlink:to="gemp_LicenseAgreementMember_636256379969140626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969140626" xlink:to="us-gaap_OtherCommitmentsAxis_636256379969140626" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_636256379969140626" xlink:to="us-gaap_OtherCommitmentsDomain_636256379969140626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_MilestonePaymentsMember" xlink:label="gemp_MilestonePaymentsMember_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_636256379969140626" xlink:to="gemp_MilestonePaymentsMember_636256379969140626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969140626" xlink:to="us-gaap_StatementEquityComponentsAxis_636256379969140626" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636256379969140626" xlink:to="us-gaap_EquityComponentDomain_636256379969140626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636256379969140626" xlink:to="us-gaap_CommonStockMember_636256379969140626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969140626" xlink:to="us-gaap_RangeAxis_636256379969140626" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636256379969140626" xlink:to="us-gaap_RangeMember_636256379969140626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636256379969140626" xlink:to="us-gaap_MinimumMember_636256379969140626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636256379969140626" xlink:to="us-gaap_MaximumMember_636256379969140626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_636256379969140626" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636256379969140626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SharesIssuablePercentageOfOffering" xlink:label="gemp_SharesIssuablePercentageOfOffering_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636256379969140626" xlink:to="gemp_SharesIssuablePercentageOfOffering_636256379969140626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ContingentLiability" xlink:label="gemp_ContingentLiability_636256379969140626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636256379969140626" xlink:to="gemp_ContingentLiability_636256379969140626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636256379969140626" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636256379969150626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636256379969140626" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_636256379969150626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_636256379969140626" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_636256379969150626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureConvertibleSeriesPreferredStockDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Convertible Series A Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_636058329478457802" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract_636058329478457802" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_636256379969150626" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636256379969150626" xlink:to="us-gaap_StatementClassOfStockAxis_636256379969150626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636256379969150626" xlink:to="us-gaap_ClassOfStockDomain_636256379969150626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636256379969150626" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_636256379969150626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636256379969150626" xlink:to="us-gaap_DebtInstrumentAxis_636256379969150626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636256379969150626" xlink:to="us-gaap_DebtInstrumentNameDomain_636256379969150626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SeriesaPreferredConvertibleDebtMember" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636256379969150626" xlink:to="gemp_SeriesaPreferredConvertibleDebtMember_636256379969150626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636256379969150626" xlink:to="us-gaap_RangeAxis_636256379969150626" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636256379969150626" xlink:to="us-gaap_RangeMember_636256379969150626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636256379969150626" xlink:to="us-gaap_MinimumMember_636256379969150626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_636256379969150626" xlink:to="us-gaap_TemporaryEquityLineItems_636256379969150626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_636256379969150626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="us-gaap_SharesIssuedPricePerShare_636256379969150626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross" xlink:label="gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross_636256379969150626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636256379969150626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_636256379969150626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_636256379969160626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal" xlink:label="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal_636256379969160626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="us-gaap_ConversionOfStockSharesIssued1_636256379969160626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="us-gaap_PreferredStockDividendRatePercentage_636256379969160626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_636256379969160626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_636256379969160626" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LiquidationPreferencePercentageOfChangeInVoting" xlink:label="gemp_LiquidationPreferencePercentageOfChangeInVoting_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="gemp_LiquidationPreferencePercentageOfChangeInVoting_636256379969160626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PreferredStockRedemptionRequestedByPercentageOfShares" xlink:label="gemp_PreferredStockRedemptionRequestedByPercentageOfShares_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="gemp_PreferredStockRedemptionRequestedByPercentageOfShares_636256379969160626" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_RedemptionPricePercentageOfLiquidationPreference" xlink:label="gemp_RedemptionPricePercentageOfLiquidationPreference_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="gemp_RedemptionPricePercentageOfLiquidationPreference_636256379969160626" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_636256379969150626" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_636256379969160626" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureStockholdersAndMembersEquityDeficitDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Stockholders&#x2019; and Members&#x2019; Equity (Deficit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable_636256379969160626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636256379969160626" xlink:to="us-gaap_StatementEquityComponentsAxis_636256379969160626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_636256379969160626" xlink:to="us-gaap_EquityComponentDomain_636256379969160626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_636256379969160626" xlink:to="us-gaap_CommonStockMember_636256379969160626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636256379969160626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636256379969160626" xlink:to="us-gaap_StatementLineItems_636256379969160626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379969160626" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_636256379969170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379969160626" xlink:to="us-gaap_CommonStockSharesIssued_636256379969170626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379969160626" xlink:to="us-gaap_CommonStockSharesOutstanding_636256379969170626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_CumulativeDividendsDeclared" xlink:label="gemp_CumulativeDividendsDeclared_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379969160626" xlink:to="gemp_CumulativeDividendsDeclared_636256379969170626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_CommonStockVotingRightsPerShare" xlink:label="gemp_CommonStockVotingRightsPerShare_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379969160626" xlink:to="gemp_CommonStockVotingRightsPerShare_636256379969170626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379969160626" xlink:to="us-gaap_PreferredStockSharesOutstanding_636256379969170626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636256379969160626" xlink:to="us-gaap_DeferredOfferingCosts_636256379969170626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Share-Based Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636256379969170626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636256379969170626" xlink:to="us-gaap_IncomeStatementLocationAxis_636256379969170626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636256379969170626" xlink:to="us-gaap_IncomeStatementLocationDomain_636256379969170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636256379969170626" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_636256379969170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636256379969170626" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_636256379969170626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636256379969170626" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636256379969170626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636256379969170626" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_636256379969170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureShareBasedCompensationRestrictedStockDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Share-Based Compensation (Restricted Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636058284398877802" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636058284398877802" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969170626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969170626" xlink:to="us-gaap_RangeAxis_636256379969170626" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636256379969170626" xlink:to="us-gaap_RangeMember_636256379969170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636256379969170626" xlink:to="us-gaap_MinimumMember_636256379969170626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636256379969170626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636256379969170626" xlink:to="us-gaap_MaximumMember_636256379969170626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969170626" xlink:to="us-gaap_AwardTypeAxis_636256379969180626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379969180626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379969180626" xlink:to="us-gaap_RestrictedStockMember_636256379969180626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969170626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969180626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636256379969180626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636256379969180626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_636256379969180626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_636256379969180626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636256379969180626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_636256379969180626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_636256379969180626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_636256379969180626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6362563799691806261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6362563799691806261" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636256379969180626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_636256379969180626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636256379969180626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_636256379969180626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_636256379969180626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6362563799691806261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_636256379969180626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6362563799691806261" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureShareBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="40903 - Disclosure - Share-Based Compensation (Stock Options) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636058287545377802" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636058287545377802" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969190626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969190626" xlink:to="us-gaap_AwardTypeAxis_636256379969190626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_636256379969190626" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379969190626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379969190626" xlink:to="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember_636256379969190626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379969190626" xlink:to="us-gaap_RestrictedStockMember_636256379969190626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969190626" xlink:to="us-gaap_PlanNameAxis_636256379969190626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_636256379969190626" xlink:to="us-gaap_PlanNameDomain_636256379969190626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember" xlink:label="gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636256379969190626" xlink:to="gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember_636256379969190626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EquityIncentivePlan2015Member" xlink:label="gemp_EquityIncentivePlan2015Member_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636256379969190626" xlink:to="gemp_EquityIncentivePlan2015Member_636256379969190626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InducementPlanMember" xlink:label="gemp_InducementPlanMember_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636256379969190626" xlink:to="gemp_InducementPlanMember_636256379969190626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969190626" xlink:to="us-gaap_TitleOfIndividualAxis_636256379969190626" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis_636256379969190626" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636256379969190626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OfficersDirectorsAndEmployeesMember" xlink:label="gemp_OfficersDirectorsAndEmployeesMember_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636256379969190626" xlink:to="gemp_OfficersDirectorsAndEmployeesMember_636256379969190626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OfficersAndEmployeesMember" xlink:label="gemp_OfficersAndEmployeesMember_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636256379969190626" xlink:to="gemp_OfficersAndEmployeesMember_636256379969190626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EmployeesDirectorsAndConsultantsMember" xlink:label="gemp_EmployeesDirectorsAndConsultantsMember_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636256379969190626" xlink:to="gemp_EmployeesDirectorsAndConsultantsMember_636256379969190626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969190626" xlink:to="us-gaap_RangeAxis_636256379969190626" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636256379969190626" xlink:to="us-gaap_RangeMember_636256379969190626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636256379969190626" xlink:to="us-gaap_MinimumMember_636256379969190626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636256379969190626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636256379969190626" xlink:to="us-gaap_MaximumMember_636256379969190626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969200626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969190626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969200626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636256379969200626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969200626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636256379969200626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636256379969200626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636256379969200626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636256379969200626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636256379969200626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636256379969200626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636256379969200626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636256379969200626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636256379969200626" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_636256379969200626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_636256379969200626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636256379969200626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_636256379969200626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6362563799692006261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636256379969200626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6362563799692006261" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_636256379969200626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636256379969200626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_636256379969200626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_636256379969200626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636256379969200626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_636256379969200626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636256379969210626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969200626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636256379969210626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636256379969210626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636256379969210626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636256379969210626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636256379969210626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_636256379969210626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_636256379969210626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_636256379969210626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_636256379969210626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6362563799692106261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6362563799692106261" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_636256379969210626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_636256379969210626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_636256379969210626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_636256379969210626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969200626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_636256379969210626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_636256379969210626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_636256379969210626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_636256379969210626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_636256379969220626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_636256379969220626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_636256379969220626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_636256379969220626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_636256379969220626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_636256379969220626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_636256379969220626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_636256379969220626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636256379969220626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636256379969220626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636256379969220626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636256379969220626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_636256379969220626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_636256379969220626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636256379969220626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636256379969220626" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross" xlink:label="gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_636256379969220626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross_636256379969220626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_636256379969220626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_636256379969220626" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636256379969230626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636256379969230626" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636256379969230626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_636256379969210626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636256379969230626" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636256379969230626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969200626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636256379969230626" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636256379969230626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636256379969230626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636256379969230626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636256379969230626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636256379969230626" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636256379969230626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_636256379969230626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636256379969230626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_636256379969230626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_636256379969230626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_636256379969230626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_636256379969230626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureShareBasedCompensationUnrecognizedDetails" xlink:type="extended" xlink:title="40904 - Disclosure - Share-Based Compensation (Unrecognized) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636058987687111319" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636058987687111319" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969240626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969240626" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636256379969240626" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636256379969240626" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969240626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969240626" xlink:to="us-gaap_EmployeeStockMember_636256379969240626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969240626" xlink:to="us-gaap_AwardTypeAxis_636256379969240626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_636256379969240626" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379969240626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379969240626" xlink:to="us-gaap_RestrictedStockMember_636256379969240626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636256379969240626" xlink:to="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember_636256379969240626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636256379969240626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969240626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636256379969240626" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_636256379969240626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_636256379969240626" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_636256379969240626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_636256379969240626" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_636256379969240626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_636256379969240626" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636256379969240626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_636256379969240626" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_636256379969240626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_636256379969240626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636256379969240626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_636256379969240626" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636256379969240626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Net Loss Per Common Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_636256379969240626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis_636256379969240626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_636256379969240626" xlink:to="us-gaap_StatementScenarioAxis_636256379969240626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis_636256379969240626" xlink:to="us-gaap_ScenarioUnspecifiedDomain_636256379969250626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PredecessorMember" xlink:label="us-gaap_PredecessorMember_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain_636256379969250626" xlink:to="us-gaap_PredecessorMember_636256379969250626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_636256379969240626" xlink:to="us-gaap_EarningsPerShareBasicLineItems_636256379969250626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_636256379969250626" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_636256379969250626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_636256379969250626" xlink:to="us-gaap_CommonStockSharesOutstanding_636256379969250626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_636256379969250626" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_636256379969250626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareEarningPerShareDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Net Loss Per Common Share - Earning Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareReconciliationAbstract_636256379969250626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract_636256379969250626" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_636256379969250626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_636256379969250626" xlink:to="us-gaap_NetIncomeLoss_636256379969250626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_636256379969250626" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_636256379969250626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConvertibleNotesPremiumUponSubstantialModificationValue" xlink:label="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_636256379969250626" xlink:to="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_636256379969250626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_636256379969250626" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636256379969250626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract_636256379969250626" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_636256379969250626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_636256379969250626" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636256379969250626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_636256379969250626" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636256379969250626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636256379969250626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636256379969250626" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636256379969250626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636256379969250626" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636256379969250626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636256379969250626" xlink:to="us-gaap_RestrictedStockMember_636256379969250626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EmployeeConsultantsAndDirectorsStockOptionsMember" xlink:label="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember_636256379969250626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636256379969250626" xlink:to="gemp_EmployeeConsultantsAndDirectorsStockOptionsMember_636256379969250626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636256379969250626" xlink:to="us-gaap_ConvertiblePreferredStockMember_636256379969260626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636256379969250626" xlink:to="us-gaap_ConvertibleNotesPayableMember_636256379969260626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636256379969250626" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636256379969260626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636256379969260626" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636256379969260626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Fair Value Measurements - Financial Instruments Measured On Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_636060785242385563" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_636060785242385563" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636256379969260626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636256379969260626" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_636256379969260626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_636256379969260626" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_636256379969260626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_636256379969260626" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_636256379969260626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_636256379969260626" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_636256379969260626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636256379969260626" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_636256379969260626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_636256379969260626" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636256379969260626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_636256379969260626" xlink:to="us-gaap_FairValueInputsLevel3Member_636256379969260626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636256379969260626" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636256379969260626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount" xlink:label="gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636256379969260626" xlink:to="gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount_636256379969260626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636256379969260626" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_636256379969260626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636256379969260626" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_636256379969260626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_636256379969260626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_636256379969260626" xlink:to="us-gaap_FairValueByLiabilityClassAxis_636256379969260626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636256379969260626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_636256379969260626" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636256379969260626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:label="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636256379969260626" xlink:to="us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_636256379969270626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_636256379969260626" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_636256379969270626" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_636256379969270626" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636256379969270626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636256379969270626" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_636256379969270626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636256379969270626" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_636256379969270626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636256379969270626" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636256379969270626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal" xlink:label="gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636256379969270626" xlink:to="gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal_636256379969270626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636256379969270626" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_636256379969270626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6362563799692706261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636256379969270626" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6362563799692706261" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_636256379969270626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636256379969270626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Income Taxes - Reconciliation of income tax (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636256379969270626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636256379969270626" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_636256379969270626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636256379969270626" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_636256379969270626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636256379969270626" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_636256379969270626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes" xlink:label="gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636256379969270626" xlink:to="gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes_636256379969270626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636256379969270626" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_636256379969270626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636256379969270626" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_636256379969270626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_636256379969270626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_636256379969270626" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_636256379969270626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitieDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Income Taxes -Significant components of deferred tax assets and liabilitie (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636256379969280626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636256379969280626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636256379969280626" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636256379969280626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_636256379969280626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636256379969280626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_636256379969280626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DeferredTaxAssetsAcquiredIntangibles" xlink:label="gemp_DeferredTaxAssetsAcquiredIntangibles_636256379969280626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" xlink:to="gemp_DeferredTaxAssetsAcquiredIntangibles_636256379969280626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_636256379969280626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_636256379969280626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DeferredTaxAssetsConvertibleNotes" xlink:label="gemp_DeferredTaxAssetsConvertibleNotes_636256379969280626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" xlink:to="gemp_DeferredTaxAssetsConvertibleNotes_636256379969280626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_636256379969280626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" xlink:to="us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards_636256379969280626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_636256379969280626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_636256379969280626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_636256379969280626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_636256379969280626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_636256379969280626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" xlink:to="us-gaap_DeferredTaxAssetsGross_636256379969280626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_636256379969290626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_636256379969290626" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_636256379969290626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_636256379969280626" xlink:to="us-gaap_DeferredTaxAssetsNet_636256379969290626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_636256379969290626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_636256379969280626" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_636256379969290626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DeferredTaxLiabilitiesRestrictedStockAwards" xlink:label="gemp_DeferredTaxLiabilitiesRestrictedStockAwards_636256379969290626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_636256379969290626" xlink:to="gemp_DeferredTaxLiabilitiesRestrictedStockAwards_636256379969290626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_636256379969290626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_636256379969290626" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_636256379969290626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_636256379969290626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_636256379969290626" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_636256379969290626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Income Taxes - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_636256379969290626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_636256379969290626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_636256379969290626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_636256379969290626" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_636256379969290626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_636256379969290626" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_636256379969300626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_636256379969290626" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_636256379969300626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DeferredTaxAssetsTaxCreditCarryforwardsState" xlink:label="gemp_DeferredTaxAssetsTaxCreditCarryforwardsState_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_636256379969290626" xlink:to="gemp_DeferredTaxAssetsTaxCreditCarryforwardsState_636256379969300626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_636256379969300626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ThresholdPercentageOfShareholdersOwnershipChange" xlink:label="gemp_ThresholdPercentageOfShareholdersOwnershipChange_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_636256379969300626" xlink:to="gemp_ThresholdPercentageOfShareholdersOwnershipChange_636256379969300626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits" xlink:label="gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_636256379969300626" xlink:to="gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits_636256379969300626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_PeriodForTestingPercentageOfOwnershipChange" xlink:label="gemp_PeriodForTestingPercentageOfOwnershipChange_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_636256379969300626" xlink:to="gemp_PeriodForTestingPercentageOfOwnershipChange_636256379969300626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_636256379969300626" xlink:to="us-gaap_UnrecognizedTaxBenefits_636256379969300626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_636256379969300626" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_636256379969300626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Supplementary Data &#x2014; Quarterly Financial Data (unaudited) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_QuarterlyFinancialDataAbstract" xlink:label="us-gaap_QuarterlyFinancialDataAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_636256379969300626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636256379969300626" xlink:to="us-gaap_GeneralAndAdministrativeExpense_636256379969300626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636256379969300626" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_636256379969300626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636256379969300626" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_636256379969300626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636256379969300626" xlink:to="us-gaap_CostsAndExpenses_636256379969300626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_OperatingIncomeLoss_636256379969300626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet_636256379969300626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_636256379969300626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_636256379969300626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636256379969300626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636256379969300626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636256379969300626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_NetIncomeLoss_636256379969310626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_636256379969310626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_6362563799693106261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_NetIncomeLoss_6362563799693106261" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_636256379969310626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ConvertibleNotesPremiumUponSubstantialModificationValue" xlink:label="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="gemp_ConvertibleNotesPremiumUponSubstantialModificationValue_636256379969310626" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636256379969310626" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636256379969310626" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_636256379969310626" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636256379969310626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialDataAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_636256379969310626" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_636256379969310626" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636256379969310626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsRentalAgreementDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Related Party Transactions - Rental agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969310626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969310626" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969310626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969310626" xlink:to="us-gaap_RelatedPartyDomain_636256379969310626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_LlcOwnedByTwoOfficersMember" xlink:label="gemp_LlcOwnedByTwoOfficersMember_636256379969310626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969310626" xlink:to="gemp_LlcOwnedByTwoOfficersMember_636256379969310626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969310626" xlink:to="us-gaap_RelatedPartyTransactionAxis_636256379969320626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_636256379969320626" xlink:to="us-gaap_RelatedPartyTransactionDomain_636256379969320626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OfficeRentalMember" xlink:label="gemp_OfficeRentalMember_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_636256379969320626" xlink:to="gemp_OfficeRentalMember_636256379969320626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969310626" xlink:to="us-gaap_RelatedPartyTransactionLineItems_636256379969320626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfOfficersInRelatedPartyTransaction" xlink:label="gemp_NumberOfOfficersInRelatedPartyTransaction_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969320626" xlink:to="gemp_NumberOfOfficersInRelatedPartyTransaction_636256379969320626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969320626" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_636256379969320626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969320626" xlink:to="us-gaap_PrepaidRent_636256379969320626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsConvertibleNotesDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Related Party Transactions - Convertible Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969320626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969320626" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969320626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969320626" xlink:to="us-gaap_RelatedPartyDomain_636256379969320626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToBoardMemberAndOfficersMember" xlink:label="gemp_InvestorsRelatedToBoardMemberAndOfficersMember_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969320626" xlink:to="gemp_InvestorsRelatedToBoardMemberAndOfficersMember_636256379969320626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoOfficersMember" xlink:label="gemp_TwoOfficersMember_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969320626" xlink:to="gemp_TwoOfficersMember_636256379969320626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969320626" xlink:to="us-gaap_RelatedPartyTransactionAxis_636256379969320626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_636256379969320626" xlink:to="us-gaap_RelatedPartyTransactionDomain_636256379969320626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtIssuedToRelatedPartiesMember" xlink:label="gemp_DebtIssuedToRelatedPartiesMember_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_636256379969320626" xlink:to="gemp_DebtIssuedToRelatedPartiesMember_636256379969320626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636256379969320626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969320626" xlink:to="us-gaap_DebtInstrumentAxis_636256379969320626" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636256379969330626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636256379969320626" xlink:to="us-gaap_DebtInstrumentNameDomain_636256379969330626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SeriesaPreferredConvertibleDebtMember" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember_636256379969330626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636256379969330626" xlink:to="gemp_SeriesaPreferredConvertibleDebtMember_636256379969330626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636256379969330626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969320626" xlink:to="us-gaap_StatementClassOfStockAxis_636256379969330626" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636256379969330626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636256379969330626" xlink:to="us-gaap_ClassOfStockDomain_636256379969330626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_636256379969330626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636256379969330626" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_636256379969330626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_636256379969330626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969320626" xlink:to="us-gaap_RelatedPartyTransactionLineItems_636256379969330626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_636256379969330626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969330626" xlink:to="us-gaap_ProceedsFromConvertibleDebt_636256379969330626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfDebtInstrumentsIssued" xlink:label="gemp_NumberOfDebtInstrumentsIssued_636256379969330626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969330626" xlink:to="gemp_NumberOfDebtInstrumentsIssued_636256379969330626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfBoardMembersInRelatedPartyTransaction" xlink:label="gemp_NumberOfBoardMembersInRelatedPartyTransaction_636256379969440626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969330626" xlink:to="gemp_NumberOfBoardMembersInRelatedPartyTransaction_636256379969440626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfOfficersInRelatedPartyTransaction" xlink:label="gemp_NumberOfOfficersInRelatedPartyTransaction_636256379969440626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969330626" xlink:to="gemp_NumberOfOfficersInRelatedPartyTransaction_636256379969440626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_636256379969440626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969330626" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_636256379969440626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsInterimNotesDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Related Party Transactions - Interim Notes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969450626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969450626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969450626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969450626" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969450626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636256379969450626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969450626" xlink:to="us-gaap_RelatedPartyDomain_636256379969450626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoOfficersAndThreeBoardMembersInvestorsMember" xlink:label="gemp_TwoOfficersAndThreeBoardMembersInvestorsMember_636256379969450626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969450626" xlink:to="gemp_TwoOfficersAndThreeBoardMembersInvestorsMember_636256379969450626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember" xlink:label="gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember_636256379969450626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969450626" xlink:to="gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember_636256379969450626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoOfficersAndFourBoardMembersInvestorsMember" xlink:label="gemp_TwoOfficersAndFourBoardMembersInvestorsMember_636256379969450626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969450626" xlink:to="gemp_TwoOfficersAndFourBoardMembersInvestorsMember_636256379969450626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToThreeOfficersMember" xlink:label="gemp_InvestorsRelatedToThreeOfficersMember_636256379969450626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969450626" xlink:to="gemp_InvestorsRelatedToThreeOfficersMember_636256379969450626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_TwoBoardMembersInvestorsMember" xlink:label="gemp_TwoBoardMembersInvestorsMember_636256379969450626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969450626" xlink:to="gemp_TwoBoardMembersInvestorsMember_636256379969450626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_636256379969450626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969450626" xlink:to="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_636256379969450626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToTwoOfficersMember" xlink:label="gemp_InvestorsRelatedToTwoOfficersMember_636256379969450626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969450626" xlink:to="gemp_InvestorsRelatedToTwoOfficersMember_636256379969450626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_InvestorsRelatedToThreeDirectorsMember" xlink:label="gemp_InvestorsRelatedToThreeDirectorsMember_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969450626" xlink:to="gemp_InvestorsRelatedToThreeDirectorsMember_636256379969460626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969450626" xlink:to="us-gaap_RelatedPartyTransactionAxis_636256379969460626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_636256379969460626" xlink:to="us-gaap_RelatedPartyTransactionDomain_636256379969460626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_DebtIssuedToRelatedPartiesMember" xlink:label="gemp_DebtIssuedToRelatedPartiesMember_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_636256379969460626" xlink:to="gemp_DebtIssuedToRelatedPartiesMember_636256379969460626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969450626" xlink:to="us-gaap_DebtInstrumentAxis_636256379969460626" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636256379969460626" xlink:to="us-gaap_DebtInstrumentNameDomain_636256379969460626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_FinancingConvertibleDebtMember" xlink:label="gemp_FinancingConvertibleDebtMember_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636256379969460626" xlink:to="gemp_FinancingConvertibleDebtMember_636256379969460626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_SeriesaPreferredConvertibleDebtMember" xlink:label="gemp_SeriesaPreferredConvertibleDebtMember_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636256379969460626" xlink:to="gemp_SeriesaPreferredConvertibleDebtMember_636256379969460626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969450626" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636256379969460626" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636256379969460626" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969460626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969460626" xlink:to="us-gaap_IPOMember_636256379969460626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_636256379969450626" xlink:to="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="us-gaap_ProceedsFromConvertibleDebt_636256379969460626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfDebtInstrumentsIssued" xlink:label="gemp_NumberOfDebtInstrumentsIssued_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_NumberOfDebtInstrumentsIssued_636256379969460626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfBoardMembersInRelatedPartyTransaction" xlink:label="gemp_NumberOfBoardMembersInRelatedPartyTransaction_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_NumberOfBoardMembersInRelatedPartyTransaction_636256379969460626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfOfficersInRelatedPartyTransaction" xlink:label="gemp_NumberOfOfficersInRelatedPartyTransaction_636256379969460626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_NumberOfOfficersInRelatedPartyTransaction_636256379969460626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfEmployeesInRelatedPartyTransaction" xlink:label="gemp_NumberOfEmployeesInRelatedPartyTransaction_636256379969470626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_NumberOfEmployeesInRelatedPartyTransaction_636256379969470626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfBoardMembers" xlink:label="gemp_NumberOfBoardMembers_636256379969470626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_NumberOfBoardMembers_636256379969470626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfInvestorsRelatedToOfficers" xlink:label="gemp_NumberOfInvestorsRelatedToOfficers_636256379969470626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_NumberOfInvestorsRelatedToOfficers_636256379969470626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors" xlink:label="gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors_636256379969470626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors_636256379969470626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfOfficers" xlink:label="gemp_NumberOfOfficers_636256379969470626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_NumberOfOfficers_636256379969470626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany" xlink:label="gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany_636256379969470626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany_636256379969470626" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector" xlink:label="gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector_636256379969470626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector_636256379969470626" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers" xlink:label="gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers_636256379969470626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers_636256379969470626" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany" xlink:label="gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany_636256379969470626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany_636256379969470626" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector" xlink:label="gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector_636256379969470626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector_636256379969470626" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers" xlink:label="gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers_636256379969470626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_636256379969460626" xlink:to="gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers_636256379969470626" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_636256379969480626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636256379969480626" xlink:to="us-gaap_SubsequentEventTypeAxis_636256379969480626" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_636256379969480626" xlink:to="us-gaap_SubsequentEventTypeDomain_636256379969480626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_636256379969480626" xlink:to="us-gaap_SubsequentEventMember_636256379969480626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636256379969480626" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636256379969480626" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636256379969480626" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969480626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636256379969480626" xlink:to="us-gaap_PrivatePlacementMember_636256379969480626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636256379969480626" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969480626" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_636256379969480626" xlink:to="us-gaap_RelatedPartyDomain_636256379969480626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ThreeBoardMember" xlink:label="gemp_ThreeBoardMember_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969480626" xlink:to="gemp_ThreeBoardMember_636256379969480626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_OneBoardMember" xlink:label="gemp_OneBoardMember_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_636256379969480626" xlink:to="gemp_OneBoardMember_636256379969480626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636256379969480626" xlink:to="us-gaap_SubsequentEventLineItems_636256379969480626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636256379969480626" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636256379969480626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636256379969480626" xlink:to="us-gaap_SharesIssuedPricePerShare_636256379969480626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636256379969480626" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_636256379969480626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfSharesIssuedPerUnit" xlink:label="gemp_NumberOfSharesIssuedPerUnit_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636256379969480626" xlink:to="gemp_NumberOfSharesIssuedPerUnit_636256379969480626" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636256379969480626" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_636256379969480626" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636256379969480626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636256379969480626" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636256379969480626" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable" xlink:label="gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable_636256379969490626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636256379969480626" xlink:to="gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable_636256379969490626" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfBoardMembers" xlink:label="gemp_NumberOfBoardMembers_636256379969490626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636256379969480626" xlink:to="gemp_NumberOfBoardMembers_636256379969490626" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gemp-20161231.xsd#gemp_NumberOfInvestorRelatedToBoardMembers" xlink:label="gemp_NumberOfInvestorRelatedToBoardMembers_636256379969490626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636256379969480626" xlink:to="gemp_NumberOfInvestorRelatedToBoardMembers_636256379969490626" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.gemphire.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails" xlink:type="extended" xlink:title="41601 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:label="us-gaap_ValuationAndQualifyingAccountsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="us-gaap_MovementInValuationAllowancesAndReservesRollForward_636256379969490626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAndQualifyingAccountsAbstract" xlink:to="us-gaap_MovementInValuationAllowancesAndReservesRollForward_636256379969490626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_636256379969490626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward_636256379969490626" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_636256379969490626" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_636256379969490626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward_636256379969490626" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_636256379969490626" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_636256379969490626" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward_636256379969490626" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_636256379969490626" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_6362563799694906261" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MovementInValuationAllowancesAndReservesRollForward_636256379969490626" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_6362563799694906261" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818133680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 03, 2017</div></th>
<th class="th"><div>Aug. 05, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gemphire Therapeutics Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,272,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811110432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,033<span></span>
</td>
<td class="nump">$ 3,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">713<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">24,746<span></span>
</td>
<td class="nump">3,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,754<span></span>
</td>
<td class="nump">4,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,008<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Convertible notes to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,121<span></span>
</td>
<td class="nump">8,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,122<span></span>
</td>
<td class="nump">8,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A convertible preferred stock, $0.001 par value; no shares authorized as of December 31, 2016 and 2,325,581 shares authorized as of December 31, 2015, no shares issued or outstanding as of December 31, 2016 and 745,637 shares issued and outstanding as of December 31, 2015, aggregate liquidation preference as of December 31, 2016 and 2015 of zero and $7,953, respectively.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2016 and no shares authorized as of December 31, 2015, no shares issued or outstanding as of December 31, 2016 and 2015.</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 and 17,674,419 shares authorized as of December 31, 2016 and 2015, respectively, 9,270,255 and 3,758,488 shares issued and outstanding at December 31, 2016 and 2015, respectively.</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">47,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(27,059)<span></span>
</td>
<td class="num">(12,392)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">20,632<span></span>
</td>
<td class="num">(12,380)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 24,754<span></span>
</td>
<td class="nump">$ 4,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of deferred costs that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6817998048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred stock, share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par Value (in dollar per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par Value (in dollar per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, share authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">17,674,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, share issued</a></td>
<td class="nump">9,270,255<span></span>
</td>
<td class="nump">3,758,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, share outstanding</a></td>
<td class="nump">9,270,255<span></span>
</td>
<td class="nump">3,758,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Convertible Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible Preferred Stock, Par Value (in dollar per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, share authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,325,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred stock, share issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">745,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred stock, share outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">745,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible Preferred Stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819600096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,389,000<span></span>
</td>
<td class="nump">$ 1,466,000<span></span>
</td>
<td class="nump">$ 1,051,000<span></span>
</td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="nump">$ 1,047,000<span></span>
</td>
<td class="nump">$ 997,000<span></span>
</td>
<td class="nump">$ 658,000<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,956,000<span></span>
</td>
<td class="nump">$ 3,177,000<span></span>
</td>
<td class="nump">$ 214,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="nump">1,936,000<span></span>
</td>
<td class="nump">789,000<span></span>
</td>
<td class="nump">1,176,000<span></span>
</td>
<td class="nump">1,464,000<span></span>
</td>
<td class="nump">1,369,000<span></span>
</td>
<td class="nump">952,000<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,740,000<span></span>
</td>
<td class="nump">3,991,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,228,000<span></span>
</td>
<td class="nump">3,402,000<span></span>
</td>
<td class="nump">1,840,000<span></span>
</td>
<td class="nump">2,226,000<span></span>
</td>
<td class="nump">2,511,000<span></span>
</td>
<td class="nump">2,366,000<span></span>
</td>
<td class="nump">1,610,000<span></span>
</td>
<td class="nump">1,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,696,000<span></span>
</td>
<td class="nump">8,076,000<span></span>
</td>
<td class="nump">266,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,228,000)<span></span>
</td>
<td class="num">(3,402,000)<span></span>
</td>
<td class="num">(1,840,000)<span></span>
</td>
<td class="num">(2,226,000)<span></span>
</td>
<td class="num">(2,511,000)<span></span>
</td>
<td class="num">(2,366,000)<span></span>
</td>
<td class="num">(1,610,000)<span></span>
</td>
<td class="num">(1,589,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,696,000)<span></span>
</td>
<td class="num">(8,076,000)<span></span>
</td>
<td class="num">(266,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="num">(475,000)<span></span>
</td>
<td class="nump">449,000<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
<td class="num">(209,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(690,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
<td class="num">(762,000)<span></span>
</td>
<td class="num">(55,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible note extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,214,000)<span></span>
</td>
<td class="num">(3,878,000)<span></span>
</td>
<td class="num">(1,391,000)<span></span>
</td>
<td class="num">(2,103,000)<span></span>
</td>
<td class="num">(2,570,000)<span></span>
</td>
<td class="num">(2,569,000)<span></span>
</td>
<td class="num">(1,611,000)<span></span>
</td>
<td class="num">(2,279,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,586,000)<span></span>
</td>
<td class="num">(9,029,000)<span></span>
</td>
<td class="num">(320,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (196,000)<span></span>
</td>
<td class="num">(7,214,000)<span></span>
</td>
<td class="num">(3,878,000)<span></span>
</td>
<td class="num">(1,391,000)<span></span>
</td>
<td class="num">(2,103,000)<span></span>
</td>
<td class="num">(2,570,000)<span></span>
</td>
<td class="num">(2,569,000)<span></span>
</td>
<td class="num">(1,611,000)<span></span>
</td>
<td class="num">(2,279,000)<span></span>
</td>
<td class="num">$ (124,000)<span></span>
</td>
<td class="num">(14,586,000)<span></span>
</td>
<td class="num">(9,029,000)<span></span>
</td>
<td class="num">(320,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,214,000)<span></span>
</td>
<td class="num">(3,878,000)<span></span>
</td>
<td class="num">(1,391,000)<span></span>
</td>
<td class="num">(2,103,000)<span></span>
</td>
<td class="num">(2,570,000)<span></span>
</td>
<td class="num">(2,569,000)<span></span>
</td>
<td class="num">(1,611,000)<span></span>
</td>
<td class="num">(2,279,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,586,000)<span></span>
</td>
<td class="num">(9,029,000)<span></span>
</td>
<td class="num">(320,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (196,000)<span></span>
</td>
<td class="num">(7,214,000)<span></span>
</td>
<td class="num">(3,878,000)<span></span>
</td>
<td class="num">(1,391,000)<span></span>
</td>
<td class="num">(2,103,000)<span></span>
</td>
<td class="num">(2,570,000)<span></span>
</td>
<td class="num">(2,569,000)<span></span>
</td>
<td class="num">(1,611,000)<span></span>
</td>
<td class="num">(2,279,000)<span></span>
</td>
<td class="num">$ (124,000)<span></span>
</td>
<td class="num">(14,586,000)<span></span>
</td>
<td class="num">(9,029,000)<span></span>
</td>
<td class="num">(320,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Adjustment to redemption value on Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,000)<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
<td class="num">(149,000)<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
<td class="num">(152,000)<span></span>
</td>
<td class="num">(149,000)<span></span>
</td>
<td class="num">(2,517,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(366,000)<span></span>
</td>
<td class="num">(2,968,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ConvertibleNotesPremiumUponSubstantialModificationValue', window );">Premium upon substantial modification of convertible notes with certain stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,047,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,047,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,214,000)<span></span>
</td>
<td class="num">$ (3,945,000)<span></span>
</td>
<td class="num">$ (1,541,000)<span></span>
</td>
<td class="num">$ (2,252,000)<span></span>
</td>
<td class="num">$ (3,767,000)<span></span>
</td>
<td class="num">$ (2,721,000)<span></span>
</td>
<td class="num">$ (1,760,000)<span></span>
</td>
<td class="num">$ (4,796,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,952,000)<span></span>
</td>
<td class="num">$ (13,044,000)<span></span>
</td>
<td class="num">$ (320,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (Note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (2.27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.57)<span></span>
</td>
<td class="num">$ (4.54)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Number of shares used in per share calculations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,809,396<span></span>
</td>
<td class="nump">2,875,053<span></span>
</td>
<td class="nump">1,521,703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ConvertibleNotesPremiumUponSubstantialModificationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for premium upon substantial modification of convertible notes to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ConvertibleNotesPremiumUponSubstantialModificationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819322880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Members' Deficit</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2013</a></td>
<td class="num">$ (264)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (264)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_StockEffectDuringPeriodValueUponMerger', window );">Effect of merger</a></td>
<td class="nump">$ 388<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_StockEffectDuringPeriodShareUponMerger', window );">Effect of merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_StockRestrictionDuringPeriodValue', window );">Restriction of initial common stock issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_StockRestrictionDuringPeriodShares', window );">Restriction of initial common stock issuances (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(556,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,605,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation - employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(320)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="num">(584)<span></span>
</td>
<td class="num">(531)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at end of period (shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,036,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Redemption value adjustment - Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,130)<span></span>
</td>
<td class="num">(1,838)<span></span>
</td>
<td class="num">(2,968)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">677,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ConvertibleNoteExtinguishmentLoss', window );">Convertible Note Extinguishment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(941)<span></span>
</td>
<td class="num">(1,047)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation - employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation - non-employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,029)<span></span>
</td>
<td class="num">(9,029)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,392)<span></span>
</td>
<td class="num">(12,380)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at end of period (shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,758,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Redemption value adjustment - Series A preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(285)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities', window );">Conversion of preferred stock to common stock, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities', window );">Conversion of preferred stock to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">827,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity', window );">Conversion of preferred stock to common stock, additional paid in capital amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes to common stock, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes to common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Conversion of convertible notes to common stock, additional paid in capital amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Separation of beneficial conversion feature associated with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">30,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,027,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs of offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation - employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation - non-employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,586)<span></span>
</td>
<td class="num">(14,586)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 47,674<span></span>
</td>
<td class="num">$ (27,059)<span></span>
</td>
<td class="nump">$ 20,632<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at end of period (shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,270,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation related to employees during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_AdjustmentsToAdditionalPaidInCapitalEmployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the conversion of convertible equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation related to non-employees during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_AdjustmentsToAdditionalPaidInCapitalNonemployeeSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ConvertibleNoteExtinguishmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of convertible note loss extinguishment during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ConvertibleNoteExtinguishmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_StockEffectDuringPeriodShareUponMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares effect during the period upon merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_StockEffectDuringPeriodShareUponMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_StockEffectDuringPeriodValueUponMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of stock effect during the period upon merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_StockEffectDuringPeriodValueUponMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_StockIssuedDuringPeriodSharesConversionOfConvertibleEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon conversion of convertible equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_StockIssuedDuringPeriodValueConversionOfConvertibleEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_StockRestrictionDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock restriction for issuance during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_StockRestrictionDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_StockRestrictionDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock restriction for issuance during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_StockRestrictionDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Beneficial Conversion Feature<br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of the preferred stock redemption discount during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAccretionOfRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gemp_MembersEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gemp_MembersEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6804520288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit - Temporary Equity - 12 months ended Dec. 31, 2016<br> $ in Thousands</strong></div></th>
<th class="th">
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, balance at beginning of period at Dec. 31, 2015</a></td>
<td class="nump">$ 7,953<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary equity, balance at beginning of period (shares) at Dec. 31, 2015 | shares</a></td>
<td class="nump">745,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Redemption value adjustment - Series A preferred stock</a></td>
<td class="nump">$ 366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_TemporaryEquityConversionOfStock', window );">Conversion of Series A preferred stock, amount converted</a></td>
<td class="num">$ (8,319)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_TemporaryEquityConversionOfStockShares', window );">Conversion of Series A preferred stock, shares converted | shares</a></td>
<td class="num">(745,637)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_TemporaryEquityConversionOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of temporary equity converted to permanent equity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_TemporaryEquityConversionOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_TemporaryEquityConversionOfStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of temporary equity converted into permanent equity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_TemporaryEquityConversionOfStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818963856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,586)<span></span>
</td>
<td class="num">$ (9,029)<span></span>
</td>
<td class="num">$ (320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">284<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NonCashInterestOnPromissoryNotesToRelatedParties', window );">Non-cash interest on promissory notes to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NoncashInterestOnConvertibleNotesToRelatedParties', window );">Non-cash interest on convertible notes to related parties</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NoncashInterestOnConvertibleNotes', window );">Non-cash interest on convertible notes</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount', window );">Non-cash discount amortization on convertible notes to related parties</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_AmortizationOnConvertibleNotesDiscount', window );">Non-cash discount amortization on convertible notes</a></td>
<td class="num">(276)<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Revaluation of premium conversion derivative</a></td>
<td class="num">(850)<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Non-cash loss on extinguishment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Non-cash interest upon conversion of convertible notes</a></td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Non-cash acquisition of in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits', window );">Prepaid expenses and other assets</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,477<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(11,043)<span></span>
</td>
<td class="num">(5,433)<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="nump">2,651<span></span>
</td>
<td class="nump">5,560<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of convertible notes to related parties</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Issuance costs related to convertible notes</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ProceedsFromRelatedPartyPromissoryNotes', window );">Proceeds from issuance of promissory notes to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from offering</a></td>
<td class="nump">30,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs</a></td>
<td class="num">(3,963)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">31,456<span></span>
</td>
<td class="nump">8,736<span></span>
</td>
<td class="nump">509<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">20,413<span></span>
</td>
<td class="nump">3,303<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">24,033<span></span>
</td>
<td class="nump">3,620<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ExerciseOfPremiumConversionDerivative', window );">Exercise of premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Redemption value change of Series A preferred stock</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">$ 2,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1', window );">Issuance of common stock for acquisition of in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes', window );">Bifurcation of premium conversion derivative related to convertible notes</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Convertible note extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment', window );">Premium conversion derivative reduction upon convertible note extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Separation of beneficial conversion feature associated with convertible notes</a></td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Offering costs</a></td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=gemp_ConversionOfInterimNotesMember', window );">Conversion of Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of debt instrument to stock</a></td>
<td class="nump">11,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=gemp_ConversionOfConvertibleNotesMember', window );">Conversion of Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of debt instrument to stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=gemp_ConversionOfRelatedPartyPromissoryNotesMember', window );">Conversion of related party promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of debt instrument to stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=gemp_ConversionOfSeriesPreferredStockMember', window );">Conversion of Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental non-cash financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of Series A preferred stock to common stock</a></td>
<td class="nump">$ 8,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_AmortizationOnConvertibleNotesDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount associated with the convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_AmortizationOnConvertibleNotesDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense to amortize debt discount associated with the convertible notes to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_AmortizationOnConvertibleNotesToRelatedPartiesDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the bifurcation of premium conversion derivative related to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_BifurcationOfPremiumConversionDerivativeRelatedToConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ExerciseOfPremiumConversionDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the exercise of premium conversion derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ExerciseOfPremiumConversionDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance that provide economic benefits in future periods and deposits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_IncreaseDecreaseInPrepaidExpensesAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NonCashInterestOnPromissoryNotesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of noncash interest on promissory notes to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NonCashInterestOnPromissoryNotesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NoncashInterestOnConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of noncash interest on convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NoncashInterestOnConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NoncashInterestOnConvertibleNotesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of noncash interest on convertible notes to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NoncashInterestOnConvertibleNotesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the premium conversion derivative reduction upon convertible note extinguishment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_PremiumConversionDerivativeReductionUponConvertibleNoteExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ProceedsFromRelatedPartyPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a promissory note made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ProceedsFromRelatedPartyPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Beneficial Conversion Feature<br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized (holding) gain (loss) which is included in the statement of income (or changes in net assets) related to those liabilities still held at the reporting date for which fair value is measured on a recurring basis using significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The after-tax amount of interest recognized in the period associated with any convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=gemp_ConversionOfInterimNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=gemp_ConversionOfInterimNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=gemp_ConversionOfConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=gemp_ConversionOfConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=gemp_ConversionOfRelatedPartyPromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=gemp_ConversionOfRelatedPartyPromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=gemp_ConversionOfSeriesPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=gemp_ConversionOfSeriesPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808833968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Basis of Presentation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">1. The Company and Basis of Presentation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On November&nbsp;10, 2008, Michigan Life Therapeutics,&nbsp;LLC (MLT) was organized as a limited liability company (LLC) in Michigan. On October&nbsp;30, 2014, Gemphire Therapeutics&nbsp;Inc. (Gemphire) was incorporated as a C corporation in the state of Delaware. On November&nbsp;1, 2014, MLT entered into a merger agreement with Gemphire whereby MLT was merged with and into Gemphire with Gemphire as the surviving entity; all outstanding membership interests of MLT were exchanged for shares of Gemphire&#x2019;s common stock. The purpose of the merger was to change the jurisdiction of MLT from Michigan to Delaware and to convert from an&nbsp;LLC to a corporation. All financial results presented prior to November 1, 2014 are from the operations of MLT. MLT and Gemphire are collectively referred to as the &#x201C;Company&#x201D; in the accompanying notes to the financial statements. The Company&#x2019;s headquarters are located in Livonia, Michigan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company is a clinical&#8209;stage biopharmaceutical entity focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease and NAFLD/NASH (nonalcoholic fatty liver disease). The Company&#x2019;s primary activities have been conducting research and development activities, planning clinical trials, performing business and financial planning, recruiting personnel and raising capital. The Company is subject to certain risks, which include the need to research, develop, and clinically test potentially therapeutic products, initially one product candidate gemcabene (also known as CI&#8209;1027); obtain regulatory approval for its products and commercialize them around the world; expand its management scientific staff; finance its operations; and, find collaboration partners to further advance development and commercial efforts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;">Initial Public Offering and Capital Requirements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">On August 4, 2016, the Company&#x2019;s Registration Statement on Form S-1 (File No 333-210815) relating to its IPO of its common stock was declared effective by the Securities and Exchange Commission (SEC). Pursuant to such Registration Statement, on August 10, 2016, the Company closed its IPO whereby 3,000,000 shares of its common stock were issued and sold at a public offering price of $10.00 per share. On September 8, 2016, the Company closed the sale of 27,755 shares of its common stock at the public offering price of $10.00 per share, representing a partial exercise of the underwriters&#x2019; over-allotment option, following which, the IPO terminated. The Company received net proceeds of approximately $26.1 million after deducting underwriting discounts and commissions of $2.1 million and other offering expenses of $2.1 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Immediately prior to the IPO, the Company amended and restated its certificate of incorporation and bylaws to, among other things, change its authorized capital stock to consist of (i) 100,000,000 shares of common stock and (ii) 10,000,000 shares of undesignated preferred stock.</font><font style="display:inline;color:#000000;background-color: #FFFFFF;"> Both the common stock and the preferred stock have a par value of $0.001 per share.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company has sustained operating losses since inception and expects such losses to continue over the next several years. Management plans to continue financing the operations with equity issuances. The Company&#x2019;s management believes the cash and cash equivalents on hand are adequate to fund the Company&#x2019;s operations for at least the next 12 months. If adequate funds are not available, the Company may be required to delay, reduce the scope of, or eliminate part or all of its research and development programs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Basis of Presentation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">Certain prior period balances have been reclassified to conform to the current period presentation. Specifically, the Company reclassified all current deferred tax liabilities as long term in the amount of $10,000 on its December 31, 2015 balance sheet in conformity with the adoption of</font><font style="display:inline;"> Accounting Standards Update (ASU) 2015&#8209;17, </font><font style="display:inline;font-style:italic;">Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</font><font style="display:inline;"> (ASU 2015&#8209;17).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;background-color: #FFFFFF;">Reverse Stock Split</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">In April 2016, the board of directors approved an amendment to the Company&#x2019;s certificate of incorporation to effect a 1-for-3.119 reverse stock split (the Reverse Stock Split) for all common and Series A preferred stock. The Reverse Stock Split became effective on April 27, 2016 upon the filing of the amendment to the certificate of incorporation. The authorized shares and par value of the common stock and Series A preferred stock were not adjusted as a result of the Reverse Stock Split. All issued and outstanding common and Series A preferred stock, options for common stock and per share amounts contained in the financial statements were retroactively adjusted to reflect the Reverse Stock Split for all periods presented.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6644918816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">2. Summary of Significant Accounting Policies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Use of Estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company considers all highly liquid investments with an original maturity of 90&nbsp;days or less at the time of deposit to be cash equivalents. The Company invests excess cash in readily available checking and savings accounts and highly liquid investments in money market accounts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s financial instruments include principally cash and cash equivalents, other current assets, accounts payable, accrued liabilities and debt. The carrying amounts for these financial instruments reported in the balance sheets approximate their fair values. See Note&nbsp;11&nbsp;&#x2014; Fair Value Measurements, for further discussion of fair value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">General and Administrative Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">General and administrative expenses consist primarily of personnel&#8209;related costs, including salaries and share&#8209;based compensation costs, for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Research and Development Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development expenses consist of costs incurred in performing research and development activities, including compensation for research and development employees, costs associated with preclinical studies and trials, regulatory activities, manufacturing activities to support clinical activities, license fees, non&#8209;legal patent costs, fees paid to external service providers that conduct certain research and development, clinical costs and an allocation of overhead expenses. Research and development costs are expensed as incurred.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Acquired In&#8209;Process Research and Development Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company includes costs to acquire or in&#8209;license product candidates in acquired in&#8209;process research and development expenses. The Company has acquired the right to develop and commercialize its product candidate gemcabene. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &#x201C;business&#x201D; as defined under GAAP or provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company utilizes the liability method of accounting for income taxes as required by Accounting Standards Codification (ASC) 740, </font><font style="display:inline;font-style:italic;">Income Taxes</font><font style="display:inline;">. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is no provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. MLT was treated as a partnership for federal and state income tax purposes. Accordingly, no provision was made for income taxes for periods prior to November&nbsp;1, 2014, since the Company&#x2019;s net loss (subject to certain limitations) was passed through to the income tax returns of its members. Upon incorporation on October&nbsp;30, 2014, the Company became taxed as a corporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Share&#8209;Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company accounts for share&#8209;based compensation in accordance with the provisions of ASC 718, </font><font style="display:inline;font-style:italic;">Compensation&nbsp;&#x2014; Stock Compensation</font><font style="display:inline;"> (ASC 718). Accordingly, compensation costs related to equity instruments granted are recognized at the grant&#8209;date fair value. Additionally, as a result of the early adoption of </font><font style="display:inline;color:#000000;">ASU 2016-09, </font><font style="display:inline;font-style:italic;color:#000000;">Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;">, the Company has made an accounting policy election to record forfeitures when they occur. Share&#8209;based compensation arrangements to non&#8209;employees are accounted for in accordance with the applicable provisions of ASC 718 and ASC 505, </font><font style="display:inline;font-style:italic;">Equity</font><font style="display:inline;">, using a fair value approach. The compensation costs of these arrangements are subject to re&#8209;measurement as the equity instruments vest and are recognized as expense over the related service period (typically the vesting period of the awards).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Common Stock Valuation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Due to the absence of an active market for the Company&#x2019;s common stock prior to the close of the IPO, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#x2019; Technical Practice Aid, </font><font style="display:inline;font-style:italic;">Valuation of Privately&#8209;Held Company Equity Securities Issued as Compensation</font><font style="display:inline;">, to estimate the fair value of its common stock. The valuation methodology included estimates and assumptions that required the Company&#x2019;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biopharmaceutical industry sector, and the likelihood of achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Convertible Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 31, 2015, the Company issued 745,637 shares of Series&nbsp;A convertible preferred stock (the Series&nbsp;A preferred stock). On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock. The Series&nbsp;A preferred stock prior to conversion was classified outside of permanent equity, in mezzanine equity, on the Company&#x2019;s balance sheet. The Company initially records preferred stock that may be redeemed at the option of the holder, or based on the occurrence of events outside of the Company&#x2019;s control, at the value of the proceeds received. Subsequently, if it is probable that the preferred stock will become redeemable, the Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying amount of the instrument to equal the redemption value at the end of each reporting period. If it is not probable that the preferred stock will become redeemable, the Company does not adjust the carrying value. In the absence of retained earnings, these charges are recorded against additional paid&#8209;in&#8209;capital, if any, and then to accumulated deficit See Note&nbsp;7&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Convertible Series&nbsp;A Preferred Stock</font><font style="display:inline;"> for further discussion. As a result of their conversion to common stock on August 10, 2016 as described above, no shares of Series A preferred stock were outstanding as of December 31, 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Segment Information</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#x2019;s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer. The Company&#x2019;s Chief Executive Officer views the Company&#x2019;s operations and manages its business in one operating segment, which is the business of development and commercialization of therapeutics for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease and NAFLD/NASH. Accordingly, the Company has a single reporting segment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Jumpstart Our Business Startups Act Accounting Election</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As an emerging growth company under the Jumpstart Our Business Startups Act (JOBS Act), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has irrevocably elected not to avail itself of this exemption and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In May 2014, the FASB issued ASU 2014&#8209;09, </font><font style="display:inline;font-style:italic;">Revenue from Contracts with Customers&nbsp;&#x2014; Topic 606</font><font style="display:inline;">, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In 2015, the FASB agreed to allow companies to delay the implementation of this standard for one year effective for annual reporting periods beginning after December&nbsp;15, 2017, including interim periods within that reporting period. Early application is permitted only for periods beginning after December&nbsp;15, 2016. The Company plans to adopt this standard on January&nbsp;1, 2018 and to select the modified retrospective transition method. The Company plans to modify its accounting policies to reflect the requirements of this standard however, the planned adoption will not affect the Company&#x2019;s financial statements and related disclosures for these periods or future periods until the Company generates revenues.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In August 2014, the FASB issued Accounting Standards Update No.&nbsp;2014&#8209;15, </font><font style="display:inline;font-style:italic;">Presentation of Financial Statements&nbsp;&#x2014; Going Concern (Subtopic 205&#8209;40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern</font><font style="display:inline;"> (ASU 2014&#8209;15), which requires management to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events that, considered in the aggregate, raise substantial doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable) and provide related disclosures. ASU 2014&#8209;15 is effective for the annual period ending after December&nbsp;15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company elected to adopt this standard early as of December 31, 2015 and did not have a material impact on the Company&#x2019;s financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In November 2015, the Financial Accounting Standards Board (FASB) issued ASU 2015&#8209;17, </font><font style="display:inline;font-style:italic;">Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</font><font style="display:inline;"> (ASU 2015&#8209;17). The new guidance simplifies the presentation of deferred income taxes by requiring that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015&#8209;17 applies to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax&#8209;paying component of an entity be offset and presented as a single amount is not affected by this ASU. For public entities, ASU 2015&#8209;17 is effective for financial statements issued for annual periods beginning after December&nbsp;15, 2016 with earlier application permitted. The new guidance may be applied either prospectively or retrospectively to all periods presented. The Company </font><font style="display:inline;color:#000000;">adopted this standard effective April 1, 2016 on a retrospective basis for each period presented. </font><font style="display:inline;">The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In January 2016, the FASB issued ASU No.&nbsp;2016&#8209;01, </font><font style="display:inline;font-style:italic;">Financial Instruments&nbsp;&#x2014; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.</font><font style="display:inline;"> The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in the first quarter of fiscal 2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently evaluating the impact of the new guidance on its financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Leases (Topic </font><font style="display:inline;color:#000000;font-size:10pt;">842). The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The Company is currently evaluating the new guidance to determine the impact it may have on its financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">In March 2016, the FASB issued ASU 2016-09, </font><font style="display:inline;font-style:italic;color:#000000;">Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;color:#000000;">. This ASU simplifies the accounting for share-based payment award transactions including: income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December&nbsp;15, 2016, including interim periods within those fiscal years. Early adoption is permitted. </font><font style="display:inline;">The Company </font><font style="display:inline;color:#000000;">adopted this standard effective July 1, 2016 on a retrospective basis for each period presented. </font><font style="display:inline;">The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">In November 2016, the FASB issued ASU No.&nbsp;2016-18, </font><font style="display:inline;font-style:italic;color:#000000;background-color: #FFFFFF;">Statement of Cash Flows (Topic 230): Restricted Cash</font><font style="display:inline;color:#000000;background-color: #FFFFFF;">. The objective of this ASU is to eliminate the diversity in practice related to the classification of </font><font style="display:inline;">restricted cash or restricted cash equivalents in the statement of cash flows. </font><font style="display:inline;color:#000000;background-color: #FFFFFF;">For public business entities, this ASU is effective for annual and interim reporting periods beginning after December&nbsp;15, 2017, with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&#x2019;s financial statements.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6809474480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">3. Accrued Liabilities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Accrued liabilities consist of the following (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued offering costs</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>575
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Legal costs</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>234
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued compensation costs</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>706
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,259
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>759
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other general and administrative expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,113
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,617
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6800399184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">4. Debt</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Promissory Notes to Related Parties</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company issued promissory notes to related parties (the Promissory Notes) at a compound interest rate of 8% per annum for an aggregate principal amount of $0.3&nbsp;million on various dates from March 2009 through October 2014 with maturity dates through October&nbsp;31, 2014. The Promissory Notes along with accrued interest were exchanged for convertible notes (the Convertible Notes) on November&nbsp;1, 2014, in the amount of $0.4&nbsp;million inclusive of accrued interest.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Convertible Notes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company completed a series of convertible note financings with certain investors beginning on November 1, 2014 and ending on February&nbsp;18, 2015 (the Convertible Notes), whereby a total of $2.7&nbsp;million was loaned to the Company, of which $2.0&nbsp;million was loaned in 2015. Interest for the Convertible Notes compounded on a daily basis at a rate of 8&nbsp;percent per annum. The Convertible Notes converted into shares of the Company&#x2019;s Series&nbsp;A preferred stock upon close of the Series A preferred stock financing on March 31, 2015. The conversion equaled 125% of the unpaid principal plus unpaid accrued interest on the Convertible Notes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">At the time of their issuance, the Convertible Notes contained a conversion premium with regard to the conversion into the Series&nbsp;A preferred stock. The Company determined that the redemption feature under the Convertible Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Convertible Notes. The discount was amortized to interest expense over the term of the Convertible Notes using the straight&#8209;line method. The embedded derivative was accounted for separately on a fair market value basis. The Company recorded the fair value changes of the premium conversion derivative associated with the Convertible Notes to interest expense that amounted to $0.4&nbsp;million and $18,000 for the years ended December 31, 2015 and 2014, respectively. As a result of their conversion into shares of Series A preferred stock on March 31, 2015 as described above, there were no Convertible Notes outstanding during 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Interim Notes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On July&nbsp;31, 2015, the Company entered into a convertible interim note financing (collectively with the notes issued in December 2015, February 2016 and April 2016, the Interim Notes), pursuant to which certain investors agreed to loan the Company approximately $2.8&nbsp;million. On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Interim Notes, together with accrued interest thereon, converted into 1,656,807 shares of common stock. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Interim Notes accrued interest at a rate of 8% per annum, compounded annually, and would automatically convert into shares issued to investors in the Company&#x2019;s next equity financing round that results in gross proceeds of at least $5.0&nbsp;million (a Qualified Financing). The conversion would be equal to unpaid principal at 115% plus any unpaid accrued interest. The investors would be paid out principal at 200% if a change of control occurred before the next financing round. In the event that a Qualified Financing, change of control, or an IPO did not occur before July&nbsp;31, 2016, the parties would then negotiate a price for conversion into a new round of stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In December 2015, the Company amended the Interim Notes and certain investors agreed to loan the Company an additional $2.7&nbsp;million for a revised financing total of $5.5&nbsp;million. The Interim Notes continued to accrue interest at an 8% rate per annum compounded annually, but were amended to automatically convert into shares of the same class of the Company&#x2019;s next convertible preferred stock financing round (the Preferred Stock Financing). The conversion into shares issued in the Preferred Stock Financing would be equal to unpaid principal at 115% plus unpaid accrued interest. In the event that either a change of control occurs or the Company completes a public transaction which results in the Company&#x2019;s stockholders holding securities listed on a national securities exchange, including an IPO, before the Preferred Stock Financing, the Interim Notes, as amended, would automatically convert into shares of the Company&#x2019;s common stock at a conversion price of $6.70585 per share (which represents the original issue price of the Series&nbsp;A preferred stock) based on 100% of outstanding principal and unpaid accrued interest. Lastly, if a Preferred Stock Financing, change of control, or public transaction did not occur before December&nbsp;31, 2016, the parties agreed to then negotiate a conversion price into a new round of stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February 2016, certain investors agreed to loan the Company an additional $0.2&nbsp;million for a revised financing total of $5.6&nbsp;million. The Interim Notes continued to accrue interest at an 8% rate per annum compounded annually, but were amended to automatically convert into shares of the same class of the Company&#x2019;s next Preferred Stock Financing. The conversion into shares issued in the Preferred Stock Financing would be equal to unpaid principal at 115% plus unpaid accrued interest. In the event that either a change of control occurs or the Company completes a public transaction which results in the Company&#x2019;s stockholders holding securities listed on a national securities exchange, including an IPO, before the Preferred Stock Financing, the Interim Notes, as amended, would automatically convert into shares of the Company&#x2019;s common stock at a conversion price of $6.70585 per share (which represents the original issue price of the Series&nbsp;A preferred stock as adjusted for the Reverse Stock Split (as defined below)) based on 100% of outstanding principal and unpaid accrued interest. Lastly, if a Preferred Stock Financing, change of control, or public transaction did not occur before December&nbsp;31, 2016, the parties agreed to then negotiate a conversion price into a new round of stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2016, the Company amended the Interim Notes and certain investors agreed to loan the Company an additional $5.0&nbsp;million for a revised financing total, including Interim Notes previously issued, of $10.6&nbsp;million. The Interim Notes continued to accrue interest at an 8% rate per annum compounded annually, but were amended so that 125% of the unpaid principal and accrued interest, would automatically convert into shares of the same class of the Company&#x2019;s next convertible preferred stock financing round of at least $5.0&nbsp;million (the Qualified Financing). In the event that either a change of control occurs or the Company completes a public transaction which results in the Company&#x2019;s stockholders holding securities listed on a national securities exchange, including an IPO, before the Qualified Financing, 100% of outstanding principal and unpaid accrued interest on the Interim Notes, as amended, would automatically convert into shares of the Company&#x2019;s common stock at a conversion price of $6.70585 per share, as adjusted for the Reverse Stock Split. Lastly, if a Qualified Financing, change of control, or public transaction did not occur, the Interim Notes would become payable on demand anytime after December&nbsp;31, 2016. The Company incurred issuance costs related to the April 2016 financing in the amount of $10,000. The Interim Notes were discounted for the issuance costs, and the discount was amortized to interest expense over their remaining term using the straight&#8209;line method.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Interim Notes, together with accrued interest thereon, converted into 1,656,807 shares of common stock. At the time of their issuance, the Interim Notes contained a conversion premium with regard to the conversion into shares at the time of the next Qualified Financing. The Company determined that the redemption feature under the Interim Notes qualified as an embedded derivative and was separated from its debt host. The bifurcation of the embedded derivative from its debt host resulted in a discount to the Interim Notes. The discount was amortized to interest expense over the term of the Interim Notes using the straight&#8209;line method. The embedded derivative was accounted for separately on a fair market value basis. The fair value of the derivative associated with the Interim Notes was $0.3 million at December 31, 2015 and was included as premium conversion derivative on the accompanying balance sheets. As a result of the conversion of the Interim Notes, together with accrued interest thereon, into common stock immediately prior to the closing of the IPO, there was no premium conversion derivative outstanding as of December 31, 2016. The Company recorded the fair value changes of the premium conversion derivative associated with the Interim Notes to interest income (expense) that amounted to $0.2 million, $(0.1) million and zero for the years ended December 31, 2016, 2015 and 2014, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As a result of their conversion to common stock on August 10, 2016 as described above, there were no Interim Notes outstanding as of December 31, 2016.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808805344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">5. Commitments and Contingencies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Pfizer License Agreement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2011, the Company and Pfizer&nbsp;Inc. (Pfizer) entered into an exclusive license agreement (the Pfizer Agreement) for the clinical product candidate gemcabene. In exchange for this worldwide exclusive right and license to certain patent rights to make, use, sell, offer for sale and import the clinical product gemcabene, the Company agreed to certain milestone and royalty payments on future sales (See Note&nbsp;6&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">License Agreement)</font><font style="display:inline;">. As of December 31, 2016, there was sufficient uncertainty with regard to both the outcome of the clinical trials and the ability to obtain sufficient funding to support any of the cash milestone payments under the license agreement, and as such, no liabilities were recorded related to the license agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Series&nbsp;A Preferred Stock Dividends</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Holders of the Series&nbsp;A preferred stock were entitled to cumulative accruing dividends at a simple rate of 8% per year on the original issue price of the preferred stock of $6.70585 per share, as adjusted for the Reverse Stock Split. The dividends effectively accrued daily on each share of preferred stock. The dividends were payable upon the earliest to occur of (1)&nbsp;the date determined by the Board, (2)&nbsp;the liquidation of the Company (including a deemed liquidation event) or (3)&nbsp;the conversion or redemption of at least a majority of the outstanding shares of Series&nbsp;A preferred stock. If the board reasonably believed that the Company was not legally able to pay the dividends in cash at the payment date, or if elected by the majority of the Series&nbsp;A preferred stockholders or if issued in connection with an IPO, the dividends were to be paid in shares of common stock at the conversion price for the Series&nbsp;A preferred stock in effect at that time, which was the original issue price of the Series&nbsp;A preferred stock as adjusted from time to time for any stock dividends, combinations, splits or recapitalizations. Since the dividends were payable upon a contingent event, the Company did not record them in the accompanying financial statements as of December 31, 2015; however, cumulative unpaid dividends for the Series&nbsp;A preferred stock totaled $0.3&nbsp;million as of December&nbsp;31, 2015. On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock, and as such, there were no cumulative unpaid dividends for the Series A preferred stock as of December 31, 2016. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Other Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Both cancellable and non-cancellable facility agreements were in place that provided for fixed monthly rent for the years ended December 31, 2016, 2015 and 2014. The total rent expense was $58,000,&nbsp;$23,000 and $6,000 for the years ended December 31, 2016, 2015 and 2014, respectively. In May 2016, the Company entered into a new lease agreement for its headquarters location, commencing in August 2016. The initial term of the agreement is 3 years with an initial monthly base rent of approximately $8,400. In conjunction with entering into the new lease agreement, the Company cancelled its original Northville, Michigan lease agreement, as amended, effective August 31, 2016 and renegotiated a new cancellable lease agreement for limited use of office space in the Northville location that expires in September 2017.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Future minimum lease payments under fixed non-cancellable operating leases that expire on various dates through August 2019 consist of the following (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>58
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;Total</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>260
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6790092144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_LicenseAgreementDisclosureAbstract', window );"><strong>License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License Agreement</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">6. License Agreement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2011, the Company entered into the Pfizer Agreement for a worldwide exclusive license to certain patent rights to make, use, sell, offer for sale and import the clinical product candidate gemcabene. In exchange for this license, the Company agreed to issue shares of its common stock to Pfizer representing 15% of the Company&#x2019;s fully diluted capital at the close of its first arms&#8209;length Series&nbsp;A financing, which occurred on March 31, 2015.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company agreed to make milestone payments totaling up to $37&nbsp;million upon the achievement of certain milestones, including the first regulatory submission in any country, regulatory approval in each of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of gemcabene or any product containing gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company also agreed to pay Pfizer tiered royalties on a country&#8209;by&#8209;country basis based upon the annual amount of net sales, as specified in the Pfizer Agreement until expiration of the last valid claim of the licensed patent rights including any patent term extensions or supplemental protection certificates. Under the Pfizer Agreement, the Company is obligated to use commercially reasonable efforts to develop and commercialize gemcabene.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 31, 2015, upon the closing of the Series&nbsp;A preferred stock financing, the Company issued 675,250 shares of its common stock, at a fair market value of $0.9&nbsp;million, to Pfizer in connection with the first equity payment, pursuant to which Pfizer became the owner of more than 5% of the Company&#x2019;s capital stock. The transaction was recorded as acquired in&#8209;process research and development expenses based on the fair market value of the common shares issued since no processes or activities that would constitute a &#x201C;business&#x201D; were acquired and none of the rights and underlying assets acquired had alternative future uses or reached a stage of technological feasibility. None of the other milestone or royalty payments were triggered as of December 31, 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Pfizer Agreement will expire upon expiration of the last royalty term. Either party may terminate the Pfizer Agreement for the other party&#x2019;s uncured material breach or upon specified bankruptcy events. Pfizer may terminate the Pfizer Agreement if the Company or any of its sublicenses challenge the validity, enforceability or ownership of the licensed patents. Upon termination of the license agreement for cause by Pfizer, we must grant Pfizer a non-exclusive license to use any intellectual property rights arising from the development or commercialization of gemcabene. Additionally, Pfizer may revoke the license if the Company is unable to adequately commercialize gemcabene by April 2021.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pfizer has a non&#8209;exclusive, sub licensable, royalty&#8209;free right and license for non&#8209;commercial research or development purposes to intellectual property rights relating to gemcabene that are developed by us after the effective date of the license with Pfizer.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_LicenseAgreementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_LicenseAgreementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808805344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Series A Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Convertible Series A Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_TemporaryEquityDisclosureTextBlock', window );">Convertible Series A Preferred Stock</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">7. Convertible Series&nbsp;A Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 31, 2015, the Company issued 745,637 shares of Series&nbsp;A preferred stock at a per share price of $6.70585, as adjusted for the Reverse Stock Split, or $5.0&nbsp;million in the aggregate, consisting of $1.5&nbsp;million in cash and $3.5&nbsp;million representing 125% of the principal and accrued and unpaid interest on the Convertible Notes, all of which converted into shares of Series&nbsp;A preferred stock. On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Prior to their conversion into shares of common stock, the Series&nbsp;A preferred stock had the following rights and preferences:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Dividend Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Dividends effectively accrued on a daily basis at a simple rate of 8% per annum on the sum of the original per share issue price. Dividends were effectively deemed declared daily and were payable upon the occurrence of certain events. In addition, the holders of the Series&nbsp;A preferred stock had rights to participate in common stock dividends, entitling holders of Series&nbsp;A preferred stock to a dividend payable at the same time as the dividend paid on common stock based on the number of shares of common stock each share of Series&nbsp;A preferred stock would convert into if such shares had converted on the record date. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There were no dividends deemed payable and accrued as of December 31, 2016 due to the conversion of the Series A preferred stock, together with accrued dividends thereon, on August 10, 2016 immediately prior to the closing of the IPO. There were no dividends deemed payable and accrued as of December 31, 2015, but unpaid dividends were $0.3&nbsp;million as of December&nbsp;31, 2015. See Note&nbsp;5&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Commitments and Contingencies</font><font style="display:inline;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Voting Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Each share of Series&nbsp;A preferred stock was entitled to vote together with the common stock on all actions to be taken by the stockholders of the Company, based on the number of shares of common stock into which each share of Series&nbsp;A preferred stock could be converted. A separate vote of a majority of the outstanding shares of Series&nbsp;A preferred stock was required to (1)&nbsp;issue or authorize any class or series of equity securities or equivalents, (2)&nbsp;effect any transaction that results in a change in control, (3)&nbsp;change the principal business of the Company, enter new lines of business, or exit the current line of business, (4)&nbsp;issue of convertible debt above a certain threshold, or (5)&nbsp;materially sell, transfer, license, pledge or encumber technology or intellectual property. A management stock option plan approved by the board of directors, however, was not subject to a separate vote of the Series&nbsp;A preferred stockholders, but any subsequent increases to the authorized option pool were subject to approval by the Series&nbsp;A preferred stock holders via a separate vote.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Liquidation Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the event of any liquidation, dissolution, or winding&#8209;up of the Company, whether voluntary or involuntary, merger, consolidation or transaction in which over 50% of the Company&#x2019;s voting power was transferred, or a sale, lease, transfer, exclusive license or disposition of all or substantially all of the assets of the Company, the Series&nbsp;A preferred stock holders were entitled to the assets of the Company legally available for distribution before any distribution or payment was made to the holders of common stock. The distribution amount would have been equal the original issue price of the Series&nbsp;A preferred stock (as adjusted for any stock dividends, combinations, splits or other recapitalizations since issuance), plus any accrued or declared but unpaid dividends thereon. After payment of the full liquidation preference to the Series&nbsp;A preferred stock holders, the remaining assets legally available for distribution would have been distributed to the holders of common stock and holders of the Series&nbsp;A preferred stock pro rata based on the number of shares of common stock each share of Series&nbsp;A preferred stock would convert into if such shares had converted immediately prior to such liquidation, dissolution, or winding&#8209;up.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Conversion Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Shares of Series&nbsp;A preferred stock, at the option of the holder, could have been converted at any time into shares of common stock. The conversion rate would have been obtained by dividing the Series&nbsp;A preferred stock original issue price of $6.70585 per share, as adjusted for the Reverse Stock Split, by the conversion price per share in effect at the time of conversion. The Series&nbsp;A conversion price was initially equal to the original issue price, but could be adjusted on a broad&#8209;based weighted average basis in connection with certain dilutive events. The Series&nbsp;A holder was also entitled to receive additional shares of common stock for any unpaid Series&nbsp;A dividends (whether or not declared).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Shares of Series&nbsp;A preferred stock would have automatically converted into common stock based upon the then&#8209;effective Series&nbsp;A conversion price upon the affirmative vote or consent of the holders of at least a majority of the outstanding shares of the Series&nbsp;A preferred stock, or at the closing of a firmly underwritten public offering. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The conversion price for the Series&nbsp;A preferred stock was $6.70585 per share (as adjusted for the Reverse Stock Split) at the time of the conversion of the Series A preferred stock, together with accrued dividends thereon, immediately prior to the closing of the IPO on August 10, 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Redemption Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The holders of at least 80% of the outstanding shares of Series&nbsp;A preferred stock could have required the Company to redeem all outstanding shares of Series&nbsp;A preferred stock at any time on or after December&nbsp;31, 2020 at a redemption price equal to the greater of 150% of the liquidation preference of the Series&nbsp;A preferred stock or the fair market value per share plus any unpaid declared dividends. The liquidation preference of the Series&nbsp;A preferred stock was defined as an amount per share equal to $6.70585, as adjusted from time to time for any stock dividends, combinations, splits or recapitalizations, plus any accrued or declared but unpaid dividends thereon.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The redemption value for redeemable preferred stock could have at times been based on fair market value. The assumptions used in calculating the estimated fair market value at each reporting period represented the Company&#x2019;s best estimate, however, inherent uncertainties were involved. As a result, if factors or assumptions changed, the estimated fair value could have been materially different. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company recognized changes in the redemption value immediately as they occurred and adjusted the carrying amount of the instrument to equal the redemption value at the end of each reporting period since it was probable that the instruments would have become redeemable. In the absence of retained earnings, these charges were recorded against additional paid&#8209;in&#8209;capital, if any, and then to accumulated deficit.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company evaluated the Series&nbsp;A preferred stock and determined that it was considered an equity host under ASC 815</font><font style="display:inline;font-weight:bold;">, &nbsp;</font><font style="display:inline;font-style:italic;">Derivatives and Hedging.</font><font style="display:inline;"> In making this determination, the Company&#x2019;s analysis followed the whole instrument approach that compared an individual feature against the entire Series&nbsp;A preferred stock instrument that included that feature. The Company&#x2019;s analysis was based on a consideration of the economic characteristics and risks of the Series&nbsp;A preferred stock. More specifically, the Company evaluated all of the stated and implied substantive terms and features of the Series&nbsp;A preferred stock, including: (1)&nbsp;redemption features and their underlying exercisability, (2)&nbsp;existence of any protective covenants, (3)&nbsp;nature of dividends rights, (4)&nbsp;nature of voting rights, and (5)&nbsp;the existence and nature of any conversion rights. As a result of the above, the Company concluded that the Series&nbsp;A preferred stock represented an equity host, and as such, the redemption and/or conversion features of the Series&nbsp;A preferred stock were considered to be clearly and closely related to the associated Series&nbsp;A preferred stock host instrument. Accordingly, the redemption and/or conversion features of the Series&nbsp;A preferred stock were not considered an embedded derivative that required bifurcation.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_TemporaryEquityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure relating to temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_TemporaryEquityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808789744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; and Members&#8217; Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; and Members&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; and Members&#8217; Equity (Deficit)</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">8. Stockholders&#x2019; and Members&#x2019; Equity (Deficit)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The membership interests of MLT were converted to 1,431,228 shares of the Company&#x2019;s common stock on November&nbsp;1, 2014. The MLT members&#x2019; deficit was transferred to stockholders&#x2019; deficit on the accompanying balance sheets upon conversion to a C Corporation at that time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Common Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company had </font><font style="display:inline;color:#000000;">9,270,255</font><font style="display:inline;"> and 3,758,488 shares of its common stock issued and outstanding as of December 31, 2016 and December&nbsp;31, 2015, respectively. Voting, dividend and liquidation rights of the holders of the common stock are subject to the Company&#x2019;s articles of incorporation, corporate bylaws and underlying shareholder agreements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Dividend Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Common stock holders are entitled to receive dividends at the sole discretion of the board of directors of the Company. There have been no dividends declared on common stock as of December 31, 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Voting Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The holders of common stock are entitled to one vote for each share of common stock along with all other classes and series of stock of the Company on all actions to be taken by the stockholders of the Company, including actions that would amend the certificate of incorporation of the Company to increase the number of authorized shares of the common stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Liquidation Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In the event of any liquidation, dissolution, or winding&#8209;up of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution post preferential distributions made to holders of the Company&#x2019;s preferred stock.&nbsp;&nbsp;There was no preferred stock outstanding as of December 31, 2016. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Deferred Offering Costs</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">IPO offering costs of $4.2 million, consisting of </font><font style="display:inline;color:#000000;">underwriting discounts and commissions,</font><font style="display:inline;"> legal, accounting and other direct fees and costs, were initially capitalized and subsequently offset against the Company&#x2019;s IPO proceeds upon the close of the offering in August 2016. There were no deferred offering costs capitalized as of December 31, 2016. As of December 31, 2015, offering costs of $0.8 million were capitalized.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6639771664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">9. Share&#8209;Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Share-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying statements of comprehensive loss (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="middle" style="width:50.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended </font></p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="middle" style="width:50.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,166
				</td>
				<td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="middle" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>284
				</td>
				<td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="middle" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>552
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total share-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,718
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>284
				</td>
				<td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53
				</td>
				<td valign="bottom" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Restricted Stock Awards</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the year ended December 31, 2016, the Company did not grant any restricted stock awards (RSAs). During the years ended December 31, 2015 and 2014, the Company granted an aggregate of 44,657 and 1,605,008 RSAs, respectively, to certain of its employees, members of its board of directors and consultants subject to a 2014 Shareholders Agreement (the Agreement). The RSAs are subject to various vesting schedules and generally vest ratably over a six to twenty four month period coinciding with their respective service periods. During the years ended December 31, 2016, 2015 and 2014,&nbsp;no RSAs were forfeited.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">A summary of RSA grant activity is as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:8pt;">Weighted-Average</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:8pt;">Fair Value (per share)</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2013 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,605,008
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(610,395)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>994,613
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,567
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.21
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(691,087)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>348,093
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(344,084)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2016 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,009
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.21
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There were no RSAs granted during the year ended December 31, 2016. The grant&#8209;date fair value of the RSAs issued during the years ended December 31, 2015 and 2014 was $9,000 and $140,000 respectively. Grant date fair market value in prior years was based on traditional valuation techniques and methods in determining the fair value of the Company&#x2019;s equity as a private company including market, income, and cost valuation approaches. A number of objective and subjective factors were considered including contemporaneous and retrospective valuations of its common stock performed by an unrelated valuation specialist, sales of the Company&#x2019;s convertible preferred stock to unrelated third parties, valuations of comparable peer public companies, the lack of liquidity of the Company&#x2019;s capital stock and general and industry&#8209;specific economic outlook. The fair value of the Company&#x2019;s common stock was determined by the Company&#x2019;s board of directors prior to the IPO.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;">Stock Options</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2015, the Company adopted a 2015 Equity Incentive Plan (the 2015 Plan) under which 320,615 shares of the Company&#x2019;s common stock were reserved for issuance to employees, directors and consultants. The 2015 Plan permits the grant of incentive and non&#8209;statutory stock options, appreciation rights, restricted stock, restricted stock units, performance stock and cash awards, and other stock&#8209;based awards. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;">Amendment and Restatement of 2015 Equity Incentive Plan</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2016 the Company&#x2019;s board of directors approved the Company&#x2019;s amended and restated 2015 Plan (the A&amp;R 2015 Plan). The A&amp;R 2015 Plan became effective immediately upon the execution and delivery of the underwriting agreement related to the IPO. The A&amp;R 2015 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance-based stock awards and other forms of equity awards, as well as performance cash awards. The Company initially reserved 2,400,000 shares of common stock for issuance under the A&amp;R 2015 Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the years ended December 31, 2016 and 2015, the Company granted an aggregate of 1,825,700 and 305,278, respectively, of stock options under the A&amp;R 2015 Plan or the 2015 Plan to its officers, directors, employees and consultants, generally vesting over a three or four-year period. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;">Inducement Plan</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">In September 2016 the Company&#x2019;s board of directors approved the Company&#x2019;s Inducement Plan (the Inducement Plan). The Company initially reserved 300,000 shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, as an inducement material to the individual&#x2019;s entry into employment with the Company within the meaning of Rule&nbsp;5635(c)(4)&nbsp;of the NASDAQ Listing Rules. The Plan was approved by the Company&#x2019;s board of directors without stockholder approval pursuant to Rule&nbsp;5635(c)(4), and the terms and conditions of the Plan are substantially similar to the Company&#x2019;s stockholder-approved A&amp;R 2015 Plan. During the year ended December 31, 2016, 198,000 stock options to newly-hired officers and employees were granted under the Inducement Plan, generally vesting over a four-year period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table summarizes the Company&#x2019;s stock option plan activity for the year ended December&nbsp;31, 2016 and 2015 as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Weighted&#x2011;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Remaining</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Aggregate</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Contractual</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Intrinsic</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Term (years)</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Value(1)</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>305,278
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.42
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,436)
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.34
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Forfeited/Cancelled </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding at December&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>302,842
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.43
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.60
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,031,000
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,023,700
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.07
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Forfeited/Cancelled </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(83,742)
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.12
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding at December 31, 2016 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,242,800
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.07
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.48
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,759,000)
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested and exercisable at December&nbsp;31, 2016 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373,158
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.86
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.06
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>740,000
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested and expected to vest at December 31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,242,800
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.07
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.48
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,759,000)
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 23.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<sup style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (1)</sup>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of December 31, 2016 and 2015 of $7.84 and $5.83 per share, respectively.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The weighted average fair value per share of options granted during the years ended December&nbsp;31, 2016 and 2015 was $6.37 and $1.50, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company measures the fair value of stock options with service&#8209;based and performance&#8209;based vesting criteria to employees, consultants and directors on the date of grant using the Black&#8209;Scholes option pricing model. The fair value of equity instruments issued to non&#8209;employees is re&#8209;measured as the award vests. The Company does not have history to support a calculation of volatility and expected term. As such, the Company has used a weighted&#8209;average volatility considering the volatilities of several guideline companies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">For purposes of identifying similar entities, the Company considered characteristics such as industry, length of trading history, and stage of life cycle. The assumed dividend yield was based on the Company&#x2019;s expectation of not paying dividends in the foreseeable future. The average expected life of the options was determined based on the mid&#8209;point between the vesting date and the end of the contractual term according to the &#x201C;simplified method&#x201D; as described in Staff Accounting Bulletin 110. The risk&#8209;free interest rate is determined by reference to implied yields available from U.S. Treasury securities with a remaining term equal to the expected life assumed at the date of grant. As a result of the early adoption of </font><font style="display:inline;color:#000000;">ASU 2016-09, </font><font style="display:inline;font-style:italic;color:#000000;">Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;">, the Company has made an accounting policy election to record forfeitures when they occur. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The weighted&#8209;average assumptions used in the Black&#8209;Scholes option&#8209;pricing model are as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year&nbsp;&nbsp;Ended </font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="3" valign="middle" style="width:17.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="middle" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:17.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected stock price volatility </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71.4
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71.0
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected life of options (years)</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.0
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.5
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected dividend yield </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Risk free interest rate </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.7
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the years ended December 31, 2016 and 2015, 276,248 and 104,907 stock options vested, respectively. The weighted average fair value per share of options vesting during the years ended December 31, 2016 and 2015 was $4.59 and $1.05, respectively. During the year ended December 31, 2016, 83,742 stock options were forfeited. During the years ended December 31, 2015 and 2014, no stock options were forfeited. As of December 31, 2016, 457,200 shares were available for future issuance under the A&amp;R 2015 and Inducement Plans.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Unrecognized share&#8209;based compensation cost for the RSAs and stock options issued under the Company&#x2019;s 2014 Shareholders Agreement, A&amp;R 2015 Plan and Inducement Plan was $11.2&nbsp;million as of December 31, 2016. Approximately $11.2 million of the unrecognized compensation cost was related to the stock options and under $1,000 related to the RSAs. The non&#8209;employee portion of the unrecognized compensation cost was estimated utilizing the Company&#x2019;s fair market value for its common stock as of December 31, 2016. The unrecognized share&#8209;based expense is expected to be recognized over a weighted average period of 3.2 years for the stock options and 0.1&nbsp;years for the RSAs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;font-size:10pt;">Adoption of 2016 Employee Stock Purchase Plan</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2016 the Company&#x2019;s board of directors approved the 2016 Employee Stock Purchase Plan (the ESPP) in order to enable eligible employees to purchase shares of the Company&#x2019;s common stock at a discount following the effective date of the IPO. The Company&#x2019;s stockholders also approved the ESPP in April, 2016 and the ESPP became effective immediately upon the execution and delivery of the underwriting agreement related to the IPO. The Company initially reserved 150,000 shares of common stock for issuance under the ESPP. As of December 31, 2016, no shares were purchased under the ESPP. &nbsp; &nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808789744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">10. Net Loss Per Common Share</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Basic earnings or loss per share of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The holders of the Series&nbsp;A preferred stock had rights to participate in common stock dividends, entitling the holders of Series&nbsp;A preferred stock to a dividend payable at the same time and rate per share as the dividend paid on common stock based the number of shares of common stock each share of Series&nbsp;A preferred stock would have converted into if such shares had converted on the record date. The Series&nbsp;A preferred stock, however, did not have a contractual obligation to share in the losses of the Company, and as such, no losses were allocated to the Series&nbsp;A preferred stock for the purposes of the basic loss per share calculation while they were outstanding. Prior to the Company&#x2019;s incorporation, no common shares were outstanding when the Company operated as MLT.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Diluted earnings or loss per share of common stock is computed similarly to basic earnings or loss per share except the weighted average shares outstanding are increased to include additional shares from the assumed exercise of any common stock equivalents, if dilutive. The Company&#x2019;s RSAs, stock options, shares of Series&nbsp;A preferred stock, Convertible Notes and Interim Notes are considered common stock equivalents while outstanding for this purpose. Diluted earnings is computed utilizing the treasury method for the RSAs and stock options, and in the case of the Series&nbsp;A preferred stock, either the two&#8209;class method or the if&#8209;converted method, whichever was more dilutive. Diluted earnings with respect to the Convertible Notes and Interim Notes utilized the if&#8209;converted method, but was not applicable during the years ended December 31, 2016, 2015 and 2014 as no conditions required for conversion had occurred during these periods while the instruments were outstanding. No incremental common stock equivalents were included in calculating diluted loss per share because such inclusion would be anti&#8209;dilutive given the net loss reported for the years ended December 31, 2016, 2015 and 2014. The following table sets forth the computation of basic and diluted loss per share as of December 31, 2016, 2015 and 2014 (in thousands, except share and per share amounts):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="bottom" style="width:36.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Numerator:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustment to redemption value on Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(366)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,968)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium upon substantial modification of convertible notes with certain stockholders</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,047)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss attributed to common stock holders</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,952)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,044)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Denominator:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted weighted average common shares outstanding</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,809,396
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,875,053
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,521,703
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted net loss per share</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.57)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.54)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.21)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following potential common shares were not considered in the computation of diluted net loss per share as their effect would have been anti&#8209;dilutive:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:29.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Restricted stock awards</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,009
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>348,093
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>994,613
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock options</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,242,800
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>302,842
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Series&nbsp;A</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>745,637
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>828,751
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808859664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">11. Fair Value Measurements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company follows accounting guidance that emphasizes that fair value is a market&#8209;based measurement, not an entity specific measurement. Fair value is defined as &#x201C;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#x201D; Fair value measurements are defined on a three level hierarchy:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Level&nbsp;1 inputs:</font><font style="display:inline;"> &nbsp;Unadjusted quoted prices for identical assets or liabilities in active markets;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Level&nbsp;2 inputs:</font><font style="display:inline;"> &nbsp;Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, weather directly or indirectly, for substantially the full term of the asset or liability;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Level&nbsp;3 inputs:</font><font style="display:inline;"> &nbsp;Unobservable inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December 31, 2016 and 2015, the fair values of cash and cash equivalents, other assets, accounts payable and accrued liabilities approximated their carrying values because of the short&#8209;term nature of these assets or liabilities. The estimated fair value of the Company&#x2019;s Interim Notes was based on amortized cost which was deemed to approximate fair value. The derivative liability associated with the conversion premium on the Interim Notes was based on cash flow models discounted at current implied market rates evidenced in recent arms&#8209;length transactions representing expected returns by market participants for similar instruments which were based on Level&nbsp;3 inputs. There were no transfers between fair value hierarchy levels during the years ended December 31, 2016 and 2015.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The fair value of financial instruments measured on a recurring basis is as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:39.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As of December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Description</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Level&nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium conversion derivative</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total liabilities at Fair Value</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table provides a roll&#8209;forward of the Company&#x2019;s premium conversion derivative liabilities measured at fair value on a recurring basis using unobservable level&nbsp;3 inputs (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 92.80%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For&nbsp;the Year Ended December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Balance as of beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Issuance of underlying convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>505
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>842
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Change in fair value of premium conversion derivative</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(850)
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>297
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Reversal of premium conversion derivative associated with note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(182)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Redemption of underlying convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(685)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Balance as of end of period</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">There were no financial instruments measured on a recurring basis as of December 31, 2016 and on a non&#8209;recurring basis for any of the periods presented.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6598269136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">12. Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The effective tax rate for the years ended December&nbsp;31, 2016, 2015 and 2014 was zero percent. MLT was treated as a partnership for federal and state income tax purposes. Accordingly, no provision was made for income taxes for periods prior to the merger, since the Company&#x2019;s net loss (subject to certain limitations) was passed through to the income tax returns of its members. Upon the incorporation of Gemphire on October&nbsp;30, 2014, the Company became taxed as a corporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">A reconciliation of income tax computed at the statutory federal income tax rate to the provision (benefit) for income taxes included in the accompanying statements of comprehensive loss is as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="bottom" style="width:40.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For the Year Ended December 31, </font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="middle" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="middle" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Income tax (benefit) provision at federal statutory rate </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34.0)
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34.0)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34.0)
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Valuation allowance </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40.2
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38.2
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36.8
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">State income tax, net of federal benefit </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.7)
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.0)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.0)
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.1
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.6
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research credits</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.0)
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.4
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.8)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Effective tax rate </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Significant components of the Company&#x2019;s deferred tax assets and liabilities are summarized in the tables below as of (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:36.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended December 31, </font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:17.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="middle" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:16.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Federal and state operating loss carryforwards </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,289
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,723
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development costs deferral election</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,254
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Acquired intangibles </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>351
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accruals</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>460
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Charitable contributions </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>633
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development credit carryforwards </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>768
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,320
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,668
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Valuation allowance </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,320)
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,657)
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total deferred tax assets, net of valuation allowance </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Restricted stock awards </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11)
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total deferred tax liabilities </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11)
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net deferred tax assets </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-size:8pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016 and 2015, the Company had gross deferred tax assets of approximately $9.3 million and $3.7&nbsp;million, respectively. Realization of the deferred assets is primarily dependent upon future taxable income, if any, the amount and timing of which are uncertain. The Company has had significant pre&#8209;tax losses since its inception. The Company has not yet generated revenues and faces significant challenges to becoming profitable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance of $9.3 million and $3.7&nbsp;million as of December&nbsp;31, 2016 and 2015, respectively. U.S. net deferred tax assets will continue to require a valuation allowance until the Company can demonstrate their realizability through sustained profitability or another source of income. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As of December&nbsp;31, 2016 and 2015, the tax effect of the Company&#x2019;s federal net operating loss carryforwards was approximately $2.1 million and $2.4&nbsp;million, respectively. The Company had federal research credit carryforwards as of December&nbsp;31, 2016 and 2015 of approximately $0.7 million and $95,000, respectively. The federal net operating loss and tax credit carryforwards will begin to expire in 2034 if not utilized. As of December&nbsp;31, 2016 and 2015, the Company had state net operating loss carryforwards with a tax effect of approximately $0.2 million and $0.3&nbsp;million, respectively. The Company had state research credit carryforwards of $24,000 as of December&nbsp;31, 2016 and no state research credit carryforwards as of December 31, 2015. The state net operating loss carryforwards will begin to expire in 2026, if not utilized, and the state research credit carryforwards will begin to expire in 2023 if not utilized.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, and similar state provisions. Generally, in addition to certain entity reorganizations, the limitation applies when one or more &#x201C;5-percent shareholders&#x201D; increase their ownership, in the aggregate, by more than 50&nbsp;percentage points over a 36&#8209;month time period testing period, or beginning the day after the most recent ownership change, if shorter. The annual limitation may result in the expiration of net operating losses and credits before utilization.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company recognizes interest and/or penalties related to uncertain tax positions in income tax expense. There were no uncertain tax positions as of December&nbsp;31, 2016 and 2015, and as such, no interest or penalties were recorded to income tax expense.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s corporate returns are subject to examination for the 2014 and 2015 tax years for federal and subject to examination for the 2015 tax year in various state jurisdictions. Prior to this period, the Company filed partnership returns, resulting in its income being passed through to its members.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6644962400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Data &#8212; Quarterly Financial Data (unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Supplementary Data &#8212; Quarterly Financial Data (unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Supplementary Data &#8212; Quarterly Financial Data (unaudited)</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 6pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">13. </font><font style="display:inline;font-weight:bold;color:#000000;">Supplementary Data &#x2014; Quarterly Financial Data (unaudited)</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">The following table presents certain unaudited quarterly financial information for each of the eight fiscal quarters in the period ended December 31, 2016. This quarterly information has been prepared on the same basis as the audited financial statements and includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the information for the periods presented. The results for these quarterly periods are not necessarily indicative of the operating results for a full year or any future period.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September 30,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June 30,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March 31,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016 (B)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands, except per share amounts)</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,389
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,466
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,051
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,050
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,839
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,936
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>789
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,176
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,228
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,402
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,840
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,226
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,228)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,402)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,840)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,226)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Interest income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(475)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>449
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss before income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision (benefit) for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other comprehensive loss, net of tax</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustment to redemption value on Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(67)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(150)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(149)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss attributable to common stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,945)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,541)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,252)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss per share:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted (A)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.78)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.56)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.42)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.65)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September 30,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June 30,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March 31,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands, except per share amounts)</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,047
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>997
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>658
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>475
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,464
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,369
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>952
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>206
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Acquired in&#x2013;process research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>908
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,511
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,366
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,610
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,589
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,511)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,366)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,610)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,589)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Interest income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>137
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(209)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(690)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss on convertible note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(198)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss before income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision (benefit) for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other comprehensive loss, net of tax</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustment to redemption value on Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(150)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(152)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(149)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,517)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium upon substantial modification of convertible notes with certain stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,047)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss attributable to common stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,767)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,721)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,760)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,796)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss per share:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted (A)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.14)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.87)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.60)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.27)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 23.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<sup style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (A)</sup>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Net loss per share for the year does not equal the sum of the four historical quarters loss per share due to changes in weighted-average shares outstanding.</font><font style="display:inline;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 23.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<sup style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (B)</sup>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Activity for the quarterly period ending December 31, 2016 reflects activity post IPO depicting a ramp-up of research and development expenses given the additional IPO proceeds and an increase in general and administrative expenses attributed to becoming a public company.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1570-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e765-108305<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=68064558&amp;loc=d3e725-108305<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6797805168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">14. Related Party Transactions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company rented an office in Northville, Michigan from an&nbsp;LLC owned by two officers under short&#8209;term agreements during the years ended December 31, 2016, 2015 and 2014. The original facility lease, as amended, was cancelled and replaced with a cancellable lease agreement in August 2016 for limited use of office space in the same Northville location. The new lease agreement became effective in August 2016 and expires in September 2017. Rent expense under the related party agreements was $21,000,&nbsp;$23,000 and $6,000 during the years ended December 31, 2016, 2015 and 2014, respectively. A prepaid rent balance related to the short&#8209;term agreements amounted to zero and $3,000 as of December&nbsp;31, 2016 and 2015, respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the first quarter of 2015, the Company issued $2.0&nbsp;million of additional Convertible Notes (the 2015 Notes) as part of the Convertible Notes described in Note&nbsp;4&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Debt</font><font style="display:inline;">. The 2015 Notes included four notes in the aggregate of $0.3&nbsp;million issued to investors who were related to one board member and three officers of the Company. On March 31, 2015, all of the Convertible Notes (including the 2015 Notes) were converted into 516,421 shares of Series&nbsp;A preferred stock. The conversion included a total of 68,649 shares of Series&nbsp;A preferred stock issued to two officers of the Company, and 63,967 shares of Series&nbsp;A preferred stock issued to investors related to one board member and three officers of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">During the third quarter of 2015, the Company issued $2.8&nbsp;million of Interim Notes as described in Note&nbsp;4&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Debt</font><font style="display:inline;">. Such Interim Notes included five notes issued to two officers and three board members (or entities they control) in the amount of $0.5&nbsp;million. In addition, such Interim Notes included four notes to investors who were related to three of the Company&#x2019;s officers and to one of the Company&#x2019;s key employees in the amount of $0.3&nbsp;million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In December 2015, the Company issued an additional $2.7&nbsp;million of Interim Notes, as described in Note&nbsp;4&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Debt,</font><font style="display:inline;"> which included six notes issued to two officers and four board members in the amount of $0.6&nbsp;million. The December 2015 Interim Note issuances also included five notes to investors who were related to three of the Company&#x2019;s officers in the amount of $0.2&nbsp;million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In February 2016, the Company issued an additional $0.2 million of Interim Notes, as described in Note&nbsp;4&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Debt,</font><font style="display:inline;"> which included two notes issued to two board members (or entities they control) in the amount of $81,000. The February 2016 Interim Note issuances also included a $20,000 note to an investor who is related to an officer of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In April 2016, the Company issued an additional $5.0 million of Interim Notes, as described in Note&nbsp;4&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Debt,</font><font style="display:inline;"> which included two notes to investors who were related to two of the Company&#x2019;s officers in the aggregate amount of $0.2&nbsp;million. The April 2016 Interim Notes issuances also included three notes to investors who were related to three of the Company&#x2019;s directors in the aggregate amount of $2.3 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The IPO included 154,450 shares sold to 5 officers and 3 board members, totaling $1.5 million. In addition, 500,000 shares were sold to 1 investor who is related to 1 of the Company&#x2019;s directors, totaling $5.0 million, and 47,000 shares totaling $0.5 million were sold to 14 investors who are related to 5 officers of the Company.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6638119904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">15. </font><font style="display:inline;font-weight:bold;">Subsequent Events</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 10 2017, the Company entered into a securities purchase agreement for a private placement with a select group of accredited investors whereby, on March 15, 2017 the Company issued and sold 1,324,256 units at a price of $9.47 per unit for gross proceeds of approximately $12.5 million. Each unit consists of one share of the Company&#x2019;s common stock and a warrant to purchase 0.75 shares of common stock. The warrants have an exercise price of $10.40 per share and are exercisable for a period of five years from the date of issuance. The private placement included 56,678 units sold to 3 board members, for aggregate proceeds totaling approximately $0.5 million and 52,798 units sold to 1 investor who is related to 1 board member, for proceeds totaling approximately $0.5 million.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The securities were issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Company have agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the private placement and issuable upon exercise of the warrant issued in the private placement.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808801392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAndQualifyingAccountsAbstract', window );"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="16" valign="bottom" style="width:99.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">SCHEDULE II</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="16" valign="bottom" style="width:99.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">VALUATION AND QUALIFYING ACCOUNTS</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="14" valign="bottom" style="width:68.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Beginning </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:34.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Additions</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Ending </font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Balance of</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:18.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Charged to </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Charged to</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Balance of</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Description</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Period</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:18.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Costs and Expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Paid in Capital</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Releases</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Period</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="16" valign="bottom" style="width:99.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in&nbsp;thousands)</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For the Year Ended December 31, 2014</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Valuation allowance for deferred taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For the Year Ended December 31, 2015</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Valuation allowance for deferred taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>72
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,447
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>138
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,657
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For the Year Ended December 31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:30.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt 0.05pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">Valuation allowance for deferred taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,657
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:16.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,937
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(274)
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 3pt 0.05pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,320
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0.05pt 0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818073920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Use of Estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company considers all highly liquid investments with an original maturity of 90&nbsp;days or less at the time of deposit to be cash equivalents. The Company invests excess cash in readily available checking and savings accounts and highly liquid investments in money market accounts.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Fair Value of Financial Instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company&#x2019;s financial instruments include principally cash and cash equivalents, other current assets, accounts payable, accrued liabilities and debt. The carrying amounts for these financial instruments reported in the balance sheets approximate their fair values. See Note&nbsp;11&nbsp;&#x2014; Fair Value Measurements, for further discussion of fair value.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">General and Administrative Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">General and administrative expenses consist primarily of personnel&#8209;related costs, including salaries and share&#8209;based compensation costs, for personnel in functions not directly associated with research and development activities. Other significant costs include legal fees related to intellectual property and corporate matters and professional fees for accounting and other services.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Research and Development Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Research and development expenses consist of costs incurred in performing research and development activities, including compensation for research and development employees, costs associated with preclinical studies and trials, regulatory activities, manufacturing activities to support clinical activities, license fees, non&#8209;legal patent costs, fees paid to external service providers that conduct certain research and development, clinical costs and an allocation of overhead expenses. Research and development costs are expensed as incurred.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development Expenses</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Acquired In&#8209;Process Research and Development Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company includes costs to acquire or in&#8209;license product candidates in acquired in&#8209;process research and development expenses. The Company has acquired the right to develop and commercialize its product candidate gemcabene. These costs are immediately expensed provided that the payments do not also represent processes or activities that would constitute a &#x201C;business&#x201D; as defined under GAAP or provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Royalties owed on future sales of any licensed product will be expensed in the period the related revenues are recognized.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Income Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company utilizes the liability method of accounting for income taxes as required by Accounting Standards Codification (ASC) 740, </font><font style="display:inline;font-style:italic;">Income Taxes</font><font style="display:inline;">. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Currently, there is no provision for income taxes, as the Company has incurred operating losses to date, and a full valuation allowance has been provided on the net deferred tax assets. MLT was treated as a partnership for federal and state income tax purposes. Accordingly, no provision was made for income taxes for periods prior to November&nbsp;1, 2014, since the Company&#x2019;s net loss (subject to certain limitations) was passed through to the income tax returns of its members. Upon incorporation on October&nbsp;30, 2014, the Company became taxed as a corporation.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Share&#8209;Based Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The Company accounts for share&#8209;based compensation in accordance with the provisions of ASC 718, </font><font style="display:inline;font-style:italic;">Compensation&nbsp;&#x2014; Stock Compensation</font><font style="display:inline;"> (ASC 718). Accordingly, compensation costs related to equity instruments granted are recognized at the grant&#8209;date fair value. Additionally, as a result of the early adoption of </font><font style="display:inline;color:#000000;">ASU 2016-09, </font><font style="display:inline;font-style:italic;color:#000000;">Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;">, the Company has made an accounting policy election to record forfeitures when they occur. Share&#8209;based compensation arrangements to non&#8209;employees are accounted for in accordance with the applicable provisions of ASC 718 and ASC 505, </font><font style="display:inline;font-style:italic;">Equity</font><font style="display:inline;">, using a fair value approach. The compensation costs of these arrangements are subject to re&#8209;measurement as the equity instruments vest and are recognized as expense over the related service period (typically the vesting period of the awards).</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Common Stock Valuation</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Common Stock Valuation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Due to the absence of an active market for the Company&#x2019;s common stock prior to the close of the IPO, the Company utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#x2019; Technical Practice Aid, </font><font style="display:inline;font-style:italic;">Valuation of Privately&#8209;Held Company Equity Securities Issued as Compensation</font><font style="display:inline;">, to estimate the fair value of its common stock. The valuation methodology included estimates and assumptions that required the Company&#x2019;s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biopharmaceutical industry sector, and the likelihood of achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could have resulted in different fair values of common stock at each valuation date.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Convertible Preferred Stock</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Convertible Preferred Stock</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">On March 31, 2015, the Company issued 745,637 shares of Series&nbsp;A convertible preferred stock (the Series&nbsp;A preferred stock). On August 10, 2016, immediately prior to the closing of the IPO, the Company&#x2019;s Series A preferred stock, together with accrued dividends thereon, converted into 827,205 shares of common stock. The Series&nbsp;A preferred stock prior to conversion was classified outside of permanent equity, in mezzanine equity, on the Company&#x2019;s balance sheet. The Company initially records preferred stock that may be redeemed at the option of the holder, or based on the occurrence of events outside of the Company&#x2019;s control, at the value of the proceeds received. Subsequently, if it is probable that the preferred stock will become redeemable, the Company recognizes changes in the redemption value immediately as they occur and adjusts the carrying amount of the instrument to equal the redemption value at the end of each reporting period. If it is not probable that the preferred stock will become redeemable, the Company does not adjust the carrying value. In the absence of retained earnings, these charges are recorded against additional paid&#8209;in&#8209;capital, if any, and then to accumulated deficit See Note&nbsp;7&nbsp;&#x2014; </font><font style="display:inline;font-style:italic;">Convertible Series&nbsp;A Preferred Stock</font><font style="display:inline;"> for further discussion. As a result of their conversion to common stock on August 10, 2016 as described above, no shares of Series A preferred stock were outstanding as of December 31, 2016.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Segment Information</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Operating segments are components of an enterprise for which separate financial information is available and is evaluated regularly by the Company&#x2019;s chief operating decision maker in deciding how to allocate resources and assessing performance. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer. The Company&#x2019;s Chief Executive Officer views the Company&#x2019;s operations and manages its business in one operating segment, which is the business of development and commercialization of therapeutics for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease and NAFLD/NASH. Accordingly, the Company has a single reporting segment.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock', window );">Jumpstart Our Business Startups Act Accounting Election</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Jumpstart Our Business Startups Act Accounting Election</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">As an emerging growth company under the Jumpstart Our Business Startups Act (JOBS Act), the Company is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. The Company has irrevocably elected not to avail itself of this exemption and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In May 2014, the FASB issued ASU 2014&#8209;09, </font><font style="display:inline;font-style:italic;">Revenue from Contracts with Customers&nbsp;&#x2014; Topic 606</font><font style="display:inline;">, which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In 2015, the FASB agreed to allow companies to delay the implementation of this standard for one year effective for annual reporting periods beginning after December&nbsp;15, 2017, including interim periods within that reporting period. Early application is permitted only for periods beginning after December&nbsp;15, 2016. The Company plans to adopt this standard on January&nbsp;1, 2018 and to select the modified retrospective transition method. The Company plans to modify its accounting policies to reflect the requirements of this standard however, the planned adoption will not affect the Company&#x2019;s financial statements and related disclosures for these periods or future periods until the Company generates revenues.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In August 2014, the FASB issued Accounting Standards Update No.&nbsp;2014&#8209;15, </font><font style="display:inline;font-style:italic;">Presentation of Financial Statements&nbsp;&#x2014; Going Concern (Subtopic 205&#8209;40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern</font><font style="display:inline;"> (ASU 2014&#8209;15), which requires management to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events that, considered in the aggregate, raise substantial doubt about an entity&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable) and provide related disclosures. ASU 2014&#8209;15 is effective for the annual period ending after December&nbsp;15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. The Company elected to adopt this standard early as of December 31, 2015 and did not have a material impact on the Company&#x2019;s financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In November 2015, the Financial Accounting Standards Board (FASB) issued ASU 2015&#8209;17, </font><font style="display:inline;font-style:italic;">Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</font><font style="display:inline;"> (ASU 2015&#8209;17). The new guidance simplifies the presentation of deferred income taxes by requiring that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. ASU 2015&#8209;17 applies to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax&#8209;paying component of an entity be offset and presented as a single amount is not affected by this ASU. For public entities, ASU 2015&#8209;17 is effective for financial statements issued for annual periods beginning after December&nbsp;15, 2016 with earlier application permitted. The new guidance may be applied either prospectively or retrospectively to all periods presented. The Company </font><font style="display:inline;color:#000000;">adopted this standard effective April 1, 2016 on a retrospective basis for each period presented. </font><font style="display:inline;">The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">In January 2016, the FASB issued ASU No.&nbsp;2016&#8209;01, </font><font style="display:inline;font-style:italic;">Financial Instruments&nbsp;&#x2014; Overall: Recognition and Measurement of Financial Assets and Financial Liabilities.</font><font style="display:inline;"> The guidance affects the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements of financial instruments. The guidance is effective in the first quarter of fiscal 2019. Early adoption is permitted for the accounting guidance on financial liabilities under the fair value option. The Company is currently evaluating the impact of the new guidance on its financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, </font><font style="display:inline;font-style:italic;color:#000000;font-size:10pt;">Leases (Topic </font><font style="display:inline;color:#000000;font-size:10pt;">842). The objective of this update is to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those annual periods and is to be applied utilizing a modified retrospective approach. The Company is currently evaluating the new guidance to determine the impact it may have on its financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">In March 2016, the FASB issued ASU 2016-09, </font><font style="display:inline;font-style:italic;color:#000000;">Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="display:inline;color:#000000;">. This ASU simplifies the accounting for share-based payment award transactions including: income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December&nbsp;15, 2016, including interim periods within those fiscal years. Early adoption is permitted. </font><font style="display:inline;">The Company </font><font style="display:inline;color:#000000;">adopted this standard effective July 1, 2016 on a retrospective basis for each period presented. </font><font style="display:inline;">The adoption of this standard did not have a material impact on the Company&#x2019;s financial statements.</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;background-color: #FFFFFF;">In November 2016, the FASB issued ASU No.&nbsp;2016-18, </font><font style="display:inline;font-style:italic;color:#000000;background-color: #FFFFFF;">Statement of Cash Flows (Topic 230): Restricted Cash</font><font style="display:inline;color:#000000;background-color: #FFFFFF;">. The objective of this ASU is to eliminate the diversity in practice related to the classification of </font><font style="display:inline;">restricted cash or restricted cash equivalents in the statement of cash flows. </font><font style="display:inline;color:#000000;background-color: #FFFFFF;">For public business entities, this ASU is effective for annual and interim reporting periods beginning after December&nbsp;15, 2017, with early adoption permitted. The amendments in this update should be applied retrospectively to all periods presented. The Company is currently evaluating the requirements of this new guidance and has not yet determined its impact on the Company&#x2019;s financial statements.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policies for Jumpstart Our Business Startups Act Accounting Election.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_JumpstartOurBusinessStartupsActAccountingElectionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6403650&amp;loc=d3e20905-112640<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21459-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808958048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Accrued liabilities consist of the following (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As&nbsp;of&nbsp;December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued offering costs</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>575
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Legal costs</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>234
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accrued compensation costs</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>706
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,259
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>759
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other general and administrative expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:69.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,113
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,617
				</td>
				<td valign="bottom" style="width:01.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6808818320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future minimum lease payments</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:17.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>58
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;Total</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>260
				</td>
				<td valign="bottom" style="width:02.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6603344224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Share-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying statements of comprehensive loss (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
						<font style="display:inline;font-size:11pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="middle" style="width:50.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended </font></p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="middle" style="width:50.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="middle" style="width:14.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:13.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,166
				</td>
				<td valign="middle" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="middle" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>284
				</td>
				<td valign="middle" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="middle" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53
				</td>
				<td valign="middle" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>552
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:42.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 6pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total share-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:04.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,718
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>284
				</td>
				<td valign="bottom" style="width:04.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>53
				</td>
				<td valign="bottom" style="width:02.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSA grant activity</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:8pt;">Weighted-Average</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Shares</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-family:Times;font-weight:bold;font-size:8pt;">Fair Value (per share)</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2013 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,605,008
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(610,395)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>994,613
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44,567
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.21
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(691,087)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>348,093
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(344,084)
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.09
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Non&#x2011;vested at December&nbsp;31, 2016 </font></p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,009
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:20.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.21
				</td>
				<td valign="bottom" style="width:02.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option plan activity</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Weighted&#x2011;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Weighted</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Average</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Remaining</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Aggregate</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Exercise</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Contractual</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Intrinsic</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:14.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Price</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Term (years)</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:16.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Value(1)</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>305,278
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.42
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,436)
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.34
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Forfeited/Cancelled </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding at December&nbsp;31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>302,842
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.43
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.60
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,031,000
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,023,700
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>10.07
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Forfeited/Cancelled </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(83,742)
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.12
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Outstanding at December 31, 2016 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,242,800
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.07
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.48
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,759,000)
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested and exercisable at December&nbsp;31, 2016 </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373,158
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.86
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.06
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>740,000
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:32.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Vested and expected to vest at December 31, 2016</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,242,800
				</td>
				<td valign="bottom" style="width:01.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.07
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9.48
				</td>
				<td valign="bottom" style="width:01.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,759,000)
				</td>
				<td valign="bottom" style="width:01.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 23.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<sup style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (1)</sup>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of our common stock as of December 31, 2016 and 2015 of $7.84 and $5.83 per share, respectively.</font></p></td></tr></table></div><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions, option-pricing model</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year&nbsp;&nbsp;Ended </font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="middle" style="width:58.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="3" valign="middle" style="width:17.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="middle" style="width:18.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="middle" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:17.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected stock price volatility </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71.4
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>71.0
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected life of options (years)</font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.0
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.5
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Expected dividend yield </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:37.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Risk free interest rate </font></p>
				</td>
				<td valign="middle" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.7
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6782911952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted loss per share</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table sets forth the computation of basic and diluted loss per share as of December 31, 2016, 2015 and 2014 (in thousands, except share and per share amounts):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="bottom" style="width:36.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Numerator:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,586)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,029)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustment to redemption value on Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(366)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,968)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium upon substantial modification of convertible notes with certain stockholders</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,047)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss attributed to common stock holders</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(14,952)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13,044)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(320)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Denominator:</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted weighted average common shares outstanding</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,809,396
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,875,053
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,521,703
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted net loss per share</font></p>
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.57)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.54)
				</td>
				<td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.21)
				</td>
				<td valign="bottom" style="width:00.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potential common shares not considered in computation of diluted net loss per share</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:29.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended </font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Restricted stock awards</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,009
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>348,093
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>994,613
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock options</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,242,800
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>302,842
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Series&nbsp;A</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>745,637
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>828,751
				</td>
				<td valign="bottom" style="width:01.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6800386528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of financial instruments measured on recurring basis</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The fair value of financial instruments measured on a recurring basis is as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:39.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">As of December&nbsp;31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Description</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Level&nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Level&nbsp;2</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Level&nbsp;3</font></p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium conversion derivative</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total liabilities at Fair Value</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:00.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of premium conversion derivative liabilities measured at fair value on recurring basis using unobservable level 3 inputs</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">The following table provides a roll&#8209;forward of the Company&#x2019;s premium conversion derivative liabilities measured at fair value on a recurring basis using unobservable level&nbsp;3 inputs (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 92.80%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For&nbsp;the Year Ended December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:07.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Balance as of beginning of period</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Issuance of underlying convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>505
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>842
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>55
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Change in fair value of premium conversion derivative</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(850)
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>297
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Reversal of premium conversion derivative associated with note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(182)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Redemption of underlying convertible notes</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(685)
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Balance as of end of period</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:06.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:05.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:01.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73
				</td>
				<td valign="bottom" style="width:00.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6761557776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of statutory federal income tax rate to the provision (benefit)</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="8" valign="bottom" style="width:40.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">For the Year Ended December 31, </font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="middle" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:11.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="middle" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="middle" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Income tax (benefit) provision at federal statutory rate </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34.0)
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34.0)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(34.0)
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Valuation allowance </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>40.2
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>38.2
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>36.8
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">State income tax, net of federal benefit </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.7)
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.0)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.0)
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.1
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.6
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research credits</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4.0)
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.4
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.8)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:55.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Effective tax rate </font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:01.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">%</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Significant components of the Company&#x2019;s deferred tax assets and liabilities are summarized in the tables below as of (in thousands):</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:36.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Year Ended December 31, </font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax assets:</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:17.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="middle" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:16.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Federal and state operating loss carryforwards </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,289
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,723
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development costs deferral election</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,254
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Acquired intangibles </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>351
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>345
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Accruals</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Convertible notes </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>460
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Charitable contributions </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Stock-based compensation</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>633
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>41
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development credit carryforwards </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>768
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9,320
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,668
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Valuation allowance </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9,320)
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,657)
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total deferred tax assets, net of valuation allowance </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Deferred tax liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Restricted stock awards </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11)
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total deferred tax liabilities </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11)
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net deferred tax assets </font></p>
				</td>
				<td valign="bottom" style="width:03.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6639808576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Data &#8212; Quarterly Financial Data (unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Quarterly Financial Data [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of unaudited consolidated quarterly financial information</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September 30,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June 30,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March 31,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016 (B)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands, except per share amounts)</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,389
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,466
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,051
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,050
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,839
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,936
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>789
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,176
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7,228
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,402
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,840
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,226
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,228)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,402)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,840)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,226)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Interest income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(475)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>449
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>127
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss before income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision (benefit) for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other comprehensive loss, net of tax</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,878)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,391)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,103)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustment to redemption value on Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(67)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(150)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(149)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss attributable to common stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(7,214)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,945)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,541)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,252)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss per share:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted (A)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.78)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.56)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.42)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.65)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">Three Months Ended</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">September 30,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">June 30,</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">March 31,</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="11" valign="bottom" style="width:44.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;">
						<font style="display:inline;font-weight:bold;font-size:8pt;">(in thousands, except per share amounts)</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:9pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,047
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>997
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>658
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>475
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,464
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,369
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>952
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>206
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Acquired in&#x2013;process research and development</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>908
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,511
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,366
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,610
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,589
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss from operations</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,511)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,366)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,610)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,589)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Interest income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>137
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(209)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(690)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss on convertible note extinguishment</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(198)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other income (expense)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Loss before income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Provision (benefit) for income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Other comprehensive loss, net of tax</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,570)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,569)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,611)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,279)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Adjustment to redemption value on Series&nbsp;A convertible preferred stock</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(150)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(152)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(149)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,517)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Premium upon substantial modification of convertible notes with certain stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,047)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:11pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss attributable to common stockholders</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,767)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2,721)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,760)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(4,796)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Net loss per share:</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:52.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 19.2pt;line-height:11pt;text-indent: -7.2pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">Basic and diluted (A)</font></p>
				</td>
				<td valign="bottom" style="width:02.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1.14)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:09.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.87)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:07.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(0.60)
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2.27)
				</td>
				<td valign="bottom" style="width:00.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:11pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt solid #000000 ;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 23.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<sup style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (A)</sup>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Net loss per share for the year does not equal the sum of the four historical quarters loss per share due to changes in weighted-average shares outstanding.</font><font style="display:inline;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 23.00pt; display: inline;">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
				<sup style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size:10pt;;"> (B)</sup>
			</p>
		</td><td style="width:13pt;"><p style="width:13pt;width:13pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;font-family:Times New Roman,Times,serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;color:#000000;">Activity for the quarterly period ending December 31, 2016 reflects activity post IPO depicting a ramp-up of research and development expenses given the additional IPO proceeds and an increase in general and administrative expenses attributed to becoming a public company.</font></p></td></tr></table></div><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=68076893&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818689136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation (IPO and Capital Requirements) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 08, 2016</div></th>
<th class="th"><div>Aug. 04, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Aug. 03, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,963<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">17,674,419<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par Value (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par Value (in dollar per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Underwriting discounts and commissions</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Other offering expenses</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Overallotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">27,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6806076128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation (Basis of Presentation) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">0.320615582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201517Member', window );">ASU 2015-17 | Adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesCurrent', window );">Current deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201517Member', window );">ASU 2015-17 | Early Adoption | Adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Long term deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201517Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201517Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementEarlyAdoptionAxis=us-gaap_NewAccountingPronouncementEarlyAdoptionEffectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818064288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred stock, share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Convertible Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred stock, share issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">745,637<span></span>
</td>
<td class="nump">745,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares converted</a></td>
<td class="nump">827,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred stock, share outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">745,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember', window );">MLT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationAdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationAdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811143536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_AccruedOfferingCostsCurrent', window );">Accrued offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal costs</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation costs</a></td>
<td class="nump">706<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_AccruedOtherResearchAndDevelopmentExpenses', window );">Other research and development expenses</a></td>
<td class="nump">1,259<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_AccruedOtherGeneralAndAdministrativeExpenses', window );">Other general and administrative expenses</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,113<span></span>
</td>
<td class="nump">$ 1,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_AccruedOfferingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for stock offering costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_AccruedOfferingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_AccruedOtherGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for other general and administrative expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_AccruedOtherGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_AccruedOtherResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for other research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_AccruedOtherResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821162464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th">
<div>Nov. 01, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 18, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,651,000<span></span>
</td>
<td class="nump">$ 5,560,000<span></span>
</td>
<td class="nump">$ 390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes to common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,431,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Promissory Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible debt, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Financing total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Promissory notes converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible debt, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Financing total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal', window );">Conversion price percentage of principal and unpaid accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember', window );">Convertible Notes | Interest income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gemp_FinancingConvertibleDebtMember', window );">Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible debt, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Financing total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600,000<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares converted | shares</a></td>
<td class="nump">1,656,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold', window );">Qualified Financing threshold for debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount', window );">Debt redemption price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.70585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.70585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes to common stock, shares | shares</a></td>
<td class="nump">1,656,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gemp_FinancingConvertibleDebtMember', window );">Interim Notes | Interest income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum gross proceeds received in an equity offering which would trigger the automatic conversion of the debt instrument into equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_DebtInstrumentAutomaticConversionEquityOfferingThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's conversion value exceeds the amount of principal and unpaid accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the redemption price as a percentage of the principal amount at which the debt instrument may be required to be redeemed in the event of a change of control.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_DebtRedemptionPriceDueToChangeOfControlAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Conversion Rate<br> -URI http://asc.fasb.org/extlink&amp;oid=6509012<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=gemp_InterestIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=gemp_InterestIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gemp_FinancingConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gemp_FinancingConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6639901936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contigencies - Pfizer License Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">No liabilities were recorded related to the license agreement</a></td>
<td class="nump">$ 4,122,000<span></span>
</td>
<td class="nump">$ 8,917,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gemp_PfizerInc.Member', window );">Pfizer, Inc. | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">No liabilities were recorded related to the license agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=gemp_PfizerInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=gemp_PfizerInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gemp_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gemp_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821192160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contigencies - Preferred Stock Dividends (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Series A Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears', window );">Cumulative unpaid dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Series A Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Original issue price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.70585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears', window );">Cumulative unpaid dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares converted</a></td>
<td class="nump">827,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAmountOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819108208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contigencies - Other Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Agreement Term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Monthly base rent</a></td>
<td class="nump">$ 8,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum lease payments of operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=gemp_OfficeRentalMember', window );">Office Rental</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=gemp_OfficeRentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=gemp_OfficeRentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6806565648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,278<span></span>
</td>
<td class="nump">$ 911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,027,755<span></span>
</td>
<td class="nump">677,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gemp_PfizerInc.Member', window );">Pfizer, Inc. | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_SharesIssuablePercentageOfOffering', window );">Percentage of shares of common stock offering issued to Pfizer</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gemp_PfizerInc.Member', window );">Pfizer, Inc. | License Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">675,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gemp_PfizerInc.Member', window );">Pfizer, Inc. | License Agreement | Common Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership by Pfizer</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=gemp_PfizerInc.Member', window );">Pfizer, Inc. | License Agreement | Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ContingentLiability', window );">Potential payments upon achievement of certain milestones</a></td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ContingentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents a contingent liability to make payments if certain conditions are achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ContingentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_SharesIssuablePercentageOfOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of preferred stock offering that agreement required to be issued to the licensor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_SharesIssuablePercentageOfOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=gemp_PfizerInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=gemp_PfizerInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=gemp_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=gemp_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=gemp_MilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=gemp_MilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811077168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Series A Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Series A Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible Series A preferred stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Cash proceeds from issuance of Series A preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,522,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends deemed payable and accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears', window );">Cumulative unpaid dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Series A Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal', window );">Conversion price percentage of principal and unpaid accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Series A Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of convertible Series A preferred stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Original issue price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.70585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross', window );">Aggregate consideration, cash and noncash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares converted</a></td>
<td class="nump">827,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears', window );">Cumulative unpaid dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.70585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Series A Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_LiquidationPreferencePercentageOfChangeInVoting', window );">Liquidation preference upon transfer of voting power, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_PreferredStockRedemptionRequestedByPercentageOfShares', window );">Percentage of outstanding shares which may require the Company to redeem shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_RedemptionPricePercentageOfLiquidationPreference', window );">Redemption price, as a percent of liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock. | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Convertible Series A Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Noncash consideration received, debt converted into stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal', window );">Conversion price percentage of principal and unpaid accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the convertible debt's conversion value exceeds the amount of principal and unpaid accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_DebtInstrumentConvertedPercentInExcessOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_LiquidationPreferencePercentageOfChangeInVoting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the change in voting power of the reporting entity, which triggers a liquidation preference to holders of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_LiquidationPreferencePercentageOfChangeInVoting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_PreferredStockRedemptionRequestedByPercentageOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the outstanding shares of convertible preferred stock needed to require mandatory redemption at a specified future date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_PreferredStockRedemptionRequestedByPercentageOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_RedemptionPricePercentageOfLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption price calculated as percentage of liquidation preference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_RedemptionPricePercentageOfLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period, before deduction of related offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_TemporaryEquityStockIssuedDuringPeriodValueNewIssuesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAmountOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6806787600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; and Members&#8217; Equity (Deficit) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Vote / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Membership interest converted into shares</a></td>
<td class="nump">1,431,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,270,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,758,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,270,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,758,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Membership interest converted into shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,656,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_CumulativeDividendsDeclared', window );">No dividends declared | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_CommonStockVotingRightsPerShare', window );">Common stock, vote per share | Vote / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_CommonStockVotingRightsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the voting rights per share for common stock of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_CommonStockVotingRightsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_CumulativeDividendsDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative cash dividends declared.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_CumulativeDividendsDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818170496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 1,718<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">$ 284<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6811180992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Restricted Stock) (Details) - Restricted stock awards - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted Stock Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value (in dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSA grant activity [Rollforward], Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non&#8209;vested , Begining Balance (in shares)</a></td>
<td class="nump">348,093<span></span>
</td>
<td class="nump">994,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,567<span></span>
</td>
<td class="nump">1,605,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(344,084)<span></span>
</td>
<td class="num">(691,087)<span></span>
</td>
<td class="num">(610,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non&#8209;vested , Ending Balance (in shares)</a></td>
<td class="nump">4,009<span></span>
</td>
<td class="nump">348,093<span></span>
</td>
<td class="nump">994,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>RSA grant activity [Rollforward], Weighted-Average Fair Value (per share)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non&#8209;vested , Begininng Balance (per share)</a></td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.21<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (per share)</a></td>
<td class="nump">0.09<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non&#8209;vested , Ending Balance (per share)</a></td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted Stock Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Restricted Stock Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6821549536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Stock Options) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">71.40%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember', window );">A &amp; R 2015 Plan | Officers, directors and employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,825,700<span></span>
</td>
<td class="nump">305,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember', window );">A &amp; R 2015 Plan | Officers, directors and employees | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember', window );">A &amp; R 2015 Plan | Officers, directors and employees | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember', window );">A &amp; R 2015 Plan | Employees, directors and consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for future issuance</a></td>
<td class="nump">457,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gemp_EquityIncentivePlan2015Member', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gemp_EquityIncentivePlan2015Member', window );">2015 Plan | Employees, directors and consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross', window );">Vested</a></td>
<td class="nump">276,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="nump">83,742<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gemp_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gemp_InducementPlanMember', window );">Inducement Plan | Officers and Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=gemp_InducementPlanMember', window );">Inducement Plan | Employees, directors and consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for future issuance</a></td>
<td class="nump">457,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gemp_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Number, Beginning Balance (in shares)</a></td>
<td class="nump">302,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,023,700<span></span>
</td>
<td class="nump">305,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/Cancelled (in shares)</a></td>
<td class="num">(83,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Number, Ending Balance (in shares)</a></td>
<td class="nump">2,242,800<span></span>
</td>
<td class="nump">302,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">373,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">2,242,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price, Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">10.07<span></span>
</td>
<td class="nump">$ 2.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled (in dollars per share)</a></td>
<td class="nump">9.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)</a></td>
<td class="nump">9.07<span></span>
</td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 9.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, Outstanding, Weighted Average Remaining Contractual Term (years)</a></td>
<td class="text">9 years 5 months 23 days<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable (years)</a></td>
<td class="text">9 years 22 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (years)</a></td>
<td class="text">9 years 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="num">$ (2,759,000)<span></span>
</td>
<td class="nump">$ 1,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and exercisable</a></td>
<td class="nump">740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="num">$ (2,759,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Common stock aggregate intrinsic value of exercise price</a></td>
<td class="nump">$ 5.83<span></span>
</td>
<td class="nump">$ 7.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options granted</a></td>
<td class="nump">6.37<span></span>
</td>
<td class="nump">1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average fair value per share of options vested</a></td>
<td class="nump">$ 4.59<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were vested during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price (at which grantees can acquire the shares reserved for issuance) for exercisable stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gemp_AmendmentAndRestatementOf2015EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=gemp_OfficersDirectorsAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=gemp_OfficersDirectorsAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=gemp_EmployeesDirectorsAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=gemp_EmployeesDirectorsAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gemp_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gemp_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=gemp_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=gemp_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=gemp_OfficersAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=gemp_OfficersAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gemp_EmployeeConsultantsAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6806500720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Unrecognized) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation cost</a></td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized share-based compensation cost - RSA</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation - Weighted average period</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=gemp_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation cost - Stock options</a></td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation - Weighted average period</a></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Purchased under the ESPP</a></td>
<td class="nump">2,023,700<span></span>
</td>
<td class="nump">305,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Purchased under the ESPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=gemp_EmployeeConsultantsAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6805710976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net Loss Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic', window );">Loss allocated to preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, share outstanding</a></td>
<td class="nump">9,270,255<span></span>
</td>
<td class="nump">3,758,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Incremental common stock equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember', window );">MLT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Net Loss Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, share outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_PredecessorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6806031392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Earning Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (196)<span></span>
</td>
<td class="num">$ (7,214)<span></span>
</td>
<td class="num">$ (3,878)<span></span>
</td>
<td class="num">$ (1,391)<span></span>
</td>
<td class="num">$ (2,103)<span></span>
</td>
<td class="num">$ (2,570)<span></span>
</td>
<td class="num">$ (2,569)<span></span>
</td>
<td class="num">$ (1,611)<span></span>
</td>
<td class="num">$ (2,279)<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
<td class="num">$ (14,586)<span></span>
</td>
<td class="num">$ (9,029)<span></span>
</td>
<td class="num">$ (320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Adjustment to redemption value on Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(150)<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(2,517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(366)<span></span>
</td>
<td class="num">(2,968)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ConvertibleNotesPremiumUponSubstantialModificationValue', window );">Premium upon substantial modification of convertible notes with certain stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,214)<span></span>
</td>
<td class="num">$ (3,945)<span></span>
</td>
<td class="num">$ (1,541)<span></span>
</td>
<td class="num">$ (2,252)<span></span>
</td>
<td class="num">$ (3,767)<span></span>
</td>
<td class="num">$ (2,721)<span></span>
</td>
<td class="num">$ (1,760)<span></span>
</td>
<td class="num">$ (4,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,952)<span></span>
</td>
<td class="num">$ (13,044)<span></span>
</td>
<td class="num">$ (320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average common shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,809,396<span></span>
</td>
<td class="nump">2,875,053<span></span>
</td>
<td class="nump">1,521,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (2.27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.57)<span></span>
</td>
<td class="num">$ (4.54)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ConvertibleNotesPremiumUponSubstantialModificationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for premium upon substantial modification of convertible notes to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ConvertibleNotesPremiumUponSubstantialModificationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6818049600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share - Antidilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="nump">4,009<span></span>
</td>
<td class="nump">348,093<span></span>
</td>
<td class="nump">994,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gemp_EmployeeConsultantsAndDirectorsStockOptionsMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="nump">2,242,800<span></span>
</td>
<td class="nump">302,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Convertible Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Potential common shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gemp_EmployeeConsultantsAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=gemp_EmployeeConsultantsAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820178768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Instruments Measured On Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount', window );">Transfers between levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Premium conversion derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities at Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets and liabilities measured on a recurring basis between levels in fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_FairValueAssetsLiabilitiesTransfersBetweenLevelsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6800741760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details) - Premium conversion derivative - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Roll-forward of the company's premium conversion derivative liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of underlying convertible notes</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of premium conversion derivative</a></td>
<td class="num">$ (850)<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal', window );">Reversal of premium conversion derivative associated with note extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Redemption of underlying convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reversal of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6759731168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6613763232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of income tax (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax (benefit) provision at federal statutory rate (as a percent)</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">40.20%<span></span>
</td>
<td class="nump">38.20%<span></span>
</td>
<td class="nump">36.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit (as a percent)</a></td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes', window );">Convertible notes (as a percent)</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research credits (as a percent)</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other (as a percent)</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_EffectiveIncomeTaxRateReconciliationConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6800679472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes -Significant components of deferred tax assets and liabilitie (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state operating loss carryforwards</a></td>
<td class="nump">$ 2,289<span></span>
</td>
<td class="nump">$ 2,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development costs deferral election</a></td>
<td class="nump">5,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_DeferredTaxAssetsAcquiredIntangibles', window );">Acquired intangibles</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accruals</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_DeferredTaxAssetsConvertibleNotes', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards', window );">Charitable contributions</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">9,320<span></span>
</td>
<td class="nump">3,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (9,320)<span></span>
</td>
<td class="num">(3,657)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net of valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_DeferredTaxLiabilitiesRestrictedStockAwards', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_DeferredTaxAssetsAcquiredIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from acquired intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_DeferredTaxAssetsAcquiredIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_DeferredTaxAssetsConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_DeferredTaxAssetsConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_DeferredTaxLiabilitiesRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_DeferredTaxLiabilitiesRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Liability<br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible charitable contribution carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCharitableContributionCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6800657664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Operating loss carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal research credit carryforwards</a></td>
<td class="nump">768,000<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_DeferredTaxAssetsTaxCreditCarryforwardsState', window );">State research credit carryforwards</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesAbstract', window );"><strong>Income tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ThresholdPercentageOfShareholdersOwnershipChange', window );">Threshold percentage of shareholders ownership change</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits', window );">Minimum increase in ownership percentage annual limitation may result in expiration of NOL and credits</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_PeriodForTestingPercentageOfOwnershipChange', window );">Period for testing percentage of ownership change</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_DeferredTaxAssetsTaxCreditCarryforwardsState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_DeferredTaxAssetsTaxCreditCarryforwardsState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum increase in ownership percentage annual limitation may result in expiration of net operating losses and credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_MinimumIncreaseInOwnershipPercentageAnnualLimitationMayResultInExpirationOfNetOperatingLossesAndCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_PeriodForTestingPercentageOfOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for testing percentage of ownership change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_PeriodForTestingPercentageOfOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ThresholdPercentageOfShareholdersOwnershipChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold percentage of shareholders ownership change.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ThresholdPercentageOfShareholdersOwnershipChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6819570736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Data &#8212; Quarterly Financial Data (unaudited) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,389,000<span></span>
</td>
<td class="nump">$ 1,466,000<span></span>
</td>
<td class="nump">$ 1,051,000<span></span>
</td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="nump">$ 1,047,000<span></span>
</td>
<td class="nump">$ 997,000<span></span>
</td>
<td class="nump">$ 658,000<span></span>
</td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,956,000<span></span>
</td>
<td class="nump">$ 3,177,000<span></span>
</td>
<td class="nump">$ 214,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="nump">1,936,000<span></span>
</td>
<td class="nump">789,000<span></span>
</td>
<td class="nump">1,176,000<span></span>
</td>
<td class="nump">1,464,000<span></span>
</td>
<td class="nump">1,369,000<span></span>
</td>
<td class="nump">952,000<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,740,000<span></span>
</td>
<td class="nump">3,991,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,228,000<span></span>
</td>
<td class="nump">3,402,000<span></span>
</td>
<td class="nump">1,840,000<span></span>
</td>
<td class="nump">2,226,000<span></span>
</td>
<td class="nump">2,511,000<span></span>
</td>
<td class="nump">2,366,000<span></span>
</td>
<td class="nump">1,610,000<span></span>
</td>
<td class="nump">1,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,696,000<span></span>
</td>
<td class="nump">8,076,000<span></span>
</td>
<td class="nump">266,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,228,000)<span></span>
</td>
<td class="num">(3,402,000)<span></span>
</td>
<td class="num">(1,840,000)<span></span>
</td>
<td class="num">(2,226,000)<span></span>
</td>
<td class="num">(2,511,000)<span></span>
</td>
<td class="num">(2,366,000)<span></span>
</td>
<td class="num">(1,610,000)<span></span>
</td>
<td class="num">(1,589,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,696,000)<span></span>
</td>
<td class="num">(8,076,000)<span></span>
</td>
<td class="num">(266,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="num">(475,000)<span></span>
</td>
<td class="nump">449,000<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
<td class="num">(209,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(690,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,000<span></span>
</td>
<td class="num">(762,000)<span></span>
</td>
<td class="num">(55,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on convertible note extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,214,000)<span></span>
</td>
<td class="num">(3,878,000)<span></span>
</td>
<td class="num">(1,391,000)<span></span>
</td>
<td class="num">(2,103,000)<span></span>
</td>
<td class="num">(2,570,000)<span></span>
</td>
<td class="num">(2,569,000)<span></span>
</td>
<td class="num">(1,611,000)<span></span>
</td>
<td class="num">(2,279,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,586,000)<span></span>
</td>
<td class="num">(9,029,000)<span></span>
</td>
<td class="num">(320,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (196,000)<span></span>
</td>
<td class="num">(7,214,000)<span></span>
</td>
<td class="num">(3,878,000)<span></span>
</td>
<td class="num">(1,391,000)<span></span>
</td>
<td class="num">(2,103,000)<span></span>
</td>
<td class="num">(2,570,000)<span></span>
</td>
<td class="num">(2,569,000)<span></span>
</td>
<td class="num">(1,611,000)<span></span>
</td>
<td class="num">(2,279,000)<span></span>
</td>
<td class="num">$ (124,000)<span></span>
</td>
<td class="num">(14,586,000)<span></span>
</td>
<td class="num">(9,029,000)<span></span>
</td>
<td class="num">(320,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,214,000)<span></span>
</td>
<td class="num">(3,878,000)<span></span>
</td>
<td class="num">(1,391,000)<span></span>
</td>
<td class="num">(2,103,000)<span></span>
</td>
<td class="num">(2,570,000)<span></span>
</td>
<td class="num">(2,569,000)<span></span>
</td>
<td class="num">(1,611,000)<span></span>
</td>
<td class="num">(2,279,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,586,000)<span></span>
</td>
<td class="num">(9,029,000)<span></span>
</td>
<td class="num">(320,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (196,000)<span></span>
</td>
<td class="num">(7,214,000)<span></span>
</td>
<td class="num">(3,878,000)<span></span>
</td>
<td class="num">(1,391,000)<span></span>
</td>
<td class="num">(2,103,000)<span></span>
</td>
<td class="num">(2,570,000)<span></span>
</td>
<td class="num">(2,569,000)<span></span>
</td>
<td class="num">(1,611,000)<span></span>
</td>
<td class="num">(2,279,000)<span></span>
</td>
<td class="num">$ (124,000)<span></span>
</td>
<td class="num">(14,586,000)<span></span>
</td>
<td class="num">(9,029,000)<span></span>
</td>
<td class="num">(320,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Adjustment to redemption value on Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,000)<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
<td class="num">(149,000)<span></span>
</td>
<td class="num">(150,000)<span></span>
</td>
<td class="num">(152,000)<span></span>
</td>
<td class="num">(149,000)<span></span>
</td>
<td class="num">(2,517,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(366,000)<span></span>
</td>
<td class="num">(2,968,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ConvertibleNotesPremiumUponSubstantialModificationValue', window );">Premium upon substantial modification of convertible notes with certain stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,047,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,047,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,214,000)<span></span>
</td>
<td class="num">$ (3,945,000)<span></span>
</td>
<td class="num">$ (1,541,000)<span></span>
</td>
<td class="num">$ (2,252,000)<span></span>
</td>
<td class="num">$ (3,767,000)<span></span>
</td>
<td class="num">$ (2,721,000)<span></span>
</td>
<td class="num">$ (1,760,000)<span></span>
</td>
<td class="num">$ (4,796,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,952,000)<span></span>
</td>
<td class="num">$ (13,044,000)<span></span>
</td>
<td class="num">$ (320,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (Note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.78)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (0.87)<span></span>
</td>
<td class="num">$ (0.60)<span></span>
</td>
<td class="num">$ (2.27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.57)<span></span>
</td>
<td class="num">$ (4.54)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Number of shares used in per share calculations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,809,396<span></span>
</td>
<td class="nump">2,875,053<span></span>
</td>
<td class="nump">1,521,703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ConvertibleNotesPremiumUponSubstantialModificationValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for premium upon substantial modification of convertible notes to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ConvertibleNotesPremiumUponSubstantialModificationValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12317-112629<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49170532&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6820222672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Rental agreement (Details) - Office Rental<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Rent expense</a></td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_LlcOwnedByTwoOfficersMember', window );">LLC owned by two officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfOfficersInRelatedPartyTransaction', window );">Number of officers | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Rent expense</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfOfficersInRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of officers in related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfOfficersInRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=gemp_OfficeRentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=gemp_OfficeRentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_LlcOwnedByTwoOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_LlcOwnedByTwoOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6805672272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Convertible Notes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Feb. 18, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,651<span></span>
</td>
<td class="nump">$ 5,560<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember', window );">Convertible Notes | Series A Convertible Preferred Stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Amount of shares issued in conversion | shares</a></td>
<td class="nump">516,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToBoardMemberAndOfficersMember', window );">Investors Related To Board Member And Officers | Convertible Notes | Series A Convertible Preferred Stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Amount of shares issued in conversion | shares</a></td>
<td class="nump">63,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToBoardMemberAndOfficersMember', window );">Investors Related To Board Member And Officers | Debt Issued To Related Parties | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfDebtInstrumentsIssued', window );">Number of notes issued to related party</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfBoardMembersInRelatedPartyTransaction', window );">Number of board members who were issued debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfOfficersInRelatedPartyTransaction', window );">Number of officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToBoardMemberAndOfficersMember', window );">Investors Related To Board Member And Officers | Debt Issued To Related Parties | Convertible Notes | Series A Convertible Preferred Stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfBoardMembersInRelatedPartyTransaction', window );">Number of board members who were issued debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfOfficersInRelatedPartyTransaction', window );">Number of officers</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoOfficersMember', window );">Two Officers | Convertible Notes | Series A Convertible Preferred Stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Amount of shares issued in conversion | shares</a></td>
<td class="nump">68,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoOfficersMember', window );">Two Officers | Debt Issued To Related Parties | Convertible Notes | Series A Convertible Preferred Stock.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfOfficersInRelatedPartyTransaction', window );">Number of officers</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfBoardMembersInRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Board members in related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfBoardMembersInRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfDebtInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of debt instruments issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfDebtInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfOfficersInRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of officers in related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfOfficersInRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToBoardMemberAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToBoardMemberAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=gemp_DebtIssuedToRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=gemp_DebtIssuedToRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6822252544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Interim Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 04, 2016 </div>
<div>USD ($) </div>
<div>person </div>
<div>director </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 18, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,651,000<span></span>
</td>
<td class="nump">$ 5,560,000<span></span>
</td>
<td class="nump">$ 390,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfBoardMembers', window );">Number of board members | director</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfInvestorsRelatedToOfficers', window );">Number of investors related to 5 officers of the company | person</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors', window );">Number of investor related to 1 of the Company&#8217;s directors | person</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfOfficers', window );">Number of officers | person</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany', window );">Number of shares sold to 14 investors who are related to 5 officers of the Company | shares</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector', window );">Number of shares sold to 1 investor related to 1 of the Company&#8217;s directors | shares</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers', window );">Number of shares sold to 3 officers and 5 board members | shares</a></td>
<td class="nump">154,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany', window );">Proceeds from issuance of shares to 14 investors who are related to 5 officers of the Company | $</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector', window );">Proceeds from issuance of shares to 1 investor related to 1 of the Company&#8217;s directors | $</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers', window );">Proceeds from issuance of shares to 3 officers and 5 board members | $</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gemp_FinancingConvertibleDebtMember', window );">Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=gemp_DebtIssuedToRelatedPartiesMember', window );">Debt Issued To Related Parties | Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoOfficersAndThreeBoardMembersInvestorsMember', window );">Investors - 2 officers and 3 Board members | Debt Issued To Related Parties | Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfDebtInstrumentsIssued', window );">Number of notes issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfBoardMembersInRelatedPartyTransaction', window );">Number of board members who were issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfOfficersInRelatedPartyTransaction', window );">Number of officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember', window );">Investors - 3 officers and 1 employee | Debt Issued To Related Parties | Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfDebtInstrumentsIssued', window );">Number of notes issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfOfficersInRelatedPartyTransaction', window );">Number of officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfEmployeesInRelatedPartyTransaction', window );">Number of employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoOfficersAndFourBoardMembersInvestorsMember', window );">Investors - 2 officers and 4 Board members | Debt Issued To Related Parties | Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfDebtInstrumentsIssued', window );">Number of notes issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfBoardMembersInRelatedPartyTransaction', window );">Number of board members who were issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfOfficersInRelatedPartyTransaction', window );">Number of officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToThreeOfficersMember', window );">Investors related to 3 officers | Debt Issued To Related Parties | Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfDebtInstrumentsIssued', window );">Number of notes issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfOfficersInRelatedPartyTransaction', window );">Number of officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoBoardMembersInvestorsMember', window );">Investor - 2 Board members | Debt Issued To Related Parties | Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfDebtInstrumentsIssued', window );">Number of notes issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfBoardMembersInRelatedPartyTransaction', window );">Number of board members who were issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember', window );">Investor related to an officer | Debt Issued To Related Parties | Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToTwoOfficersMember', window );">Investors related to 2 officers | Debt Issued To Related Parties | Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfDebtInstrumentsIssued', window );">Number of notes issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfOfficersInRelatedPartyTransaction', window );">Number of officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToThreeDirectorsMember', window );">Investors related to three directors | Debt Issued To Related Parties | Interim Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfDebtInstrumentsIssued', window );">Number of notes issued to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfBoardMembersInRelatedPartyTransaction', window );">Number of board members who were issued debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of board members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfBoardMembersInRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Board members in related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfBoardMembersInRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfDebtInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of debt instruments issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfDebtInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfEmployeesInRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of employees in related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfEmployeesInRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of investor related to one of the Company&#8217;s directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfInvestorRelatedToOneOfCompanysDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfInvestorsRelatedToOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of investors related to officers of the company during the period of the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfInvestorsRelatedToOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of officers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfOfficersInRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of officers in related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfOfficersInRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares sold to fourteen investors who are related to 5 officers of the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfSharesSoldToFourteenInvestorsRelatedToFiveOfficersOfCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares sold to one investor who is related to one of company's director.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfSharesSoldToOneInvestorRelatedToOneOfComapnySDirector</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares sold to 3 officers and 5 board members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfSharesSoldToThreeOfficersAndFiveBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proceeds from issuance of shares to investors related to 5 officers of the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ProceedsFromIssuanceOfSharesToFourteenInvestorRelatedToFiveOfficersOfCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proceeds from issuance of shares to a investor related to one of the Company&#8217;s directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ProceedsFromIssuanceOfSharesToOneInvestorRelatedToOneOfComapnySDirector</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proceeds from issuance of shares to officers and board members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ProceedsFromIssuanceOfSharesToThreeOfficersAndFiveBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gemp_FinancingConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gemp_FinancingConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=gemp_SeriesaPreferredConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=gemp_DebtIssuedToRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=gemp_DebtIssuedToRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoOfficersAndThreeBoardMembersInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoOfficersAndThreeBoardMembersInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_ThreeOfficersAndOneKeyEmployeeMembersInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoOfficersAndFourBoardMembersInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoOfficersAndFourBoardMembersInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToThreeOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToThreeOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoBoardMembersInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_TwoBoardMembersInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToTwoOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToTwoOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToThreeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_InvestorsRelatedToThreeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6807693232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 15, 2017 </div>
<div>USD ($) </div>
<div>person </div>
<div>director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,278<span></span>
</td>
<td class="nump">$ 911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">1,324,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per issue and sold units | $ / shares</a></td>
<td class="nump">$ 9.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds | $</a></td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfSharesIssuedPerUnit', window );">Number of shares per unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants per unit</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant | $ / shares</a></td>
<td class="nump">$ 10.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable', window );">Exercisable period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Private placement | Three Board Members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">56,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds | $</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfBoardMembers', window );">Number of board members | director</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Private placement | One Board Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="nump">52,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds | $</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfBoardMembers', window );">Number of board members | director</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gemp_NumberOfInvestorRelatedToBoardMembers', window );">Number of investor | person</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which the warrant is exercisable, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_ClassOfWarrantOrRightWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of board members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfInvestorRelatedToBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investors related to board members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfInvestorRelatedToBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gemp_NumberOfSharesIssuedPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes te number of shares made available per units issued under the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gemp_NumberOfSharesIssuedPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gemp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_ThreeBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_ThreeBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_OneBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=gemp_OneBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6761422656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>VALUATION AND QUALIFYING ACCOUNTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance of Period</a></td>
<td class="nump">$ 3,657<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions Charged to Costs and Expenses</a></td>
<td class="nump">5,937<span></span>
</td>
<td class="nump">3,447<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Additions Charged to Paid in Capital</a></td>
<td class="num">(274)<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance of Period</a></td>
<td class="nump">$ 9,320<span></span>
</td>
<td class="nump">$ 3,657<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the allowances and reserves, which consist of the valuation and qualifying accounts that are either netted against the cost of an asset or that reflect a liability established to represent expected future costs, from charges to costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the allowances and reserves, which consist of the valuation and qualifying accounts that are either netted against the cost of an asset or that reflect a liability established to represent expected future costs, from charges to accounts other than costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6798820384">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Temporary Equity, Accretion to Redemption Value</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
<td class="nump">$ 2,968,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Temporary Equity, Stock Issued During Period, Value, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
<td class="nump">4,985,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=gemp_MembersEarningsMember', window );">Members Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_NetIncomeLoss</td>
<td class="num">(124,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_NetIncomeLoss</td>
<td class="num">$ (196,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=gemp_MembersEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=gemp_MembersEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MKK_\3L+6:[,Q9VQ\%.Q:^',7W3=02P,$%     @ 6:YT2IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M55EY[\3FV.FJ&WZ#W:4SNIYZL5;JXG6\ELUPO4W]OX7A 6P*8', %>\&\"F
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M4:@ADF,V]%G#1-!N["&#J9%=_0=02P,$%     @ 6:YT2MOD1%,A!@  P20
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M,+3\ Z4_(=(+%-76$)', X]:(T1RYM*U9PQ)J>C$G6 2/8;".'VPK<R@3Z[
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MO/RJBN_IX4<UAXL\V=<_&').OUKJ_P=02P,$%     @ 6:YT2JVT\97B!
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MZFFJYGS\&<>%9/UTSZ#YLBO^ U!+ P04    " !9KG1*?ACP)YD%  !W'@
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M"IH-9K,!</9\'3&(SB9S8I8#G7?6<M>HNT+A'F%04P:R04DHPN@DA$X^O0A
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M(L/>2:'A9(CME>+F^0@2AYQNZ8OC3C2M"PY69!UOX">X7]W)>(O-+)50H*U
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MR9_-.&:CX;";?A";OW'Q!U!+ P04    " !9KG1*),D[A[,!  #2 P  &
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;'U386_<( S]*X@?4'*YK.M.2:1>
MIVF3-NG4:>UG+G$25, ID$OW[P<D3;,MVQ? QN_YV9A\1/-D.P!'7I34MJ"=
M<_V!,5MUH+B]PAZTOVG0*.Z\:5IF>P.\CB E69HDUTQQH6F91]_)E#D.3@H-
M)T/LH!0W/X\@<2SHCKXZ[D7;N>!@9=[S%KZ#^]&?C+?8PE(+!=H*U,1 4]#;
MW>&8A?@8\"!@M*LS"96<$9^"\:4N:!($@83*!0;NMPO<@92!R,MXGCGIDC(
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M:&5E=#$R+GAM;'U386_;(!#]*X@?4!*2M5UD6VHZ39NT25&G=9^)?;91@?,
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M?[#%4%"[<'SOSV8:L\EPV,\_B"W?N/@-4$L#!!0    ( %FN=$HQ5JSTM $
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M"BH?CM=XMN.8C88WW?2#V/R-\S=02P,$%     @ 6:YT2K>;Q1FT 0  T@,
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M'9[M-&:3X4T__R"V?./B-U!+ P04    " !9KG1*RGHIG;(!  #2 P  &0
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M8CR^;.Q_;8P'E+*[P1%J\8,MAH+:A^,[/-MIS";#FW[^06SYQL5O4$L#!!0
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M#.."PUG;Z=+,9=\W^X46W?!/0,8?D^(O4$L#!!0    ( %FN=$JZ/F%@MP$
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M!YL-!94/QVL\VW',1L.;;OI!;/[&^5]02P,$%     @ 6:YT2B'8E#BX 0
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MP69#0.W"\9L_FW',1L/I;OI!9/[&Q7]02P,$%     @ 6:YT2I.#4MK= 0
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M AOUU8+X+,[D/SKQTR-OA9&C1UMZ&/L%8J] [ 3B?UHDNQ9]F,AODGA-$H]
MO#/Q81*_2>HU23T"Z<[$A\G\)IG7)/,(''<F/LR'G0G>'$$.LG673P65N WN
MXF^RZ_U^).X(O\/GQ^$;E6T_J. JM+D([K@V0F@PI80/9E<[\QZM 8-&VVEF
MYG*^E7.@Q;@\.'A]]<J_4$L#!!0    ( %FN=$J4WFP@P0$  #<$   9
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M3?$2"*BMWWYR>SV]Y2FPJI_'E"S_%<5?4$L#!!0    ( %FN=$IY#DQ!P@$
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M%N:;OC F006,GE11M;KEYP&%B]3=0O7Y>->- \GZZ1I'\[^D^@M02P,$%
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MST(-$SEF?>_I)X*VIJ]Z0W//_P)02P,$%     @ 6:YT2M5EB0\V @  \@8
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M;$C$<!$^6J>OX_U1G1<(&$K - $;$01&HUI,H#&%QAAE+&\B5M<0(YD!*C-
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M?<Y76"\4T L=G DB4' H"$"&"@8+B@(%B G4 ($([FFL.AJHCO&XMT @35!
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M@P<VJ+=P%'I/@2&*+9ZXCPAV4PO/O379 R!+'X[" X5Z!L"[$>K! #X(X!L
M_P; 'V6JM8F,3=5F"JD:5#^8*0"9 H I@ %"$"!\7&L$ D1 !.%(:S35.JMS
M ;(L )9HQ +9+&"2)4BRG ($,[E +EPB[N/I1#-5A@ 9RW&9H4^^/0BLMPW"
M#^05,EK.\< 5A3P  HUY6J-@( J[V(O<48'O $//#7 T<]@(+E($5.D2ST#
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M";6,Y9KU\[/?"-H.OP8T_I_ROU!+ P04    " !9KG1*D?Z/#-@#   M$0
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M) ]Y<>GJZ[0ZP%<WN3K7+R>LY@W)]"]02P,$%     @ 6:YT2B\&J5)Q @
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M@]G!#XQ)4'+!BY++U5] -Z%PD'J8JC%OC\)V(EEMCWG4_6LL_@%02P,$%
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M5.SI./;' R?]=*.!^5HM_@%02P,$%     @ 6:YT2@CW5EO@ 0  ( 4  !D
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M5UX;N24Q'GM1*_<;[2]*BV;(8E :]MY?J]9=;T/^CS X  \!> Q V7\#R!!
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MM&@2;MZY+0$W-I2%79K._(\1W+50V+:RDOJD84]:S*+"30D!78EFOD\>OJ+
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M<.(53;SQL#!0I)T;G'D XM0#$.<>@#CY"(391R!,/XH1YA^!4  (Q H ))8
MZLT%#018 P'5@/$T. C PDT%0*D;M L/*2<$V'U HYSNP6,4&WC> ,%QE[8Z
M URU19GI!,TRNN4M@#OETSFQ!)R4UDQJG$E-,VD\D8\U4*$&V\IUKA%066/"
MVLFE(1D5P*!F&D-)Q06H&_"8BC":EC' :%(F@ )+1;O(YNTB6P ,/'A>&[-F
M<FR%+2/)T:Z9'(:6?Z#T)T1Z@:+:&B*2>>!1:X1(SERZ]HPA*16=N!-,HL=0
M&*</MI49],D5V 6@3R$#L T@5+N<.EW"H>>N71"6^I5Q*@C6;.NA9LYK'M)'
M3L*Q!6*I@QDMA+51"#\R6GP52Q0=QT$-MI$P("T2!J1%PH"T2!B16,*0A!)&
M<6()(Y](PL]PX#D=SCELW*)U@%JTCG)T2>N6JIO1LEN;93>CI9Y-.8"T* >0
M%N4 TJ(<1&+E0!(J!\6)E8-\XL4/^;0( J 60:"AOR0(2TG.:$U.UQS9=LVA
M9;E-.8"T* >0%N4 TJ(<1&+E0!(J!\6)E8-\XC4'#3Q<<U#C%HD!U"(QE*-+
M$K,<LS!ZSJ*%J0=:U]_X] EPB#@&#F1'$ 3UUKBMQPD&Z?/SM&W3,P06!3SM
M]AR1J(!?0)?:OU#"6(Y(&#TCT=(<.E3<HV/O11NR&9:E:F>T;-?FT4W-J!:K
M$" ]+4#QCD@F!5J% ,DYT,D8MJZ ZB?09]$EH#T49W6(0L0'2*' JCZ'/@4Z
MFUY U',%'?LE[/VEU<52_;-#S7[^^DDK[();RG5.RW5MG" ,:D:?A^O>FJ_^
MGC!6O6SY_Y]17 RQD3"VX1'&?'-6(HS=,F/%G6!OYAG8U-*H(29$\5MN.)MC
M3!K8 F'B5AH]6.+0N.7=([<<!W!&]:,M+FPO0&D!R<@LXK0\E(&K/7/Y6@"0
M!TJZTC/[3\%B/RJV#\\(WSE[Z5_^NF<>IA^;7=9Y3?(\V58O^=^3)(\*IX56
MNYUU%*Y.%W'TGI=?5?$]/?RJYG"1)_OZ%T/.Z6=+_?\ 4$L#!!0    ( %FN
M=$I_G<%\0P(  $8'   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;(U5
MVXZ;,!#]%<0'K+F31 1IDVC52JT4;=7MLT,F :W!K.V$[=_7%Y82<+=YB>WQ
MF>,S,V$FZRA[Y26 <-YKTO"U6PK1KA#B10DUY@^TA4;>G"BKL9!'=D:\98"/
MVJDF*/"\!-6X:MP\T[8]RS-Z$:1J8,\<?JEKS'YO@-!N[?KNA^&Y.I="&5">
MM?@,/T#\;/=,GM# <JQJ:'A%&X?!:>T^^JO=4N$UX*6"CH_VCHKD0.FK.GP]
MKEU/"0("A5 ,6"Y7V (ABDC*>.LYW>%)Y3C>?[ _Z=AE+ ?,84O)K^HHRK6[
M<)TCG/"%B&?:?8$^GMAU^N"_P16(A"LE\HV"$JY_G>+"!:U[%BFEQN]FK1J]
M=N8F#7HWNT/0.P2#0Q!_ZA#V#N&]#E'O$$T<D E%YV:'!<XS1CN'F>JV6/V)
M_%4DLU\HHTZVOI/IX=)ZS>-DF:&K(NHQ&X,)1AA_0"#)/CP1V)[8!#/W./5N
MG]C:,/XM9F?#!'8AH3764!.$(X+ C^P$D94@T@31B"!,HDFR#";5F,:H7'C>
M--XY*@AGJ-T<E8Q!-XICJ^)XICA.0SM!8B5([L]9:B5(+0JF.3.8>)R-2;[^
MB]A]AKB1N;#*7-Q1VL6\:/Z\M!:4I;1SU+]+N[0J7EH2&T\4+V>O3-7.$>%<
M!QIUDQK867=J[A3TT@CU18ZLPS!XU UR8M_((6%Z^E\:,V&^8W:N&NX<J)"]
M3G>D$Z4"I$;O05:UE$-M.! X";5-Y9Z9UFX.@K;]U$+#Z,S_ %!+ P04
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MUF;+T>67CH5TR9]4Y(U&+]6&(T= /0?%IH9SVC0(DAPGR<R^RD"=;TW+EH)
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ML18D^3YP,TO,XG34J^".>P0I3E,^3;C8)=LH5NU!.&;C:T*S1SWU&%WNEV1
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M+/Z!JCODE14GLK(A/LK>:'AA-_5"R;&H468Z+EGH:S 30\(,ILJ!:C" QRH
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M+I:/P0->+WII[-7=/E2VFGST$B&PJS)5AV5,]EAB'HTID6@-RJFXS]U=)<'
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MH 3O[9T\I>)+'=>[9YZ&WYC[<Q3I$KINR<.36*4^OK[R@)2!]U+.\^P,9MZ
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M=-DJ^R"K*6AA)C56G9G6/0KJ[JRN?^XJLMCKY>  65A)*8K&Q(+'B[4B0GG
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M<C)03? 286:#CU@.98O8]O: S..M\?;@O>NI35FQL4'<9R*'S^@,4W][HSZ
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M@OTDF=U@7)V_D5&#LX)J$;@3^U25W/^*TI"H:_929B/A=Y,4=75^QM$FMR8
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ME2?=<AO8.$]*.D]+]L0I;OQ@7V)Z[\&Z^>D;?*U'9@8<U_&;.ZTP-V'N[Y]
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M+80;;&>G04$WX-^) ]')POO\.KX<&SKH0X2MZ)G&-VV[_,/_!5!+ P04
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M_<V >WXW:]%)A+"W;W%"*F9[WOXM*_H-4$L#!!0    ( %JN=$IS-Q\1V00
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MF0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 6:YT2IE<G",0!@
MG"<  !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " !9KG1*]L@)[)<"  "<"0  &               @ 'X"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 6:YT2G!SY\U- P
MJ@X  !@              ( !Q0L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( %FN=$K^:!]JL0(  -0*   8              "  4@/
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !9KG1*V^1$
M4R$&  #!)   &               @ $O$@  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ 6:YT2JVT\97B!   $AD  !@
M ( !AA@  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( %FN
M=$K7T@_7XP$  /@$   8              "  9X=  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " !9KG1*?ACP)YD%  !W'@  &
M        @ &W'P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ 6:YT2I;A<?*T 0  T@,  !@              ( !AB4  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( %FN=$HDR3N'LP$  -(#   8
M              "  7 G  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " !9KG1*)CUM3;,!  #2 P  &0              @ %9*0  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( %FN=$J2BU;2LP$
M -$#   9              "  4,K  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ 6:YT2HA4.#FS 0  T@,  !D              ( !
M+2T  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !9KG1*
MUOOBR[0!  #2 P  &0              @ $7+P  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( %FN=$I 'MUKM $  -(#   9
M      "  0(Q  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ 6:YT2G9Y5+^T 0  T@,  !D              ( ![3(  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !9KG1*B\@[>+0!  #2 P
M&0              @ '8-   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( %FN=$HQ5JSTM $  -(#   9              "  <,V  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 6:YT2K>;Q1FT
M 0  T@,  !D              ( !KC@  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " !9KG1*RGHIG;(!  #2 P  &0
M@ &9.@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( %FN
M=$IU4W\OM $  -(#   9              "  8(\  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ 6:YT2L9+I!NT 0  T@,  !D
M         ( !;3X  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " !9KG1*/^6+/K0!  #2 P  &0              @ %80   >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %FN=$HX2/#1M $  -(#
M   9              "  4-"  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ 6:YT2DT?TJ5= @  I @  !D              ( !+D0
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !9KG1*NCYA
M8+<!  #2 P  &0              @ '"1@  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( %FN=$HAV)0XN $  -(#   9
M  "  ;!(  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M6:YT2I.#4MK= 0   04  !D              ( !GTH  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " !9KG1*E-YL(,$!   W!   &0
M            @ &S3   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( %FN=$IY#DQ!P@$  #<$   9              "  :M.  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 6:YT2L0&7YG$ 0
M-P0  !D              ( !I%   'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " !9KG1*\NO&F;<!  #2 P  &0              @ &?
M4@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( %FN=$H5
M5^HXR@(  (\+   9              "  8U4  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ 6:YT2LP6@(,9 @  "08  !D
M     ( !CE<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %FN=$HV":3.( (  )L&   9              "
M 8UE  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 6:YT
M2LK3Q>*& @  E0@  !D              ( !Y&<  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " !9KG1**"$/VY "  #?"0  &0
M        @ &A:@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( %FN=$I(:)"$ @,  $8-   9              "  6AM  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 6:YT2G7\%1E? @  Z <
M !D              ( !H7   'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    " !9KG1*U66)#S8"  #R!@  &0              @ $W<P
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( %FN=$J #)]G
M'0,    -   9              "  :1U  !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ 6:YT2I\?WQ&Y!0  '"   !D
M ( !^'@  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !9
MKG1*U92CYHP"   J"0  &0              @ 'H?@  >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( %FN=$I"IL*9- (  *L&   9
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M970U,2YX;6Q02P$"% ,4    " !9KG1*"/=66^ !   @!0  &0
M    @ ';CP  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M %FN=$H*=1"H90(  (((   9              "  ?*1  !X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @ 6:YT2G+/,&J> @  O@D  !D
M             ( !CI0  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    " !9KG1*8H\^M'T"  "9"   &0              @ %CEP  >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( %FN=$J1&#4<(P8
M ,(D   9              "  1>:  !X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @ 6:YT2G^=P7Q# @  1@<  !D              ( !
M<:   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !9KG1*
MI]E;?@T#  #L#0  &0              @ 'KH@  >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    ( %FN=$KO]<)='@4  #$>   9
M      "  2^F  !X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%
M  @ 6:YT2J6ZD)K6 @  < L  !D              ( !A*L  'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " !9KG1*S \K8#8"  "<!@
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !:KG1*<S<?$=D$  "(*   #P
M            @ $+*@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 6JYT
M2@[LKP$> @  ?R4  !H              ( !$2\! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ 6JYT2N/:#*KL 0  ]"0  !,
M         ( !9S$! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $< 1P!C
)$P  A#,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>188</ContextCount>
  <ElementCount>315</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/StatementStatementsOfComprehensiveLoss</Role>
      <ShortName>Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficit</Role>
      <ShortName>Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit - Temporary Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/StatementStatementsOfChangesInConvertiblePreferredStockAndStockholdersDeficitTemporaryEquity</Role>
      <ShortName>Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit - Temporary Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - The Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation</Role>
      <ShortName>The Company and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureLicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Convertible Series A Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureConvertibleSeriesPreferredStock</Role>
      <ShortName>Convertible Series A Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Stockholders??? and Members??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockholdersAndMembersEquityDeficit</Role>
      <ShortName>Stockholders??? and Members??? Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureNetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Supplementary Data ??? Quarterly Financial Data (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Supplementary Data ??? Quarterly Financial Data (unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureAccruedLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureNetLossPerCommonShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Supplementary Data ??? Quarterly Financial Data (unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Supplementary Data ??? Quarterly Financial Data (unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40101 - Disclosure - The Company and Basis of Presentation (IPO and Capital Requirements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationIpoAndCapitalRequirementsDetails</Role>
      <ShortName>The Company and Basis of Presentation (IPO and Capital Requirements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40102 - Disclosure - The Company and Basis of Presentation (Basis of Presentation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentationBasisOfPresentationDetails</Role>
      <ShortName>The Company and Basis of Presentation (Basis of Presentation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureCompanyAndBasisOfPresentation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureAccruedLiabilitiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureDebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureDebt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Commitments and Contigencies - Pfizer License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPfizerLicenseAgreementDetails</Role>
      <ShortName>Commitments and Contigencies - Pfizer License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Commitments and Contigencies - Preferred Stock Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesPreferredStockDividendsDetails</Role>
      <ShortName>Commitments and Contigencies - Preferred Stock Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Commitments and Contigencies - Other Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureCommitmentsAndContigenciesOtherAgreementsDetails</Role>
      <ShortName>Commitments and Contigencies - Other Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40601 - Disclosure - License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureLicenseAgreementDetails</Role>
      <ShortName>License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureLicenseAgreement</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Convertible Series A Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureConvertibleSeriesPreferredStockDetails</Role>
      <ShortName>Convertible Series A Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureConvertibleSeriesPreferredStock</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Stockholders??? and Members??? Equity (Deficit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureStockholdersAndMembersEquityDeficitDetails</Role>
      <ShortName>Stockholders??? and Members??? Equity (Deficit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureStockholdersAndMembersEquityDeficit</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureShareBasedCompensationDetails</Role>
      <ShortName>Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Share-Based Compensation (Restricted Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureShareBasedCompensationRestrictedStockDetails</Role>
      <ShortName>Share-Based Compensation (Restricted Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40903 - Disclosure - Share-Based Compensation (Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureShareBasedCompensationStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation (Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40904 - Disclosure - Share-Based Compensation (Unrecognized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureShareBasedCompensationUnrecognizedDetails</Role>
      <ShortName>Share-Based Compensation (Unrecognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureNetLossPerCommonShareTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Net Loss Per Common Share - Earning Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureNetLossPerCommonShareEarningPerShareDetails</Role>
      <ShortName>Net Loss Per Common Share - Earning Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Net Loss Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureNetLossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Fair Value Measurements - Financial Instruments Measured On Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureFairValueMeasurementsFinancialInstrumentsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Instruments Measured On Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureFairValueMeasurementsRollForwardOfPremiumConversionDerivativeLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Roll-Forward of Premium conversion Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Income Taxes - Reconciliation of income tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxDetails</Role>
      <ShortName>Income Taxes - Reconciliation of income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Income Taxes -Significant components of deferred tax assets and liabilitie (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitieDetails</Role>
      <ShortName>Income Taxes -Significant components of deferred tax assets and liabilitie (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Supplementary Data ??? Quarterly Financial Data (unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Supplementary Data ??? Quarterly Financial Data (unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureSupplementaryDataQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Related Party Transactions - Rental agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsRentalAgreementDetails</Role>
      <ShortName>Related Party Transactions - Rental agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Related Party Transactions - Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsConvertibleNotesDetails</Role>
      <ShortName>Related Party Transactions - Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41403 - Disclosure - Related Party Transactions - Interim Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureRelatedPartyTransactionsInterimNotesDetails</Role>
      <ShortName>Related Party Transactions - Interim Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41601 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gemphire.com/role/DisclosureScheduleIiValuationAndQualifyingAccountsDetails</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gemphire.com/role/DisclosureScheduleIiValuationAndQualifyingAccounts</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="gemp-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - gemp-20161231.xml</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - gemp-20161231.xml</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>gemp-20161231.xml</File>
    <File>gemp-20161231.xsd</File>
    <File>gemp-20161231_cal.xml</File>
    <File>gemp-20161231_def.xml</File>
    <File>gemp-20161231_lab.xml</File>
    <File>gemp-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0001558370-17-001962-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-17-001962-xbrl.zip
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M1J=C[9C,#<C1D,@K(H,\$G(R+/(?^BF.&1]B[SY J,)LV[16QQ>H[E4,B5R
M1'%PT4G=SR*=']-*FP>U&4R@,ESS!'T?CQ1@\L/:M#ZC.\G7K1CYJM;_^)CR
M=V=LH$ZFO61GUA ^P8A1+DG>2&G)H<(X=(H$J'I<O_K>[Q2QP%\!=G][,7V.
M G.3AM@.I"$K:[99QE.P)J6^WQ#>?#)=ZR#6#$IF3>][[RH>$]:9,P>QHE<R
M*P:> 6L *];]%3=B'[W;-D]NN.*$M 7.,G+8([9+VJM4RA[ @29Y<13YB*^
M?/2?='7K'1LNRF%(!IPLC!H>F?1-"I,V>("\YD:2O+3(='1DTLO(<V/D632I
M962Y,[*4),]#\M#2'%O$_7#I;$M!1PDBD[6ZW51.88T_:UIF<88K.N.=5-Y*
ML"P$!OSQU!#?RV0')N_("WU[X)4.YQ8,0]/BB_KID4HF5IMA2T&D-+"3 7(&
M&+-9TJQ7^>XTC6+:K[C_1S_0&'[65=Q3I+U?%>"!=I*C<!(>]>!GE>*#PTI,
MR="L)$:EI(92UG>3\"2GG.LB[.6LQ):H0 WG_IHJEL/@$M5['+&0,LVJKB(V
ME4\%E_3+# I[VX.-VO*HH-)_F6%@4UE3\!)!^2G5QB-",E+?2<)!A(2R7%T\
M6T1C0X'C [5PIDQ5T6J4,W=6_5+0VTB$1U,'/J"]<2@UUCGTB3T'_B&H'!ZY
MEK:^LR)R,UX!X.\@!D28&^NF9&FL'OVZZ:G),(R=(#L$\AT42,;<2,43'F!9
M%_#A8##<AO@N@"/X^CUQK6] )S"6T?.?P;%(<1 TWXG\A_[H5P_$''-$(8ME
MG.'U9-BP ,9!-Q8=2.#?G&.Z$Y_!>]$A3L?-%U=K+G<*>)%FXB1:_-K38H]^
M1J\O*02\&+JF2JEF?[+,!=I\B $"JJR;QAR&/< ZT&W ND@]WW!39D"GXO#*
M3*[];']9E,I&JGV\PO81<_F'TQ.GFT..\GB.R$#16#-Q&+304ZC1OK<9YX]
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M=Q_IU,G37&V]R5YB=#O6:&\#1%F:ZZ%Z=0>#)$T.1S<_ 2-]_/"_Q%#I!SS
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MJT? XG[&8^S8^P#<,W'H@TY47AE.#\ G42/6N_BEVVD/H@9L'_0S4/"+B\
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M>&.15ZF?)\\:SHB^ T%\7->8Y3V&UBK>.J&++83>BL-E]+L9445 '<2IGK7
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M&UXB"Q$F"<_,Z:A%E(>K^ U_!?_W-:+N0L]2?U.F5(6!%3J;>6Z>+<"'@^9
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M:TK_T@M,Y^;&RRTG'4':Q;GFLLDOJTFRFG3F[)'5I/I26U:3CDY_0,M>$F!
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MV)O?$Y) W#B GML+[ % HU$41""K%@=LP:(RMS3!^<8<JF\.N%K[3A,1]>8
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M"@]^1F!<?]*X=/OP&*V'S HQ-? @ +$#@A<DQT^$S4%/)YY3_DXJXORY+IU
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MV*LUY:&\$1A'ZLQ0YPC$BG&DSHES4=["SHN-T8ES62RT20-7ZQ*;=3,7*1X
M*"1QPP3)MET7&$7DNH.^UZ!@YO'EK^HR3I8N*M"7&E'$8-0F0 P0R:4W#I"_
MNIG8+Z[0:Q(YC.>B&V!4S$QH!1@OJZLKFS)01*\/)0;$2QLT:7E:LD]/-(@7
MD(?Y..9EQ?MY>4"D_.*7GQ-V>6_;\ZM/MA?] VL^?/'LL>=[L4?9;]1F243=
MF^ ;=9(H@@E^9S./_1&$8QC( \KK<S!/8O@X#!SXE8W9%+=@&>_\T/GS[7_\
MC9!?5EI('XLG*?Z?%T]7GL86'[?8=M:]I[_;7O E9.QSX/B)2]W/P4<[PDL[
M&.9OH'5^HY-?+SXD$7_*G07_1_?^[C:\L]IWG?15VKN[O'?OGO(FWOLV8]<_
M/)9_Z^-L3%UH[$-^7N23%]C05]O_'+ X2G!0(#>\Z?6")($G.O$'_&&U+XA+
M'6]F^^S7B\O.Q5MK"(BU9@:.+1\5IZ6W,"T]F=/2'@W,O&3STE^8E[[,>;D<
M]EH:3@R6VZ6UP:Q>[YA3(&0A6]P*8=&PV]9?W@IA3*]5=_W^3N/8YP^IC9+W
MAT<5>DDBU4B>;6B(/VM!Z-?L[F:B"'(/.I4(^=G!2Y:O5"WN=*O1XD,$?#-9
MU_&OH>\Y3_M [\7;-&S, \7M43#?V+&.M*N\)1SF/RQ?L<I_B6(A_\CJ%^:2
M(271/!,X*SI4_L7;*27OP]G<#IZ*#:O1&T8F^2"]8I#P-_=DR1RTR?'FMN^#
M-MAL2NS %7_0OQ+0?!^_W2!A/*410>6#UU@'@>*[MN.$"3YM;C^ASO)WHH2Z
MQ"^8 OY$EX[C)L$^.G84\9,4]DS\=A)&!)[.Z(:>1G0>1EARP0OP>V2<I@FP
M*85.$'L^C\(?8&PQQ8]A>HL:E:Q)OE-*?@]C6A CEK5^:X^4=*-DES!,[.$D
MB;@(0/1.PEAZ,*1HJGD,ON4YVUTR]^Q[)8HF?\P'Z+,?XH#V7H%*@O@4@4;0
MP'E:P,EU4,9^#X,H0ZH=(;*,CKN-I7(!K%TBC  .$L"W/4>_LD*J)(+\S__V
M:&1'SO3I"WV@_GHIB'6;?Z$C!F^DNC9N.R?+JE  ^^K 2T>/U!=#[HNRF^#C
M0JVCF\D'6-;W"26W$WG6:)'YWMI\-;UM2>HN#0!1_.O O79G7N#!&L]CC8\_
MYC1@=!_F;SMW;747N_I\V]5UE NUL[-,NX.>Q'[N,?D=:S X<4^[I9[V[SJM
MW3K:[PU/W,]!J9^CG?LY&IU:GH?:O=7JGKRKI:B\DP?EVSNZM#%RVHZ6Z(.M
M].JHUY=C3?VR->TD4DN..?7+YK1#1[O]4TLTLZ=])[_=&8X.[^KGP EG%%?=
M3U$X>P\=\X($5MZ;.17]8N\HQ/!4?._6_D$9+,V1'48N>$31T^>8SM"QQ"%%
MH>_#3S_#X"+*GG=N]EV!+SOM16,\8L?5D-">2_]ENST8G:&$]O$X1ZWVN8CH
M,&_GTNI;UIE(Z# _Z[+=ZY^+#AT<V;5[@S,#ZSU=R\NVU>J<H83V<&LNK6YO
MV#\3&1WF35]:G=&9H?6>;OQE9S@8GHF$#HT?+@?+[-:)900/* C4/,GY_/;7
MK7:3"(D0+M,:;Z;3R80ZO.Q_;/\@$>XOIUO5Y(G:$<,3ZM0E'ZC#B?AB4[EC
M-0C.*/]WCV]_8WA('FU&_DVC$,^T.S2(F^2W+[?\W3BB_%(!^-,F<SN*(?AE
M4V\N=IZIBZ$P?PZ+L1N>$#!V:YY$\Y#A1O>UXW#=O?>?&B2 1J+PP>/[U-C"
MS'9%]XO?4K'U+@[8,TP$P-&%?( S&MW3J$&8ASOM\:;4@H#&!%2>D5<L&?\+
MI(6_=V@4VUY ?&_FQ<+47O,^S#%MP(6G16%R/\V:*@TFHG$2!?STOQ=#G[E<
M86A_S,,@_RZ,5]@1?NWO=#:?>A$E\/+&B</%>6CQ&>@VR@,@8^K8J0!2@9>>
M^=PNOLKZ>@VR*R<*<1$6@H4_Y@E7L)C+ M4HB</H*5>N\BSP3 HQ.842O1K3
M@$Z\^/6J%J6I)'F"!F:%<%ECE@?76)'( 7W"#R(ZI0%#N^*JXS&<A0E ;/C(
MKG:0?^G(E#C@Q.6<GYGB)W5 "7T_/7?TZT7K@K]F<]O)7J<'IM ,<0\M?5YZ
MD,F!SMAS1J^R/]Z(ALBPU<2VQ,2+TU*K<[5O#9%>CS]4WOFL3%VA&\5IMN.?
MU@H?:#2!2;\B4\]U:5 R@7T/)98.Y&6_/&H5I7;3ZIL9>W[&JCV>:[6:'6,D
M)Q6YT?+3B]QJ]J76 CE#D0^; Z/EIP86@^4&6#07N64U.P983@TL72/RDSN)
M4HN+:"7RI<HC]:03UE2(M9,X5*4,S.%%5/2(JA2?GKWA"0;!YC:(>WCQO.2[
MK>9 "\,H59<2_&4E<S$\A',K[_\4S\H?]2G=+_DGM2/R<6&[A. NR7',2[7Z
MV+4T+[,4F:7HS*?G\*6HO64ILHX0J+SX&@;-UR+<D7^1#<W T?>I:L2*VA-Y
M+*M:.Q<6!('&JDYN53UC536TJFV65#EW:2QIJR5UCV!)QM.0:TK:!*3JR5_7
M$%6M^[1V"%(_%\F#19I@D3IHQWF:89%XR+,,SR.F56L^-<O+>N864_$Z7:>4
MN=.TTVVV7G2IJ='PER/6?QT!>12,6=2:%\T2M\X1>53%>D4TW""/FO.B66;7
M.2*/W,0NY35<$O(H2&ZH-2_G168H(O0=C %+7HJ3DC8>/.0%I35D(Q29$,TX
MAVI6V>-?&]AM-=M&>Q737NG>NIY2E<T&U 43.L.78H)<[-53>PTFZ!BGUP83
M^LUAG:-S+;57>FQ=-ZEJ$4$K3VCL$%M_7RI2U>!UHO"VI#0+(,T1T#'@5G[^
M- O%:T>%=YL#L_M?'P67[IF?F[QEQ_$U!!2SJ5\G!3> <EXDP!D"BMFK/R>>
M0!]Y:\$@*"+T'7B"]V'P0*/8PWJ]01A#0QH2 HI,AV9A?UV8=:MI&>553'FE
M>^!Z2E5VX%X72&@U^W4.U_547@,).H;>=8$$ZZ4I.6;[7;^PNFY2U2)X5I[+
MV"&L_D89M2-G2IR(NEZ\> 67'D&U\M.D6;A]AARV4?!S\K_/3=ZR@_7JY+V(
M/_60ONP8_MRTW:#+><7]YXXN9O_]G(@"?>2M!86@B-!W( INXBF-S)Z[?+V7
M1@+L5\FU/G1Z5S'MW4_.6JJO="?\!?5NA5;60\Q'B.QEH$3EC&"K.50M3=Z@
M@D&%^D;D1]5> GX!:8E_5F5^DJC\>0=ZL0L";G#._O,'UO$_SF5-D@OYZPE
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M%21S^,DDB9.(8K_XA<%>X(0SVB >="YX$L.Q9V!:,>]1[,W G+"=QZF'EQ_
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MWO6HB\TL=N +QBVPQ'[#+6<_E>GZGO1*$NKM2O4/N^5^K&UMN4/@Q5'\(CA
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M=J_1KAUI%!<QB;0J1!T.(S\03PJWDV=6/L(L90>E4]WA5]Q?XK';=-'FNX4
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M/ NOQ% R-2G/(.].>I,9GR7H4@^,N-NV<J9X B 3>905@^1&/*%11)&6 T]
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M93I>)%A<!^Z'(KWBFC$:7SM_)2 R]P;Z'-U.[>!V&H7)_?1=PD M&(-AC+V
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MPX_C,S U *(!V+ZWRSYWPY3W8M\7VH'(=8^9K<$^MR/D#]>!=EN6U4/(0,@
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M.(@XB#B(.+B=HTEP8P1A 43H>R#.!QJ$<R\PM:<B$$7 =K8H51#UC&9*%1$
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M,KT-XS"!2%4]:.C9OK+R&+T_&F@=H0.9SX9E_T"DJAHE5#.+<$.+?E_K?=I
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M:MJ*:SC2.F< ,I_ATQ ($S X3DUAPAITM"8R@4QHQ D=Q*I\_S4<L^]/,#Q
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M&L@>FM-A5@\B$+R\]S 0#<X'JE O1\A5B#739W;'WNH*527]K:U6IS_2.2T
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M]K@O_O+/07O<(POVQ7AF1[1%(AISPMJ[I_YC>T<,LJ;6UTLPV ZV.1Z]7O^
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M,ZX7WML,Y=A$X7#'?R2>\\OEI]\^O/YR>?U?:\3T.FEI\X6E.Y^6O&4F%6/
MZ%\LZV/(&R7DB@4>[W+M7O,_I8N8[P(I+TA_S,A:_88O>7F1*[/8E#_1';F+
MP@<6V3LY792M9%.RCU1>_.OJW35_]7(],R(L?[\3/ISG(WSKCNW>L[R;&9U(
M!K*%1_J#YAFWV$]S;\MYOYQL&=>1\=ABDT^T0D:SZ\N*TRSMER,IJG'XMWGX
MM7W WK8B)(]YYON07SUCYAG8\DMP;.1PS$&#^E-IV7RH^2"X967KW,S*F??/
M5\]+'#(74\Q7.0.F6U'T>.^)0KOE!(N+B@<>!IPT-OWFZ*[B6V=U.88%@F'
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MYB!%ZB[ C[EC$AVGZ_ANY/=@S&K6S!<_36R])0C2'WPZ.PN6H/L"4TZ>\57
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M?&N->KX[?:'8.UT_O 30=8$^K+0VH">Q15%5<96%7-2O]HTM:ID- 614DXX
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M]*R5HZA"X.T:#I5ALF' MX7*;IGHH0)XHR6']J16X8L'V5ADQ;\BC]-E(=2
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MV^<'D,<FFT<1:-VX=P2;D%*N1NF4L33%G8%+U3KHR")#GM B/S:25*2S/2Z
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M*KN.EA+2EWQQ+&^C[E.?<SAE(^:O_P=02P,$%     @ 6JYT2K7&OEZX-0
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M(1%5Z!2FKZ9A@JJ.L,8JUT:DM;HU?1R91@NT,I+%X=38R)1J=@M=(ZN)$CV
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M7O%)%V)=@#:U( 3PM8G0ADYH:L..8\G&E)/AS!9SY&":*!EN1%,F*L6R2%J
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M(?=D$^047IP7YS[3: ""TJ<'F@YU - <LW$-(!L7=$]OHTQ:VK[<'F.325"
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M9RP1)X3N+ _E#UI5"V^*"=_^,]I%/^Z_S: *8Q5DVQ>4!_0V8 O(EUV$7"8
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MYU<&#0 0R 6I.,55UJYJ>3BNT8;K5Y4T $ 5!R5<O%@%H:U:/&$K!7XRZ("
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M+J\"F$PT,JP8I\9?&-E%>U@7.8?\;M9%-A< (BE4^7B%@2QR(JD4@0$HK,@
M'.7XFD^P HF:0<0DK8T-Z)OKH2@.?+0QV/!W(&Y1"%N06)SRG89+ S1+9'[-
M, WPQI0]X5&+-R!)G1YV(H[ML9N=2,(. "#O#$RX!'+* MF0E,2UE&*730X
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MU1\W=*XY"T_]YB"$$[2^VM1G#S2YR;TQ!0[EM&P].KS]2;4VA*B%]O<@56X
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M -@5!R5<T%@%@2QE4ODKO>S$H , #G/D(+0B,E3OX32-^A!60;[8E?5H9:)
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M9 F_/*" $H&828 !%$5B#)KR YY?8+U6:@(N)H'P$!3&!''*@H@/D@FB "1
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MT)UW /Z=1M'_CI-/\2WULB2FP466[6C::H3V]N@'9(^J]8'9TACU .V3>>1
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MNK+A,*!&]BORX^K;'[Y9??O]][S%=ZL?OO_+ZD]_^4O?8B379N$0-4Z"@!>
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MZ"/'J//UFOKYV2YE[*XY*W[N!\X%?:#I TWW=!_6$RF,&*A?GF/4ZX;]V.)
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ME3YX<?@[GV\AB99$82 .<L?!M9CCY'JUS+[=LM_PTU=]CT?8HHW<H:V:4(4
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MW+[>B*'#0 D;%V\E,Z)P([]R?N[1PI%)/&F2J.*& 2;>[7(6O'\(XW"SV]S
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MEC7-KCU1F^ D#J[R1YI6CR;W(<QXJLC1QI+9ZH=N1I%$C$*V-#,_KE,L5KD
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M[)(L <?=?)X#=)]7#.R8[\@:&&:"[O"^U($H2A#0PND$L;#O-=K8Y-4S90L
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M0:$>[=&AT*JZ05.)3$#FA86-,WZ,TF)B)Y4?YB-/)8\%;F]U&6^2JE\Z#)>
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MF+?Y&09!^JU2C>7 JD< [N(^Y+LDE;^"=FW'"6<7XJ7"?>='F07W&R5XB1-
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M8 X5"P9T1XP()EJ,]H8*"=A:I>!'@"&I<70%#G,:I3@.!P%"QG?[DM(BL U
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MIPSB= Y[ZG1"BAG#E&Z/W99V9E-?@45&;:X/2$YOWJ9(#<?!Q^EU/SCEB"A
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MCQ1)C$W1?OF[H_."-IWT=<%[)5R4U(.F3<>A75\"G]*V3??!VRX0".B=]_+
M_!81^#KHTL!\ 5^9O__(!GJ:>V&L<<:GMQ-2R!VFM!JB=?= '(AI"FXZMI4G
M(6H,$.23YM&<0;S-LSAW[*_98Q(%U;-R5VM^*Q)^R3#MZE/,_O<QW(I':YO
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MP$J_7+V!!X990R) IL>^J-9N".:"^8S9/ OD(@O0G1T 0;ZHT@)()H#93=<
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MQY/W%^_^<7'Y,SDY/;WZ>'EWBV'F;C+"6R^"7_4B>7=?Y& RR 3-LW)'1\2
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MA+9D@T-PF\AJ=8!3[R*@ KGIM4\:M)\([&3MU&LOS9^O&3"$69:DSP-P3X?
M4B!0VQB-:-C;>TG J*^,!8P$+%1Q<LM&/EN72*2LHV11AWD+DL&[Q%(T-0+<
MPU&'2#F]&>N@651IY@Q)Q1$7@LYJE=XQXRY%)8M.W3Y2FK\'-MTYV8[F2!%6
M5U$U1=76%G&*JE=DX_IDLBH9ITP*TLY3JTWZ=B97.SLL<.RV)UC;6R]L_%I*
M/+:-8*=I5CSZSN>SHFQ0EM&\^[1M4SOD'MJJFNJ8!XT0^V.[K*;#4M:WXB0=
M'ZJ=5CF'%U-D2:YK[QE>/3B) _:;=$>#]Z%W'T;\U<WN6RI#""!WR>'&J-U?
MT>Z-V(D-E#"^XE&\%R!Y$<:,2&Y$8>?ZGHM#BWC-%G%8U61WGX5!Z*7/MUY$
M-4K;=;1'#@:]JM8JF;0U1NSJ_3(;'Y=G]/!4ME.T@_,#5^N[U(LSS^]=_VEU
MQ#Z*M96O#>?>7IC'M;[PHP9X_? \^Y?"Q_%2<2X3(*JE=W%]U1FGJG]'[K,'
MJJBN6?X1L0<>RF@ZRB[(-;ER' !:U.;ZRF$JY8DM8*,HR6$W[8J?=NU.J72T
M1^Y O:K64BQMC1$[6+_,QED)>)2[)$VNY*EHM[F72;7U"LHNJX/\UR[C,F3O
MDO22?I(+P3!^N$Z3F/WH\W*#7;4CA]) [L)&)JE7$QE  +&KF^EA7G:CY,8?
M&V#\2,60U#DZ7]G=,097ZY,@Z9_-6IHB]X(N!=7!WM0.\9CN%->X=AXC"JNP
M@JSC26LZ'1-51^?KK@H=;G,O#KPTR#YN R^GK/WW;W[0V3OH[8O<2P>9H&''
MH+LC8C\>)O_(K#C,/R4;HO+!L4$PM15N/Q(@^/K-#^Z<O3W\./?2Z+F I8XP
M=1@%Y(YO8 [5_0=T1PP")EJ8.D%7.+HBG)\R-SJ.3O<,$\9^N(UH5K-*Y_0X
MB,"R7$7#&!V>TM%[.8ZBHX0U/RF8'?B(TYD3@T4.8<-Y2*V)J.?K-?7S(0BB
M26E94#+$/ :SKTIF.> R2)LI9N-]KQ*,<>'-+$:JVP'!>T2W/HV]-$QTWB':
M:XL<&#I5;'QW2&V(V+F[Y37>P9?$G ?*A2 ?XVQ+_7 =TJ#[7$Y'>^Q#M$_5
MVC!M:XQYJ/;*/'JX*J1='[.97-F5EK;SNVJU3]09?W8T7XBCMBG:Y*?[;1?@
MIJTBC_;2BK+CH&\R57E,1P-WSGB=TH#Z%"X%=WIA4SOD[M>JFNIW!XT0.UR[
MK*;#3Z'HV,/LZ_;A_9W;$HP7<9:GO.Y$3[71@X;(':M=N?V"B_56B%VK0]A1
MA0<KFLY72'45M:J"MC1?U/#LKPK:U'8Q0]5VI4QEP"*I"CJ'KA:J@EI*VT-9
M%GESCU_NE3]WWY_M[X7<9375KJ7>N[L@=F!=R8U3ZKS@47']4UP1+UBX3IY/
MK/I^V2>+I>-$,4*O+'&OE*D#,&DO&:?;$:F+#E>^+!&GU0M[:;AA2A@73TG2
M-/D$.V"?'D/_D?A>3.XIH9_]1T:0!OP@-9)ZF/-81')1WI10"T/R^=MA3;=Y
M;#!E*<QW8>S%/AMQVD#6VP,S@NFI6T)7=W/LF*4I_:1@I58CAV?E]Q\,\G)>
M_#(/-[1XG![^/Z7;).5' 9B"8?[\149B^CDG:;*+ VBX+G2;&?4FMFE)'A7,
M3:STZ)KF=A9=%S$;K+3<(->H1]G= RD.#E"W=EF\O3GB19:.U.;#%FB3DCB>
M\I0M6G<F^OKZ+',TMZ?\.CLL;T1;2HAUC&FG&4!L6H^(N/EL1[-<,#W_O*5Q
M1B]I1\3=VP.I;PY0MXRXNYMCC[@UI3?/:X4;+WTN@E\O8D%T,61]3YR.#6,9
MCHL0&L)PS\\SXMTGNQP>U. "LA_XD']%A8Q?KLBC]T19_$Z!A!_M AK,'%I/
M;+R"/)'>+AD0QL%E;#V7UOL?W.4CXSL0BM>BA_V6C@"[I2E2O--1L/Z>^&$[
MQ)%'I[CFN:V*J-Q]<QP\W] ML]HCD^[D(:4<7/<U[PRDA_1'/I 'FT(=W=J=
M$0_YX3J8^D'%B92L2(-S.(W"YS.'ON8C(O'K=?@[3=G$^U5[[-W0!JG3=JI4
MQM?[#;!'U*WRCG"TII?IZB\N":X0*<X< UM75]'$990[D5ZKQD\T>]6H-(4-
MCYXCGFUMD<*)EHH-A:/J#1'/[=WRCBZK5-'EI=<OD_BUI_Q.J:+KOOB9(FQV
M$@=,5D545=+N$DR#J2 ?^H9FJ95E^O^KNY;>R'$C_%=X"A+ BR [R2E!@/',
M.#%B3QLS3G*F6^HQLVJI5X_NU;\/BWI1+8FBV*)8O"QF;;)>9GTJ%HO%9200
MNXNI)L978B1^XCF'/L<K!W+;M<FE:>;!9?W ^8GM(8?4;@*FP^?)D4A=7T.]
M-I0>'X8]H)Z1VK@WP6_[J,C8.227)(V""PM"$E6LQ).D57A-3C2'!9JR'^^Y
M>*OT2'\)[TB1\?]D813=\6_G@<>K4#J2T?K9$G:$3#8\6QD4^WSCB-R2O6JR
MTF;?872^E8XNDWH!%P%JC*42EK9L3SP\H(QMELQ'"FW&IN@G]30G(XYDENM@
MGFMH./7*N;I:UOK%"Z?1RW;F: N7%<9PN)F7'V66(BC%EEX] ST.S*K;]_S)
MX:A]?5YJ<^^6GQKOO=CC_ AK5.N98ROU'#]7L^IX2C'!OQ6]VC'4Y)IV?/*$
M2^L;-L^[PX''Q=]@CQ9-;YQ'1R'UP1FUV@WS< CVS;)"8O.U!L0@19P(XE"P
M]95O;]_/+(KX+OB9[=_9#QH3L"W?_I*GIT\DN<1\>;Z5)+\D];PTVW@C;,$6
M%4E2F\3A!MBV;HY?/?^4'(\LGWOV9V(H4M#147#P_/G5.,2?>:6XQFM27 *7
MJ#J/5*_55(:HDX,]6Z+30>GX2(^6Z4H!V<A"=1I^.E?SAGCSF45AEB=Q^$)+
MP60ZZ)P>BM3#=!1LP\^)<=ACT#FQS4OLFF77G,.08\.*G&I>A!L?KN'"J.+$
M-T241Z?A&<JDNEZB/Q(:;1V-VK)*2Y<TA%W&I=MIZ3!9!<?6JB2K]'ND,#2I
M2B_AU/P2\>=\**/Q-A<H.0\OA13J@[W>"!_6E^)PKOLU]C6V5C*E6F5NS\_6
MU\=Y_[EG%K-C<51ZSO48Y+XSJI+L/;T!B/UG7$[S2$!0<^Q#5G1RZ#[TMWGW
MN1J#W7W&5.JYCSP L_N,RFF\U"IJKMW'AD[NW.<?81RF-/H8!Q^#(_?E+$_Y
M[OC<7(Y6NI7N7.3NML@$LAMJ343LGLOD-UWB-1=15][GT[8%<.O1VYH!BFQI
MCX_+VI4LY([RSE7_')[#*#F)1]4T7%]O)G+'7Z!^OYIE=AIBIU\BO?FY>\5#
M^+S$!8G#;VH"\/>@X^+PXMF%I@%<F5/D_Z['('?@495Z5\+D 8B=<EQ.XSM+
M0(V(VY&NDX+?WVD:WG.I@D_)$?RK:@DH7:JZ+[LQ=8)<R-^9) Y>N"%F>X%8
M8H7<!6P:N/=8F@4^B!W2JKK&-?W D B.1!:+]"XIWI=$'EC+1BI0D* !OLT@
M((9F)RC-_>77@N5E;3+W>6(>4>0IV^=Z5ZC&QR(',Z6*5R'X<"!B.%'+>T.,
M65-%<KG)LI)U%W/PQS7;\G\YGJ*D#.%*5E9$.:UNEG]F:;CG)#*AS.XTW9/!
MF A2;[S-*&T)T&(*V(N#S!4R#N1C(K<:N+R':?A60J%Z6,MR!T5#M31WT//_
M*#@W[?WO$_AV\?]II20LJ]K\1]RA\H3P'X>0BF.QF' H\B*%^^'%V__X!!AQ
MY@X(-4BPD4U$$5U:NR1H>D<HB8N&9P;?Z*PA5CTG ,\.4*F"Z<2G<@XTX]OB
M X-:^WHX;:XN;US>M/W?M>%())95KJ3],U6 7K-U61:UO74JU9.*IL-G>NMH
M4I$NN1J"%,]5"O7>Y95^CSB6&A73N+59MP%RG"G1RG'XEIV8SRMXDQ%8>7.)
M9>>]N5HW!.H?>7 0B)U_',"VH&['OCOPH7^I=NN/?$G&<*@&@DQ'Z\:4D/K;
M"N9IXW8S,MB#]QNULMH!E3:RB1@[[:2#D!KD(V&5BF*-A.3$Y=DX3'9DP9:M
M") EQJ3B3.HT7<N[2FHZC)A=&8K\CAY/?R7?JB4#E-=,D@SE!C:*A,C,!,Q(
MJJ5LE^A0C<:.BWK"6X6_47 3BWCK1(!56XSBE'!5E[M[JRK; *+'."CV E#5
M(=[$.,RPHU)->K1I. @[R"AE7AE;4N@O4R,+9!4[WF(EWHGLZ2CB%%G=]V/D
M3522T_1'"(<0%)[W"=B9!06-,A(GT"PS/+.DR**RS<MFD(L-VFP>A=ZQ,*\1
MA<4 ?&)PE=IE^;M@#.>?-"XW?P[*PA_HRO)N'WZRKY_#SOB0S=\='MMEJ>J,
M/S$6*2YJJ=CKC#\V$'%:22VO<6=\H J[QXZN\P3G0-/_<LP3W< @S__.3J_)
M%X&UR@SH<BJ^K6P]LRC7O)J$3]Z@J<EM?K+K^0FP)#)/\IJ0BJOC7.W6UND9
M(9\UPLU]^M*L/5;\& ?-P:.BZ$)O&E( 6*KX56L_Y1SL&X(E*JRP/VBZ^-W)
M(7D<R-'Z0:I8<-+LSZXQ&AY2A0&D4ULV[AL";J/_Y JP &;+,,Q;Z%J 6/X"
ME5U\ NB9SH\VZ-5?L(Y RB8VH4,DF\I265D+U:P].)6*M^9+6&=G8D:E9>H/
MBE75T["CU4(M5D"N%HZN/ZQ[J;+197"UD4DZV.H'6'*!)X(BSJVLH%@-[A)0
MC73SUV?&1R*%/0WUY&31R##$"2&5M#=77V.X-&-%P>\O+P[OF7.8#UA4P,':
M]W!?I"QG82;>K O"X(&O63CC*JJOV.[PA:80Z&8O85K=\"O'":ANK5OEB-SM
M-S!W[T:]/7:(86@+K<TO"76D24?;^7G/N,JS)>X:T[ST2'49_-P<[WQCQ9KR
MJ06.H'K>E>YWM]?8K^/DTNN"7Y,\S%YH":\;*J/KN3G(W5M+9=FWE1,0.[:>
MW.8M\;MW*05Y4M-W')!OIW4,Y-VY[@-EZ7]H5/#HY#FD69&*4J:'-/RU".-]
MJ8BW]68B=^,%ZLO.K#$-L4LOD=ZXI6E'F+24G4>CK>9C>BL#4KV9OJSV>?5'
M5_OT-!]6NX;TIJL=>!#!A$PL?*<!ZK8FN%MH [?NGWV#>#KE&W5EN*HYU4,
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M465U;2^]V-8B7U\\RK;I1[W2%E,?/-NZ[BM\RR49F[@](+M82F$+.8DL:!4
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MR+"P,2JLK/(N1H (UG2J",H:_>V/'?<G_B_^P^9']?R__Q]02P,$%     @
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M^M3,I*4@1Q;CZVGJE3QSKV-NJQ[/8S^J,R2<L!@RF]5'YCM:94%D K-9*<3
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M_Y%^XD/ZC4GU(Y,?JY_Y\^3'_$M_AH.N/3\B< U]$VT??E!@77:TS1=5<IZ
MA\H%70=1'#7V-[0L#_T&1=@\N?AR^>7SIR^?3T]/ST\O%5E>4362<1962@WF
MLX_J+:D$ +082:GL(YQ85?MNDM?(=5PKW#Y;*?6H^M[TW<46^,2UUPXV<B7:
M@B NSC @0E56O-WL'ZPU_.<+Y%,$-0E.\"9 CU]QT*!VU \C7#)KD7DWDB4X
ML%0@Y7:]\8(M "G]7P&AI%%+2_VPT$V635"P$FL("C)#";]"6#5J;?23_, K
M!9T;!,>=ZOU"9P[MJ/:=1\_RD9*1UQ,)G](.>W0L=#C0BV*,(1;J"<"C@(M\
M?O25JK6M=J@9# %-\+$S2#EZ,*'AQ?I\'?A1XL4H)AXRX\8-@0V'J-4?;X5*
MMT&.&!+*.0E76UHNI]2H%=$.=TPXC Z '?I +X>%4J^5%.T*RR,/"-]<&^,Y
M?PC\MRQM F)2]!+$EE?].W+D/03Q/T#\5+J^*;YAZ=_53PGD@))PBAV4M5)#
M>Q3%@4KCY-!*H9TRJ,'H@+HB54?0!'1YI2:-@[N1LD[S> 7"EY7EYUO,H76(
M-I^CC@VM8YTD8F)DG3P.5XYT@^M;Y=M'W1I<MVC<-S'&3AHWL^>%=T&8_X3:
MX<*[AYW$4;.&UBQV,0P3B#<2MYE>J06/BC(PIP6ENM4OP4>/Q\+[^;::F6XD
M?NFH#P-E4</Q6G+JV3*&36:@]@.([R%]D%3(JW7@IXSABLT^/3DYW8_-AJ-.
MT+ 3..XD&SB+UQY+-/:M%:(Z%8@OZ;QIOG1L<[7ATOOS@HAW[:MM)I%KSXHB
MMK!HQG'TLT@4,;9',?>A5N-H9<CYU/H]V\"WX&Q(D<IM;;63KAB)M2"!F7J-
MI9U/_9L?;8#M+ES@D /&<.WK=%]H('5FZ;3I. ^5RH-PQ$#A$4X4V""*@I 8
MOM5HIY_HN<37%#\;A8:(O=4FTD)?R)TT!(2<%: #&Z3>:BA:1!ZM,'9M=V.A
M#.S/P$[@;%P0P:U^'+JO25;%XYOO[/Z[8!S:_*=,P]F:_B-K!\8.H&DQ49(8
M(S4X1-%KJ_S$BNY),@]6I80,!G>D+F8"BIMB$Z]G]Q*Q9G[/&]=#^M/@RM3Y
M[R2*T0X3 Z*.HYF)+Y',&.9&<W!W6L[G@LV\WK4S=N_:ATG^K?1/1X^;JLDC
MU[5ONYZ;J3,?*>V=M;<>)-]:#Q(-.8U!G9WYT&  I+AE8M>7H+(\KP(/DIKM
MX2B0Z3B:]ACBP$439"*98N)VN<8?%F!I!Q>1$J;@YV!0\0)W,T%HA=O;WQ,X
MCZEMAP"1]1(\ 0=DF:NR1%:T;7&'D0X,8:(XU/>(=IGAT$]KK#K2Z@A=HZO^
M,'8A!Q^"&$2/(5B[R?K;!G(R>45G@MBUO*^!XRY<VRJ);WLRVG&H \&7<!;U
M/8A1 *8HVH>3^6+V7@<"09'<$15UV?I(1R</5!%Y5_60D#?^O,-HASZA.WXA
MW)#J[U3T;)+$F I?,@5'"012=UT'S.$'TPYY0L#"AT%.[@@Z7N#B"54]X6WS
M,E-!1^EU*.CJP@9!!HU:/FYP/_H4[F =1+C[!BI7HYSN]',>=WKUDY/=-X].
M]4'#6-L%?_MN>PF4\1U41!3HG620:\:"L,6XBOB(=F:I6P"L-%;H&R_9D^2K
M;?L I+R.\KZH'0P'@%83ST,S>&S@IB:1I'73#F9#2YP5<Q26&7+%*3A5I+9X
MHDBS"0IV8I4C0>.TC^/'@T N&)+"L7)G\5A,G&X\*+WJ#/LT>MCT(5M"1)UB
MG&1W6]86;0194=+L<P 8821:0HH+?;:XS%N_>\J[&%'#:X>[,9[,R-PT\2%.
M3X9-UT&"#=L1,K9VN)8*,>&()C!QF)@SF;[\LA3B5V"A_TZ33-^YON7;KN7-
M?'@X2M+?\K\[<_\)L3#,K\TX/?RGS704: :3= J3ZAS07XII3"KS*!HYD[D_
M*:<R2><R%L]_R?0=(VC% DE=TDIPGTX^?[DX^WAV_N4"HE2-):S6U03IT>G>
MM5Y1S7.H;RT @@T> E0/LH(GTGV L/&ULXC<XFU:.;G,T==_6M)]M:W8C[L0
M_)X W]X2G/P,/?4%BA0I$U#%R:,1X*6-'J++G:&GOGCAE!\!"9S4*W>;RH--
M5*H9T=G!TE5?X'"*FPTX3.2;C)RJ4>8'3[/WH>&'D0.&N.(K5KS\YW^X((3B
M6&WOP1OPV+8YA,[Z FCXG0XOF_2M:ME^O&^0Q[WMP8ZA+XSXQ<IHBKA88=J:
M-O,W21RE?#QG6\>:/?3%3&<Q$Z##2+]I0.EAQ6GW/T*_H2\8AUX'I7%3KT*!
MF*B:/394>)"63U^@1W(@_@Z GZIRU'J-TV,D(W'(>G,CFF]2[VE.555C>06.
M YP;$+IO%KK;*ADV7S3_6+!OBWM>T'&X@\:I%.:9F..MO,JKR*+ES@.WP+/U
M/D*Q)Z]$+<SD HR#7V<_!9YW%X1I$8E%GGDAB\6*X*>::LG];NVTF08.?ZN-
M9O,AG\XD6$SR"4WL<D:3W90FE3D=Z.VVXG,+66-3%?WF!Z\1"-_0)CL]W=7?
MS3/=: OZC+XFD "&UM.'3(:,X'+R:EMN$M($V6S^W68??0$A4\!$[RXCDT8
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M^-ZST4-PYVK[\CV8+Q:N#;_P%: ]59L/F-!<:U$3)+/G[N6E4+E@I2X*_*M
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M4]]Y@6U!_2271Y4R!5XRC* U( CRVSO3""!:6T0@8BK$S7WPGV![N]YXP18
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M+GAM;%!+ 0(4 Q0    ( %JN=$HU\#-.Q1,  /GJ   1              "
M <%/ 0!G96UP+3(P,38Q,C,Q+GAS9%!+ 0(4 Q0    ( %JN=$H&BB :Z X
M -S2   5              "  ;5C 0!G96UP+3(P,38Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    " !:KG1*M<:^7K@U  "1  0 %0              @ '0<@$
M9V5M<"TR,#$V,3(S,5]D968N>&UL4$L! A0#%     @ 6JYT2J5,Z-S7A0
M].\( !4              ( !NZ@! &=E;7 M,C Q-C$R,S%?;&%B+GAM;%!+
M 0(4 Q0    ( %JN=$ID-]U%?5H  */Q!@ 5              "  <4N @!G
J96UP+3(P,38Q,C,Q7W!R92YX;6Q02P4&      8 !@"* 0  =8D"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
